<SUBMISSION>
<ACCESSION-NUMBER>0001193125-10-152828
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>10
<PERIOD>20100625
<ITEMS>1.01
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20100701
<DATE-OF-FILING-DATE-CHANGE>20100701
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>Abraxis BioScience, Inc.
<CIK>0001409012
<ASSIGNED-SIC>2834
<IRS-NUMBER>300431735
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33657
<FILM-NUMBER>10931781
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
<PHONE>310-883-1300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Abraxis Biosciences, Inc.
<DATE-CHANGED>20071120
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>New Abraxis, Inc.
<DATE-CHANGED>20070806
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): June&nbsp;25, 2010 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ABRAXIS BIOSCIENCE, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33657</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30-0431735</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11755 Wilshire Boulevard, Suite 2000 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Los Angeles, California 90025 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(310) 883-1300 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Merger Agreement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;30, 2010,
Abraxis BioScience, Inc. (&#147;Abraxis&#148;) entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with Celgene Corporation (&#147;Celgene&#148;), and Artistry Acquisition Corp., a direct wholly-owned subsidiary of
Celgene (&#147;Merger Sub&#148;), pursuant to which, subject to the satisfaction or waiver of certain conditions, Merger Sub will merge with and into Abraxis and Abraxis will become a direct wholly-owned subsidiary of Celgene (the
&#147;Merger&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On the terms and subject to the conditions of the Merger Agreement, at the effective time of the Merger (the
&#147;Effective Time&#148;), each share of common stock, par value $0.001 per share, of Abraxis (the &#147;Abraxis Common Stock&#148;) issued and outstanding immediately prior to the Effective Time (other than treasury shares of Abraxis and any
shares of Abraxis Common Stock owned by Celgene, Merger Sub or any wholly owned subsidiary of Celgene or Abraxis) will be converted into the right to receive the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an amount in cash, without interest, equal to $58.00 (the &#147;Cash Consideration&#148;), </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2617 (the &#147;Exchange Ratio&#148;) of a share of common stock, par value $.01 per share, of Celgene (the &#147;Celgene Common Stock&#148;), and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">one contingent value right (a &#147;CVR&#148;) issued by Celgene subject to and in accordance with the CVR Agreement described below.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All outstanding stock options (&#147;Options&#148;), stock appreciation rights (&#147;SARs&#148;) and restricted stock
units (&#147;RSUs&#148;) of Abraxis will be canceled at the Effective Time. Holders of Options and SARs with an exercise or base price below the Per Share Amount will receive, for each share of Abraxis Common Stock subject to such Option or SAR:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a cash payment equal to the difference between the Per Share Amount and the exercise price or base price of the Option or SAR, as applicable, and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">one CVR. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of
Options and SARs with an exercise or base price below the Per Share Amount (as defined below) will be given the right to elect, during a period of at least five business days ending the business day preceding the closing of the Merger, to pay to
Abraxis a cash payment equal to the difference between the exercise price or base price of the Option or SAR, as applicable, and the Per Share Amount, and in exchange receive one CVR. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of RSUs will receive, for each RSU: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a cash payment equal to the Per Share Amount, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">one CVR. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The &#147;Per Share Amount&#148; means the sum of (x)&nbsp;the amount obtained by multiplying (1)&nbsp;the
Exchange Ratio and (2)&nbsp;the Celgene Share Cash Value (as defined below), with such amount rounded up to the nearest cent, and (y)&nbsp;the Cash Consideration. The &#147;Celgene Share Cash Value&#148; will be an amount equal to the average of the
closing sale prices for Celgene Common Stock on NASDAQ, as reported in The Wall Street Journal, for each of the ten consecutive trading days ending with the seventh complete trading day prior to the Effective Time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis and Celgene&#146;s respective obligations to complete the Merger are subject to customary conditions, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the approval of the Merger by the Abraxis&#146; stockholders, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effectiveness of Celgene&#146;s Registration Statement on Form S-4 covering shares of Celgene Common Stock and CVRs to be issued in the Merger.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Merger Agreement prohibits Abraxis from soliciting or knowingly encouraging competing proposals (the &#147;No-Shop
Prohibition&#148;). However, before its stockholders vote to approve the Merger, Abraxis may, subject to the terms and conditions set forth in the Merger Agreement, provide information to a third party that makes an unsolicited acquisition proposal,
subject to the execution of a confidentiality agreement, and may engage in discussions and negotiations with a third-party that makes an unsolicited acquisition proposal that the Abraxis&#146; board of directors determines constitutes or is
reasonably likely to result in a &#147;Superior Proposal&#148; (as defined in the Merger Agreement). The Merger Agreement also permits Abraxis to terminate the Merger Agreement to enter into a definitive agreement for a Superior Proposal with a
third-party if Abraxis shall have complied in all material respect with the No-Shop Prohibition, shall have provided Celgene with five business days to match the Superior Proposal and simultaneously pays to Celgene a termination fee of $145 million.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Merger Agreement also provides for certain other termination rights for both Celgene and Abraxis. Abraxis may be required to pay Celgene
a termination fee of $145 million upon termination of the Merger Agreement under specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This summary of Merger Agreement
has been included, and the Merger Agreement has been included as an Exhibit, to provide investors and security holders with information regarding its terms. It is not intended to provide any other financial information regarding Abraxis or Celgene.
The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of that agreement and as of specific dates; were solely for the benefit of the parties to the Merger Agreement; may be subject to limitations
agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts; and may be subject to
standards of materiality applicable to the contracting </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
parties that differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual
state of facts or condition of Abraxis or Celgene. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be
fully reflected in public disclosures by Abraxis or Celgene. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Voting Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Patrick Soon-Shiong and related entities holding, in the aggregate, approximately 82% of the outstanding Abraxis Common Stock (the
&#147;Principal Stockholders&#148;) entered in a Voting Agreement with Celgene and Merger Sub (the &#147;Voting Agreement&#148;), pursuant to which the Principal Stockholders have agreed, subject to the terms thereof, to vote their shares of Abraxis
Common Stock in favor of the approval and adoption of the Merger Agreement and the transactions contemplated thereby, and against, among other things, any business combination or extraordinary corporate transaction other than the Merger or another
business combination or transaction with Celgene or any of its affiliates. The Principal Stockholders also granted Celgene an irrevocable proxy to vote their shares of Abraxis Common Stock in accordance with the preceding sentence. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Voting Agreement also limits the ability of the Principal Stockholders to sell or otherwise transfer their shares of Abraxis Common Stock, other than
to certain permitted transferees. The Voting Agreement will terminate upon the earlier to occur of (i)&nbsp;the Effective Time, (ii)&nbsp;a material amendment of the Merger Agreement that is adverse to the Principal Stockholders that is not
consented to by the Principal Stockholders (including a decrease or change in the form of the Merger Consideration) and (iii)&nbsp;the termination of the Merger Agreement in accordance with its terms. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contingent Value Rights Agreement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At
the closing of the Merger, Celgene and a mutually acceptable trustee will enter into a Contingent Value Rights Agreement (&#147;CVR Agreement&#148;) governing the terms of the CVRs. A holder of a CVR is entitled to receive a pro rata portion of each
of the following cash payments that Celgene is obligated to pay to all holders of CVRs: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Milestone Payment #1</I>. Celgene will be obligated to pay $250 million upon the achievement of U.S. regulatory approval of Abraxane&reg; for use in
the treatment of non-small cell lung cancer, which permits Celgene to market such Product under a label that includes a progression free survival claim, but only if the foregoing milestone is achieved no later than the fifth anniversary of the
execution of the CVR Agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Milestone Payment #2</I>. Celgene will be obligated to pay $400 million (if achieved no later than April&nbsp;1, 2013) or $300 million (if achieved
after April&nbsp;1, 2013 and before the fifth anniversary of the CVR Agreement) upon the achievement of U.S. regulatory approval of Abraxane&reg; for use in the treatment of pancreatic cancer, which permits Celgene to market such Product under a
label that includes an overall survival claim. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Net Sales Payments</I>. For each full one-year period ending December&nbsp;31 during the term of the CVR Agreement (a &#147;Net Sales Measuring
Period), Celgene will be obligated to pay to the CVR holders: </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5% of that portion of Net Sales of Abraxane&reg; and the other Products (as each such term is defined in the CVR Agreement) that exceeds $1 billion
but is less than or equal to $2 billion for such period, plus </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an additional amount equal to 5.0% of that portion of Net Sales of Abraxane&reg; and the other Products that exceeds $2 billion but is less than or
equal to $3 billion for such period, plus </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an additional amount equal to 10.0% of that portion of Net Sales of Abraxane&reg; and the other Products that exceeds $3 billion for such period
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Net Sales Payments will be due following a Net Sales Payment Termination Date. &#147;Net Sales Payment
Termination Date&#148; is defined as the last day of the Net Sales Measuring Period ending on December&nbsp;31, 2025; provided that, if Net Sales of the Products for the Net Sales Measuring Period ending on December&nbsp;31, 2025 are equal to or
greater than $1 billion, then the Net Sales Payment Termination Date shall be extended until the earlier of (x)&nbsp;the last day of the Net Sales Measuring Period subsequent to December&nbsp;31, 2025 during which Net Sales of the Products are less
than $1 billion and (y)&nbsp;December&nbsp;31, 2030. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene has agreed to use diligent efforts to achieve each of the
Milestones above through the fifth year anniversary of the CVR Agreement and to obtain FDA regulatory approval for the commercial manufacture, marketing and sale of
Abraxane<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the treatment of melanoma, ovarian cancer, bladder cancer and first-line metastatic breast cancer
unless the data generated in an appropriate clinical trial does not support further development of Abraxane<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for
the applicable indication. Celgene has also agreed to use diligent efforts to sell Abraxane<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> or any other the
Products for which Celgene has obtained regulatory approval for the commercial manufacture, marketing and sale thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene has also
agreed to use its reasonable best efforts to cause the CVRs to be approved for listing for trading on Nasdaq and to maintain such listing for as long as CVRs remain outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene may, at any time on and after the date that 50% of the CVRs issued pursuant to the terms of the Merger Agreement either are (i)&nbsp;no longer
outstanding, and/or (ii)&nbsp;repurchased, acquired, redeemed or retired by Celgene, redeem all (but not less than all) of the outstanding CVRs at a cash redemption price equal to the average price paid for all CVRs by Celgene in prior transactions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the Merger Agreement, the Voting Agreement, and the CVR Agreement does not purport to be complete, and is
qualified in its entirety by reference to such agreements. Copies of the Merger Agreement, the Voting Agreement and the form of CVR Agreement are filed as Exhibits 2.1, 10.1 and 10.2, respectively, and are incorporated into this Item&nbsp;1.01 by
reference. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Additional Information </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene will file a registration statement, and Abraxis will file a proxy statement, with the Securities and Exchange Commission (SEC) relating to the
proposed transaction. Abraxis stockholders are advised to read the registration and proxy statements when they become available because they will contain important information.&nbsp;Investors may obtain a free copy of the registration and proxy
statements (when they become available) and other relevant documents filed by Celgene and Abraxis with the SEC at the SEC&#146;s Web site at http://www.sec.gov. In addition, stockholders may obtain free copies of the documents filed with the SEC by
directing a written request to: Celgene Corporation, 86 Morris Avenue, Summit, New Jersey, 07901, Attention: Investor Relations, or Abraxis Bioscience Inc., 11755 Wilshire Blvd., Los Angeles, CA, 90025, Attention: Investor Relations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis and its directors and executive officers will be deemed to be participants in the solicitation of proxies from the Abraxis stockholders in
connection with the proposed transaction.&nbsp;Information concerning the interests of Abraxis&#146; participants in the solicitation, which may be different than those of Abraxis&#146; stockholders generally, is set forth in the amendment filed
with the SEC on April&nbsp;26, 2010 to Abraxis&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2009 and in Item&nbsp;5.02, and will be described in the proxy statement relating to the Merger. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;25, 2010, the compensation committee of the board of directors of Abraxis approved a retention agreement for
Bruce Wendel, Abraxis&#146; chief executive officer. Under the terms of the retention agreement, Abraxis would be obligated to pay to Mr.&nbsp;Wendel certain benefits if a change of control occurs on or before December&nbsp;31, 2011 and
Mr.&nbsp;Wendel&#146;s employment is terminated by Abraxis without cause or by Mr.&nbsp;Wendel for good reason at anytime during an 18 month period following such change of control. In such event, Abraxis would be obligated to pay Mr.&nbsp;Wendel an
amount equal to two times the sum of his then base salary and target bonus, continue to pay his COBRA benefits for 18 months and provide him life insurance coverage for 2 years. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the retention agreement does not purport to be complete, and is qualified in its entirety by reference to such agreement. A
copy of the retention agreement is filed as Exhibit 10.3 and is incorporated into this Item&nbsp;5.02 by reference. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, by and among Abraxis BioScience, Inc., Celgene Corporation and Artistry Acquisition Corp., dated as of June 30, 2010. Schedules have been omitted
pursuant to Item 601(b)(2) of Regulation S-K. The registrants hereby undertake to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Voting Agreement, by and among Abraxis Bioscience, Inc., Celgene Corporation, Artistry Acquisition Corp. and the signatory stockholders thereto, dated as of June 30,
2010.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Contingent Value Rights Agreement to be entered into by and among Celgene Corporation and Trustee.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Retention Agreement, dated as of June 25, 2010, between Bruce Wendel and Abraxis BioScience, Inc.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ABRAXIS BIOSCIENCE, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: July&nbsp;1, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Bruce Wendel</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bruce Wendel</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Index to Exhibits </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, by and among Abraxis BioScience, Inc., Celgene Corporation and Artistry Acquisition Corp., dated as of June 30, 2010. Schedules have been omitted
pursuant to Item 601(b)(2) of Regulation S-K. The registrants hereby undertake to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Voting Agreement, by and among Abraxis Bioscience, Inc., Celgene Corporation, Artistry Acquisition Corp. and the signatory stockholders thereto, dated as of June 30,
2010.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Contingent Value Rights Agreement to be entered into by and among Celgene Corporation and Trustee.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Retention Agreement, dated as of June 25, 2010, between Bruce Wendel and Abraxis BioScience, Inc.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>dex21.htm
<DESCRIPTION>AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML><HEAD>
<TITLE>Agreement and Plan of Merger</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 2.1 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AGREEMENT AND PLAN </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">OF MERGER </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">DATED
AS OF </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">JUNE 30, 2010 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMONG </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">CELGENE
CORPORATION, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTISTRY ACQUISITION CORP. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AND </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ABRAXIS
BIOSCIENCE, INC. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD COLSPAN="5" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;I</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE&nbsp;MERGER</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Merger</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Time of the Merger</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Incorporation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By-laws</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board of Directors and Officers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effects of Merger</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;II</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONVERSION OF SHARES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of Shares</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment and Exchange of Certificates</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dissenting Company Shares</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Further Ownership Rights in the Shares</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing of Company Transfer Books</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock Options, RSUs, SARs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Withholding of Tax</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;III</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Organization, Standing and Power</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital Structure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authority; Non-Contravention</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC Documents</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxy Statement/Prospectus and Registration Statement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absence of Certain Events</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Litigation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Violation of Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee Benefit Plans; ERISA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Matters</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Environmental Matters</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Affiliate Transactions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual Property</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Takeover Statutes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.16</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title to Properties; Assets/Services</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.17</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Material Contracts</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.18</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Financial Advisors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.19</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical Matters</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.20</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brokers and Finders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.21</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.22</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-Corruption and Anti-Bribery</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.23</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Other Representations or Warranties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;IV</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Organization, Standing and Power</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-i- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(continued) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD COLSPAN="5" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital Structure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operations of Sub</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authority; Non-Contravention</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC Documents</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absence of Certain Events</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxy Statement/Prospectus and Registration Statement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Availability of Funds; Parent Common Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Litigation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Violation of Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brokers and Finders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ownership of Shares</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Solvency</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Other Representations or Warranties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;V</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">COVENANTS RELATING TO CONDUCT OF BUSINESS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conduct of Business by the Company Pending&nbsp;the&nbsp;Merger</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Control of the Company&#146;s Operations</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;VI</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADDITIONAL AGREEMENTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Stockholder Approval; Proxy Statement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors&#146; and Officers&#146; Indemnification</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Solicitation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Access to Information; Confidentiality</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reasonable Best Efforts; Notification</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Benefit Plans</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees and Expenses</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public Announcements</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sub</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CVR Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer Taxes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Listing</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain Notices</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 16 Matters</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">State Takeover Laws</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.16</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">FIRPTA Statement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.17</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further Actions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;VII</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONDITIONS PRECEDENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conditions to Each Party&#146;s Obligation to Effect the Merger</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Conditions to Obligations of Parent and Sub</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Conditions to Obligations of the Company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Frustration of Closing Conditions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Invoking Certain Provisions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;VIII</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TERMINATION, AMENDMENT AND WAIVER</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-ii- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(continued) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR>
<TD COLSPAN="5" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of Termination</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Extension; Waiver</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Procedure for Termination, Amendment, Extension or Waiver</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;IX</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">MISCELLANEOUS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Survival of Representations, Warranties and Agreements</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notices</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specific Performance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment; Binding Effect</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entire Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Governing Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Counterparts</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Headings and Table of Contents; Interpretation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Third Party Beneficiaries</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporation of Exhibits</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severability</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Person</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable Jurisdictions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Knowledge of the Company; Knowledge of Parent</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.16</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mutual Drafting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.17</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax Reporting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-iii- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF DEFINED TERMS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2007 Separation and Distribution Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9(f)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2007 Spin-Off</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9(f)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2007 Tax Allocation Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9(f)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition Proposal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Affiliate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-Corruption and Anti-Bribery Laws</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.22(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antitrust Approval</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.1(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antitrust Division</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.5(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable Exercise Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable Jurisdiction</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable SAR Base Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7(b)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board of Directors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7(e)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book Entry Shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Business Day</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash Consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Incorporation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 1.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 1.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.9</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.9</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Code</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Financial Advisors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.18</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Financial Statements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Intellectual Property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.14(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Material Adverse Effect</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.14(e)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Permits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company SEC Documents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Stock Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Stockholder Meeting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Copyrights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CVR</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CVR Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recitals</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CVR Certificate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DGCL</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 1.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosure Schedule</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Article III</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dissenting Company Shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Time</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 1.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effects</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.1</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-iv- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF DEFINED TERMS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.6(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee Benefit Plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.10(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Practices</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.11(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Environmental Laws</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.12(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Environmental Liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.12(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ERISA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.10(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ERISA Affiliate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.10(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange Act</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Article III</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange Fund</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange Ratio</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excluded Company Shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.7(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.19(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDCA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.19(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.10(h)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FTC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.5(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Governmental Entity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.3(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hazardous Materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.12(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HSR Act</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.3(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnified Parties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnified Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance Policies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.21</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual Property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IRS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.10(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Knowledge of Parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 9.15</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Knowledge of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 9.15</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Law</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.3(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leased Real Property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.16(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liens</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.2(d)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Material Contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.17(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Material Employment Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.10(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recitals</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger Consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nab&reg;Technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Competition and Confidentiality Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recitals</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.7(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.7(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Common Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Financial Statements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4.5(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Material Adverse Effect</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4.6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Permits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4.10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.6(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Review Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.3(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent SEC Documents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4.5(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parent Share Cash Value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.2(e)</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-v- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF DEFINED TERMS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paying Agent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per Share Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7(a)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Person</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 9.13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical Products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pipeline Products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.19(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxy Statement/Prospectus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Real Property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.16(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.3(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registration Statement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory Authorities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.19(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory Registrations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.19(f)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Related Agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recitals</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representatives</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">RSU</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.7(c))</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">RSUs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.7(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SAR</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7(b)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes Oxley Act</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.4(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SARs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.7(b)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Screening Test</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.19(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securityholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Solvent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4.13</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock Consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholder Approval</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 7.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sub</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiary</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 9.12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Superior Proposal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.3(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Surviving Corporation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 1.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.9(f)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax Return</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.9(f)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.1(b)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade Secrets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trademarks</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.14</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer Taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.11</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transition Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 6.6(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trust Indenture Act</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4.4(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recitals</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. GAAP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Voting Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recitals</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">WARN Act</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.11(e)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">willful and material breach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 8.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Worker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.11(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3.11(c)</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-vi- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;), dated as of
June&nbsp;30, 2010, is entered into by and among Celgene Corporation, a Delaware corporation (&#147;<U>Parent</U>&#148;); Artistry Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (&#147;<U>Sub</U>&#148;); and
Abraxis BioScience Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>W I T N E S S E T H</U>: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the respective Boards of Directors of Parent, Sub and the Company have approved the acquisition of the Company by Parent on the
terms and subject to the conditions set forth in this Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the respective Boards of Directors of Parent, Sub
and the Company have approved a merger of Sub with and into the Company (the &#147;<U>Merger</U>&#148;), upon the terms and subject to the conditions set forth in this Agreement, and have declared the Merger advisable; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Company, Parent and Sub desire to make certain representations, warranties, covenants and agreements in connection with this
Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, concurrently with the execution of this Agreement, Parent, Sub and certain stockholders of the Company
are entering into a voting agreement of even date herewith (the &#147;<U>Voting Agreement</U>&#148;) pursuant to which such stockholders have agreed, subject to the terms thereof, to vote their shares of Company Common Stock (as defined below) in
favor of adoption of this Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, (i)&nbsp;concurrently with the execution of this Agreement, Parent,
Dr.&nbsp;Patrick Soon-Shiong will execute and deliver a Noncompetition and Confidentiality Agreement in substantially the form attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<U>Noncompetition and Confidentiality Agreement</U>&#148;), which will
become effective at the Effective Time (as hereinafter defined), and (ii)&nbsp;as of or prior to the Closing, Parent and a trustee mutually agreeable to Parent and the Company (the &#147;<U>Trustee</U>&#148;) will enter into a Contingent Value
Rights Agreement in substantially the form attached hereto as <U>Exhibit&nbsp;B</U> (the &#147;<U>CVR Agreement</U>&#148; and, together with the Noncompetition and Confidentiality Agreement and the Voting Agreement, the &#147;<U>Related
Agreements</U>&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties and
agreements contained herein, the parties hereto agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE I </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE MERGER </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.1 <U>The Merger</U>. Upon the terms and subject to the conditions hereof, and in accordance with the
General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;), at the Effective Time, Sub shall be merged with and into the Company and the separate existence of Sub shall thereupon cease, and the Company, as the corporation
surviving the Merger (the &#147;<U>Surviving Corporation</U>&#148;), shall by virtue of the Merger continue its corporate existence under the laws of the State of Delaware. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.2 <U>Effective Time of the Merger</U>. The Merger shall become effective at the date and time (the
&#147;<U>Effective Time</U>&#148;) when the certificate of merger (the &#147;<U>Certificate of Merger</U>&#148;) shall have been duly executed and filed with the Secretary of State of the State of Delaware in accordance with the DGCL, or at such
other time as is specified in the Certificate of Merger in accordance with the DGCL, which Certificate of Merger shall be filed on the Closing Date as soon as practicable following the Closing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.3 <U>Certificate of Incorporation</U>. Subject to <U>Section&nbsp;6.2(a)</U>, at the Effective Time, the
amended and restated certificate of incorporation of the Company (the &#147;<U>Certificate of Incorporation</U>&#148;) shall, by virtue of the Merger, be amended and restated in a form mutually agreed and, as
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
so amended, shall be the certificate of incorporation of the Surviving Corporation, until thereafter changed or amended in accordance with its terms and as provided by Law and this Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.4 <U>By-laws</U>. Subject to <U>Section&nbsp;6.2(a)</U>, at the Effective Time, the by-laws of
Sub in effect immediately prior to the Effective Time shall be the by-laws of the Surviving Corporation, except that all references to Sub therein shall be automatically amended and replaced with references to the Surviving Corporation, until
thereafter changed or amended in accordance with their terms and as provided by Law and this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.5 <U>Board of Directors and Officers</U>. The directors of Sub and the officers of the Company in office
immediately prior to the Effective Time shall, from and after the Effective Time, be the directors and officers, respectively, of the Surviving Corporation, in each case until their respective successors have been duly elected or appointed and
qualified or until their earlier death, resignation or removal, in accordance with the Surviving Corporation&#146;s Certificate of Incorporation and by-laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.6 <U>Effects of Merger</U>. The Merger shall have the effects set forth in the DGCL. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE II </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>CONVERSION OF SHARES </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1 <U>Conversion of Shares</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Conversion of Shares</U>. As of the Effective Time, by virtue of the Merger and without any action on the part of
Parent, Sub, the Company or any holders of shares of capital stock of the Company: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Each outstanding
share of common stock, par value $0.001 per share, of the Company (the &#147;<U>Company Common Stock</U>&#148;) that is held in the treasury of the Company and any shares of Company Common Stock owned by Parent, Sub or any wholly owned subsidiary of
Parent or the Company shall be canceled and no consideration shall be delivered in exchange therefor (such shares, the &#147;<U>Excluded Company Shares</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Subject to <U>Section&nbsp;2.3</U>, each share of Company Common Stock issued and outstanding immediately prior to
the Effective Time (other than Excluded Company Shares) shall be converted into the right to receive from Parent (1)&nbsp;an amount in cash, without interest, equal to $58.00 (the &#147;<U>Cash Consideration</U>&#148;), (2)&nbsp;0. 2617 (the
&#147;<U>Exchange Ratio</U>&#148;) of a share of common stock, par value $.01 per share (the &#147;<U>Parent Common Stock</U>&#148;), of Parent (the &#147;<U>Stock Consideration</U>&#148;), and (3)&nbsp;one contingent value right (a
&#147;<U>CVR</U>&#148;) issued by Parent subject to and in accordance with the CVR Agreement (the consideration contemplated by subclauses (1), (2)&nbsp;and (3)&nbsp;together, the &#147;<U>Merger Consideration</U>&#148;). Each CVR issued as Merger
Consideration hereunder will be substantially in the form attached as Annex A to the CVR Agreement (the &#147;<U>CVR Certificate</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All such shares of Company Common Stock, when so converted, shall no longer be outstanding and shall automatically be canceled and retired, and each
holder of a certificate or certificates (the &#147;<U>Certificates</U>&#148;) representing any such shares of Company Common Stock, and each holder of non-certificated shares of Company Common Stock represented by book-entry on the records of the
Company or the Company&#146;s transfer agent (&#147;<U>Book-Entry Shares</U>&#148;), shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration, any cash in lieu of fractional shares payable pursuant to
<U>Section</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<U></U><U>2.2(e)</U> and any dividends or other distributions to which such holder is entitled pursuant to <U>Section&nbsp;2.2(d)</U>, without interest. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Each share of common stock of Sub issued and outstanding immediately prior to the Effective Time shall, by virtue of
the Merger and without any action on the part of the holder thereof, be converted into and become at the Effective Time one validly issued, fully paid and nonassessable share of common stock, par value $0.001 per share, of the Surviving Corporation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.2 <U>Payment and Exchange of Certificates</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Prior to the mailing of the proxy statement/prospectus to be included in the registration statement on Form S-4 to be
filed by Parent with the SEC (as defined in <U>Section&nbsp;3.4(a)</U>) to register the shares of Parent Common Stock and CVRs to be issued in connection with the Merger (such proxy statement/prospectus, together with any amendments or supplements
thereto, the &#147;<U>Proxy Statement/Prospectus</U>&#148;, and such registration statement, together with any amendments, supplements and exhibits thereto, the &#147;<U>Registration Statement</U>&#148;), Parent shall appoint a commercial bank or
trust company reasonably acceptable to the Company to act as paying agent hereunder (the &#147;<U>Paying Agent</U>&#148;) for the purpose of payment of the aggregate Merger Consideration to be paid and delivered to Securityholders (as defined in
<U>Section&nbsp;2.2(b)</U>) under this <U>ARTICLE II</U>. Parent will enter into a paying agent agreement in form and substance reasonably acceptable to the Company at least two Business Days prior to the mailing of the Proxy Statement/Prospectus to
the stockholders of the Company. As used herein, &#147;<U>Business Day</U>&#148; means any day of the year on which national banking institutions in New York are open to the public for conducting business and are not required or authorized to close.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) At the Closing, Parent shall deposit, or cause to be deposited, with the Paying Agent (i)&nbsp;cash in an
amount sufficient to pay the aggregate Cash Consideration (ii)&nbsp;certificates representing a number of shares of Parent Common Stock equal to the Exchange Ratio multiplied by the number of outstanding shares of Company Common Stock held by
holders (collectively, the &#147;<U>Securityholders</U>&#148;) of all shares of Company Common Stock (other than Excluded Company Shares and Dissenting Company Shares), and (iii)&nbsp;CVR Certificates representing the aggregate number of CVRs
issuable pursuant to the CVR Agreement in accordance with <U>Section&nbsp;2.1(a)(ii)</U> to which the Securityholders will become entitled under this ARTICLE II at the Effective Time. Parent further agrees to deposit, or cause to be deposited, with
the Paying Agent, from time to time as needed, immediately available funds sufficient to pay cash in lieu of fractional shares pursuant to <U>Section&nbsp;2.2(e)</U> and any dividends and other distributions pursuant to <U>Section&nbsp;2.2(d)</U>.
The aggregate amount of such Cash Consideration and other cash amounts, certificates representing shares of Parent Common Stock and CVRs deposited with the Paying Agent is referred to herein as the &#147;<U>Exchange Fund</U>.&#148; The Paying Agent
shall cause the Exchange Fund to be (1)&nbsp;held for the benefit of the Securityholders and (2)&nbsp;promptly applied to making the payments and deliveries provided for in this <U>ARTICLE II</U>. The Exchange Fund shall not be used for any purpose
that is not provided for herein. The Paying Agent shall invest any cash included in the Exchange Fund as directed by Parent, in direct obligations of the United States of America or obligations for which the full faith and credit of the United
States of America is pledged to provide for the payment of all principal and interest, or a combination thereof. Any interest and other income resulting from such investments shall be kept in the Exchange Fund. To the extent that there are losses
with respect to such investments, or the Exchange Fund diminishes for other reasons below the level required to make prompt payments of the aggregate cash consideration to be paid to Securityholders as contemplated hereby, Parent shall promptly
replace or restore the portion of the Exchange Fund lost through investments or other events so as to ensure that the Exchange Fund is, at all times, maintained at a level sufficient to make such payments. Any portion of the Exchange Fund (including
the proceeds of any interest and other income received by the Paying Agent in respect of such funds) that remains undistributed to the Securityholders one year after the Effective Time of the Merger shall be delivered to
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Parent at such time. Thereafter, Securityholders shall look only to Parent (subject to the terms of this Agreement and to abandoned property, escheat or other similar Laws) as a general creditor
for payment of the consideration payable to them under this <U>ARTICLE&nbsp;II</U>, without interest, upon the surrender of any Certificates held by them. Notwithstanding any provision of this Agreement to the contrary, none of the Paying Agent,
Parent, the Surviving Corporation or any other party hereto shall be liable to any Person for any amount properly paid to a public official pursuant to any applicable abandoned property, escheat or other similar Law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) As soon as practicable (but in any event within two Business Days) after the Effective Time, Parent shall cause the
Paying Agent to mail to each holder of record of shares of Company Common Stock represented by Certificates and to each holder of Book-Entry Shares, other than Excluded Company Shares and Dissenting Company Shares: (i)&nbsp;a letter of transmittal
(which shall specify that delivery shall be effected, and risk of loss and title to the Certificates or Book-Entry Shares shall pass, only upon actual delivery of the Certificates or transfer of Book-Entry Shares, as the case may be, to the Paying
Agent and shall be in a form reasonably agreed upon by Parent and the Company prior to the Closing); and (ii)&nbsp;instructions for use in effecting the surrender of the Certificates or transfer of Book-Entry Shares, as the case may be, in exchange
for the Merger Consideration. Upon surrender of a Certificate (or delivery of such customary affidavits and indemnities with respect to a lost Certificate which the Paying Agent and/or the Company&#146;s transfer agent may reasonably require) or
transfer of Book-Entry Shares for cancellation to the Paying Agent, together with such letter of transmittal duly executed and in proper form, and such other documents as may reasonably be required by the Paying Agent, the holder of such Certificate
or Book-Entry Shares shall be entitled to receive in exchange therefor the Merger Consideration into which the shares of Company Common Stock theretofore represented by such Certificate or Book-Entry Shares shall have been converted pursuant to
<U>Section&nbsp;2.1</U>, any cash in lieu of fractional shares payable pursuant to <U>Section&nbsp;2.2(e)</U> and any dividends or other distributions to which such holder is entitled pursuant to <U>Section&nbsp;2.2(d)</U>, and the Certificates so
surrendered or Book-Entry Shares so transferred shall forthwith be canceled. No interest will be paid or will accrue on the Merger Consideration, cash in lieu of fractional shares payable pursuant to <U>Section&nbsp;2.2(e)</U> or dividends or other
distributions to which such holder is entitled pursuant to <U>Section&nbsp;2.2(d)</U>, payable upon the surrender of any Certificate or transfer of Book-Entry Shares. In the event of a transfer of ownership of Company Common Stock that is not
registered in the transfer records of the Company, payment may be made to a Person other than the Person in whose name the Certificate so surrendered is registered, if such Certificate shall be properly endorsed or otherwise be in proper form for
transfer and the Person requesting such payment shall pay any transfer or other Taxes required by reason of such Certificate and establish to the satisfaction of Parent that such Tax has been paid or is not applicable. Until surrendered or
transferred as contemplated by this <U>Section 2.2</U>, each Certificate or Book-Entry Share (other than Certificates or Book-Entry Shares representing any Dissenting Company Shares or Excluded Company Shares) shall be deemed at any time after the
Effective Time to represent only the right to receive upon such surrender or transfer the amount of Merger Consideration, without interest, into which the shares of Company Common Stock theretofore represented by such Certificate or Book-Entry
Shares shall have been converted pursuant to <U>Section&nbsp;2.1</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) No dividends or other distributions
declared or made after the Effective Time with respect to Parent Common Stock, with a record date after the Effective Time, shall be paid to the holder of any unsurrendered Certificate, and no cash payment in lieu of fractional shares shall be paid
to any such holder pursuant to <U>Section&nbsp;2.2(e)</U>, unless and until the holder of such Certificate shall surrender such Certificate in accordance with <U>Section&nbsp;2.2(c)</U>. Subject to the effect of escheat, Tax or other applicable
Laws, following surrender of any such Certificate, there shall be paid to the holder of the certificates representing whole shares of Parent Common Stock issued in exchange therefor, without interest, (i)&nbsp;the amount of any cash payable with
respect to a fractional share of Parent Common Stock to which such holder is entitled pursuant to <U>Section&nbsp;2.2(e)</U> and the amount of dividends or other distributions with a </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
record date after the Effective Time theretofore paid with respect to such whole shares of Parent Common Stock and (ii)&nbsp;at the appropriate payment date, the amount of dividends or other
distributions, with a record date after the Effective Time but prior to surrender and a payment date occurring after surrender, payable with respect to such whole shares of Parent Common Stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) No certificates or scrip representing fractional shares of Parent Common Stock, or book-entry credit of the same,
shall be issued upon the surrender for exchange of Certificates, no dividend or distribution with respect to Parent Common Stock shall be payable on or with respect to any fractional share and such fractional share interests shall not entitle the
owner thereof to any rights of a stockholder of Parent. For purposes of this <U>Section&nbsp;2.2(e)</U>, all fractional shares to which a single holder of shares of Company Common Stock would be entitled shall be aggregated and calculations shall be
rounded to the fourth decimal point. In lieu of any such fractional share of Parent Common Stock, each holder of Company Common Stock otherwise entitled to a fraction of a share of Parent Common Stock will be entitled to receive from the Paying
Agent a cash payment in an amount, rounded up to the nearest cent, equal to the product of (i)&nbsp;such fractional part of a share of Parent Common Stock multiplied by (ii)&nbsp;an amount equal to the average of the closing sale prices for Parent
Common Stock on NASDAQ, as reported in The Wall Street Journal, for each of the ten consecutive trading days ending with the seventh complete trading day prior to the Effective Time (the &#147;<U>Parent Share Cash Value</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.3 <U>Dissenting Company Shares</U>. Notwithstanding any provision of this Agreement to the contrary,
shares of Company Common Stock which are issued and outstanding immediately prior to the Effective Time and which are held by holders who have properly exercised appraisal rights with respect thereto in accordance with Section&nbsp;262 of the DGCL
(the &#147;<U>Dissenting Company Shares</U>&#148;) will not be converted as described in <U>Section&nbsp;2.1(a)(ii)</U>, and holders of such shares will be entitled to receive payment of the value of such shares determined in accordance with the
applicable provisions of the DGCL. Notwithstanding the foregoing, if, after the Effective Time, any such holder fails to perfect or effectively withdraws or loses its right to appraisal and payment under the DGCL, the shares of Company Common Stock
held by such holder that were Dissenting Company Shares will thereupon be treated as if they had been converted into, at the Effective Time, the right to receive the Merger Consideration, any cash in lieu of fractional shares payable pursuant to
<U>Section&nbsp;2.2(e)</U> and any dividends or other distributions to which such holder is entitled pursuant to <U>Section&nbsp;2.2(d)</U>, without any interest thereon. Upon the Company&#146;s receipt of any notice of intent to demand payment in
accordance with the provisions of the DGCL, or any withdrawal of such notice, and any other instruments served pursuant to Section&nbsp;262 of the DGCL and received by the Company, the Company shall as promptly as reasonably practicable provide
Parent with a copy of such notice or instrument. The Company shall give Parent the opportunity to participate in and control all negotiations and proceedings with respect to the exercise of dissenters&#146; rights under Section&nbsp;262 of the DGCL.
The Company, on the one hand, and Parent, prior to the Closing, on the other hand, shall not, except with the prior written consent of the other party hereto or pursuant to a court order, make any payment with respect to any such election to dissent
or offer to settle or settle any such election to dissent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.4 <U>No Further Ownership Rights in
the Shares</U>. From and after the Effective Time, the holders of shares of Company Common Stock which were outstanding immediately prior to the Effective Time shall cease to have any rights with respect to such shares except as otherwise provided
in this Agreement or by applicable Law. All cash paid (including pursuant to <U>Section&nbsp;2.2(d)</U> or <U>Section&nbsp;2.2(e)</U>) and all shares of Parent Common Stock and CVR Certificates issued upon the surrender of Certificates and
Book-Entry Shares, in each case in accordance with the terms hereof, shall be deemed to have been paid and issued in full satisfaction of all rights pertaining to the shares of Company Common Stock represented by such Certificates and/or such
Book-Entry Shares, as applicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.5 <U>Closing of Company Transfer Books</U>. At the Effective
Time, the stock transfer books of the Company shall be closed and no transfer of shares of Company Common Stock outstanding immediately prior to the Effective Time shall thereafter be made. If, after the Effective Time, Certificates representing
shares of Company Common Stock outstanding immediately prior to the Effective Time are presented to the Surviving Corporation or the Paying Agent for any reason, they shall be canceled and exchanged as provided in this <U>ARTICLE II</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.6 <U>Adjustments</U>. If prior to the Effective Time there is an increase in the number of shares of
outstanding Company Common Stock or Company Common Stock subject to outstanding Options or SARs (as each such term is defined in <U>Section&nbsp;2.7</U>) as a result of a distribution, reclassification, stock split (including a reverse split), stock
dividend or distribution, recapitalization, reorganization, merger, subdivision, spin-off, issuer tender or exchange offer, or other similar transaction, the Cash Merger Consideration, the Exchange Ratio, and any other payments to Securityholders
based upon the Merger Consideration will be equitably adjusted to eliminate the effects of such event on the Merger Consideration and such other payments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.7 <U>Stock Options, RSUs, SARs</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Options</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) At least five Business Days prior to the Closing Date, each holder of an outstanding option, whether vested or
unvested (individually, an &#147;<U>Option</U>&#148; and collectively, the &#147;<U>Options</U>&#148;), that was granted under any Company stock option or equity incentive plan (&#147;<U>Company Stock Plan</U>&#148;) and that has an exercise price
per share of Company Common Stock underlying such Option (the &#147;<U>Applicable Exercise Price</U>&#148;) that is greater than the Per Share Amount shall be provided with written notice that such holder shall, during the period beginning on the
date of such notice and ending on the Business Day preceding the Closing Date (the &#147;<U>Exercise Period</U>&#148;), have the right to exercise such Option by providing the Company with a notice of exercise and a cash amount equal to (A)&nbsp;the
Applicable Exercise Price, less (B)&nbsp;the Per Share Amount, with such exercise conditioned on the occurrence of the Effective Time. Each Option that is exercised pursuant to this <U>Section&nbsp;2.7(a)(i)</U> shall be settled at the Effective
Time in exchange for, in respect of each share of Company Common Stock subject to such Option, one CVR. Any Option described in this <U>Section&nbsp;2.7(a)(i)</U> that is not exercised during the Exercise Period shall be cancelled at the Effective
Time for no consideration therefor. For purposes of this Agreement, &#147;<U>Per Share Amount</U>&#148; means the sum of (x)&nbsp;the amount obtained by multiplying (1)&nbsp;the Exchange Ratio and (2)&nbsp;the Parent Share Cash Value, with such
amount rounded up to the nearest cent, and (y)&nbsp;the Cash Consideration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Each Option that remains
outstanding immediately prior to the Effective Time and that has an Applicable Exercise Price that is equal to or less than the Per Share Amount shall be cancelled at the Effective Time in exchange for the right of the holder of such Option to
receive, for each share of Company Common Stock subject to such Option, (A)&nbsp;an amount in cash, without interest, equal to the excess, if any, of the Per Share Amount over the Applicable Exercise Price, with the aggregate amount of such payment
rounded down to the nearest cent, and (B)&nbsp;one CVR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>SARs</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) At least five Business Days prior to the Closing Date, each holder of an outstanding stock appreciation right,
whether vested or unvested (individually, a &#147;<U>SAR</U>&#148; and collectively, the &#147;<U>SARs</U>&#148;), that was granted under any Company Stock Plan and that has a base appreciation amount (the &#147;<U>Applicable SAR Base
Amount</U>&#148;) that is greater than the Per Share Amount shall be provided with written notice that such holder shall have the right to exercise such SAR during the Exercise Period by </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
providing the Company with a notice of exercise and a cash amount equal to (A)&nbsp;the Applicable SAR Base Amount, less (B)&nbsp;the Per Share Amount, with such exercise conditioned on the
occurrence of the Effective Time. Each SAR that is exercised pursuant to this <U>Section&nbsp;2.7(b)(i)</U> shall be settled at the Effective Time in exchange for one CVR. Any SAR described in this <U>Section&nbsp;2.7(b)(i)</U> that is not exercised
during the Exercise Period shall be cancelled at the Effective Time for no consideration therefor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Each
SAR that remains outstanding immediately prior to the Effective Time and that has an Applicable SAR Base Amount that is equal to or less than the Per Share Amount shall be cancelled at the Effective Time in exchange for the right of the holder of
such SAR to receive (A)&nbsp;an amount in cash, without interest, equal to the excess, if any, of the Per Share Amount over the Applicable SAR Base Amount, with the aggregate amount of such payment rounded up to the nearest cent, and (B)&nbsp;one
CVR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>RSUs</U>. Each restricted stock unit (individually, an &#147;<U>RSU</U>&#148; and collectively,
the &#147;<U>RSUs</U>&#148;) granted by the Company under any Company Stock Plan which is outstanding immediately prior to the Effective Time shall vest as of the Effective Time and shall be cancelled and converted at the Effective Time into the
right to receive, and the holder thereof shall be entitled to receive, (i)&nbsp;cash, without interest, equal to the Per Share Amount, with the aggregate amount of such payment rounded up to the nearest cent, and (ii)&nbsp;one CVR. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Payment for Awards</U>. Parent shall pay, or cause the Surviving Corporation to pay through its payroll system, to
each holder of Options, SARs and RSUs the cash payments and CVRs subject to and in accordance with this <U>Section&nbsp;2.7</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Termination of Plans; Determinations by the Board</U>. Each Company Stock Plan shall terminate as of the Effective
Time, and any other plan, program or arrangement providing for the issuance or grant of any interest in respect of the capital stock (or any interest convertible into or exchangeable for such capital stock) of the Company or any Subsidiary thereof
shall be canceled as of the Effective Time. At or prior to the Effective Time, the Company&#146;s board of directors (the &#147;<U>Board of Directors</U>&#148;) (or a committee thereof) will (i)&nbsp;adopt amendments to, or make determinations with
respect to, the Employee Benefit Plans (as defined in <U>Section&nbsp;3.10(a)</U>), the Company Stock Plans, and the individual agreements evidencing the grant of Options, SARs and RSUs, as necessary, to implement the provisions of this
<U>Section&nbsp;2.7</U> and (ii)&nbsp;take such other actions as may be reasonably requested by Parent to implement the provisions of this <U>Section&nbsp;2.7</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.8 <U>Withholding of Tax</U>. Notwithstanding anything to the contrary in this Agreement, Parent, the
Company, any Affiliate thereof (including the Surviving Corporation, as applicable), Trustee or the Paying Agent shall be entitled to deduct and withhold, or cause to be deducted and withheld, from amounts (including shares of Parent Common Stock
and CVRs) otherwise payable pursuant to this Agreement or the Related Agreements to any holder of shares of Company Common Stock, Options, SARs or RSUs, such amounts as Parent, the Company, any Affiliate thereof, Trustee or the Paying Agent is
required to deduct and withhold with respect to the making of such payment under the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), or any provision of state, local or foreign Tax Law. To the extent that amounts are so
withheld by Parent, the Company, any Affiliate thereof, Trustee or the Paying Agent, such withheld amounts shall be (a)&nbsp;paid over to the applicable Governmental Entity (as defined in <U>Section&nbsp;3.3(c)</U>) in accordance with applicable Law
and (b)&nbsp;treated for all purposes of this Agreement as having been paid to such holder in respect of which such deduction and withholding was made by Parent, the Company, any Affiliate thereof, Trustee or the Paying Agent, as the case may be.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.9 <U>Closing.</U> The closing of the transactions contemplated by this
Agreement (the &#147;<U>Closing</U>&#148;) shall take place at the offices of Fried, Frank, Harris, Shriver&nbsp;&amp; Jacobson LLP, One New York Plaza, New York, New York 10004, at 9:00 A.M. local time on the day which is no later than two Business
Days after the day on which the last of the conditions set forth in <U>ARTICLE VII</U> (other than those that can only be fulfilled at the Closing, but subject to the fulfillment or waiver of such conditions) is fulfilled or waived, or at such other
time and place as Parent and the Company shall agree in writing. The date on which the Closing is required to occur pursuant to the foregoing is referred to herein as the &#147;<U>Closing Date</U>.&#148; </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE III </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES OF THE COMPANY </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except (i)&nbsp;as disclosed in the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2009, as amended, the
Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2010 or any of the Company&#146;s Current Reports on Form 8&#150;K dated after December&nbsp;31, 2009 filed by the Company with the SEC pursuant to the Securities
Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;) prior to the date of this Agreement but excluding any disclosures contained or referenced therein under the captions &#147;Risk Factors,&#148; &#147;Forward-Looking
Statements,&#148; and &#147;Quantitative and Qualitative Disclosures About Market Risk&#148; and any other disclosures contained or referenced therein of information, factors or risks that are predictive, cautionary or forward-looking in nature, and
provided that any matters required to be disclosed for purposes of <U>Section&nbsp;3.2(a)</U> (Capital Structure), <U>Section&nbsp;3.14</U> (Intellectual Property) and <U>Section&nbsp;3.17</U> (Material Contracts) of this Agreement shall be
specifically disclosed in sections of the Disclosure Schedule pertaining thereto, or (ii)&nbsp;as set forth in the Disclosure Schedule of the Company delivered concurrent with the execution of this Agreement (the &#147;<U>Disclosure
Schedule</U>&#148;) (it being understood that any information set forth in one section or subsection of the Disclosure Schedule shall be deemed to apply to and qualify the Section or subsection of this Agreement to which it corresponds in number and
each other Section or subsection of this Agreement to the extent that it is reasonably apparent that such information is relevant to such other Section or subsection), the Company represents and warrants to Parent and Sub as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.1 <U>Organization, Standing and Power</U>. Each of the Company and its Subsidiaries (as defined in
<U>Section 9.12</U>) is a legal entity duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its properties
and assets and to carry on its business as presently conducted and is qualified to do business and is in good standing as a foreign legal entity in each jurisdiction where the ownership, leasing or operation of its assets or properties or conduct of
its business requires this qualification, except where the failure to be so organized, qualified or in good standing, or to have such power or authority, would not reasonably be expected to have a Company Material Adverse Effect. For purposes of
this Agreement, &#147;<U>Company Material Adverse Effect</U>&#148; means any change, effect, event, development, occurrence, condition or state of facts (collectively, &#147;<U>Effects</U>&#148;), that, in the aggregate with all other Effects, is,
or would reasonably be expected to be, (1)&nbsp;materially adverse to the business, assets, financial condition or results of operations of the Company and its Subsidiaries taken as a whole, or (2)&nbsp;prevent the consummation of the Merger;
provided that in no event shall any of the following, alone or in combination, be deemed to constitute, nor shall any of the following be taken into account in determining whether there has been, or there would reasonably be expected to be, a
Company Material Adverse Effect: (a)&nbsp;any Effect relating to, or resulting from, any change or developments in or to local, regional, national or foreign political, economic or financial conditions or in or to local, regional, national or
foreign credit, financial, banking or securities markets (including any disruption thereof), including any Effect caused by acts of terrorism or war or armed hostilities (whether or not declared), (b)&nbsp;any Effect affecting generally any of the
industries, geographic areas or business segments in which the Company or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any of its Subsidiaries operates, (c)&nbsp;any Effect relating to, or resulting from, any hurricane, earthquake or other natural disasters, (d)&nbsp;any change in the share price or trading
volume (as opposed to the facts underlying such change) of the Company Common Stock on the Nasdaq Global Select Market of The NASDAQ Stock Market LLC (&#147;<U>NASDAQ</U>&#148;) (provided, however, that the facts and circumstances giving rise to
such Effect that are not otherwise excluded from the definition of Company Material Adverse Effect may be considered for purposes of determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect),
(e)&nbsp;any Effect relating to, or resulting from, the adoption, implementation, promulgation, repeal, modification or proposal of any Law (as defined in <U>Section&nbsp;3.3(b)</U>) or U.S. generally accepted accounting principles (&#147;<U>U.S.
GAAP</U>&#148;), after the date of this Agreement, (f)&nbsp;any failure, in and of itself (as opposed to the facts underlying such failure), to meet any budgets, plans, projections or forecasts of the Company&#146;s or its Subsidiaries&#146;
revenue, earnings or other financial performance or results of operations, or any published financial forecasts or analyst estimates with respect to the revenue, earnings or other financial performance or results of operations of the Company or its
Subsidiaries or any change in analyst recommendations, for any period (provided, however, that the facts and circumstances giving rise to such failures that are not otherwise excluded from the definition of Company Material Adverse Effect may be
considered for purposes of determining whether there has been, or there would reasonably be expected to be, a Company Material Adverse Effect may be considered for purposes of determining whether there has been, or would reasonably be expected to
be, a Company Material Adverse Effect) or (g)&nbsp;any Effect directly relating to, or resulting from, the execution, performance or announcement of this Agreement or the Related Agreements (including the impact thereof on relationships, contractual
or otherwise, with customers, suppliers, licensors, licensees, distributors, partners or employees, the loss or departure of officers or other employees of the Company or its Subsidiaries and any pending or threatened Proceeding (as defined in
<U>Section&nbsp;3.7</U>) challenging this Agreement, any of the Related Agreements or the transactions contemplated hereby or thereby, or otherwise resulting from the pursuit of the consummation of the transactions contemplated hereby or thereby;
except that clauses (a), (b), (c)&nbsp;and (e), shall not be applicable with respect to Effects to the extent, but only to the extent, that any such Effects have had, or would reasonably be expected to have, a disproportionate impact on the Company
and its Subsidiaries, taken as a whole, relative to other participants in the industry in which the Company and its Subsidiaries operate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.2 <U>Capital Structure</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The authorized capital stock of the Company consists of 100,000,000 shares of Company Common Stock and 6,000,000
shares of preferred stock, par value $0.001 per share. As of the close of business on June&nbsp;25, 2010, (i)&nbsp;40,403,163 shares of Company Common Stock were issued and outstanding, (ii)&nbsp;no shares of preferred stock were outstanding,
(iii)&nbsp;an aggregate of 1,810,167 shares of Company Common Stock were issuable upon exercise of then outstanding Options and SARs (whether or not exercisable as of such date), and (iv)&nbsp;939,570 RSUs were outstanding. In addition to the shares
of Company Common Stock referred to in clauses (i), (iii)&nbsp;and (iv), as of the close of business on June&nbsp;25, 2010, 3,472,973 shares of Company Common Stock were available for additional grants under the Company Stock Plans. All of the
outstanding shares of Company Common Stock are validly issued and outstanding, fully paid and non assessable and free of preemptive rights. All shares of Company Common Stock subject to issuance under the Company Stock Plans, including outstanding
Options, SARs and RSUs, will upon issuance be validly issued and outstanding, fully paid and non-assessable and free of preemptive rights. <U>Section&nbsp;3.2(a)</U> of the Disclosure Schedule sets forth an accurate and complete list of the Options
and SARs outstanding as of June&nbsp;25, 2010 and the exercise or base prices thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Each Option and
SAR was validly and properly approved by the Board of Directors (or a duly authorized committee or subcommittee thereof), was granted in compliance in all material respects with all applicable legal requirements and was recorded on the
Company&#146;s financial statements in accordance with GAAP consistently applied, and no such grants involved any &#147;back </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
dating,&#148; &#147;forward dating&#148; or similar practices with respect to the effective date of grant. All Options, SARs and RSUs are in compliance in all material respects with the terms of
the applicable Company Stock Plan under which such Options, SARs and RSUs were granted. The Company has not granted any Options or SARs at an exercise or base price that represents a discount from the fair market value of the Company Common Stock
underlying such Option or SAR on the date of grant and the Company has disclosed any re-pricing of Options or SARs in the Company Financial Statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Except as otherwise set forth in this <U>Section 3.2</U>, as of the date of this Agreement, the Company has no
(i)&nbsp;outstanding stock or securities convertible into or exchangeable for any shares of its equity securities, or any outstanding rights to subscribe for or to purchase any shares of its equity securities, or any outstanding options for the
purchase thereof, (ii)&nbsp;any agreements providing for the issuance of any equity securities or any stock or securities convertible into or exchangeable for any equity securities of the Company or (iii)&nbsp;outstanding bonds, debentures, notes or
other indebtedness having the right to vote (or convertible into or exchangeable for securities having the right to vote) on any matters on which stockholders of the Company may vote. The Company is not subject to any obligation to repurchase or
otherwise acquire any shares of its equity securities or any convertible securities, rights or options of the type described in the preceding sentence (other than the acquisition of Company Common Stock, Options, SARs or RSUs upon the exercise,
settlement or forfeiture thereof). From June&nbsp;25, 2010 to the date of this Agreement, the Company has not (i)&nbsp;issued any shares of Company Common Stock except in connection with the conversion, exercise or settlement of any Options or RSUs
or (ii)&nbsp;issued or granted any options, warrants or securities convertible into or exercisable for shares of its Company Common Stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) All of the outstanding shares of capital stock or other equity securities of each Subsidiary of the Company are
validly issued, fully paid, nonassessable and free of preemptive rights and are owned directly or indirectly by the Company free and clear of any pledges, liens, charges, mortgages, encumbrances and securities interests (&#147;<U>Liens</U>&#148;)
(other than Liens arising by operation of Law, under securities Laws or under the organizational documents applicable to such Subsidiary of the Company). There are no subscriptions, options, warrants, rights, calls, contracts, voting trusts, proxies
or other arrangements to which the Company or any of its Subsidiaries is a party (other than with the Company or any of its Subsidiaries) relating to the issuance, sale, voting, transfer, ownership or other rights with respect to any shares of
capital stock or other equity securities of any Subsidiary of the Company, including any right of conversion or exchange under any outstanding securities, instrument or agreement. <U>Section&nbsp;3.2(d)</U> of the Disclosure Schedule sets forth, as
of the date of this Agreement, (i)&nbsp;for each Subsidiary of the Company, the name of such Subsidiary, together with the jurisdiction of organization or incorporation, as the case may be, of such Subsidiary and (ii)&nbsp;for each Subsidiary of the
Company that is not wholly-owned by the Company, the percentage of equity of such Subsidiary owned by the Company or any of its Subsidiaries. No Subsidiary of the Company owns any share of capital stock or other equity security of the Company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3 <U>Authority; Non-Contravention</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company has the requisite corporate power and authority to enter into this Agreement and, subject to approval of
this Agreement by the stockholders of the Company, to consummate the Merger and the transactions contemplated by this Agreement. The execution and delivery of this Agreement by the Company and the consummation by the Company of the Merger and the
transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of the Company, subject only to the receipt of the Stockholder Approval. The only vote of the stockholders of the Company necessary
to approve this Agreement, the Related Agreements, and the transactions contemplated by this Agreement and the Related Agreements is the Stockholder Approval. The Company has duly executed and delivered this Agreement and (assuming the valid
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
authorization, execution and delivery of this Agreement by Parent and Sub, as applicable) this Agreement constitutes a valid and binding obligation of the Company, enforceable against the Company
in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#146; rights and general equity principles. The Board of
Directors has unanimously determined that the transactions contemplated by this Agreement, including the Merger, and the Related Agreements, are advisable and fair to, and in the best interest of, the Company and its stockholders, adopted this
Agreement, approved the execution of this Agreement, approved and declared advisable the Merger, and resolved to recommend adoption of this Agreement by the holders of shares of Company Common Stock (subject to its right to change its recommendation
in accordance with this Agreement). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The execution and delivery of this Agreement and/or any of the
Related Agreements does not, and the consummation of the Merger and compliance with the provisions hereof and thereof will not, (i)&nbsp;conflict with, or result in any violation of, the certificate of incorporation or by-laws of the Company,
(ii)&nbsp;conflict with, or result in any violation of organizational documents of any of the Subsidiaries of the Company, (iii)&nbsp;result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give
rise to a right of termination, cancellation or acceleration of any obligation, or result in the creation of any Lien upon any of the properties or assets of the Company or any of its Subsidiaries under, or impair the Company&#146;s or any of its
Subsidiaries&#146; rights under, or alter the rights of a third party under, any provision of any agreement, note, bond, mortgage, indenture, lease or other contractual obligation (each, a &#147;<U>Contract</U>&#148;) binding on the Company or any
of its Subsidiaries or any of their properties or assets (each, a &#147;<U>Company Contract</U>&#148;), except for any such violation, breach, default or right of termination, cancellation or acceleration or Lien as to which requisite waivers or
consents have been obtained or (iv)&nbsp;assuming that the Registrations and Consents set forth in <U>Section 3.3(c)</U> are duly and timely made or obtained and that Stockholder Approval (as defined in <U>Section 7.1(a)</U>) has been duly obtained,
violate any foreign, federal, state, local or municipal laws, rules, judgments orders, regulations, statutes, ordinances, codes, decisions, injunctions, orders, decrees or requirements of any Governmental Entity (each a &#147;<U>Law</U>&#148;)
applicable to the Company or any of its Subsidiaries or their properties or assets, other than, in the case of clauses (iii)&nbsp;or (iv), any such conflict, violation, default, termination, cancellation, acceleration or Lien that would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) No
registration or filing with (each, a &#147;<U>Registration</U>&#148;) or clearance, authorization, consent or approval (each, a &#147;<U>Consent</U>&#148;) of any domestic (federal or state), or foreign court, commission, governmental body,
regulatory or administrative agency or other political subdivision thereof (each, a &#147;<U>Governmental Entity</U>&#148;) is required on the part of the Company or any of its Subsidiaries in connection with the execution and delivery of this
Agreement, the Related Agreements by the Company or the consummation by the Company of the Merger or by the Company of the other transactions contemplated hereby or thereby, except for (i)&nbsp;compliance with and filings under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the &#147;<U>HSR Act</U>&#148;), (ii)&nbsp;compliance with the provisions of the Exchange Act and the rules of any national securities exchange, (iii)&nbsp;the filing of the Certificate of Merger with
the Secretary of State of the State of Delaware and appropriate documents with the relevant authorities of other states in which the Company or any of its Subsidiaries is qualified to do business, (iv)&nbsp;such as may be required in connection with
the Taxes described in <U>Section&nbsp;6.11</U> and (v)&nbsp;such other Consents or Registrations the failure of which to be obtained or made would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.4 <U>SEC Documents</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Since January&nbsp;1, 2008, the Company has filed with, or furnished to, the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) all documents required to be filed or furnished by the Company </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
under the Securities Act or the Exchange Act (collectively, the &#147;<U>Company SEC Documents</U>&#148;). None of the Subsidiaries of the Company is, or has at any time been, subject to the
reporting requirements of Sections 13(a) and 15(d) of the Exchange Act. As of their respective dates, the Company SEC Documents complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be,
and as of their respective dates and except as amended or supplemented prior to the date hereof (or with respect to Company SEC Documents filed or furnished after the date hereof, except as amended or supplemented prior to the Closing Date), none of
the Company SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading, except that no representation is made by the Company with respect to information supplied by Parent, Sub or their respective Subsidiaries in writing for inclusion in the Proxy Statement/Prospectus. Each of the consolidated
financial statements of the Company (including, in each case, any notes thereto) included in the Company SEC Documents (collectively, the &#147;<U>Company Financial Statements</U>&#148;) have been prepared in accordance with U.S. GAAP applied on a
consistent basis during the periods involved (except as may be indicated therein or in the notes thereto) and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as at the dates thereof and
the results of their operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments and to any other adjustments set forth therein). As of the date of this Agreement, neither
the Company nor any of its Subsidiaries has any pending or unresolved comments from the SEC or any other Governmental Entity with respect to any of the Company SEC Documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) To the Knowledge of the Company, neither the Company nor any of its Subsidiaries has any liability or obligation of
any nature (whether accrued, absolute, contingent or otherwise), except for liabilities, obligations or contingencies which (i)&nbsp;are reflected, or for which reserves are established, on the consolidated balance sheet of the Company as of
March&nbsp;31, 2010, (ii)&nbsp;were incurred in the ordinary course of business since March&nbsp;31, 2010, (iii)&nbsp;would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect or (iv)&nbsp;have
been incurred in connection with the performance by the Company of its obligations under this Agreement or the transactions contemplated hereby. As of the date of this Agreement, neither the Company nor any of its Subsidiaries has any indebtedness
for borrowed money or has guaranteed indebtedness for borrowed money of another Person (other than the Company or a wholly owned Subsidiary of the Company). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Each of the principal executive officer and the principal financial officer of the Company (or each former principal
executive officer and each former principal financial officer of the Company, as applicable) has made the certifications required by Rules 13a-14 and 15d-14 promulgated under the Exchange Act or Sections 302 and 906 of the Sarbanes-Oxley Act of 2002
and the related rules and regulations promulgated thereunder (the &#147;<U>Sarbanes-Oxley Act</U>&#148;) with respect to the Company SEC Documents. For purposes of the preceding sentence, &#147;principal executive officer&#148; and &#147;principal
financial officer&#148; have the meanings ascribed to those terms under the Sarbanes-Oxley Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) To the
Knowledge of the Company, since January&nbsp;1, 2008 and prior to the date of this Agreement, none of the Company, any of its Subsidiaries or any director, officer, auditor, accountant or representative of the Company or any of its Subsidiaries has
received any substantive complaint, allegation, assertion or claim, whether written or oral, that the Company or any of its Subsidiaries has engaged in questionable accounting or auditing practices. No current or former attorney representing the
Company or any of its Subsidiaries has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees
or agents, to the current Board of Directors or any committee thereof or to any current director or executive officer of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The Company and its Subsidiaries have designed and maintain internal
controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) to provide reasonable assurances (i)&nbsp;regarding the reliability of the Company&#146;s financial reporting and the preparation of
financial statements for external purposes in accordance with U.S. GAAP (ii)&nbsp;that receipts and expenditures of the Company and its Subsidiaries are being made only in accordance with the authorization of management and directors of the Company
and such Subsidiaries and (iii)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#146;s or its Subsidiaries&#146; assets that could have a material effect on the Company&#146;s
financial statements. The Company has designed and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) to ensure that material information required to be disclosed by the
Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms and is accumulated and communicated to the
Company&#146;s management as appropriate to allow timely decisions regarding required disclosure and to make the certifications of the principal executive officer and principal financial officer of the Company required under the Exchange Act with
respect to such reports. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Neither the Company nor any of its Subsidiaries is a party to, or has any
commitment to become a party to, any joint venture, off balance sheet partnership or any similar Company Contract (including any Company Contract or arrangement relating to any transaction or relationship between or among the Company and any of its
Subsidiaries, on the one hand, and any unconsolidated affiliate, including any structured finance, special purpose or limited purpose entity or person, on the other hand, or any &#147;off balance sheet arrangements&#148; (as defined in
Item&nbsp;303(a) of Regulation S-K under the Exchange Act)), where the result, purpose or intended effect of such Company Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company or any of its
Subsidiaries in the Company&#146;s or such Subsidiary&#146;s published financial statements or other Company SEC Documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Since January&nbsp;1, 2009, the Company has not received any oral or written notification of any &#147;material
weakness&#148; in the Company&#146;s internal control over financial reporting. There is no outstanding &#147;significant deficiency&#148; or &#147;material weakness&#148; that the Company&#146;s independent accountants certify has not been
appropriately and adequately remedied by the Company. For purposes of this Agreement, the terms &#147;significant deficiency&#148; and &#147;material weakness&#148; shall have the meanings assigned to them in Release No.&nbsp;2007-005 of the Public
Company Accounting Oversight Board, as in effect on the date hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.5 <U>Proxy
Statement/Prospectus and Registration Statement</U>. None of the information supplied or to be supplied by the Company for inclusion or incorporation by reference in the Registration Statement or the Proxy Statement/Prospectus, at the time the
Registration Statement becomes effective under the Securities Act, at the time the Proxy Statement/Prospectus is mailed to stockholders of the Company and at the time of the Company Stockholders Meeting, will contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, except that no representation is made by
the Company with respect to information supplied by Parent or Sub in writing expressly for inclusion in any of such documents. The Proxy Statement/Prospectus and the Registration Statement shall each comply in all material respects with the
requirements of the Securities Act and the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.6 <U>Absence of Certain Events</U>.
From March&nbsp;31, 2010 to the date of this Agreement, (i)&nbsp;the Company and its Subsidiaries have conducted their operations in all material respects in the ordinary course of business, (ii)&nbsp;there has not occurred any Effect that,
individually or in the </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
aggregate with all other Effects, has had, or would reasonably be expected to have, a Company Material Adverse Effect, and (iii)&nbsp;there has not been any action taken by the Company or any of
its Subsidiaries that, if taken after the date of this Agreement, would constitute a breach of <U>Section&nbsp;5.1(a)</U>, <U>(c</U>), <U>(d</U>), <U>(e</U>), <U>(f</U>), <U>(g</U>), <U>(h</U>), <U>(k</U>), <U>(l</U>), <U>(o</U>), <U>(p</U>),
<U>(q)</U>&nbsp;or <U>(r</U>). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.7 <U>Litigation</U>. There is no material suit, action,
arbitration, proceeding, claim, charge, regulatory or accrediting agency investigation or other proceeding (each, a &#147;<U>Proceeding</U>&#148;) pending or, to the Knowledge of the Company (as defined in <U>Section 9.14</U>), threatened against
the Company or any of its Subsidiaries or any property or asset of the Company or any of its Subsidiaries. None of the Company or any of its Subsidiaries is subject to any writ, judgment, settlement agreement, injunction or decree that would
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.8 <U>No Violation of Law</U>. Neither the Company nor any of its Subsidiaries is or since January&nbsp;1,
2008 has been in material violation of any Law. To the Knowledge of the Company, no material investigation or review by any Governmental Entity is pending or threatened against the Company or any of its Subsidiaries. The Company and its Subsidiaries
have all material permits, licenses, franchises, variances, exemptions, orders and other governmental authorizations, consents and approvals necessary to conduct its businesses in all material respects as presently conducted (collectively, the
&#147;<U>Company Permits</U>&#148;). None of the Company or any of its Subsidiaries is in violation of the terms of any Company Permit, except for delays in filing reports or violations which would not reasonably be expected to have, individually or
in the aggregate, a Company Material Adverse Effect. This <U>Section&nbsp;3.8</U> does not relate to matters which are the subject of <U>Section&nbsp;3.10</U> or <U>Section&nbsp;3.12</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9 <U>Taxes</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except as would not be material to the Company, (i)&nbsp;the Company and its Subsidiaries have timely filed or have
had timely filed on their behalf (taking into account extensions of time to file) all Tax Returns required to be filed by them, and such Tax Returns are correct and complete in all respects, (ii)&nbsp;the Company and its Subsidiaries have paid (or
have had paid on their behalf) all Taxes due and payable with respect to such Tax Returns, except with respect to Taxes for which adequate reserves have been established in accordance with U.S. GAAP on the most recent financial statements of the
Company or its Subsidiaries, (iii)&nbsp;the Company and its Subsidiaries have withheld or collected, and have paid over to the appropriate Governmental Entities (or are properly holding for such payment), all Taxes required to be withheld or
collected, (iv)&nbsp;neither the Company nor any of its Subsidiaries has received any written notice of any pending or ongoing audit, investigation, assessment, deficiency, or claim with respect to Taxes (including any Taxes described in clause
(viii)(B) of this <U>Section&nbsp;3.9(a)</U>) which remains unresolved, (v)&nbsp;there are no Liens on any of the assets of the Company or any of its Subsidiaries that arose in connection with any failure or alleged failure to pay Taxes (other than
Taxes not yet due and payable, or Taxes for which adequate reserves have been established in accordance with U.S. GAAP on the most recent financial statements of the Company or its Subsidiaries), (vi)&nbsp;neither the Company nor any of its
Subsidiaries has incurred any liability for Taxes subsequent to the date of its most recent respective financial statements other than in the ordinary course of business, (vii)&nbsp;no written claim has been received by the Company or its
Subsidiaries from any Governmental Entity in a jurisdiction where the Company or any of its Subsidiaries does not file Tax Returns that the Company or any of its Subsidiaries is or may be subject to taxation in that jurisdiction, (viii)&nbsp;with
the exception of the affiliated group of which the Company is the parent within the meaning of Section&nbsp;1504 of the Code, neither the Company nor any of its Subsidiaries (A)&nbsp;is or has ever been a member of an affiliated group filing a
consolidated federal income Tax Return or (B)&nbsp;has any liability for the Taxes of any Person (other than the Company and its Subsidiaries) under Section&nbsp;1.1502-6 of the Treasury Regulations (or any similar provision of Law), as a transferee
or successor, by contract, or otherwise, (ix)&nbsp;neither the Company nor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any of its Subsidiaries is a party to, has participated in, or is currently participating in, a &#147;tax shelter&#148; or &#147;listed transaction&#148; as defined in Section&nbsp;6111 of the
Code or a &#147;reportable transaction&#148; within the meaning of Section&nbsp;1.6011-4(b) of the Treasury Regulations or any transaction requiring disclosure under a corresponding or similar provision of state, local or foreign Law,
(x)&nbsp;neither the Company nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Effective Time as a result
of any (A)&nbsp;change in the method of accounting for a taxable period ending on or prior to the Effective Time, (B)&nbsp;&#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of
state, local or foreign Tax Law) executed prior to the Effective Time, (C)&nbsp;installment sale or open transaction disposition made prior to the Effective Time, or (D)&nbsp;prepaid amount received prior to the Effective Time, and (xi)&nbsp;the
Company is not now, nor has it ever been, a &#147;United States real property holding corporation&#148; within the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Neither the Company nor any of its Subsidiaries is a party to any agreement providing for the allocation
or sharing of Taxes with any entity (other than the Company or any of its Subsidiaries). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Without regard
to the execution of this Agreement and the consummation of the transactions contemplated by this Agreement and the Related Agreements, the 2007 Spin-Off qualified for nonrecognition treatment under Sections 355(a) and 361(c) of the Code. The Company
has not constituted either a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; (within the meaning of Section&nbsp;355 or Section&nbsp;361 of the Code) in a distribution of stock purported to or intended to be governed by
Section&nbsp;355 or Section&nbsp;361 of the Code in any transaction other than the 2007 Spin-Off. Neither the Company or its Subsidiaries, nor any of their respective stockholders, has received, as a result of its rights under Section&nbsp;3.01 of
the 2007 Tax Allocation Agreement or otherwise, any notice of, or is otherwise aware of, any pending or ongoing audit, investigation, review, assessment, deficiency, or claim with respect to Taxes related to the qualification of the 2007 Spin-Off
for nonrecognition treatment under Sections 355(a) and 361(c) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Neither the Company nor any of
its Subsidiaries has any deferred intercompany gain, excess loss account or gain recognition agreement in effect under any applicable U.S., state, local or foreign Tax Law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) None of the Tax Returns of the Company or any of its Subsidiaries contains any position that is, or would be, subject
to material penalties under Section&nbsp;6662 of the Code (or any corresponding provisions of state, local, or foreign Tax Law). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) For purposes of this Agreement: &#147;<U>Tax</U>&#148; means any federal, state, local or foreign income, profits,
gross receipts, license, payroll, employment, severance, stamp, occupation, premium, windfall profits, environmental, customs duty, capital stock, franchise, sales, social security, unemployment, disability, use, property, withholding, excise,
transfer, registration, production, value added, alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, together with any interest, penalty or addition thereto, imposed by any Governmental Entity responsible for the
imposition of any such tax, whether disputed or not; &#147;<U>Tax Return</U>&#148; means any return, report, declaration, claim or other statement (including attached schedules) relating to Taxes; &#147;<U>2007 Tax Allocation Agreement</U>&#148;
means that certain Tax Allocation Agreement entered into by the Company, APP Pharmaceuticals, Inc., APP Pharmaceuticals, LLC and Abraxis BioScience, LLC and dated November&nbsp;13, 2007; &#147;<U>2007 Separation and Distribution Agreement</U>&#148;
means that certain Separation and Distribution Agreement entered into by the Company, APP Pharmaceuticals, Inc., APP Pharmaceuticals, LLC and Abraxis BioScience, LLC and dated November&nbsp;13, 2007; and &#147;<U>2007 Spin-Off</U>&#148; means the
distribution by </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
APP Pharmaceuticals, Inc. to its stockholders, on November&nbsp;13, 2007, of all of the then-issued and outstanding shares of common stock of the Company pursuant to the 2007 Separation and
Distribution Agreement, and the transactions entered into therewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.10 <U>Employee Benefit Plans; ERISA</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Section 3.10(a)</U> of the Disclosure Schedule includes a complete list as of the date of this
Agreement of (i)&nbsp;each material employee benefit plan, program or policy providing benefits to any current or former employee, officer, director, independent contractor or consultant of the Company or its Subsidiaries, or any beneficiary or
dependent thereof, that is sponsored or maintained by the Company or any of its Subsidiaries or any trade or business (whether or not incorporated) under common control with the Company or any of its Subsidiaries and which, together with the Company
or any of its Subsidiaries, is treated as a single employer within the meaning of Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code (an &#147;<U>ERISA Affiliate</U>&#148;) or with respect to which the Company or any of its Subsidiaries or
ERISA Affiliates has any current or potential material liability, including any employee welfare benefit plan within the meaning of Section&nbsp;3(1) of the Employee Retirement Income Security Act of 1974, as amended (&#147;<U>ERISA</U>&#148;), any
employee pension benefit plan within the meaning of Section&nbsp;3(2) of ERISA (whether or not such plan is subject to ERISA) and any material bonus, incentive, deferred compensation, vacation, stock purchase, stock option, severance, employment,
change of control or fringe benefit plan, program or policy (collectively, the &#147;<U>Employee Benefit Plans</U>&#148;) (but excluding, for all purposes of this Agreement other than <U>Section&nbsp;6.6</U> and <U>Section&nbsp;3.10(h)</U> hereof,
any Employee Benefit Plan that is primarily subject to the Laws of any jurisdiction outside of the United States), (ii)&nbsp;each employment and severance agreement pursuant to which the Company or any of its Subsidiaries has or would have any
obligation to provide compensation and/or benefits in an amount or having a value reasonably likely to be in excess of $200,000 per year or $500,000 in the aggregate; and (iii)&nbsp;any agreement which prohibits the Company or any of its
Subsidiaries from terminating the employment of any employee on an at-will basis (which means that their employment cannot be terminated at any time, with or without notice, for any reason or no reason at all and/or they have been granted the right
to continued employment by the Company, its Subsidiaries, or any successor) (each agreement referenced in (ii)&nbsp;and (iii), a &#147;<U>Material Employment Agreement</U>&#148;). As of the date of this Agreement, neither the Company nor any of its
Subsidiaries has agreed or committed to institute any material plan, program, arrangement or agreement for the benefit of employees or former employees of the Company or its Subsidiaries other than the Employee Benefit Plans or Material Employment
Agreements or to make any amendments to any of the Employee Benefit Plans or Material Employment Agreements, and the Company and/or its Subsidiaries, as applicable, have reserved all rights necessary to amend or terminate each Employee Benefit Plan
with regard to their respective service providers without the consent of any other person. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) With respect
to each Employee Benefit Plan, the Company has delivered or made available to Parent a true, correct and complete copy of: (i)&nbsp;all plan documents and trust agreements; (ii)&nbsp;the most recent Annual Report (Form 5500 Series) and accompanying
schedule, if any; (iii)&nbsp;the current summary plan description, if any; (iv)&nbsp;the most recent annual financial report, if any; (v)&nbsp;the most recent actuarial report, if any; and (vi)&nbsp;the most recent determination letter from the
Internal Revenue Service (&#147;<U>IRS</U>&#148;), if any. The Company has delivered or made available to Parent a true, correct and complete copy of each Material Employment Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company has an IRS determination letter or opinion letter with respect to each Employee Benefit Plan that is
intended to be a &#147;qualified plan&#148; within the meaning of Section&nbsp;401(a) of the Code, and the trust maintained pursuant thereto has been determined to be so qualified and exempt from federal income taxation under Section&nbsp;501 of the
Code by the IRS, and to the Knowledge of the Company, nothing has occurred with respect to the operation of any such Employee Benefit Plan that </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
would reasonably be expected to cause the loss of such qualification or exemption from Tax that cannot be corrected without material liability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse
Effect (i)&nbsp;each Employee Benefit Plan and each Material Employment Agreement has been administered in accordance with its terms and the applicable provisions of ERISA, the Code and other applicable Laws and (ii)&nbsp;neither the Company nor any
of its Subsidiaries has engaged in any &#147;prohibited transaction&#148; (as defined in Section&nbsp;4975 of the Code or Section&nbsp;406 of ERISA) with respect to any Employee Benefit Plan which could subject the Company or any of its Subsidiaries
to any tax or penalty imposed under Section&nbsp;4975 of the Code or Section&nbsp;502 of ERISA, and no Proceeding has been brought, or to the Knowledge of the Company is threatened, against or with respect to any such Employee Benefit Plan,
including any audit or inquiry by the IRS or United States Department of Labor (other than routine benefits claims). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Except as set forth in <U>Section&nbsp;3.10(e)</U> of the Disclosure Schedule, neither the execution and delivery of
this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in conjunction with any other event) (i)&nbsp;constitute an event under an Employee Benefit Plan or a Material Employment Agreement that will result
in, cause the accelerated vesting, funding or delivery of, or increase the amount or value of, any material payment or benefit to any employee, officer or director of the Company or any of its Subsidiaries or (ii)&nbsp;could reasonably be expected
to cause any material amount to fail to be deductible under Section&nbsp;280G of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Neither the
Company nor any Subsidiary or ERISA Affiliate has ever (i)&nbsp;maintained an Employee Benefit Plan or any other plan, program or arrangement that (A)&nbsp;was subject to Section&nbsp;412 of the Code or Title IV of ERISA, (B)&nbsp;is a
&#147;multiple employer plan&#148; (as defined in Section&nbsp;210(a) of ERISA), or had any liability with respect to such a plan, program or arrangement or (C)&nbsp;is funded through or maintained by a &#147;voluntary employees&#146; beneficiary
association&#148; within the meaning of Section&nbsp;501(c)(9) of the Code, or a &#147;welfare benefit fund&#148; as defined in Section&nbsp;419(e) of the Code or a supplemental unemployment benefit plan within the meaning of Section&nbsp;501(c)(17)
of the Code or (ii)&nbsp;been obligated to contribute to a &#147;multiemployer plan&#148; (as defined in Section&nbsp;4001(a)(3) of ERISA). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Except as required by Law or as provided in a Material Employment Agreement, upon a severance event, no Employee
Benefit Plan provides any retiree or post-employment health, disability, life insurance or other welfare benefits (whether or not insured) to any Person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) The term &#147;<U>Foreign Plan</U>&#148; shall mean any Employee Benefit Plan or Material Employment Contract that is
maintained pursuant to the laws of any country other than the United States. Each Foreign Plan complies with all applicable Law (including applicable Law regarding the form, funding and operation of the Foreign Plan) in all material respects. The
Company Financial Statements accurately reflect the material Foreign Plan liabilities and accruals for contributions required to be paid to the Foreign Plans, in accordance with applicable generally accepted accounting principles consistently
applied. All material contributions required to have been made to all Foreign Plans as of the Closing will have been made as of the Closing. There are no material actions, suits or claims pending or, to the Knowledge of the Company, threatened with
respect to the Foreign Plans (other than routine claims for benefits). There have not occurred, nor are there continuing any transactions or breaches of fiduciary duty under applicable Law with respect to any Foreign Plan which would reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse Effect. With respect to each Foreign Plan, there are (A)&nbsp;no pending material investigations by any Governmental Entity, (B)&nbsp;no material claims pending or, to
the Knowledge of the Company, threatened in writing (except for claims for benefits payable in the normal operation of such plan) and (C)&nbsp;no material suits or proceedings against such plan or asserting any rights or claims to benefits under
such plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.11 <U>Employment Matters</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or any other
labor-related agreement with any labor union, labor organization or works council. As of the date of this Agreement, (i)&nbsp;no such agreement is presently being negotiated by the Company or any of its Subsidiaries, (ii)&nbsp;no labor union, labor
organization or works council has made a pending demand of the Company or any of its Subsidiaries for recognition or certification, (iii)&nbsp;there are no representation or certification proceedings or petitions seeking a representation proceeding
with respect to the Company or any of its Subsidiaries presently pending or, to the Knowledge of the Company, threatened in writing to be brought or filed with the National Labor Relations Board or any other labor relations tribunal or authority,
(iv)&nbsp;to the Knowledge of Company, there are no labor union organizing activities with respect to any employees of the Company or its Subsidiaries and (v)&nbsp;there are no threatened, labor strikes, slowdowns, work stoppages, lockouts, or any
similar activity, by employees of the Company or its Subsidiaries. None of the Company or any of its Subsidiaries has experienced any strike, lockout or work stoppage or other material labor difficulty involving its employees since January&nbsp;1,
2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company and its Subsidiaries are in compliance in all material respects with all Laws
respecting employment and employment practices, harassment, discrimination, retaliation, terms and conditions of employment, immigration, workers&#146; compensation, long term disability, occupational safety, plant closings, compensation and
benefits, wages and hours, proper classification of employees and independent contractors, and the payment of social security and other Taxes (&#147;<U>Employment Practices</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Except as indicated in <U>Section&nbsp;3.11(c)</U> of the Disclosure Schedule, (i)&nbsp;there are no material
Proceedings pending or, to the Knowledge of the Company, threatened involving any individuals providing services as an employee or independent contractor to the Company and/or any of its Subsidiaries (collectively &#147;<U>Worker</U>&#148; or
&#147;<U>Workers</U>&#148;), group of Workers, or individual and (ii)&nbsp;there are no material Proceedings relating to any Employment Practices pending, or to the Knowledge of the Company, threatened, before the Equal Employment Opportunity
Commission, the National Labor Relations Board, the U.S. Department of Labor, the U.S. Occupational Health and Safety Administration, the Workers Compensation Appeals Board, or any other Governmental Authority against the Company or any of its
Subsidiaries pertaining to any Worker, nor, to the Knowledge of the Company, are there any facts or circumstances which would reasonably be expected to give rise to such a claim being made. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) To the Knowledge of the Company, neither the Company nor any of its Subsidiaries are delinquent in any material
payments to any current or former Worker for any wages, salaries, commissions, bonuses, or other compensation for any services performed by any current or former Worker or for any other amounts required to be reimbursed by the Company or any of its
Subsidiaries to any current or former Worker (including vacation, sick leave, other paid time off or severance pay). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) (i) The Company and its Subsidiaries are in compliance in all material respects with the Worker Readjustment and
Notification Act (the &#147;<U>WARN Act</U>&#148;) (29 USC &#167;2101) and any applicable state laws or other Laws regarding redundancies, reductions in force, mass layoffs, and plant closings, including all obligations to promptly and correctly
furnish all notices required to be given thereunder in connection with any redundancy, reduction in force, mass layoff, or plant closing to affected employees, representatives, any state dislocated worker unit and local government officials, or any
other governmental authority, (ii)&nbsp;neither the Company nor any of its Subsidiaries have taken any action that would constitute a &#147;mass layoff&#148; or &#147;plant closing&#148; within the meaning of the WARN Act or would otherwise trigger
notice requirements or liability under any other comparable state or local law in the </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
United States and (iii)&nbsp;neither the Company nor any of its Subsidiaries have taken any action that resulted in the termination of employment of 50 or more employees or more than 10% of the
employees in any country outside of the United States during any 90 day period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) As of the date of this
Agreement, to the Knowledge of the Company, no employee of the Company or any of its Subsidiaries is in violation in any material respect of any term of any employment agreement, non-disclosure or confidentiality agreement with the Company or any of
its Subsidiaries or non-competition agreement, non-solicitation agreement or any restrictive covenant with a former employer relating to the right of any such employee to be employed by or provide services to the Company or any of its Subsidiaries
because of the nature of the business conducted or presently proposed to be conducted by it or to the use of trade secrets or proprietary information of others. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.12 <U>Environmental Matters</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except as otherwise set forth in <U>Section&nbsp;3.12</U> of the Disclosure Schedule, (i)&nbsp;to the Knowledge of
the Company, the Company and its Subsidiaries are and have been since January&nbsp;1, 2008 in material compliance with all applicable Environmental Laws (as defined in <U>Section&nbsp;3.12(c)</U>), (ii)&nbsp;there are no pending or, to the Knowledge
of the Company, threatened, material Proceedings under or pursuant to Environmental Laws against the Company or any of its Subsidiaries or, to the Knowledge of the Company, any other Person whose Environmental Liabilities the Company or any of its
Subsidiaries has or may have retained or assumed by contract or operation of Law, or involving any real property currently or, to the Knowledge of the Company, formerly owned, operated or leased by the Company or its Subsidiaries; (iii)&nbsp;the
Company and its Subsidiaries and, to the Knowledge of the Company, Persons whose Environmental Liabilities the Company or its Subsidiaries has or may have retained or assumed by contract or operation of Law are not subject to any material
Environmental Liabilities; and (iv)&nbsp;to the Knowledge of the Company, there are no actions, activities, circumstances, conditions, events or incidents, including the release, threatened release or presence of any Hazardous Material (as defined
in <U>Section&nbsp;3.12(c)</U>), which could reasonably be expected to form the basis of any such material Environmental Liability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company has delivered to or otherwise made available for inspection by Parent true, correct and complete copies
and results of any reports, studies, analyses, tests or monitoring initiated by the Company or its Subsidiaries since January&nbsp;1, 2008 pertaining to Hazardous Materials in, on, beneath or adjacent to any property currently or formerly owned,
operated or leased by the Company or any of its Subsidiaries, or regarding the Company&#146;s or its Subsidiaries&#146; compliance with applicable Environmental Laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) As used herein, &#147;<U>Environmental Laws</U>&#148; means any and all Laws concerning pollution, Hazardous
Materials (as defined below) or the protection of human health or safety, or the environment, and includes the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section&nbsp;9601 <I>et seq</I>., the Hazardous Materials
Transportation Act, 49 U.S.C. Section&nbsp;1801 <I>et seq</I>., the Resource Conservation and Recovery Act, 42 U.S.C. Section&nbsp;6901 <I>et seq</I>., the Clean Water Act, 33 U.S.C. Section&nbsp;1251 <I>et seq</I>., the Clean Air Act, 33 U.S.C.
Section&nbsp;2601 <I>et seq</I>., the Toxic Substances Control Act, 15 U.S.C. Section&nbsp;2601 <I>et seq</I>., the Occupational Safety and Health Act, 29 U.S.C. Section&nbsp;651 <I>et seq</I>. (but solely as it relates to the exposure of Hazardous
Materials) and the Oil Pollution Act of 1990, 33 U.S.C. Section&nbsp;2701 <I>et seq</I>., as such laws have been amended or supplemented, and the regulations promulgated pursuant thereto, and all analogous state or local statutes. As used in this
Agreement, &#147;<U>Environmental Liabilities</U>&#148; with respect to any Person means any and all liabilities of or relating to such Person (including any entity which is, in whole or in part, a predecessor of such Person), whether vested or
unvested, contingent or fixed, actual or potential, known or unknown, which arise under or relate to the presence, release or threatened release of any Hazardous Materials at any location or </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which otherwise arise under or relate to matters covered or regulated by, or for which liability is imposed under, Environmental Laws, including the alleged violation of any Environmental Law. As
used in this Agreement, &#147;<U>Hazardous Materials</U>&#148; means all substances defined in, regulated under or for which liability is imposed by Environmental Laws, including hazardous substances, oils, pollutants or contaminants, asbestos,
mold, polychlorinated biphenyls and radioactive materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The representations and warranties in this
<U>Section&nbsp;3.12</U> constitute the sole representations and warranties of the Company in this Agreement concerning Environmental Laws and Hazardous Materials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.13 <U>Affiliate Transactions</U>. As of the date of this Agreement, there are no transactions, agreements,
arrangements or understandings between the Company or its Subsidiaries, on the one hand, and the Company&#146;s Affiliates (other than wholly-owned Subsidiaries of the Company) or other Persons on the other hand, that would be required to be
disclosed under Item&nbsp;404 of Regulation S-K under the Securities Act. For purposes of this Agreement, the term &#147;<U>Affiliate</U>&#148; when used with respect to any Person, means any other Person directly or indirectly controlling,
controlled by, or under common control with such Person. As used in the definition of Affiliate the term &#147;<U>control</U>&#148; means possession, directly or indirectly, of the power to direct or cause the direction of the management or policies
of a Person, whether through the ownership of voting securities, by contract or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.14
<U>Intellectual Property</U>. For purposes of this Agreement, &#147;<U>Intellectual Property</U>&#148; means any or all of the following in any jurisdiction throughout the world:&nbsp;(i)&nbsp;patents, patent applications, provisional patent
applications and similar instruments (including any and all substitutions, divisions, continuations, continuations-in-part, reissues, renewals, extensions, reexaminations, patents of addition, supplementary protection certificates, inventors&#146;
certificates, pediatric data package exclusivity extensions, or the like) (collectively, &#147;<U>Patents</U>&#148;); (ii)&nbsp;trademarks, service marks, trade dress, trade names and Internet domain names (including all registrations or
applications for any of the foregoing), together with all goodwill associated with each of the foregoing (collectively, &#147;<U>Trademarks</U>&#148;); (iii)&nbsp;copyrights, copyright registrations, and copyright applications (collectively,
&#147;<U>Copyrights</U>&#148;); (iv)&nbsp;trade secrets, know-how and other confidential and proprietary information, including product specifications, manufacturing processes, batch records and other documentation outlining manufacturing processes,
design of and modifications to machinery necessary for use in the manufacturing process, compounds, formulae, and inventions (&#147;<U>Trade Secrets</U>&#148;); and (v)&nbsp;all other intellectual property or proprietary rights (in each case whether
or not subject to statutory registration or protection). For purposes of this Agreement, &#147;<U>Nab&reg; Technology</U>&#148; means (A)&nbsp;any and all methods, techniques, know-how, trade secrets, and other technologies (including manufacturing
methods, techniques, know-how, trade secrets, and other technologies) for the noncovalent association of, or related to the association of, any agent (such as a therapeutic or diagnostic agent) with one or more polymers such as carbohydrates or
polypeptides (including albumin), (B)&nbsp;any product resulting therefrom, including any intermediate or the Product (as defined in the CVR Agreement), and (C)&nbsp;any methods of using such product; &#147;<U>Product</U>&#148; means the
Pharmaceutical Product comprising the chemical compound having a chemical name of 5&szlig;,20-Epoxy-1,2a,4,7&szlig;,10&szlig;,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine known by the
generic name &#147;paclitaxel&#148; and bound to albumin that is in the subject of the New Drug Application No.&nbsp;21-660 filed with the FDA and subject of the European Medicines Agency Marketing Authorization granted on January&nbsp;11, 2008,
together with all amendments and supplements to such FDA and European Medicines Agency approvals (identified by the Company as ABRAXANE); &#147;<U>Pharmaceutical Products</U>&#148; means all biological and drug candidates, compounds or products
being researched, developed, labeled, manufactured, tested, stored, used, sold, offered for sale, imported, and otherwise distributed or commercially exploited by the Company or any of its Subsidiaries; and &#147;<U>Pipeline Products</U>&#148; means
COROXANE, nab-docetaxel (ABI-008), nab-rapamycin (ABI-009), nab-17AAG (ABI-010), nab-thiocolchicine dimer (ABI-011), and nab-novel taxane (ABI 013). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Section&nbsp;3.14(a)</U> of the Disclosure Schedule sets forth a
true, correct, and complete list (with owner(s), country(ies) or region, registration and application numbers and dates indicated, as applicable) of all U.S. and foreign (i)&nbsp;Patents, (ii)&nbsp;Trademarks that are registered or for which an
application for registration is pending, and (iii)&nbsp;Copyrights that are registered or for which an application for registration is pending, in each case that is owned (in whole or in part) by, or licensed to, the Company or its Subsidiaries, in
each case as directed to the Product, the Pipeline Products or the Nab&reg; Technology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company or
its Subsidiaries owns or has a valid and enforceable right to use or practice the Intellectual Property required to be listed on <U>Section&nbsp;3.14(a)</U> of the Disclosure Schedule and the Trade Secrets used in connection with the Nab&reg;
Technology or necessary for the manufacturing of the Product and the Pipeline Products (collectively, the &#147;<U>Company Intellectual Property</U>&#148;) in all material respects.&nbsp;As of the date hereof, and to the Knowledge of the Company, no
Proceedings are pending or threatened against the Company or its Subsidiaries challenging in any material respect the validity, enforceability, use, inventorship, or ownership, or seeking to deny or restrict the use by the Company or its
Subsidiaries of, the Company Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) As of the date hereof, and to the Knowledge of the
Company, (i)&nbsp;neither the Company nor any Subsidiary nor the operation of their respective businesses (including the use and practice of the Company Intellectual Property, the products and services of the Company and its Subsidiaries, and the
research, development, labeling, manufacture, use, sale, offer for sale, importation, and other distribution or commercial exploitation of the Product, the Pipeline Products or the Nab&reg;Technology) infringes, dilutes, misappropriates or otherwise
violates in any material respect the Intellectual Property of any other Person; and (ii)&nbsp;no Proceeding is pending or threatened, and no third party is asserting or threatening to assert, a claim of such infringement, dilution, misappropriation
or violation against the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) To the Knowledge of the Company, no third party is infringing,
diluting, misappropriating, or otherwise violating in any material respect any Company Intellectual Property, and the Company has not asserted or threatened to assert a claim of such infringement, dilution, misappropriation or violation against any
third party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) To the Knowledge of the Company, as of the date hereof, (i)&nbsp;none of the Company
Intellectual Property that consists of Patents (the &#147;<U>Company Patents</U>&#148;) is the subject of any litigation, reissue, interference, reexamination, or opposition, (ii)&nbsp;the Company and its Subsidiaries have not received any written
notice that any such proceeding will hereafter be commenced, (iii)&nbsp;the issued Company Patents are subsisting and have not been declared invalid and/or unenforceable, and (iv)&nbsp;the Company Patents have been prosecuted in compliance in all
material respects with all applicable Laws. The Company Patents listed in the FDA&#146;s Orange Book with respect to New Drug Application No.&nbsp;21-660 for the Product cover the Product; and U.S. Patent Application No.&nbsp;11/553,339, when
issued, will be listed and is properly listable in the FDA&#146;s Orange Book with respect to such New Drug Application. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) All current and former employees of, and all consultants and independent contractors to, the Company and its
Subsidiaries who have contributed in any material respect to the creation or development of any Company Intellectual Property owned by the Company or any of its Subsidiaries have executed and delivered to the Company or its Subsidiaries an agreement
regarding the assignment to the Company or its Subsidiaries of any Intellectual Property rights arising from services performed for the Company or its Subsidiaries by such Persons, the current forms of which agreements have been made available to
Parent.&nbsp;All current and former employees of, and all consultants and independent contractors to, the Company and its Subsidiaries, and all other Persons, with access to the Company&#146;s and its Subsidiaries&#146; Trade Secrets included in the
Company Intellectual Property owned by </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Company or any of its Subsidiaries are parties to written agreements under which each is obligated to maintain the confidentiality of such Trade Secrets of the Company and its Subsidiaries
and not to use such Trade Secrets except as authorized by the Company or its Subsidiaries.&nbsp;To the Knowledge of the Company, none of such employees, consultants, contractors or other Persons is in violation in any material respect of such
inventions or confidentiality agreements.&nbsp;To the Knowledge of the Company, no current or former employee, stockholder, consultant, contractor, or independent contractor of the Company or its Subsidiaries owns or claims any rights in (nor has
any of them made application for) any Company Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) The Company and its Subsidiaries
have taken commercially reasonable actions to maintain and preserve the Company Intellectual Property, including such measures to protect the secrecy and confidentiality of the Company&#146;s and its Subsidiaries&#146; Trade Secrets included in the
Company Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) All manufacturing operations conducted by, or, to the Knowledge of the
Company, for the benefit of, the Company and its Subsidiaries with respect to any Product or Pipeline Product and all manufacturing facilities of the Company or its Subsidiaries have since January&nbsp;1, 2008 been and are being conducted in all
material respects in accordance with the FDA&#146;s current Good Manufacturing Practice Regulations at 21 C.F.R. Parts 210 and 211 for products sold in the United States and the respective counterparts thereof promulgated by Governmental Entities in
countries outside the United States.&nbsp;The Company has sufficient capacity and capability and all Regulatory Registrations and Company Permits necessary as of the date of this Agreement to manufacture the Product in sufficient quantities, taking
into account safety stock, to meet the current and the Company&#146;s expected demand for the Product for the next 12 months in all countries where it is sold. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.15 <U>Takeover Statutes</U>. No &#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share
acquisition,&#148; &#147;business combination&#148; or other similar antitakeover statute or regulation enacted under state or federal laws in the United States (with the exception of Section&nbsp;203 of the DGCL) is applicable to the transactions
contemplated by this Agreement. The Company has taken all action necessary such that the restrictions contained in Section&nbsp;203 of the DGCL do not apply to the Merger, this Agreement and the transactions contemplated hereby; provided, however,
that, for purposes hereof, Parent and Sub hereby specifically represent and warrant to the Company that neither of them is an &#147;interested stockholder&#148; in the Company, as such term is defined in Section&nbsp;203 of the DGCL. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.16 <U>Title to Properties; Assets/Services</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company and its Subsidiaries have valid and legal title to, a leasehold interest in, license or easement in the
real and personal properties as reflected in the Company&#146;s consolidated balance sheet as of March&nbsp;31, 2010, except for properties and assets that have been disposed of in the ordinary course of business since March&nbsp;31, 2010, free and
clear of all Liens of any nature whatsoever, except (i)&nbsp;Liens for current Taxes, payments of which are not yet delinquent and for which adequate reserves have been established in accordance with GAAP on the books and records of the Company;
(ii)&nbsp;mechanics, carriers&#146;, workmen&#146;s, warehouseman&#146;s, repairmen&#146;s, materialmen&#146;s or other Liens or security interests arising in the ordinary course of business securing obligations that are not yet due and payable or
are being contested in good faith; (iii)&nbsp;Liens imposed by applicable Law (other than Tax Law) arising in the ordinary course of business securing obligations for sums that are not yet due and payable or are being contested in good faith;
(iv)&nbsp;pledges or deposits to secure obligations under workers&#146; compensation Laws or similar legislation or to secure public or statutory obligations; (v)&nbsp;pledges and deposits to secure the performance of bids, trade contracts, leases,
surety and appeal bonds, performance bonds and other obligations of a similar nature; or (vi)&nbsp;such imperfections in title and easements and encumbrances as are not substantial in character, amount or extent and do not materially detract from
the business subject </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
thereto or affected thereby, or materially interfere with or materially adversely affect or impair the present and continued use of the property subject thereto or affected thereby, or otherwise
materially impair the operations of the Company or any of its Subsidiaries (in the manner presently carried on by the Company and its Subsidiaries). <U>Section&nbsp;3.16(a)</U> of the Disclosure Schedule sets forth a true, complete and correct list
of all real property owned, leased, subleased or licensed by the Company and each of its Subsidiaries and the location of such properties (collectively, the &#147;<U>Real Property</U>&#148;). All Real Property leased or subleased by the Company or
its Subsidiaries is referred to herein as the &#147;<U>Leased Real Property</U>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) As of the date of
this Agreement, there are no material leases, subleases, licenses, concessions or other agreements, written or oral, granting to any party or parties the right of use or occupancy of any portion of any Real Property and Leased Real Property. Except
as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company or its Subsidiaries have a valid and subsisting leasehold estate in and the right to quiet enjoyment of each Leased Real
Property for the full term of the lease or sublease creating such interest. As of the date of this Agreement, to the Knowledge of the Company there are no eminent domain, condemnation or other similar actions or proceedings pending or threatened
with respect to any of the Real Property by any Governmental Entity having jurisdiction over any such Real Property. As currently operated and maintained, each of the Real Properties is in compliance in all material respects with all federal, state
and local Law applicable to each such Real Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.17 <U>Material Contracts</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Section&nbsp;3.17(a)</U> of the Disclosure Schedule sets forth a true and complete list as of the date of this
Agreement of each of the following Company Contracts, together with all amendments thereto: (i)&nbsp;each Company Contract that restricts in any material respect the ability of the Company or any of its Subsidiaries or any of the Company&#146;s
current or future Affiliates to sell products in or otherwise compete in any geographic area or line of business; (ii)&nbsp;any Company Contract pursuant to which any Person provides manufacturing services involving the Product, any Pipeline Product
or any product using Nab&reg; Technology for the Company or any of its Subsidiaries, (iii)&nbsp;each Company Contract pursuant to which the Company or any of its Subsidiaries grants or is granted any license to use or exploit, covenant not to sue,
immunity from suit or similar rights under any Intellectual Property of a third party that, in each case, is related to the Product, any Pipeline Product, or the Nab&reg; Technology; (iv)&nbsp;each Company Contract pursuant to which raw materials
are supplied, or equipment is supplied or leased, to the Company or any of its Subsidiaries (excluding purchase orders given or received in the ordinary course of business), in each case relating to any key component or manufacturing involved in the
compounding or formulation of the Product or any products using Nab&reg; Technology; (v)&nbsp;each Company Contract that grants any right of first refusal or right of first offer or similar right or that limits or purports to limit the ability of
the Company or any of its Subsidiaries to own, operate, sell, transfer, pledge or otherwise dispose of any material amount of assets or businesses relating to the Product, any Pipeline Product, or the Nab&reg; Technology; (vi)&nbsp;each Company
Contract providing for future performance by the Company or any of its Subsidiaries in consideration of amounts previously paid, the balance of which exceeds $5,000,000 as of the date of this Agreement; and (vii)&nbsp;any other &#147;material
contract&#148; (as such term is defined in Item&nbsp;601(b)(10) of Regulation S-K of the Securities Act) that were required to be filed with or furnished to the SEC prior to the date of this Agreement. Each Company Contract (A)&nbsp;of the type
described in <U>Section&nbsp;3.17(a)</U> of the Disclosure Schedule, whether or not disclosed in response to this <U>Section&nbsp;3.17(a)</U>, or referred to in <U>Section&nbsp;3.17(b)</U>, whether or not provided or publicly filed, and
(B)&nbsp;entered into after the date of this Agreement and of the type required to be described in <U>Section&nbsp;3.17(a)</U> or referred to in <U>Section&nbsp;3.17(b)</U>, whether or not provided or publicly filed of the Disclosure Schedule if
such Company Contract were in effect as of the date of this Agreement, is referred to herein as a &#147;<U>Material Contract</U>.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company has provided to Parent or publicly filed with the SEC true
and complete copies of each Company Contact referred to in <U>Section&nbsp;3.17(a)</U> and each of the following Company Contacts, in each case that are in effect as of the date of this Agreement: (i)&nbsp;each Company Contract with customers
(excluding purchase orders given or received in the ordinary course of business) under which the Company or any of its Subsidiaries received in excess of $10,000,000 in 2009 or is expected to receive in excess of $10,000,000 in 2010 or any year
thereafter; (ii)&nbsp;each Company Contract pursuant to which the Company or any of its Subsidiaries occupies Leased Real Property and under which the Company or any of its Subsidiaries is required to pay an annual rental in excess of $5,000,000 in
2010 or any year thereafter; and (iii)&nbsp;each Company Contract for any joint venture (whether in partnership, limited liability company or other organizational form), co-promote agreements or co-branding agreements (other than distribution
agreements) or agreements pursuant to which the Company or any of its Subsidiaries permitted distribution of the Product or the Pipeline Products under another party&#146;s name or trademarks. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) All Material Contracts are valid and in full force and effect and enforceable in accordance with their respective
terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#146; rights and general equity principles, except to the extent that
(i)&nbsp;such Material Contracts have previously expired or otherwise terminated in accordance with their terms or (ii)&nbsp;the failure to be in full force and effect would not reasonably be expected to have a Company Material Adverse Effect.
Neither the Company nor any of its Subsidiaries, nor, to the Knowledge of the Company, any counterparty to any such Material Contract, has violated any provision of, or committed or failed to perform any act which, with or without notice, lapse of
time or both, would constitute a default under, or give rise to a right of termination, modification, cancellation, foreclosure, imposition of a Lien, prepayment or acceleration under the provisions of any Material Contract, except in each case for
those violations or defaults which would not reasonably be expected to have a Company Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received written notice that it has breached, violated or defaulted under any Material
Contract. Prior to the date of this Agreement, the Company and its Subsidiaries have not received any written claims for indemnification pursuant to the 2007 Separation and Distribution Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.18 <U>Opinion of Financial Advisors</U>. The Company&#146;s financial advisors, Goldman, Sachs&nbsp;&amp;
Co., Lazard, Freres&nbsp;&amp; Co. LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated (the &#147;<U>Company Financial Advisors</U>&#148;), have each delivered to the Board of Directors an opinion, to the effect that, as of the date
of this Agreement and subject to the matters and assumptions set forth in their respective opinions, the Merger Consideration to be paid to the holders (other than Parent, Patrick Soon-Shiong, M.D. and any of their respective Affiliates) of shares
of Company Common Stock pursuant to the Merger Agreement is fair to such holders from a financial point of view. The Company will provide, solely for informational purposes, a true, complete and correct copy of such opinions to Parent after receipt
thereof in writing by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.19 <U>Pharmaceutical Matters</U><I></I>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company and its Subsidiaries and to the Knowledge of the Company its respective directors, officers, employees,
and agents (while acting in such capacity) are, and at all times have been, in compliance, and the Company&#146;s business (including the research, development, labeling, manufacture, testing, storage, use, sale, offer for sale, importation, and
other distribution or commercial exploitation of the Product, the Pipeline Products, and the cervical cancer screening test marketed by the Company&#146;s Subsidiary Neodiagnostix, Inc. (the &#147;<U>Screening Test</U>&#148;) and all preclinical
studies, clinical trials, and other studies and tests conducted thereon) has been operated in accordance, in all material respects with (i)&nbsp;all applicable Laws of the United States Drug Enforcement Administration, the United
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
States Department of Health and Human Services and its constituent agencies, the Centers for Medicare&nbsp;&amp; Medicaid Services, the Office of Inspector General and the United States Food and
Drug Administration (the &#147;<U>FDA</U>&#148; and, collectively with other applicable U.S. or foreign drug regulatory authorities, &#147;<U>Regulatory Authorities</U>&#148;), (including the federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;
321 et seq.) (the &#147;<U>FDCA</U>&#148;), the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.), the federal Anti-kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Anti-Inducement Law (42 U.S.C. &#167; 1320a-7a(a)(5)), the Stark Law (42
U.S.C. &#167; 1395nn), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), the exclusion laws (42 U.S.C. &#167;&nbsp;1320a-7), the regulations promulgated pursuant to the foregoing laws, and the Federal
Acquisition Regulations (48 C.F.R. Parts 1-53)), (ii)&nbsp;the drug price reporting requirements of titles XVIII and XIX of the Social Security Act, (iii)&nbsp;the applicable laws precluding off-label marketing of drugs, (iv)&nbsp;all other United
States laws and regulations with respect to the marketing, sale, pricing, price reporting, and reimbursement of prescription drug products, including the provisions of the Federal False Claims Act, 31 U.S.C. &#167;3729 et seq., the Medicare Program
(Title XVIII of the Social Security Act), the Medicaid Program (Title XIX of the Social Security Act), the regulations promulgated pursuant to such Laws, requirements of the Medicaid Drug Rebate Program (42 U.S.C. &#167; 1396r-8) and any state
supplemental rebate program, requirements of Medicare average sales price reporting (42 U.S.C. &#167; 1395w-3a), the Public Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126) state pharmaceutical
assistance programs and regulations under such Laws, and (v)&nbsp;comparable state and foreign laws. The Company and its Subsidiaries have complied with any and all obligations pertaining to listing any relevant Patents included in the Company
Intellectual Property in the FDA Orange Book and have also complied with any and all obligations under the Bayh-Dole Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Neither the Company nor any of its Subsidiaries is excluded or debarred under the Generic Drug Enforcement Act of
1992 or any government health care program, including Medicare and Medicaid; and no employee of the Company or any of its Subsidiaries or to the Knowledge of the Company no consultants or subcontractors of the Company or any of its Subsidiaries is
excluded or debarred. No claims, actions, proceedings or investigations that would reasonably be expected to result in such a material debarment are pending, and the Company has not received written notice that any such claims, actions, proceedings
or investigations are threatened against the Company, the Company&#146;s Subsidiaries, or any of their respective officers or key employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) (i) Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect, the Company and its Subsidiaries meet all of the requirements of participation and payment of Medicare, Medicaid, any other state or federal government health care programs, and any other public or private third party payor programs
(collectively, &#147;<U>Programs</U>&#148;) that the Company or any of its Subsidiaries participates in or receives payment from, and (ii)&nbsp;there is no investigation, audit, claim review, or other action pending, or, to the Knowledge of the
Company, threatened, against the Company or any of its Subsidiaries which could reasonably be expected to result in the exclusion of the Company&#146;s business from any Program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Except as set forth on <U>Section&nbsp;3.19(d)</U> of the Disclosure Schedule, (i)&nbsp;to the Knowledge of the
Company, there is no pending action, investigation or inquiry of any type by any Regulatory Authority (other than non-material routine or periodic inspections or reviews) against the Company or its Subsidiaries relating to the Product, the Pipeline
Products, or the Screening Test; (ii)&nbsp;since January&nbsp;1, 2008, no Product, Pipeline Product, or Screening Test has been recalled, suspended or discontinued; and (iii)&nbsp;since January&nbsp;1, 2008, none of the Company or any of its
Subsidiaries has received any written notification, correspondence or any other written communication from any Governmental Entity, including the FDA, the Centers for Medicare and Medicaid Services, and the Department of Health and Human Services
Office of Inspector General, of potential or actual material non-compliance </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
by, or liability of, the Company or any of its Subsidiaries, under any of the Laws referenced in <U>Section&nbsp;3.19(a)</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) To the Knowledge of the Company, there are no facts or circumstances that could reasonably be construed as indicating
that marketing approval for the Product will be withdrawn. Neither the Company nor its Subsidiaries has received any written notification, correspondence or any other written communication from the FDA or the European Medicines Agency requesting
that the Company or its Subsidiaries make any material change in the labeling of the Product or any Pipeline Product, or indicating that such a request may be made. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Neither the Company nor its Subsidiaries have marketed, sold, offered for sale, or distributed any Pharmaceutical
Products other than the Product and the Screening Test. For purposes of this Agreement, &#147;<U>Regulatory Registrations</U>&#148; means all investigational new drug applications, new drug applications, product license application, or biologics
license application or similar regulatory applications of the Company and its Subsidiaries that have been submitted to or approved by the FDA or any applicable Governmental Entity. All applications, notifications, submissions, information, claims,
reports and statistics and other data, utilized as the basis for or submitted in connection with any and all Regulatory Registrations from the FDA or other Regulatory Authority relating to the Company and its Subsidiaries or their respective
business operations and Pharmaceutical Products, when submitted to the FDA or other Regulatory Authority were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes,
corrections or modification to such applications, submissions, information and data have been submitted to the FDA or such other Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) None of the Company or any of its Subsidiaries is a party to any corporate integrity agreements, monitoring
agreements, consent decrees, settlement orders, or other similar written agreements, in each case, entered into with or imposed by any Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.20 <U>Brokers and Finders</U>. The Company has not entered into any Contract, arrangement or understanding
with any Person which may result in the obligation of the Company to pay any investment banking fees, finder&#146;s fees, brokerage or agent commissions or other like payments in connection with the Merger, other than fees payable to the Company
Financial Advisors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.21 <U>Insurance</U>. Each of the material insurance policies and material
self insurance programs and arrangements relating to the business, assets and operations of the Company and its Subsidiaries (the &#147;<U>Insurance Policies</U>&#148;) is in full force and effect, all premiums due thereon have been paid in full and
the Company and its Subsidiaries are in compliance in all material respects with the terms and conditions of such Insurance Policies. Since January&nbsp;1, 2009, and prior to the date of this Agreement, none of the Company or any of its Subsidiaries
has received any written notice regarding any actual or possible (a)&nbsp;cancellation of any Insurance Policy that has not been renewed in the ordinary course without any lapse in coverage, (b)&nbsp;invalidation of any Insurance Policy,
(c)&nbsp;refusal of any coverage, limitation in coverage or rejection of any material claim under any Insurance Policy, or (d)&nbsp;material adjustment in the amount of the premiums payable with respect to any Insurance Policy. As of the date of
this Agreement, there is no material claim by the Company or any of its Subsidiaries pending under any of the Insurance Policies and no material claim made since January&nbsp;1, 2009 that is still pending has been questioned or disputed by the
underwriters of such Insurance Policies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.22 <U>Anti-Corruption and Anti-Bribery</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) For the purposes of this Agreement, the term &#147;<U>Anti-Corruption and Anti-Bribery Laws</U>&#148; shall mean all
applicable Laws governing corrupt or illicit business practices, including laws </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
dealing with improper or illegal payments, gifts or gratuities and/or the payment or receipt of money or anything of value directly or indirectly to or from any Person (whether a government
official or private individual) for the purpose of illegally inducing any Person or government official, or political party or official thereof, or any candidate for any such position, in making any decision or illegally assisting any Person in
obtaining or retaining business or taking any other action favorable to such Person, and/or dealing with business practices in relation to investments outside of the United States (including, by way of example, if applicable, the United States
Foreign Corrupt Practices Act of 1977, as amended, any rules or regulations thereunder). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Neither the
Company nor its directors, officers, agents, employees, Subsidiaries or Affiliates has, directly or indirectly, (i)&nbsp;used any corporate funds in a manner which would cause it to be in violation of any Anti-Corruption or Anti-Bribery Laws,
(ii)&nbsp;established or maintained any unrecorded fund or asset for any purpose or made any false entries on the books and records of the Company or any of its Subsidiaries for any reason, (iii)&nbsp;paid, delivered or received any fee, commission
or any other sum or money or item of property, however characterized, to or from any finder, principal, agent, governmental official or other party in the United States or any other country, which in any manner relates to the assets, business or
operations of the Company or any of its Subsidiaries in violation of any Laws or (iv)&nbsp;made or received any other unlawful payment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) There are no pending or, to the Knowledge of the Company, threatened claims against the Company with respect to such
Anti-Corruption or Anti-Bribery laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Company has established and maintains a compliance program and
internal controls and procedures appropriate to the requirements of the Anti-Corruption and Anti-Bribery Laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.23 <U>No Other Representations or Warranties</U>. Except for the representations and warranties expressly
contained in this Agreement, each of Parent and Sub acknowledges that neither the Company nor any other Person on behalf of the Company makes any other express or implied representation or warranty with respect to the Company, any of its
Subsidiaries or their respective businesses or any other matter or with respect to any other information provided or made available to Parent or Sub, and that all such representations and warranties, other than the representations and warranties of
the Company expressly contained in this Agreement, are expressly disclaimed. Neither the Company nor any other Person makes any representation or warranty with respect to any such information, including any information, projections, forecasts or
other material made available to Parent and Sub in a &#147;data room&#148; or &#147;virtual data room,&#148; confidential information memoranda or management presentations in expectation of the transactions contemplated by this Agreement, except
that the foregoing limitations shall not (i)&nbsp;apply to the Company to the extent the Company makes the specific representations and warranties set forth in this Agreement, but always subject to the limitations and restrictions contained herein,
or (ii)&nbsp;preclude Parent or Sub from seeking any remedy for fraud. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE IV </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as disclosed in Parent&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2009, Parent&#146;s Quarterly Report on Form 10-Q
for the quarter ended March&nbsp;31, 2010 or any of Parent&#146;s Current Reports on Form 8&#150;K dated after December&nbsp;31, 2009 filed by Parent with the SEC pursuant to the Exchange Act prior to the date of this Agreement but excluding
(i)&nbsp;any disclosures contained or referenced therein under the captions &#147;Risk Factors,&#148; &#147;Forward-Looking Statements,&#148; and &#147;Quantitative and Qualitative Disclosures About Market Risk&#148; and any other disclosures
contained or referenced therein of information, factors or risks that are predictive, cautionary or forward-looking in nature, and (ii) </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
with respect to <U>Section&nbsp;4.2(a)</U>, any disclosures contained or referenced therein, Parent and Sub, jointly and severally, represent and warrant to the Company as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.1 <U>Organization, Standing and Power</U>. Each of Parent and Sub is a legal entity duly organized,
validly existing and in good standing under the Laws of its jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets and to carry on its business as presently
conducted and is qualified to do business and is in good standing as a foreign legal entity in each jurisdiction where the ownership, leasing or operation of its assets or properties or conduct of its business requires such qualification, except
where the failure to be so organized, qualified or in good standing, or to have such power or authority, would not reasonably be expected to have a Parent Material Adverse Effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.2 <U>Capital Structure</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The authorized capital stock of Parent consists of 575,000,000 shares of Parent Common Stock and 5,000,000 shares of
preferred stock, par value $0.01 per share. As of the close of business on May&nbsp;31, 2010, (i)&nbsp;459,949,694 shares of Parent Common Stock were issued and outstanding, (ii)&nbsp;no shares of preferred stock were outstanding, (iii)&nbsp;an
aggregate of 40,736,541 shares of Parent Common Stock were issuable upon exercise of then outstanding stock options (whether or not exercisable as of such date) and the vesting of restricted stock units, and (iv)&nbsp;35,000 shares of Parent Common
Stock were issuable upon the exercise of then outstanding warrants. In addition to the shares of Parent Common Stock referred to in clauses (i)&nbsp;and (iii), as of the close of business on May&nbsp;31, 2010, 20,935,840 shares of Parent Common
Stock were available for additional grants under Parent&#146;s stock option or equity incentive plans. All of the outstanding shares of Parent Common Stock are validly issued and outstanding, fully paid and non assessable and free of preemptive
rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Except as otherwise set forth in this <U>Section 4.2</U>, as of the date of this Agreement,
Parent has no (i)&nbsp;outstanding stock or securities convertible into or exchangeable for any shares of its equity securities, or any outstanding rights to subscribe for or to purchase any shares of its equity securities, or any outstanding
options for the purchase thereof, (ii)&nbsp;any agreements providing for the issuance of any equity securities or any stock or securities convertible into or exchangeable for any equity securities of Parent or (iii)&nbsp;outstanding bonds,
debentures, notes or other indebtedness having the right to vote (or convertible into or exchangeable for securities having the right to vote) on any matters on which stockholders of Parent may vote. From June&nbsp;25, 2010 to the date of this
Agreement, Parent has not (i)&nbsp;issued any shares of Parent Common Stock except in connection with the conversion, exercise or settlement of any stock options or (ii)&nbsp;issued or granted any options, warrants or securities convertible into or
exercisable for shares of its Parent Common Stock other than in the ordinary course of business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The
shares of Parent Common Stock to be issued in the Merger have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will have been validly issued and will be fully paid and nonassessable and the issuance
thereof is not subject to any preemptive or other similar right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.3 <U>Operations of Sub</U>.
All of the issued and outstanding capital stock of Sub is, and at the Effective Time will be, owned by Parent or a direct or indirect wholly-owned Subsidiary of Parent. Sub was formed solely for the purpose of effecting the Merger. Sub has not
conducted any business prior to the date hereof and has no, and prior to the Effective Time will have no, assets, liabilities or obligations of any nature other than those incident to its formation and pursuant to this Agreement and the Merger and
the other transactions contemplated by this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.4 <U>Authority; Non-Contravention</U>. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Each of Parent and Sub has the requisite power and authority to enter
into this Agreement and to consummate the Merger and the transactions contemplated by this Agreement. The execution and delivery of this Agreement by each of Parent and Sub and the consummation by Parent and Sub of the Merger and the transactions
contemplated by this Agreement have been duly authorized by all necessary action on the part of each of Parent and Sub. This Agreement has been duly executed and delivered by each of Parent and Sub and (assuming the valid authorization, execution
and delivery of this Agreement by the Company) constitutes a valid and binding obligation of Parent and Sub, enforceable against Parent and Sub in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar Laws of general applicability relating to or affecting creditors&#146; rights and general equity principles. No vote or approval of the stockholders of Parent is required in connection with the execution, delivery or
performance by Parent and Sub of their obligations hereunder or for the consummation of the Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The
execution and delivery of this Agreement does not, and the consummation of the Merger and compliance with the provisions hereof will not, (i)&nbsp;conflict with, or result in any violation of, the organizational documents of Parent,
(ii)&nbsp;conflict with, or result in any violation of the organizational documents of any of Parent&#146;s Subsidiaries, (iii)&nbsp;result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give
rise to a right of termination, cancellation or acceleration of any obligation, or result in the creation of any Lien upon any of the properties or assets of Parent or any of its Subsidiaries under, any provision of any Contract to which Parent or
any of its Subsidiaries is a party or by which their respective properties and assets are bound, except for any such violation, breach, default or right of termination, cancellation or acceleration or Lien as to which requisite waivers or consents
have been obtained or (iv)&nbsp;assuming that the Registrations and Consents set forth in this <U>Section&nbsp;4.3(b)</U> are duly and timely made or obtained, violate any Law applicable to Parent or any of its Subsidiaries or any of their
respective properties or assets, other than, in the case of clauses (iii)&nbsp;or (iv), any such conflict, violation, default, termination, cancellation, acceleration or Lien that would not, individually or in the aggregate, reasonably be expected
to materially impair the ability of Parent and/or Sub to perform their obligations hereunder or prevent or materially delay the consummation of the Merger or any of the other transactions contemplated hereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) No Consents of, or Registrations with, any Governmental Entity is required on the part of Parent or any of its
Subsidiaries in connection with the execution and delivery of this Agreement by Parent or Sub or is necessary for the consummation by Parent and Sub of the Merger and the other transactions contemplated hereby, except for (i)&nbsp;compliance with
and filings under the HSR Act, (ii)&nbsp;compliance with the provisions of Exchange Act and the Securities Act or the rules of any national securities exchange, (iii)&nbsp;the qualification of the CVR Agreement under the Trust Indenture Act of 1939,
as amended (the &#147;<U>Trust Indenture Act</U>&#148;), if required by Law, (iv)&nbsp;the filing of the Certificate of Merger with the Secretary of State of Delaware and appropriate documents with the relevant authorities of other states in which
the Company is qualified to do business, (v)&nbsp;such as may be required in connection with the Taxes described in <U>Section&nbsp;6.11</U>, and (vi)&nbsp;such other Consents or Registrations the failure of which to be obtained or made would not,
individually or in the aggregate, materially impair the ability of Parent and Sub to perform their obligations hereunder or prevent or materially delay the consummation of the Merger or any of the transactions contemplated hereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.5 <U>SEC Documents</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Since January&nbsp;1, 2008, Parent has filed with, or furnished to, the SEC all documents required to be filed or
furnished by Parent under the Securities Act or the Exchange Act (collectively, the &#147;<U>Parent SEC Documents</U>&#148;). As of their respective dates, Parent SEC Documents complied in all material respects with the requirements of the
Securities Act or the Exchange Act, as the case may be, and as of their respective dates and except as amended or supplemented prior to the date </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
hereof (or with respect to Parent SEC Documents filed or furnished after the date hereof, except as amended or supplemented prior to the Closing Date), none of Parent SEC Documents contained any
untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, except that no
representation is made by Parent with respect to information supplied by the Company or its Subsidiaries in writing for inclusion in the Registration Statement. Each of the consolidated financial statements of Parent (including, in each case, any
notes thereto) included in Parent SEC Documents (collectively, the &#147;<U>Parent Financial Statements</U>&#148;) have been prepared in accordance with U.S. GAAP applied on a consistent basis during the periods involved (except as may be indicated
therein or in the notes thereto) and fairly present in all material respects the financial position of Parent and its consolidated Subsidiaries as at the dates thereof and the results of their operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit adjustments and to any other adjustments set forth therein). As of the date of this Agreement, neither Parent nor any of its Subsidiaries has any pending or unresolved comments
from the SEC or any other Governmental Entity with respect to any of Parent SEC Documents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) To the
Knowledge of Parent, neither Parent nor any of its Subsidiaries has any liability or obligation of any nature (whether accrued, absolute, contingent or otherwise), except for liabilities, obligations or contingencies which (i)&nbsp;are reflected, or
for which reserves are established, on the consolidated balance sheet of Parent as of March&nbsp;31, 2010, (ii)&nbsp;were incurred in the ordinary course of business since March&nbsp;31, 2010, (iii)&nbsp;would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect or (iv)&nbsp;have been incurred in connection with the performance by Parent of its obligations under this Agreement or the transactions contemplated hereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Each of the principal executive officer and the principal financial officer of Parent (or each former principal
executive officer and each former principal financial officer of Parent, as applicable) has made the certifications required by Rules 13a-14 and 15d-14 promulgated under the Exchange Act or Sections 302 and 906 of the Sarbanes-Oxley Act with respect
to Parent SEC Documents. For purposes of the preceding sentence, &#147;principal executive officer&#148; and &#147;principal financial officer&#148; have the meanings ascribed to those terms under the Sarbanes-Oxley Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) To the Knowledge of Parent, since January&nbsp;1, 2008 and prior to the date of this Agreement, none of Parent, any
of its Subsidiaries or any director, officer, auditor, accountant or representative of Parent or any of its Subsidiaries has received any substantive complaint, allegation, assertion or claim, whether written or oral, that Parent or any of its
Subsidiaries has engaged in questionable accounting or auditing practices. No current or former attorney representing Parent or any of its Subsidiaries has reported evidence of a material violation of securities Laws, breach of fiduciary duty or
similar violation by Parent or any of its Subsidiaries, or any of their respective officers, directors, employees or agents, to Parent&#146;s current board of directors or any committee thereof or to any current director or executive officer of
Parent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Parent and its Subsidiaries have designed and maintain internal controls over financial reporting
(as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) to provide reasonable assurances (i)&nbsp;regarding the reliability of Parent&#146;s financial reporting and the preparation of financial statements for external
purposes in accordance with U.S. GAAP (ii)&nbsp;that receipts and expenditures of Parent and its Subsidiaries are being made only in accordance with the authorization of management and directors of Parent and such Subsidiaries and
(iii)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#146;s or its Subsidiaries&#146; assets that could have a material effect on Parent&#146;s financial statements. Parent has designed
and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) to ensure that material information required to be disclosed by Parent in the reports that
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Parent files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms and is accumulated and
communicated to Parent&#146;s management as appropriate to allow timely decisions regarding required disclosure and to make the certifications of the principal executive officer and principal financial officer of Parent required under the Exchange
Act with respect to such reports. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Neither Parent nor any of its Subsidiaries is a party to, or has any
commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract binding on Parent or any of its Subsidiaries or any of their properties or assets (including any Contract binding on Parent or any of its
Subsidiaries or any of their properties or assets or arrangement relating to any transaction or relationship between or among Parent and any of its Subsidiaries, on the one hand, and any unconsolidated affiliate, including any structured finance,
special purpose or limited purpose entity or person, on the other hand, or any &#147;off balance sheet arrangements&#148; (as defined in Item&nbsp;303(a) of Regulation S-K under the Exchange Act)), where the result, purpose or intended effect of
such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, Parent or any of its Subsidiaries in Parent&#146;s or such Subsidiary&#146;s published financial statements or other documents required to be
filed or furnished by Parent under the Securities Act or the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Since January&nbsp;1, 2009,
Parent has not received any oral or written notification of any &#147;material weakness&#148; in Parent&#146;s internal control over financial reporting. There is no outstanding &#147;significant deficiency&#148; or &#147;material weakness&#148;
that Parent&#146;s independent accountants certify has not been appropriately and adequately remedied by Parent. For purposes of this Agreement, the terms &#147;significant deficiency&#148; and &#147;material weakness&#148; shall have the meanings
assigned to them in Release No.&nbsp;2007-005 of the Public Company Accounting Oversight Board, as in effect on the date hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.6 <U>Absence of Certain Events</U>. From March&nbsp;31, 2010 to the date of this Agreement, there has not
occurred any Effect that, individually or in the aggregate with all other Effects, has had, or would reasonably be expected to have, a Parent Material Adverse Effect. For purposes of this Agreement, &#147;<U>Parent Material Adverse Effect</U>&#148;
means any Effects, that, in the aggregate with all other Effects, is, or would reasonably be expected to be, (1)&nbsp;materially adverse to the business, assets, financial condition or results of operations of Parent and its Subsidiaries taken as a
whole, or (2)&nbsp;prevent the consummation of the Merger; provided that in no event shall any of the following, alone or in combination, be deemed to constitute, nor shall any of the following be taken into account in determining whether there has
been, or there would reasonably be expected to be, a Parent Material Adverse Effect: (a)&nbsp;any Effect relating to, or resulting from, any change or developments in or to local, regional, national or foreign political, economic or financial
conditions or in or to local, regional, national or foreign credit, financial, banking or securities markets (including any disruption thereof), including any Effect caused by acts of terrorism or war or armed hostilities (whether or not declared),
(b)&nbsp;any Effect affecting generally any of the industries, geographic areas or business segments in which Parent or any of its Subsidiaries operates, (c)&nbsp;any Effect relating to, or resulting from, any hurricane, earthquake or other natural
disasters, (d)&nbsp;any change in the share price or trading volume (as opposed to the facts underlying such change) of Parent Common Stock on NASDAQ (provided, however, that the facts and circumstances giving rise to such Effect that are not
otherwise excluded from the definition of Parent Material Adverse Effect may be considered for purposes of determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect), (e)&nbsp;any Effect relating to,
or resulting from, the adoption, implementation, promulgation, repeal, modification or proposal of any Law or U.S. GAAP, after the date of this Agreement, (f)&nbsp;any failure, in and of itself (as opposed to the facts underlying such failure), to
meet any budgets, plans, projections or forecasts of Parent&#146;s or its Subsidiaries&#146; revenue, earnings or other financial performance or results of operations, or any published financial forecasts or analyst estimates with respect to the
revenue, earnings or other financial performance or results of operations of Parent or its Subsidiaries or any change in analyst recommendations, for any period (provided, however, that the </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
facts and circumstances giving rise to such failures that are not otherwise excluded from the definition of Parent Material Adverse Effect may be considered for purposes of determining whether
there has been, or there would reasonably be expected to be, a Parent Material Adverse Effect may be considered for purposes of determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect), or
(g)&nbsp;any Effect directly relating to, or resulting from, the execution, performance or announcement of this Agreement or the Related Agreements (including the impact thereof on relationships, contractual or otherwise, with customers, suppliers,
licensors, licensees, distributors, partners or employees, the loss or departure of officers or other employees of Parent or its Subsidiaries and any pending or threatened Proceeding challenging this Agreement, any of the Related Agreements or the
transactions contemplated hereby or thereby, or otherwise resulting from the pursuit of the consummation of the transactions contemplated hereby or thereby; except that clauses (a), (b), (c)&nbsp;and (e), shall not be applicable with respect to
Effects to the extent, but only to the extent, that any such Effects have had, or would reasonably be expected to have, a disproportionate impact on Parent and its Subsidiaries, taken as a whole, relative to other participants in the industry in
which Parent and its Subsidiaries operate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.7 <U>Proxy Statement/Prospectus and Registration
Statement</U>. None of the information supplied or to be supplied by Parent or any of its Subsidiaries for inclusion or incorporation by reference in the Registration Statement or the Proxy Statement/Prospectus at the time the Registration Statement
becomes effective under the Securities Act or at the time the Proxy Statement/Prospectus is mailed to stockholders of the Company and at the time of the Company Stockholders Meeting will contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, except that no representation is made by Parent or Sub with respect
to information supplied by the Company for inclusion or incorporation by reference in any of such documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.8 <U>Availability of Funds; Parent Common Stock</U>. Parent shall have available at the Closing
(i)&nbsp;sufficient funds to pay the Cash Consideration and all amounts payable in lieu of fractional shares pursuant to Section&nbsp;2.2(e) in respect of all of the then outstanding shares of Company Common Stock, pay all cash amounts payable in
respect of then outstanding Options, SARs and RSUs, and pay all fees, expenses and other amounts payable by the Company and its Subsidiaries in connection with the Merger, and (ii)&nbsp;sufficient authorized but unissued shares of Parent Common
Stock to issue the shares of Parent Common Stock to be issued pursuant to <U>Section&nbsp;2.1(a)(ii)</U>. Parent and Sub expressly acknowledge and agree that their obligations hereunder, including their obligations to consummate the Merger, are not
subject to, or conditioned on, receipt of financing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.9 <U>Litigation</U>. There is no
Proceeding pending or, to the Knowledge of Parent (as defined in <U>Section&nbsp;9.15</U>), threatened against Parent or Sub or any of their Subsidiaries or any property or asset of the Parent or Sub or any of their respective Subsidiaries which, if
adversely determined, would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. As of the date of this Agreement, neither Parent nor Sub is subject to any writ, judgment, injunction or decree that
would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.10 <U>No Violation of Law</U>. Except for which would not reasonably be expected to have, individually or
in the aggregate, a Parent Material Adverse Effect: (i)&nbsp;neither Parent nor any of its Subsidiaries is or since January&nbsp;1, 2008, has been in violation of any Law; (ii)&nbsp;to the Knowledge of Parent, no investigation or review by any
Governmental Entity is pending or threatened against Parent or any of its Subsidiaries; (iii)&nbsp;Parent and its Subsidiaries have all permits, licenses, franchises, variances, exemptions, orders and other governmental authorizations, consents and
approvals necessary to conduct </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
its businesses in all material respects as presently conducted (collectively, the &#147;<U>Parent Permits</U>&#148;); and (iv)&nbsp;none of Parent or any of its Subsidiaries is in violation of
the terms of any Parent Permit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.11 <U>Brokers and Finders</U>. No broker, investment banker or
other Person, other than Morgan Stanley&nbsp;&amp; Co. Incorporated, the fees and expenses of which will be paid by Parent, is entitled to any broker&#146;s, finder&#146;s or other similar fee or commission in connection with the Merger and the
transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Parent or Sub. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.12 <U>Ownership of Shares</U>. As of the date of this Agreement, none of Parent, Sub or their respective
Affiliates owns (beneficially or of record) any shares of Company Common Stock, and none of Parent, Sub or their respective Affiliates is a party to any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or
disposing of any shares of Company Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.13 <U>Solvency</U>. Assuming satisfaction of
the conditions to Parent&#146;s obligation to consummate the Merger, and after giving effect to the transactions contemplated by this Agreement, and the payment of the aggregate cash consideration payable to the Securityholders pursuant to
<U>ARTICLE&nbsp;II</U>, payment of all amounts required to be paid in connection with the consummation of the Merger and the other transactions contemplated hereby, and payment of all related fees and expenses, each of Parent and the Surviving
Corporation will be Solvent as of the Effective Time and immediately after the consummation of the transactions contemplated hereby.&nbsp;For the purposes of this Agreement, the term &#147;<U>Solvent</U>&#148; when used with respect to any Person,
means that, as of any date of determination (a)&nbsp;the amount of the &#147;fair saleable value&#148; of the assets of such Person will, as of such date, exceed (i)&nbsp;the value of all &#147;liabilities of such Person, including contingent and
other liabilities,&#148; as of such date, as such quoted terms are generally determined in accordance with applicable Laws governing determinations of the insolvency of debtors, and (ii)&nbsp;the amount that will be required to pay the probable
liabilities of such Person on its existing debts (including contingent and other liabilities) as such debts become absolute and mature, and (b)&nbsp;such Person will be able to pay its liabilities, including contingent and other liabilities, as they
mature.&nbsp;For purposes of this definition, &#147;able to pay its liabilities, including contingent and other liabilities, as they mature&#148; means that such Person will be able to generate enough cash from operations, asset dispositions or
refinancing, or a combination thereof, to meet its obligations as they become due. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.14 <U>No
Other Representations or Warranties</U>. Except for the representations and warranties expressly contained in this Agreement, the Company acknowledges that neither Parent, Sub or any other Person on behalf of Parent or Sub makes any other express or
implied representation or warranty with respect to Parent, any of its Subsidiaries or their respective businesses or any other matter or with respect to any other information provided or made available to the Company, and that all such
representations and warranties, other than the representations and warranties of Parent and Sub expressly contained in this Agreement, are expressly disclaimed. Neither Parent, Sub nor any other Person makes any representation or warranty with
respect to any such information, including any information, projections, forecasts, confidential information memoranda or management presentations in expectation of the transactions contemplated by this Agreement, except that the foregoing
limitations shall not (i)&nbsp;apply to Parent or Sub to the extent Parent or Sub makes the specific representations and warranties set forth in this Agreement, but always subject to the limitations and restrictions contained herein, or
(ii)&nbsp;preclude the Company from seeking any remedy for fraud. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE V </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">COVENANTS RELATING TO CONDUCT OF BUSINESS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.1 <U>Conduct of Business by the Company Pending&nbsp;the&nbsp;Merger</U>. Except as otherwise expressly
contemplated by this Agreement, as consented in writing by Parent, as set forth in the Disclosure Schedule or as required by applicable Law, during the period from the date of this Agreement to the earlier to occur of (x)&nbsp;the date of the
termination of this Agreement or (y)&nbsp;the Effective Time, the Company shall, and shall cause each of its Subsidiaries to, in all material respects carry on their respective businesses in the ordinary course and, to the extent consistent
therewith, use its reasonable best efforts to preserve intact its current business organizations, keep available the services of its current officers and employees and preserve its relationships with customers, suppliers and others having
significant business dealings with the Company or any of its Subsidiaries. Without limiting the generality of the foregoing, and except as otherwise expressly contemplated by this Agreement or as set forth in <U>Section&nbsp;5.1</U> of the
Disclosure Schedule or as required by applicable Law, and subject to the provisions of <U>ARTICLE VIII</U>, the Company shall not, and shall cause each of its Subsidiaries not to, without the prior written consent of Parent (which consent shall not
be unreasonably withheld or delayed): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) (i)&nbsp;split, combine, reclassify, subdivide or amend the terms
of any of its capital stock, (ii)&nbsp;declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any shares of its capital stock or enter into any agreement with respect to the
voting or registration of any shares of its capital stock, or (iii)&nbsp;repurchase, redeem or otherwise acquire any shares of its capital stock or any securities convertible into or exchangeable or exercisable for shares of its capital stock;
provided that (A)&nbsp;the Company may acquire Options, RSUs and SARs upon their exercise, settlement or forfeiture and (B)&nbsp;each wholly-owned Subsidiary of the Company may repurchase, redeem or otherwise acquire shares of its capital stock or
other equity interests or securities convertible into or exchangeable or exercisable for any shares of its capital stock or other equity interests; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) issue, deliver, sell, pledge, transfer, convey, dispose of or encumber any shares of its capital stock, other equity
securities or any securities convertible into, or any rights, warrants or options to acquire, any such shares of its capital stock, such other equity securities or such convertible securities (provided that the Company may issue shares of Company
Common Stock upon exercise of Options and/or vesting of RSUs); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) amend the Company&#146;s certificate of
incorporation or by-laws or other organizational documents of the Company or its Subsidiaries; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) merge or
consolidate with any other Person, except for any such transactions between wholly-owned Subsidiaries of the Company or between the Company and any of its wholly-owned Subsidiaries; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) make any acquisition or agree to make any acquisition of any business, by merger or otherwise; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) transfer, sell, lease, license, dispose of or encumber, or agree to transfer, sell, lease, license, dispose of or
encumber, any of assets of the Company or any of its Subsidiaries that have a value in excess of $1,000,000 individually and $5,000,000 in the aggregate, except sales of inventory or obsolete assets in the ordinary course of business; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) except for trade payables of the Company or any of its Subsidiaries incurred in the ordinary course of business,
(i)&nbsp;incur any additional indebtedness; (ii)&nbsp;issue any debt securities or assume, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
guarantee or endorse, or otherwise become responsible for (whether directly, contingently or otherwise), the obligations of any Person for borrowed money; or (iii)&nbsp;make any loans, advances
or capital contributions to, or investments in, any other Person (other than any wholly-owned Subsidiary of the Company); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) except as may be required as a result of a change in regulatory accounting standards and practice or in U.S. GAAP (or
any interpretation), change any of the accounting principles or practices used by it materially affecting the reported consolidated assets, liabilities or results of operations of the Company and its Subsidiaries; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) waive, settle or compromise any Proceeding, other than waivers, settlements or compromises that involve only the
payment of monetary damages by the Company or any of its Subsidiaries of no more than $2,000,000 individually and $6,000,000 in the aggregate, in any case without the imposition of equitable relief on, or the admission of wrongdoing by, the Company
or any of its Subsidiaries; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) (i) terminate, establish, adopt, enter into, make any new grants or awards of
stock based compensation or other benefits under, amend or otherwise modify, any Company Stock Plans, Employee Benefit Plans or employment agreements (or any plan or arrangement that would be a Company Stock Plan, Employee Benefit Plan or employment
agreement if in existence on the date hereof) or increase the salary, wage, bonus or other compensation of any directors or employee of the Company or any of its Subsidiaries except (A)&nbsp;with respect to employees with a designation or title that
is below the level of &#147;Vice President,&#148; or the equivalent, increases in compensation in connection with annual performance and salary reviews or upon promotion, payment of annual bonuses or non-material increases in benefits, in each case,
in the ordinary course of business, (B)&nbsp;for grants of RSUs as permitted under <U>Section&nbsp;5.1(b)</U> or (C)&nbsp;to the extent required by any of the Employee Benefit Plans, Company Stock Plans or employment agreements existing as of the
date of this Agreement; (ii)&nbsp;enter into any severance, change of control, termination or retention arrangements with, or accelerate the compensation or benefits of, any employee or director; (iii)&nbsp;hire any Person or promote any Person
(A)&nbsp;to be an officer or an employee with a designation of &#147;Vice President&#148; or above, except to fill a vacancy in the ordinary course of business or (B)&nbsp;with an annual base salary in excess of $200,000, other than Persons hired
(x)&nbsp;to replace employees who are no longer with the Company or its Subsidiaries, or (y)&nbsp;to fill vacancies created by employee promotions; or (iv)&nbsp;make or forgive any loan to employees or directors (other than making advances of
reasonable travel and other business expenses in the ordinary course of business); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) except as required by
applicable Law, make or change any material Tax election, change any Tax accounting period, adopt or change any Tax accounting method, amend any material Tax Return, enter into any material closing agreement, settle any material Tax claim or
assessment relating to the Company or any of its Subsidiaries, surrender any right to claim a refund of material Taxes, or consent to any extension or waiver of the limitation period applicable to any material Tax claim or assessment relating to the
Company or any of its Subsidiaries; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l) authorize, recommend, adopt, propose or announce an intention to
adopt a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization of the Company or any of its Subsidiaries; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) make or commit to any capital expenditures in excess of the capital expenditures budget set forth in
<U>Section&nbsp;5.1(m)</U> of the Disclosure Schedule, except to the extent that such excess is not greater than $10,000,000 in the aggregate; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) (i) except for Material Contracts of the type described in
<U>Section&nbsp;3.17(b)(i)</U> and entered into in the ordinary course of business with respect to customers and suppliers, enter into, terminate (except at the end of its term) or modify in any material respect any Material Contract (or any
contract or agreement that if in existence on the date hereof would be a Material Contract) or waive, release or assign any material rights or claims thereunder, (ii)&nbsp;grant or acquire, agree to grant or to acquire from any third party, or
dispose of or permit to lapse any right, title or interest to, any Intellectual Property, or encumber, impair, abandon, fail to diligently maintain, transfer or otherwise dispose of any right, title or interest of the Company or any of its
Subsidiaries in any Company Intellectual Property (other than, in each case, pursuant to any Company Contract that is (A)&nbsp;a material transfer or sponsored research agreement, (B)&nbsp;a clinical trial agreement, or (C)&nbsp;a clinical research
agreement entered into with a clinical research organization, in each case, that solely grants non-exclusive rights in the ordinary course of business consistent with past practices), or (iii)&nbsp;divulge, furnish to or make accessible any trade
secrets within the Company Intellectual Property to any Person who is not subject to an enforceable written agreement to maintain the confidentiality of such trade secrets; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) announce, implement or effect any reduction in force, lay-off, early retirement program, severance program or other
program or effort concerning the termination of employment of employees of the Company or any of its Subsidiaries; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(p) enter into, amend or cancel any insurance policies other than in ordinary course of business; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q) adopt or enter into stockholder rights agreement or &#147;poison pill&#148;; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(r) acquire or dispose of any manufacturing facilities; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(s) agree in writing or otherwise to take any of the foregoing actions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.2 <U>Control of the Company&#146;s Operations</U>. Nothing contained in this Agreement shall give to
Parent, directly or indirectly, rights to control or direct the Company&#146;s or its Subsidiaries&#146; operations prior to the Effective Time. Prior to the Effective Time, the Company and its Subsidiaries shall exercise, consistent with the terms
of this Agreement, complete control of its business and operations. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE VI </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADDITIONAL AGREEMENTS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.1 <U>Company Stockholder Approval; Proxy Statement</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company shall take all lawful action reasonably necessary in accordance with the DGCL and its certificate of
incorporation and by-laws to call a meeting of its stockholders (the &#147;<U>Company Stockholder Meeting</U>&#148;) for the purpose of voting upon the adoption of this Agreement and the approval of the Merger, as soon as reasonably practicable
after the Registration Statement is declared effective by the SEC, the Proxy Statement/Prospectus is cleared by the SEC and, if required by Law, the CVR Agreement has been qualified under the Trust Indenture Act. Without limiting the generality of
the foregoing, the Company, in consultation with Parent, shall establish a record date for, call, give notice of, convene and shall use its reasonable best efforts to hold the Company Stockholder Meeting within the shortest time period allowed under
Law and the rules and regulations of the NASDAQ after the date that the Registration Statement has been declared effective by the SEC. The Board of Directors shall, subject to the provisions of <U>Section&nbsp;6.3</U> and their fiduciary duties
under applicable Law as determined by the </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Board of Directors in good faith after consultation with the Company&#146;s outside counsel, recommend to the Company&#146;s stockholders the adoption of this Agreement and approval of the
Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) As soon as is reasonably practicable (A)&nbsp;Parent, the Company and Sub shall prepare the
Registration Statement, which shall include the Proxy Statement/Prospectus, (B)&nbsp;Parent shall file the Registration Statement, and the Company shall file the Proxy Statement/Prospectus, in each case with the SEC, and (C)&nbsp;each party shall
cooperate with the other party in the preparation of, and will provide the other party with all information within such party&#146;s control that is required to be included in, the foregoing documents. Each of the parties shall use its reasonable
best efforts to respond to any comments of the SEC or its staff and to cause the Registration Statement to be declared effective by the SEC, to have the Proxy Statement/Prospectus cleared by the SEC and, if required by Law, to have the CVR Agreement
become qualified under the Trust Indenture Act, in each case as soon as reasonably practicable after the date of this Agreement. The parties shall use their respective reasonable best efforts to keep the Registration Statement effective as long as
is necessary to consummate the Merger and the transactions contemplated by this Agreement. Each of the Company, Sub and Parent agrees to use its reasonable best efforts, after consultation with the other parties hereto, to respond promptly to all
such comments of and requests by the SEC. Each of the Company, Sub and Parent agrees to notify the other parties promptly of the receipt of any written or oral comments from the SEC or its staff and of any request by the SEC or its staff for
amendments or supplements to the Registration Statement or the Proxy Statement/Prospectus or for additional information and shall supply the other parties with copies of all correspondence between such party or any of its representatives, on the one
hand, and the SEC or its staff, on the other hand, with respect to the Registration Statement or the Proxy Statement/Prospectus. Notwithstanding the foregoing, prior to filing the Registration Statement or Proxy Statement/Prospectus (or any
respective amendment or supplement thereto) or responding to any comments of the SEC with respect thereto, each party (i)&nbsp;shall provide the other parties with a reasonable opportunity to review and comment on such document or response and
(ii)&nbsp;shall reasonably consider all comments reasonably proposed by the other party. As soon as practicable and in any event within 10 Business Days after the date that the Registration Statement has been declared effective by the SEC, the
Company shall mail the Proxy Statement/Prospectus (including, with the cooperation of Parent, all Company SEC Documents and Company SEC Documents incorporated therein by reference) to the holders of shares of Company Common Stock, soliciting each of
the Company&#146;s stockholders to vote in favor of adopting this Agreement and approving the Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)
Each of the Company, Sub, and Parent shall advise the other party, promptly after it receives notice, after the time when the Registration Statement has become effective, of the issuance of any stop order or the suspension of the qualification of
the CVRs issuable in connection with the Merger. If, at any time prior to the Effective Time, any information relating to Sub or the Company or any of their respective Affiliates is discovered by the Company, Sub or Parent that should be set forth
in an amendment or supplement to any of the Registration Statement or the Proxy Statement/Prospectus so that any of such documents would not include any misstatement of a material fact or omit to state any material fact necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading, the party discovering this information shall promptly notify the other parties and, to the extent required by Law, the parties shall cause an appropriate
amendment or supplement describing this information to be promptly filed with the SEC and, to the extent required by Law, disseminated to the stockholders of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.2 <U>Directors&#146; and Officers&#146; Indemnification</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Parent shall cause the Surviving Corporation and its Subsidiaries (and their successors) to establish and maintain
for a period of not less than six years from and after the Effective Time provisions in their certificates of incorporation, by-laws and other organizational documents </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
concerning the indemnification and exoneration (including provisions relating to expense advancement) of the Company&#146;s and its Subsidiaries&#146; former and current officers, directors and
employees that are no less favorable to those persons than the provisions of the certificate of incorporation, by-laws and other organizational documents of the Company and its Subsidiaries as in effect as of the date hereof, and such provisions
shall not be amended, repealed or otherwise modified in any manner adverse to such officer, director or employee, except as required by applicable Law. Parent shall assume, be jointly and severally liable for, and honor, guaranty and stand surety
for, and shall cause the Surviving Corporation to honor, in accordance with their respective terms each of the covenants contained in this <U>Section&nbsp;6.2</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In addition to and not in limitation of the terms of <U>Section&nbsp;6.2(a)</U>, during the period ending on the
sixth anniversary of the Effective Time, each of Parent and the Surviving Corporation shall indemnify and hold harmless, and provide advancement of expenses to, to the fullest extent permitted under applicable Law, each present and former director,
officer and employee of the Company or any of its Subsidiaries (each such director, officer or employee, together with such person&#146;s heirs, executors or administrators, an &#147;<U>Indemnified Party</U>&#148; and collectively, the
&#147;<U>Indemnified Parties</U>&#148;) against any costs or expenses (including attorneys&#146; fees), judgments, fines, losses, claims, damages, liabilities and amounts paid in settlement in connection with any actual or threatened claim, action,
suit, Proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of, relating to or in connection with (i)&nbsp;any acts or omissions occurring or alleged to occur prior to, or as of, the Effective Time in
their capacities as officers, directors, employees or controlling stockholders of the Company or any of its Subsidiaries or taken by them at the request of the Company or any of its Subsidiaries (including acts or omissions in connection with such
persons serving as an officer or director or in their capacity as a controlling stockholder in any entity if such service was at the request or for the benefit of the Company) or (ii)&nbsp;the negotiation, execution, adoption and approval of this
Agreement, the Merger or the other transactions contemplated by this Agreement or arising out of or pertaining to the transactions contemplated by this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) For a period of six years after the Effective Time, Parent shall cause to be maintained in effect, without any lapse
in coverage, the current policies of directors&#146; and officers&#146; liability insurance and fiduciary liability insurance maintained by the Company and its Subsidiaries (provided that Parent may substitute therefor policies of at least the same
coverage and amounts containing terms and conditions that are no less advantageous to the directors and officers than the current policies) for a claims-reporting or discovery period of at least such six year period with respect to matters arising
on or before the Effective Time; provided, however, that (i)&nbsp;in lieu of the purchase of such insurance by Parent, the Company or the Surviving Corporation may purchase a six-year extended reporting period endorsement under the Company&#146;s
existing directors&#146; and officers&#146; liability insurance coverage effective for claims asserted for the full six year period referred to above, and (ii)&nbsp;during this period, Parent shall not be required to procure any coverage in excess
of the amount that can be obtained for the remainder of the period for an annual premium of 250% of the current annual premium paid by the Company for its existing coverage. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Surviving Corporation and Parent shall pay all reasonable expenses, including reasonable attorneys&#146; fees,
that may be incurred by any Indemnified Party in enforcing the indemnity and other obligations provided in this <U>Section&nbsp;6.2</U> as such fees are incurred upon the written request of any Indemnified Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Each Indemnified Party shall, at the cost and expense of Parent, reasonably cooperate with Parent and the Surviving
Corporation in the defense of any Proceeding for which indemnification may be sought pursuant to this <U>Section&nbsp;6.2</U> and shall furnish, at the cost and expense of Parent, or cause to be furnished records, documents, information and
testimony, as may be reasonably requested by Parent in connection therewith. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) In the event of any Proceeding for which indemnification may be sought
pursuant to this <U>Section&nbsp;6.2</U>, at the Effective Time, Parent will have the right to control the defense thereof; provided, that any Indemnified Party may participate in such defense with counsel retained by such Indemnified Party
reasonably satisfactory to Parent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) The rights of each Indemnified Party hereunder shall be in addition
to, and not in limitation of, any other rights such Indemnified Party may have under the certificate of incorporation or by-laws or any other organizational documents of the Company or any of its Subsidiaries, any other indemnification arrangement
in existence as of the date of this Agreement, the DGCL or otherwise. The provisions of this <U>Section&nbsp;6.2</U> shall survive the consummation of the Merger and are expressly intended to be for the benefit of, and shall be enforceable by, each
of the Indemnified Parties and shall be binding on the Parent, the Surviving Corporation and their respective successors and assigns. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) If Parent or the Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or
merges into any other corporation or entity and is not the continuing or surviving corporation or entity of the consolidation or merger or (ii)&nbsp;transfers all or substantially all of its properties and assets to any individual, corporation or
other entity, then and in each case, proper provisions will be made so that the successors and assigns of Parent or the Surviving Corporation, as applicable, assume all of the obligations set forth in this <U>Section&nbsp;6.2</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.3 <U>No Solicitation</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Subject to the provisions of this <U>Section&nbsp;6.3</U>, after the date hereof and prior to the Effective Time, the
Company agrees that the Company and its Subsidiaries shall not, and that it shall use its reasonably best efforts to cause the officers, directors, employees, investment bankers, attorneys and other advisors or representatives (collectively,
&#147;<U>Representatives</U>&#148;) of the Company or its Subsidiaries to not, (i)&nbsp;solicit, initiate, or knowingly encourage the making, submission or announcement of any inquiry regarding, or any proposal or offer which would reasonably be
expected to lead to, a merger, acquisition, consolidation, tender offer, exchange offer or other transaction involving, or any proposal or offer to purchase or acquire in any manner, directly or indirectly, (A)&nbsp;assets (including equity
interests of a Company Subsidiary) representing 15% or more of the assets or revenues of the Company and its Subsidiaries taken as a whole, or (B)&nbsp;15% or more of the voting securities of the Company, other than, in each case, transactions with
Parent (any such proposal or offer being hereinafter referred to as an &#147;<U>Acquisition Proposal</U>&#148;), (ii)&nbsp;enter into, participate, continue or otherwise engage in discussions or negotiations with, or provide any non-public
information to any Person (other than Parent, Sub and their Representatives) with respect to any inquiries regarding, or the making, submission or announcement of, an Acquisition Proposal, (iii)&nbsp;enter into or approve any letter of intent,
agreement in principle, option agreement, share purchase agreement, acquisition agreement or similar agreement for an Acquisition Proposal, or (iv)&nbsp;terminate, waive, amend or modify any provision of, or grant permission under, any standstill,
confidentiality agreement or similar contract to which the Company or any Company Subsidiary is a party; provided, that the foregoing shall not prohibit the Board of Directors from terminating, waiving, amending or modifying any provision of, or
granting permission under, any standstill, confidentiality agreement or similar contract if the Board of Directors determines in good faith that the failure to take such action, would be reasonably likely to constitute a breach of the Board of
Directors&#146; fiduciary duties to the Company&#146;s stockholders under applicable Law. The Company shall (i)&nbsp;immediately cease and cause to be terminated any existing solicitation, discussion or negotiation with any Person (other than
Parent, Sub or their Representatives) conducted prior to the date of this Agreement by the Company, its Subsidiaries or any of their respective Representatives with respect to any actual or potential Acquisition Proposal and (ii)&nbsp;as promptly as
reasonably practicable request that all confidential information provided by or on behalf of the Company or any of its Subsidiaries to such third party be returned or destroyed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to the provisions of this <U>Section&nbsp;6.3</U>, the Company
may, and may authorize any of its Representatives to, prior to the date on which the Stockholder Approval is obtained, (A)&nbsp;in response to a request by a Person who has made a bona fide written Acquisition Proposal that was not initiated or
solicited in violation of <U>Section&nbsp;6.3(a)</U>, provide information to such Person (including to potential financing sources of such Person), if the Company receives from such Person so requesting the information an executed confidentiality
agreement no more favorable in any material respect to such Person than the Confidentiality Agreement (as defined in <U>Section&nbsp;6.4</U>) is to Parent (it being agreed that&nbsp;the Company shall promptly provide to Parent, in accordance with
the terms of the Confidentiality Agreement, any information concerning the Company or its Subsidiaries provided to such other Person which was not previously provided to Parent); and/or (B)&nbsp;engage in discussions or negotiations with any Person
(and such Person&#146;s potential financing sources) who has made a bona fide written Acquisition Proposal that was not initiated or solicited in violation of <U>Section&nbsp;6.3(a)</U>, if, in each case, the Board of Directors determines in good
faith after consultation with the Company&#146;s financial advisor and outside legal counsel that (1)&nbsp;failure to take this action would be reasonably likely to constitute a breach of its fiduciary duties to the Company&#146;s stockholders under
applicable Law and (2)&nbsp;the Acquisition Proposal either constitutes a Superior Proposal or is reasonably likely to lead to a Superior Proposal. As used in this Agreement, &#147;<U>Superior Proposal</U>&#148; means an unsolicited, bona fide
written Acquisition Proposal made after the date hereof (for this purpose substituting &#147;60%&#148; for each reference to 15% in the definition of &#147;Acquisition Proposal&#148;) and that the Board of Directors determines in good faith (after
consultation with the Company&#146;s financial advisor and outside legal counsel) is reasonably expected to be consummated on the terms proposed, taking into account all legal, financial and regulatory aspects of the proposal, including the
financing terms thereof and the Person making such proposal, and if consummated would result in a transaction that is more favorable to the stockholders of the Company from a financial point of view than the transactions contemplated by this
Agreement (after taking into account any revisions to the terms of the transactions contemplated by this Agreement agreed to by Parent pursuant to <U>Section&nbsp;6.3(c)</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company shall notify Parent orally and in writing promptly (and in any event within 24 hours) after receipt of
any Acquisition Proposal or any request for information or inquiry which could reasonably be expected to lead to an Acquisition Proposal. The written notice shall include the identity of the Person making such Acquisition Proposal, request or
inquiry, the material terms of the Acquisition Proposal, request or inquiry (including any material written amendments or modifications, or any proposed material written amendments or modifications, thereto), and the Company shall keep Parent
reasonably informed on a current basis of any material changes with respect to such Acquisition Proposal, request or inquiry. The Company shall provide Parent with at least 36 hours prior notice (or such shorter notice as may be provided to the
Board of Directors) of any meeting of the Board of Directors at which the Board of Directors is reasonably expected to determine that an Acquisition Proposal is a Superior Proposal. The Company shall not exercise its right to terminate this
Agreement pursuant to <U>Section&nbsp;8.1(e)</U> hereof, and any purported termination pursuant thereto shall be void of no force or effect, until after the fifth Business Day following Parent&#146;s receipt from the Company of written notice
(i)&nbsp;advising Parent that the Board of Directors has received a Superior Proposal, specifying the material terms and conditions of the Superior Proposal (and attaching a copy of the definitive agreement related thereto, if available) and stating
that the Board of Directors intends to exercise its right to terminate this Agreement pursuant to <U>Section&nbsp;8.1(e)</U>. The Company agrees that after notifying Parent that an Acquisition Proposal is a Superior Proposal, including during the
five-Business Day period specified in the preceding sentence (such period, the &#147;<U>Parent Review Period</U>&#148;), Parent will be permitted to propose to the Company revisions to the terms of the transactions contemplated by this Agreement,
and the Company and its Representatives will, if requested by Parent, consider in good faith any revisions to the terms of the transactions contemplated by this Agreement proposed by Parent. The Company shall not be entitled to terminate this
Agreement pursuant to <U>Section&nbsp;8.1(e)</U> if Parent has, during the Parent Review Period, made a binding offer that, after consideration of such offer by the Board of Directors in good faith and after consultation with the Company&#146;s
financial advisor and outside legal counsel, results in the Board of Directors concluding that </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such Superior Proposal no longer constitutes a Superior Proposal. In the event of any amendment to the consideration or any other material revisions to the Superior Proposal, the Company shall be
required to deliver a new written notice to Parent and to comply with the requirements of this <U>Section&nbsp;6.3(c)</U> with respect to such new written notice (including a new Parent Review Period except that the new Parent Review Period shall be
three Business Days). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Company agrees that any action taken by any of its Subsidiaries or a
Representative of the Company or any of its Subsidiaries that, if taken by the Company, would constitute a breach of the restrictions set forth in this <U>Section&nbsp;6.3</U>, shall be deemed to be a breach of this Agreement (including this
<U>Section&nbsp;6.3</U>) by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Nothing contained in this <U>Section&nbsp;6.3</U> shall prohibit
the Company or its Board of Directors from taking and disclosing to the Company&#146;s stockholders a position with respect to a tender offer by a third party pursuant to Rules 14d-9 and 14e-2(a) promulgated under the Exchange Act or from making
such disclosure to the Company&#146;s stockholders which, in the judgment of the Board of Directors after receiving advice of outside legal counsel, is reasonably likely to be required under applicable Law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.4 <U>Access to Information; Confidentiality</U>. The Company shall, and shall cause each of its
Subsidiaries to, (i)&nbsp;afford to Parent and its Representatives, upon reasonable notice, reasonable access during normal business hours during the period prior to the Effective Time to all their respective employees, agents, properties, books,
Contracts, commitments and records; provided, however<I>,</I> that such access shall not unreasonably disrupt the Company&#146;s operations, and (ii)&nbsp;furnish promptly such information concerning the business, properties, Contracts, assets,
liabilities, personnel and other aspects of the Company and its Subsidiaries as Parent or its Representatives may reasonably request. Notwithstanding anything to the contrary in this <U>Section&nbsp;6.4</U>, (x)&nbsp;the Company shall not be
required to provide any information which it reasonably believes it may not provide Parent or Sub by reason of applicable Law (including antitrust Laws), which constitutes information protected by attorney/client privilege, or which the Company or
any Subsidiary is required to keep confidential by reason of Contracts with third parties and (y)&nbsp;with respect to the Trade Secrets included in the Company Intellectual Property, prior to the Effective Time the Company will provide during
normal business hours, to not more than three Representatives of Parent selected by Parent, reasonable access to documentation related to Trade Secrets, provided that such individuals execute a separate confidentiality agreement with the Company
covering chemistry, manufacturing and controls and related matters in a form substantially identical to the form previously executed by Parent&#146;s employees. The parties will use reasonable best efforts to make appropriate substitute disclosure
arrangements under circumstances in which the restrictions of the preceding sentence apply. All information exchanged pursuant to this <U>Section&nbsp;6.4</U> shall be subject to the confidentiality agreement, dated October&nbsp;16, 2009 (the
&#147;<U>Confidentiality Agreement</U>&#148;), between the Company and Parent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.5 <U>Reasonable
Best Efforts; Notification</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon the terms and subject to the conditions set forth in this Agreement,
each of the parties shall use its reasonable best efforts to take, or cause to be taken, all reasonable actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things reasonably necessary, proper or
advisable to consummate and make effective, in the most expeditious manner practicable, the Merger, including (i)&nbsp;the obtaining of all Consents and the making of all Registrations specified in <U>Section&nbsp;3.3(c)</U> and
<U>Section&nbsp;4.4</U> and the taking of all reasonable steps as may be necessary to obtain such Consents and to make such Registrations, (ii)&nbsp;the obtaining of all necessary consents, approvals or waivers from third parties, (iii)&nbsp;the
defending of any lawsuits or other Proceedings, whether judicial or administrative, challenging this Agreement or the consummation of the Merger, including, seeking to have any stay or temporary restraining order entered by any court or other
Governmental </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Entity vacated or reversed, and (iv)&nbsp;the execution and delivery of any additional instruments necessary to consummate the Merger and to fully carry out the purposes of this Agreement;
<I>provided, however</I>, that the obligations set forth in this sentence shall not be deemed to have been breached as a result of actions taken by the Company that are permitted under <U>Section&nbsp;6.3</U>. Notwithstanding the foregoing, neither
Parent or Sub, on the one hand, and the Company, on the other hand, shall be obligated to amend or waive the provisions of any Contract, or obligated to pay any consent or similar fees or payments, unless such action is conditioned upon the
consummation of the Merger. Without limiting the foregoing, none of the parties shall take or agree to take any action that could reasonably be expected to result in any of the conditions set forth in <U>Article VII</U> not being satisfied or to
prevent or materially delay the consummation of the Merger or the transactions contemplated by this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Without limiting the foregoing, each of Parent and the Company undertakes and agrees to file as soon as practicable,
and in any event prior to 10 Business Days after the date hereof, a Notification and Report Form under the HSR Act with the United States Federal Trade Commission (the &#147;<U>FTC</U>&#148;) and the Antitrust Division of the United States
Department of Justice (the &#147;<U>Antitrust Division</U>&#148;). Each of Parent and the Company shall (i)&nbsp;respond as promptly as practicable to any inquiries received from the FTC or the Antitrust Division for additional information or
documentation and to all inquiries and requests received from any state attorney general or other Governmental Entity in connection with antitrust matters, and (ii)&nbsp;not extend any waiting period under the HSR Act or enter into any agreement
with the FTC or the Antitrust Division not to consummate the transactions contemplated by this Agreement, except with the prior written consent of the other parties hereto (which consent shall not be unreasonably withheld or delayed). Parent shall
use its reasonable best efforts to avoid or eliminate impediments under any antitrust, competition, or trade regulation law that may be asserted by the FTC, the Antitrust Division, any state attorney general or any other Governmental Entity with
respect to the Merger so as to enable the consummation thereof as promptly as reasonably practicable and shall defend through litigation on the merits any claim asserted in any court by any party, including appeals. Without limiting the foregoing
and subject to this <U>Section&nbsp;6.5(b)</U>, Parent shall propose, negotiate, commit to and effect, by consent decree, hold separate order, or otherwise, the sale, divestiture or disposition of such assets or businesses of Parent or, effective as
of the Effective Time, the Surviving Corporation, or their respective Subsidiaries or otherwise commit to take any action which it is capable of taking, take or commit to take such action that limits its freedom of action with respect to, or its
ability to retain, any of the businesses, services or assets of Parent, the Surviving Corporation or their respective Subsidiaries, in order to avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other
order in any suit or Proceeding, or any impediment under any antitrust Law, competition, or trade regulation Law, which would otherwise have the effect of preventing the consummation of the Merger. Notwithstanding any of the foregoing, nor anything
else contained in this Agreement, Parent shall not be required to sell, divest or otherwise dispose of, hold separate, enter into any license or similar agreement with respect to, restrict the ownership or operation of, or agree to sell, divest or
otherwise dispose of, hold separate, enter into any license or similar agreement with respect to, or restrict the ownership or operation of (i)(A) any assets or businesses of the Company or any of its Subsidiaries or (B)&nbsp;any assets or
businesses of Parent or any of its Affiliates or Subsidiaries, in the case of either clause (A)&nbsp;or (B), to the extent that such sale, divestiture, disposition, or agreement would have a material adverse effect on the business, operations,
financial condition or results of operations of the combined business of Parent and the Company after giving effect to the consummation of the transactions contemplated by this Agreement, or (ii)&nbsp;the Product to the extent such sale,
divestiture, disposition, agreement or restriction would have a material adverse effect on the ability of the Company to exploit the Product in the Applicable Jurisdictions. The Company shall agree if, and solely if, requested by Parent, to divest,
hold separate or otherwise take or commit to take any action that limits its freedom of action with respect to, or its ability to retain, any of the businesses, services, or assets of the Company or any of its Subsidiaries, provided that any such
action shall be conditioned upon the consummation of the Merger and the transactions contemplated hereby. Each party shall (i)&nbsp;promptly notify the other party of any material communication
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to that party from the FTC, the Antitrust Division, any state attorney general or any other Governmental Entity and, subject to applicable Law, permit the other party to review in advance any
proposed written communication to any of the foregoing; (ii)&nbsp;to the extent practicable not agree to participate in any substantive meeting or discussion with any Governmental Entity in respect of any filings, investigation or inquiry concerning
this Agreement or the Merger unless it consults with the other party in advance and, to the extent permitted by such Governmental Entity, gives the other party the opportunity to attend and participate thereat; and (iii)&nbsp;furnish the other party
with copies of all correspondence, filings, and communications (and memoranda setting forth the substance thereof) between them and their Affiliates and their respective Representatives on the one hand, and any Governmental Entity or members of
their respective staffs on the other hand, with respect to this Agreement and the Merger. Subject to its obligations in <U>Section&nbsp;6.5(a)</U>, Parent shall have the right to determine and direct the strategy and process by which the parties
will seek required approvals under antitrust, competition or trade regulation Laws; provided that Parent will consult with and consider in good faith the views of the Company in connection with proceedings under or relating to any such Laws.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.6 <U>Benefit Plans</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) During the period beginning on the Effective Time and ending no earlier than December&nbsp;31, 2011 (the
&#147;<U>Transition Period</U>&#148;), Parent shall provide, or shall cause the Surviving Corporation to provide, each active employee of the Company or its Subsidiaries as of the Effective Time (each, an &#147;<U>Employee</U>&#148;) with salary,
cash bonus opportunities and employee benefits (including equity-based benefits) that are not materially less favorable in the aggregate than (i)&nbsp;the salary, cash bonus opportunities and employee benefits in effect with respect to such Employee
on the date of this Agreement or as increased after the date of this Agreement consistent with the provisions of <U>Section&nbsp;5.1(j)</U>; (ii)&nbsp;the salary, cash bonus opportunities and employee benefits generally provided by Parent and its
Subsidiaries (other than the Surviving Corporation and its Subsidiaries) from time to time to employees of Parent and its Subsidiaries (other than the Surviving Corporation and its Subsidiaries) in the country that is such Employee&#146;s principal
place of employment who are similarly situated to such Employee in title, rank, tenure (counting tenure with the Company and its Subsidiaries prior to the Effective Time to the extent recognized by the Company or its Subsidiaries prior to the
Effective Time and reflected on the books and records of the Company) and job duties; or (iii)&nbsp;any combination of the foregoing (e.g., during the Transition Period, Parent may transition an Employee into one or more of its employee benefit
programs while maintaining the Employee&#146;s salary and cash bonus opportunities as in effect immediately prior to the Effective Time); provided, that, (x)&nbsp;for purposes of and subject to this <U>Section&nbsp;6.6(a)</U>, Parent shall determine
in its sole discretion the combination of compensation and benefits described in clauses (i)&nbsp;through (iii)&nbsp;to be provided to any Employee during the Transition Period and (y)&nbsp;nothing in this <U>Section&nbsp;6.6(a)</U> shall be deemed
to prohibit Parent from changing the title, rank or job duties of any Employee at any time after the Effective Time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) To the extent that Employees become eligible to participate in any &#147;employee benefit plan,&#148; as defined in
Section&nbsp;3(3) of ERISA, maintained by Parent or any of its Subsidiaries (collectively, the &#147;<U>Parent Plans</U>&#148;), then for purposes of determining eligibility to participate and vesting and, with respect to any Parent Plan that
provides severance, vacation or paid-time off benefits, for purposes of benefit accrual, service with the Company or any of its Subsidiaries prior to the Effective Time shall be treated as service with Parent or any of its Subsidiaries, in each case
except as prohibited by an insurer or service provider under a Parent Plan or by applicable Law; <I>provided, however,</I> that such service shall not be recognized to the extent that such recognition would result in any duplication of benefits. In
addition, subject to the terms of the applicable Parent Plan and applicable Law, Parent shall use reasonable best efforts to (i)&nbsp;waive all limitations as to preexisting conditions, exclusions and waiting periods with respect to participation
and coverage requirements applicable to the Employees under any Parent Plan that is a welfare benefit plan in which such Employees may be eligible to participate after the </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Effective Time and (ii)&nbsp;provide each Employee with credit for any co-payments and deductibles paid prior to the Effective Time in satisfying any applicable deductible or out-of-pocket
requirements under any Parent Plans that are welfare plans in which such Employees are eligible to participate after the Effective Time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Unless Parent directs the Company otherwise in writing no later than five Business Days prior to the Effective Time,
the Board of Directors shall adopt resolutions terminating, effective at least one day prior to the Effective Time, the Company&#146;s 401(k) Retirement Plan. Prior to the Effective Time, the Company shall provide Parent with executed resolutions of
the Board of Directors authorizing such termination in a form reasonably acceptable to Parent. The Company shall also take such other actions in furtherance of the termination of the Company&#146;s 401(k) Retirement Plan as Parent may reasonably
require. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Nothing contained in this <U>Section&nbsp;6.6</U> shall (i)&nbsp;be treated as an amendment of
any particular Parent Plan, (ii)&nbsp;give any third party any right to enforce or confer upon the applicability of the provisions of this <U>Section&nbsp;6.6</U> or (iii)&nbsp;obligate Parent or any of its Subsidiaries to (A)&nbsp;maintain any
particular Employee Benefit Plan or Parent Plan or (B)&nbsp;retain the employment of any particular Employee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Parent shall, or shall cause the Surviving Corporation to, comply with the provisions set forth on
<U>Section&nbsp;6.6(e)</U> of the Disclosure Schedule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.7 <U>Fees and Expenses</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except as otherwise provided by this Agreement, all fees and expenses incurred in connection with the Merger and the
other transactions contemplated by this Agreement shall be paid by the party incurring such fees or expenses, whether or not the Merger is consummated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to <U>Section&nbsp;6.7(d)</U>, the Company agrees to pay Parent a fee equal to $145,000,000 if: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) this Agreement is terminated by (A)&nbsp;the Company pursuant to <U>Section&nbsp;8.1(e)</U> (in which case, the fee
shall be payable at the time of termination) or (B)&nbsp;Parent pursuant to <U>Section&nbsp;8.1(c)(ii)</U> or <U>Section&nbsp;8.1(d)</U> (in which case, the fee shall be payable within two Business Days after such termination); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) (x) this Agreement is terminated by Parent pursuant to <U>Section&nbsp;8.1(c)(i)</U>, (y)&nbsp;prior to the date
upon which the breach giving rise to Parent&#146;s right to terminate this Agreement pursuant to <U>Section&nbsp;8.1(c)(i)</U> occurs but after the date hereof, a bona fide Acquisition Proposal (which, for purposes of this
<U>Section&nbsp;6.7(b)</U>, shall have the meaning set forth in the definition of Acquisition Proposal contained in <U>Section&nbsp;6.3(a)</U>, except that all references to 15% shall be deemed references to &#147;60%&#148;) for the Company shall
have been publicly announced (other than by Parent or its Affiliates) and (z)&nbsp;within 12 months after such termination either the Company shall have entered into a definitive agreement relating to an Acquisition Proposal or a transaction
contemplated by an Acquisition Proposal for the Company shall have been consummated (in which case, the fee shall be payable within two Business Days thereafter); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) (x) this Agreement is terminated by Parent or the Company pursuant to <U>Section&nbsp;8.1(b)(iii),</U>
(y)&nbsp;prior to the date of the Company Stockholder Meeting but after the date hereof, a bona fide Acquisition Proposal for the Company shall have been publicly announced (other than by Parent or its Affiliates) and (z)&nbsp;within 12 months after
such termination either the Company shall have </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
entered into a definitive agreement relating to an Acquisition Proposal or a transaction contemplated by an Acquisition Proposal for the Company shall have been consummated (in which case, the
fee shall be payable within two Business Days thereafter); or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) (w)&nbsp;this Agreement is terminated by
Parent or the Company pursuant to <U>Section&nbsp;8.1(b)(i)</U>, (x)&nbsp;prior to such termination, the Antitrust Approval shall have been obtained, (y)&nbsp;prior to such termination but after the date hereof, a bona fide Acquisition Proposal for
the Company shall have been publicly announced (other than by Parent or its Affiliates) and (z)&nbsp;within 12 months after such termination either the Company shall have entered into a definitive agreement relating to an Acquisition Proposal or a
transaction contemplated by an Acquisition Proposal for the Company shall have been consummated (in which case, the fee shall be payable within two Business Days thereafter). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The fee payable pursuant to <U>Section&nbsp;6.7(b)</U> shall be made by wire transfer of same day funds to an account
designated in writing by Parent. The Company acknowledges that the agreements contained in <U>Section&nbsp;6.7(b)</U> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, Parent and Sub would
not enter into this Agreement; accordingly, if the Company fails to promptly pay the amount due pursuant to <U>Section&nbsp;6.7(b)</U>, and, in order to obtain such payment, Parent or Sub commences a suit which results in a binding nonappealable
judgment rendered by a court of competent jurisdiction against the Company for the fee set forth in <U>Section&nbsp;6.7(b)</U>, the Company shall pay to Parent or Sub its reasonable documented costs and expenses (including reasonable attorneys&#146;
fees) in connection with such suit together with interest on the amount due at the prime rate of Bank of America N.A. in effect on the date such payment was required to be made hereunder plus 2%&nbsp;per annum. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Parent agrees that, except in the case of fraud or a willful and material breach hereof (as defined in
<U>Section&nbsp;8.2</U>), the payment provided for in <U>Section&nbsp;6.7(b)</U> shall be the sole and exclusive remedy of Parent upon termination of this Agreement under circumstances giving rise to an obligation (or potential obligation) of the
Company to pay the amounts set forth in <U>Section&nbsp;6.7(b)</U> and such remedy shall be limited to the aggregate of the sums stipulated in such <U>Section&nbsp;6.7(b)</U>. In no event shall the Company be required to pay to Parent more than one
termination fee pursuant to <U>Section&nbsp;6.7(b)</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.8 <U>Public Announcements</U>. The
initial press release with respect to this Agreement, the Merger and the other transactions contemplated hereby shall be a joint release mutually agreed upon by the Company and Parent. Thereafter, Parent and Sub, on the one hand, and the Company, on
the other hand, shall use reasonable efforts to consult with each other before issuing, and provide each other the opportunity to review and comment upon, any press release or other public statements with respect to the Merger and the other
transactions contemplated by this Agreement and, unless it has made reasonable efforts to do the foregoing, shall not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable
Law, court process or by obligations pursuant to any listing agreement with any national securities exchange. Notwithstanding the foregoing provisions of this <U>Section&nbsp;6.8</U>, Parent and the Company and their respective Representatives may
make public releases or announcements concerning the transactions contemplated hereby that are not inconsistent with previous press releases or other public statements made by Parent and/or the Company in compliance with this
<U>Section&nbsp;6.8</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.9 <U>Sub</U>. Parent will take all action necessary (a)&nbsp;to cause
Sub to perform its obligations under this Agreement to consummate the Merger in accordance with the terms and subject to the conditions set forth in this Agreement and (b)&nbsp;to ensure that, prior to the Effective Time, Sub shall not conduct any
business or make any investments other than as specifically contemplated by this Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.10 <U>CVR Agreement</U>. At or prior to the Closing, Parent
will duly adopt, execute and deliver, and shall ensure that a duly qualified Trustee executes and delivers, the CVR Agreement, subject to any reasonable revisions to the CVR Agreement that are requested by such Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.11 <U>Transfer Taxes</U>. Parent shall assume liability for and pay all sales, use, transfer, real
property transfer, documentary, recording, gains, stock transfer and similar Taxes and fees, and any deficiency, interest or penalty asserted with respect thereof (collectively, &#147;<U>Transfer Taxes</U>&#148;) resulting from the transactions
effected pursuant to this Agreement. The Company shall cooperate with Parent as to the filing of all necessary documentation and Tax Returns with respect to such Transfer Taxes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.12 <U>Listing</U>. As promptly as practicable after the date hereof, Parent shall prepare and submit to
the NASDAQ (or such other exchange(s), electronic trading networks or other suitable trading platforms as are mutually agreed by Parent and the Company) an application covering the CVRs and the shares of Parent Common Stock being issued in the
Merger and shall use its reasonable best efforts to cause the CVRs and the shares of Parent Common Stock being issued in the Merger (including any CVRs which may be issued pursuant to <U>Section&nbsp;2.7(a)(i)</U> and <U>Section&nbsp;2.7(b)(i)</U>)
to be approved for listing (subject to notice of issuance) for trading on the NASDAQ (or such other exchange(s), electronic trading networks or other suitable trading platforms as are mutually agreed by Parent and the Company) at or prior to the
Effective Time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.13 <U>Certain Notices</U>. Subject to compliance with all applicable Laws, the
Company and Parent, as the case may be, shall confer on a regular basis with each other, report on operational matters and shall promptly advise each other orally and in writing upon becoming aware of any Event having, or which would be reasonably
likely to have, individually or in the aggregate, a Company Material Adverse Effect. Parent and the Company shall give prompt notice to the other of any Event of which it obtains Knowledge that would be reasonably expected to materially delay or
prevent the consummation of the Merger. Furthermore, the Company shall give prompt notice to Parent, and Parent or Sub shall give prompt notice to the Company, upon, to the Knowledge of the Company or the Knowledge of Parent, as applicable
(i)&nbsp;any representation or warranty made by it in this Agreement becoming untrue or inaccurate in any material respect, (ii)&nbsp;the occurrence of any condition, event or circumstance that would be reasonably expected to result in any of the
conditions in <U>Section&nbsp;7.2(a)</U> or <U>Section&nbsp;7.3(a)</U> not being met, or (iii)&nbsp;the failure by it to comply with or satisfy in any material respect any covenant or agreement to be complied with or satisfied by it under this
Agreement; provided, however, that no such notification shall affect the representations, warranties, covenants or agreements of, or the conditions to the obligations of, the parties hereto under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.14 <U>Section&nbsp;16 Matters</U>. Prior to the Effective Time, the Board of Directors, or an appropriate
committee of non-employee directors thereof, shall adopt a resolution consistent with the interpretive guidance of the SEC so that the disposition by any officer or director of the Company who is a covered Person of the Company for purposes of
Section&nbsp;16 of the Exchange Act and the rules and regulations thereunder (&#147;<U>Section 16</U>&#148;) of Company Common Stock, Options, RSUs and SARs pursuant to this Agreement and the Merger shall be an exempt transaction for purposes of
Section&nbsp;16. Prior to the Effective Time, Parent&#146;s board of directors, or an appropriate committee of non-employee directors thereof, shall adopt a resolution consistent with the interpretive guidance of the SEC so that the acquisition by
any officer or director of the Company who is a covered Person of the Company for purposes of Section&nbsp;16 of Parent Common Stock pursuant to this Agreement and the Merger shall be an exempt transaction for purposes of Section&nbsp;16.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.15 <U>State Takeover Laws</U>. If any &#147;fair price,&#148; &#147;moratorium,&#148;
&#147;control share acquisition,&#148; &#147;business combination&#148; or other similar anti-takeover statute or regulation enacted under </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
state or federal laws in the United States becomes or is deemed to be applicable to the Company, Parent, Sub, the Merger or the Voting Agreement or any other transaction contemplated by this
Agreement, the Board of Directors shall take all action necessary to render such Law inapplicable to the foregoing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.16 <U>FIRPTA Statement</U>. The Company shall use reasonable best efforts to deliver to Parent on or prior
to the Closing Date a statement conforming to the requirements of Section&nbsp;1.1445-2(c)(3) of the Treasury Regulations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.17 <U>Further Actions</U>. The Company shall use reasonable best efforts to take the actions listed on
<U>Section&nbsp;6.17</U> of the Disclosure Schedule prior to the Effective Time. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE VII </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONDITIONS PRECEDENT </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.1 <U>Conditions to Each Party&#146;s Obligation to Effect the Merger</U>. The respective obligation of
each party to effect the Merger is subject to the satisfaction or waiver on or prior to the Closing Date of the following conditions: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Stockholder Approval</U>. This Agreement and the Merger shall have been duly adopted by the holders of a majority
of the outstanding shares of Company Common Stock in accordance with the DGCL (the &#147;<U>Stockholder Approval</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>No Injunctions or Restraints</U>. No Governmental Entity in an Applicable Jurisdiction shall have issued or
entered a temporary restraining order, preliminary or permanent injunction or other order that is in effect and that prohibits the consummation of the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>HSR Act</U>. The waiting period (and any extension thereof) under the HSR Act applicable to the Merger shall have
expired or been terminated (the &#147;<U>Antitrust Approval</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Registration Statement</U>.
The Registration Statement shall have been declared effective and no stop order suspending the effectiveness of the Registration Statement shall be in effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.2 <U>Additional Conditions to Obligations of Parent and Sub</U>. The obligation of Parent and Sub to
effect the Merger is subject to the satisfaction or waiver by Parent on or prior to the Closing Date of the following additional conditions: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Representations and Warranties</U>. (i)&nbsp;The representations and warranties of the Company set forth in
<U>Section&nbsp;3.2(a)</U> shall be true and correct in all but de minimis respects (which for purposes of this <U>Section&nbsp;7.2</U> shall mean 2% or less of the aggregate outstanding shares of Company Common Stock on a fully diluted basis) on
the date of this Agreement and at the Closing as though made on and as of the Closing Date (except to the extent that such representation and warranty speaks as of a particular date, in which case such representation and warranty shall be true and
correct as of that date), and (ii)&nbsp;the other representations and warranties of the Company set forth in this Agreement shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material
Adverse Effect&#148; set forth therein) on the date of this Agreement and at the Closing as though made on and as of the Closing Date (except to the extent that such representation and warranty speaks as of a particular date, in which case such
representation and warranty shall be true and correct as of that date), except where the failure of the representations and warranties to so be true and correct has not had and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Parent shall have received a certificate to such effect signed on behalf of the Company by an executive officer of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Performance of Obligations</U>. The Company shall have performed or complied with, in all material respects, its
obligations and covenants required to be performed or complied with by it under this Agreement at or prior to the Closing, and Parent shall have received a certificate signed on behalf of the Company by an executive officer of the Company to such
effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Absence of Material Adverse Effect</U>. Since the date of this Agreement, there shall not have
occurred any Company Material Adverse Effect, and Parent shall have received a certificate signed on behalf of the Company by an executive officer of the Company to such effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Related Agreements</U>. The Related Agreements shall be in full force and effect in accordance with their terms.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.3 <U>Additional Conditions to Obligations of the Company</U>. The obligation of the Company to
effect the Merger is subject to the satisfaction or waiver by the Company on or prior to the Closing Date of the following additional conditions: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Representations and Warranties</U>. The representations and warranties of Parent set forth in this Agreement shall
be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Parent Material Adverse Effect&#148; set forth therein) on the date of this Agreement and at the Closing as though made on and as of the Closing Date
(except to the extent that such representation and warranty speaks as of a particular date, in which case such representation and warranty shall be true and correct as of that date), except where the failure of the representations and warranties to
so be true and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. The Company shall have received a certificate to such effect signed on behalf of Parent by an
executive officer of Parent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Performance of Obligations</U>. Parent and Sub shall have performed or
complied with, in all material respects, its obligations and covenants required to be performed or complied with by them under this Agreement at or prior to Closing, and the Company shall have received a certificate signed on behalf of Parent and
Sub by an executive officer of each of Parent and Sub to such effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Absence of Material Adverse
Effect</U>. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect, and the Company shall have received a certificate signed on behalf of Parent by an executive officer of Parent to such effect.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>CVR Agreement</U>. The CVR Agreement shall have been duly executed and delivered by Parent and the
Trustee and be in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Listing</U>. The shares of Parent Common Stock being issued
in the Merger shall have been approved for listing (subject to notice of issuance) for trading on NASDAQ. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.4 <U>Frustration of Closing Conditions</U>. None of the Company, Parent or Sub may rely on the failure of
any condition precedent set forth in this <U>ARTICLE VII</U> to be satisfied if such failure was caused by such party&#146;s failure to comply with its obligations set forth in this Agreement to consummate and make effective the transactions
provided for herein, as required by and subject to <U>Section&nbsp;6.5</U>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.5 <U>Invoking Certain Provisions</U>. If Parent and Sub wish
to invoke any of the conditions set forth in <U>Section&nbsp;7.2</U> as a basis not to consummate the Merger, Parent or Sub, as applicable, will have the burden of proof to establish that such condition has not been satisfied; provided, that if
Parent and Sub satisfy the burden of proof that a Company Material Adverse Effect has occurred (without regard to the exclusions applicable thereto), the Company will have the burden of proof to establish that any exclusion in the definition of
Company Material Adverse Effect is applicable. If the Company wishes to invoke any of the conditions set forth in <U>Section&nbsp;7.3</U> as a basis not to consummate the Merger, the Company will have the burden of proof to establish that such
condition has not been satisfied; provided, that if the Company satisfies the burden of proof that a Parent Material Adverse Effect has occurred (without regard to the exclusions applicable thereto), Parent will have the burden of proof to establish
that any exclusion in the definition of Parent Material Adverse Effect is applicable. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE VIII </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">TERMINATION, AMENDMENT AND WAIVER </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.1 <U>Termination</U>. This Agreement may be terminated at any time prior to the Effective Time, whether
before or after receipt of the Stockholder Approval: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) by mutual written consent of Parent and the Company;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) by either Parent or the Company: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) if the Closing shall not have occurred on or before March&nbsp;31, 2011 (the &#147;<U>Termination Date</U>&#148;);
provided, however<I>,</I> that the right to terminate this Agreement under this <U>Section&nbsp;8.1(b)(i)</U> shall not be available to any party whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the
failure of the Closing to occur on or before the Termination Date; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) if any Governmental Entity in an
Applicable Jurisdiction shall have issued or entered a permanent injunction or other order that is in effect preventing or prohibiting the consummation of the Merger and such injunction or order shall have become final and nonappealable; provided
that the right to terminate this Agreement pursuant to this <U>Section&nbsp;8.1(b)(ii)</U> shall not be available to any party whose failure to fulfill any obligation under this Agreement (including such party&#146;s obligations set forth in
<U>Section&nbsp;6.5</U>) has been the cause of, or resulted in, such action; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) if, upon a vote at a
duly held Company Stockholder Meeting (including any postponement or adjournment thereof) to obtain the Stockholder Approval in accordance with this Agreement, the Stockholder Approval is not obtained; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) by Parent, if (i)&nbsp;the Company breaches or fails to perform any of its representations, warranties, covenants or
obligations contained in this Agreement, in any case, as a result of which a condition set forth in <U>Section&nbsp;7.2(a)</U> or <U>Section&nbsp;7.2(b)</U> will not be able to be satisfied prior to or as of the Termination Date (provided that
Parent or Sub is not then in breach of any representation, warranty or covenant contained in this Agreement such that the conditions set forth in <U>Section&nbsp;7.3(a)</U> or <U>Section&nbsp;7.3(b)</U> would not then be satisfied), or (ii)&nbsp;the
Company breaches or fails to perform in any material respect its obligations under <U>Section&nbsp;6.3</U>; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) by Parent, prior to the Company Stockholder Meeting, if (i)&nbsp;the Board of Directors shall have publicly withdrawn
its approval or recommendation of this Agreement or the Merger or shall have publicly recommended to the stockholders of the Company any Acquisition Proposal, or (ii)&nbsp;a tender </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or exchange offer, that if successful, would result in any Person or group becoming the beneficial owner of 15% or more of the outstanding Company Stock, has been commenced (other than by Parent
or any Affiliate of Parent) and the Board of Directors fails to recommend that the stockholders of the Company not tender their shares in such tender or exchange offer within 10 Business Days of such commencement; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) by the Company, prior to the date on which the Stockholder Approval is obtained, in order to concurrently enter into
a definitive agreement with respect to a Superior Proposal, provided that the Company shall have complied in all material respects with the terms of <U>Section&nbsp;6.3</U> and concurrently pays to Parent all amounts payable pursuant to
<U>Section&nbsp;6.7(b)</U>; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) by the Company, if Parent or Sub breaches or fails to perform any of its
representations, warranties, covenants or obligations contained in this Agreement, in any case, as a result of which a condition set forth in <U>Section&nbsp;7.3(a)</U> or <U>Section&nbsp;7.3(b)</U> will not be able to be satisfied prior to or as of
the Termination Date (provided that the Company is not then in material breach of any representation, warranty or covenant contained in this Agreement). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.2 <U>Effect of Termination</U>. In the event of termination of this Agreement by either the Company or
Parent as provided in <U>Section&nbsp;8.1</U>, this Agreement shall forthwith become void and have no effect, without any liability or obligation on the part of Parent, Sub or the Company, other than the last sentence of <U>Section&nbsp;6.4</U>,
<U>Section&nbsp;6.7</U>, this <U>Section&nbsp;8.2</U> and <U>Article IX</U>, which provisions shall survive such termination, and provided that nothing herein shall relieve any party from liability for any fraud or willful and material breach
hereof. For purposes hereof, a &#147;<U>willful and material breach</U>&#148; shall mean a material breach that is a consequence of an act undertaken by a breaching party with the knowledge (actual or constructive) that the taking of such action
would, or would reasonably be expected to, give rise to a breach hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.3 <U>Amendment</U>.
Subject to applicable Law, this Agreement may be amended, modified or supplemented by the parties at any time before or after receipt of the Stockholder Approval. This Agreement may not be amended, modified or supplemented except by an instrument in
writing signed on behalf of each of the parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.4 <U>Extension; Waiver</U>. At any time prior
to the Effective Time, the parties may (a)&nbsp;extend the time for the performance of any of the obligations or other acts of the other parties, (b)&nbsp;waive any inaccuracies in the representations and warranties of the other parties contained in
this Agreement or in any document delivered pursuant to this Agreement or (c)&nbsp;subject to the proviso of <U>Section&nbsp;8.3</U>, waive compliance with any of the agreements of the other parties or conditions in favor of such party contained in
this Agreement (provided, that a waiver must be in writing and signed by the party against whom the waiver is to be effective). Any agreement on the part of a party to any such extension or waiver shall be valid only if set forth in an instrument in
writing signed on behalf of such party. The failure of any party to this Agreement to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.5 <U>Procedure for Termination, Amendment, Extension or Waiver</U>. A termination of this Agreement
pursuant to <U>Section&nbsp;8.1</U>, an amendment of this Agreement pursuant to <U>Section&nbsp;8.3</U> or an extension or waiver pursuant to <U>Section&nbsp;8.4</U> shall, in order to be effective, require in the case of Parent, Sub or the Company,
action by its board of directors or the duly authorized designee of its board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE IX </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">MISCELLANEOUS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.1 <U>Non-Survival of Representations, Warranties and Agreements</U>. All representations and warranties
set forth in this Agreement or in any instrument delivered pursuant to this Agreement shall terminate at the Effective Time. None of the covenants or agreements of the parties in this Agreement shall survive the Effective Time, other than
(a)&nbsp;the covenants and agreements of the parties contained in this <U>ARTICLE IX</U>, in <U>ARTICLE II</U> and in <U>Section&nbsp;6.2</U> and <U>Section&nbsp;6.6</U>, and (b)&nbsp;those other covenants and agreements contained herein that by
their terms apply, or that are to be performed in whole or in part, after the Effective Time, which shall survive the consummation of the Merger until fully performed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.2 <U>Notices</U>. Except for notices that are specifically required to be delivered orally, all notices,
requests, claims, demands and other communications hereunder shall be in writing and shall be deemed given (a)&nbsp;on the date of delivery, if delivered in person or by facsimile or e-mail (upon confirmation of receipt) prior to 5:00 p.m. in the
time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m. in the time zone of the receiving party, (b)&nbsp;on the first Business Day following the date of dispatch, if delivered by a recognized overnight courier
service (upon proof of delivery) or (c)&nbsp;on the fifth Business Day following the date of mailing, if delivered by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="82%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">11755 Wilshire Blvd., 20th Floor</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, CA 90025</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 310.883.1300</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 310.998.8553</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Patrick Soon-Shiong, Executive Chairman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>pss@abraxisbio.com</U></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="82%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">with copies to:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">11755 Wilshire Blvd., 20th Floor</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, CA 90025</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 310.883.1300</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 310.998.8553</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charles Kim, General Counsel</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>CKim@abraxisbio.com</U></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">and</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="82%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fried, Frank, Harris, Shriver&nbsp;&amp; Jacobson LLP</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">One New York Plaza</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10004</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 212.859.8000</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 212.859.4000</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Philip Richter, Esq.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>philip.richter@friedfrank.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brian Mangino, Esq.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>brian.mangino@friedfrank.com</U></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Parent or Sub:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="82%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 Morris Avenue</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Summit, New Jersey 07901</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 908.673.9000</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 908.673.2769</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">George Golumbeski, Senior Vice President Business Development</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ggolumbeski@celgene.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">with copies to:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 Morris Avenue</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Summit, New Jersey 07901</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 908.673.9000</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 908.673.2771</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thomas Perone, Corporate Counsel</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>tperone@celgene.com</U></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">and</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jones Day</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">3161 Michelson Drive</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 800</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irvine, CA 92612</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 949.851.3939</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 949.553.7539</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jonn R. Beeson, Esq.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>jbeeson@jonesday.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin Espinola, Esq.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>kbespinola@jonesday.com</U></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such
other address as any party may have furnished to the other parties in writing in accordance with this <U>Section&nbsp;9.2</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.3 <U>Specific Performance</U>. The parties hereby acknowledge and agree that the failure of any party to
perform its agreements and covenants hereunder in accordance with their specific terms, including its failure to take all actions as are necessary on its part to consummate the </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
transactions contemplated hereby, will cause irreparable injury to the other party, for which damages, even if available, will not be an adequate remedy. Accordingly, each party hereby consents
to the issuance of temporary, preliminary and permanent injunctive relief in any court of the United States or any state having jurisdiction to compel performance of such party&#146;s obligations, or to prevent breaches or threatened breaches of
this Agreement, and to the granting by any such court of the remedy of specific performance of its obligations hereunder, without, in any such case, the requirement to post any bond or other undertaking, in addition to any other rights or remedies
available hereunder or at law or in equity. Each of the parties further agrees that it will not oppose, and hereby waives any defense to, the granting of an injunction, specific performance and other equitable relief on the basis that the other
parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity. Each of the parties further waives any requirement under any Law to post security as a prerequisite to obtaining
equitable relief. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.4 <U>Assignment; Binding Effect</U>. Neither this Agreement nor any of the
rights, interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of Law or otherwise) without the prior written consent of the other parties. Subject to the preceding sentence, this Agreement shall be
binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.5 <U>Entire Agreement</U>. This Agreement, the Disclosure Schedule, the Confidentiality Agreement, the
Related Agreements constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and understandings among the parties with respect thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.6 <U>Governing Law</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT
REGARD TO ITS RULES OF CONFLICT OF LAWS. Each of the parties hereto (i)&nbsp;consents to submit itself to the personal jurisdiction of any court of the United States located in the State of Delaware or of the Court of Chancery in the State of
Delaware in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (ii)&nbsp;agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any
such court and (iii)&nbsp;agrees that, except as permitted by <U>Section&nbsp;9.3</U>, it will not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than a court of the United States
located in the State of Delaware or the Court of Chancery in the State of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) EACH PARTY
ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A
TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i)&nbsp;NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS
WAIVER, (iii)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (iv)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.7 <U>Counterparts</U>. This Agreement may be executed by the
parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies hereof
each signed by less than all, but together signed by all of the parties hereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.8 <U>Headings
and Table of Contents; Interpretation</U>. Headings of the Articles and Sections of this Agreement, the Table of Contents, and the Index of Defined Terms are for the convenience of the parties only, and shall be given no substantive or interpretive
effect whatsoever. If a term is defined as one part of speech (such as a noun), it shall have a corresponding meaning when used as another part of speech (such as a verb). Whenever the context so requires, the singular shall include the plural, the
plural shall include the singular, and the use of a gender shall include all genders. The terms &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and terms of like import used in this Agreement shall refer to this Agreement as a whole
and not to any particular provision of this Agreement. Whenever the terms &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation,&#148;
whether or not they are in fact followed by those words or words of like import. The terms &#147;writing&#148; and &#147;written&#148; and terms of like import used in this Agreement shall refer to printing, typing and other means of reproducing
words (including electronic media) in a visible form. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.9 <U>No Third Party Beneficiaries</U>.
Except as provided in <U>Section&nbsp;2.2(c)</U> (Exchange of Certificates) and <U>Section&nbsp;6.2</U> (Directors&#146; and Officers&#146; Indemnification) and except for the right of the Company, on behalf of its stockholders, to pursue damages in
the event of Parent&#146;s or Sub&#146;s breach of this Agreement, this Agreement is not intended to, and does not, confer upon any Person other than the parties hereto any rights or remedies hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.10 <U>Incorporation of Exhibits</U>. The Disclosure Schedule and the Exhibits attached hereto and referred
to herein are hereby incorporated herein and made a part hereof for all purposes as if fully set forth herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.11 <U>Severability</U>. Any term or provision of this Agreement which is invalid or unenforceable in any
jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or
enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as is enforceable.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.12 <U>Subsidiaries</U>. As used in this Agreement, &#147;<U>Subsidiary</U>&#148; of any Person
means another Person, an amount of the voting securities, other voting ownership or voting partnership interests of which is sufficient to elect at least a majority of its board of directors or other governing body (or, if there are no such voting
interests, 50% or more of the equity interests of which) is owned directly or indirectly by such Person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.13 <U>Person</U>. As used in this Agreement, &#147;<U>Person</U>&#148; means an individual, corporation,
partnership, joint venture, limited liability company, association, trust, unincorporated organization, entity (including Governmental Entity) or group (as defined in the Exchange Act). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.14 <U>Applicable Jurisdictions</U>. As used in this Agreement, &#147;<U>Applicable Jurisdiction</U>&#148;
means any of the United States, the European Union, Canada or Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.15 <U>Knowledge of
the Company; Knowledge of Parent</U>. As used in this Agreement, &#147;<U>Knowledge of the Company</U>&#148; means the actual knowledge of the individuals listed in <U>Section&nbsp;9.14</U> of the Disclosure Schedule. As used in this Agreement,
&#147;<U>Knowledge of Parent</U>&#148; means the </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
actual knowledge of Parent&#146;s Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and General Counsel. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.16 <U>Mutual Drafting</U>. This Agreement shall be deemed to be the joint work product of Parent, Sub, and
Company, and any rule of construction that a document shall be interpreted or construed against a drafter of such document shall not be applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.17 <U>Tax Reporting</U>. Except to the extent any portion of any CVR Payment (as that term is defined in
the CVR Agreement) is required to be treated as imputed interest pursuant to applicable Law, the parties hereto agree to treat the Cash Consideration, the Stock Consideration, the CVRs and all CVR Payments for all Tax purposes as consideration for
the shares of Common Stock, the Options, the SARs and the RSUs, and none of the parties hereto shall take any position to the contrary on any Tax Return or for other Tax purposes except as required by applicable Law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, Parent, Sub and the Company have caused this Agreement to be signed by
their respective officers thereunder duly authorized all as of the date first written above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CELGENE CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert J. Hugin</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert J. Hugin</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTISTRY ACQUISITION CORP.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sandesh Mahatme</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sandesh Mahatme</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary and Treasurer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ABRAXIS BIOSCIENCE, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Patrick Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Chairman</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<I>Signature Page
to Agreement and Plan of Merger</I>] </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>dex101.htm
<DESCRIPTION>VOTING AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Voting Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>VOTING AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">This VOTING AGREEMENT (this &#147;<U>Agreement</U>&#148;) is entered into as of June&nbsp;30, 2010, by and among Celgene
Corporation, a Delaware corporation (&#147;<U>Parent</U>&#148;), Artistry Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (&#147;<U>Sub</U>&#148;), and the Persons whose names are set forth on the signature pages
hereto under the caption &#147;Stockholders&#148; (each individually a &#147;<U>Stockholder</U>&#148; and, collectively, the &#147;<U>Stockholders</U>&#148;). </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">W I T N E S S E T H: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, as of the date of this Agreement, each Stockholder owns the number of shares of Common Stock, par value $.001
per share (the &#147;<U>Company Stock</U>&#148;), of Abraxis BioScience, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), set forth opposite such Stockholder&#146;s name on <U>Schedule A</U> attached hereto; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, concurrently herewith, Parent, Sub and the Company are entering into an Agreement and Plan of Merger, dated as
of this date (the &#147;<U>Merger Agreement</U>&#148;), pursuant to which Sub will merge with and into the Company and the Company will survive as a wholly-owned subsidiary of Parent (the &#147;<U>Merger</U>&#148;), and each share of Company Stock
(other than Excluded Company Shares) will be converted into the right to receive the Merger Consideration, in accordance with the terms of, and subject to the conditions set forth in, the Merger Agreement; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, as a condition to the willingness of Parent and Sub to enter into the Merger Agreement, and as an inducement and
in consideration therefor, Parent and Sub have required that the Stockholders agree, and the Stockholders have agreed, to enter into this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing and the mutual premises, representations, warranties, covenants and
agreements contained in this Agreement, the parties, intending to be legally bound, hereby agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE I </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITIONS </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 1.1 </B><U>Defined Terms</U>. For purposes of this Agreement, terms used in this Agreement that are defined in
the Merger Agreement but not in this Agreement shall have the respective meanings ascribed to them in the Merger Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 1.2 </B><U>Other Definitions</U>. For purposes of this Agreement: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) &#147;<U>Company Options</U>&#148; means options to acquire Company Stock granted to a Stockholder by the Company and
held by a Stockholder as of the date of this Agreement as set forth on <U>Schedule A</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) &#147;<U>Company RSUs</U>&#148; means restricted stock units with
respect to Company Stock granted to a stockholder by the Company and held by a Stockholder as of the date of this Agreement as set forth on <U>Schedule A</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) &#147;<U>Immediate Family</U>&#148; means lineal descendants (whether by blood or marriage), ancestral forebears,
current and former spouses, and persons related by blood, adoption or marriage to any of the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
&#147;<U>New Shares</U>&#148; means any shares of Company Stock (other than Owned Shares) acquired by a Stockholder at any time during the Voting Period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) &#147;<U>Option Shares</U>&#148; means any shares of Company Stock issued or issuable upon exercise of Company
Options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) &#147;<U>Owned Shares</U>&#148; means all of the shares of Company Stock owned by such
Stockholder as of the date of this Agreement as set forth on <U>Schedule A</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) &#147;<U>Permitted
Transferee</U>&#148; means PSS and any PSS Entity or any charitable foundation or organization, in each case only if such parties agree to be bound by the terms of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) &#147;<U>PSS</U>&#148; means Dr.&nbsp;Patrick Soon-Shiong. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) &#147;<U>PSS Entity</U>&#148; means any trust for the benefit of PSS or any members of PSS&#146; Immediate Family and
any other entity in which PSS or any members of PSS&#146; Immediate Family separately or collectively hold, directly or indirectly, a majority of the outstanding equity interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) &#147;<U>Representative</U>&#148; means, with respect to any particular Person, the officers, directors, employees,
trustees, investment bankers, attorneys and other advisors or representatives of such Person. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k)
&#147;<U>RSU Shares</U>&#148; means any shares of Company Stock issued or issuable upon vesting of Company RSUs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l) &#147;<U>Transfer</U>&#148; means sell, transfer, tender, assign, pledge, encumber or otherwise dispose. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) &#147;<U>Voting Period</U>&#148; means the period from and including the date of this Agreement through and including
the earliest to occur of (i)&nbsp;the Effective Time, and (ii)&nbsp;the termination of the Merger Agreement in accordance with its terms. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE II </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>VOTING AGREEMENT AND IRREVOCABLE PROXY </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 2.1 </B><U>Agreement to Vote</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Each Stockholder hereby agrees that, during the Voting Period, such Stockholder shall vote or execute consents, as
applicable, with respect to the Owned Shares and any New Shares owned by such Stockholder as of the applicable record date (or cause to be voted or a consent to be executed with respect to the Owned Shares or any New Shares owned by such Stockholder
as of the applicable record date) in favor of the approval and adoption of the Merger Agreement and the transactions contemplated by the Merger Agreement, at any meeting (or any adjournment or postponement thereof) of, or in connection with any
proposed action by written consent of, the holders of Company Stock at or in connection with which any of the holders vote or execute consents with respect to any of the foregoing matters. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to Section&nbsp;3.2 hereof, each Stockholder hereby agrees that, during the Voting Period, such Stockholder
shall vote or execute consents, as applicable, with respect to the Owned Shares and any New Shares owned by such Stockholder as of the applicable record date (or cause to be voted or a consent to be executed with respect to the Owned Shares and any
New Shares owned by such Stockholder as of the applicable record date) against each of the matters set forth in clauses (i), (ii), (iii)&nbsp;and (iv)&nbsp;below at any meeting (or any adjournment or postponement thereof) of, or in connection with
any proposed action by written consent of, the holders of Company Stock at or in connection with which any of the holders vote or execute consents with respect to any of the following matters: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) any merger agreement or merger (other than the Merger Agreement, the Merger or any business
combination or transaction with Parent or any of its affiliates), consolidation, combination, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company or any other business combination or extraordinary corporate
transaction involving the Company or any of its Subsidiaries, or any sale, lease or transfer of a material amount of assets of the Company or any of its Subsidiaries; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) any amendment of the Company&#146;s certificate of incorporation, as amended to date, unless such
amendment is consented to by Parent; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) any action, proposal, transaction or agreement that
would reasonably be expected to result in a breach in any respect of any covenant, representation or warranty or any other obligation or agreement of the Company contained in the Merger Agreement or of such Stockholder contained in this Agreement;
and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) any action, proposal, transaction or agreement involving the Company or any of its
Subsidiaries that would reasonably be expected to prevent, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-3- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
impede, frustrate, interfere with, delay, postpone or adversely affect the Merger and the other transactions contemplated by the Merger Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Any vote required to be cast or consent required to be executed pursuant to this Section&nbsp;2.1 shall be cast or
executed in accordance with the applicable procedures relating thereto so as to ensure that it is duly counted for purposes of determining that a quorum is present (if applicable) and for purposes of recording the results of that vote or consent.
Nothing contained in this Section&nbsp;2.1 shall require any Stockholder to vote or execute any consent with respect to any Option Shares or RSU Shares not issued to the Stockholder prior to the applicable record date for that vote or consent.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 2.2 </B><U>Grant of Irrevocable Proxy</U>. Each Stockholder hereby irrevocably appoints Parent and
any designee of Parent, and each of them individually, as such Stockholder&#146;s proxy and attorney-in-fact, with full power of substitution and resubstitution, to vote or execute consents during the Voting Period, with respect to the Owned Shares
and any New Shares owned by such Stockholder as of the applicable record date, in each case solely to the extent and in the manner specified in Section&nbsp;2.1. This proxy is given to secure the performance of the duties of such Stockholder under
this Agreement, and its existence will not be deemed to relieve such Stockholder of its obligations under <U>Section&nbsp;2.1</U>. Other than as described in this <U>Section&nbsp;2.2</U> and other than the granting of proxies to vote Owned Shares or
New Shares with respect to the election of directors and ratification of the appointment of the Company&#146;s auditors at the Company&#146;s annual meeting of Stockholders, in accordance with the recommendation of the Board of Directors of the
Company, such Stockholder shall not directly or indirectly grant any Person any proxy (revocable or irrevocable), power of attorney or other authorization with respect to any of such Stockholder&#146;s Owned Shares or New Shares. For Owned Shares or
New Shares as to which the Stockholder is the beneficial but not the record owner, such Stockholder will cause any record owner of such Owned Shares or New Shares to grant to Parent a proxy to the same effect as that contained in this <U>Section
2.2</U>.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 2.3 </B><U>Nature of Irrevocable Proxy</U>.<B> </B>The proxy and power of attorney
granted pursuant to Section&nbsp;2.2 by each Stockholder shall be irrevocable during the Voting Period, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies
granted by such Stockholder with regard to such Stockholder&#146;s Owned Shares or any New Shares acquired by such Stockholder, and such Stockholder acknowledges that the proxy constitutes an inducement for Parent and Sub to enter into the Merger
Agreement. The power of attorney granted by each Stockholder is a durable power of attorney and shall survive the bankruptcy, dissolution, death or incapacity of such Stockholder. The proxy and power of attorney granted hereunder shall terminate
only upon the expiration of the Voting Period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-4- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE III </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>COVENANTS </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 3.1 </B><U>Voting Period Restrictions</U>. Each Stockholder agrees that such Stockholder shall not, during the
Voting Period, (i)&nbsp;Transfer any or all of such Stockholder&#146;s Owned Shares or New Shares, or any interest therein, or enter into any agreement with respect to the Transfer of any or all of such Stockholder&#146;s Owned Shares or New Shares,
or any interest therein, or (ii)&nbsp;except pursuant to the terms of this Agreement, grant any proxies or powers of attorney, deposit any Owned Shares or New Shares into a voting trust or enter into a voting agreement with respect to any Owned
Shares or New Shares; <U>provided</U> that the foregoing shall not prevent (a)&nbsp;the Transfer of Owned Shares or New Shares upon the death of such Stockholder pursuant to the terms of any trust or will of such Stockholder or by the laws of
intestate succession, but only if, and any such Transfer shall be void unless, the transferee executes and delivers to Parent an agreement to be bound by the terms of this Agreement to the same extent as such Stockholder, (b)&nbsp;the Transfer of
Owned Shares or New Shares to a Permitted Transferee, (c)&nbsp;the Transfer of Owned Shares or New Shares solely in connection with the payment of the exercise price and/or the satisfaction of any tax withholding obligation arising from the exercise
of any Company Option or the vesting of any Company RSU, (d)&nbsp;the conversion of any Owned Shares and New Shares into the right to receive the Merger Consideration pursuant to the Merger in accordance with the terms of the Merger Agreement, or
(e)&nbsp;the granting of proxies to vote Owned Shares or New Shares with respect to the election of directors and ratification of the appointment of the Company&#146;s auditors at the Company&#146;s annual meeting of Stockholders, in accordance with
the recommendation of the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 3.2 </B><U>No Shop Obligations of
Each Stockholder</U>. Each Stockholder agrees that such Stockholder shall not, and that such Stockholder shall use its reasonable best efforts to cause the Representatives of such Stockholder to not, directly or indirectly, (i)&nbsp;solicit,
initiate, or knowingly encourage the making, submission or announcement of any inquiry regarding, or any proposal or offer which would reasonably be expected to lead to, an Acquisition Proposal, (ii)&nbsp;enter into, participate, continue or
otherwise engage in discussions or negotiations with, or provide any non-public information to any Person (other than Parent, Sub and their Representatives) with respect to any inquiries regarding, or the making, submission or announcement of, an
Acquisition Proposal, or (iii)&nbsp;enter into or approve any letter of intent, agreement in principle, option agreement, share purchase agreement, acquisition agreement or similar agreement relating to an Acquisition Proposal; <U>provided</U>,
<U>however</U>, that each Stockholder may, and may authorize and permit any Representative of such Stockholder to, provide non-public information to, and participate in discussions or negotiations, with any Person if at such time such Stockholder
has been notified by the Company that the Board of Directors of the Company is permitted to provide non-public information to, or engage in discussions or negotiations with, such Person in accordance with the Merger Agreement. The Stockholder shall
immediately cease and cause to be terminated any ongoing solicitation, discussion or negotiation with any Person conducted prior to the date of this Agreement by the Stockholder or any of its Representatives with respect to any actual or potential
Acquisition Proposal. A Stockholder shall notify Parent orally and in writing promptly </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-5- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(and in any event within 24 hours) after receipt of any Acquisition Proposal or any request for information or inquiry which could reasonably be expected to lead to an Acquisition Proposal. The
written notice shall include the identity of the Person making such Acquisition Proposal, request or inquiry, the material terms of the Acquisition Proposal, request or inquiry (including any material written amendments or modifications, or any
proposed material written amendments or modifications, thereto), and the Stockholder shall keep Parent reasonably informed on a current basis of any material changes with respect to such Acquisition Proposal, request or inquiry. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 3.3 </B><U>General Covenants</U>. Each Stockholder agrees that such Stockholder shall not: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) enter into any agreement, commitment, letter of intent, agreement in principle, or understanding with any Person or
take any other action that violates or conflicts with or would reasonably be expected to violate or conflict with, or result in or give rise to a violation of or conflict with, such Stockholder&#146;s covenants and obligations under this Agreement
or make any of its representations and warranties contained herein untrue or incorrect; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) take any
action that could restrict or otherwise affect such Stockholder&#146;s legal power, authority and right to comply with and perform such Stockholder&#146;s covenants and obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 3.4 </B><U>Stockholders&#146; Capacity</U>. Parent and Sub acknowledge that no Stockholder is making any
agreement or understanding herein in such Stockholder&#146;s capacity as a director or officer of the Company and that each Stockholder is executing this agreement solely in such Stockholder&#146;s capacity as the owner of Company Stock and nothing
herein shall limit or affect any actions taken by such Stockholder in such Stockholder&#146;s capacity as a director or officer of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 3.5 </B><U>Letter of Transmittal and Delivery of Merger Consideration</U>. Parent agrees to provide the
Stockholders a copy of the letter of transmittal referenced in Section&nbsp;2.2 of the Merger Agreement a reasonable time period prior to the anticipated Closing Date to allow the Stockholders to complete the letter of transmittal and provide such
letter of transmittal to the Paying Agent prior to or on the Closing Date. Parent agrees to use reasonable best efforts to cause the Paying Agent to deliver by wire transfer of immediately available funds the Merger Consideration to which the
Stockholders are entitled under the terms of the Merger Agreement on the same date as the Closing Date. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IV </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Stockholder hereby represents and warrants to Parent and Sub as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 4.1 </B><U>Authorization</U>. Such Stockholder has all power and authority (or legal capacity in the case of
an individual) to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly and validly </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-6- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
authorized, executed and delivered by such Stockholder and, assuming it has been duly and validly authorized, executed and delivered by Parent and Sub, constitutes a legal, valid and binding
obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, except to the extent that enforceability may be limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance or other similar laws now or hereafter in effect relating to creditor&#146;s rights generally, and (ii)&nbsp;general principles of equity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 4.2 </B><U>Ownership of Shares</U>. As of the date hereof, all Owned Shares, Company Options and Company RSUs
owned by such Stockholder are listed on <U>Schedule A</U> attached hereto. Such Stockholder (a)&nbsp;is the sole beneficial owner of all of the Owned Shares, Company Options and Company RSUs listed opposite such Stockholder&#146;s name on
<U>Schedule A</U> hereto free and clear of any Liens, voting agreements or commitments of every kind that would reasonably be expected to violate or conflict with, or result in or give rise to a violation of or conflict with, or adversely affect the
exercise or fulfillment of, such Stockholder&#146;s covenants and obligations under this Agreement, and (b)&nbsp;has the sole power to vote (or cause to be voted or consents to be executed) and to dispose of (or cause to be disposed of) such Owned
Shares without restriction, and no proxies through and including the date hereof given in respect of any or all of such Stockholder&#146;s Owned Shares, Company Options or Company RSUs are irrevocable and any such proxies have been revoked.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 4.3 </B><U>No Conflicts</U>. Except for a filing of an amendment to a Schedule 13D and a filing of
a Form 4 as required by the Exchange Act, (i)&nbsp;no filing with any Governmental Entity, and no authorization, consent or approval of any other Person is necessary for the execution of this Agreement by such Stockholder or the performance by such
Stockholder of such Stockholder&#146;s obligations hereunder and (ii)&nbsp;none of the execution and delivery of this Agreement by such Stockholder, or the performance by such Stockholder of such Stockholder&#146;s obligations hereunder shall
(A)&nbsp;result in, give rise to or constitute a violation or breach of or a default (or any event which with notice or lapse of time or both would become a violation, breach or default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, or result in the creation of a Lien on, any of the Owned Shares pursuant to any of the terms of any understanding, agreement, or other instrument or obligation to which such Stockholder is a party or by which such
Stockholder or any of such Stockholder&#146;s Owned Shares are bound, or (B)&nbsp;violate any applicable law, rule, regulation, order, judgment, or decree applicable to such Stockholder, except for any of the foregoing as would not reasonably be
expected to impair such Stockholder&#146;s ability to perform such Stockholder&#146;s obligations under this Agreement in any material respect. <B> </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE V </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of Parent and Sub hereby represent and warrant to the Stockholders as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-7- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 5.1 </B><U>Authorization</U>. Such party has all power and
authority to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly and validly authorized, executed and delivered by such party and, assuming it has been duly and validly authorized, executed and
delivered by the Stockholders, constitutes a legal, valid and binding obligation of such party, enforceable against it in accordance with the terms of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 5.2 </B><U>No Conflicts</U>. The execution and delivery of this Agreement by such party does not and the
performance of this Agreement by such party will not (i)&nbsp;conflict with, result in any violation of, require any consent under or constitute a default (whether with notice or lapse of time or both) under any mortgage, bond, indenture, agreement,
instrument or obligation to which it is a party or by which it or any of its properties is bound; (ii)&nbsp;violate any judgment, order, injunction, decree or award of any court, administrative agency or other Governmental Entity that is binding on
such party or any of its properties; or (iii)&nbsp;constitute a violation by such party of any law, regulation, rule or ordinance applicable to such party, in each case, except for any violation, conflict or consent as would not reasonably be
expected to materially impair the ability of such party to perform its obligations under this Agreement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VI </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>TERMINATION </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>This Agreement shall terminate upon the earliest to occur of (i)&nbsp;the Effective Time, (ii)&nbsp;any material
amendment to the Merger Agreement that is adverse to the Stockholders that has not been approved by the Stockholders (it being understood that any decrease in or change in form of the Merger Consideration shall constitute a material amendment to the
Merger Agreement that is adverse to the Stockholders), and (iii)&nbsp;the termination of the Merger Agreement in accordance with its terms. Upon the termination of this Agreement, neither Parent, Sub nor the Stockholders shall have any rights or
obligations hereunder and this Agreement shall become null and void and have no effect; <U>provided</U>, that, with respect to termination pursuant to clause (i)&nbsp;above, Sections 7.1, 7.3 and 7.5 through 7.12 shall survive such termination.
Notwithstanding the foregoing, termination of this Agreement shall not prevent any party from seeking any remedies (at law or in equity) against any other party for that party&#146;s breach of any of the terms of this Agreement prior to the date of
termination. <B> </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VII </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>MISCELLANEOUS </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.1 </B><U>Publication</U>. Each Stockholder hereby permits Parent, Sub and/or the Company to publish and
disclose in press releases, Schedule 13D filings, and the Proxy Statement/Prospectus (including all documents and schedules filed with the SEC) and any other disclosures or filings required under the Merger Agreement or by applicable Law such
Stockholder&#146;s identity and ownership of shares of the Company Stock, the nature of such Stockholder&#146;s commitments, arrangements and understandings pursuant to this Agreement and/or the text of this Agreement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-8- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.2 </B><U>Waiver of Appraisal Rights and Actions</U>. Each
Stockholder hereby (i)&nbsp;waives any rights of appraisal or rights to dissent from the Merger or the adoption of the Merger Agreement that such Stockholder may have under applicable law and shall not permit any such rights of appraisal or rights
of dissent to be exercised with respect to such Stockholder&#146;s Owned Shares, any New Shares, any Option Shares or any RSU Shares and (ii)&nbsp;agrees not to commence or participate in, and to take all actions necessary to opt out of any class in
any class action with respect to, any claim, derivative or otherwise, against Parent, Sub, the Company or any of their respective successors relating to the negotiation, execution or delivery of this Agreement or the Merger Agreement or the
consummation of the Merger, including any claim alleging a breach of any fiduciary duty of the Board of Directors of the Company in connection with the Merger Agreement or the transactions contemplated thereby.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.3 </B><U>Amendments, Waivers, etc</U>.<B> </B>This Agreement may be amended by the parties at any time. This
Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties. Except as provided in this Agreement, no action taken pursuant to this Agreement, including any investigation by or on behalf of any party,
shall be deemed to constitute a waiver by the party taking the action of compliance with any representations, warranties, covenants or agreements contained in this Agreement. The waiver by any party of a breach of any provision hereunder shall not
operate or be construed as a waiver of any prior or subsequent breach of the same or any other provision hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.4 </B><U>Enforcement of Agreement; Specific Performance</U>.<B> </B>The Stockholders agree and acknowledge
that Parent and Sub would suffer irreparable damage in the event that any of the obligations of the Stockholders in this Agreement were not performed in accordance with its specific terms or if the Agreement was otherwise breached by the
Stockholders. It is accordingly agreed by the Stockholders that Parent shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in
addition to any other remedy to which Parent may be entitled at law or in equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.5
</B><U>Notices</U>.<B> </B>Except for notices that are specifically required to be delivered orally, all notices, requests, claims, demands and other communications hereunder shall be in writing and shall be deemed given (a)&nbsp;on the date of
delivery, if delivered in person or by facsimile or e-mail (upon confirmation of receipt), (b)&nbsp;on the first Business Day following the date of dispatch, if delivered by a recognized overnight courier service (upon proof of delivery) or
(c)&nbsp;on the fifth Business Day following the date of mailing, if delivered by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If to the Parent or Sub, addressed to it at: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 Morris Avenue </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Summit, New Jersey 07901 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 908.673.9000 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-9- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 908.673.2769 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: George Golumbeski, Senior Vice President Business </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;Development <U>ggolumbeski@celgene.com</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">with copies to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celgene Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 Morris Avenue </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Summit, New Jersey 07901 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 908.673.9000 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 908.673.2771 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Thomas Perone, Corporate Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<U>tperone@celgene.com</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">and a copy (which shall not constitute notice) to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jones Day </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3161 Michelson Drive </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 800 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Irvine, CA 92612 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 949.851.3939 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 949.553.7539 </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Jonn R. Beeson, Esq. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;jbeeson@jonesday.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;Kevin Espinola, Esq. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;kbespinola@jonesday.com </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If to the Stockholders, addressed to them at: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11755 Wilshire Blvd., 20th Floor </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, CA 90025 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 310.883.1300 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 310.998.8553 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Dr.&nbsp;Patrick Soon-Shiong, Executive Chairman </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<U>pss@abraxisbio.com</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">with copies to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11755 Wilshire Blvd., 20th Floor </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, CA 90025 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 310.883.1300 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 310.998.8553 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Charles Kim, General Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-10- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<U>CKim@abraxisbio.com</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">and a copy (which shall not constitute notice) to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fried, Frank, Harris, Shriver&nbsp;&amp; Jacobson LLP </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">One New York Plaza </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10004 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 212.859.8000 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 212.859.4000 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Philip Richter, Esq. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;philip.richter@friedfrank.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;Brian Mangino, Esq. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;brian.mangino@friedfrank.com </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to that other address as any party shall specify by written notice so given, and notice shall be deemed to have been delivered as of
the date so telecommunicated or personally delivered. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.6 </B><U>Headings; Titles</U>.<B>
</B>Headings and titles of the Articles and Sections of this Agreement are for the convenience of the parties only, and shall be given no substantive or interpretative effect whatsoever. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.7 </B><U>Severability</U>.<B> </B>Any term or provision of this Agreement which is invalid or unenforceable
in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of this invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or
enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. Upon determination that any term or other provision is invalid or incapable of being enforced, the parties shall negotiate in good faith to modify this
Agreement as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.8 </B><U>Entire Agreement</U>.<B> </B>This Agreement (together with the Merger Agreement, to the extent
referred to in this Agreement) and any documents delivered by the parties in connection herewith constitutes the entire agreement among the parties with respect to the subject matter of this Agreement and supersedes all prior agreements and
understandings among the parties with respect thereto. No addition to or modification of any provision of this Agreement shall be binding upon any party unless made in writing and signed by all parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.9 </B><U>Assignment; Binding Effect; No Third Party Beneficiaries; Further Action</U>.<B> </B>Neither this
Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties. This Agreement shall be binding upon and shall inure to the benefit of Parent and Sub and their respective successors and assigns and shall
be binding upon the Stockholders and the Stockholders&#146; successors, assigns, heirs, executors and administrators. Notwithstanding anything contained in this Agreement to the contrary, nothing in this Agreement, expressed or implied, is intended
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-11- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to confer on any Person (other than, in the case of Parent and Sub, their respective successors and assigns and, in the case of the Stockholders, the Stockholders&#146; successors, assigns,
heirs, executors and administrators) any rights, remedies, obligations or liabilities under or by reason of this Agreement. The Stockholders shall take any further action and execute any other instruments as may be reasonably requested by Parent to
effectuate the intent of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.10 </B><U>Mutual Drafting</U>.<B> </B>Each party has
participated in the drafting of this Agreement, which each party acknowledges is the result of extensive negotiations between the parties. This Agreement shall not be deemed to have been prepared or drafted by any one party or another or any
party&#146;s attorneys. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.11 </B><U>Governing Law and Consent to Jurisdiction</U>. This Agreement
shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its rules of conflict of laws. The Stockholders hereby irrevocably and unconditionally consent to submit to the jurisdiction of the federal
courts located in the State of Delaware or any Delaware state courts (and, if appropriate, appellate courts therefrom) in connection with any action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby
(and agree not to commence any suit, action or proceeding relating thereto except in those courts), waive any defense or objection they may have or hereafter have relating to the laying of venue of any suit, action or proceeding in any such courts
and agree not to plead or claim that any suit, action or proceeding brought therein has been brought in an inconvenient forum. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 7.12 </B><U>Counterparts; Facsimiles</U>.<B> </B>This Agreement may be executed by the parties in separate
counterparts, each of which when so executed and delivered shall be an original, but all counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies each signed by less than all, but
together signed by all of the parties. This Agreement or any counterpart may be executed and delivered by facsimile copies, each of which shall be deemed an original. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Signature page follows.) </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-12- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, Parent, Sub and the Stockholders have caused this
Agreement to be duly executed as of the day and year first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CELGENE CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert J. Hugin</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert J. Hugin</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTISTRY ACQUISITION CORP.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sandesh Mahatme</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sandesh Mahatme</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary and Treasurer</FONT></TD></TR></TABLE></DIV>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>

<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>STOCKHOLDERS</U>:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DR. PATRICK SOON-SHIONG</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CALIFORNIA CAPITAL LP</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Themba LLC, its general partner</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven H. Hassan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven H. Hassan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manager</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PATRICK SOON-SHIONG 2009 GRAT 1</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature Page to Voting
Agreement] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PATRICK SOON-SHIONG 2009 GRAT 2</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MICHELE B. SOON-SHIONG GRAT 1</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-bottom:1px;margin-top:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michele B. Chan Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michele B. Chan Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MICHELE B. SOON-SHIONG GRAT 2</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michele B. Chan Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michele B. Chan Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SOON-SHIONG COMMUNITY PROPERTY REVOCABLE TRUST</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michele B. Chan Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michele B. Chan Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature Page to Voting
Agreement] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE CHAN SOON-SHIONG FAMILY FOUNDATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Charles Kenworthy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charles Kenworthy</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature
Page to Voting Agreement] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CALIFORNIA CAPITAL TRUST</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michele B. Chan Soon-Shiong</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michele B. Chan Soon-Shiong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven H. Hassan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven H. Hassan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I acknowledge that I have read the Voting
Agreement, dated as of June&nbsp;30, 2010, among by and among Celgene Corporation, a Delaware corporation, Artistry Acquisition Corp., a Delaware corporation, and the other parties thereto, and understand its contents. I am aware that by its
provisions all or part of the shares of common stock, par value $.001 per share, of Abraxis BioScience, Inc., a Delaware corporation, held by my spouse, Dr.&nbsp;Patrick Soon-Shiong, including my community interest in such shares, if any, are
subject to the provisions of such agreement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MICHELE B. CHAN SOON-SHIONG</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michele B. Chan Soon-Shiong</FONT></TD></TR></TABLE></DIV>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature Page to Voting Agreement] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE A </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">STOCKHOLDERS </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:41pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stockholder</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Owned&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company&nbsp;Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company&nbsp;RSUs</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Patrick Soon-Shiong</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Soon-Shiong may be deemed the beneficial owner</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,635</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,204</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">California Capital LP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,987,159</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Soon-Shiong 2009 GRAT 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,759,109</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Soon-Shiong 2009 GRAT 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,759,109</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michele B. Soon-Shiong GRAT 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,759,109</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michele B. Soon-Shiong GRAT 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,759,110</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soon-Shiong Community Property Revocable Trust</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">716,916</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">California Capital Trust</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,555</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Chan Soon-Shiong Family Foundation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,301,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,186,067</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,635</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,204</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR></TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 29,545 vested and 154,090 unvested Company Options as of the date hereof. </FONT></P></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>dex102.htm
<DESCRIPTION>FORM OF CONTINGENT VALUE RIGHTS AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Contingent Value Rights Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.2 </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM OF </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTINGENT VALUE RIGHTS AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>by and between </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CELGENE CORPORATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>and </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[TRUSTEE] </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated as of [<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT><B></B>], 2010 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 1</B> DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Compliance and Opinions</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Form of Documents Delivered to Trustee</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Acts of Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notices, etc., to Trustee and Company</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notice to Holders; Waiver</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Conflict with Trust Indenture Act</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Effect of Headings and Table of Contents</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Benefits of Agreement</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Governing Law</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Legal Holidays</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Separability Clause</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>No Recourse Against Others</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Counterparts</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Acceptance of Trust</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 2</B> SECURITY FORMS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Forms Generally</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 3</B> THE SECURITIES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Title and Terms</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Registrable Form</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Execution, Authentication, Delivery and Dating</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Temporary Securities</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Registration, Registration of Transfer and Exchange</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Mutilated, Destroyed, Lost and Stolen Securities</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Payments with respect to CVR Certificates</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Persons Deemed Owners</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Cancellation</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 4</B> THE TRUSTEE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Certain Duties and Responsibilities</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Certain Rights of Trustee</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notice of Default</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Not Responsible for Recitals or Issuance of Securities</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>May Hold Securities</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Money Held in Trust</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Compensation and Reimbursement</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Disqualification; Conflicting Interests</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Corporate Trustee Required; Eligibility</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Resignation and Removal; Appointment of Successor</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Acceptance of Appointment of Successor</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Merger, Conversion, Consolidation or Succession to Business</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Preferential Collection of Claims Against Company</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 5</B> HOLDERS&#146; LISTS AND REPORTS BY THE TRUSTEE AND COMPANY</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Company to Furnish Trustee Names and Addresses of Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Preservation of Information; Communications to Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reports by Trustee</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reports by Company</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 6</B> AMENDMENTS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Amendments Without Consent of Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Amendments with Consent of Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Execution of Amendments</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Effect of Amendments; Notice to Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Conformity with Trust Indenture Act</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Reference in Securities to Amendments</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 7</B> COVENANTS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Payment of Amounts, if any, to Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Maintenance of Office or Agency</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Money for Security Payments to Be Held in Trust</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Certain Purchases and Sales</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Books and Records</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Audits</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Listing of CVRs</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Conflicting Arrangements</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Product Transfer</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Milestones</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Product Sale and Development</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notice of Default</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Confidentiality</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Non-Use of Name</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 8</B> REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Event of Default Defined; Waiver of Default</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Collection by the Trustee; the Trustee May Prove Payment Obligations</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Application of Proceeds</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Suits for Enforcement</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Restoration of Rights on Abandonment of Proceedings</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Limitations on Suits by Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Unconditional Right of Holders to Institute Certain Suits</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Control by Holders</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Waiver of Past Defaults</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>The Trustee to Give Notice of Default, But May Withhold in Certain Circumstances</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Right of Court to Require Filing of Undertaking to Pay Costs</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 9</B> CONSOLIDATION, MERGER, SALE OR CONVEYANCE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Company May Consolidate, etc., on Certain Terms</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Successor Person Substituted</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Opinion of Counsel to the Trustee</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Successors</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 10</B> SUBORDINATION</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Agreement to Subordinate</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">iii </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Liquidation; Dissolution; Bankruptcy</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Default on Senior Obligations</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>When Distribution Must Be Paid Over</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notice by Company</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Subordination Effective Notwithstanding Deficiencies with Respect to Senior Obligations; Waiver of Right to Contest Senior Obligation; Reinstatement of Subordination
Provisions</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Subrogation</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Relative Rights</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Subordination May Not Be Impaired by Company</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Distribution or Notice to Representative</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Rights of the Trustee</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Authorization to Effect Subordination</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Amendments</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 11</B> REDEMPTION OF SECURITIES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notice to Trustee</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Selection of Securities to be Redeemed</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Notice of Redemption</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Effect of Notice of Redemption</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Deposit of Redemption Price</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Optional Redemption by the Company</U>.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annex&nbsp;A&nbsp;-</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of CVR Certificate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">This table of contents shall not, for any purpose, be deemed to be a part of this CVR Agreement.</FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">iv </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Reconciliation and tie between Trust Indenture Act of 1939 and Contingent Value Rights Agreement,
dated as of [<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], 2010. [<I>to be updated</I>]<I> </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:96pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Trust Indenture Act Section</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Agreement&nbsp;Section</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;310</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not&nbsp;Applicable</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not Applicable</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8, 4.10</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;311</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.13(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.13(a)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;312</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1, 5.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2(c)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;313</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3(b)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;314</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not Applicable</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not Applicable</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not Applicable</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2(b)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;315</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1(a), 4.1(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.11</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1(a), 4.1(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1(c)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1(c)(iii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.12</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;316</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(last sentence)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(1)(A)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(1)(B)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.10</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not Applicable</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;317</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;318</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note: This reconciliation and tie
shall not, for any purpose, be deemed to be a part of this CVR Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">v </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of
[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], 2010 (this &#147;<U>CVR Agreement</U>&#148;), by and between Celgene Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;), and
[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], a national banking association, as trustee (the &#147;<U>Trustee</U>&#148;), in favor of each person who from time to time holds one or more Contingent Value Rights (the
&#147;<U>Securities</U>&#148; or &#147;<U>CVRs</U>&#148;) to receive cash payments in the amounts and subject to the terms and conditions set forth herein. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>W I T N E S S E T H</U>: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, this CVR Agreement is entered into pursuant to the Agreement and Plan of Merger, dated as of June&nbsp;30, 2010
(as amended prior to the effective time thereof, the &#147;<U>Merger Agreement</U>&#148;), by and among the Company, Artistry Acquisition Corp., a Delaware corporation and wholly owned Subsidiary of the Company (&#147;<U>Sub</U>&#148;), and Abraxis
BioScience, Inc., a Delaware corporation (&#147;<U>Abraxis</U>&#148;); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, pursuant to the Merger
Agreement, Sub will merge with and into Abraxis (the &#147;<U>Merger</U>&#148;), with Abraxis being the surviving corporation in the Merger and becoming a wholly-owned Subsidiary of the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, in the Merger, one (1)&nbsp;CVR will be issued in respect of (a)&nbsp;each share of common stock, par value
$0.001 per share, of Abraxis (&#147;<U>Common Stock</U>&#148;) (other than shares of Common Stock that are Excluded Company Shares or Dissenting Company Shares) (all as defined in the Merger Agreement), (b)&nbsp;each share of Common Stock underlying
each Option (as defined in the Merger Agreement) having an exercise price that is less than or equal to the Per Share Amount (as defined in the Merger Agreement), (c)&nbsp;each share of Common Stock underlying each Option having an exercise price
that is greater than the Per Share Amount, if such Option is exercised and settled in accordance with the Merger Agreement, (d)&nbsp;each SAR (as defined in the Merger Agreement) having a base appreciation amount that is less than or equal to the
Per Share Amount, (e)&nbsp;each SAR having a base appreciation amount that is greater than the Per Share Amount, if such SAR is exercised and settled in accordance with the Merger Agreement, and (f)&nbsp;each RSU (as defined in the Merger
Agreement), in each case, outstanding immediately prior to the Effective Time (as defined in the Merger Agreement); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, a registration statement on Form S-4 (No. 333-[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>]) (the
&#147;<U>Registration Statement</U>&#148;) with respect to the CVRs has been prepared and filed by the Company with the Commission (as defined below) and has become effective in accordance with the Securities Act of 1933, as amended (the
&#147;<U>Securities Act</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing premises and the
consummation of the transactions contemplated by the Merger Agreement, it is covenanted and agreed, for the equal and proportionate benefit of all Holders of the Securities, as follows: </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.1 Definitions. For all purposes of this CVR Agreement, except as otherwise expressly provided or unless
the context otherwise requires: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the terms defined in this Article have the meanings assigned to them in
this Article, and include the plural as well as the singular; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) all accounting terms used herein and not
expressly defined herein shall, except as otherwise noted, have the meanings assigned to such terms in accordance with applicable Accounting Standards, where &#147;<U>Accounting Standards</U>&#148; means (A)&nbsp;GAAP (United States Generally
Accepted Accounting Principles); or (B)&nbsp;to the extent that the Company adopts International Financial Reporting Standards (IFRS), then &#147;<U>Accounting Standards</U>&#148; means International Financial Reporting Standards (IFRS), in either
case consistently applied; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) all capitalized terms used in this CVR Agreement without definition shall have
the respective meanings ascribed to them in the Merger Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) all other terms used herein which are
defined in the Trust Indenture Act (as defined herein), either directly or by reference therein, have the respective meanings assigned to them therein; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) the words &#147;<U>herein</U>,&#148; &#147;<U>hereof</U>&#148; and &#147;<U>hereunder</U>&#148; and other words of
similar import refer to this CVR Agreement as a whole and not to any particular Article, Section or other subdivision. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Affiliate</U>&#148; of any specified Person means any other Person directly or indirectly controlling or
controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, &#147;control&#148; when used with respect to any specified Person means the power to direct the management and policies of
such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms &#147;controlling&#148; and &#147;controlled&#148; have meanings correlative to the foregoing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Board of Directors</U>&#148; means the board of directors of the Company or any other body performing similar
functions, or any duly authorized committee of that board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Board Resolution</U>&#148; means a copy
of a resolution certified by the Secretary or an Assistant Secretary of the Company, to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Business Day</U>&#148; means any day (other than a Saturday or a Sunday) on which banking institutions in The
City of New York, New York are not authorized or obligated by Law or executive order to close and, if the CVRs are listed on a national securities exchange, electronic trading network or other suitable trading platform, such exchange, electronic
network or other trading platform is open for trading. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Call Notice</U>&#148; shall have the meaning
set forth in Section&nbsp;11.3 of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Combination Product</U>&#148; means any
product that comprises a Product sold in conjunction with another active component (whether packaged together or in the same therapeutic formulation or otherwise) or service. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Commission</U>&#148; means the Securities and Exchange Commission,
as from time to time constituted, created under the Exchange Act (as defined herein), or if at any time after the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture
Act, then the body performing such duties at such time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Common Stock</U>&#148; shall have the
meaning set forth in the Recitals of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Company</U>&#148; means the Person (as
defined herein) named as the &#147;Company&#148; in the first paragraph of this CVR Agreement, until a successor Person shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter &#147;Company&#148; shall mean
such successor Person. To the extent necessary to comply with the requirements of the provisions of Trust Indenture Act Sections 310 through 317, inclusive, to the extent that they are applicable to the Company, the term &#147;Company&#148; shall
include any other obligor with respect to the Securities for the purposes of complying with such provisions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Company Request</U>&#148; or &#147;<U>Company Order</U>&#148; means a written request or order signed in the
name of the Company by the chairman of the Board of Directors or the president or any vice president, the controller or assistant controller and the treasurer or assistant treasurer or the secretary or any assistant secretary, and delivered to the
Trustee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Confidential Information</U>&#148; shall have the meaning set forth in Section&nbsp;7.13 of
this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Consent and Purchase Offer</U>&#148; shall have the meaning set forth in
Section&nbsp;11.1 of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Corporate Trust Office</U>&#148; means the office of the
Trustee at which at any particular time its corporate trust business shall be principally administered, which office at the date of execution of this CVR Agreement is located at [<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>]. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>CVRs</U>&#148; shall have the meaning set forth in the Preamble of this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>CVR Agreement</U>&#148; means this instrument as originally executed and as it may from time to time be
supplemented or amended pursuant to the applicable provisions hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>CVR Certificate</U>&#148;
means a certificate representing any of the CVRs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>CVR Payment</U>&#148; means any Net Sales Payment
and any Milestone Payment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>CVR Shortfall</U>&#148; shall have the meaning set forth in
Section&nbsp;7.6(b) of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Default Interest Rate</U>&#148; means a rate equal to the
sum of three percent (3%)&nbsp;plus the prime rate of interest quoted in the Money Rates section of <I>The Wall Street Journal</I> (New York Edition), or similar reputable data source, calculated daily on the basis of a three hundred sixty-five
(365)&nbsp;day year or, if lower, the highest rate permitted under applicable Law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Diligent Efforts</U>&#148; means, with respect to any Product,
efforts of a Person to carry out its obligations in a diligent manner using such effort and employing such resources normally used by such Person in the exercise of its reasonable business discretion relating to the research, development or
commercialization of a product, that is of similar market potential at a similar stage in its development or product life, taking into account issues of market exclusivity (including patent coverage, regulatory and other exclusivity), safety and
efficacy, product profile, the competitiveness of alternate products in the marketplace or under development, the launch or sales of a generic or biosimilar product, the regulatory structure involved, and the profitability of the applicable product
(including pricing and reimbursement status achieved), and other relevant factors, including technical, commercial, legal, scientific, and/or medical factors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Existing Licenses</U>&#148; means those licenses and related agreements (for so long as they are in effect) with
respect to the Products granted by the Company or its Affiliates to third parties (other than the Company or its Affiliates) as in effect immediately prior to the consummation of the Merger (with such modifications thereto after the consummation of
the Merger that do not reduce the amounts of royalties, milestone payments or profit split payments thereunder). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Event of Default</U>&#148; shall have the meaning set forth in Section&nbsp;8.1 of this CVR Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Exchange Act Documents</U>&#148; shall have the meaning set forth in Section&nbsp;5.4 of this CVR Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration or any successor agency.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Governmental Entity</U>&#148; means any domestic (federal or state), or foreign court, commission,
governmental body, regulatory or administrative agency or other political subdivision thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Holder</U>&#148; means a Person in whose name a Security is registered in the Security Register. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Independent Accountant</U>&#148; shall have the meaning set forth in Section&nbsp;7.6(a) of this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Indications</U>&#148; means U.S. Regulatory Approval of the Product described in clause (a)&nbsp;of the
definition of &#147;Product&#148; for use in the treatment of: (i)&nbsp;melanoma; (ii)&nbsp;ovarian cancer; (iii)&nbsp;bladder cancer; and (iv)&nbsp;first-line metastatic breast cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Junior Obligations</U>&#148; has the meaning set forth in Section&nbsp;10.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Law</U>&#148; means any foreign, federal, state, local or municipal laws, rules, judgments orders, regulations,
statutes, ordinances, codes, decisions, injunctions, orders, decrees or requirements of any Governmental Entity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Majority Holders</U>&#148; means, at the time of determination,
Holders of at least a majority of the Outstanding CVRs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Merger</U>&#148; shall have the meaning set
forth in the Recitals of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Merger Agreement</U>&#148; shall have the meaning set
forth in the Recitals of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone</U>&#148; means each of (i)&nbsp;Milestone
#1, and (ii)&nbsp;Milestone #2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone #1</U>&#148; means U.S. Regulatory Approval of the Product
described in clause (a)&nbsp;of the definition of &#147;Product&#148; for use in the treatment of non-small cell lung cancer (NSCLC), which U.S. Regulatory Approval permits the Company to market such Product under a label that includes a progression
free survival claim, but only if the foregoing milestone is achieved no later than the Milestone Target Date. For the avoidance of doubt, an &#147;approvable letter&#148; or similar communication published by the FDA shall not constitute approval
for purposes of the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone #2</U>&#148; means U.S. Regulatory Approval of the Product
described in clause (a)&nbsp;of the definition of &#147;Product&#148; for use in the treatment of pancreatic cancer, which U.S. Regulatory Approval permits the Company to market such Product under a label that includes an overall survival claim, but
only if the foregoing milestone is achieved no later than the Milestone Target Date. For the avoidance of doubt, an &#147;approvable letter&#148; or similar communication published by the FDA shall not constitute approval for purposes of the
foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone Payment</U>&#148; means, as applicable, (i)&nbsp;two hundred fifty million
dollars ($250,000,000), with respect to the achievement of Milestone #1; and (ii)&nbsp;(a)&nbsp;four hundred million dollars ($400,000,000), with respect to the achievement of Milestone #2 if Milestone #2 is achieved no later than April&nbsp;1,
2013, and (b)&nbsp;three hundred million dollars ($300,000,000), with respect to the achievement of Milestone #2 if Milestone #2 is achieved after April&nbsp;1, 2013 but no later than the Milestone Target Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone Payment Date</U>&#148; means, with respect to each Milestone, the date that is twenty
(20)&nbsp;Business Days following the date of the achievement of such Milestone. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Milestone Target
Date</U>&#148; means the fifth anniversary of the date of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Sales</U>&#148;
means, for each Net Sales Measuring Period, the sum of, without any duplication: (i)&nbsp;the gross amounts invoiced for the Products sold by the Company, its Affiliates or its licensees (other than licensees under Existing Licenses) to third
parties (other than the Company, its Affiliates or its licensees) during such Net Sales Measuring Period, including wholesale distributors, less deductions from such amounts calculated in accordance with Accounting Standards so as to arrive at
&#147;net sales&#148; under Accounting Standards as reported by the Company, its Affiliate or its licensee, as applicable, in such Person&#146;s financial statements, and further reduced by write-offs of accounts receivables or increased for
collection of accounts that were previously written off; plus (ii)&nbsp;(A)&nbsp;the amount of royalties and profit split payments received by the Company or its Affiliates from their respective licensees under Existing Licenses
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
for sales (but not the supply) of Products sold by such licensees to third parties (other than the Company or its Affiliates) during such Net Sales Measuring Period, and (B)&nbsp;the amount of
any milestone payments received during such Net Sales Measuring Period by the Company or its Affiliates from their licensees under Existing Licenses with respect to the Products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any and all set-offs against gross invoice prices shall be calculated in accordance with Accounting Standards. Sales or
other commercial dispositions of a Product between the Company and its Affiliates and its licensees shall be excluded from the computation of Net Sales; Product provided to third parties without charge, in connection with research and development,
clinical trials, compassionate use, humanitarian and charitable donations, or indigent programs or for use as samples shall be excluded from the computation of Net Sales; and no payments will be payable on such sales or such other commercial
dispositions, except where such an Affiliate or licensee is an end user of the Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the
foregoing, if a Product is sold or otherwise commercially disposed of for consideration other than cash or in a transaction that is not at arm&#146;s length between the buyer and the seller, then the gross amount to be included in the calculation of
Net Sales shall be the amount that would have been invoiced had the transaction been conducted at arm&#146;s length and for cash. Such amount that would have been invoiced shall be determined, wherever possible, by reference to the average selling
price of such Product in arm&#146;s length transactions in the relevant country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the
foregoing, in the event a Product is sold as a Combination Product in a particular country, Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by the fraction A/(A+B), where A is the gross invoice price of the
Product if sold separately in a country and B is the gross invoice price of the other product(s) included in the Combination Product if sold separately in such country. If no such separate sales are made by the Company, its Affiliates or licensees
in a country, Net Sales of the Combination Product shall be calculated in a manner determined by the Company in good faith based upon the relative value of the active components of such Combination Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px;" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Sales Measuring Period</U>&#148; means the one-year period beginning
January&nbsp;1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each year during the term of this CVR
Agreement and ending December&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each year
during the term of this CVR Agreement; provided that the first Net Sales Measuring Period will begin on January&nbsp;1, 2011 and end on December&nbsp;31, 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Sales Payment</U>&#148; means, with respect to any Net Sales Measuring Period, an amount equal to
(i)&nbsp;two and one-half percent (2.5%)&nbsp;of that portion of Net Sales of the Products that exceeds one billion dollars ($1,000,000,000) but is less than or equal to two billion dollars ($2,000,000,000) for such period, plus (ii)&nbsp;an
additional amount equal to five percent (5.0%)&nbsp;of that portion of Net Sales of the Products that exceeds two billion dollars ($2,000,000,000) but is less than or equal to three billion dollars ($3,000,000,000) for such period, plus
(iii)&nbsp;an additional amount equal to ten percent (10.0%)&nbsp;of that portion of Net Sales of the Products that exceeds three billion dollars ($3,000,000,000) for such period; provided that no Net Sales Payments will be due following a Net Sales
Payment Termination Date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%;padding-bottom:0px;" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Sales Payment Dates</U>&#148; means the
fifteenth (15</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;day after the date the Company is
required to provide the Net Sales Statement pursuant to Section&nbsp;5.4 for the Net Sales Measuring Period in respect of which a Net Sales Payment is due. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Sales Payment Termination Date</U>&#148; means the last day of the Net Sales Measuring Period ending on
December&nbsp;31, 2025; provided that, if Net Sales of the Products for the Net Sales Measuring Period ending on December&nbsp;31, 2025 are equal to or greater than one billion dollars ($1,000,000,000), then the Net Sales Payment Termination Date
shall be extended until the earlier of (a)&nbsp;the last day of the first Net Sales Measuring Period subsequent to December&nbsp;31, 2025 during which Net Sales of the Products are less than one billion dollars ($1,000,000,000) and
(b)&nbsp;December&nbsp;31, 2030. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Net Sales Statement</U>&#148; means, with respect to each Net Sales
Measuring Period, the written statement of the Company, certified by the Chief Financial Officer of the Company and setting forth with reasonable detail (i)(a), for the Products for all countries in the aggregate, (X)&nbsp;the total of the gross
invoice price charged by the Company, its Affiliates and its licensees (other than licensees under Existing Licenses) for sales of the Products by the Company, its Affiliates and their respective licensees (other than licensees under Existing
Licenses) to third parties (other than the Company or its Affiliates) during the applicable period, (Y)&nbsp;an itemized calculation of Net Sales for the Products showing deductions for such Net Sales Measuring Period provided for in accordance with
the definition of Net Sales, and (Z)(1) the total of all royalties and profit split payments received by the Company and its Affiliates from their respective licensees under Existing Licenses for sales of the Products by their respective licensees
during the applicable period, and (2)&nbsp;the amount of any milestone payments received during such Net Sales Measuring Period by the Company or its Affiliates from their licensees under Existing Licenses with respect to the Products, (b)&nbsp;to
the extent that Net Sales for the Products for an applicable period is determined based on Net Sales of a Combination Product for such period, the method of determining the Net Sales of the Combination Product attributable to the Products in
accordance with the definition of Net Sales, and (c)&nbsp;to the extent that sales for the Products for an applicable period is recorded in currencies other than United States dollars, the exchange rates used for conversion of such foreign currency
into United States dollars and (ii)&nbsp;the calculation of the Net Sales Payment due, if any, in respect of the applicable Net Sales Measuring Period in accordance with this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Officer&#146;s Certificate</U>&#148; when used with respect to the Company means a certificate signed by the
chairman of the Board of Directors or the president or any vice president, the controller or assistant controller and the treasurer or assistant treasurer or the secretary or any assistant secretary of the Company delivered to the Trustee or any
other person authorized to act on behalf of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Opinion of Counsel</U>&#148; means a
written opinion of counsel, who may be counsel for the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Outstanding</U>&#148; when used with
respect to Securities means, as of the date of determination, all Securities theretofore authenticated and delivered under this CVR Agreement, except: (i)&nbsp;Securities theretofore cancelled by the Trustee or delivered to the Trustee for
cancellation and (ii)&nbsp;Securities in exchange for or in lieu of which other Securities have been </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
authenticated and delivered pursuant to this CVR Agreement, other than any such Securities in respect of which there shall have been presented to the Trustee proof satisfactory to it that such
Securities are held by a bona fide purchaser in whose hands the Securities are valid obligations of the Company; provided, however, that in determining whether the Holders of the requisite Outstanding Securities have given any request, demand,
direction, consent or waiver hereunder, Securities owned by the Company or any Affiliate of the Company, whether held as treasury securities or otherwise, shall be disregarded and deemed not to be Outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Party</U>&#148; shall mean the Trustee, the Company and/or Holder(s), as applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Paying Agent</U>&#148; means any Person authorized by the Company to pay the amount determined pursuant to
Section&nbsp;3.1, if any, on any Securities on behalf of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Payment Date</U>&#148; means
any Net Sales Payment Date, any Milestone Payment Date, and any such date as shall be required for any CVR Shortfall payment pursuant to the review procedure set forth in Section&nbsp;7.6. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Person</U>&#148; means any individual, corporation, partnership, joint venture, association, joint-stock
company, trust, limited liability company, unincorporated organization or government or any agency or political subdivision thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Products</U>&#148; means each of: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the pharmaceutical product comprising the chemical compound having the chemical name of
5&szlig;,20-Epoxy-1,2a,4,7&szlig;,10&szlig;,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (with the structure below), known by the generic name &#147;paclitaxel&#148; and bound to albumin
that is the subject of the New Drug Application No.&nbsp;21-660 filed with the FDA and subject of the European Medicines Agency Marketing Authorization granted on January&nbsp;11, 2008, together with all amendments and supplements to such FDA and
European Medicines Agency approvals (identified by the Company as ABRAXANE); provided that in all cases such Product is an injectable formulation.</FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g21538g70q57.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the pharmaceutical product comprising the chemical compound having the
chemical name of (2R,3S)-N-carboxy-3-phenylisoserine,N-<I>tert</I>-butyl ester, 13-ester with 5&szlig;-20-epoxy-1,2 ,4,7&szlig;,10&szlig;,13 -hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, anhydrous(with the structure below) bound to albumin that
is the subject of the Investigational New Drug Application No.&nbsp;73,527 filed with the FDA together with all amendments (identified by the Company as &#147;nab-docetaxel (ABI-008)&#148;); provided that in all cases such Product is an injectable
formulation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) the pharmaceutical product comprising the chemical compound having the chemical name of
(3<I>S</I>, 6<I>R</I>, 7<I>E</I>, 9<I>R</I>, 10<I>R</I>, 12<I>R</I>, 14<I>S</I>, 15<I>E</I>, 17<I>E</I>, 19<I>E</I>, 21<I>S</I>, 23<I>S</I>, 26<I>R</I>, 27<I>R</I>, 34a<I>S</I>)-9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1<I>R</I>)-2-[(1<I>S</I>, 3<I>R</I>, 4<I>R</I>)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6, 8, 12, 14, 20, 26-hexamethyl-23, 27-epoxy-3<I>H</I>-pyrido[2, 1-c][1,4] oxaazacyclohentriacontine
-1, 5, 11, 28, 29 (4H,6H,31H)-pentone (with the structure below) bound to albumin that is the subject of the Investigational New Drug Application No.&nbsp;74.610 filed with the FDA together with all amendments (identified by the Company as
&#147;nab-rapamycin (ABI-009)&#148;); provided that in all cases such Product is an injectable formulation.</FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">

<IMG SRC="g21538g61j13.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the pharmaceutical product comprising the chemical compound having the chemical name of
17-allylamino-17-demethoxygeldanamycin, 17-allylamino geldanamycin (with the structure below) bound to albumin that is the subject of the Investigational New Drug Application No.&nbsp;78,298 filed with the FDA together with all amendments
(identified by the Company as &#147;nab-17AAG (ABI-010)&#148;); provided that in all cases such Product is an injectable formulation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g21538g18e07.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) the pharmaceutical product comprising the chemical compound having the chemical name of
N-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9- tetrahydro-benzo[a]heptalen-7-yl)-3-[3-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-ureido]-propionamide(with the structure below) bound to albumin that is
the subject of the Investigational New Drug Application No.&nbsp;103,698 filed with the FDA together with all amendments (identified by the Company as &#147;nab-thiocolchicine dimer (ABI-011)&#148;); provided that in all cases the Product is an
injectable formulation. </FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">

<IMG SRC="g21538g46m25.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) the pharmaceutical product comprising the chemical compound having the chemical name of
(<I><FONT SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT>R,
&szlig;S</I>)-<I>&szlig;</I>-[[(1,1-Dimethylethoxy)carbonyl]amino]-<I><FONT SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></I>-(hexanoyloxy)benzenepropanoic acid
(2a<I>R</I>,4<I>S</I>,4a<I>S</I>,6<I>R</I>,9<I>S</I>,11<I>S</I>,12<I>S</I>,12a<I>R</I>,12b<I>S</I>)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1<I>H</I>-cyclodecal[3,4]benz[1,2-b]oxet-9-yl
 ester (with the structure below) bound to albumin (identified by the Company as &#147;nab-novel taxane (ABI-013)&#148;) provided that in all cases the Product is an injectable formulation.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g21538g83j58.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) the pharmaceutical product comprising the chemical compound having the chemical name of
Benzenepropanoic acid, &szlig;-(benzoylamino)-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-hydroxy-,6,12bbis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12bdodecahydro-
4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1<I>H</I>-cyclodeca[3,4]benz[1,2-b]-oxet-9-yl
ester,[2a<I>R</I>-[2a<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>,4&szlig;,4a&szlig;,6&szlig;,9<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>(<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>R*,&szlig;S*),11<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;
</FONT>,12<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>,12a<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, 12b<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>]] bound to albumin that is the subject of the Investigational New Drug Application
No.&nbsp;63,082 filed with the FDA together with all amendments (identified by the Company as &#147;COROXANE&#148;); provided that in all cases the Product is an injectable formulation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Redemption Eligibility Date</U>&#148; means the date that fifty percent (50%)&nbsp;of the Securities issued
pursuant to the terms of the Merger Agreement either are (i)&nbsp;no longer Outstanding, and/or (ii)&nbsp;repurchased, acquired, redeemed or retired by the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Registration Statement</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Regulatory Approval</U>&#148; means all approvals from the FDA or other non-U.S. regulatory
authority necessary for the commercial manufacture, marketing and sale of a product in the United States or other jurisdiction in accordance with applicable Law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Representatives</U>&#148; shall have the meaning set forth in Section&nbsp;7.13 of this CVR Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Responsible Officer</U>&#148; when used with respect to the Trustee means any officer assigned to
the Corporate Trust Office and also means, with respect to any particular corporate trust matter, any other officer of the Trustee to whom such matter is referred because of his knowledge of and familiarity with the particular subject. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Securities</U>&#148; shall have the meaning set forth in the Preamble of this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Securities Act</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Security Register</U>&#148; shall have the meaning set forth in Section&nbsp;3.5(a)
of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Senior Obligations</U>&#148; means any existing or future obligations of the Company,
including the principal of, premium (if any), interest (including, without limitation, any interest accruing subsequent to the filing of a petition of bankruptcy at the rate provided for in the documentation with respect thereto, whether or not such
interest is an allowed claim under applicable Law) on, and all other amounts owing thereon, (i)&nbsp;with respect to borrowed money, (ii)&nbsp;evidenced by notes, debentures, bonds or other similar debt instruments, (iii)&nbsp;with respect to the
net obligations owed under interest rate swaps or similar agreements or currency exchange transactions, (iv)&nbsp;reimbursement obligations in respect of letters of credit and similar obligations, (v)&nbsp;in respect of capital leases, or
(vi)&nbsp;guarantees in respect of obligations referred to in clauses (i)&nbsp;through (v)&nbsp;above; unless, in any case, the instrument creating or evidencing the same or pursuant to which the same is outstanding provides that such obligations
are pari passu to or subordinate in right of payment to the Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing,
&#147;Senior Obligations&#148; shall not include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Junior Obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade debt incurred in the ordinary course of business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">any intercompany indebtedness between the Company and any of its Subsidiaries or Affiliates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">indebtedness of the Company that is subordinated in right of payment to Senior Obligations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">indebtedness or other obligations of the Company that by its terms ranks equal or junior in right of payment to the Junior Obligations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">indebtedness of the Company that, by operation of Law, is subordinate to any general unsecured obligations of the Company; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">indebtedness evidenced by any guarantee of indebtedness ranking equal or junior in right of payment to the Junior Obligations.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Shortfall Interest Rate</U>&#148; means a rate equal to the sum of two percent
(2%)&nbsp;plus the prime rate of interest quoted in the Money Rates section of <I>The Wall Street Journal</I> (New York Edition), or similar reputable data source, calculated daily on the basis of a three hundred sixty-five (365)&nbsp;day year or,
if lower, the highest rate permitted under applicable Law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Shortfall Report</U>&#148; shall have the
meaning set forth in Section&nbsp;7.6(b) of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Sub</U>&#148; shall have the meaning
set forth in the Recitals of this CVR Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any
corporation, limited liability company, association, partnership or other business entity of which more than fifty percent (50%)&nbsp;of the total voting power of shares of Voting Securities is at the time owned or controlled, directly or
indirectly, by: (i)&nbsp;such Person; (ii)&nbsp;such Person and one or more Subsidiaries of such Person; or (iii)&nbsp;one or more Subsidiaries of such Person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Tax</U>&#148; means any federal, state, local or foreign income, profits, gross receipts, license, payroll,
employment, severance, stamp, occupation, premium, windfall profits, environmental, customs duty, capital stock, franchise, sales, social security, unemployment, disability, use, property, withholding, excise, transfer, registration, production,
value added, alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, together with any interest, penalty or addition thereto, imposed by any Governmental Entity responsible for the imposition of any such tax, whether
disputed or not. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Tax Return</U>&#148; means any return, report, declaration, claim or other
statement (including attached schedules) relating to Taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Trust Indenture Act</U>&#148; means the
Trust Indenture Act of 1939, as amended from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Trustee</U>&#148; means the Person named
as the &#147;Trustee&#148; in the first paragraph of this CVR Agreement, until a successor Trustee shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter &#147;Trustee&#148; shall mean such successor
Trustee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Vice President</U>&#148; when used with respect to the Company or the Trustee, means any
vice president, whether or not designated by a number or a word or words added before or after the title of &#147;vice president.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Voting Securities</U>&#148; means securities or other interests having voting power, or the right, to elect or
appoint a majority of the directors, or any Persons performing similar functions, irrespective of whether or not stock or other interests of any other class or classes shall have or might have voting power or any right by reason of the happening of
any contingency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.2 <U>Compliance and Opinions</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon any application or request by the Company to the Trustee to take any action under any provision of this CVR
Agreement, the Company shall furnish to the Trustee an Officers&#146; Certificate stating that, in the opinion of the signor, all conditions precedent, if any, provided for in this CVR Agreement relating to the proposed action have been complied
with and an Opinion of Counsel stating, subject to customary exceptions, that in the opinion of such counsel all such conditions precedent, if any, have been complied with, except that, in the case of any such application or request as to which the
furnishing of such documents is specifically required by any provision of this CVR Agreement relating to such particular application or request, no additional certificate or opinion need be furnished. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Every certificate or opinion with respect to compliance with a condition or covenant provided for in this CVR
Agreement shall include: (i)&nbsp;a statement that each individual signing such certificate or opinion has read such covenant or condition and the definitions herein </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
relating thereto; (ii)&nbsp;a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are
based; (iii)&nbsp;a statement that, in the opinion of each such individual, he or she has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been
complied with; and (iv)&nbsp;a statement as to whether, in the opinion of each such individual, such condition or covenant has been complied with. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.3 <U>Form of Documents Delivered to Trustee</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) In any case where several matters are required to be certified by, or covered by an opinion of, any specified Person,
it is not necessary that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so certified or covered by only one document, but one such Person may certify or give an opinion with respect to some
matters and one or more other such Persons as to other matters, and any such Person may certify or give an opinion as to such matters in one or several documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any certificate or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon a
certificate or opinion of, or representations by, counsel. Any such certificate or Opinion of Counsel may be based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of the
Company stating that the information with respect to such factual matters is in the possession of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Any certificate, statement or opinion of an officer of the Company or of counsel may be based, insofar as it relates
to accounting matters, upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of the Company. Any certificate or opinion of any independent firm of public accountants filed with the Trustee shall
contain a statement that such firm is independent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Where any Person is required to make, give or execute
two or more applications, requests, consents, certificates, statements, opinions or other instruments under this CVR Agreement, they may, but need not, be consolidated and form one instrument. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.4 <U>Acts of Holders</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Any request, demand, authorization, direction, notice, consent, waiver or other action provided by this CVR Agreement
to be given or taken by Holders may be embodied in and evidenced by one or more instruments of substantially similar tenor signed by such Holders in person or by an agent duly appointed in writing; and, except as herein otherwise expressly provided,
such action shall become effective when such instrument or instruments are delivered to the Trustee and, where it is hereby expressly required, to the Company. Such instrument or instruments (and the action embodied therein and evidenced thereby)
are herein sometimes referred to as the &#147;Act&#148; of the Holders signing such instrument or instruments. Proof of execution of any such instrument or of a writing appointing any such agent shall be sufficient for any purpose of this CVR
Agreement and (subject to Section&nbsp;4.1) conclusive in favor of the Trustee and the Company, if made in the manner provided in this Section. The Company may </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
set a record date for purposes of determining the identity of Holders entitled to vote or consent to any action by vote or consent authorized or permitted under this CVR Agreement. If not
previously set by the Company, (i)&nbsp;the record date for determining the Holders entitled to vote at a meeting of the Holders shall be the date preceding the date notice of such meeting is mailed to the Holders, or if notice is not given, on the
day next preceding the day such meeting is held, and (ii)&nbsp;the record date for determining the Holders entitled to consent to any action in writing without a meeting shall be the first date on which a signed written consent setting forth the
action taken or proposed to be taken is delivered to the Company. If a record date is fixed, those Persons who were Holders of Securities at such record date (or their duly designated proxies), and only those Persons, shall be entitled to take such
action by vote or consent or, except with respect to clause (d)&nbsp;below, to revoke any vote or consent previously given, whether or not such Persons continue to be Holders after such record date. No such vote or consent shall be valid or
effective for more than one hundred twenty (120)&nbsp;days after such record date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The fact and date of
the execution by any Person of any such instrument or writing may be proved in any reasonable manner which the Trustee deems sufficient. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The ownership of Securities shall be proved by the Security Register. Neither the Company nor the Trustee nor any
Agent of the Company or the Trustee shall be affected by any notice to the contrary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) At any time prior to
(but not after) the evidencing to the Trustee, as provided in this Section&nbsp;1.4, of the taking of any action by the Holders of the Securities specified in this CVR Agreement in connection with such action, any Holder of a Security the serial
number of which is shown by the evidence to be included among the serial numbers of the Securities the Holders of which have consented to such action may, by filing written notice at the Corporate Trust Office and upon proof of holding as provided
in this Section&nbsp;1.4, revoke such action so far as concerns such Security. Any request, demand, authorization, direction, notice, consent, waiver or other action by the Holder of any Security shall bind every future Holder of the same Security
or the Holder of every Security issued upon the registration of transfer thereof or in exchange therefor or in lieu thereof, in respect of anything done, suffered or omitted to be done by the Trustee, any Paying Agent or the Company in reliance
thereon, whether or not notation of such action is made upon such Security. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.5 <U>Notices,
etc., to Trustee and Company</U>. Any request, demand, authorization, direction, notice, consent, waiver or Act of Holders or other document provided or permitted by this CVR Agreement to be made upon, given or furnished to, or filed with:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the Trustee by any Holder or by the Company shall be sufficient for every purpose hereunder if made,
given, furnished or filed, in writing, to or with the Trustee at its Corporate Trust Office; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the
Company by the Trustee or by any Holder shall be sufficient for every purpose hereunder if in writing and mailed, first-class postage prepaid, to the Company addressed to it at Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901, Legal
Department, Attention: Senior Vice President and Chief Counsel, or at any other address previously furnished in writing to the Trustee by the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.6 <U>Notice to Holders; Waiver</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Where this CVR Agreement provides for notice to Holders of any event, such notice shall be sufficiently given (unless
otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at his address as it appears in the Security Register, not later than the latest date, and not earlier than the
earliest date, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of
such notice with respect to other Holders. Where this CVR Agreement provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and such waiver shall be the
equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in reliance upon such waiver. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In case by reason of the suspension of regular mail service or by reason of any other cause, it shall be
impracticable to mail notice of any event as required by any provision of this CVR Agreement, then any method of giving such notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.7 <U>Conflict with Trust Indenture Act</U>. If any provision hereof limits, qualifies or conflicts with
another provision hereof which is required to be included in this CVR Agreement by any of the provisions of the Trust Indenture Act, such required provision shall control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.8 <U>Effect of Headings and Table of Contents</U>. The Article and Section headings herein and the Table
of Contents are for convenience only and shall not affect the construction hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.9
<U>Benefits of Agreement</U>. Nothing in this CVR Agreement or in the Securities, express or implied, shall give to any Person (other than the Parties hereto and their successors hereunder, any Paying Agent and the Holders) any benefit or any legal
or equitable right, remedy or claim under this CVR Agreement or under any covenant or provision herein contained, all such covenants and provisions being for sole benefit of the Parties hereto and their successors, any Paying Agent and of the
Holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.10 <U>Governing Law</U>. THIS CVR AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK INCLUDING, WITHOUT LIMITATION, SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. EACH OF THE COMPANY, THE TRUSTEE AND EACH
OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING IN THE BOROUGH OF
MANHATTAN IN THE CITY OF NEW YORK IN RESPECT OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS CVR AGREEMENT AND THE </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
SECURITIES, AND IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID COURTS. EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT
PROCESS MAY BE SERVED UPON THEM IN ANY MANNER AUTHORIZED BY THE LAWS OF THE STATE OF NEW YORK FOR SUCH PERSONS AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO UNDER APPLICABLE LAW, ANY OBJECTION IT MAY NOW OR HEREAFTER HAVE TO
SUCH SERVICE OF PROCESS, THE LAYING OF THE VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT AND ANY CLAIM THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.11 <U>Legal Holidays</U>. In the event that a Payment Date shall not be a Business Day, then
(notwithstanding any provision of this CVR Agreement or the Securities to the contrary) payment on the Securities need not be made on such date, but may be made, without the accrual of any interest thereon, on the next succeeding Business Day with
the same force and effect as if made on such Payment Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.12 <U>Separability Clause</U>. In
case any provision in this CVR Agreement or in the CVRs shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.13 <U>No Recourse Against Others</U>. A director, officer or employee, as such, of the Company or the
Trustee shall not have any liability for any obligations of the Company or the Trustee under the Securities or this CVR Agreement or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a Security
each Holder waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.14 <U>Counterparts</U>. This CVR Agreement shall be signed in any number of counterparts with the same
effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.15 <U>Acceptance of Trust</U>. [<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], the Trustee named
herein, hereby accepts the trusts in this CVR Agreement declared and provided, upon the terms and conditions set forth herein. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 2 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY FORMS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.1 <U>Forms Generally</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Securities and the Trustee&#146;s certificate of authentication shall be in substantially the forms set forth in
Annex A, attached hereto and incorporated herein by this reference, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this CVR Agreement and may have such letters, numbers or other
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
marks of identification and such legends or endorsements placed thereon as may be required to comply with the rules of any securities exchange or as may be required by Law or any rule or
regulation pursuant thereto, all as may be determined by the officers executing such Securities, as evidenced by their execution of the Securities. Any portion of the text of any Security may be set forth on the reverse thereof, with an appropriate
reference thereto on the face of the Security. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The definitive Securities shall be typewritten, printed,
lithographed or engraved on steel engraved borders or produced by any combination of these methods or may be produced in any other manner permitted by the rules of any securities exchange on which the Securities may be listed, all as determined by
the officers executing such Securities, as evidenced by their execution of such Securities. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 3 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE SECURITIES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.1 <U>Title and Terms</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px;" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The aggregate number of CVRs in respect of which CVR Certificates may be authenticated and
delivered under this CVR Agreement is limited to a number equal to
[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>]</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1
</SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or
in lieu of, other Securities pursuant to Section&nbsp;3.4, 3.5, 3.6 or 6.6. From and after the Effective Time, the Company shall not be permitted to issue any CVRs that have the right to receive any portion of the Milestone Payments or the Net Sales
Payments, except as provided and in accordance with the terms and conditions of the Merger Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The
Securities shall be known and designated as the &#147;Series A Contingent Value Rights&#148; of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) On each Net Sales Payment Date, the Company shall pay to the Trustee, by wire transfer to the account designated by
the Trustee, the Net Sales Payment due, if any, in respect of the Net Sales Measuring Period ended immediately preceding such Net Sales Payment Date, and the Trustee shall pay the Holders of the Securities as of such Net Sales Payment Date, a pro
rata portion of such Net Sales Payment based on the number of CVRs held by each Holder as of such date. Notwithstanding the foregoing, the Company&#146;s obligations to pay any Net Sales Payment shall terminate in its entirety on the Net Sales
Payment Termination Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) On each Milestone Payment Date, the Company shall pay to the Trustee, by wire
transfer to the account designated by the Trustee, the applicable Milestone Payment, and the Trustee shall pay to the Holders of the Securities as of such Milestone Payment Date, a pro rata portion of such Milestone Payment based on the number of
CVRs held by each Holder as of such date. Notwithstanding the foregoing, the Company&#146;s obligations to pay any Milestone Payment shall terminate in its entirety if the corresponding Milestone for such Milestone Payment has not been achieved by
the Milestone Target Date. </FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insert total, as of the closing of the Merger, of all CVRs to be issued pursuant to the Merger Agreement. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The Holders of the CVR Certificates, by acceptance thereof, agree that
no joint venture, partnership or other fiduciary relationship is created hereby or by the Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)
Other than in the case of interest on amounts due and payable after the occurrence of an Event of Default or with respect to any CVR Shortfall, no interest or dividends shall accrue on any amounts payable in respect of the CVRs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Except to the extent any portion of any CVR Payment is required to be treated as imputed interest pursuant to
applicable Law, the Parties hereto agree to treat the CVRs and all CVR Payments for all Tax purposes as additional consideration for the shares of Common Stock, the Options, the SARs and the RSUs pursuant to the Merger Agreement, and none of the
Parties hereto will take any position to the contrary on any Tax Return or for other Tax purposes except as required by applicable Law. The Company shall report imputed interest on the CVRs pursuant to Section&nbsp;483 of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) The CVRs and any interest thereon may be sold, assigned, pledged encumbered or in any manner transferred or disposed
of, in whole or in part, only in compliance with applicable United States federal and state securities Laws and, to the extent applicable, in accordance with Section&nbsp;3.5 hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The Holder of any CVR or CVR Certificate is not, and shall not, by virtue thereof, be entitled to any rights of a
holder of any Voting Securities or other equity security or other ownership interest of the Company or in any constituent company to the Merger, either at Law or in equity, and the rights of the Holders are limited to those contractual rights
expressed in this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) Except as provided in this CVR Agreement (including, without limitation,
Section&nbsp;7.6), none of the Company or any of its Affiliates shall have any right to set-off any amounts owed or claimed to be owed by any Holder to any of them against such Holder&#146;s Securities or any CVR Payment or other amount payable to
such Holder in respect of such Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) In the event that all of the CVR Certificates not previously
cancelled shall have become due and payable pursuant to the terms hereof, all disputes with respect to amounts payable to the Holders brought pursuant to the terms and conditions of this CVR Agreement have been resolved, and the Company has paid or
caused to be paid or deposited with the Trustee all amounts payable to the Holders under this CVR Agreement (including any amounts determined in accordance with Section&nbsp;7.6 herein), then this CVR Agreement shall cease to be of further effect
and shall be deemed satisfied and discharged. Notwithstanding the satisfaction and discharge of this CVR Agreement, the obligations of the Company under Section&nbsp;4.7(c) shall survive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.2 <U>Registrable Form</U>. The Securities shall be issuable only in registered form. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.3 <U>Execution, Authentication, Delivery and Dating</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Securities shall be executed on behalf of the Company by its chairman of the Board of Directors or its president
or any vice president or its treasurer, but need not be attested. The signature of any of these officers on the Securities may be manual or facsimile. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Securities bearing the manual or facsimile signatures of individuals who were, at the time of execution, the proper
officers of the Company shall bind the Company, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the authentication and delivery of such Securities or did not hold such offices at the date of such
Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) At any time and from time to time after the execution and delivery of this CVR Agreement, the
Company may deliver Securities executed by the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Securities; and the Trustee, in accordance with such Company Order, shall
authenticate and deliver such Securities as provided in this CVR Agreement and not otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Each
Security shall be dated the date of its authentication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) No Security shall be entitled to any benefit
under this CVR Agreement or be valid or obligatory for any purpose unless there appears on such Security a certificate of authentication substantially in the form provided for herein duly executed by the Trustee, by manual or facsimile signature of
an authorized officer, and such certificate upon any Security shall be conclusive evidence, and the only evidence, that such Security has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this CVR
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.4 <U>Temporary Securities</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Pending the preparation of definitive Securities, the Company may execute, and upon Company Order, the Trustee shall
authenticate and deliver, temporary Securities which are printed, lithographed, typewritten, mimeographed or otherwise produced, substantially of the tenor of the definitive Securities in lieu of which they are issued and with such appropriate
insertions, omissions, substitutions and other variations as the officers executing such Securities may determine with the concurrence of the Trustee. Temporary Securities may contain such reference to any provisions of this CVR Agreement as may be
appropriate. Every temporary Security shall be executed by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If temporary Securities are issued, the Company will cause definitive Securities to be prepared without unreasonable
delay. After the preparation of definitive Securities, the temporary Securities shall be exchangeable for definitive Securities upon surrender of the temporary Securities at the office or agency of the Company designated for such purpose pursuant to
Section&nbsp;7.2, without charge to the Holder. Upon surrender for cancellation of any one or more temporary Securities, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a like amount of definitive
Securities. Until so </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
exchanged, the Temporary Securities shall in all respects be entitled to the same benefits under this CVR Agreement as definitive Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.5 <U>Registration, Registration of Transfer and Exchange</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company shall cause to be kept at the office of the Trustee a register (the register maintained in such office
and in any other office or agency designated pursuant to Section&nbsp;7.2 being herein sometimes referred to as the &#147;<U>Security Register</U>&#148;) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide
for the registration of Securities and of transfers of Securities. The Trustee is hereby initially appointed &#147;Security Registrar&#148; for the purpose of registering Securities and transfers of Securities as herein provided. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Upon surrender for registration of transfer of any Security at the office or agency of the Company designated
pursuant to Section&nbsp;7.2, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new CVR Certificates representing the same aggregate number of CVRs
represented by the CVR Certificate so surrendered that are to be transferred and the Company shall execute and the Trustee shall authenticate and deliver, in the name of the transferor, one or more new CVR Certificates representing the aggregate
number of CVRs represented by such CVR Certificate that are not to be transferred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) At the option of the
Holder, CVR Certificates may be exchanged for other CVR Certificates that represent in the aggregate the same number of CVRs as the CVR Certificates surrendered at such office or agency. Whenever any CVR Certificates are so surrendered for exchange,
the Company shall execute, and the Trustee shall authenticate and deliver, the CVR Certificates which the Holder making the exchange is entitled to receive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) All Securities issued upon any registration of transfer or exchange of Securities shall be the valid obligations of
the Company, evidencing the same rights, and entitled to the same benefits under this CVR Agreement, as the Securities surrendered upon such registration of transfer or exchange. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Every Security presented or surrendered for registration of transfer or for exchange shall (if so required by the
Company or the Security Registrar) be duly endorsed, or be accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar, duly executed by the Holder thereof or his attorney duly authorized in
writing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) No service charge shall be made for any registration of transfer or exchange of Securities, but
the Company may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in connection with any registration of transfer or exchange of Securities, other than exchanges pursuant to Section&nbsp;3.4 or 6.6
not involving any transfer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.6 <U>Mutilated, Destroyed, Lost and Stolen Securities</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If (i)&nbsp;any mutilated Security is surrendered to the Trustee, or (ii)&nbsp;the Company and the Trustee receive
evidence to their satisfaction of the destruction, loss or theft of </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any Security, and there is delivered to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, then, in the absence of notice to the
Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and, upon delivery of a Company Order, the Trustee shall authenticate and deliver, in exchange for any such mutilated Security or in lieu
of any such destroyed, lost or stolen Security, a new CVR Certificate of like tenor and amount of CVRs, bearing a number not contemporaneously outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In case any such mutilated, destroyed, lost or stolen Security has become or is to become finally due and payable
within fifteen (15)&nbsp;days, the Company in its discretion may, instead of issuing a new CVR Certificate, pay to the Holder of such Security on the applicable Payment Date, as the case may be, all amounts due and payable with respect thereto.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Every new Security issued pursuant to this Section&nbsp;3.6 in lieu of any destroyed, lost or stolen
Security shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all benefits of this CVR Agreement
equally and proportionately with any and all other Securities duly issued hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The provisions of
this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.7 <U>Payments with respect to CVR Certificates</U>. Payment of any amounts pursuant to the CVRs shall be
made in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts. The Company may, at its option, pay such amounts by wire transfer or check payable in such money. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.8 <U>Persons Deemed Owners</U>. Prior to the time of due presentment for registration of transfer, the
Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name any Security is registered as the owner of such Security for the purpose of receiving payment on such Security and for all other purposes whatsoever,
whether or not such Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.9 <U>Cancellation</U>. All Securities surrendered for payment, registration of transfer or exchange shall,
if surrendered to any Person other than the Trustee, be delivered to the Trustee and shall be promptly canceled by it. The Company may at any time deliver to the Trustee for cancellation any Securities previously authenticated and delivered
hereunder which the Company may have acquired in any manner whatsoever, and all Securities so delivered shall be promptly canceled by the Trustee. No Securities shall be authenticated in lieu of or in exchange for any Securities canceled as provided
in this Section, except as expressly permitted by this CVR Agreement. All cancelled Securities held by the Trustee shall be destroyed and a certificate of destruction shall be issued by the Trustee to the Company, unless otherwise directed by a
Company Order. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 4 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE TRUSTEE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.1 <U>Certain Duties and Responsibilities</U>. (a)&nbsp;With respect to the Holders, the Trustee, prior to
the occurrence of an Event of Default (as defined in Section&nbsp;8.1) with respect to the Securities and after the curing or waiving of all Events of Default which may have occurred, undertakes to perform such duties and only such duties as are
specifically set forth in this CVR Agreement and no implied covenants shall be read into this CVR Agreement against the Trustee. In case an Event of Default with respect to the Securities has occurred (which has not been cured or waived), the
Trustee shall exercise such of the rights and powers vested in it by this CVR Agreement, and use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his own
affairs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the absence of bad faith on its part, prior to the occurrence of an Event of Default and
after the curing or waiving of all such Events of Default which may have occurred, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to
the Trustee which conform to the requirements of this CVR Agreement; but in the case of any such certificates or opinions which by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to
examine the same to determine whether or not they conform to the requirements of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) No
provision of this CVR Agreement shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that (i)&nbsp;this Subsection (c)&nbsp;shall not be
construed to limit the effect of Subsections (a)&nbsp;and (b)&nbsp;of this Section; (ii)&nbsp;the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee was
negligent in ascertaining the pertinent facts; and (iii)&nbsp;the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the Holders pursuant to Section&nbsp;8.9
relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Whether or not therein expressly so provided, every provision of this CVR Agreement relating to the conduct or
affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this Section. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.2 <U>Certain Rights of Trustee</U>. Subject to the provisions of Section&nbsp;4.1, including without
limitation, the duty of care that the Trustee is required to exercise upon the occurrence of an Event of Default: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document believed by it to be genuine and to have been signed or presented by the proper
party or parties and the Trustee need not investigate any fact or matter stated in the document; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) any request or direction or order of the Company mentioned herein shall
be sufficiently evidenced by a Company Request or Company Order and any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution and the Trustee shall not be liable for any action it takes or omits to take in good
faith reliance thereon; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) whenever in the administration of this CVR Agreement the Trustee shall deem it
desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part, rely upon an
Officers&#146; Certificate and the Trustee shall not be liable for any action it takes or omits to take in good faith reliance thereon or an Opinion of Counsel; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the Trustee may consult with counsel and the written advice of such counsel or any Opinion of Counsel shall be full
and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this CVR Agreement
at the request or direction of any of the Holders pursuant to this CVR Agreement, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in
compliance with such request or direction; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) the Trustee shall not be bound to make any investigation into
the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document, but the Trustee in its
discretion may make such further inquiry or investigation into such facts or matters as it may see fit, and if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises
of the Company, personally or by agent or attorney; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) the Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder;
and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) the Trustee shall not be liable for any action taken, suffered or omitted to be taken by it in good
faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.3 <U>Notice of Default</U>. If a default occurs hereunder with respect to the Securities, the Trustee
shall give the Holders notice of any such default actually known to it as and to the extent applicable and provided by the Trust Indenture Act; provided, however, that in the case of any default of the character specified in Section&nbsp;8.1(b) with
respect to the Securities, no notice to Holders shall be given until at least thirty (30)&nbsp;days after the occurrence thereof. For the purpose of this Section&nbsp;4.3, the term &#147;default&#148; means any event that is, or after notice or
lapse of time or both would become, an Event of Default with respect to the Securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.4 <U>Not Responsible for Recitals or Issuance of
Securities</U>. The Trustee shall not be accountable for the Company&#146;s use of the Securities or the proceeds from the Securities. The recitals contained herein and in the Securities, except the Trustee&#146;s certificates of authentication,
shall be taken as the statements of the Company, and the Trustee assumes no responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this CVR Agreement or of the Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.5&nbsp;<U>May Hold Securities</U>. The Trustee, any Paying Agent, Security Registrar or any other agent of
the Company, in its individual or any other capacity, may become the owner or pledgee of Securities, and, subject to Sections 4.8 and 4.13, may otherwise deal with the Company with the same rights it would have if it were not Trustee, Paying Agent,
Security Registrar or such other agent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.6 <U>Money Held in Trust</U>. Money held by the
Trustee in trust hereunder need not be segregated from other funds except to the extent required by Law. The Trustee shall be under no liability for interest on any money received by it hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.7 <U>Compensation and Reimbursement</U>. The Company agrees: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) to pay to the Trustee from time to time reasonable compensation for all services rendered by it hereunder in such
amount as the Company and the Trustee shall agree from time to time (which compensation shall not be limited by any provision of Law in regard to the compensation of a trustee of an express trust); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) except as otherwise expressly provided herein, to reimburse the Trustee upon its request for all reasonable expenses,
disbursements and advances incurred or made by the Trustee in accordance with any provision of this CVR Agreement (including the reasonable compensation and the reasonable expenses and disbursements of its agents and counsel), except any such
expense, disbursement or advance as may be attributable to the Trustee&#146;s negligence or willful misconduct; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) to indemnify the Trustee and each of its agents, officers, directors and employees (each an &#147;indemnitee&#148;)
for, and to hold it harmless against, any loss, liability or expense (including attorneys fees and expenses) incurred without negligence or bad faith on its part, arising out of or in connection with the acceptance or administration of this trust
and the performance of its duties hereunder, including the reasonable costs and expenses of defending itself against any claim or liability in connection with the exercise or performance of any of its powers or duties hereunder. The Company&#146;s
payment obligations pursuant to this Section shall survive the termination of this CVR Agreement. When the Trustee incurs expenses after the occurrence of an Event of Default specified in Section&nbsp;8.1(c) or 8.1(d) with respect to the Company,
the expenses are intended to constitute expenses of administration under bankruptcy Laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.8
<U>Disqualification; Conflicting Interests</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If applicable, to the extent that the Trustee or the
Company determines that the Trustee has a conflicting interest within the meaning of the Trust Indenture Act, the Trustee shall, within ninety (90)&nbsp;days after ascertaining that it has such conflicting interest, either
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
eliminate such conflicting interest or resign to the extent and in the manner provided by, and subject to the provisions of, the Trust Indenture Act and this CVR Agreement. The Company shall take
prompt steps to have a successor appointed in the manner provided in this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the event the
Trustee shall fail to comply with the foregoing subsection 4.8(a), the Trustee shall, within ten (10)&nbsp;days of the expiration of such ninety (90)&nbsp;day period, transmit a notice of such failure to the Holders in the manner and to the extent
provided in the Trust Indenture Act and this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If the Trustee fails to comply with
Section&nbsp;4.8(a) after written request therefore by the Company or any Holder, any Holder of any Security who has been a bona fide Holder for at least six (6)&nbsp;months may on behalf of himself and all others similarly situated, petition any
court of competent jurisdiction for the removal of such Trustee and the appointment of a successor Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.9 <U>Corporate Trustee Required; Eligibility</U>. There shall at all times be a Trustee hereunder which
satisfies the applicable requirements of Sections 310(a)(1) and (5)&nbsp;of the Trust Indenture Act and has a combined capital and surplus of at least one hundred fifty million dollars ($150,000,000). If such corporation publishes reports of
condition at least annually, pursuant to Law or to the requirements of a supervising or examining authority, then for the purposes of this Section&nbsp;4.9, the combined capital and surplus of such corporation shall be deemed to be its combined
capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it shall resign immediately in the manner and with the
effect hereinafter specified in this Article. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.10 <U>Resignation and Removal; Appointment of Successor</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to this
Article shall become effective until the acceptance of appointment by the successor Trustee under Section&nbsp;4.11. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Trustee, or any trustee or trustees hereafter appointed, may resign at any time by giving written notice thereof
to the Company. If an instrument of acceptance by a successor Trustee shall not have been delivered to the Trustee within thirty (30)&nbsp;days after the giving of such notice of resignation, the resigning Trustee may petition any court of competent
jurisdiction for the appointment of a successor Trustee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Trustee may be removed at any time by an act
of the Majority Holders, delivered to the Trustee and to the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) If at any time: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) the Trustee shall fail to comply with Section&nbsp;4.8 after written request therefor by the Company
or by any Holder who has been a bona fide Holder of a Security for at least six months, or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) the Trustee shall cease to be eligible under
Section&nbsp;4.9 and shall fail to resign after written request therefor by the Company or by any such Holder, or </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3) the Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent, or a
receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, then, in any case,
(i)&nbsp;the Company, by a Board Resolution, may remove the Trustee, or (ii)&nbsp;the Holder of any Security who has been a bona fide Holder of a Security for at least six months may, on behalf of himself and all others similarly situated, petition
any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy shall occur in the office of
Trustee for any cause, the Company, by a Board Resolution, shall promptly appoint a successor Trustee. If, within one year after any removal by Holders of a majority of the Outstanding Securities, a successor Trustee shall be appointed by act of the
Holders of a majority of the Outstanding Securities delivered to the Company and the retiring Trustee the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment in accordance with Section&nbsp;4.11, become the
successor Trustee and supersede the successor Trustee appointed by the Company. If no successor Trustee shall have been so appointed by the Company or the Holders of the Securities and accepted appointment within sixty (60)&nbsp;days after the
retiring Trustee tenders its resignation or is removed, the retiring Trustee may, or, the Holder of any Security who has been a bona fide Holder for at least six (6)&nbsp;months may on behalf of himself and all others similarly situated, petition
any court of competent jurisdiction for the appointment of a successor Trustee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) The Company shall give
notice of each resignation and each removal of the Trustee and each appointment of a successor Trustee by mailing written notice of such event by first-class mail, postage prepaid, to the Holders of Securities as their names and addresses appear in
the Security Register. Each notice shall include the name of the successor Trustee and the address of its Corporate Trust Office. If the Company fails to send such notice within ten (10)&nbsp;days after acceptance of appointment by a successor
Trustee, it shall not be a default hereunder but the successor Trustee shall cause the notice to be mailed at the expense of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.11 <U>Acceptance of Appointment of Successor</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Every successor Trustee appointed hereunder shall execute, acknowledge and deliver to the Company and to the retiring
Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the
rights, powers, trusts and duties of the retiring Trustee; but, upon request of the Company or the successor Trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor Trustee
all the rights, powers and trusts of the retiring Trustee, and shall duly assign, transfer and deliver to such successor </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Trustee all property and money held by such retiring Trustee hereunder. Upon request of any such successor Trustee, the Company shall execute any and all instruments for more fully and certainly
vesting in and confirming to such successor Trustee all such rights, powers and trusts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) No successor
Trustee shall accept its appointment unless at the time of such acceptance such successor Trustee shall be qualified and eligible under this Article. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.12 <U>Merger, Conversion, Consolidation or Succession to Business</U>. Any corporation into which the
Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all of
the corporate trust business of the Trustee, by sale or otherwise shall be the successor of the Trustee hereunder, provided such corporation shall be otherwise qualified and eligible under this Article, without the execution or filing of any paper
or any further act on the part of any of the Parties hereto. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion, sale or consolidation to such authenticating
Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities; and such certificate shall have the full force which it is anywhere in the
Securities or in this CVR Agreement provided that the certificate of the Trustee shall have; provided that the right to adopt the certificate of authentication of any predecessor Trustee shall apply only to its successor or successors by merger,
conversion or consolidation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4.13 <U>Preferential Collection of Claims Against Company</U>. If
and when the Trustee shall be or shall become a creditor, directly or indirectly, secured or unsecured, of the Company (or any other obligor upon the Securities), excluding any creditor relationship set forth in Section&nbsp;311(b) of the Trust
Indenture Act, if applicable, the Trustee shall be subject to the applicable provisions of the Trust Indenture Act regarding the collection of claims against the Company (or any such other obligor). </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 5 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HOLDERS&#146; LISTS AND REPORTS BY THE TRUSTEE AND COMPANY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.1 <U>Company to Furnish Trustee Names and Addresses of Holders</U>. The Company will furnish or cause to
be furnished to the Trustee (i)&nbsp;promptly after the issuance of the Securities, and semi-annually thereafter, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a recent date, and
(ii)&nbsp;at such times as the Trustee may request in writing, within thirty (30)&nbsp;days after receipt by the Company of any such request, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of
a date not more than fifteen (15)&nbsp;days prior to the time such list is furnished; provided, however, that if and so long as the Trustee shall be the Security Registrar, no such list need be furnished. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.2 <U>Preservation of Information; Communications to
Holders</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Trustee shall preserve, in as current a form as is reasonably practicable, the names and
addresses of Holders contained in the most recent list furnished to the Trustee as provided in Section&nbsp;5.1 and the names and addresses of Holders received by the Trustee in its capacity as Security Registrar. The Trustee may destroy any list
furnished to it as provided in Section&nbsp;5.1 upon receipt of a new list so furnished. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The rights of
the Holders to communicate with other Holders with respect to their rights under this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as provided by Section&nbsp;312(b)(2) of the Trust Indenture Act, if applicable.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Every Holder of Securities, by receiving and holding the same, agrees with the Company and the Trustee
that neither the Company nor the Trustee shall be deemed to be in violation of Law or held accountable by reason of the disclosure of any such information as to the names and addresses of the Holders made pursuant to the Trust Indenture Act (if
applicable) regardless of the source from which such information was derived. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.3 <U>Reports by
Trustee</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Within sixty (60)&nbsp;days after December&nbsp;31 of each year commencing with the
December&nbsp;31 following the date of this CVR Agreement, the Trustee shall transmit to all Holders such reports concerning the Trustee and its actions under this CVR Agreement as may be required pursuant to the Trust Indenture Act to the extent
and in the manner provided pursuant thereto. The Trustee shall also comply with Section&nbsp;313(b)(2) of the Trust Indenture Act, if applicable. The Trustee shall also transmit by mail all reports as required by Section&nbsp;313(c) of the Trust
Indenture Act, if applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) A copy of each such report shall, at the time of such transmission to the
Holders, be filed by the Trustee with each stock exchange, if any, upon which the Securities are listed, with the Commission and also with the Company. The Company will promptly notify the Trustee when the Securities are listed on any stock
exchange. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5.4 <U>Reports by Company</U>. The Company shall: (a)&nbsp;file with the Trustee,
(i)&nbsp;within fifteen (15)&nbsp;days after the Company is required to file the same with the Commission, copies of the annual and quarterly reports and of the information, documents and other reports (or copies of such portions of any of the
foregoing as the Commission may from time to time by rules and regulations prescribe) which the Company is required to file with the Commission pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act (such required information,
documents and other reports, together the &#147;<U>Exchange Act Documents</U>&#148;); and (ii)&nbsp;if the Company is not required to file Exchange Act Documents under Section&nbsp;13 or 15(d) of the Exchange Act, within forty-five (45)&nbsp;days
after each calendar quarter of the Company (other than the last quarter of each calendar year), quarterly financial information and, within ninety (90)&nbsp;days after each calendar year of the Company, annual financial information that would be
required pursuant to Section&nbsp;13 of the Exchange Act in respect of a security listed and registered on a national securities exchange as may be prescribed from time to time in such rules and regulations (provided that the Company also delivers
with, or includes within, the annual reports </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
referred to in (i)&nbsp;and (ii)&nbsp;a calculation of Net Sales for the Products for the annual period to date), (iii)&nbsp;within ten (10)&nbsp;days after the Company files its annual report
with the Commission for any year if the Company is required to file Exchange Act Documents under Section&nbsp;13 or 15(d) of the Exchange Act, or if the Company is not required to file Exchange Act Documents under Section&nbsp;13 or 15(d) of the
Exchange Act within ninety (90)&nbsp;days after each calendar year, a Net Sales Statement with respect to the last completed calendar year, and (iv)&nbsp;within four (4)&nbsp;Business Days after the occurrence of any Milestone, a notice setting
forth the Milestone that occurred, the amount of the Milestone Payment payable in connection therewith and the applicable Milestone Payment Date; (b)&nbsp;file with the Trustee such additional information, documents and reports with respect to
compliance by the Company with the conditions and covenants of this CVR Agreement as may be required from time to time by the rules and regulations of the Commission, and (c)&nbsp;make available to the Holders on the Company&#146;s website as of an
even date with the filing of such materials with the Trustee, the information, documents and reports required to be filed by the Company pursuant to subsections (a)&nbsp;or (b)&nbsp;of this Section&nbsp;5.4. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 6 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.1 <U>Amendments Without Consent of Holders</U>. Without the consent of any Holders, the Company and the
Trustee, at any time and from time to time, may enter into one or more amendments hereto or to the Securities, for any of the following purposes: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) to convey, transfer, assign, mortgage or pledge to the Trustee as security for the Securities any property or assets;
or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) to evidence the succession of another Person to the Company, and the assumption by any such successor
of the covenants of the Company herein and in the Securities; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) to add to the covenants of the Company
such further covenants, restrictions, conditions or provisions as its Board of Directors and the Trustee shall consider to be for the protection of the Holders of Securities, and to make the occurrence, or the occurrence and continuance, of a
default in any such additional covenants, restrictions, conditions or provisions an Event of Default permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as herein set forth; provided, that in respect of
any such additional covenant, restriction, condition or provision, such amendment may provide for a particular period of grace after default (which period may be shorter or longer than that allowed in the case of other defaults) or may provide for
an immediate enforcement upon such an Event of Default or may limit the remedies available to the Trustee upon such an Event of Default or may limit the right of the Majority Holders to waive such an Event of Default; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) to cure any ambiguity, or to correct or supplement any provision herein or in the Securities which may be defective
or inconsistent with any other provision herein; provided, that such provisions shall not materially reduce the benefits of this CVR Agreement or the Securities to the Holders; or </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) to make any other provisions with respect to matters or questions
arising under this CVR Agreement; provided, that such provisions shall not adversely affect the interests of the Holders; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) to make any amendments or changes necessary to comply or maintain compliance with the Trust Indenture Act, if
applicable; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) make any change that does not adversely affect the interests of the Holders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) Promptly following any amendment of this CVR Agreement or the Securities in accordance with this Section&nbsp;6.1,
the Trustee shall notify the Holders of the Securities of such amendment; provided that any failure so to notify the Holders shall not affect the validity of such amendment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.2 <U>Amendments with Consent of Holders</U>. With the consent of the Majority Holders, by Act of said
Holders delivered to the Company and the Trustee, the Company (when authorized by a Board Resolution) and the Trustee may enter into one or more amendments hereto or to the Securities for the purpose of adding any provisions to or changing in any
manner or eliminating any of the provisions of this CVR Agreement or to the Securities or of modifying in any manner the rights of the Holders under this CVR Agreement or to the Securities; provided, however, that no such amendment shall, without
the consent of the Holder of each Outstanding Security affected thereby: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) modify in a manner adverse to
the Holders (i)&nbsp;any provision contained herein with respect to the termination of this CVR Agreement or the Securities, (ii)&nbsp;the time for payment and amount of any Net Sales Payment or any Milestone Payment, or otherwise extend the time
for payment of the Securities or reduce the amounts payable in respect of the Securities or modify any other payment term or payment date. Notwithstanding the foregoing, each Holder of a Security, by acceptance thereof, consents to the optional
redemption provisions set forth in Article 11 hereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) reduce the number of CVRs, the consent of whose
Holders is required for any such amendment; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) modify any of the provisions of this Section, except to
increase any such percentage or to provide that certain other provisions of this CVR Agreement cannot be modified or waived without the consent of the Holder of each Security affected thereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">It shall not be necessary for any Act of Holders under this Section to approve the particular form of any proposed
amendment, but it shall be sufficient if such Act shall approve the substance thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.3
<U>Execution of Amendments</U>. In executing any amendment permitted by this Article, the Trustee (subject to Section&nbsp;4.1) shall be fully protected in relying upon an Opinion of Counsel stating that the execution of such amendment is authorized
or permitted by this CVR Agreement. The Trustee shall execute any amendment authorized pursuant to this Article if the amendment does not adversely affect the Trustee&#146;s own rights, </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
duties or immunities under this CVR Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such amendment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.4 <U>Effect of Amendments; Notice to Holders</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon the execution of any amendment under this Article, this CVR Agreement and the Securities shall be modified in
accordance therewith, and such amendment shall form a part of this CVR Agreement and the Securities for all purposes; and every Holder of Securities theretofore or thereafter authenticated and delivered hereunder shall be bound thereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Promptly after the execution by the Company and the Trustee of any amendment pursuant to the provisions of this
Article, the Company shall mail a notice thereof by first class mail to the Holders of Securities at their addresses as they shall appear on the Security Register, setting forth in general terms the substance of such amendment. Any failure of the
Company to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such amendment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.5 <U>Conformity with Trust Indenture Act</U>. Every amendment executed pursuant to this Article shall
conform to the applicable requirements of the Trust Indenture Act, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6.6 <U>Reference in
Securities to Amendments</U>. If an amendment changes the terms of a Security, the Trustee may require the Holder of the Security to deliver it to the Trustee. Securities authenticated and delivered after the execution of any amendment pursuant to
this Article may, and shall if required by the Trustee, bear a notation in form approved by the Trustee as to any matter provided for in such amendment. If the Company shall so determine, new Securities so modified as to conform, in the opinion of
the Trustee and the Board of Directors, to any such amendment may be prepared and executed by the Company and authenticated and delivered by the Trustee in exchange for Outstanding Securities. Failure to make the appropriate notation or to issue a
new Security shall not affect the validity of such amendment. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 7 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COVENANTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.1 <U>Payment of Amounts, if any, to Holders</U>. The Company will duly and punctually pay the amounts, if
any, on the Securities in accordance with the terms of the Securities and this CVR Agreement. Such amounts shall be considered paid on the applicable Payment Date if on such date the Trustee or the Paying Agent holds in accordance with this CVR
Agreement money sufficient to pay all such amounts then due. Notwithstanding any other provision of this CVR Agreement, the Company or any of its Affiliates (including the Surviving Corporation, as applicable), the Trustee or the Paying Agent, shall
be entitled to deduct and withhold, or cause to be deducted and withheld, from amounts (including CVRs) otherwise payable pursuant to this CVR Agreement or the Merger Agreement to any holder of shares of Common Stock, Options, SARs, RSUs or CVRs,
such amounts as the Company or any of its Affiliates, the Trustee or the Paying Agent is required to deduct and withhold with respect to the making of such payment under the Internal Revenue Code of 1986, as amended, or any provision
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of state, local or foreign Tax Law. To the extent that amounts are so withheld by the Company or any of its Affiliates, the Trustee or the Paying Agent, such withheld amounts shall be
(a)&nbsp;paid over to the applicable Governmental Entity in accordance with applicable Law and (b)&nbsp;treated for all purposes of this CVR Agreement as having been paid to such Holder in respect of which such deduction and withholding was made by
the Company or any of its Affiliates, the Trustee or the Paying Agent, as the case may be. The consent of Holder shall not be required for any such withholding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.2 <U>Maintenance of Office or Agency</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) As long as any of the Securities remain Outstanding, the Company will maintain in the Borough of Manhattan, The City
of New York, an office or agency (i)&nbsp;where Securities may be presented or surrendered for payment, (ii)&nbsp;where Securities may be surrendered for registration of transfer or exchange and (iii)&nbsp;where notices and demands to or upon the
Company in respect of the Securities and this CVR Agreement may be served. The office or agency of the Trustee at [<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>] shall be such office or agency of the Company, unless the Company shall designate
and maintain some other office or agency for one or more of such purposes. The Company or any of its Subsidiaries may act as Paying Agent, registrar or transfer agent; provided that such Person shall take appropriate actions to avoid the commingling
of funds. The Company will give prompt written notice to the Trustee of any change in the location of any such office or agency. If at any time the Company shall fail to furnish the Trustee with the address thereof, such presentations, surrenders,
notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company may from time to time designate one or more other offices or agencies (in or outside of The City of New
York) where the Securities may be presented or surrendered for any or all such purposes, and may from time to time rescind such designation; provided, however, that no such designation or rescission shall in any manner relieve the Company of its
obligation to maintain an office or agency in the Borough of Manhattan, The City of New York for such purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and any change in the location of any
such office or agency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.3 <U>Money for Security Payments to Be Held in Trust</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If the Company or any of its Subsidiaries shall at any time act as the Paying Agent, it will, on or before the
Payment Date, as the case may be, segregate and hold in trust for the benefit of the Holders all sums held by such Paying Agent for payment on the Securities until such sums shall be paid to the Holders as herein provided, and will promptly notify
the Trustee of any default by the Company in making payment on the Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Whenever the Company shall
have one or more Paying Agents for the Securities, it will, on or before a Payment Date deposit with a Paying Agent a sum in same day funds sufficient to pay the amount, if any, so becoming due; such sum to be held in trust for the benefit of the
Persons entitled to such amount, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee of such action or any failure so to act. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Company will cause each Paying Agent other than the Trustee to
execute and deliver to the Trustee an instrument in which such Paying Agent shall agree with the Trustee, subject to the provisions of this Section, that (i)&nbsp;such Paying Agent will hold all sums held by it for the payment of any amount payable
on Securities in trust for the benefit of the Persons entitled thereto until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will notify the Trustee of the sums so held and (ii)&nbsp;that it will give the
Trustee notice of any failure by the Company (or by any other obligor on the Securities) to make any payment on the Securities when the same shall be due and payable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment on
any Security and remaining unclaimed for one year after the Payment Date shall be paid to the Company on Company Request, or (if then held by the Company) shall be discharged from such trust; and the Holder of such Security shall thereafter, as an
unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money shall thereupon cease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.4 <U>Certain Purchases and Sales</U>. Nothing contained herein shall prohibit the Company or any of its
Subsidiaries or Affiliates from acquiring in open market transactions, private transactions or otherwise, the Securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.5 <U>Books and Records</U>. The Company shall keep, and shall cause its Subsidiaries to keep, true,
complete and accurate records in sufficient detail to enable the amounts payable under this CVR Agreement to be determined by the Holders and their consultants or professional advisors, for a period of three (3)&nbsp;years following the end of any
Net Sales Measuring Period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.6 <U>Audits</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon the written request of the Majority Holders and no more than once during any calendar year, and upon reasonable
notice, the Company shall provide an independent certified public accounting firm of nationally recognized standing selected by the Majority Holders and the Company (the &#147;<U>Independent Accountant</U>&#148;) with access during normal business
hours to such of the records of the Company as may be reasonably necessary to verify the accuracy of the Net Sales Statements and the figures underlying the calculations set forth therein for any period within the preceding three (3)&nbsp;years that
has not previously been audited in accordance with this Section&nbsp;7.6. The Company shall pay for the fees charged by the Independent Accountant in the event that the Independent Accountant determines that the amount paid by the Company is more
than ten percent (10%)&nbsp;below the amount due; provided, however, that the Majority Holders shall pay for the fees charged by such Independent Accountant in the event that the Independent Accountant determines that the amount paid by the Company
is equal to or less than ten percent (10%)&nbsp;below the amount due, which amount the Company may deduct from any future CVR Payments payable pursuant to this CVR Agreement. The Independent Accountant shall disclose to the Majority Holders only the
amounts that the Independent Accountant believes to be due and payable by the Company, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. The Independent
Accountant shall provide the Company with a copy of </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
all disclosures made to the Majority Holders. This covenant shall survive the termination of this CVR Agreement for a period of three (3)&nbsp;years; provided that the Holders shall only be
entitled to one audit following termination of this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If the Independent Accountant
concludes that any Net Sales Payment amount should have been greater than the Net Sales Payment set forth in an applicable Net Sales Statement (the difference being the &#147;<U>CVR Shortfall</U>&#148;), the Company shall pay the CVR Shortfall,
within six (6)&nbsp;months of the date the Majority Holders deliver to the Company the Independent Accountant&#146;s written report (the &#147;<U>Shortfall Report</U>&#148;); provided that the CVR Shortfall amount shall bear interest at the
Shortfall Interest Rate beginning from thirty (30)&nbsp;days after the date the Majority Holders deliver to the Company the Shortfall Report until payment is made to the Trustee. The decision of such Independent Accountant shall be final, conclusive
and binding on the Company and the Holders, shall be non-appealable and shall not be subject to further review. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Upon the expiration of three (3)&nbsp;years following the end of any Net Sales Measuring Period, the calculation of
the Net Sales Payment payable with respect to such Net Sales Measuring Period shall be conclusive and binding on each Holder, and the Company shall be released from any liability or accountability with respect to payments in respect of such Net
Sales Measuring Period in excess of such Net Sales Payment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Each person seeking to receive information
from the Company in connection with a review or audit shall enter into, and shall cause its accounting firm to enter into, a reasonable and mutually satisfactory confidentiality agreement with the Company obligating such party to retain all such
financial information disclosed to such party in confidence pursuant to such confidentiality agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)
The Company shall not, and shall cause its Affiliates not to, enter into any license or distribution agreement with any third party (other than the Company or its Affiliates) with respect to any Product unless such agreement contains provisions that
would allow any Independent Accountant appointed pursuant to this Section&nbsp;7.6 such access to the records of the other party to such license or distribution agreement as may be reasonably necessary to perform its duties pursuant to this
Section&nbsp;7.6; provided that the Company and its Affiliates shall not be required to amend any Existing Licenses. The Parties agree that, if the Company or its Affiliates have exercised audit rights under any license or distribution agreement
prior to the Majority Holders&#146; request for an audit under this Section&nbsp;7.6 and under such license or distribution agreement the Company and its Affiliates cannot request another audit, the results of the Company&#146;s prior audit of such
licensee or distributor will be used for purposes of the audit requested by the Majority Holders under this Section&nbsp;7.6 and that the Company shall not have any further obligation to provide access to an Independent Accountant with respect to
such licensee until such time as the Company may again exercise its rights of audit under the license agreement with such licensee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.7 <U>Listing of CVRs</U>. The Company hereby covenants and agrees to use reasonable best efforts to cause
the Securities to be approved for listing (subject to notice of issuance) for trading on the Nasdaq Capital Market and will use its reasonable best efforts to maintain such listing for so long as any CVRs remain Outstanding. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.8 <U>Conflicting Arrangements</U>. So long as any of the
Securities remain Outstanding, the Company shall not enter into any binding agreement, arrangement or understanding, or take or permit to be taken any action, which would, or would reasonably be expected to, delay or prevent the Company&#146;s
ability to timely make any CVR Payment that becomes due under this CVR Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.9 <U>Product
Transfer</U>. Subject to Article 9, so long as the Securities remain Outstanding, the Company and its Affiliates may not, directly or indirectly, by a sale or swap of assets, merger, reorganization, joint venture, lease, license or any other
transaction or arrangement, sell, transfer, convey or otherwise dispose of their respective rights in and to any Product to a third party (other than the Company or its Affiliates), unless at all times after any such sale, transfer, conveyance or
other disposition, the gross amounts invoiced for the Products by the applicable transferee (or the amounts of royalties, profit split payments and milestone payments, as described in clause (ii)&nbsp;of the definition of &#147;Net Sales,&#148; with
respect to Existing Licenses, as applicable) will be reflected in Net Sales in accordance with the terms hereunder (with the transferee substituted for the Company for purposes of the definition of &#147;Net Sales&#148;) as if such transferee was
the Company, and the contract for such sale, transfer, conveyance or other disposition (which the Company shall take all reasonable actions necessary to enforce in all material respects) shall provide for such treatment and shall require the
transferee to comply with the covenants in this Section&nbsp;7.9 and Sections 7.6, 7.10 and 7.11 hereof to the same extent as the Company. For purposes of clarification, this Section&nbsp;7.9 shall not apply to sales of Products made by the Company
or its Affiliates or ordinary course licensing arrangements between the Company and its Affiliates, on the one hand, and third party licensees, distributors and contract manufacturers, on the other hand, entered into in the ordinary course of
business for purposes of developing, manufacturing, distributing and selling Products and for which the gross amounts invoiced for sales of Products by the applicable third party licensee, distributor or contract manufacturer (or the amounts of
royalties, profit split payments and milestone payments, as described in clause (ii)&nbsp;of the definition of &#147;Net Sales,&#148; with respect to Existing Licenses, as applicable) will be reflected in Net Sales of such Products in accordance
with the terms of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.10 <U>Milestones</U>. The Company shall use Diligent Efforts
to achieve each of the Milestones; provided, however, that such obligation to use Diligent Efforts to achieve each of the Milestones shall terminate upon the Milestone Target Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.11 <U>Product Sale and Development</U>. The Company shall use Diligent Efforts to obtain Regulatory
Approval for the Indications; provided, however, that such obligation to use Diligent Efforts to obtain such Regulatory Approval shall terminate upon the earlier of (a)&nbsp;the Net Sales Payment Termination Date and (b)&nbsp;on an
Indication-by-Indication basis, such time as the data generated in an appropriate clinical trial does not support further development of the Product described in clause (a)&nbsp;of the definition of &#147;Product.&#148; The Company shall use
Diligent Efforts to sell the Products for which the Company has obtained Regulatory Approval; provided, however, that such obligation to use Diligent Efforts to sell the Products shall terminate upon the Net Sales Payment Termination Date.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.12 <U>Notice of Default</U>. The Company shall file with the
Trustee written notice of the occurrence of any Event of Default or other default under this CVR Agreement within five (5)&nbsp;business days of its becoming aware of any such Default or Event of Default. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.13 <U>Confidentiality</U>. The Trustee and the Holders hereby agree that any confidential or non-public
information (including Net Sales Statements) they receive from or on behalf of the Company or any Affiliate of the Company, which receipt arises out of the transactions contemplated by this CVR Agreement (the &#147;<U>Confidential
Information</U>&#148;), shall: (a)&nbsp;not be used for any purpose other than for purposes permitted under this CVR Agreement; (b)&nbsp;not be used directly or indirectly in any way that is for competitive purposes; and (c)&nbsp;not be disclosed
by, and be kept confidential by, such Trustee and the Holders and its directors, officers, members, managers, employees, affiliates, and agents (collectively, &#147;<U>Representatives</U>&#148;); provided, however, that any such Confidential
Information may be disclosed only to their Representatives (including the Independent Accountant) who (i)&nbsp;need to know such Confidential Information and (ii)&nbsp;are bound in writing to a non-disclosure agreement no less restrictive than this
Section&nbsp;7.13. It is understood that such Representatives shall be informed by the Trustee or the applicable Holder of the confidential nature of such Confidential Information, and that the Trustee or such Holder, as applicable, shall be
responsible for any disclosure or use made by its Representatives in breach of obligations under this CVR Agreement to the same extent as if such disclosure or use had been made directly by the Trustee or such Holder, as applicable. Each of the
Trustee and the Holders will as soon as practicable notify the Company of any breach of this CVR Agreement of which they become aware, and will use commercially reasonable efforts to assist and cooperate with the Company in minimizing the
consequences of such breach. &#147;Confidential Information&#148; shall not include any information that is (i)&nbsp;publicly available other than because of disclosure by the Trustee or the Holders or any of their respective Representatives or
(ii)&nbsp;is lawfully disclosed to the Trustee or Holders by sources (other than the Company or its Affiliates) rightfully in possession of the Confidential Information. If the Trustee, Holders or their respective Representatives are legally
required or requested to disclose any Confidential Information, they will in advance of such disclosure, unless otherwise prohibited by Law, promptly notify the Company of such request or requirement so that the Company may seek to avoid or minimize
the required disclosure and/or obtain an appropriate protective order or other appropriate relief to ensure that any Confidential Information so disclosed is maintained in confidence to the maximum extent possible by the person receiving the
disclosure, or, in the Company&#146;s discretion, to waive compliance with the provisions of this CVR Agreement. In any such case, the Trustee and the Holders agree to cooperate and use reasonable efforts to avoid or minimize the required disclosure
and/or obtain such protective order or other relief. If, in the absence of a protective order or the receipt of a waiver hereunder, the Trustee, Holders or their respective Representatives are legally obligated to disclose any Confidential
Information, they will disclose only so much thereof to the party compelling disclosure as they believe in good faith, on the basis of advice of counsel, is required by Law. The Trustee and Holders shall give the Company prior written notice of the
specific Confidential Information that they believe they are required to disclose under such circumstances. All Confidential Information disclosed by or on behalf of the Company or any of its Affiliates shall be, and shall remain, the property of
the Company or such Affiliate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7.14 <U>Non-Use of Name</U>. Neither the Trustee nor the Holders
shall use the name, trademark, trade name, or logo of the Company, its Affiliates, or their respective </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
employees in any publicity or news release relating to this CVR Agreement or its subject matter, without the prior express written permission of the Company. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 8 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REMEDIES OF THE TRUSTEE AND HOLDERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ON EVENT OF DEFAULT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.1 <U>Event of Default Defined; Waiver of Default</U>. <U>&#147;Event of Default</U>&#148; with respect to
the Securities, means each one of the following events which shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of Law or pursuant to any
judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) default in the payment of all or any part of any CVR Payment after a period of ten (10)&nbsp;Business Days after such
CVR Payment shall become due and payable on a Payment Date or otherwise; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) material default in the
performance, or breach in any material respect, of any covenant or warranty of the Company in respect of the Securities (other than a covenant or warranty in respect of the Securities, a default in whose performance or whose breach is elsewhere in
this Section specifically dealt with), and continuance of such default or breach for a period of ninety (90)&nbsp;days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by
the Majority Holders, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a &#147;Notice of Default&#148; hereunder; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) a court having jurisdiction in the premises shall enter a decree or order for relief in respect of the Company in an
involuntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of the Company or for any
substantial part of its property or ordering the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of ninety (90)&nbsp;consecutive days; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the Company shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar Law now or
hereafter in effect, or consent to the entry of an order for relief in an involuntary case under any such Law, or consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar
official) of the Company or for any substantial part of its property, or make any general assignment for the benefit of creditors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an Event of Default described above occurs and is continuing, then, and in each and every such case, either the
Trustee or the Trustee upon the written request of the Majority Holders by notice in writing to the Company (and to the Trustee if given by the Majority Holders), shall bring suit to protect the rights of the Holders, including to obtain payment for
any </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
amounts then due and payable, which amounts shall bear interest at the Default Interest Rate until payment is made to the Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing provisions, however, are subject to the condition that if, at any time after the Trustee shall have begun
such suit, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay all amounts which shall have
become due (with interest upon such overdue amount at the Default Interest Rate to the date of such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the Trustee, its agents, attorneys and counsel, and
all other expenses and liabilities incurred and all advances made, by the Trustee, and if any and all Events of Default under this CVR Agreement shall have been cured, waived or otherwise remedied as provided herein, then and in every such case the
Majority Holders, by written notice to the Company and to the Trustee, may waive all defaults with respect to the Securities, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent default or shall impair any
right consequent thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.2 <U>Collection by the Trustee; the Trustee May Prove Payment
Obligations</U>. The Company covenants that in case default shall be made in the payment of all or any part of the Securities when the same shall have become due and payable, whether at a Payment Date or otherwise, then upon demand of the Trustee,
the Company will pay to the Trustee for the benefit of the Holders of the Securities the whole amount that then shall have become due and payable on all Securities (with interest from the date due and payable to the date of such payment upon the
overdue amount at the Default Interest Rate); and in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their
respective agents, attorneys and counsel, and any expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or bad faith. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders by such
appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this CVR Agreement or in aid of the exercise of any power granted
herein, or to enforce any other remedy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In case the Company shall fail forthwith to pay such amounts upon
such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may prosecute any such
action or proceedings to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon such Securities and collect in the manner provided by Law out of the property of the Company or other
obligor upon such Securities, wherever situated, the moneys adjudged or decreed to be payable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In any
judicial proceedings relative to the Company or other obligor upon the Securities, irrespective of whether any amount is then due and payable with respect to the Securities, the Trustee is authorized: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) to file and prove a claim or claims for the whole amount owing and
unpaid in respect of the Securities, and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for reasonable compensation to the Trustee and each predecessor Trustee,
and their respective agents, attorneys and counsel, and for reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of negligence or bad faith) and of the Holders
allowed in any judicial proceedings relative to the Company or other obligor upon the Securities, or to their respective property; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) unless prohibited by and only to the extent required by applicable Law, to vote on behalf of the Holders in any
election of a trustee or a standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or person performing similar functions in comparable proceedings; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) to collect and receive any moneys or other property payable or deliverable on any such claims, and to distribute all
amounts received with respect to the claims of the Holders and of the Trustee on their behalf; and any trustee, receiver, or liquidator, custodian or other similar official is hereby authorized by each of the Holders to make payments to the Trustee,
and, in the event that the Trustee shall consent to the making of payments directly to the Holders, to pay to the Trustee such amounts as shall be sufficient to cover reasonable compensation to the Trustee, each predecessor Trustee and their
respective agents, attorneys and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or bad faith, and all other amounts due to the
Trustee or any predecessor Trustee pursuant to Section&nbsp;4.6. To the extent that such payment of reasonable compensation, expenses, disbursements, advances and other amounts out of the estate in any such proceedings shall be denied for any
reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, moneys, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation
or under any plan of reorganization or arrangement or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing herein contained shall be deemed to
authorize the Trustee to authorize or consent to or vote for or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities, or the rights of any Holder thereof, or to authorize
the Trustee to vote in respect of the claim of any Holder in any such proceeding except, as aforesaid, to vote for the election of a trustee in bankruptcy or similar person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All rights of action and of asserting claims under this CVR Agreement, or under any of the Securities, may be enforced by
the Trustee without the possession of any of the Securities or the production thereof and any trial or other proceedings instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment, subject
to the payment of the expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be for the ratable benefit of the Holders. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In any proceedings brought by the Trustee (and also any proceedings
involving the interpretation of any provision of this CVR Agreement to which the Trustee shall be a party) the Trustee shall be held to represent all the Holders, and it shall not be necessary to make any Holders of such Securities parties to any
such proceedings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.3 <U>Application of Proceeds</U>. Any monies collected by the Trustee
pursuant to this Article in respect of any Securities shall be applied in the following order at the date or dates fixed by the Trustee upon presentation of the several Securities in respect of which monies have been collected and stamping (or
otherwise noting) thereon the payment in exchange for the presented Securities if only partially paid or upon surrender thereof if fully paid: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">FIRST: To the payment of costs and expenses in respect of which monies have been collected, including
reasonable compensation to the Trustee and each predecessor Trustee and their respective agents and attorneys and of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its
negligence or willful misconduct, and all other amounts due to the Trustee or any predecessor Trustee pursuant to Section&nbsp;4.6; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">SECOND: To the payment of the whole amount then owing and unpaid upon all the Securities, with interest at
the Default Interest Rate on all such amounts, and in case such monies shall be insufficient to pay in full the whole amount so due and unpaid upon the Securities, then to the payment of such amounts without preference or priority of any security
over any other Security, ratably to the aggregate of such amounts due and payable; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIRD:
To the payment of the remainder, if any, to the Company or any other person lawfully entitled thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.4 <U>Suits for Enforcement</U>. In case an Event of Default has occurred, has not been waived and is
continuing, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this CVR Agreement by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights,
either at Law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this CVR Agreement or in aid of the exercise of any power granted in this CVR Agreement or to enforce any other
legal or equitable right vested in the Trustee by this CVR Agreement or by Law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.5
<U>Restoration of Rights on Abandonment of Proceedings</U>. In case the Trustee or any Holder shall have proceeded to enforce any right under this CVR Agreement and such proceedings shall have been discontinued or abandoned for any reason, or shall
have been determined adversely to the Trustee or to such Holder, then and in every such case the Company and the Trustee and the Holders shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and
powers of the Company, the Trustee and the Holders shall continue as though no such proceedings had been taken. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.6 <U>Limitations on Suits by Holders</U>. Subject to the right of the Majority Holders under
Section&nbsp;7.6, no Holder of any Security shall have any right by virtue or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
by availing of any provision of this CVR Agreement to institute any action or proceeding at Law or in equity or in bankruptcy or otherwise upon or under or with respect to this CVR Agreement, or
for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy hereunder, unless such Holder previously shall have given to the Trustee written notice of default and of the continuance thereof, as
hereinbefore provided, and unless also the Majority Holders shall have made written request upon the Trustee to institute such action or proceedings in its own name as trustee hereunder and shall have offered to the Trustee such reasonable indemnity
as it may require against the costs, expenses and liabilities to be incurred therein or thereby and the Trustee for fifteen (15)&nbsp;days after its receipt of such notice, request and offer of indemnity shall have failed to institute any such
action or proceeding and no direction inconsistent with such written request shall have been given to the Trustee pursuant to Section&nbsp;8.9. For the protection and enforcement of the provisions of this Section, each and every Holder and the
Trustee shall be entitled to such relief as can be given either at Law or in equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.7
<U>Unconditional Right of Holders to Institute Certain Suits</U>. Notwithstanding any other provision in this CVR Agreement and any provision of any Security, the right of any Holder of any Security to receive payment of the amounts payable in
respect of such Security on or after the respective due dates expressed in such Security, or to institute suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such
Holder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.8 <U>Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except as provided in Section&nbsp;8.6, no right or remedy herein conferred upon or reserved to the
Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter
existing at Law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) No delay or omission of the Trustee or of any Holder to exercise any right or power accruing upon any Event of
Default occurring and continuing as aforesaid shall impair any such right or power or shall be construed to be a waiver of any such Event of Default or an acquiescence therein; and, subject to Section&nbsp;8.6, every power and remedy given by this
CVR Agreement or by Law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.9 <U>Control by Holders</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Majority Holders shall have the right to direct the time, method, and place of conducting any proceeding for any
remedy available to the Trustee, or exercising any power conferred on the Trustee with respect to the Securities by this CVR Agreement; provided that such direction shall not be otherwise than in accordance with Law and the provisions of this CVR
Agreement; and provided further that (subject to the provisions of Section&nbsp;4.1) the Trustee shall have the right to decline to follow any such direction if the Trustee, being advised by </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
counsel, shall determine that the action or proceeding so directed may not lawfully be taken or if the Trustee in good faith by its board of directors, the executive committee, or a committee of
directors or responsible officers of the Trustee shall determine that the action or proceedings so directed would involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forbearances specified
in or pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities not joining in the giving of said direction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Nothing in this CVR Agreement shall impair the right of the Trustee in its discretion to take any action deemed
proper by the Trustee and which is not inconsistent with such direction or directions by Holders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.10 <U>Waiver of Past Defaults</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) In the case of a default or an Event of Default specified in clause (b), (c)&nbsp;or (d)&nbsp;of Section&nbsp;8.1,
the Majority Holders may waive any such default or Event of Default, and its consequences except a default in respect of a covenant or provisions hereof which cannot be modified or amended without the consent of the Holder of each Security affected.
In the case of any such waiver, the Company, the Trustee and the Holders of the Securities shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair
any right consequent thereon. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Upon any such waiver, such default shall cease to exist and be deemed to
have been cured and not to have occurred, and any Event of Default arising therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this CVR Agreement; but no such waiver shall extend to any subsequent or other
default or Event of Default or impair any right consequent thereon. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.11 <U>The Trustee to Give
Notice of Default, But May Withhold in Certain Circumstances</U>. The Trustee shall transmit to the Holders, as the names and addresses of such Holders appear on the Security Register (as provided under Section&nbsp;313(c) of the Trust Indenture
Act, if applicable), notice by mail of all defaults which have occurred and are known to the Trustee, such notice to be transmitted within ninety (90)&nbsp;days after the occurrence thereof, unless such defaults shall have been cured before the
giving of such notice (the term &#147;default&#148; for the purposes of this Section being hereby defined to mean any event or condition which is, or with notice or lapse of time or both would become, an Event of Default); provided that, except in
the case of default in the payment of the amounts payable in respect of any of the Securities, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of
directors or trustees and/or Responsible Officers of the Trustee in good faith determines that the withholding of such notice is in the interests of the Holders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.12 <U>Right of Court to Require Filing of Undertaking to Pay Costs</U>. All Parties to this CVR Agreement
agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this CVR Agreement or in any suit against the
Trustee for any action taken, suffered or omitted by it as the Trustee, the filing by any party litigant in </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including attorneys&#146; fees, against any party litigant in such
suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section&nbsp;8.12 shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder or
group of Holders holding in the aggregate more than ten percent (10%)&nbsp;of the Securities Outstanding or to any suit instituted by any Holder for the enforcement of the payment of any Security on or after the due date expressed in such Security.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 9 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATION, MERGER, SALE OR CONVEYANCE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.1 <U>Company May Consolidate, etc., on Certain Terms</U>. The Company covenants that it will not merge or
consolidate with or into any other Person or sell or convey all or substantially all of its assets to any Person, unless, (i)&nbsp;the Company shall be the continuing Person, or the successor Person or the Person which acquires by sale or conveyance
substantially all the assets of the Company (including the shares of Abraxis) shall be a Person organized under the Laws of the United States of America or any State thereof and shall expressly assume by an instrument supplemental hereto, executed
and delivered to the Trustee, in form satisfactory to the Trustee, the due and punctual payment of the Securities, according to their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this CVR
Agreement to be performed or observed by the Company and (ii)&nbsp;the Company, or such successor Person, as the case may be, shall not, immediately after such merger or consolidation, or such sale or conveyance, be in default in the performance of
any such covenant or condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.2 <U>Successor Person Substituted</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) In case of any such consolidation, merger, sale or conveyance, and following such an assumption by the successor
Person, such successor Person shall succeed to and be substituted for the Company with the same effect as if it had been named herein. Such successor Person may cause to be signed, and may issue either in its own name or in the name of the Company
prior to such succession any or all of the Securities issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such successor corporation instead of the Company and subject
to all the terms, conditions and limitations in this CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any Securities which previously shall have been signed and delivered to the Trustee for authentication, and any
Securities which such successor corporation thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the Securities so issued shall in all respects have the same legal rank and benefit under this CVR Agreement as the
Securities theretofore or thereafter issued in accordance with the terms of this CVR Agreement as though all of such Securities had been issued at the date of the execution hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In case of any such consolidation, merger, sale or conveyance, such changes in phraseology and form (but not in
substance) may be made in the Securities thereafter to be issued as may be appropriate. The successor entity to such consolidation, merger, sale or conveyance may satisfy the obligations of Section&nbsp;5.4(a)(i) and (ii)&nbsp;of this CVR Agreement
by providing copies of such successor entity&#146;s Exchange Act Documents in the case of Section&nbsp;5.4(a)(i) or such successor entity&#146;s financial information in the case of Section&nbsp;5.4(a)(ii). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event of any such sale, transfer or conveyance (other than a
conveyance by way of lease) the Company or any Person which shall theretofore have become such in the manner described in this Article shall be discharged from all obligations and covenants under this CVR Agreement and the Securities and may be
liquidated and dissolved. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.3 <U>Opinion of Counsel to the Trustee</U>. The Trustee, subject to
the provisions of Sections 4.1 and 4.2, shall receive an Officer&#146;s Certificate and Opinion of Counsel, prepared in accordance with Sections 1.3 and 1.4, as conclusive evidence that any such consolidation, merger, sale or conveyance, and any
such assumption, and any such liquidation or dissolution, complies with the applicable provisions of this CVR Agreement, and if a supplemental agreement is required in connection with such transaction, such supplemental agreement complies with this
Article and that there has been compliance with all conditions precedent herein provided for or relating to such transaction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9.4 <U>Successors</U>. All covenants, provisions and agreements in this CVR Agreement by or for the benefit
of the Company, the Trustee or the Holders shall bind and inure to the benefit of their respective successors, assigns, heirs and personal representatives, whether so expressed or not. The Company may assign this CVR Agreement without the prior
written consent of the other Parties to this CVR Agreement to one or more of its direct or indirect Subsidiaries, provided, however, that in the event of any such assignment the Company shall remain subject to its obligations and covenants
hereunder, including but not limited to its obligation to make any Net Sales Payments and any Milestone Payments. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE
10 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBORDINATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.1 <U>Agreement to Subordinate</U>. The Company agrees, and each Holder by accepting a Security hereunder
agrees, that the CVR Payments, all other obligations under this CVR Agreement and the Securities and any rights or claims relating thereto (collectively, the &#147;<U>Junior Obligations</U>&#148;) are subordinated in right of payment, to the extent
and in the manner provided in this Article 10, to the prior payment in full in cash or cash equivalents of all Senior Obligations of the Company (whether outstanding on the date hereof or hereafter created, incurred, assumed or guaranteed), and that
the subordination is for the benefit of the holders of such Senior Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.2
<U>Liquidation; Dissolution; Bankruptcy</U>. Upon any distribution to creditors of the Company in a liquidation or dissolution of the Company or in a bankruptcy, reorganization, insolvency, receivership or similar proceeding relating to the Company
or its property, in an assignment for the benefit of creditors or any marshaling of the Company&#146;s assets and liabilities: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) holders of Senior Obligations will be entitled to receive payment in full in cash or cash equivalents of all Senior
Obligations of the Company (including interest after the commencement of any bankruptcy proceeding at the rate specified in the applicable Senior Obligation, whether or not permitted under such bankruptcy proceedings) before the Holders will be
entitled to receive any payment of any kind with respect to the Junior Obligations; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) until all Senior Obligations of the Company (as provided in clause
(a)&nbsp;above) are paid in full in cash or cash equivalents, any distribution to which Holders would be entitled but for this Article 10 will be made to holders of Senior Obligations of the Company, as their interests may appear. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.3 <U>Default on Senior Obligations</U>. The Company may not make any payment or distribution to any
Holder in respect of Junior Obligations or acquire from any Holder for cash or property any Junior Obligations: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) if any default on any Senior Obligations exceeding twenty-five million dollars ($25,000,000) in aggregate principal
amount would occur as a result of such payment, distribution or acquisition; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) during the continuance of
any payment default in respect of any Senior Obligations (after expiration of any applicable grace period) exceeding twenty-five million dollars ($25,000,000) in aggregate principal amount; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) if the maturity of any Senior Obligations representing more than twenty-five million dollars ($25,000,000) in
aggregate principal amount is accelerated in accordance with its terms and such acceleration has not been rescinded; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) following the occurrence of any default (other than a payment default, and after the expiration of any applicable
grace period) with respect to any Senior Obligations with an aggregate principal amount of more than twenty-five million dollars ($25,000,000), the effect of which is to permit the holders of such Senior Obligations (or a trustee or agent acting on
their behalf) to cause, with the giving of notice if required, the maturity of such Senior Obligations to be accelerated, for a period commencing upon the receipt by the Trustee (with a copy to the Company) of a written notice of such default from
the representative of the holders of such Senior Obligations and ending when such Senior Obligations are paid in full in cash or cash equivalents or, if earlier, when such default is cured or waived. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.4 <U>When Distribution Must Be Paid Over</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) In the event that the Trustee or any Holder receives any payment of any Junior Obligations at a time when such
payment is prohibited by this Article 10, such payment will be held by the Trustee or such Holder, in trust for the benefit of, and will be paid forthwith over and delivered, upon written request, to, the holders of Senior Obligations of the Company
as their interests may appear or their representative under the agreement, indenture or other document (if any) pursuant to which such Senior Obligations may have been issued, as their respective interests may appear, for application to the payment
of all such Senior Obligations remaining unpaid to the extent necessary to pay such Senior Obligations in full in accordance with their terms, after giving effect to any concurrent payment or distribution to or for the holders of Senior Obligations.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any amount received by any Holder as a result of direct or indirect credit support for the Junior
Obligations from any Affiliate of the Company shall be treated as payments received by such Holder from the Company that are subject to the provisions of this Article 10. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) With respect to the holders of Senior Obligations, the Trustee
undertakes to perform only those obligations on the part of the Trustee as are specifically set forth in this Article 10, and no implied covenants or obligations with respect to the holders of Senior Obligations will be read into this CVR Agreement
against the Trustee. The Trustee will not be deemed to owe any fiduciary duty to the holders of Senior Obligations, and will not be liable to any such holders if the Trustee pays over or distributes to or on behalf of Holders or the Company or any
other Person money or assets to which any holders of Senior Obligations are then entitled by virtue of this Article 10, except if such payment is made as a result of the willful misconduct or gross negligence of the Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.5 <U>Notice by Company</U>. The Company will promptly notify the Trustee of any facts known to the
Company that would cause a payment of any Junior Obligations to violate this Article 10, but failure to give such notice will not affect the subordination of the Junior Obligations to the Senior Obligations as provided in this Article 10.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.6 <U>Subordination Effective Notwithstanding Deficiencies with Respect to Senior Obligations;
Waiver of Right to Contest Senior Obligation; Reinstatement of Subordination Provisions</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Holders
hereby agree that subordination provisions contained in this Article 10 are unconditional, irrespective of the validity, regularity or enforceability of the Senior Obligations, the absence of any action to enforce the same, any waiver or consent by
any holder of Senior Obligations with respect to any provisions thereof, the recovery of any judgment against the Company, any action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or
defense. Without limiting the foregoing, and notwithstanding anything to the contrary contained elsewhere in this CVR Agreement, in the event that the amount of Senior Obligations are reduced or diminished for any reason (other than as a result of
the payment in cash or cash equivalents thereof), whether because of the applicability of fraudulent conveyance or other applicable Laws, or any other invalidity or limitation on the amount of Senior Obligations, the subordination provisions thereof
shall apply to the full amount of Senior Obligations (without giving effect to any reduction, invalidity or diminution thereof), and the turnover provisions hereunder shall be fully enforceable with respect to the full amount of Senior Obligations
(without giving effect to any such reduction, invalidity or diminution thereof), even if the effect thereof is that there will be no (or a limited amount of) Senior Obligations to which the Junior Obligations are subrogated after the payment in full
in cash of any of then remaining Senior Obligations (without giving effect to any reductions, invalidity or diminution thereof, except for reductions as a result of payments thereof in cash or cash equivalents). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Trustee and the Holders agree that they shall not (and hereby waive any right to) take any action to contest or
challenge (or assist or support any other Person in contesting or challenging), directly or indirectly, whether or not in any proceeding (including in any proceeding commenced by or against any Person under any provision of Title 11 of the United
States Code, as now and hereinafter in effect, or any successor statute or under any other state or federal bankruptcy or insolvency Law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with
creditors, or proceedings seeking </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
reorganization, arrangement, or other similar relief), the validity or enforceability of the Senior Obligations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If any payment made or in respect to the Senior Obligations must be disgorged or returned for any reason, the Senior
Obligations shall be reinstated hereunder and for all purposes of this Article 10 (including, without limitation, the turnover provisions hereof) such payment shall be deemed to have never been made with respect to the Senior Obligations.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.7 <U>Subrogation</U>. After all Senior Obligations are paid in full in cash or cash
equivalents and until the Junior Obligations are paid in full, Holders will be subrogated to the rights of holders of Senior Obligations to receive distributions applicable to Senior Obligations to the extent that distributions otherwise payable to
the Holders have been applied to the payment of Senior Obligations. The Holders by accepting the Securities acknowledge that to the extent that the Senior Obligations are determined to be unenforceable, or the Senior Obligations are subordinated to
other obligations of the Company, such subrogation rights may be impaired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.8 <U>Relative
Rights</U>. This Article 10 defines the relative rights of Holders and holders of Senior Obligations. Nothing in this CVR Agreement will: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) impair, as between the Company and Holders, the obligations of the Company under this CVR Agreement and the
Securities; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) affect the relative rights of Holders and creditors of the Company other than their rights
in relation to holders of Senior Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If the Company fails because of this Article 10 to pay any
amounts due in respect of the Securities on a due date in violation of Section&nbsp;8.1, the failure is still an Event of Default. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.9 <U>Subordination May Not Be Impaired by Company</U>. No right of any holder of Senior Obligations to
enforce the subordination of the Junior Obligations may be impaired by any act or failure to act by the Company or any Holder or by the failure of the Company or any Holder to comply with this CVR Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.10 <U>Distribution or Notice to Representative</U>. Whenever a distribution is to be made or a notice
given to holders of Senior Obligations, the distribution may be made and the notice given to their representative in accordance with the terms of the instrument or other agreement governing such Senior Obligations. Upon any payment or distribution
of assets of the Company referred to in this Article 10, the Trustee and the Holders will be entitled to rely upon any order or decree made by any court of competent jurisdiction or upon any certificate of such representative or of the liquidating
trustee or agent or other Person making any distribution to the Trustee or to the Holders for the purpose of ascertaining the Persons entitled to participate in such distribution, the holders of the Senior Obligations and other obligations of the
Company, the amount thereof or payable thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this Article 10. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.11 <U>Rights of the Trustee</U>. Notwithstanding the
provisions of this Article 10 or any other provision of this CVR Agreement, the Trustee will not be charged with knowledge of the existence of any facts that would prohibit the making of any payment or distribution by the Trustee, and the Trustee
may continue to make payments on the Securities, unless the Trustee has received at its address for notice specified in Section&nbsp;1.5 at least five (5)&nbsp;Business Days prior to the date of such payment written notice of facts that would cause
the payment of any Junior Obligations to violate this Article 10. Only the Company or a representative of Senior Obligations may give the notice. Nothing in this Article 10 will impair the claims of, or payments to, the Trustee under or pursuant to
Section&nbsp;4.7 hereof. The Trustee in its individual or any other capacity may hold Senior Obligations with the same rights it would have if it were not the Trustee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.12 <U>Authorization to Effect Subordination</U>. Each Holder, by the Holder&#146;s acceptance of the
Securities, authorizes and directs the Trustee on such Holder&#146;s behalf to take such action as may be necessary or appropriate to effectuate the subordination as provided in this Article 10, and appoints the Trustee to act as such Holder&#146;s
attorney-in-fact for any and all such purposes. If the Trustee (or any other Person acting on behalf of and at the direction of the Majority Holders) does not file a proper proof of claim or proof of debt in the form required in any proceeding
referred to in Section&nbsp;8.2 hereof at least thirty (30)&nbsp;days before the expiration of the time to file such claim, the representatives of the Senior Obligations are hereby authorized to file an appropriate claim for and on behalf of the
Holders of the Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10.13 <U>Amendments</U>. The provisions of this Article 10 are
expressly made for the benefit of the holders from time to time of the Senior Obligations, and may not be amended or modified without the written consent of the representatives of the holders of all Senior Obligations. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 11 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REDEMPTION OF SECURITIES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.1 <U>Notice to Trustee</U>. If the Company elects to redeem Securities pursuant to the optional
redemption provisions of Section&nbsp;11.6 hereof, it shall furnish to the Trustee, at least forty five (45)&nbsp;days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60)&nbsp;days before a redemption date (but
in any event prior to the notice provided pursuant to Section&nbsp;11.3 hereof), an Officer&#146;s Certificate (a &#147;<U>Consent and Purchase Offer</U>&#148;) setting forth (i)&nbsp;the clause of this CVR Agreement pursuant to which the redemption
shall occur, (ii)&nbsp;the redemption date, (iii)&nbsp;the amount of CVRs to be redeemed and (iv)&nbsp;the redemption price. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.2 <U>Selection of Securities to be Redeemed</U>. If less than all of the Securities are to be redeemed or
purchased in a Consent and Purchase Offer at any time, the Trustee shall select the Securities to be redeemed or purchased among the Holders in compliance with the requirements of the principal national securities exchange, if any, on which the
Securities are listed or, if the Securities are not so listed, on a pro rata basis, by lot or in accordance with any other method the Trustee considers fair and appropriate. In the event of partial redemption by lot, the particular Securities to be
redeemed shall be selected, unless otherwise provided herein, not less than thirty (30)&nbsp;nor more than sixty (60)&nbsp;days prior to the </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
redemption date by the Trustee from the outstanding Securities not previously called for redemption. The Trustee shall promptly notify the Company in writing of the Securities selected for
redemption or purchase. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.3 <U>Notice of Redemption</U>. At least thirty (30)&nbsp;days but not
more than sixty (60)&nbsp;days before a redemption date, the Company shall mail or cause to be mailed, by first class mail, a notice of redemption to each Holder whose Securities are to be redeemed at its registered address. The notice,
substantially in the form of Exhibit A hereto (the &#147;<U>Call Notice</U>&#148;), shall identify the amount of Securities to be redeemed and shall state: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) the redemption date; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the redemption price; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) the name and address of the paying agent; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) that Securities called for redemption must be surrendered to the Paying Agent to collect the redemption price;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) that, unless the Company defaults in making such redemption payment, all right title and interest in and
to the Securities and any Net Sales Payment, Milestone Payment or any other amounts due under this CVR Agreement, if any, on Securities called for redemption ceases to accrue on and after the redemption date; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) the clause of this CVR Agreement pursuant to which the Securities called for redemption are being redeemed; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN number, if any,
listed in such notice or printed on the Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Company&#146;s request, the Trustee shall give the
notice of redemption in the Company&#146;s name and at its expense; provided, however, that the Company shall have delivered to the Trustee at least forty five (45)&nbsp;days (unless a shorter period shall be agreed to by the Trustee) but not more
than sixty (60)&nbsp;days prior to the redemption date, an Officer&#146;s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.4 <U>Effect of Notice of Redemption</U>. Once notice of redemption is mailed in accordance with
Section&nbsp;11.3 hereof, Securities called for redemption shall become irrevocably due and payable on the redemption date at the redemption price. A notice of redemption shall be deemed to be given when mailed, whether or not the Holder receives
the notice. In any event, failure to give such notice, or any defect in such notice, shall not affect the validity of the proceedings for the redemption of the Securities held by Holders to whom such notice was properly given. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.5 <U>Deposit of Redemption Price</U>. On or one (1)&nbsp;Business Day prior to the redemption date, the
Company shall deposit with the Trustee or with the paying agent (if different from the Trustee) money sufficient to pay the redemption price of all Securities to be </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
redeemed on that date. The Trustee or the paying agent shall promptly return to the Company any money deposited with the Trustee or the paying agent by the Company in excess of the amounts
necessary to pay the redemption price of all Securities to be redeemed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company complies with the provisions of the
preceding paragraph, on and after the redemption or purchase date, as applicable, all right title and interest of a Holder to any Net Sales Payment or Milestone Payment, if any, shall cease to accrue on the Securities called for redemption or
subject to purchase. If any Security called for redemption or subject to purchase shall not be so paid upon surrender for redemption or purchase because of the failure of the Company to comply with the preceding paragraph, interest shall be paid on
the unpaid redemption price from the redemption date or Purchase Date, as applicable, until such redemption price is paid at the Shortfall Interest Rate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11.6 <U>Optional Redemption by the Company</U>. The Company may, at any time on and after the Redemption
Eligibility Date, redeem all (but not less than all) of the outstanding Securities at a cash redemption price equal to the average price paid per Security for all Securities previously purchased by the Company calculated as of the Business Day
immediately prior to the date of the Call Notice mailed by the Company in accordance with Section&nbsp;11.3 hereof. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed,
all as of the day and year first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CELGENE CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>],</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">as the Trustee</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">CELGENE CORPORATION </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate for</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent Value Rights</FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">This certifies that
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, or registered assigns (the &#147;<U>Holder</U>&#148;), is the registered holder of the number of Contingent Value Rights
(&#147;<U>CVRs</U>&#148; or &#147;<U>Securities</U>&#148;) set forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in the CVR Agreement referred to on the reverse hereof, to payments from Celgene Corporation, a
Delaware corporation (the &#147;<U>Company</U>&#148;), in an amounts and in the forms determined pursuant to the provisions set forth on the reverse hereof and as more fully described in the CVR Agreement referred to on the reverse hereof. Such
payments shall be made on a Payment Date, as defined in the CVR Agreement referred to on the reverse hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of any amounts pursuant to this CVR Certificate shall be made only to the registered Holder (as defined in the
CVR Agreement) of this CVR Certificate. Such payment shall be made in the Borough of Manhattan, The City of New York, or at any other office or agency maintained by the Company for such purpose, in such coin or currency of the United States of
America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by wire transfer or check payable in such money. [TRUSTEE] has been initially appointed as Paying Agent at its
office or agency in the Borough of Manhattan, The City of New York. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference is hereby made to the further
provisions of this CVR Certificate set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless the certificate of authentication hereon has been duly executed by the Trustee referred to on the reverse hereof
by manual signature, this CVR Certificate shall not be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attest:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized Signature</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Form of Reverse of CVR Certificate] </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. This CVR Certificate is issued under and in accordance with the Contingent Value Rights Agreement, dated as of
[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], 2010 (the &#147;<U>CVR Agreement</U>&#148;), between the Company and [<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], a national banking association, as trustee (the
&#147;<U>Trustee</U>,&#148; which term includes any successor Trustee under the CVR Agreement), and is subject to the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder of this CVR Certificate
consents by acceptance hereof. The CVR Agreement is hereby incorporated herein by reference and made a part hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective rights, limitations of rights, duties,
obligations and immunities thereunder of the Company, the Trustee and the Holders of the CVRs. All capitalized terms used in this CVR Certificate without definition shall have the respective meanings ascribed to them in the CVR Agreement. Copies of
the CVR Agreement can be obtained by contacting the Trustee. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. On each Net Sales Payment Date, the Company
shall pay to the Holder hereof, for each CVR represented hereby, a pro rata portion of the Net Sales Payment, if any, with respect to the Net Sales Measuring Period ended immediately prior to such Net Sales Payment Date. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. In the event of any conflict between this CVR Certificate and the CVR Agreement, the CVR Agreement shall govern and
prevail. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. Subject to the terms and conditions of the CVR Agreement, on each Milestone Payment Date (or, in
any such case, if such day is not a Business Day, without accruing any interest, on the next succeeding Business Day), the Company shall pay to the Holder hereof, for each CVR represented hereby, a pro rata portion of the applicable Milestone
Payment with respect to the occurrence of a Milestone. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. Each CVR Payment, if any, and interest thereon, if
any, shall be payable by the Company in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by its check or wire
transfer payable in such money. [TRUSTEE] has been initially appointed as Paying Agent at its office or agency in the Borough of Manhattan, The City of New York. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. If an Event of Default occurs and is continuing, either the Trustee may or the Majority Holders, by notice to the
Company and to the Trustee shall bring suit in accordance with the terms and conditions of the CVR Agreement to protect the rights of the Holders, including to obtain payment of all amounts then due and payable, with interest at the Default Interest
Rate from the date of the Event of Default through the date payment is made or duly provided for. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. No
reference herein to the CVR Agreement and no provision of this CVR Certificate or of the CVR Agreement shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay any amounts determined pursuant to the terms
hereof and of the CVR Agreement at the times, place and amount, and in the manner, herein prescribed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. Each CVR Payment or any other right, claim or payment of any kind under
this CVR Certificate, if any, shall be subordinated in right of payment, as set forth in Article 10 of the CVR Agreement, to the prior payment in full in cash or cash equivalents of all Senior Obligations whether outstanding on the date of the CVR
Agreement or thereafter incurred. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. As provided in the CVR Agreement and subject to certain limitations
therein set forth, the transfer of the CVRs represented by this CVR Certificate is registrable on the Security Register, upon surrender of this CVR Certificate for registration of transfer at the office or agency of the Company maintained for such
purpose in the Borough of Manhattan, The City of New York, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new CVR Certificates, for the same amount of CVRs, will be issued to the designated transferee or transferees. The Company hereby initially designates the office of [TRUSTEE] at
[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>] as the office for registration of transfer of this CVR Certificate. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. As provided in the CVR Agreement and subject to certain limitations therein set forth, this CVR Certificate is
exchangeable for one or more CVR Certificates representing the same number of CVRs as represented by this CVR Certificate as requested by the Holder surrendering the same. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. No service charge will be made for any registration of transfer or exchange of CVRs, but the Company may require
payment of a sum sufficient to cover all documentary, stamp or similar issue or transfer taxes or other governmental charges payable in connection with any registration of transfer or exchange. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. Prior to the time of due presentment of this CVR Certificate for registration of transfer, the Company, the Trustee
and any agent of the Company or the Trustee may treat the Person in whose name this CVR Certificate is registered as the owner hereof for all purposes, and neither the Company, the Trustee nor any agent shall be affected by notice to the contrary.
</FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. Neither the Company nor the Trustee has any duty or obligation to the holder of this CVR Certificate,
except as expressly set forth herein or in the CVR Agreement. </FONT></P> <P STYLE="margin-top:14px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <U>Redemption</U>. </FONT></P>
<P STYLE="margin-top:14px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Notice to Trustee</U>. If the Company elects to redeem Securities pursuant to the optional redemption provisions
of Section&nbsp;11.6 of the CVR Agreement, it shall furnish to the Trustee, at least forty five (45)&nbsp;days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60)&nbsp;days before a redemption date (but in any
event prior to the notice provided pursuant to Section&nbsp;11.3 of the CVR Agreement), an Officer&#146;s Certificate (a &#147;<U>Consent and Purchase Offer</U>&#148;) setting forth (i)&nbsp;the clause of the CVR Agreement pursuant to which the
redemption shall occur, (ii)&nbsp;the redemption date, (iii)&nbsp;the amount of CVRs to be redeemed and (iv)&nbsp;the redemption price. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Selection of Securities to be Redeemed</U>. If less than all of the
Securities are to be redeemed or purchased in a Consent and Purchase Offer at any time, the Trustee shall select the Securities to be redeemed or purchased among the Holders in compliance with the requirements of the principal national securities
exchange, if any, on which the Securities are listed or, if the Securities are not so listed, on a pro rata basis, by lot or in accordance with any other method the Trustee considers fair and appropriate. In the event of partial redemption by lot,
the particular Securities to be redeemed shall be selected, unless otherwise provided herein, not less than thirty (30)&nbsp;nor more than sixty (60)&nbsp;days prior to the redemption date by the Trustee from the outstanding Securities not
previously called for redemption. The Trustee shall promptly notify the Company in writing of the Securities selected for redemption or purchase. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Notice of Redemption</U>. At least thirty (30)&nbsp;days but not more than sixty (60)&nbsp;days before a
redemption date, the Company shall mail or cause to be mailed, by first class mail, a notice of redemption to each Holder whose Securities are to be redeemed at its registered address. The notice, substantially in the form of Exhibit A of the CVR
Agreement (the &#147;<U>Call Notice</U>&#148;), shall identify the amount of Securities to be redeemed and shall state: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) the redemption date; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the redemption price; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) the name and address of the paying agent; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) that Securities called for redemption must be surrendered to the Paying Agent to collect the
redemption price; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) that, unless the Company defaults in making such redemption payment, all right title
and interest in and to the Securities and any Net Sales Payment, Milestone Payment or any other amounts due under the CVR Agreement, if any, on Securities called for redemption ceases to accrue on and after the redemption date; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) the clause of the CVR Agreement pursuant to which the Securities called for redemption are being redeemed; and
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN number, if any,
listed in such notice or printed on the Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Company&#146;s request, the Trustee shall give the notice of
redemption in the Company&#146;s name and at its expense; provided, however, that the Company shall have delivered to the Trustee at least forty five (45)&nbsp;days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty
(60)&nbsp;days prior to the redemption date, an Officer&#146;s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Effect of Notice of Redemption</U>. Once notice of redemption is
mailed in accordance with Section&nbsp;11.3 of the CVR Agreement, Securities called for redemption shall become irrevocably due and payable on the redemption date at the redemption price. A notice of redemption shall be deemed to be given when
mailed, whether or not the Holder receives the notice. In any event, failure to give such notice, or any defect in such notice, shall not affect the validity of the proceedings for the redemption of the Securities held by Holders to whom such notice
was properly given. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Deposit of Redemption Price</U>. On or one (1)&nbsp;Business Day prior to the
redemption date, the Company shall deposit with the Trustee or with the paying agent (if different from the Trustee) money sufficient to pay the redemption price of all Securities to be redeemed on that date. The Trustee or the paying agent shall
promptly return to the Company any money deposited with the Trustee or the paying agent by the Company in excess of the amounts necessary to pay the redemption price of all Securities to be redeemed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company complies with the provisions of the preceding paragraph, on and after the redemption or purchase date, as applicable, all right title and
interest of a Holder to any Net Sales Payment or Milestone Payment, if any, shall cease to accrue on the Securities called for redemption or subject to purchase. If any Security called for redemption or subject to purchase shall not be so paid upon
surrender for redemption or purchase because of the failure of the Company to comply with the preceding paragraph, interest shall be paid on the unpaid redemption price from the redemption date or Purchase Date, as applicable, until such redemption
price is paid at the Shortfall Interest Rate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Optional Redemption by the Company</U>. The Company
may, at any time on and after the Redemption Eligibility Date, redeem all (but not less than all) of the outstanding Securities at a cash redemption price equal to the average price paid per Security for all Securities previously purchased by the
Company calculated as of the Business Day immediately prior to the date of the Call Notice mailed by the Company in accordance with Section&nbsp;11.3 of the CVR Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TRUSTEE&#146;S CERTIFICATE OF AUTHENTICATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This is one of the CVR Certificates referred to in the within-mentioned CVR Agreement. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>],</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">as the Trustee</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized Signatory</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-6 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>dex103.htm
<DESCRIPTION>RETENTION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Retention Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.3 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RETENTION AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS RETENTION AGREEMENT (this &#147;Agreement&#148;) is entered into as of June&nbsp;25, 2010 (the &#147;Effective Date&#148;) among
Abraxis BioScience, Inc., a Delaware corporation (&#147;Parent&#148;), and its wholly-owned operating subsidiary Abraxis BioScience, LLC, a Delaware limited liability company (the &#147;Company&#148;), and Bruce Wendel (&#147;Executive&#148;).
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>RECITALS </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. Executive is currently the Chief Executive Officer of Parent and the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. Parent and the Company recognize that, as is the case with many publicly-held corporations, the possibility of a change in control of
Parent (and/or the Company) exists and that the uncertainties raised by such a possibility may result in the distraction or even the premature departure of Executive to the detriment of Parent and its stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. The Company has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication
of Executive without distraction from the possibility of a change in control of Parent and/or the Company and related events and circumstances. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>AGREEMENT </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and the mutual promises set forth in this Agreement, the parties hereby agree as
follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Definitions</U>. Unless otherwise defined herein, the capitalized terms defined in Exhibit&nbsp;A attached
hereto shall have the meanings therein specified for all purposes of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Term of Agreement</U>. This
Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall terminate upon the first to occur of: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) December&nbsp;31, 2011, if a Change in Control Transaction has not occurred prior to such date; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If a Change in Control Transaction has occurred at any time prior to the December&nbsp;31, 2011, the 18- month anniversary of the
Change in Control Date if Executive&#146;s employment with the Company has not been terminated by the Company without Cause, or by Executive for Good Reason, prior to such date; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If (i)&nbsp;a Change in Control Transaction has occurred at any time prior to December&nbsp;31, 2011 and (ii)&nbsp;within 18 months
following the Change in Control Date and Executive&#146;s employment with the Company has been terminated by the Company without Cause, or by Executive for Good Reason, the date on which the Company has fulfilled of all of its obligations under
Section 4. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Employment Status</U>. Executive acknowledges that this Agreement does not constitute
a contract of employment or impose on the Company any obligation to retain Executive as an employee. Executive acknowledges and aggress that he is an &#147;at will&#148; employee of the Company and may be terminated by the Company (or its successor)
at any time for any reason or no reason, with or without cause or prior notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Consequences of Termination following a
Change in Control</U>. If (x)&nbsp;a Change in Control Transaction on or prior to December&nbsp;31, 2011 and (y)&nbsp;within 18 months following the Change in Control Date the employment of Executive under this Agreement is terminated, then
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If the employment of Executive is terminated for any reason other than a termination by the Company without Cause or by
Executive for Good Reason, then Executive shall not be entitled to any compensation or benefits from the Company under this Agreement or otherwise, except for the following: (i)&nbsp;the Company shall pay Executive (or, as applicable, his heirs,
estate or representative) the Accrued Compensation, (ii)&nbsp;the Company shall provide to Executive (or his dependents, as applicable) such benefits, if any, as may be required to be provided by the Company under the Consolidated Omnibus Budget
Reconciliation Act (&#147;COBRA&#148;) and any disability policy of the Company applicable to Executive, and (iii)&nbsp;Executive (or, as applicable, his heirs, estate or representative) shall be entitled to any then-vested benefits, stock options
and other equity awards as applicable pursuant to the terms of such benefits, options or award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If the employment of
Executive under this Agreement is terminated by the Company without Cause or by Executive for Good Reason, then Executive shall not be entitled to any compensation or benefits from the Company under this Agreement or otherwise, except for the
following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) the Company shall pay Executive the Accrued Compensation; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the Company shall pay Executive a lump sum payment equal to (i)&nbsp;two (2)&nbsp;times his then annual base salary and
(ii)&nbsp;two times his most-recently established target bonus; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) the Executive shall be entitled to any then-vested
benefits, stock options and other equity awards as applicable pursuant to the terms of such benefits, options or awards; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) the Company shall provide reimbursement of Executive&#146;s COBRA premiums until he obtains new employment, up to a maximum of
eighteen months from the Termination Date, subject to Executive&#146;s submission of appropriate documentation; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) for a
period of twenty-four (24)&nbsp;months the Company shall continue to provide life insurance coverage at least the same levels as was provided on the Termination Date; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided, that, except as otherwise required by law, Executive shall not be entitled to receive or retain any post-termination benefits
described in this subsection (b)&nbsp;unless, within twenty-one (21)&nbsp;days (or forty-five&nbsp;(45) days if required by applicable law) following the </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Termination Date, he executes and delivers to the Company a Release of Claims in the form attached as Exhibit B hereto, and does not revoke such Release of Claims during any applicable revocation
period. Any payments due pursuant to this subsection (b)&nbsp;shall be made or begun during the second month following the month in which the Termination Date occurs, subject to any delay required by Section&nbsp;16(b)below. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Representations</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Executive represents that he has full authority to enter into this Agreement and is not under any contractual restraint which would
prohibit Executive from satisfactorily performing his duties to the Company (and, if applicable, Parent) under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Executive acknowledges that he is free to seek advice from independent counsel with respect to this Agreement. Executive has either
obtained such advice or, after carefully reviewing this Agreement, has decided to forego such advice. Executive is not relying on any representation or advice from the Company or Parent or any of their respective officers, directors, attorneys or
other representatives regarding this Agreement, its content or effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>Arbitration</U>. The parties acknowledge and
agree to the provisions of the Arbitration Agreement attached hereto as Exhibit C and incorporated by this reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.
<U>Governing Law</U>. This Agreement shall be governed by and construed and enforced in accordance with the internal substantive laws (and not the laws of conflicts) of the State of California. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <U>Entire Agreement</U>. It is understood, acknowledged and agreed that there are no oral agreements between the parties hereto or
their affiliates with respect to the matters described herein and that this Agreement constitutes the parties&#146; and their affiliates&#146; entire agreement and supersedes and cancels any and all previous negotiations, arrangements, agreements
and understandings, if any, between the parties hereto and their affiliates with respect to such matters, and none thereof shall be used to interpret or construe this Agreement. This Agreement, the Proprietary Interest Protection Agreement, the
agreements contemplated herein and the exhibits attached hereto, contain all of the terms, covenants, conditions, warranties and agreements of the parties and their affiliates, shall be considered to be the only agreement between the parties hereto
and their affiliates and their respective representatives and agents with respect to the matters described herein. Except as expressly stated in this Agreement, no party or its affiliates has made any statement or representation to the other party
or its affiliates regarding any fact, which statement or representation is relied upon by the other party in entering into this Agreement. Except as expressly stated in this Agreement, in connection with the execution of this Agreement, no party to
this Agreement or its affiliates has relied upon any statement, representation or promise of the other party or its affiliates not expressly contained herein. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <U>Assignability</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) This Agreement is personal in nature and Executive shall not, without the written consent of the Company, assign or transfer this
Agreement or any rights or obligations hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Nothing expressed or implied in this Agreement is intended or shall be
construed to confer upon or give to any person, other than the parties to this Agreement, any right, remedy or claim under or by reason of this Agreement or of any term, covenant or condition of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Except as may otherwise be agreed to by the Company and Executive: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) in the event of a Change in Control Transaction, this Agreement shall, subject to the provisions hereof, be binding upon and inure
to the benefit of such successor (if any) and such successor shall discharge and perform all the promises, covenants, duties, and obligations of the Company hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The Company may assign this Agreement only to a successor to all or substantially all of the business and/or assets of the Company,
provided that the Company shall require such successor to expressly assume in writing and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken
place. As used in this Agreement, &#147;Company&#148; shall mean the Company and any successor to its business and/or assets, which assumes and agrees to perform the duties and obligations of the Company under this Agreement by operation of law or
otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <U>Amendments; Waivers</U>. This Agreement may be amended, modified, superseded, canceled, renewed or extended
and the terms or covenants of this Agreement may be waived only by a written instrument executed by the parties to this Agreement or, in the case of a waiver, by the party waiving compliance. The failure of any party at any time or times to require
performance of any provision of this Agreement shall in no manner affect the right at a later time to enforce the same. No waiver by any party of the breach of any term or provision contained in this Agreement, whether by conduct or otherwise, in
any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. <U>Notice</U>. All notices, requests or consents required or permitted under this Agreement shall be made in writing and shall be
given to the other party by personal delivery, registered or certified mail (with return receipt), overnight air courier (with receipt signature) or facsimile transmission (with &#147;answerback&#148; confirmation of transmission), sent to such
party&#146;s addresses or telecopy numbers as are set forth below such party&#146;s signature to this Agreement in the case of the Company or Parent or the address listed on the Company&#146;s records in the case of Executive, or such other
addresses or telecopy numbers of which the parties have given notice pursuant to this Section&nbsp;11. Each such notice, request or consent shall be deemed effective upon the date of actual receipt, receipt signature or confirmation of transmission,
as applicable (or if given by registered or certified mail, upon the earlier of (i)&nbsp;actual receipt or (ii)&nbsp;three (3)&nbsp;days after deposit thereof in the United States mail) </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <U>Section&nbsp;280G Parachute Tax Gross Up Letter</U>. The parties acknowledge that the Company and the Executive executed a letter
agreement dated April&nbsp;22, 2010 pursuant to which the Company agreed to pay to Executive an additional amount if the Executive is deemed to receive &#147;parachute payments&#148; under Section&nbsp;280G of the Internal Revenue Code (&#147;Gross
Up Agreement&#148;). The parties acknowledge and agree that the Gross Up Agreement shall apply to any payments under this Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. <U>Severability</U>. Any provision of this Agreement that is prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <U>Construction</U>. Executive and Company
acknowledge and agree that (a)&nbsp;each party hereto is of equal bargaining strength, (b)&nbsp;each such party has actively participated in the drafting, preparation and negotiation of this Agreement, (c)&nbsp;each such party has consulted with
such party&#146;s own, independent counsel, and such other professional advisors as such party has deemed appropriate, relating to any and all matters contemplated under this Agreement, (d)&nbsp;each such party and such party&#146;s counsel and
advisors have reviewed this Agreement, (e)&nbsp;each such party has agreed to enter into this Agreement following such review and the rendering of such advice and (f)&nbsp;any rule of construction to the effect that ambiguities are to be resolved
against the drafting party shall not apply in the interpretation of this Agreement, or any portions hereof, or any amendments hereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. <U>Survival</U>. The representations and agreements of the parties set forth in Sections 5 (Representations), 6 (Arbitration), 12
(Section 280G) and 16 (General 409A Compliance) shall survive the expiration or termination of this Agreement (irrespective of the reason for such expiration or termination). </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16. <U>General 409A Compliance</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The intent of the parties is that payments and benefits under this Agreement comply with or be exempt from Section&nbsp;409A and,
accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. If Executive notifies the Company (with specificity as to the reason therefor) that Executive believes that any provision of this
Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section&nbsp;409A and the Company concurs with such belief, or outside counsel to the Company
makes such determination and informs the Company thereof, the Company shall, after consulting with Executive, to the extent legally permitted, reform such provision to try to comply with Section&nbsp;409A through good faith modifications to the
minimum extent reasonably appropriate to conform with Section&nbsp;409A. To the extent that any provision hereof is modified in order to comply with or be exempt from Section&nbsp;409A, such modification shall be made in good faith and shall, to the
maximum extent reasonably possible, maintain the original intent and economic benefit to Executive and the Company of the applicable provision without violating the provisions of Section&nbsp;409A. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the
payment of any amounts or benefits that is considered nonqualified deferred compensation under Section 409A upon or following a termination of employment unless such termination is also a &#147;separation from
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
service&#148; within the meaning of Section&nbsp;409A and, for purposes of any such provision of this Agreement, references to a &#147;termination,&#148; &#147;termination of employment&#148; or
like terms shall mean &#147;separation from service.&#148; If Executive is deemed on the date of termination to be a &#147;specified employee&#148; within the meaning of that term under Section&nbsp;409A(a)(2)(B), then with regard to any payment or
benefit that is considered nonqualified deferred compensation under Section&nbsp;409A payable on account of a &#147;separation from service&#148; that would otherwise be made or paid within the six (6)-month period measured from the date of such
&#147;separation from service&#148; of Executive, such payment or benefit shall be made or provided at the date which is the earlier of (i)&nbsp;the expiration of the six (6)-month period measured from the date of such &#147;separation from
service&#148; of Executive, and (ii)&nbsp;the date of Executive&#146;s death (the &#147;Delay Period&#148;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section&nbsp;21(b) (whether they would have
otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Executive in a lump sum with interest at the prime rate as published in <I>The Wall Street Journal</I> on the first business day
of the Delay Period, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by
Section&nbsp;409A, (i)&nbsp;the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, of in-kind benefits, provided during any
taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the foregoing clause (ii)&nbsp;shall not be violated without regard to expenses reimbursed under any
arrangement covered by Internal Revenue Code Section&nbsp;105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii)&nbsp;such payments shall be made on or before the last day of
Executive&#146;s taxable year following the taxable year in which the expense occurred. Any tax gross-up payment as provided herein shall be made in any event no later than the end of the calendar year immediately following the calendar year in
which Executive remits the related taxes, and any reimbursement of expenses incurred due to a tax audit or litigation shall be made no later than the end of the calendar year immediately following the calendar year in which the taxes that are the
subject of the audit or litigation are remitted to the taxing authority, or, if no taxes are to be remitted, the end of the calendar year following the calendar year in which the audit or litigation is completed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) For purposes of Section&nbsp;409A, Executive&#146;s right to receive any installment payments pursuant to this Agreement shall be
treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (<I>e.g.</I>, &#147;payment shall be made within thirty (30)&nbsp;days
following the date of termination&#148;), the actual date of payment within the specified period shall be within the sole discretion of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Retention Agreement as of the
Effective Date first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="41%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Charles Kim</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: Charles Kim</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its: General Counsel</FONT></TD></TR></TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Address&nbsp;for&nbsp;Notices:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience, LLC</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11755&nbsp;Wilshire&nbsp;Blvd.,&nbsp;Suite&nbsp;2000</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, California 90025</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:&nbsp;&nbsp;General Counsel</FONT></TD></TR></TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="41%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Charles Kim</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: Charles Kim</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its: General Counsel</FONT></TD></TR></TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Address&nbsp;for&nbsp;Notices:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abraxis BioScience, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11755&nbsp;Wilshire&nbsp;Blvd.,&nbsp;Suite&nbsp;2000</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, California 90025</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:&nbsp;&nbsp;General Counsel</FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>By signing
below, the undersigned acknowledges and agrees that, except as expressly set forth in a written agreement signed by an authorized representative of the Company or Parent, the undersigned (i)&nbsp;has not been promised any equity interests in the
Company or Parent or any of their respective subsidiaries, affiliates or predecessors and (ii)&nbsp;does not and will not have any right to any equity interests in the Company or Parent or any of its respective subsidiaries, affiliates or
predecessors. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Bruce Wendel</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bruce Wendel</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT A </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>DEFINITIONS </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Accrued Compensation&#148; shall mean (i)&nbsp;all earned but unpaid salary and vacation pay accrued through the Termination Date, (ii)&nbsp;any
vested but unpaid bonus for fiscal years prior to the year in which the termination of employment occurs, (iii)&nbsp;reimbursement for reasonable, documented and necessary expenses incurred by Executive on behalf of the Company or Parent on or prior
to the Termination Date and (iv)&nbsp;all other payments and benefits Executive is entitled to under the terms of any applicable benefit plan or program. The Accrued Compensation shall be paid within thirty (30)&nbsp;days following the Termination
Date; provided, that the benefits and amounts accrued under the plans and programs shall be paid or provided in accordance with such plans or programs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Cause&#148; shall mean any of the following (i)&nbsp;Executive commits a material breach of this Agreement, the Proprietary Interest Protection
Agreement or any material policy of the Company, and such material breach is not cured to the good-faith reasonable satisfaction of the Company within twenty&nbsp;(20) days after written notice to Executive from the Company; (ii)&nbsp;Executive
willfully fails to substantially perform his duties hereunder, or to implement or follow a lawful policy or directive of the Company, and such failure continues for a period of twenty&nbsp;(20) days after written notice to Executive from Company;
(iii)&nbsp;Executive is indicted for any felony, or for any misdemeanor involving dishonesty, breach of trust, physical harm to any person or serious moral turpitude; (iv)&nbsp;Executive engages in embezzlement, gross negligence as to a material
matter or willful misconduct in the performance of his duties; or (v)&nbsp;Executive engages in misconduct which is materially injurious to the Company (monetarily or otherwise) or which Executive knows constitutes a material violation of a material
federal or state law relating to the Company or its business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Change in Control Date&#148; shall mean the date on which a Change in
Control Transaction is consummated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Change in Control Transaction&#148; shall mean (i)&nbsp;a transaction (including, but not limited
to, a sale of equity interests, merger, consolidation, reorganization or recapitalization) pursuant to which the holders of the voting equity securities of the Company immediately prior to such transaction (or their affiliates) cease to beneficially
own more than fifty percent (50%)&nbsp;of voting equity securities of the Company or its successor (or, if there is a parent of the Company following such transaction, of the ultimate parent) immediately following such transaction, (ii)&nbsp;a
transaction (including, but not limited to, a merger, consolidation, reorganization or recapitalization) pursuant to which the holders of the voting capital stock of Parent immediately prior to such transaction (or their affiliates) cease to
beneficially own more than fifty percent (50%)&nbsp;of voting capital stock of Parent or its successor (or, if there is a parent of Parent following such transaction, of the ultimate parent) immediately following such transaction or (iii)&nbsp;the
Company sells all or substantially all of its assets to a third party; provided, that a Spin Transaction shall not be considered a &#147;Change in Control Transaction&#148; for purposes of this Agreement </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Code&#148; shall mean the Internal Revenue Code of 1986, as amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Good Reason&#148; means, without Executive&#146;s express written consent, the occurrence of any of
the following circumstances: (i)&nbsp;there is a change in Executive&#146;s responsibilities which represents a material and adverse change from Executive&#146;s overall responsibilities, taken as a whole (except any changes resulting from a Spin
Transaction); (ii)&nbsp;Executive is required to be based at any place outside a twenty-five&nbsp;(25) mile radius from the Company&#146;s current headquarters in Los Angeles, California, except for travel that is reasonably necessary in connection
with the Company&#146;s business; (iii)&nbsp;a material reduction in Executive&#146;s base salary; or (iv)&nbsp;any material breach by the Company or Parent of this Agreement, including any breach of Section&nbsp;9(d); provided, that
Executive&#146;s voluntary termination shall be deemed for purposes hereof to have occurred for Good Reason only if (i)&nbsp;Executive provides written notice to the Company prior to resignation and within twenty (20)&nbsp;days after Executive
becomes aware of the circumstances giving rise to Good Reason, (ii)&nbsp;the Company fails to correct the circumstances giving rise to Good Reason prior to resignation and within thirty (30)&nbsp;days following receipt of such notice and
(iii)&nbsp;Executive resigns within fifteen (15)&nbsp;days following such thirty (30)&nbsp;day period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Section 409A&#148; shall mean
Section&nbsp;409A of the Code, together with and the related final regulations thereunder and other guidance relating thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Spinco&#148; shall mean (i)&nbsp;an entity, the equity securities of which (or the equity securities of the parent of which) are distributed in a
Spin Transaction, or (ii)&nbsp;any entity that (A)&nbsp;is directly or indirectly controlled by the current controlling stockholder of Parent and (B)&nbsp;acquires certain assets of the Company in connection with a Change in Control Transaction.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Spin Transaction&#148; shall mean any transaction substantially similar to the transaction described in the in the Registration
Statement on Form 10 filed with the Securities and Exchange Commission by Abraxis Health, Inc. on August&nbsp;4, 2009 (since withdrawn). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Termination Date&#148; means the date on which Executive&#146;s employment with the Company is terminated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT B </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>RELEASE </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration for the payments described in Section&nbsp;4(b) of the Retention Agreement, Executive hereby releases and discharges
Abraxis BioScience, LLC, Abraxis BioScience, Inc., and any subsidiaries or affiliates thereof (collectively the &#147;Company&#148;), and their respective (and limited to such capacities) directors, officers, employees, benefit plans and
administrators, successors and assigns (collectively with the Company, the &#147;Released Parties&#148;) from any and all claims, obligations, and liabilities, whether known or unknown, at law or in equity, arising out of Executive&#146;s employment
with the Company and the termination thereof. This Release is to be broadly construed so as to resolve all pending or potential disputes including, but without limiting the generality of the foregoing, any and all claims under the Age Discrimination
in Employment Act, as amended by the Older Workers Benefit Protection Act of 1990, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Employee Retirement Income Security Act of 1974, the Equal Pay Act, the Family and
Medical Leave Act, and any other federal, state or local statute, regulation or ordinance, and any and all claims based upon alleged wrongful or retaliatory discharge, negligence, intentional infliction of emotional distress, defamation, invasion of
privacy, other torts, harassment, employment discrimination or breach of contract (express or implied). Notwithstanding the foregoing, Executive does not waive (i)&nbsp;any rights Executive may have to enforce the terms of the Retention Agreement,
(ii)&nbsp;to insurance protection and/or indemnification for actions taken by Executive while an employee, officer and/or director of the Company or to make any claims for workers&#146; compensation, (iv)&nbsp;rights as stockholder or investor in
Parent and (v)&nbsp;any rights to exercise any equity awards pursuant to the terms of applicable equity award agreement and equity plan </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive represents and agrees that he has not and will not file or initiate any legal proceedings, complaints or charges of any kind to
the extent released herein with any court or governmental or administrative agency against any one or more of the Released Parties relating to his employment or positions with Parent or the Company, and that he will not participate in or accept any
monies from any such action either in his individual capacity or as part of a representative or class action. Executive further agrees that he will not solicit, encourage, assist or cooperate in any proceedings, complaints or charges against the
Company or any other Released Party brought by any other person or entity unless specifically subpoenaed to appear or otherwise required by court order or in an official governmental investigation or otherwise required by law. The Company and the
other Released Parties shall be entitled to plead this Release as a complete defense to any claim or entitlement relating to Executive&#146;s employment or positions with Parent or the Company which hereafter may be asserted by Executive or other
persons or agencies acting on his behalf in any suit or claim against the Company or any other Released Party. In the event that Executive sues the Company or any other Released Party in violation of this Agreement, Executive agrees and acknowledges
that he will pay such Released Party its litigation costs and expenses, including reasonable attorneys&#146; fees, associated with its defense. Executive understands that nothing in this Agreement precludes him from filing a charge with or
participating in an investigation by the Equal Employment Opportunity Commission; provided, however, Executive hereby waives any right to receive any monetary award resulting from such a charge or investigation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">G-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive acknowledges that he is familiar with the provisions of Section&nbsp;1542 of the
Civil Code of the State of California, which reads as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive hereby waives and relinquishes all rights and benefits which it has or may have under Section&nbsp;1542 of the Civil Code of the State of
California (or the law of any other state or jurisdiction to the same or similar effect) to the full extent permitted by law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive understands and acknowledges that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) This Agreement constitutes a voluntary waiver of any and all rights and claims he has or may have against the Released Parties as of
the Effective Date arising under the Age Discrimination in Employment Act, 29 U.S.C. &#167; 623 <I>et seq</I>.; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) He is
waiving these substantive rights and claims pursuant to this Agreement in exchange for consideration, the value of which exceeds any payment or remuneration to which he was already entitled; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) He is hereby advised that he may consult with an attorney of his choosing concerning this Agreement prior to executing it;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) He has been afforded a period of at least twenty-one (21)&nbsp;days to consider the terms of this Agreement, and in the
event he should decide to execute this Agreement in less than twenty-one (21)&nbsp;days, he has done so with the express understanding that he has been given and declined the opportunity to consider this Agreement for a full twenty-one
(21)&nbsp;days; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) He may revoke this Agreement at any time during the seven (7)&nbsp;days following the date of
execution of this Agreement, and this Agreement shall not become effective or enforceable until such revocation period has expired. Any revocation must be in writing and must be delivered, either by hand, overnight courier, or certified mail, return
receipt requested, to the General Counsel of the Company or his designee, Abraxis BioScience, LLC, 11755 Wilshire Boulevard, Suite 2000, Los Angeles, California 90025. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive will not directly or indirectly, individually or in concert with others, engage in any conduct or make any statement calculated
or likely to have the effect of undermining the other, disparaging the other or otherwise reflecting poorly upon the Company and Parent, the business or the business reputation of the Company or Parent (or any of their subsidiaries or affiliates) or
their respective employees, officers, directors, customers, suppliers, successors and assigns, including, without limitation, negative comments about any such company, its management methods, policies and/or practices. Notwithstanding the foregoing,
nothing herein shall prohibit Executive from responding accurately and fully to any question, inquiry or request made in connection with any governmental inquiry, investigation, review, audit or proceeding, or as otherwise required by law.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">G-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive hereby acknowledges and reaffirms his confidentiality obligations to the Company,
as an individual who was and may continue to be privy to trade secrets and other proprietary information of the Company. Executive agrees to comply with the provisions of the Proprietary Interest Protection Agreement which he signed at the time of
hire, which agreement is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">G-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT C </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ARBITRATION </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
and Executive hereby agree that, to the fullest extent permitted by law, any and all claims or controversies between them (or between Executive and any present or former officer, director, agent, or Executive of the Company or any of its affiliates)
relating in any manner to this Agreement or to the employment or the termination of employment of Executive shall be resolved by final and binding arbitration. Except as specifically provided herein or otherwise agreed to by the parties, any
arbitration proceeding shall be conducted in accordance with the JAMS Arbitration Rules and Procedures, which can be found at &#147;www.jamsadr.com&#148; (&#147;the JAMS Rules&#148;) or by a non-JAMS process to which the parties may otherwise agree.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Claims subject to arbitration shall include, without limitation: contract claims, tort claims, claims relating to compensation and stock
options, as well as claims based on any federal, state, or local law, statute, or regulation, including but not limited to any claims arising under Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Americans
with Disabilities Act, and the California Fair Employment and Housing Act. However, claims for unemployment benefits, workers&#146; compensation claims, and claims under the National Labor Relations Act shall not be subject to arbitration.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A neutral and impartial arbitrator shall be chosen by mutual agreement of the parties; however, if the parties are unable to agree upon an
arbitrator within a reasonable period of time, then a neutral and impartial arbitrator shall be appointed in accordance with the arbitrator nomination and selection procedure set forth in the JAMS Rules. The parties further agree that the arbitrator
shall not have any power to add to, subtract from, modify, amend, or refuse to enforce, any of the terms of this Agreement. The arbitrator shall prepare a written decision containing the essential findings and conclusions on which the award is based
so as to ensure meaningful judicial review of the decision. The arbitrator shall apply the same substantive law, with the same statutes of limitations and same remedies, that would apply if the claims were brought in a court of law. The arbitrator
shall have the authority to rule on a motion to dismiss and/or summary judgment by either party, and the arbitrator shall apply the standards governing such motions under the California Code of Civil Procedure. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Either the Company or Executive may bring an action in court to compel arbitration under this Agreement and to enforce an arbitration award. Otherwise,
neither party shall initiate or prosecute any lawsuit or claim in any way related to any arbitrable claim, including without limitation any claim as to the making, existence, validity, or enforceability of the agreement to arbitrate. Nothing in this
Agreement, however, precludes a party from filing an administrative charge before an agency that has jurisdiction over an arbitrable claim. Moreover, the parties agree that this Agreement shall not apply to any disputes or claims relating to or
arising out of the alleged misuse or misappropriation of Executive&#146;s or the Company&#146;s trade secrets or proprietary information, and that nothing in this Agreement prohibits either party from seeking provisional relief pursuant to
Section&nbsp;1281.8 of the California Code of Civil Procedure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule A-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All arbitration hearings under this Agreement shall be conducted in Los Angeles, California, unless
otherwise agreed by the parties. Unless otherwise specifically provided for herein, the arbitration provisions of this Arbitration Agreement shall be governed by the Federal Arbitration Act. In all other respects, this Arbitration Agreement shall be
construed in accordance with the laws of the State of California, without reference to conflicts of law principles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each party shall pay its
own costs and attorney&#146;s fees. The arbitrator shall not be entitled to award attorneys fees or costs to a prevailing party. The Company shall pay the fees and expenses of the arbitrator. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company and Executive understand and agree that this Arbitration Agreement contains a full and complete statement of any agreements and
understandings regarding resolution of disputes between the parties, and the parties agree that this Arbitration Agreement supersedes all previous agreements, whether written or oral, express or implied, relating to the subjects covered in this
agreement. The parties also agree that the terms of this Arbitration Agreement cannot be revoked or modified except in a written document signed by both Executive and an officer of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as expressly provided in the following sentence, neither party may disclose to any person or entity (i)&nbsp;any testimony or evidence presented
or submitted in the arbitration proceedings, (ii)&nbsp;the nature or terms of any award or judgment rendered in such arbitration, or any portion thereof or (iii)&nbsp;the opinion of the arbitrator or arbitration panel, or any portion thereof
(collectively, the &#147;Arbitration Information&#148;). To the extent either party brings an action to enforce or appeal any such judgment or award, then the filing party shall (x)&nbsp;file under seal all documents filed or submitted in such
action (including all Arbitration Information) and (y)&nbsp;fully cooperate with the non-filing party in ensuring that all documents filed or submitted in such action (including all Arbitration Information) shall be kept confidential. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE PARTIES ALSO UNDERSTAND AND AGREE THAT THIS AGREEMENT CONSTITUTES A WAIVER OF THEIR RIGHT TO A TRIAL BY JURY OF ANY CLAIMS OR CONTROVERSIES COVERED
BY THIS AGREEMENT. THE PARTIES AGREE THAT NONE OF THOSE CLAIMS OR CONTROVERSIES SHALL BE RESOLVED BY A JURY TRIAL. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule A-2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g21538g18e07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21538g18e07.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-=6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YL<&%V86QA;6%N:3PO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\
M+V1C.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2`R,34S.%]%6$)?0U927R!%>&5C=71I;VXN9&]C/"]R9&8Z;&D^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V54
M97)M<SX*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G
M951E<FUS/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@
M("`@27!T8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O
M<F4Z0VE!9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX]
M(B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM
M<$-O<F4Z0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K
M/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T
M>&UP0V]R93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H\/WAP86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`TP$/
M`P$1``(1`0,1`?_$`+X``0`"`04!`0`````````````("0<!`@,%!@0*`0$!
M`0`#`0$!`````````````0(#!`4&!P@0```&`0,"`P0'!`4)!0D```$"`P0%
M!@<`$0@A$C$3"4%1(A1Q,A6U%G<Y88%"%Y&Q(S,*\*%2<I(DMQEYP2<W&#A#
M<S0F-K8H>+@1``(!`P,"!`0#!@0%!0`````!`A$#!"$Q$D$%43(3!F%Q@2*1
MH13PL<%",P?1\5(5X6)R(T.")#06"/_:``P#`0`"$0,1`#\`_5=Z)OZ4W!_\
MEV7W_.ZKW,P\J+2M0T-`-`-`-`-`-`-`-`-`-`-`-`=7*F6*1L*+@$#`Y)OW
M$*8JA>P_]F)C=4]QV$!#Q$-AZ#K$[2NI-[1U_`Q-R3BH34&W355K7I_$BA)\
MMN/+7)X8>>98AF>02S[:)6C/LVTGBB32PKM@AW-M3A34E"4%ZGY1F:K\IDG7
M:@8H.!*774_W2U8O?I6N4]_A3_JI2NGC\-S[J/\`;GWSD]K7>L?%F\#]+SYI
M6^7HTJ[BM\_4<==)*#K"LO*JDG(M=$7OEJ.P5=F(MVI^69/S$B&#=4H>`;C[
M!Z@'CUUZ.MVWZ\52W_B?#R=_&X863<BYN-5&BJTNM?!?F>GU@HT`T`T`T`T`
MT`T`T`T`T`T`T`T`T`T`T!5KZ)OZ4W!_\EV7W_.ZKW,P\J+2M0T-`-`-`-`-
M`-`-`-`-`-`-`-`=3+**)I-^U,JB!G!2O`.GWD*T[#BL8YO_`&8%*'UO?J2E
M&,7R\#4.$I*U*$YRG]L>/1O9OX%-LYB'D`C4;OQE+AYW(U"Y\M9C-)>0I+I3
MT*=&PMAY(ES^G$.*6N]+D%U,Q48B2).9!F=%22V63,9L!CA\_>[5D9-WC"7_
M`&^#K]VBK<]2O'>JV;\?@?O5GW'[8A.S[FEW;'LY=CL2P%BR5QW7=6&\32XE
MZ2JVYI.2:CHUR:1;M$I*$F#"LF<^Z3DZ:A2G`&QE%>XZ3LYMRF=*E'N$`'QU
M]):^S$5NOAON_B?@61^G=ZS;@IW+]FSP=RM8Z='UKX5UH>RU@HT`T`T`T`T`
MT`T`T`T`T`T`T`T`T`T`T!5KZ)OZ4W!_\EV7W_.ZKW,P\J+2M0T-`-`-`-`-
M`-`;#CL4WT#_`%#K@R+CA;;5=G^YE2JS%67[JMCC&F0LD(L'$RKCW'UUO"<,
M5Z+%"3/4*W)V$D<NY31<KM0E3QX(>>"2X)[[]@CL!MX/;?\`=\C%QW=G;]2Y
M:C5.GFDE5^.^OP%R7!U6]"NS'WJ>8XS)R?XI<>L4NZ)D!#D3@6[Y@N=LH^5(
MRU'Q'8:?78J;3Q])PL,R7(J]>K/U2&4=.62Y`;B/D;"(!]IF?VZR(^U^\=YO
MW[MFYA=PLV>#3BY.;:Y1>\8T57&E'7<ZTKZ61&W"CK%OQ2I^\M;8B<"&2.<3
M&3*F)@.?N4`RG>(]P`)M@';I\0Z^%L698V+"VY2G*-=6VZU?5]=SN2UBI4HV
M?84P]YR^PH%$!_UM]_ZM<ZDW-PIHJ'&<FM@^5V(E1,;L!0``VY!(*@&W(8``
M2!T,`B/7?IMK@R)NW;JE7Z5+5Q^Z.DDJHH5D.0.<93D[ZL5+'(,E'U#CEQT@
ML@89C181QFU%MJV*;)87LXW[$#OIHH3;-)R!'9C%^$2%V`=?.YO<\W&G?5M5
MC"-GC2.JYQDY.NC:T7[,_IWN/]O_`&OD_P!L_8>:K=B/=.Z]^MK*FFN3MJ[;
M@E-=$TY-U57XTT+FL*2[^R8LQC99=3YJ9G<=TR7E7IDRHK.I&3K<<]>O%T@,
M8"*/'*QC[!OV@;;P#7T%G(G.<K<HZ*FM/@C^?O=.%8[=[F[AA8KC^GM9EZ"X
MZ)QC<DH[))T2HG0RUKLGA#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0%6OHF_I
M3<'_`,EV7W_.ZKW,P\J+2M0T-`?./>`B'<.P]^Q#%W,)BF[@$IBF#8O;T`/'
M5(1@S;RZQ%@Z:CJ1.2,Y;,JV!-!>O8@QI&)7+)\HQ<J%3^US5U%R@RK4"V`I
MC*2<XZC(LA2F_P!X,;X14Z`D'7+1!7"$C[/49V%M5:FVZ3R&L%<E6$W#2;-3
MX`>QDQ&N7L7(-^\!`#(G,01`=A'4!Z(OA[]Q$0ZCX"/3Q\/HT*;M`<:G0IQ]
MR9A_9OL.N'(IZ$Z_Z'^YFE_$PER$<PK3!F8'EFAE;'66^(\CKV.N(2"T.O8(
M%*E3SF<@T)=N`KQ:\O%MU6Y'"8&4;F."@%'MUU\"'<[N=@P[;+C>=RU1ZT3Y
MJCTWIIIUV)<I1\M]2H'#V>N)N7>6OIH3>/./]JA[_>>'^8G&*[Q)W%["O\'T
M^K0T`QM>*,B8W037:3]G>-0113=OE"O&?P*>645^OZQW7LWN_%]G=]4<N"P;
M7<[$;\$JJ[<DY.-R,Z:):Z+1OKH=&=RW^J@FJ3:='U2\*?$O?9%4(B4B@`!B
ME*!M@\"@`@0F^^XF*`=>@=!#7Y%B?J(8-I9']2CY;OKIO]#T9:[;=#[@#;?P
MWZ;C[1]VO2T^IQ]6;M4'722YD$`$I!.8QA(4`\=Q3..W3_2VV_?K48QDGRI1
M(SR2O6XR\LKB3?1+XGY'+[E*)I'/W_$TQ]KR)"T\ZO!#`L=CQM.6EE!@K:I+
MB)DZ5/%TQ.1?L_GK.^=MP7,W:;N5E4]^T1#<.&>/A7)R5V,6I*/1=$Z?AT^!
M[61[D]TW+>)VNU>O/&PKOK8T.5RD.,TU.W&M(-NCK%+78_3QQV4=CAO"17`B
M8JF&\:K@(CN!5!HU?!4I1#L,8QU1,<W<!NH]!UV5"U&U)Q\U5X?F>3G95_*S
M;=S(J\J<9SNMMMNY*;;JV]6O%JK,^:XC(T`T`T`T`T`T`T`T`T`T`T`T`T`T
M`T`T!4WZ*<U%$]*[A<U&69%7A\*1J\R@#IKYL4@ZE[&[;+2I?-\R-;J-4C*D
M.J!`.F03`(@`CJF8O1%I#:1;N6S)VR>$?L)!FW=LGK-PBZ9.&"J7GA)I/TC'
M269K(*$.14IA*<HAVB.^^A3PS7*54GJE8K=39Z/R)'U-I+.G_P#*]\RO*\@_
MB(M216KL*WA'KT)*QJM^T$H\QTUU5U$@VV.`B'R*V,N7_-.1JL^OG)[)!_3_
M`.*RQ$/DZ;!61LCRBR603)F186&TQXK)X_";*8B98."0=S@BH9!P<G40"IY7
M"L19)B.E(/T_\!(X-H]B?*$OW+WDG6I)]=KDFL)$W2U"J4X=Q:[^NF3^R1>2
MZC>$141,F9$3%'>%,NU?T[9W!T2G(\4>363L4WUPM*2EY-:FL3DC&.4K$_D'
MLNN_LN,99-&`J#A>1<`T2<0!6JS",3300(/E@;5)0]M7>9EJQ+-QF/N<-$:X
M2GY1<(Z!S?5EWL[QCO+\ZIDVX-;D^+]I8YFGY@V)%SX(G\3%5$!#0=*E@C%\
MWDFC=ZQ=-W;-VBBX9OF:R3MH\;K%!1)PU<HG40<-U4Q`2G*80$H@(#UT%3`^
M;.36'L"+045?K,K^*[49PE4J!7F#BSWVU`U24=R*\+4XHJ\H[9L&+=555<Y4
MT"D1.4#"?8H\D<?]1!II.'6NWR*I4^9BM&(SER,@+\ROK%/"F%<@XVNM"@*0
MJR:S.6)!*]UYS"$NUP=N1&.IR\(P>JJM8E$#J]ZHD>&W(4![5FY:P)VYX>F1
M:G&49+11<6FDODU6HTEI(Q'5O35Q52^7V%.9-?O-T:W+$N"38)D*B<&"U3O3
M,*JVJ32W/&0`"M=M)&2/>Z,S`"OS^6*V_E$$/7G[R[I'L>3[<NW92P<O(C>F
MJ[SBW)-^.K^FM-S+MVI7/6DJS2I7P,Q63)7('!\K-S.0*L7,>&%Y!W(-;CB^
M$53R50HI9VJJ5O:\>)G\NS5^%9J%(+^,.+HK=,RZY-^FO*]+#RJ*U]ERB34G
M52?PET;>RV1R5KHMC->&\]8ISS"R-BQ/?(.]1<5(FB)5S""Z*>+EB(`N+%\R
MD$6L@U653."B(*)%!1(0$HCKJW\.]B3I=33DJJOA]/S(]$=UDO,>,<.P@V#*
MF0:GCV%,!DT)*V3#*'(\73("JJ;!-RJ55^=)+J8B)#F+[0VUPZ$(6CG?D=RH
M,5IQ:JH8=P\J\035Y.YGK"YY>RQP@W54?X*Q&^!)U.`N@L`LYB<!&,5#O`J8
MJ$`!(S*,9>95H<%?]++A6"][F<IXHB\^Y'R=`EALKY9S?_\`/.1<@,UDCH)A
M.R[LB:;9O',3$91R2"9!CV214$C`F'Q<;LVFZ\4V=R&?F6[\,F%V:OV[:A&5
M=8P3JHKX)GSL\8<HN'A&RF$9)YRBP#%%43-AK)5@3:9NQY7VR(`A&XBR*^*2
M.N,%%-4BD;PTR)5RID(BU6$P@&MI45%L=>]<GDY$LJ^^61)MN3W;>YGK!O,C
M%6:I=S2S(6[%67&217LCA#--=6Q[E1C&KD,JT?M:_)*F3G6#U%,QTU&*S@2!
MN"@$[=4Q74E@"AC=@[`4#F#H<#$,!#$$P%V$/[X!#J'NU"G/H!H!H#:<3`0P
MEV$P%,)=Q``[MAVW$>@!OH54KKHC#TQD:NP]NAZ[*W>N1<VZ3*4*LZL4*TEW
M:S[N(R1;1+EZE)O5'0E$6_EIF%0`,)-]M3]39C)V&H^HWIX_15UJ=Z?8.[9L
MK>9VRW<E@1C/E*DJ27^ITBTE'JZ_;I4R<51T5-1,@IJK(]O;WJ["H)Q[A\W;
MJ3M+X>_6[BK'EY4_`\]N,(>G:?J7UO73X]/@=H&^P;^.W7Z=9*:Z`:`:`:`:
M`:`:`:`_'5Z6>!>95EX@YGLF%\APN(Z-D#ASQXBXAG<>-,KEU;,\E"X*R)7Y
M1''UG2RSC=%LO&/ERQ#ANW9RQTI`Q=S`(F1&G&J]/`M"N5OS&IP,IW`*DXFR
MK5.1F2?2VBF&);$PL%<@UX_)]:P7%0$M4+"TC+0WR3AQ_6)LR+-2QS\;#UT)
M9TVCDI`\BNDU-?B:^'6AG_AQ%\>9'*ZUVX\\'\O<?(6/QW(TR?RC,8PL'%;&
M<C:PDH&2E:ZKQDLLEC^;MMI?I^2X+>PH[ELHW:'8!-_V7RP3YA46J)8PW$G$
M".8IG/EK;6'*F474LL_J\SE":);([%3%10%&L)B6L'0:U:D,X\=P2>HM#S:B
M9A(L^5+L`"DH"E#J;M*!C=#"7Q$"B/:`FV`1VW_=J%->PNXCL`";83"'3<2^
M`CMMUZ?T:`Z*QU:MVZ!EJO:J_"VBM3K16/FZY8HQG-04Q'K_`-^QDXJ21<L'
MK57VIJIF(/NU2$#S<$'&,Y96<XA9YR!QN>/A<I2]*ETY#.&&'C%TD9)(K'&M
MUM+-6IOX-,YQB_L:6CF+8PAYC1PF4$]!\C-^`N*>.<&.).VE=3^2LS6AN1"]
MYWR2[2F\F6X/-2='8%D"(MF54JJ;A(@HPL2@RC2`D0QTE%NY8]YR2X5T")-^
M2F!2E[0V)]41W,8OCU`YA$_=U\=]]8G61=#3Y='Q\LH#W&-N'PB)C``&.(EV
M$QS`'41ZZX?0MR=;B3:V!N\LGL*'B`^WQ`!#<?>(@8=_?K<I.*I`J*[N=.&8
M^OXUS+R_Q?:+7B#D'A7"&1;M&6^D/R$A[^UQY4YFXL*9E>EO$G%=O-:?.8@K
M<ZITF\PW;G$C5\@4-M:MWLFY'T[WD6VM=_\`)$E2AA/C'CS"-DR]CN,SS&6+
MDGRCR9Q9K'*E[E/,,?7+-1Z77[!/0M><4K$U-<JKQ.-T(^7E"@C\DP,Z78$`
M'4BX-\.MLB?0M]\I/X?@+\!A.38H!VF,(B8Q=MMC&$1W'V[COXZA34$R%'N`
MH`;8`WZ[[`&P;^\=O;XZ`T.DDJ``H0I]N[;<-Q#NZ&V'Q#?0$*N;U=X[+X\H
MTKGG&KJYI/<R89Q/1+#6/*B\B8_N6<\JTW%5=L]2NB$C#V"K-8^?LS1Q)F9.
MP,Y9(*$41<E'R#W<CT/+<(+'D9O:.6>#+]D*;RU&\9,]UK%F-[[<&[`F0).C
MV+CSA?,"#;($G&`RCK+9827R.[9_:*;)D=RU22$Z7?WF%T"W+`M0HT`T!L4`
M!3.`[;"0P#W?5VV'?N_9[]1UHZ;D>SKL?G^SY0$7+KE_CR7P=;[%R3R;EQW-
M\:\J-\,RML1K]:FXJG(TP(CD<G!O*]C-*&D(J0.FV5FHX\**@F,5`5P$_P`M
MFJ_;RHQ49.]*-ZDN*=&Z>G]_\M-::I1^!_57L'N?:\?,]J=RM9$+/M;`[7*/
M<K+NT4KBE?\`4KC<E*\YPE;3<82C=T3KQ+V1,F=1\#?M3=E(V%TJ0!54.8I"
MG32,F?RP*J=#IO[-]?4XL[DL6#N.L-=/K^)_)M(/(NK'2AEMQU_STV_>>J+]
M4/H#Q\?#5.SKUW-=`-`-`-`-`-`-`-`59^B>4I_2IX0',&XCAEF?8?J@8;#/
M'W*3ZA1`1Z;`&P=`Z:KW,Q\J)00_"_!D!R7M?+>*2RDWS5>6$7$W!Z;/.;W%
M"L</`P4G7J[#2V'W.05L2NXBM,IMZK&M30OD,'SQ9X@4CI4ZPPM%6I*@4DQ'
MN$OQ?#\0"(&V((B4`,`]P%`3#T\.H^_0IJ"292@0"%`@#N4NP=I1WW#M`>A=
MA\-O#0&_0#0&WM#KN&^X@/41$`$.@"`#N!?W:`=I>H[;[^._4/#8>@]`W`>O
MOT!J!0*&P``![`#H`?0'@`:C2;J]P:ZH-IB%-MW!OMX=1_[-<4[-NXTYJK14
MVC=MMK<8QBJ1V(12YW%+_P"2#F0.P;DXJ\AS%'VE-_*&XE[BC[![3"'T#K2)
M)U1"WC<`%YM\=2%`"E#T@,=@!0```H%RW30*!0_A``'P#5(NGR+?]0T-`-`5
M^>I%UPQAD/?SL]/;_P#M#"6A'L:<0RE'DSZGVX`/;RYQ<)=^O:/_`)&.)O4-
M_#ZX_P!.J1;OYE@FH:&@&@.-8O>DJ0/$Z9R_[11#]GOTK345DM8Z26WS*0(?
M(F3/^;CR@Q8:]VM6A57@S3;!7J2><?J52$L2[V6!Q8HN`.Y&,93KON`JKM,@
M+JE*`&,(``!\O/U<CNF;:NMRL1Q[<HK9*3;J]-WIU/Z9O^U^Q6O_`,X]L]UQ
MLQ_^UYWN+TK]^LJSMV]%!1;X05/]"C5ZNK2+#^%LC*VOB7QRL-BD7DU89K">
M,Y6:F)9=21E)64?5*+=.I&0?.3G7=NW+A8ZAU#F,8QC"(COKO]GR<F6$KE^3
MDW;MM;;M5>WQ_P"!^0?W1P,;%][]QP<.*A@V<V]&$5M&*E1)5^6^[W9+,/`/
MHU[)\*:Z`:`:`:`:`:`:`:`JU]$W]*;@_P#DNR^_YW5>YF'E1:5J&AH!H!H!
MH!H!H!H!H!H!H"*?.W<>$7,<NW0W%7D.`^`#_P"$5OV`!'H`C^WIJHCV(6<;
MRF#F]QW`PAT](#'9=MMQ[OYN4_O$3@/8(!L&VW[?V:$6_P!"W_4-#0#0%?7J
M3=P84PZ)!*"@<Z?3Y%/N*8Q1.',["8E`P%$#"41]PZJ(]AQ"W#DUZGP;[B;E
MMBX^VY1V(/!SBD0#!V]0^)(2[#UW+H1;OYE@NH:&@&@-!\!]O3P\-]`?GKAK
M@X_Y]'/.I?(-O(K_`*6F,+BW>`JK\RL[<7*3CE6RI!'R02[!`0$`W#;]O3H6
M,6/ZS(OM_P!11A\DDG7\V??W_?6=+V+A>RG&/Z/&RY947I5RE*54]-E1=>OX
MV><`Y-U(\&^%LP9--)Q8>+F")U=!'<R:(RN+JO(G*4Q]]PW<F`-O#;4P['H=
MNG;_`-*4?HI4_<CY;W1W6]W?OUSN$D^=^].<MJ5E1NGPJ]";.N^MCR1J@:`\
M+=LB4S'<,O8;W<ZA1(1%ZWCB3-WL415(5:1=`L=M'_:TX\8L`<O$T3>40%/,
M,)#"`"`"&J0[UO88=X\9QK:8B%I1[#DGV\:C),UGCB$453;DET&R:QG"\29R
ML1,KHA10,<P`!MQ`-!4^N(F(N=8)24-)QLPP45=MBOXE\VD6!W4<\7CI%NF[
M:*K(G582+15!8O=W)+)&(8`,40"%.RT`T`T!5KZ)OZ4W!_\`)=E]_P`[JO<S
M#RHM*U#0T`T`T`T`T`T`T`T`T!QG$VY>T0`!'XA$-]@#8W7J&P"4!#?V"(:`
M@IZA=S6:\;K9AF$CCSN4>5D5/\;L8U1LJG\TXF<I5F4KMAL3K<W:6`Q_4WCZ
M9?+F[4@!HD@)@.NGW54V)N1MHF0WW#N5J4ES(P@$78*#A.JX!JW,G#D7:+WC
M>WX\KAV$G^'+;7&9%['B9\>:8%>*&DV7V>Z<;@U>*$+V`&VA:30<ATW*%5B[
MQCVT05UJ$XW1=0=BK<FRE8F7:K(IK).FKQFLJD!%BJ@(%,)3AMOML(:`]F)^
MTIA,8-@'J80$"@&P"'7J`A[-_?H#A.Y\I-957M3(FF93<YB]I2$#<53F*81*
MEMU$1`.T-`5]\D^1&&+A((X"K>.%^7F9(2Q8]R,PPYCF0;JLZ59Z5:HF[X_O
M&2[X>1CJKC.(A+37T)!DO*O$A=JM/*325.()F4%=3!V/Z'Z@W'FZYTSBC1<!
M9S3Y&7^"R_E'#U&MUBJ-[HLY6\747$C*IXIL=OAF-0O)'-+H$6]6<3[B"`'P
M.2)@?S4=^*_ZOI2]"GJTTKJMQL3GP1RKQ?GY*3CZP\DX&^U=9%E?,3WF%DJ=
ME"B2)A[%&UAIDVW:2Z+<ZNX(.R)G:NB!YB1S)B!A[LL/(LV8W;Z^V2TDE]K^
M3";)$I/?-`3IF(HF(G!,Q.I#"D*@'^,!$`^),0'?;82CKRUD37)RB^,:OZ+]
MNHUV1SE7`Q>X#%V,;8@G^$#!X[%`-Q'8/;[==BS=C?CSA6@=4Z&!LV\EL2<>
MZ^VL&5K6W@`DY-I!5VM,F;N>NMSL$@!C1U<I]0B$W,_.SDF'PH-T4#*&$/#7
M8_1Y=W[L?6VM6Z-KK77;\"<J;E*J'#SG9E_GIGOU!,8.L?\`%Z&SQQ3JO&B)
MQOGZO.;MD-W$4F>=65"8FH*I2Y&M/2N8."I*HK+JRD0@!SG:J+`"6N**2DVM
MVZ_6E/X%>K3\":W$G.L7QNQEQ^X7\G*]*8.REC#%V/L,4:R6MRQ4Q3G?^7M3
MCZ='3>,<C,U5JRM-V-*!^>/77B[>98(JAYR(!L88H15MV_Y7_C4TYN4U<?G5
M?ST+2&SDRR":NQ0,8?C3[TS]@[;F1!5$ZB*ATA^$1`W;O[=6A&S[0'<`'PW`
M!V]W]'30&*LJYKQCA*G/+]E.ZUZCU)DL#0\O/2"+=-P\5<%9M64>W*)W4E(.
MGJA4DVZ)#JG/T`-4%<',$K"[Y.X3\C[A@;)^9>+L!0.0R&2,7ML%VG+=M8W+
M+,9A=?#$K9.-[>O3UG<R,42K3Z9WR\2H:OJ.#)K'0%YL<9^/0PVCQXY-3O*S
M!%LXQJ/N#M%@^!$Y29$V0L2,N1\?"O7_`"'B+'#8F<2;[*$!'P=J:1)3RAD0
MDGJR+0PM_*3%#8H?(]?P/R/D[B1@[@UQES7B6\+6WD!G+FA39C)[B-KU&@:E
M=FN8.16<ZW)6S'\A.JV>'C,U4J)=2$"#`CYH@==LW67#YAN94Q':A=(W4,JD
M10Y3$,?<1(8"[DZC\&Y1,4W;X=P"(&\0U"K8YM"C0%6OHF_I3<'_`,EV7W_.
MZKW,P\J+2M0T-`-`-`-`-`-`-`-`-`?.X5!$@JG,":21%%5E3`!@(D0HB;IO
MW#[^@=0#W[:J!7W@2T81YA<@+3RDQ].2-^JV$H);`.+;*7RW6.)"5F@C[CE2
M\X\>@5,[Z2=NW;&KRYU2F!!U6S)I]H]YC0%A`D$2"05#[B`AW_!W=?;]3MWV
M_9H"".0^%[.OV.:RWQ,OJW%[+LRY,^GF\3%EG\$9+E51.`*Y4PL9Y'1<@^>+
MK"=:4@',#/.UNSYAZN4H$U5OJ1D*%O6DK6*\A<H<!\@^.^72YMX88\KF0,V*
M<>*](9CQ@K%VFE3.1J\X@;&LWJ<E"-YRB0+F0%2=:1S%BL0[4[M10J9U@J26
MK.(,Y\T(>%O7)NZEQO@RU1$1:*MQDPC8)A@YF(6::(2D.&=<Q$0B9VVJ.8AV
MF+F#@D(B,2.<R*Z\BF&X@3FQ/AC$^"J@VH.',>5+&U,:.5WJ-=J$(QAHWYYT
MIYCE^NFT2(=V^7,``994QU!*4I>[M*4`A3(BJ!.P1V.;M`=@[C&'XC;B("(B
M8#!N.P@(;?N#;%RX[4'<BFVO`)59A;+''S%^8D&+NW0[AO:($IC57(4`]4K^
M0JBKW"H0\#;6(HR:*!5?B.V6.LT7VV624#IKM6<^];MN*?&U+=/9_3I]*"6J
MUU(79:RSR*XA3_'>"E;`/)FJY7S<ZJ-JD9"H?8>0Z1AZ#QE=KM<+?YE&(NSN
M<K3$:R@_2:MH3YR303<-0`5G":R/N]M[=VSNN+E3E+T;EG'YIMIQG-SC&,-4
MJ*7)JK=$Z.M$RQ71ZO\`<M3)^&<IY-Y:X":WO'.3J;25)C-><H.*O=*K[2[0
MD[C#%^9<E8YJ9Z\L\GW<<E(6:'K$:]6E>UXT4'Y@B;<@*IBGYE[&L8-[@X52
MA&J>C4I13?1;5I1ZHS).E4]3,^*>.=&QD_<VIVXG\C94ER'-8LNY!>EF;I*.
M'!^]VA%*%1:1U,@%5.I(J#;1T6GMN"'<(F'JY'<[S2QXQ<;">BBOM^OB^K)%
M=>I(8C9!/S!(F!15.*BABAV"=0P`4R@B3MV4,4``3!L80`-QUP&J'D;[CFAY
M2JTQ2,D5&O7JGSZ(H3%:M<0QGX9\D)0()58^40=-P$"A\)BE`R9OB()3?%H"
M!Q^)N5>.;@9;@YDURTBD4$%;#QJY`7.ZY(Q;9"E4\TZ]1R%/2EARCBBSOMO+
M*Y^8F(4I-@+&!MOJD(E2WKCTQQ#<;8JI\9<WDR?RNR4ZP;B1O?(=Q3\.N,R!
M(S4)'03K,"D>[9S%=D).O/52R,2P>BDR;]SE)LN<B&@J3\Q/Q+;_`(P1SSR3
M>0^8N2:WF*,YHZ4RXQ3B)LX078A`8'Q_8W\JPJ`$A%03D)PY%)F7<*JF6<$;
M&29-P)L$22,'F`4`%3L4$0#81,```&[NTI]P(`%_U0V\-"FTC1$F^WF&Z[[G
M54/X`(%`W<804`H#T[N[4!B#(''W%>4[UC#(E^A)6Q3^'G\C,45@XN%Q;4EM
M./U(]PC/V#&S">:8\NT_7W\4W>0KV:BY!S!/DP<QYVR_]II4E$9G```-@``#
MJ/0`#Q'<?#]NA370#0%6OHF_I3<'_P`EV7W_`#NJ]S,/*BTK4-#0#0#0#0#0
M#0#0#0#0$`>:=OL%VG,8<*\;RCZ#O_)MI;'EWM46NLQD\?<9J*I`MLV6Z(D4
M!37:6*74M<36(I5$P+,Y*PHO``2MC:$9+S&6,\?X?J<?CW&%4@Z13(/Y@T57
M*ZQ;1L4U.^=+/I%RDS:)I(E<OI)=59<X@)E%CF,/CJ]`9"U"GQOCF(@)B>6!
M@'N`53B1,IB`)RB<P>!`,4-]^FVK]J3E+9*I*I2CRTMU^Y^"ZL_*_/4^>7YV
M_P")BF&Q&*C7*O`3#=?JWENBF.>3K/$_)-=D"NR%#=$AWTBF*9MQ`Y1]FW7S
M+7=+$\FYCS:3M)-NJ_F\E-?!/DNC/T.7]L/<K]O]I]Q6GC?H^]YRQL9.XU)R
M<H1K-<?M3<U1IRKKX'Z...BX#A#"+-+8$F6'<;(&+WB!BJ)TJ#3$AR`80W(8
MHAL/AMN&O4E1-+^9JI\3EX5S`RLK`RJ?J\7(E9DDZKE#26OS3IHM.AG363IF
M@^&LR=(U*CC6*4Z1@,;M`0'<>X"[;]/K#OMXZXK\/5M.-6JKH%HR&?)7(&&<
M=9*XIR682Q$9]I9/R+%4B_6RY,*?4:!-KX%R1]INK&,H\8Q,\UL=82>Q"#9=
M4O\`O3Y-0@"H0H:]/MEC(_27H69SE%0BY*E7)<XT6BZ.DJ_`J2;K(W\%5L+)
M\>HYGQ_ID?0,31F4\^U^I5Z(LC>Q0X_8.=LA0\I+5Z09J+-"5NRR\>YD8MHW
M.9!E&N$6Z0^4F40N?Z_K.61)SO.*;;5-U6GTV,N*6S="98D`1[OXO8/CV_0`
M[@&NA%U2;2J*&_6@-`<((@4=RG.!A4$YA$PG$0$W<*?Q]VR?L`/X0\-M"'XX
M\GAVX9_PU``)NGJLK^)A$=OQOFKIN.^X;=/V!JF5LOVZG['5$2J@8#"8.XH%
M$Q#"0_:`]P@!RB!MA]H:AO<Y`#8`#QV``WT!KH!H!H!H!H"K7T3?TIN#_P"2
M[+[_`)W5>YF'E1:5J&AH!H!H!H!H!H!H!H!H"N3(`;^K%Q<'_1X&\T!\-]_^
M_/A27;]GCJ]#+\R7P+&$R`F`@`[[B(^`!L'L#8.GTC[1ZZAHWZ`ZJ91^88+H
M;"/G)JI[`H5/?O2.7ZY_A`.OMZ:X[L>5J26]&:X>I:N6UO*#7X^'Q*47_$'-
M43R&]3_(AX:#6J7*+CM"8TPT\3LT49Q,7!GB>8J165B8D_MZPV:S[XB17*W]
MD9(XJ;[%';Y&SVJ>3GY5R.BGZ23TT=M24G]6T_CNC^D,G^Z'M+$_M9[+[)<Q
MY_[SV#OL<C(?I7'RLJ=J<7R6DDG"2:AMIXHMBP?6UJAC+'E:D2D";@J'482:
M[#$5`LM#UZ/CY$H+I#Y:Q2.VYRE.4-C%`!#H.OL)67ZGK5T2I0_`^_9]CN7?
M,WNV,FK'<,J[D)4:^V<VXZ/79]=3,.M'DFAAV`1'7'=?&VV5;FA@[BB`^T/\
MO'IJRUMOY$,!9=X\4G-5KPQ8KNVCYJ.P[<[+=$*G-5^'L-?L\A8\>V?'P)2[
M*:;O&Z*<8A9SO$3D3$X.$2;"7QUSXN5<LVKD(;S25:M-)-/I\BK1G98&P?`8
M"H!L>5IX9W#$OV5KTQ)]F1T4A&CE/)MMR4M!LX^-229H1U<6MAV#,2%*/RJ!
M-P`1$-6[>E>ERGO1+\%0-U,VZX4J$&J!H!H#\;V4/_!K_#4?]5E?_P"]LU:I
MA;+]NI^R'4-C0#0#0#0#0#0%6OHF_I3<'_R79??\[JO<S#RHM*U#0T`T`T`T
M`T`T`T`T`T!7-?\`]6'B[_\`H9S/_P".O"C5Z&'YU\BQG4-C0'P2"1%42D4$
MP$\TAA`@F`YA+N)0()3%^+N]@@(&\!#8=9G.4+<G#?B_H9:CSA.3IQDG\VME
MH?GYL%CKWGWN9D,@S:'.EES'E:U2:F3*-F8WAQB-#DFE"5YW%8(2L"-/D:PO
MQ]14%!RI!KJK1)3O_F#K%^8#Y>"R;-^5Z=V4LJ49-0V_\E%I6G]/7:M-3^HH
M8UN"L=KA>BO:-WVQ^JG+T;;BK[PY3E%W6O4K',_[;:G&*FDN*KQ+YX8#+2"C
MHQ2A\"H"H03&!P8Z@B"@&'H"8$`-@V[M_:(:^ELW+D[:;>C7YG\N2Y7(XMZY
M).;Q^BVU/7:Y39M,'<40\-]8G'G!PVJ%H;M::K'B#0`VUFW#@J;E;J:ZV0:`
M:`^-%T=8IMTNPY3"42&43$4_$$C*@4QA)YVVX!L)@*(;@`[@%(;@<AL!C@"1
M14,F(JB*>Q@,)"@43@4I^XP#]41`0ZAN&E!4_(5R@QYF3"T7Z&6-LGX4R/68
MSBGSN9Y^SKEQ./B;!AK'^.WMNRH]D)&Q7JLR\PTA!KT?8&*[TSY-JB1)QW)G
M4!-02"):(_7#`6>OVR%B+)59N(LM=GV;>2A9Z"DFDK$2\<Z3\UN^BY%BJNR?
M-5B?$4Z:@E,`#L/34+7H=\`[@`AX#U#0HT`T`T`T`T!5KZ)OZ4W!_P#)=E]_
MSNJ]S,/*BTK4-#0#0#0#0'"JL*8!LF8XB<I"@'3N$P".Y1`#=`'QWV`/?H0X
M_FB=Y"B4WQ@&Q@*?M[Q$0`FXD`.O:/4=@Z?MT*:G<E(4AC```94B0[")]A4-
MVDV\LI]]]P\=@V$.N@-Q5N\J8E+L)^[<BARE.02_6*)2]^YBFZ"`>&A##%]Y
M(X'QBRG'EWRS0X4]<B;+-R\2%A92=D0C::+8+<Z;U2&-(V>1)5Q>)?:`-V:I
MV?F%\TI=PU14KHR5GBH1GJ)<9L]3,7;X+CHAQEY'X&)R$GJ^K#8I5S)DO.>#
M#U:AK2DBNWFX=1\3!LP9.7D(]G770+L1:R#@'B0Z="4^ZOP+?P5`0$P=HAVB
MH0"'*<QT]@$#E`.@@;V==M0T<@&W]FW0!#W["'M#;H.@/AD&@.RMRB/:"3@B
MHB``)NT`,4Y2B/4GF$,)1$.NPCMK<7%)\NJ."_9];BNBDF><7K,<;=8C9%-T
MH],JJZ(W;&6.LH(`8QE5DSJ^2"/<3L`P;@<1'XMA#@GC1G-3;UX_EX'>N]RR
MIV?2J_(K7C]GU_SIHF>A9LDF7DI$`#B5(0\P2D*8PAT[A`H!\7;T^@-<D4HQ
MXHZUNUPM)/5PT7R.RT-#0#0#0#0#0#0%4O-FRU)3D5QSQEF_-UIP%Q?LF*N1
M-QMMQKV<;1QC8N\V4^V8&C\5U^5S73;50)-NZ>U.[6UPA7#RQ6TP#8[L[9P:
M/341IG]Q&^0SYGF.R+Z>K;B]D&\<V6MXC.<[.?9\A[`XX=I9"AZ2?%;>(?V>
M-B^.<>TF!Q>H\4902RE.[Y1HY.^^>6,J=PX!5Z:GON$///$M7XN<$:!RYRW(
MQO(+EPM=Z70HBV-<CY!;Y`NQ<MV^"5HJ&26E4<51T_BBD18-#RCB.5<,$"JE
M031`Q2*"NE'N2?L?'',F#)R2O7"^U1;6MNI)Y.6?B-D9RJEA.<D7RXNIN1Q;
M9VZ#BP8*LDJ=0R_DLR/JB9\NX=+0YW:ZCG3;4IZ3'?/G%<[<H[$N7JY=^-V9
M71R1YJ;EZ!?1-6DK`*95PA:7EM!H?&]Q<O6BB;ADDB^1?.T%2[-2JE612@J3
MA^8*)A*4!,(`4VP=P?"<-RF^(@;EV\>WNV'H.K0IS@.X`.PAO[^@_P!&H#70
M#0#0%6OHF_I3<'_R79??\[JO<S#RHM*U#0T`T`T`T!#KGOR/<\0^*&7N1[6(
MAIT,7,JC+O(J==232+5C9:_5>KS+V06B2+2/R\7#S:SHI42&.=5`I=AWVU41
MZ*KV,,8.]17"?)OE\.`,`6JLY,J\3QMM67[7<F+6WQ,Q"6&/RE2*/#U@6,]#
M0[-U&2D;/NW9UD@.H19H0-P*?JZ$33=$=ME;/7)NT\F+IQNXJ0."(R>Q%B+%
MF5L@V?D,3(;R(F8W-MAR97J?#4B-QL\9O6SN!<8AD%)960$R:H/&I4`+Y2PZ
M#KIN8AY>4GFGD./PK:<;%M-;<7ZK?@7-F!V%J9SM`KUJ08S4XBC:IM@DW3=8
M\MS:1EZQ8)=J)5$O,AG29=VQATT"J;N-WIAU*MM%+)GJ3"_W-O=8"UT)5,"-
M+!0:FTC4"R..+):FQE'5T;6P#!'VG<2Q]A9,&_>GL)ATJ6A92KB/':^,D<,N
M*?`NL5-:FRH;:A/&17E:3ID=#HP3"NFCW0J@I&LHMNFFB03;I^600,!@`=`0
M&6@W'IM%34HM*MUOX42:WVC=&;"Q6>]7?CC87+A09FX0L)*+2,E*X>EMTWLF
MV9&5=QL@H[=[&04!,HM"QFHW&LWJM0MRID[$6FL6./;RL-8("1;RD-*1JY0%
M)XQ?MC'1<$$GB`#W%-N40`P"&A*G?E7*L<4D^X#`3S`/VB)"@($$@'$=NTYN
M_<"^X!U*?@6KHZ;T!DG`JE.55,"@EVF*)!W%7??S-]]NW]FMUCQXZUK^1QJ,
M_4Y-KCQI3X^)O`BW>F8QR"4$Q*H`$V$Q]^ABCO\`"'[-9=.A4KE55KC37XLY
M]0V-`-`-`-`:".P"/N#?0+5T/C%X(.$$/).(+IJG!7<O83RPW`IO;N?V:W&'
M*VYUV:T\3CNS].]&S2KDGKT5"&N?<H,4LW\8>.R^,*?D@^;;-?Y^V-[FP9S"
M-,QMC&ENG$Q>(F/=L7S%U,M;O9("+*+@H%*A)*B4=P*`\"O1E)0ZL[/H3]%7
MUMU5/+\*]27B4(T!5D[7:LEGT<DY08O!:(_,L$79$$7"+!P)/.:)JH-DR'\L
M2^8"90-OVAMRU.&A!GE7P08\HKMQZEW62DL?T;`%V2R+#TZOXNHS^R)WIN]!
M=M<L?Y0?))VS$-K;L%7#4KZ&`%.UR=3;S-AT#39/LR/<8#&'J`=NX=!$!$@F
M#?V%-V=2^`Z5%"L3U+*!3\D&X$4#(%>B[=3+-Z@V-&<[79AOY\9*M?Y)<BGI
M$'C?N`%"HNT$U2;"`@HF4?$--R/I\SU'IVE6^R^9;#YERHTAO4"Y,PD2W<.7
M#E&-A8QY56<;%,R+J*`W81S5,"(HD[4R`'0/'1A=:>)8P`;!MN(^/41W'J.^
MH:-=`-`-`5:^B;^E-P?_`"79??\`.ZKW,P\J+2M0T-`-`-`-`80Y!X#I7);%
MEJP[D5682IUP+7@E%*Z_)%S:9ZS;8"ZQAF;]1J\22(,U6VWFE,D?N2[R@)1.
M(A2-5,1<F..E3OB&3LKJ4O(F2LAO.+V3>/3#']!O,=0Y"V5*]3$';9&*K5@E
M;%0VM9NSV=J[0K.36L<4@U*`E,LF(@J01D<L0\"[7.8@P38KWF+/G'GD?7,!
M8PPEE.X8-R955K5D^I8F;RC7&J&89:[T3)D-*WBN-;!)/)$8A55HC.S4FFG(
MRC8K1WIL$JKXED]%HD!CFEU>@5<C]*N4^%CH"%3E9>5GY(L?&-R-VXO9J;>/
MY>2>F*0#*.'*ZRRAA$3&'?4+30]6BB"1UC]!%8X',/M'8H%`!';<=OIV]P!H
M4Y]`;#D*<-C@!B]=RCX&W`2B!@\#%$HB`@.X#H"LO)6#<L<17-]S?PQ"D*8^
M=M;!>\L<6KY)2]:QPN]C6#J7EKIAV;@8F?6QQ9GB+=51U$I1YXB6=F*819B)
MSC2$X<&Y(B<T8=Q/FB`C)&&@\OXSHF4H:)EU$596,C<AU>)MK..DC-G+MK]H
M,FTH1)8$5#H^84>PPEZZ!&5M0HT`T`T`T`T`T!H8=BB(^``(C^X-1["M-3SS
M^7C8IB\EY%R@TCV:1UE'JZZ*#=JV(F)G#A9PJH5)%%``$3&$0#IHKG_:2^&I
MO#Q;N?EJW;BY7)O[4DVW\$E5D,,/S&/<ZY^><D*!DK'V5*I3\9+8<J[NDRI9
MV0KU@EK&6QY00?KM@%FDG*-X*NB0A5#*B=J<!*`=G=YN-*U=R7=MSC*'%)4?
M7J?:]XP+G;^TQQLFQ<M79W7<BY*B<=(Z>/W)KZ:D\0ZAO[_?T'^C7IGPXT`T
M!7ASX_\`K'TZ_P#J'XT_X$<CM5$?\3A].S_X;F]_U%>4_P!ZUG1DCU^98KJ&
MAH!H!H"K7T3?TIN#_P"2[+[_`)W5>YF'E1:5J&AH!H!H!H!H#@4035$?,*0Y
M3$,F(&(!A$AOK$,)MRF3-MOL("&X:$ZF],@D+L)S''VF,(;FV`"@.Q2E*7<`
M\```WT*<F@&@&@&@,29^#?!.:MNA@Q)DCM-L`B41ILR&X:$>QB'T_P#_`-!W
M";V?_B-QNZ>P/^YNF:!;?0ESH4XEE01)WF*<X=Q2[)E[C!W#MN(;A\(>T=5*
MIF4N*K1OY'&J[11+W*"($#^+X>WV!XB8`ZB.WTZ*,FZ).IND5'DY12^+H=(E
M:HQ111(X.6ZB92&['"1$S'\P=B`F'FFWW'V]`_;L`ZYKF/.VJIJ2_P"77\3@
MQ[WKU]2,K$4]'=^Q2ZOBWYJ=:;57B?2XGV+9:/0.5P)Y%?Y=`2)E$I#]G?NK
MW'*8I1#H&P&$?9TZZS;M2N0E--)1772OR\3EO<[5R-M0E<<GJX+DHK_5.GEB
M^C?4^IM*-72GEHB8QMS@/U-BB0_EF`VQQ$![MNGCU#7!<<K<E&49?=\/VT'*
M#N.U"49M*K<75?+YK9^#.QUHIL4W\M3;Q[#[;CL&_:.VX[#MUT9)>5_(B-RS
MQ3?,S<:\O8PIKR+3L-UI;^'A%)60DHY#YY51%=-)>0BFYW+$!,AV%.1,XB(A
MN`!N(<5ZV[F/.S'^JX-*NU6O'_@?8_V][MVWLWNOM?>.YJ<NV8_/UXQ47*7)
M-1XJ347OKR:TV(A*Y\J7&.1Y4\^N5$5,<8<%HXQPU16,!E0]/)?%IG&C_)\N
MZ<Q-;H]FNL0Y&WAD=FRC$$Y(7[I=JX%5NU23(JIY.#A96-.-S(XNEM1=&VZJ
M4VFOI)+\>B1[7N/N.#>]K=L[%BW/4[EC9.7<OW%_3E"]Z"MJ$])2<96I\DXI
M*L>+DZDO>%_.3CGS]PNSSYQDN)[KCMQ8)ZK.G;EF$1*P\]7716KZ.FH9TN+V
M.66*H19OWEV6;J$4*/:8!'VZ'YJR7F@.,%2B;M$#%$3&*7N*/Q@0`$Q@VWV*
M`CMUVW$/HTH2I6]ZBD_`UB:]/^PV:;B*W7X3U`<=24S/3\DSAX:)8(8'Y'&5
M>2<G(+-V;!J0/%54Y$R^TP:J#-_IR2#)Y'\UW3%RB_;.O4/Y0.&R[%5)T@N@
MZ>U1VT6361.9$R+MHN15(_=VJ)'*8HB4P"(BTK\RR$!`0W#^L!^D.FX=!U#1
MKH!H!H"K7T3?TIN#_P"2[+[_`)W5>YF'E1:5J&AH!H!H!H!H!H!H!H!H!H#:
M8P%VW_B-VAT$>H@(]=O`.F@,19_62)@K-)3J%*8<29*,!1'XA*G39D3F`GUS
M%*'CL`Z$Z&(_3^.4>"'"=/</,+Q%XV&,3<.XH&PW30`1`-_$2CJL+9?(EUOX
MA[O\NFH4XEU`23$XE[@W`-MA-XCL'0.H]=54KJ:C&4W2&YTLPZ:H1Z@.$/,W
M()_+%!95(I4E"=QU2(@"ADB&$.XH?$8`';5Y3A647JOB=:]<Q$E'(3=C>BC5
MZ?#YD%,H9)SI9\Y/<)<>8?#$39*7CFH9*MUCS5&WF2@I&%R%8;E6J["5EE0Y
MR`?(/XI?'[E9\LY.LFJ@Z033*4Q%#&\Q]PNXV3Z=R246EKK+1NG1I+7QZ4/T
MCM79>Q/LO^Z^^8Y-['E<G;Q_TTK$IQG'B[WJ1O0E1.,X<'&E9*57H1,F?4T@
M8]2NV:<@XNIQ\]Q,>9YK44[C[A87;O)<':K#4G-)<N*M&23-K6S_`&(55-\N
M5L/]KVBKL40UY^3[ELXSM0N?;;O67<3I)O=T6E=73PZ[GZ1A?V$]R9W=<+MV
M+*,,R7?X866X7[-OGCSLV[D&I7.*E**GY-4J5XEI&&;J2[XXQA?)!BVA)B]8
MTHEYE(F/'NBF3VW5V*L$BT9.UCF%T*+Y\9,@[]QTR@.O:[=FSS\&&3<HW*"T
M>ZK&+_*M/FC\,]S]MP/;7NCN'MBPG&>)G9%OE15FK=Z=M*4E1/EQJZ+?4S8W
M>(.2$41,)DU""H4XAVE`G>)"B81V[1.)1V`>H;=0`>FN<\DW`X042*<I]R*)
M]Y!$!+W%-N`;`<"["/N'0;Z>)\A%$>T"I`!R;;@4X`)1#V"0"[@;XNG3?KK5
M%)ZU3)*W=QDE'8K-]3_TM,*>J;@-+#>8)JV4^1K;^0LF-KK3Y==NZJEO<(+-
M4I"4AEQ/%VN(5;'\I9F\3.4I!W1%,X`8)*"3W=1&YDW(\9M\?G_B?E-X8\:^
M=7^&3Y9-9W,CLW('TVL_+0]2S)E/%45.KUS$UD5=M6T-DJXU-\BZ>TQ2JJ&.
M@^=@<6KV.'S#*D\HA-*F4G%_`_>[!6*#LT'#V6O2K&:KU@BV4W!S4:Y2=QLK
M#R+1-]'R;!VB<Z3ID]9K$534((E,0P#J4-D';_RTO%OND[B/AYCI#,%U@7)6
M-RRU:5'L+QQQ:_$H?,LYRW-!%_D&Q,FZI3GAJ]N<IR'36>)*D.D6D1\,+P)B
M+M8:_?N6N2K7RBM$*]1LD72;4HE$\?ZC;44#-VDS3,-,"A6T7L0R.+9F]>E=
M/"I]ZASBJNJ8P$]F42RC2*)1K)E'(K*&6508-&[1(RQR)I&7,5LFEW.!23*7
MO'J(%`/``T!V1`[2@7J.P;;B.X[!X;C[1VU"F[0#0#0%6OHF_I3<'_R79??\
M[JO<S#RHM*U#0T`T`T`T`T`T`T`T!P*N4D3D(H82F.`]GPB(&$/X0$`V[A]@
M>.L2N1C)1>[)552ZLZU">C7`.Q244$&1DBN.Y!4O:*P#V=O<4.\-P$!$-P`0
MZZ[/H7*1>E))TU70XKM^%F[=LW.2G9:4M'3[E54>S^A"'F;ZE_"3@36D[+R=
MSU4<?R#EBHZ@*4DX^WLE69-11-$OX8H$29S89D3*[!N1`2!XB8`ZZX:JKCU1
MV;EN5MTE_P`/QV,<\6N1V8?4*QY=KLKQVL7'7C%D*D6*M8MLF87/V=G7(#>P
MQ<A"C>$,8LR.VE1I#AJ[\]F22=HR#L0(;R2ICW:O4XSX,9Y=O'`Z@X\P?R=Q
MZJTP7B:B4/%E"Y3XW,_ME#_"%$JL/4X>4SM#@S;V/$TRLTA/F9!^HV5K2*S@
MB"+U0XAN28V++*]:JU;86-L56GHBR0,P@BYBYF#D&LI&OVSA/S$5VSQDJL@J
MFH3KN!M0IVSC99'X%>S82G`X>`]H[[;CT`!'IUUJ+HZM5,RY./VNC_;3ZE2G
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MC\:U&?\`W(]XY=^.=>R9WLC&S_U]J,N-)Y2C&$>3:^V,8PBM$](KKJ9VQ]C=
MA0*C2*>R:]D-0JE6JG%J/W@23X(^K1$=#L%G;GRVZ3QZ9G'$%PL*28J*`8P%
M#?;7>A8LXR]+%_II46E--J?DCY+N.=D]_P`^[W[O24^\9%V<YJM8J5R<KDIQ
M>FO.3HJ;%7G-?)U7A^4JE+Y(<Q\L<(,!1>%,?VC#-NQC?HC$;;+F5+#=<I,<
MTU^;LDY5;<SMYL?UFO4YRDS13:*1GVZ=0YE0>$\O1U7\3!N9<X^H,VMDVAQP
MM-:N$1&^E:EE^SRG(VMY(P?/%R#^,LI1S+(M5Q_4Z1<7$1EIY"P3?SXB24;H
MI@BV[0`#GVI-?R)Z8#YF5)!QPZX\Y.8YD2S7GKCWC^WP-]G\27%'&=ZM[3"H
M9(O<8;+"<0C139`:Q4'(2+Z+!9-PCMU(`G*&M.E-"QO7)45WP_;7]M"Q@_?V
MAVD*<?:!C`7VA[=9C3^82<E_3U/"Y"_`C>@W=UDU&O.,=,JQ-N[VG:VK>0K?
MX/CHU=U/FFF+U%PU=1B$:@H=8BA%"B4!T_<-=WN56X&XRS/)+%5<L\Y><H8*
MXKNW+AQQ^XGXLLSVEQKC$;EVY+#+Y<M(LE[?+1>1HY47:<`S6:M8ADLD1NY.
M!S`03K4M1H./:AB^EP..\=5:/IE&K<.$?7:Y!))LF4(B"JCHZ2)1.HH=V[=N
MU%E5C]YU%^]14YSG$1&CWQ`$"%`P]Q@*`";8`W$`ZCL'0-]0`3E*.PCMT$?V
M=/V^&K1M5)55X]6=,M88Q#YKS%50^3.B1?9NL;8SC;R@3V(/F[[]>W?;VZO!
MZ;:EQ_\`W.7+"M?_`"([IZ+;EN]-D?0QEF<@DFLV%82*[]GF(+)&Z"("!BJ$
M*8H@)?;JRA*#XRW)CR63863:_I.N^CT=-GJ?5\VCYH([G\P=@`/+/MU\/BVV
MU.#I7H<?K0Y\->7R9SE.4P"(;[%$0'<!#J7Q\=9.9Q:=&5;^B;^E-P?_`"79
M??\`.ZKW,0\J+2M0T-`-`-`-`-`-`-`-`=3*BH)2D2/Y:AB*F*80#;9(@J'`
M#["*(G(`AW;&V]VCM\X\OYDTOQ-V;D5D1M3CRC/2E:*O1NGAO3J5C8OY,Y7M
MMPPY9Y9Q2%,6<ELJ9AP_6:&Q@7B-HQF[Q,TRDF,_)Y(5L;F/O32R?RF<B+-.
M%C3MU9),@+G%L<R_S$>\WK>0[,N/I6[SM_\`553=6_AQT2\=S]M]R^Q.T]MP
M.Y=MMNY/+[+@XMZ<VZ1RGESQG16UKCNS'(:UE<=SC5\.5%![&?\`A].)#[U`
M[ESAS`_N&<DXME3C8APYEF;D+Q5Z98(N%:M)&W622LJ\M)VU\659F<1<>N8&
M$<)N[L4V2*E]?<M0A:C=C6LZ_D?A59XMV78I2=R&+JIMK[O4^]KBDDN+=$ZN
MJH]-C]$C1`S8ID0*4J1#%*@"*1$44FY$RD11*F"I_P"Z(4"B(%(`[!L4`#7`
M<AR.$Q6;+I&126\U)5,453CY"I3D,7RU1%,VR:@#L;X1Z#X#H4@//<!:75I-
MS?.*UPL?%K)BCS[4'\(",]AR<>J"*KMC;<$RKG\$$AIEX/FOQK05J466,=0C
MY,ZBHJ"4(WY1]1?)6`K%BSB[R+Q.UJ'+/DW>F&'>-\UCBR?:^"<FS4PHLVD,
MADMSF(F;AC)I4(Q,\B_CIFONET5O);M?M,ACKE`]3B/TI\2U3-,WG_-MLF>3
MN89R"L=4EK+?X"K0$9=ZI+QT5#D7RQ0ZM&1=)O-H;QB+ABHX(QCHY\T%G\VP
M7=,&KY($6NH)&2`A>P"]NY?@!/L*EU[$P[02'M2*``7X>@=.O4=`?5J%-BA`
M43.F;?M.42CL<Y!V$-AV.02G+]("`Z`K%]7GEQEC@-Z<G)CECB.-I4]D;$,3
M1I.K1=_CY.;I[I2SY1IE+D&TU$PLE6I)=LSB;(J*`(OD#"LF0YAV`Q#4R]"P
MJDR+Z<J=3GWR"";ZP5J$FI$&AS_+)/I2*9O7::(K&,Y%JFX7,"(=P;$#80#Q
MT*1\O7%!ED;/N/,YVC+^75HG%[QC.4[!S)UCV(Q5#W%@SDF'XT;R\5CUIFE*
M3D$)(P2#%.W)PTJW+\J]9KM%%VZH4ZDLO-3^+XRCV[`8`'<0[@[B]`W'X@\/
M?J%J5P\I327(+.6-^#L0N9C4GE=B^0G)EV95)NYE,(1MI>0-2Q\S`P$,[6R=
MD6`<I2GD@<&\=%=JGPO!+JZD+$F#!O'M6[)FT:L&+)!!JR9,D4FS1NS;(D0:
MM$6R294FS=JDF!4TT]B$*``'0-M`=AJ%&@.KETUUFGE-1V6%5$_\/]V10HJ?
M7$"_5_?KFL."G6?EHSJY<;L[2C9_J<E^">NYA?,>3X3$%-E+]8TI&4:L)*M5
MJ$KT2W35DK':;Q8(VJU&LQBB[QHQ9R$]99-LU3<O%&[-`RX'6632*<Y>K=EZ
M5)):RT^;KI^.U6?5]E[/<[_WNSA8#2R(6[T[G_+"%MW)3=:)J,(M\55NE%J?
M/A/-#+*)+.Q>PELHMXHD^VJ][QQ<T(%S8JK*OH2.L\(D\F*=,6>H2R<S5)ME
M()J1\D[*DDY*DN*3@BJ1+9R(7K-8QI1T=6</=?;^5A78Y]IQEVR_#E;E'RR4
M6X3:4FIJDXM?<E6E5549GE)05#")5.XNV_U0#;J/7J`".N5IQ56CQ>=JY'[/
M-]3F("G8;O'<^YNT=B]`_AZ!TU&XO5;''%3H^6]2KKT3?TIN#_Y+LOO^=T>Y
M8>5%I6H:&@&@&@&@&@&@&@-ICE*(`8=M]@#H/41WV#?;;V#H#P.1;;`T>M35
MNL[A-E7JU"O9Z7D%3B!6;*.+YZJB:9`!59P?M`B1`,7N4,`=-]]<-ZYZ:K5)
M+6IVL3%NYMZ&-&$I0E)4HTON6L5NOFWX+9D.\2<4:W^(\?91;73(ZN/:X]L&
M5<1X$L\768AOB:UY=CI9Y:9"1G&+$;Y.2RGXXF^]A*RK]DU7?G(F79JU%+S+
M>#;=WU82;;ES>BI5II/QVD]-OP/O.\>\NY9.%E=HR(6XW,VU"SEWE5N_&Q.W
M*TN/EM\':MJMM1;2?+S.LZ8ANJU.Z35^,QA3-YP`8H*;%$@`(&54^(`+N(AM
MOON/41U[LY-QC%[+8_-4ZW).?W7W1N2T3Z))=*+0[O7&<@T`T!6YR88MEO4!
M],]55JW5505YD"V55;H*+-0+A&$[3('4(<Q3@M\0"`@/7Z0&]#+W2+'4R'#M
M,82!\([D*0"AON'8.XB8P"5,-AZ[;ZA4<VA1H!X=1T!1/_B7!`WHB\ZBEW$0
MJV)3]`$0[1S_`(JV$!VV$-BC]`:IE_Q+G,9*D#&N/1$VP?@>H^("'UH"/[=]
MPZ`/]>A5L>T<.FS1!9T[<(M6K=,RSARY4(@W02*`B=15=42))ID`-Q$1``]N
MH4KYY%>I+Q9PS5+,G7,M8_RME=./=1U.Q50;(G<)"PW1^`1]<K<^_IZ<XQH\
M>_F5T4W,C++,FL>B855E2)@(ZI'IJ>EX88&R%BV(MV0>0=\A,K\ELL2;"0OU
M_@X<(&(:U&$8IQV/Z+7XTHKILHVLU])('A$%!2?2AUW9OC5WU6I;LXH7[,WQ
MA).2)S]P``;CMT#WAKCY1.=)O8T*H0XB!3`(AOOX]-O'^O533V(;C&`H;F'8
M/?HVEN-CJ)%V9%'SVY!54[R$*4!*7=(QP!4^YP[0`I-Q]X^S7+8@FVYND-Z_
MN.OD3G%1>.G.]X+PKJ]?!$0.4],6R=17]$J<A`?CD+=BS*U8@9664BU+DIAC
M)-0OBE?%VF5PK`L9=6,3CS22C=R@S4>D441.!?+4Z&;<NSA%6J-VW%M;/22:
M5?C\4T?<^P^Y6?;W>+ONE<IX4K5RQ?G%5C9_56+EBWSKNVI2DHI)M1>O5;N.
M.,,F0T[FC,>3*O#TZ[YNO$#<%:!!VE.Y-:>A6,>57&#9K^."1%=0L"DPRJ))
M+;[-;_*?,_+B)_*[Q\[MT<ZRI6;ENEN<N55)-*J\=^G@=[W;[@Q9]HQ/;_:;
MDK^-@VIP4W!6^?.[*]7@^37%SDJN;Y4JJ(EW'M5FI.TR1NY10_F&W``(F)NX
MNX=P]P@/B(>.OH;D^6G1(_.L*Q&U;E*;I<JW3Z_@=FD)Q3/W)B00,<"E$P#W
M%#ZI@$/`#:X4J(Y5.4ON:HTRKST3?TIN#_Y+LOO^=UI[DAY46E:AH:`:`:`:
M`:`XEET6Y#*+JD23('<<ZA@(0A0\3G,(@!"%]HCL`>W0'7M)V$D!CRL9B,>&
MEF"LI%%;/VJYI.+0,V(M)1Y4U3&>QZ1GB(&63[D@\XGQ?&7<#X+/;*M3HT)F
MWV6O5:$!=-J>5LLS'048#I<#"W;"_E'+5J5=;L-VD[NXVP[`.PZI/W%>F>*E
MR-Y%<H<9XSAXY&L\+*$G5,D9>N:ADR2V6[HR>!;*31Z<H(JMI_&KC[/!I9B!
ML.SA,"[@(CKH9=B=Z44G2VE5_/I\3TL#/6#RG"-;[T3\$UK\*_0LB:)^6*P=
MA2!W_!VB`@8@[F`=_K%^(P_"/@/4/'7/:A*/F1T[MWU75ZM'U%(!1,(?Q;?Y
MM=ER;5#@4:.IOUDT-`-`5U\D_P#U_P#II_3S(_X*0>KT,OS(L3`P&#<!WZB'
M[P\0_=J&C70#PZCH#YU73=-)951=)))%$ZRJRARD211(43'554.($(DF4!$P
MB(``!N/30E4S\J7K09VM//SB[F?B]@*TQ]5P7?92-QC%Y#2QY8LKW/EGF"BW
M>$M-CQYQNHE8`)R;Q_C!*I.5[#<&Q3,_M%L5F@<Q"KF%U%"SG#6`?4.S+B#&
MLKGGE@MQP5EZ#536#"''[&U8;S]17+&MDE8HV8[*Y>6(9-FW("9SIM2D*IW=
M!$H!H#*9?2NXJ3CHLEEICE?D)-D,50\WG?,E\NCF1=)_W;N0;-)2%CUCH@78
MH&;]A?`"[:H)4,N,F!(>BV#',)AS'T!2[17)6FV"$KE3AH<\O6["R6AY:/?2
M$>V0E%0<,71R*JF6,H8OQ`("&F^@/R+M>=F5O\.ISC@^&/+"U7S.GIX9ZBHW
M(>)LTVEP[G;OAN<L;Q1ID0`=*%=R,Q38NU)K&7B#J"X:M#%=(@!#B72C6DFM
M3EN9]BY6,+;C-4IM67C_`)[UT/V5X^R+0<M4:L9&QG:H2]46WQ#&;K-HK,BA
M)1$Q%/FY'#5TT=MU#D$#I*!N4=CD,/:8`,`AHHM=#AB[=Y5C))'MB&`A.\P=
MH;?"&VPCTW#]X[:D8?=I6IJ;A".C-"KD5#8-@,/U2CMN8``!W`/WZL[>FNQQ
MV[L)NCT9'?D/FZJ<<L=SN4[LK++,V+R/C86`KT<K.6>U3<NY(SCJM4ZZB!W%
M@L\JL(@U:IAW&[1'IMK-V[&W:^[RJ/[?4]3MN+;[AFP[19NV\25^:<KU[6$5
M'=Z:J--TOP(2H6?),>T_F@I#)->5/+0Q*_@^G/VQ'7\I,8L@!\$K,1JYNTK:
M'K8!.S@`!3+/E$&)A\TB0#Y%/4EZE:2;XK6J2EY6Z>&K?X'[K;[3[9[I<M8=
MN+E[#]M6Y/-R[;X0S+U]UC26E7*:C9M<TY)*3BJ-EH%&@5JO3ZW77,O)3[J%
MAF$<[G)A4J\I+NVK<B3F2?JD`"'<O%RF4-MTW-TUZ=GEZ24_,E0_!NX94LW,
MN94N%9R;^U<8TZ42VT/5ZY3IC0%6OHF_I3<'_P`EV7W_`#NJ]S,/*BTK4-#0
M#0#0#0#0'B,C,%Y*AWEDV9J/W#ZEVA@@R;HF6=/E7<(^138H$(50YSN53%*4
M`*(F,(``#OJD91?Z>_'SF/C7+7IR3?(&R-[G4*?Z7M[QZQAHSCK-8>D>/E@>
M*<,#L\59-LSO(-Z):+N[CZFX013<LX%P=6!D%0;;]R2#0RDU2O@>JRCEZK\J
M)[C;GO*W%K+LYQNPODCF]@7D1@>P8>#E)-0>:ZA8JACJ@34WA'"33-I+PR1F
M:-/K1D^S8R+>(0>`95PU^=*"@NY;CQWBHB(PMCN.@,;6S$-?;UY(T%C6\2GV
MM:*?$N';Q>/AI=<]AM*[9=)HH10C-1Z<T<BH1H)$3(&02"E3-8``>`:A4J&N
MA1H#:<Y$P`3F*0!,4@"80`!,<P$(4!'^(QC``![1'0&H&*/@(#U$.@^THB`A
M]("&@*J.8^4J/0^</`NR6&8,6%QC$<HK'DU[#Q\C9!QK5;ICB.IE6N5^:5]M
M(O:E39JWLU(M&5?)H,!?$%$50.`@%1E^9$[\4<C,!YT8KR.',RXTR>S9J`BZ
M<4BY05B*V5W$G8X)'/5U&ZO?N`E,`"`]!ZZ,T9IW_P`_34!T%GM%<IU:G+?:
MIN+K]6KD2^G)^?F'K=A$1$-'-U'4A)2+YRHFW;,F;9(QU#F,``4HZ?,'Y[>4
MO.%7EQ5XNH8YKV6:_P`8KM/$IT'$1<'8*5GCGW?%0<G;85P9$O48R>J.!WD8
M5"3L^1E.V."#6`K90$C*N4:3]Q8KPNX5J8>7+F?,S2J27(:6KD=4(F%I<:1I
MBWC3B]DV:A#X$P#'*M4&L=3X=LDF23EDD&KNPO""NX*0"HH(OB&6,[]H"(@;
MIX"`=PB`^P`(`CL`C[M0IOT`T!2QZOWI54?U:L$5##D_;4,<WG'638.[TZ_J
ML/M.2A89R(,;["-VI%//.I9X4A02$W]F11%(>@`;?FNVYP@I+5/KT.Q#,QLN
MY*QZ,HRC%<M%5*OV]=$UU>_B>IPZ?$7IRXQAN&G%/CWEK)5,XX4N'FLCO:U9
M:(Q&F-[1'O9H+1:'.2+O5GE@EK8QAW<@HE"IO$6PI>48J2IB$-X>3G_IGQ;B
M]=:RC'5INGW-5?&K25=C[GVY_;6UWG&L9^5GV,/$S+\[6.[GK2]>]%QC.$':
MMS58RE&+<J;II4)DRG,CC9!5NAS,QEZJLE\AT6K9&J,"^<+$M\S3K@P;O8"9
M;4_M_$14)`K@A2E.@!RJ[IF`#@(:YGG6)687(S3A**::KJFJIT6M&CRX^R>]
M6^ZY7:KN/)7L3(NV9\I145.U-PE'FZ*7%IJJWW,>S?/O%40+4L5CGE#?UWW<
MG'(XVXIY]MC5P<NP$55G8S'[BO1C=;Q!9T\12$!W`=M6SE<G]O)KY/\`B<?=
M?:F3VR'+)E9@Z5_J0EXZ?:VZ]-BN'.7,*;JV=X_ESRKXL<GZ+Q*X^UL#8DG)
M*E1B[*L9,LS88^<ON2:)&VES?E9U<APBX%PG#NHF+24,Z=KM%MC:]!QMW%&;
M3=56BIH_B?%Y6-.-I=_P)R5["4K%RS-IRO.\]+EFW6LX0C]LY;J6M$B=O$RL
MW#(LU,\WLF1[@EMS="1Z.'*EYI'C?$?'5-47]0A6@IG,Q3L.3&QD)Z=63[1$
M#M&QQ[V@`/'9QH\FW12>GA1+HSTX=ZN9G9<?A'*L68<I7K#E*#NSE)J$W;KP
MF[:VY?=%2;C2K+&X\ATVB1#@(&#N^$0,':43F$I?BV-L4!]NN67&OV>4X9.X
MW6[PY_\`+HOV\?B?;K')+=HR-6H*M?1-_2FX/_DNR^_YW5>YF'E1:5J&AH!H
M!H!H!H!H#Y7!C%^J50XB42B4A>[QZEW*8Q""!Q#M$=]PW]FXCJD9AC!''_'/
M'RO3L%C]K9%U+19'UKM5HO5QM>1[]:YMZ1)!-S9\@7R7G[G8DH:-01CXU-Z\
M6)'1K9%HW`B"1"`82H9QU"F@B!0$QA`I2@(F,(@```!N(B(]```T!KOH#3<-
M]MPW]V_7^C0$5>8'**`XC8H/E:S5.PV6*))#"D>,%4HRH5Z9?QD@:N.\H6Q0
MC[\!428GD6\8O.G82#:+7>I+.4TVQ55TQ&4F94Y6\Y.6C*G4C&E9<P^#<]VJ
MRX_@,E<>YB?1R11`?R":J3'.#&)G(RVX7R5@*Q0?V>]<M9]&OVI",GTR.&ZB
MT6@:UZBA=AQ8XMT[C%4[!7XQZM<KI?)I6XY4RA8*]66%WR=:G""+,9JZSD!#
MQ[JXOF:2(H-WLTM(3(MNT'+QP8!4$*'L,E\8<!9D7;R.0L24N<G&*1D(NTK0
M;1C=(+??9>N6^+^6L%?=%W^%9HX24#V#I\!N8:)Q)OU'0!#"G+7D%0XU`#N6
MU8NTG6,\PKB0/W@DC+6+,M<N>330Y5%`V;LYQIV``=IBAN`@05Y=8,]1C)[B
M@5R^P6%^36)8A<CU3'.-WMCP57+=EX[W>A6CD%7[7.W^0M6!:$<GSLO"1LRD
M:4=IE[V:R)B(HSIL&3/XK<+W&%;0_P`S9MR5,<C>3-@BDZTME.?@X>$AL?4U
M4&CQSC+$-0B&D?#T.AL9,5?+%%,S]\U20*]<.%$BZHH3^U"C0#0#0'2EBVR4
MB=^(%\Y4$REV`G3RBB4!'X`,'0??KE5R4[*MKRQ;?XF()6LBY>5:WHQB_P#T
MD$<M<:<T/<F94O.&,CXUK;#.=%K--R?"Y+Q]9;N],C5F,Q7XY2B2=:N]++7U
M',%/.16&00E2B\*D<I2I`=(_A=U[5^L@G!I-34G553I%Q5'\F?HOM[W=;Q.T
M=J[1F0G*WVON-W)@XSHZ790G*JDWKRA&E*:56]&2CQ?BFL8YQQCO&T:W6DF6
M.*+4*+&2<TU8K3;N(IT(RA(YQ(.D6B#8[U;Y$%502(DGW&'M3(&Q==K%P%AV
M+=F+K"$(Q5=Z))*NA\[WGW3G=Z[YF]UOMQO965>O24:\5*[-RE35Z:Z5;=*-
MNIE%%N1FB`-T@2,(!N0J*1``=MAW!$-PZA[]=^$$WN>%E9-VZJRJW\:LZ&PU
M2"ML#*0-I@HZT0<ZV4835>L3!"7AYA@L8HN(]ZP?%5;N62_:`@FL!T2[?4UI
M_;+1G!"K@N7FH0<H$&IP?ORU$<OUQXE9:M9U,8K.3OWA>/&3+*Z,M(8Z?/W9
ME2L\1W696,M7U#"FE"2BBC,0%N[0,UY8IWHM159K7YF]2PQ%R15-,_:<@G*4
M>P_;WEW#<"F$IC%,;;V@(@/B`B&NG*["-UVF_N1IHY^\@@`]Q=C;;#N'7?H&
MW7KN.M/ANZ$J:%43,05"G(9,.[<Y3%$GPB(&^(![?A$!W]VVB<6JJG$%7'HF
M_I3<'_R79??\[K;W,P\J+2M0T-`-`-`-`-`-`-`-`-`?.NFHIV@4VP`8HB4`
M+N;90FX;F`0[13[@$/$0'IHB,J#]6QERX/@H_P#*%3$KG#07KC(KDE@O#90>
M9[</2<J\3JR"N-W54DTJPC$-H?RCN32#98P(%="H();;70CVT,$^JMR#SKFO
MC?RDPKP2A^1D%R1XU<C>,=<RRTJD0]JLS(8JNDU%W.W6*FR+24.:T8UL.-`>
MB^63\KS4B*IG2'80$&3+X2P7"6UUW,T%P]J4NXP!-(5J*L4"Z@+0PXXSE@>,
MK*WL#.B5>ZMT$U;2:.4;%MIDF::3A$T6!SJ&3`"/F%3^78S_`,8N%_'?B*UG
M6N#L>,JB[LZ:2<_-&=/I6:E(MG*S$G`5QQ+R2RSP\!3OMM=K$M1$09L1(D`B
M!=]"HEAJ%&@&@&@&@&@&@&@&@.@?2)DEW"!4%#&333,50$E!#<Y0'X3`';N'
MMUS0MJ,(RKHVSKSDYQO+K:@I+XU\/'Z'V-DCJJ"N<3!NF4`W\0,'7<`$-P\=
M8<TEP\'4YN+4^:VE;2.PV*4/#Z1`.HC[1'8/$=9;;"I%&S<!$=A.'L\!UPRN
M./0Y%)/2ARAX:URK#D3J>*NM4KE]@9NGW""CK%4YQ@>/L$+,-2N8^59J@`@W
M.!MPW3.`#X`)#"!BCW`&W/C7'"DX.ERNE.GB6,:R*K:]ZDR#*BYABY*@P](R
M3BSD9(83QG5)U:2;P.7L90_(RM8+_F#47@?"#ADA)/FSA@#@'19>'<G(@9F4
M#:]]>WOU.3"\FIQN6^4I)IN$O3E/C+K6BJG2CBUK4X;DZ3<:T:?X['>H>I##
M*W_^39VE:4RJ'/-WQ;&JD:VYJNEC,+,[BBY%^V2L0@3V12);E7%L5P"(GW`$
MP^KKCR/;]V&+'):IC3Q5=Y<H[M5XI;G'S5>-=>5"UM%,Q&:B1C;&,53M,.P"
M/<0`[@*4`'J8?;\0C].OG86(VT[:;<6W^9RQY<77<K%]$W]*;@_^2[+[_G=<
MCW+#RHM*U#0T`T`T`T`T`T`T`T`T`T!P+F`@%-X"`CU`-S`40V,/;L)C%+N`
MB`>[W!H1D=\9<=*MC_,N8,ZEM60+;>,PFC&SW\7S<<ZAJ;68<`-'4RFQ<-`5
M[R*^V=]SA(98TK)-Q5,DD[*V'R0K"WJ2/U"C0#0#0#0#0#0#0#0#0#0#0#0#
M0#0&GCK,H\E0'Q.?,[#F2V*<A3]G>()E%4``$S&,8-A3`3?TZMA)?:RIT9#.
MU<',&W7&#'$]J@I2;@(7D:ZY25QS(3"J<[7\Q.,GSF6/Q%#2S-%0K</MZ??(
M%2.D<OV:Z40$H&,"A?1Q^[7[7<)7[<N,E95O1:<7#@U1TZ?@_P`^.Y'E*LEH
MW7ZH]*[XL8W;12J35K;9$K3DFZY=M&*5C:-7K_+YY=S9BQJ*[AHW:(U9Q)*B
MF1FX,F`%,`'7`H"?7!D9LKMR$;M.4;:MJBVBE1?-F.+KM]O*N_4AYQ=I')&N
MS_)2^W[B5:L1+V6J7]U3,21')6I9'H^2I@TBK)U]*:G)+(,Q)53*-T%Q\J0S
M=.+K->:F7*#IP*R9T?8[AF6[_H*-Y7'!1K+TU%QITHHI24==75R>^QR0=+;3
M5-^O\3VGHK>5_P`JWA)Y'D>5_)EEV?+?.>1V_;T[_=_:'^^]O_O/BU\^]Q#R
MHM$U#0T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`
MT`UGJ#BZ>8/AOT]^_A_LZX/_`#.F^GS_`,"]#4?KAX;_`+]_;X;=-67FU\0<
*FN=5IUK]"'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g21538g46m25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21538g46m25.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-=6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YL<&%V86QA;6%N:3PO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\
M+V1C.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2`R,34S.%]%6$)?0U927R!%>&5C=71I;VXN9&]C/"]R9&8Z;&D^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V54
M97)M<SX*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G
M951E<FUS/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@
M("`@27!T8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O
M<F4Z0VE!9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX]
M(B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM
M<$-O<F4Z0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K
M/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T
M>&UP0V]R93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H\/WAP86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`IP'T
M`P$1``(1`0,1`?_$`*$``0`"`04!`0`````````````("0<"`P0%!@$*`0$!
M`0```````````````````0(0```&`@(!`P(#!00&!@0/``$"`P0%!@`'$0@2
M(3$3%`E!(A5183(C%G&!0A>1H;$S&`I28B2W>#G!4R4X\-'A<I)S5'0V=BBX
M&7FY$0$``@,``@("`P`#`````````1$A,4%A<5&Q@9'!`C*A$D+_V@`,`P$`
M`A$#$0`_`/W\8&$)3<M<A]O)ZCDH>T1\G_EM.;9/:W,.W2H25;AI1I"2K9Q9
MSR13HV!NN](J+7Z?GZ8!.*@%`<J3.7S16\Z]OZA,]DU.O7""JLLN\4K;VX1D
M4Q_JNOH+"FRMM:6AIV>92-7GD/!RQ<_,0RK=0IC)D'DH"V;4Q\DR#Y"?DH#Y
MB'`FY#WX`"@'/]@9%:\!@,#C*E5`PF2.(&/XE`#A\A"CSP)REY*8H@7WX'C]
MH914S%]F]Q3GW6ZQH25I.]:7JDO6KL0Y9-)VJ5UCJ^YS-1V%UX)![>AYMI9G
MLA+ILFEGDXM4[AHW!JH_;D(B;ZE10IGJV=O\G"GGX>(JG%+Q*<H_&(\\G\S&
MY,8W(\AP'''ID:AR,!@,#I;"BW=0THS=(O7+9Y&R+9PUC3BG(.FZK)<B[=B<
MJB)R/5DS"5$2G((*"'!B^^!%#I="7>MT*R1-C2VM'4T+?(K:BKV\G:3_`&O7
M*&FTCVOZ-9GB<C,.%F;>917/'B\>.7?TJH>1P(!"%LI"9.13`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&DPB!3"'N!1$/[0#T_`<"HSO7HG6
M_8+L)UVK5V;PE[EUX78M/CM56K5/]2*5C7NUJ=8Z+LO;5#V6,28NL[_',U$6
M9Q_42(O&)"E,W,I\:@5E:73ZK'T6HU*D0)/&#IU;@*K$I*#RHG%UZ-:Q+'R,
M(B)CD9,R![^HX5ZK(I@,#KG3I%%!554QB$0*LJL)/D^4B#<HK*F`$"F,)@(7
MGP#U,'M[Y?:*H-`]TK#VF[6[/H6J+_%M*+J*3IDQ:*(ZUO<X2V.*V\'9E8L#
M2:GKO4X--6<=6*!B7S<(Q<Z2#$01!13A83U,3I;8EY_&3S+XG\0\B@//`_LY
M].1S+3<P&`P&!BB][EUIKRXZNUY<K8RKUTW9/3-5U-$/FDHI_6%I@:S+6^4A
MX]VS:JL4'K*L0KQZ9-PL@91NW4%,3"40"P,453MWUYO&S3:8@=DM%]J1T]>*
MNI3%8"WQHNI_7$1$S%X:0LM*5R/@+(VK<7.-5EG;!PY;""X`DH8_D`-89A*%
MF<#?(4JORAXHJ!R"O)063\@#A3@"D$H!XE``$/Q]1Q*N;D5Y]R^;,U62;UZV
M1%X\*T9D<N$D?J9`"GX;LBK*I&55\"F\4B^1S``B`>F7C**EZUWMV<[3T[8U
M26TG*ZYK&E[_`*]N4':96W*W\EHM2S67JX-8V)B'U;1JCMQ&E3D1>G!T=H)A
M1(<0\1?-+EVO6S7$7HN"L%#F9#7-=L5RNLS?D-94.15:4VI(249#1[F(UU`S
MA8^7_I@QHP[U4"-DD2OGBX)ID(!0P?26:9@,0A@#@!*`@'(#P`AZ!R'(#D5K
MP&`P/$WN]4_6E<E[K?K3!4^I0K4SN5L%CDF\;&1I$2&4$QEW)DT^3IE'@A1,
M<YO0"C[94E!(_<2TV.PPNRZ'U`VC?='HPTBQ_P`\$(Z&8[!>P,LNQ<'E=7ZA
MDBI;0OE#?'8MW*ZD>B!7Z0-G*)%4TQ.4)C:@W1K;=E50MFL[C#W"&,HLV=*,
M'A#2,/(-3'1?Q=@C#_&\AY1@\3.BL@J0IDCD$H^H8])'EELOJ(CR(\\>G^'V
M]R^GL.1IJP.MD5_IRD.)SHD!-<QW'D4&[<$P(K\KOR_@0*4@^2@\%(7GD?4,
M"`,[N[8G9^=?ZZZH2:E6UDR66BK[VP5CC/X@K\BYTI:JZ&8O"D:W.R-2IG2>
M37D,5$*_E\E%R>&5':GZE;:I40I':/[G;WK<PJERT?[D;U_L#7VJP#\RBH0D
MZC4%C*.U!,)B%>^AS^90*`<`/3N0E>]U$=NSN:GH_?5=:QC-TU_I^;G]4[,F
MY``.D[35B[*R6ULP^1),@IA^I@9,XB"@`7Q,(:2]RUZXG&L-X]<NPVGY-Z#A
M9\[+25=GT*$2:B40&=V?J\\_3(XB_D'@*C@`_;[#B"61*EV3UAO;5U]O76[8
M=5VVI5XF=;BWI\NV?.6EM:M7WTL8]2$2KL7:;J.4(1-5,I%S)&\1$`$<NDQS
M2%_VD7EGD-;[:EK9M)'?D_8MD)V*T[O3JDQ0E['?']3KI;M19"GR$O*QL8^U
M)-)'@1!@#9---H5)=('2:QC25A;AD4P&`P&`P&`P&`P&`P&`P-A3D#%X-ZCP
M(%$!-Z@8`]`#U`.#>H^N$4<;C[;=M*[9=D56MZ;V)_EBT[GZ?U\T[)L-L:0_
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M->G-EW)NH7\Q$RP%39R"YU3\<$*`_G'V#$#H![&=A[NM'HZGZA7U."EXIRX;
M7;=MIJ^IV\/()%1^D:V36DD\4VT@BY.OZJI1IB$!,X#^<`*+!X=6_I'W`+]#
MLG#OL!H[1EA;G.H\AM:ZND]KUZ1=H+"JUBG%@V&\J4TP17!(I'2B+,Z@$,?P
M`/RCBAZG3?9"7DKN?1_8"LEU-V`9D%TPBSO/J==[=ATB"A_6.FK0J":4LS<`
M45'D0J(2\<?DBZ)0X,(31R*8#`\W)3<;7V,G,3\FQB(6/3<.Y"5D%T(V.B6Z
M"8BHX>R#E1-$B0I^ORG$"EX\?4>,J?:&5`[F=2[GM!\2NV0T?<+G'QU>KEXM
M-?L=0I6X8>KOY#P:ZOOEH;1]4O#2NR<VY(H,>J8P.53IAY&$H`$[DQ`4R"'/
M`E`0\N>?;\>?7)*M>`P&`P(&]P=:[<ONXN@ECUM0!N-<TOVK=;2VM*_U76J\
M-6I+K0>ZM4?J#:.GGS-U8G:<UM!JX%NR*JN#9JL`!Y&(!JG6GJSH1W1K)>K7
M*ZQ?:QKZ-PF'.I]?6/83+9KJ@DG6+>.O\W59./DIUK5H?8+QBF\/$INS_&H8
M1,1$?Y8%3O3Y]>??TY'_``F$.0\@X#CR-QZ^^0;N!5?]T35EUV55=`3&OH*S
M3%KTMN=OO>O/*I%KS+^-G=8P[J809ECVYTR/']IC3/8IJDI^0SEZ7GU*&5%$
M2%N^Y#I[?W97?M*U?LO5J7:ZP=2MPWU\]JNU+`C!VYSKC8#-GJ59*E=6^RED
ME:M6XY%@TL+%C"Q'Z<^6\#R[0QR"8SF\+)+I4ZR\MUTC-G=;-AVC[@]JV;4+
MCJ3>]2TQ=)V-BJ^LM17D&_J'9%:!85;5&LZ<C&NF\I6967B7*Z;5WYQ;Q1X(
M.7&NK(WO:?9FNS/&6[NKNYX!C$Q0NWFS-3-([>5`<*$3,5RA'Q%/<)[E>/\`
MS2\P(6G"F)3@"9E!Y+@9*UIV]ZY;6DXZJU'<=-/?G<6C,FUG9G:M#VPE$G)Y
M?J3_`%7>$JWL.+:`(<&57C"%*("`@4?0%6?21QEA*47!E@*@!`5^0RJ)6H(I
M\G.J97P$2E$@\^0_E$H`/(<X,H7V3MF^N4S*Z^ZG59MOF[Q[UU&3=W4DS1&@
MM=NV9SMGI+3LUBWDVE@F8IP02N(6#+(2)%BB1<&H#YE$--5Z?L[!98S:':*V
MF[(;,AWC6<J\1/101>D]7R2"I7C1SK'49W\Q%MYJ$=<BSL$PI+SZ!_S(.40-
M\8"8MEW<NB*OO:(ATGLW;*;9:L[/)4C8]"G7E4O]%EU$P(62AUS$=1[ILH1(
MA'$9)LW4<]*7A=NH3\HC*L_:6J]KZAMZ>R=I&LT9,MC+QT7WBZJ5EX:[IQR[
MEBV81G;?K4V:S4)LJ-391[-L[L<4VD%A*5<[=M`(&\PN(2NI&Z\[M254A8-]
MV)"H2.O;`H+2J=O=(225TZXV=0'OT2+:ZHLW[^QZ3L*I@$SA*2*_@60@*9YL
M5OY(9X9G2:MKVWKNBZ\=;3MUYKD30&C%*2"UEE&SZ&D4)`WT\2E#N6GF:P/)
ME=9--@W8E.X?.5")(%5.<I34M"QC`[3[PII36U8FU:3ZD.%S.Z]J)^>0K.WM
M_0H>:,=+[L(V6:2FN-=3?!7:%41.A-/T%$B2IFW+B.%FUM8#5H2'K4)'5N"B
MH^!B(1BUC8VOQ#9JTB(=@T2*@T:1S-F@W0:-`1(`D3\"<!_A#"O1<!^P/P_U
M>W^C('`<B/`<C[CQZCQ[<C@:3F$I1$..?0`\AX*'(\<F'\`P(#[C*TT#V;UU
MV%BXQFTJF[EH#K_V$DF[9!LX0<K.'!-"WF<>%,1=4(*V/CP`&6'X&L;-N%A$
M!3#*DIZ)B(&%,PB<Y0*8QQX`#<E`I3@7DWCY``@/[P'T]<$-_(I@,!@,!@,!
M@,!@,!@,!@?!`!]P`>!`?4.?4!Y`?7\0$,"OJ!G'4]]P?L+HF:;5^0U)!=5.
MJ^[8ZBN:O6EH\-K6W=G9R)L-_7.$2:5D;"LQU;7RI*K*J%;JQR2B0$5Y,-M.
MI_-R^)1$W'R'\3*"`B("82A[";\_''X#[?AZ8GQH<C(I@,!@,!@,#PEHUEK>
MY3E2MENU_3+3:=?O7DG0K)/U>%F;#2I.29JQK^0J$T_9+R5:?OF#@Z"J[-5!
M0Z1S%,82B(81!!K2*!W?[![&D=IT:N;.T#UK?.],U&N72*B+AKK86ZD5D'NV
M;BM6'[B;@9+_`"ZD6[>MHI2;074=,1KQ9(P%5*.71U8C`UROU:,:PE9@H>NP
MS),B3.)@XQE$QK1),`*FFV8L$6[9`A"AP`%*``&17;?&G_ZLG_T"_P#6_=_U
MQ_TC^W`U#Z`/`>P>P<<_V!SZ8&$-YZ&UGV*I"E&V9#K2K%%XC)0,[$O9&`N5
M*M#`WRQ=MHMP@EVL[3[/$+@!DGC)9)00`2&$R9C$-4WM%^O[KVIU<L,7K/M4
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M'LKUF5:*Z+EW/8G3C=ZT_4M*[6M"Z&U*A!@8XO2ZEW!+N7Q+BK'M0`R$):0^
M1=0P^4Z@0I4L+EGW3'9/66]/U>'K<D]@[_6T2GNFJKBP=UC9U+(LJ9N12>IT
MB*$F6-7<I&3;2;4'$6]X`S9RJ4P82[QUG]%0JJ9%2&,8#@(AY!XF#DPB)#E]
M!*=/^$0$.0$./?$JZ2Q6>NU2*>SUHL,-6(2+3,XD9F>EHV'B&2"8`*J[V0DG
M#9LV02Y_,90Z8!^W$*BV/>/0<O.1-=UE*VS>4O,K$2:.-*4JS7^F%*5<$'"T
MKL^,CQU;`IL^3'.1W-(*F`O!2G$0`5<3RK7L.QJN&Q;;8Y[>M\B?N$QO8Z.I
MM"Z]1&UK@"CK3)MQ1,'4D6G6=693I5@UU;M2*FD)>XGKBJD>J\=?^T2F:$`H
MQ*KGK#VF[3S757K5K67V)OV\7G2+RH=TK;:GM@L*MFWM0M@I7&P:NT4TO$:>
M2?VJNL[JF^JKMF[^1^X^@;B=LJ4I3G2S$XC:\[[7_=7=7<6N[/FMITZKUIA`
M2$"XA7<!+:I0EX"4GVKI]-ZPN=2U_OO?4A#V6BJID;+.IH];D'I@.8\.T,4Y
M"V2)GNUL7Y_+W+X<^W`\\>/OY>7'\7[LRTUX5\\0`1-QZCZ".`X#GG^W_7QS
M_LP-/Q)\F-X%Y-P)AXX$1``*'/[>`*`?W8&-=B:;U-MB*?0FR]<TN\1DBB"#
MYI9J_&R973<H@((K*.6YUC)`/X>7'.,BIGM5U0U70]W]"-?4R4VG5]0[O[+6
M76VU=&P6WMB1NDKK1JYU;["[3C:M+ZO:V!.I&C5+G0HMRN)6Y3N$VXHJF,D<
MQ<J3++$1NG9-L^TYK_L1IJNSVJ]CV'K'2-P0E#ZSZSIE_F(^8D:U%32M1U]0
M=F`K6Y:/^H=`BH5XI]45@54Z9Q7`@@3BPS2UN6V!J+6EV=NQ?O;32*S.2+H\
M=^D*'E7T0T6E"K17K^FN$9(52*(<B"1RB4!X`,BQIDT2$$#`)0$#`(&#CT,!
MO<!_;SA6DY`-S^4O/B)0$P>0<&X`Q1+_`-$P`'.!!_9_3MJ,_+[%ZWW)7K_M
M*PJ_46IHPB6M@TUMHB*:AG,3MS5$@!J],)RB1@;J3#$C.?:MQ$K9VER/-WM$
M1#=?J;IO>UEM\;JJ=V%(ZDZZ$W-4>NNM7,N[U*7?ZZZ[*QV?3.J+)835N"NE
MB`RZ#510R2Q$7)`,I\AC*9.UPGYZCOI[[E.\XV8U94IFL6&)/:>TVY:OM5AV
MZK9M=;.5H3V_(1%2-I7]!V/)5HI:9,6!.-<,%D7S=!-J+<IT5")'<ZK%I<_A
M^AU`/%10G!!$H!RH`!YJ&-ZB8XE*4I1_=[_CDRL.5D4P-)R%.42'*!BC[E,'
M(#Z\^H?VA@8WW!J^N[GUE>=7VA,QH6\UN2KSU9$PIN6GUJ!BMGS58OYT7<>Z
M\%DCEX,4Y`$!`<#"74/9=OOVI$HG9ZQT=OZDL,SIO;1#@1-9U;Z.N@P97(Z!
M$2?"ELZJN8VS-D^!31:RI$^?0PC>,NTM7:*-IV]ZEHN1T]OB0_J]S&1J.WX:
MB1[W24)/S$<ZE&-<GKFI9VTFVEUFC,YQ!&+603$0*90!'%+>:2CR*8#`8#`8
M#`8$2=_=B[EI"Y4!LCI:<O6K[(^+#W'94+:F#!>AS\FG+A58]&DJ1#R3MC:3
M=18DD'!'34D:FX;J`1?S$I*F61-%[8L.WZI-V2?UQ.ZP=Q=SL53;5^PNROI%
M^R@W"2+:S#X1\8"#"8(H)T"`"GY`Y\Q_`,X%'DH#SS[AS^W@>.?8/?C(K5@,
M!@5S4/\`\V3L[_X!.E__`'^]W\O&?_?X6,``````<`'L`9&GW`8#`8#`V5U"
MHIBJ=0$DT@,JJ<PD*4$DR&.?R,?\I2^)?41$./VX$/M8=]>INX+^PU;K_;[2
M7V!*V&>JT/57M8OU<DI:8J\!*VN?;1_]6U.";/R1M>A';H[ANHJW,BB(IJ&$
M2@-2)B7K>UNX9C3NG)B4IS4)3:-P>Q&MM.PQ$2R!I39M]?$K]8=*Q_(F>0M4
M<NOUB7,`"",0P<JCP!<#V.A]30^DM74;6L08[P*M$%;R4L]44>2T[87X!(62
MR2<DKRXE)2PS2ZSETY5,=5513DP\\X&:<BF`P//V>=852OS=GDBK&85^)?RK
MTK5NJY=G:1[95VJDV00*HLNL<J7Y2$*8QS<``"/IE29I^?*H?<FV7MFD=P=U
M0[:H]C=2ZGV?=-,0/5=U7'VGIS9S>_5GK79M:-"VW8VO5YL9JG0<EL!.08+-
M1%\X.G\A44"LU2U(N<PS1$:ZVB]DE=0:.V+M&$Z_2/6JH]BJYUNC[6P@K6XE
M[S.V6(1T-";[?Q$G:]:ZI^2,0\RLB@XC4!.BW$K7E`8O4A=2]#_K:S#Q6_4Z
MBUUZT.@O#]3=1HJP>@X+XQ2<D<WMXL0+1O"TME@$[ES.N%H\SHOSM&S?RXRS
ME%F$9&QT5',HR*8LHZ,9-4FK)A'MT6K!HU3(4B2#5N@0B*2!"``%*4```S+3
MG"4HCR)0$>!#G@.>!XY#_5@19[>[4O&CM'WO;=-DZ#"N*1'IS+^2V/7KG9JP
MA#LG")GJ+F)U\HC;%G,F"OPD<('^&/\`]^LFHF0P81$3LC+UNP=1]O\`;W>N
MJXLUCT'0;3N;3UQTE=W=>OAJA"ZYB+I$2E-VLV,9TV<SC]9ZU*?P,Q722(*K
M<Q3F`;Z+_3J>OJ7:K>6Q>SFJ;YVWML55^JN^J[I]M)477>MJQ<-L5V>T/J'<
MI7]]GS5URYK=@8J;0&.,K7!C"*@T^7@#']&DB>)8UGHIUJ83]=N]JH[G;NP:
MB+XM;V'NVRS>WKO#IR"QEG9(^PW-W)NV:+@W'\LG!"D`"E`"@`8E82X9147'
M-/H(^-81[$`$`9L6B#1KXF]P!NW332`!Y]0XR*TC#1!I$LN:*C32Q$Q1)*&8
MMC2)$1$1%$KX4A<E2$1_A`W&!K3BHM$I2(QK!(A"))D*FS;D*1-$XJ(D*4J8
M`4B2AA,4`]"B/(8'QC$Q48+@8V,CX\7:QG#L6+)LT%TX-R)EW`H)I_,L81]3
M&Y,/[<#G\![<?CS_`'\\\_Z<#[@,!@,#YP'K^_W_`'_A@5S]TR%'LO\`:O\`
MRA^;NAL+R_?QT5[=\>G]V5F=P\5T)TMK/?7VJNAU(VS60MM72ZX=?K&2+4EY
MZ&#]9AJ-%*QKPSNO2D2_4!`ZQN4S*BDH`\'*8/3$[/Z_YCTM!C8UA#Q[**BV
MJ+&.CFJ#)BS;D!-!JU;)E2002('L1-,H`'XY&G-P&!H%,AN1$O(B`ASZ^P^H
M_CZ<XL12CB%_XT[-Z<>?7J&$_'(`8?ZW4)Y"`#QY>(`'/OP&.C/,GK+6\VZC
M7TUK^DS#Z'6>N(A[*U6"D7<6XDGS.4D7$<Y>,%EF2\A)Q[=PN=,Q3++H)J'$
M3D*($J'LR)$3X\"\<!X^XCZ<B/KR(\^HX5N8#`8&DXB!1XXYXX`!$`Y$?8O(
M^W.!`N_MSZ%[9T;;#9T];:^[/H1>D=DQZ*7S1\9M>OM9>6U7>%R%`J;!2<@V
M\A`2#Y03"L9")1_PERX3RQGL#OMTQ1V=K^UK=BZ#;$*=%Q@,*CKU\M>K.,AN
MZHV6UTJX3L%!E>"SI,Y2-;/G$)*"4"K+>12FX63\A;*<=]Q/K7-7RIZO@;#9
MI&]76EU:]U>(/3YQFC+0EWT;?NPU7^:5>MD(^*=2&M];2JYB+G+].Z2(W4\5
M%2`)+_:'=U^\Q4$>LRF\==Z8MDA9YZRL]>T*H6^:KD5'.;O/]!H_OO7%[3*1
M\B\7C:K_`$G*(5]XN@FJY+*"=1),[<"J"H_[.M=_>/K43?-:L+56ZEK[74QK
M73EFW1:;C9I`K_1][NVSMP:MV/1;*DPCUHI(==V+6!&P.5%2$=N71B@(%*`B
MHOX6!=2>VM&[;Q&UK7K*P5:V:_H>V)G6U8NE4G#3C"U-XJ.C'2TDL<6Z!6SL
MKR0%(4PY)XD`0,.%B;3#R*QC;]J:^U[)4N'NMVA*I)[*NI*%K]A9'Q8]W;[F
M\2=O4*O`)K`4SZ0<,6:BS=,G)C)$$0Y`.<J>VY2]IZ]V2]L;*A7JN7!2KJLV
M5@1K<NRD5X!X]!R+5O)D;***-UWI6:ID_(H<@D;CV'`R5D5#?L;KBXV>_P"I
M;H/96&TYK*E3I'$[KF<HU+DT-EV11<BD4JRO%EL,2]K$RW02,T:_3H.1!-=8
M?`?,#$M)-_A+MLX*LBDJ91(QG*(*E*@L"Z0E`.1^%7^!8``?40]!]P],2.63
M^$OKSR'(#QQ^4?4OI^X,DJ\](66#82[.`=3D2VG7Z"CZ/A%I6/;R[UFB54B[
MEK%JN"OWS5$Z8^1DTS`!O3GT'+$6DNT82#*31%=B];/$@,!3&:KH+@F<O\22
MAD3J`4X"'J`CR&16_P"8_(4IA,F)@$WB(`)3%*;PX`P\`4PF.4?VC^S*BBEO
MVI4H_>3M[L>>J00^QE$^JW5C6M=E),`I6Q=1U7=ME),[-BK$V15?C?("Q=D'
M;:4@"HF!DW;Q:YE/%^/C"JFUZC4HD*9,5E5OC$"@982BIQZ\`80X,)N/<1`!
M'+*MMZHJ0$RHG!,ZAO$#G$/C_*'F)#%Y^3E4I1+Y%`1+SSQA$-MD=UZ32]XM
M>NM8JEMVIM`:%(;`D(.B'@W+B.:QMIUI!J5UTF^D6JQ;($'LM&>5;`3S2AF:
MBQO]XD!E"5E;FWECKT+,N(F4K3F69-W+R"FTR(3$.JL``HQ?E0,JD@^;CZ"4
M!$HF_'C`JAV%]V[4U4>SNMH"R:MG.QL-V+2TLMI)S;WZ5B0KB$@S1D[@[10C
MU%DUHV)="\53+RC\9/X_0>$1\I?[8TI7WI*V2E:EO.Y-?,]?M3]3-^=A>R];
MAI20M%JU#:=,FZXO(NGUQBW9IH6:'O-5W^UFV+U4Z1E(]1J8@&,HJ5-6#_MF
MG0Z5_P"98^SGO5!5`O::.U>LJ"3=TRWE6YC6B(?4(\F^-Y86R46]:`4>%#I*
MG3]?7C!<:ZG3U^W%U1W=;K1NVK;MT!M&1>65-35\S3-E4^U(P5-C:XXJD6^@
M_AD3JPLK8(V8>MY!-+Q!8@D*/L&17<5U9SV"[@2MG1<@MJ'J4R5J5=30617C
MK1V!O,`D]LL\0B7R%%/7&M)MLQ9N"'`BBUB>IB`F0'QHG>4A"``%*!0`1$``
M/;R'D>/V`(Y%:L!@,#X8I3`)3%`Q1]RF`!`?[0'T'`P+9^KV@+G$V^#LVKJY
M*Q=]V?$[HM[94'Z`SNTX..J\1&75TX:/4'))AO%4N+:B*9R)JMV94U"F()P,
M&&*+4:Y0NY)J34(M&#JU6Z<ZW@8"';*.%$(Z(A]H;!:1K))1TLNY43:-P\2F
M4.<XA[B.7C-93>,D0WEY%Y\PX-R(^H?L]_;(U36`````````<``>@``>P`'X
M`&!]P,';VTXPWI4D*7+;"VAKR)"6;N9175]I;U)_:F'QJH/*A87;J%F@?U.>
M:K&1>MR%2453,(%4*/KE1%3[E5:@J=]JWN74*U%-H2MU7IOMFN0$,T3^-I$P
MT%K.3C8N.:D$.2MV3-HFFG_U2ACJ3_F?37TL*7_B5^Z@7@!*'<S7`<"'(>G1
M7J'Q[\_C@C<^_P"%C`%*4."@`!P`>@<>@>W^C(T^X#`8#`8#`8#`8#`KH[I_
M^\O]JW_QH;#_`/V*]O,K,[A@#J?M;;NF_M*]&+WJ+5\!M9:N]6]'SU^B++?%
MJ`VB=;PM"B'EME*T\9U.W.;#?2QOD>+B#HM6K\Z!TU'C8PIBHZ1_F/2WNM3C
M>SUZ#L;--=)E/Q$9-LDW*?Q.",Y9BWD&Q%T_(PD6(BX`IP'C@X"'[QC3N\!@
M,""NP+JMK7L;M;8B57L%T_HOJTE8%*K5CPA)^?2B[:Y?*Q<,-BE8&#"6=)(&
M!`7C]FU`W^\5('J"-I.(MT^U?N`UO4#ZNGL6C=YR%/M>O#7.O[&B8VAEISVP
MI106EQJPRDQ>XB=3OK6C).II53Z$8'Z-@NFG(G=%!N:U<%S=)?ZMVC0=R4J(
MV!K.Z5:_U*:3,9E8J=/1%DA5%TQ`KQ@$G!OI&.%_&.!%!RB58YT%B&(?@P"&
M)\$7UD/(I@,#X/M_\/\`Y,"!MP:K]@^VM0H@J+CJ[JNWC]HW5(BYP:6?=MO8
MRS"A5%Z5(_Q+AKFJ+.)N0:+"=,59N'73+R3D+Y3PS8ZZC]6G:4RG_P`.VEF*
MM@KT35):0AM:U*!FG%>KT-,5ZM1:<["14?-,T*K"6!\UB1073/%(O%BM#(_(
M;F%0\BUZ,]6HVUP=\A]5L8>[U>JP%,K%H93UJ-(0$!5-3W+1]9;,6[R<=Q:J
MD)J^_P`O%I'<-UC'(\%57Y%R)J$%0BPS^TAUF)K*&T\,WMU*L5N]US9$=(JV
MFN?U&><K?31MT4BFSMX2H"U-#!J2,)(E2*0#_P!0*'<?RT!!H-RE1KC+A_MY
M:(>=EO\`BN:.+I$[-4BM-1#YFPG6Y*O+-]%/+H[I4E(0CR!55;S,@-W<DDCH
M*(D6!),0("P*JJH6HXR%8M%[%J:5NM/7C8[:N7JZ;*D=FV6#V-#IV:AVQ=]$
M-XEY5E$&!(2P5^/%%DF=JY1<K*M5^53IN"!\(B'1ZY[C,PFH;6O9>E..MFXY
M-R2(B8VP3+6>U3LF;*FH"Z6H=M-46D39$SJIC\$?*MX2QJ%X$8PH>HJX6U=Q
MB;#-':*=ZUU!<]KOZ[V6UC9[.PITE18MQ6J@Q"=;SES76V'<J1'NF,&$T1=P
M1BLX>F1`P$24.`)&$I`5+7^NM9%FY*HU6*J;22*R4GY4CD$&[QC`$?+LI"1?
M.W:P'09DDE_B.8P?E./F)2@'!/I&"P=M[;M"9_HSI;166['17!HV<W787KVK
M];:8NA)'8RAT;\BS?/MH6"*3:.OCBJLTDFRCI#Z9](1GD"@ER[&!Z0T6V/\`
M^M.U<JAVRV`J@(-E]E5UBGJZD+'^J,N76>H7#B5J]17;JOUDVLHL5]84FP@D
M>1.`"(AT)]&;MZV*/Y3JE9%=B:^)PX<]9]R6*0=LXH$6XH?'IG;,D1]9JL#M
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MON[9L802/!3@-=.7Q4=30#Y`Y!"0GR+SB*@"BK!HB/RE%VY^R^A.B-JMZZXN
M"-K>3=1["PW9.IV%A/$CYZ(V-#+Q"RS']5918&6I5D&`;A*1:Z:S5?P(;@#H
M-C(O"MFR7CM#U[G)6:L]85[)Z'?23E^>8U["IQF]=4Q[E8RBR<K2"NE8W;M:
MB$Q$WU4)]-.?&`$3C'0@*@A(_66Y-:[KKA+3K"YP%V@BK`@[<1;WXW,-)HJ%
M^6'LL6H9.;K<XW$I@582#5LY3.42*ID-^7!;RQNM775#=@=EVVE-9M.P85^4
MKCO<T?2(=CL20A)=.N(OV5@L[-HC*SH)M:O'HM0>J.%VC=#XFIDTU%"F4FLP
MQ3<^S5BN6QO\G.K$)7]CV6N6-%ANG:<H^<*ZCTJUCER#,U^7D(@XN+9M-1`A
MD"5YDJ0T>H83R+AKX`10LN[NO4366P:$MKZ4F;DE"K[CCM[`LTFF"+\UMCY-
MG,MVPO%X9T0*^1VS(4$P(8XD-P)QY`<9+A'W8OVF^K&U',$ZMQ+XJM#=09_I
M/(?IM@CFX6S3,\^HCP7E@\X%0IKNB37C1).2:@UX266*)!+\/Q#""D-_RL/V
M:HE!B@XZ]V><,R`GFXEMH7,SF0\?_MXL9"/;&'_ZLJ?IA*9.B?\`EJ_LL0"I
M'C?I5!OWB2Z2S99YM;=+9PT7(<#)J-%8S8L>*:Q3AR7U]P]!#!2673^G4OI]
MM>Z]&JX8L)0G,8\WIUD@I"1D)22+K9TYCX/:%.2G+%.S%IMBVO+\[;/%'KU1
M55%E96C<#&(F`E+"RO(I@,#X8>"B/[`$?Q_`.?P`1P/"RFR:%`3U5JD_=*O"
M6J^/96.I%:E9Z,CIZW24&R-)S4;5X9^NWE)U_#1A#.7:+9%4[9`HJ*`4OKE9
MO.=L>4SL]UYOLA&PU,WYIFZS4U<[5KB&B*ELNFSDO*7VC,7LM=:8TCH^87<+
M6ZG0\>NZE(],#NF;=`ZJJ9"%$<M?"VPG2;K4[KW=N4I3[17[<PB^NT94Y*1K
MTM'RY(VS5/=VRZ]9*V^2CW*YD96O3K%=H^2#E1NZ0435*D)>!G$3J#]_O^/'
MI_JY'(T8#`Q_L?8%:U;3['?+FY?,:Y7(QQ(R*T-7;%;9Q5N@43_##5JI1LQ:
M+))J@`@FQCVB[M00_ED-EXBM3O9V&U)V`^V%WQF=1VPENAT>G.SIP[Y**G8Q
M--A9*%;TXLJB<W&1RZ+\KF#>H.VJ@`Z8NFQT'!$U2&("DG4^F4^E8\]EONH"
M("7_`/6;KGT'CGTZ*]1/V"(>N)(W/M8QD:,!@,!@,!@8--O:MM]LW/44S$6N
ML2%*UY';/6NL_%1['7=BK#E^:.E!K5@"8<.WCRLO/C2DTUF;;X#+I^!U.1XO
MTENZU#MVL;RH,/LNA*2:E4L2LXE".9>*5AW:QH&:E*X[.X8O!^L;HJR46H9(
M%$TU13\1,4HB)0#*Q1\BE,`\\@`\\"'^H>!#(KKG\K'Q31_(R<@T81\:W5>/
MWCY=%DR8,VY1.NY>/'1T6[9NF0HF,<YRE*4!'G@!RHIW[)=@&VZMS=0ME]?]
M:;2WQJKJ;V`L>V=N[.UO76S^IK5ZP=>=TZ<38ZT=RC^+4VC*QLGM9E).C1)%
MF7Z0BLJ@X76`J(C>60M;:*UWN;I+H'0?5WMW>(/7>BJY0Z2\M-;I^MK'<[.Q
MHM=CV$;6-N4;:%$DDJI*^!4)!Q'.(R.>$<%25`A?C3QU(JO%+085F>+AXJ-.
M_6DC1[!@Q4E'A4BN)$[9LD@H]7!N5)`CAV=,3G`A2IE,80*```!A6+8+=</.
M[DO^D4ZW<F%CUY4ZC<Y">D8AFG49N'NSNQ,8E&NS",DJJZE6;BLN!=H+MD"I
MD,F)3J"8P%%LKOI)O',5Y)^Y08,&*2CJ0>NE$T6C5HW3^1RNLY6.FB@BB`")
MU3B"9"%,8P@`<@,J[=C=\"2J%E8]>6$'/P%>1<%LW9_9*XU?J[2723D63B/C
M;-]4C,;?M;93A1O&0)`:NRCP20$X?&*BT5K9V5L%DM=WN4I4K-K/7FR>NCC0
M-)[<[@U])0VBIO;KM8B[.SSM)8S["]5?4EDDWH`QD9!2/^91-1%3Z8@$<*2L
M^!FNY]1^VFUHS7-&N.X>NY-05_1+S7\ZWK&M-DFLW^8,U17\!+7JCNIK9LQ4
MDX-1TN@1LA*,)!TTC"N&R3@IW*BAKX3REUU(TE:=&Z^DX.^3M1G[U8["[LUJ
M<:ZJ;FDZ\:OW**#1%I4:X_DIF29L09M2'.=R[<KJK&.8Q_4`"+"5.%;#A;X$
MA4$IS!R`""8`90`'W.4@_P`?QA^80]^`'W]L;$.[!W5HU*W6[U#L+7NW=<5I
MI`V*>_XD;]!4ZI]9G"-5C6,C--!V-+WM"38.6H2":0&=Q;5LHN!BD6,``8;2
M6RWM[>53U5H^U[Q4>(66M0555LD'_33IK*_U@NX1*->C*VHT761F7%C>K)(M
M`0.?Y_E+X<B.$OO'C>HVI[+J?4;-+83DLAMS8DW-[6W')@H9P1SL2\K(2DC$
M1[LQS'<05'CC-:_&B;U".BT"\!XY&DHL!@;/TZ("8P$`!-Y<\>GJ;GR-Z>QC
M#[C^X,MRE0^_`D(&#XR\&/YG``X`Y_?R/Q_$/(<^OXY%:OC)P(<<@(\\"(\%
M']I0_P`/O^&$J'D;MKVC;(K4G3;_`%.`N54F6QVDG7['&-9:+=MU"^!R*-7:
M:J8"(?X@X,`^H#SA56.\E]S?;_DM#H]=II[NG7V]^QU:T5&=?=V7!X=I39B]
MPM_N/ZEKS<$DSG+/4J]&)5`[-I$.TI.+9(*%(V;D`H%'3.G&ZI538_W$]%Z\
M[!]T)6(/5KTVL3QAU5UBK+1.DHME&6^;K?Z5M-ZZD'<UNV10-!"*A7RB4"94
M/G18(F\<FEQ,+<8>#AH*+81,'&1T1%1Z""+"/B&J+&.:(HD`B9&;5L1-%%+X
M_P`O!0#DOID*=J!2E#@`X#TX#\`X#C@`]@#_`-.%:02(!O+C\P^X\CR;TX#S
M_P"GP`^G.!AC<F@M3[WAT(C9=4:2JL:J#FOV5DLX@KC57I3%,D_JEQBU6M@K
MDDF?U*JT73'CTPB)B=`[[:OM3FFZZVW5MP:WL,`UBZ]>=YMXM">T:O$RC]VM
M)SL74X6*LV\I>U1LHG&LSK3#!)B$4BNY(Y47<"K4[AG'4_4VE4BP)[+V#-3F
M\MW*MR(N]J[*.VD9"+3*8RAHVC5QNDC5]>P1%3<E:1+1L03E`Y_)01,*96DJ
M?B3]/RAZ#Y!_\X#>0&_M`WKD6@4B"8#"'Y@\O7GU$#"(B4?VE$1]O;TP4^%1
M3(!0*7@"<@0.1X(`^X%#G@H?^C`BGM7J?3KC:4MF:ZG9S1.ZT?(S?:.M3M&#
MF9.4IOC8[`J;E!2K;+@PY$QFDPW<$`0\B"4X%,%A)51Z5[2=S>W>SM;=;]M,
M:+I_6ET>=\V%@W1I.U3[+8NVV'2'L-4-!2,#$Q,F15WI!&Z+6TKR1?MG[UZ<
MI`39J-$_(AB1*\C6&K==:>I=?UYK&HPM*I]88@SAJ]!M2-635(P_SUS>(>;U
MX\5Y.NY5$ZSA01.<QC"(XFU>_*W1('`$#^,5!Y]1%01`?,1'W-^4/7]@9%?0
M13`1$`'\PF$_J/Y_(..#^OY@*7T#GV#!3<*4"@!2@`%`.``/0``/P#`V'2";
ME`Z*I2G(IP42'#R3/Z\@50OL8@C[@/I@E#/N;3IQO4JKV%H<>[D=E]7;&XVO
M#L8U!RXD;?0"Q+V(V[K1-LR6;KS2MHH;UZK&,5SBT_J%G&N3E$S5,2WQ"4D?
M%[3HLO0(O:[:VUM'6DE66ML"ZNYJ+0K*,$\:I/$I1>Q*OB0[9@@D<?E5.H!"
MB'N'`Y"_T["D;#HVS8!C;];7:H[!ITD=5-A:J/986VUYXJW4^)=-E-5]W(QC
ML4U/RJ>"HBF;T'C*?3VN16DX<D,'B!^2F#P$0`#>@_E$1Y``-[8$)NSKF<C]
M@]4EX+3>R=GLO\XW1K'.T.`KLLPUS"NJR^;NK'<7$W.P;Z-K;@3`U/\`0)NE
ME1,!3(B01'*BGO>.GMH;TO-?W32>H';;2#?779DSV9K6NE*CI/:[ZHJ=:^Q>
MBJGL75,A4-E+@Z?KW+9[!S9Y4KV,<$@!1`S=R9J9)6VE3*4>O]P:TZU]G)'7
M"TM3'6X776"%>V&)--N*M1KIV"L.U[M>=BU:0V>^@WM&J^PIN=MX2)V<@]^J
M7/(D^)N'GR$E5ANGNWVL]M3CC7KY*>U-NN+13&<TOM:/)5[LU75;"Y`\(HLJ
M>!O,49(/D([@W<@0$1*98$1'P"8$J@.?Q*)B`4PE+Y`!O,$U#`'Y1X`HF(`C
M[AQSA6"*[V8TE:K+/4R"V%%R-KJ6VC:*LT*E'3;9S&;;1I9-B+TI<CR,3X>#
M2%TY1-8HF:J-CD$JQA,`#:2WH=R2FRX;6=ME-.TR`OVU&D8HM2:K:;02E04M
M8!-\;(CVRKP]D+#MT?(R@*&9KAR4"B7@<'5>6S.OEH7^USV/TU+U'56A=E;/
MT%N>NR*$SL:.>T6L3MV:6M\#R[;?&MUUB[AU+/:GK]1[^FMD&23WX4T>$^3$
MS.)VZS[?.^=77KLQ]Q]*!MK4[O8O:^N6K73*8CYNK/\`8=4J'5#K;K:R6VB,
M;/%0[BY56,N-.D61I*-*Y9F4;&,!RD,0QA&Y^5NJ"OS)@H`@8HB8"F#CQ.4!
M$"G*(&,!BF#U`?3G]F1IO8'E)ZX5NN2<#$S=HKT'*6IVK&5:+F)5@P?V24;M
M7$DZCH)DZ<HO)N11C6:JWT[4IU01344$HE((A4:"7"M!+EK9[37QL93%*$$$
MU$C.K\M2OT@"(^4CPBKF/5(N4O@'\HP&#DH^0AZA%05`,(\<<_EX#V`0_@/P
M8P?(0?0WX9%;V!YZQ6.+JD%.6BQ2+*'KM;B9&>GI=^X3;,(F&AV2TC*RCYTJ
M8J+9@PCVYUU5#B`$(0<M):K#8B5,[&;GK4Z;L?JFO]>>W^B6NO.N]OTQMJ<@
M>PNSK-"21-FSLAKN5)$2E)=UIM!PGR"+)1=PHV^4RQ`\2ACE).\Z9FU4.J_M
MH]7:Y7>RO8[XZ[%7.WBEM+=-V4E)&6?WFZV*S1,6>7D(V-D)&0;L9(A5@!N`
M"L153D"B/#>C6V0;SW2UK#$@:_J-K)]C]I7"O1EHIVM]3*-I-V^KDPD52+M=
MEL[DZ=<HU-?%'DLK*KMVXCP4/(P@&%O#'<?UJVQO*8+:^YUUCY6LK+QKRN=7
MM;+OX_4E?<D3,80O]C\F<YN*;^84E0^=)G&L5TC@D#A(X"+4X3>T]H2#B*]%
M1L)`Q<=!PT.R;1L5#PS!M%1$6Q9D!%!E&1K-)%JP9))E`I$DRE(4@````!D:
M1:V[U,I=VM)=GZ\GIG1&\&A_F;[5UYXL5IY4GFK]!LJK`=M!;.@'!CE^I2?\
M.U"D(4'!0*&7:/`L.S&P=!+(USN/4DJ_74U4VT9V;HK1>1TW8SK*$30/=HQL
MFYE]02[@3`!@D`&+46-X-W*F#F7B;O==L:J[#WG?M9HM>WEKC;>FZA1=44[5
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M97+%8`,9,3%$@MR:AU._NR>]NKFV-@VVRJUG<&E'6KI2QTS4\&TKVN[S`76*
MGZY"5JL,-A6R<:U^W36R32;P$6+KZ-4B[=,&OS$^82J+3.T3N&.WYI+5FZX6
MOS]:BMK:ZJ>PH^MV=LFUL,"E:XEM)D@9PC=19JG+1HN11<?$<Y"G*(@(E$HB
M+E&[N9URMV]Z;L1C'6'7D:UGM<QE'C8G9B+Q>FD;NK4E*7D]@<%C)1%DE8X`
MH,04207.)44P$`*(B6QJB4<-(UM&U7S0'3^+LM&L5(Z7P$?LW>)]=OS2E,?6
MZ3DYQWUMUDD@_$KU(D8W:'L_R>)TTUJ^5N)2D5#,BX,"\&YY'W$??D!\N/?]
M@E\0X_=A6O`8#`8#`8%:WW$$4PLOVY"^/)0^Y+I7@!]0#XM2[_43#U_]6?U#
M]@@&5F<5[=C]I\@J_;\Z]F.H<3&8['*(\@`CSN#8')O0H!Y#Q_9B=G]?\K%P
M````````#@`#T``#V``_``R-/N`P-!B`<!`?Q`0_LY_$.>>#!^W`T'0(H!`-
MR($_#GT.`AP('#C@P"/K_:'.6QN%*!0X#GC\/W?N#]P9!JP&`P/@@`B`C^'M
M^X?VX'YZNB12_P#$GU9#Q#^99/\`F#O/D.?+C[DVCR\#SR''B'M[96.Q^7Z%
M"D`H\ASR(``B/N/'MD;:L!@,#X(<@(<B'/XAZ#_=@;*Q2^!P%(%BJ^*2B9A*
M!#)J&!-3R!00((>!AY#_`!`'&!7/HN/@-?63=_2:\UB.F]=U1D?:NE*F]C6L
MG&VGK]<W[E^2E,X%PD9JJGK"\,W<&W8'*)E&2+<YP\52\U/2)-(H'8W5G<OK
M!'4BJ;=U7H^/B[?/;FHNL:HBXZX7J7V\#]DW<6>#@(5E`Z^M.M)4L>H(IK%4
M,D91<R/PD.ICV=I:QV&V3=]3ZQDKW3HNI3;^%G*@,HRMTC+0\8%9E;3$1%A,
MR=0\?)O/UMM%.UE6(+)$:JN`(58Z:8F.":$?[KV*[)TS<\_1E=-4*R4F:IS2
M[:O<5JUV%[>C05:LL!#;,4V)$C"$AHA9U#SHR%:*Q<N!>@S70<?$L3QQ7P99
MBZ\]J]0]F=:S^V]82TPE3JM<[Q0+5_7E9G-=S-9M.N)`8RUL9V'MS6-?1Y(E
MP`"*IB`DHB8%"&$!P7A'AWMC9/=)V_I_727GM9=?X^7_`$JY]K&S7Z.7V&FQ
M6\YZL]:F[P@++ID70^C<7)9,8]JJ"Q60.7*!BX+XE5!=9-%0.J%-)(ZVK<EK
M=VB<DM`3[).>&>>K(@B[G)Y_*`Y?RMC>\>:D@JH+OS'R*<O!>(J".V>EEQJ3
M!8FM46?8/4<5]0I#]>]JS"S/8NMC"N!E%NMG8(RPS5',Q8))MXZ$EU"QB9B>
M2CL1$J8WC-9>2TMV:W)3))Y6JZZL?8ZOU@&Q[GHK9B2-`[S:3:N5FC1J5:&G
M%6,-O"K1T8R?OA?-U"R\H4409(KE.41;VOIZ[H,];[3VYWRW>YI[5&G[`[45
M;8&IY&6E8AU:H@]5ZRZCTE.-;?3$%OZGUA;6<E1WJJL?*H(.P9ORB)?(#``K
M:1FPNWT<K9I?5G7BH.^Q6XHSX6LS#5:0;L-?Z]4=`'@^VGLESS!5INU*/S@S
M346DG:)1^G1.?@N#Z='7NIECV3.MK_W(V`TW;)(RB,M5=.0#!W#]=M?J`DE]
M"@C5'QSN]GS#)91?QF)U-/YD5_C,S+X%$1[9_P!K==--;MKL;6MD42&F$(;Z
M!6ORK(%H&Q5=U$.DG\:O5['!'CY6"482;<BP)-UB-SBF`*)G)R7$G$;TD.VW
M5T6S5D,[W*TLU1(10[Y=C&]E*4V(8XG<KN7`MH/<;%-,1,<B(-9LP@5-%NJ'
MJ,,PDCJ/L5JG><>^=:XMC.1D8)VNPM=7DT%X"Z5&59`0SZ$M%1F2,YR!D6WF
M`*%<(E`@#[B(AS1&OMQ;J\^LG4>Q5ZIS6VC5KM;7$'$[K6I)[)1UNK+42\5,
M)^VRD*=V>C5].3LC=N^>G,0Z:"QO00`0Q'A)^&!NF6C>PD3VJ[$7OM/6M&N;
M*T7ID_3KMJF:V0^<V*<D:8TJ]ADU8^]P<8T;0[*'CF[<A6IQ*S?D61)Y)@!L
M8Z7*WE`?4X`7\@%3$IO,A@.(@;R$"D]2CZ>HC_%SB5AR<BL$]DJS8[IUWW[3
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MKA5-?/[#'J%2F%M>04DA&%4:F)'ID1^-JFFW`A,$1A-4$RB`CZB)O7R`1Y]>
M!'Q'D1`HB'/'MD::RAP`!R(\``<CQR/`>X\``<C^X,#X)"C^'`^0&Y*(E$1`
M.`\A*("8./P'TP.(\CF4@U=L'S=)VQ?HK-WK-R4%VSMNX**:Z#A%0#$5063$
M2F(/Y3%$0$.!'`I[O'5W6C3O=K/K]7W5SI_7O;'6WL)NO9&BJA;92`UC9KYK
M;:'7&L5==O`LCE4J%>*PV1(G?0\"M%14HMX&>-UBBL5;4,]KPMRK55K=,@XR
MLU""B:O7(5F2/AX"OQS.'A8IDD'"36.BV"*#%D@E_A(FF4H?LXS+3NDDB)>?
MAY<'.90P&.8_YS?Q"7R$?$HC_A#@H?@`8&[@:1(`F*;D0$O/'`^@@/'("`\@
M(#P'[\"IKO)TQU^.O-N;'KT?%AKFP(#>NR/7Z>NMLH.I-U-ZHX;V(LVA*4V5
MBI?7NRR/HU-9)U&F393STJ99-!=007"VDQA@2.T8W[2(/MV0'V]]BU:9VVVH
M<@[7[@=T=EUB)=Q48V@IBJ6^$U]JC9F[XZN3T7X$^B4!A"S*BY506%$JZICD
M^TSJ)UD[)1%/B]7MNQ%7TMJFMUMC6J73NO>KP2L-#B(Q)=FTBF&R=J638C*7
M"*1!(&Q5*XT*@!`()52!XX7P]^AT7T>K.(W/94MMC<]G)&(Q+M]M?;ETD:]+
M$`PB=:2UI"2E:U&N]=K&$PF_02@41X(!"^F#B$%WISO5>^XYCHC76O.K^[ZZ
MY=R6BF%3CF-+T%WEU"V;&=VG1-_181L.PKFY:VL1PZCUU4%WT8J9-\T,_8#(
M-\&9TM&T;O6H;WJAY^MIOX:>@Y1Q6MBT"?2%C<]97B.3+^K4^XPZA2KLGS8Q
MRJMG!0%E),U$GC159JNBJH&;LBF`P&`P&!6W]Q'_`/$WVY?_`.R33'_=%O\`
MRPS_`&Y[<_[3?_E]=>O_`+GL;_O?V!B=G]/\K%<C1@,!@,!@,!@,!@?GJZ)?
M^\IU6_\`S)_S!_\`_I/H_*QV/<OT*Y&S`8#`T'\_$?C$H&_`3`(@'[1X#CR$
M`_#D.?VX&+=I[AH.E*)8MC[7L<?4*96FWU,E-.R.7*8**N4F4;%1[5L@L\F;
M!+R"Z39BP:)K/'SM4J#=-500YM):H5Y86_8KLYIB1W9![P@=TVR.FI;177S4
MUA5J-SZB:$G&QDYS>?:*P5ZS-Z\>;V3)0C1)&$DU'R"2IBLX]H]6:/G6+->T
MZSZ"[24TS0=3=P7\ZQ)*)/)"%[%ZNKFSEE8H#"9S#P\[KV7TXO#.%!-_*=N4
M9/X1`.4E`Y`73TQ#V$;]Q;YJ2Z:QV/I>?D(B:>UUO&77I%NC6I-O.FD3-,)9
MR_/7NT%&J=`KA7GT($<-R/)<XHG.5$Y3^)P#!-CO?7.H6O>=T[&[A[STF/O^
MH7^O+KK#<NKGC/6M<@[;#,Z*".M[]K[1QHZ6M[QPK].T81UME4S2L@)TF@K.
MDC*7Z-9=IU@Z-REDJ;:+V"\VI4NKR]U=[(K?6V[S4,%ZVC+/46*36V]BGU8K
MM>"-@E`CVSM"FL!(@"R90DCN.5&F"?E<C'PT7$LF49%L6L9&QJ"#6/CXYN@P
M8LF;7@&S-FS9IHMFC1```"IIE(7@H`("`9DIV>%<86B)BG*<OR%4$1."@$-Y
M!R`E*(B7D03$/R\B(Y;2KVPWN;KSJG?,:R9["KHKRT(I]34[K`O'-:V!2)#Y
M2.`D:==84[2P0:QW")#K))K"U=`0"+I*I\D%:JV](ZYW%OO;_;G2.[=_6R?T
M=UGW;1-9U^-K$&QUWLS<#65T/I_;9)?=^V:NLR?648]6_EBP)!,Z^9R1E_/.
M8AQ2Q]LQY6OT77M'UE5HBDZ\J4#2:C!I"C%5RLQK:(B&13")E#$9LDT43K+J
M")U%#@91101,<1,(CD:>M%$@^0>P'$?/QX()N?;DQ`*;T_#UYP4%13)Y\`/\
MPP&.!C&,41``#T*81*7T#\..1]??+8U>`>7GR(?M`/'@1`.`,/IY<@'I[\9!
M#+N3I=&WZBV_:]=4%M(;U>ZNFJI$V*J_2UK9EDK*YT7,I08VZLSL99,LNW1.
M5HFJN9!!T)52@10`,%%-F_\`K93>R;=[6NFG7S8W7[6:B]-:WLHZ&V+U[83/
M8.NWF`MFJKLG1[)3:0YGY#6DK7UEY:VM4'<>_*[0!207*F8R<GB(RVJ2^X9&
M;WV=W-I&FMW:FLG8WKWI2M;)7=U.[.+OK6HZWWCL^K5Z)B&%8T9V5?-+R[JC
M%E)2D?$TRR.A:/BKF+XJ_4A:9[;]/G5:8VQ8.O&HYO>2T&OM>3IS!U=%JZQM
MD;%+R1U7'P+D87JF:[MS-ZM&@@9VD^@HE8COY`^E1+XD"-1I('"MH4B#QY!S
MQQQ[<`(`(>10]BF]?</7"4T"V2\1`"^(\F/Y!_%YF#Q,<3>YC'+Z#S[X*AM_
M1)>!D_(YBF("?"IA6_)^0#E'Y?/D%")@`\_O'W'+:M?TP`4I2G/RF4"I'.(*
M'(7@H'`3*>0J>8%]1-R.1*<G"F`P&!7U>?\`S1NN7_@4[@_]^?3'+'\L_P#O
M\)^KJG2$@@D*A#>AC$Y,8AA,4`Y)Z%\!*(B)A,4"@'X\@&1IJ06^<GR`0Q"B
M(^`G`Q1.`>GD!#E*<I1'VY`!$/7C`WL#:54^/@``3&$IS`4`$3"!"\CXAZ`8
MW(@`!R'/.!5IW<V]6;)//]4V94BFF-(1,'N/M(@F!UT;,JHZ0=:6Z]F,FFJ"
MDQL^RE:O'344C'_3RH*%$.1'*F]I2=2=:7JDZZD[-MV6DY;;VY;1(;8V2U?/
MW;R+JDK8V,8VBM>UJ.=+.$*[!4>MQ[)B=HV$&ZTDD[>`'+HV!*@$R%'DH`7\
MH%'Q*`<@7^$.0`!X+R/']N10Z8'`0$1#G@?3C\/V@/("`A^&!B;=6G*'NV@2
M5%O;%X>/6.@^AYN#D',#;Z;861P6A[=1K/&J-YBKV^!=E*LR?,U4G"2I0X-P
M(@-A%1LU*;FU1V)JD.^>QK#MY'PZJ%.MZK5K7-5_<JT)73*.Y"A3SINLE$U7
MM#KIBJ+Q$%"D%-PH=PQ^2+>O6K47^UMVE=VTO>].0N-,7>(D2>.H.QUN;9JQ
M5JIMKBSBC.56T0[GQ7CI>(<E$APX%)8O"J)U$CD.)68<@8#`8#`K`^XK_6<\
M_P"G41K"K-[UNBE]JH;?-%U<_F!J<7?874U"N4-;&,UL%6.FV5`8-&NS6C@T
MBJPD"$4*5N")C*?(2I/\O9?;#CY6D]2JGIFV,3P^QM&66\Z\V;#F\EV<;<E+
M?,7!\W@9(2(?U%7"-;4BFSE")))/@2.H5,@?E!*1B*6&Y&C`8#`8#`8#`8'"
M>/`9`154"`U`JQW*IC"!D$T43K"J4A2G,J4/#\P!P)2\F_#C`_/;U6A=IZR[
M"Z$V=9M="3K1&[)^Y'1Z3N-O8FBMAMUK[R=I:_OBMN9?5A61GM/H=3_RL=0R
M4R,H_4F5GK1R5FT35%,MVS53E^AE%45?(1+X@`AX^_J4?8P\@`AY?L$`$,BM
M["F!MJG%,AC@43"`>@![C_L]1_VX'@MB;,IVJJ;/7[8,TTK-1KC$SN5EG8G4
M$#&$$V[!DT;E5=/Y1VX.5)%LB11=98Q4TRF,(9<<15!L&_[,VGL:CS$U0$YS
M:DVF[F^IG5>PG6"NZSK::OT:_;?M0N@11FQ?0A%`/$0XB5=!14&4>)G:CMXV
M2+$.O>@8W2C">DY2<6V%M[83YO/;EV_-MTT[)L&T%9HHIJ$;H`#.N56'0*#>
M)A&14XZ+9%(D@F4`'E]HD:9,ABB0Q0,41Y$#`!@Y_`>!Y]LBTT?'X@)C*'$W
MB/)AX$.`Y'D$^/`!#G\`]>,*@QWN:V.,U;&7E)JWM.I:>Y?L.R&JG$8=^VO>
M@[8P&#O<C$$(8BK*TZW*5O/,W'EPBQ9OO$IEC(B6I7PX_2G9[IS%S'7VXV$;
M->-.,H=Q6+6\6:%';&AK`U3>:AV_#H-`%H*,M"*IL9!%#@&;U`"*"*AL78GK
MD4P&`P*X^F)>>T'W4R\CQ_QCZP'^P#=%NIIC``#Z!SR/M^/KE9C<^UC8!P`!
MZ^G[1$1_O$1$1R-/N`P&!QCMBF5!8IS)J?RP-X\>)R$-R)3D$!*81`1`#<>1
M0'T$,#Z#9,#$.43$,0IB!XCP42&.!^#$_@,(>H`(AR4!'CWRE-SP_P"D;S`!
M$Q?("_E'D>.!``'DH#P`^^0?2$`@<`)A]1'DYC'-Z_\`6,(F$`P->`P&`P&`
MP&`P-`B;D>"\@`>WL(F_``$?R\8%>UZ7`OW2>MQ3!^4_13N`)S`<HBB0-X=-
MSJ**%`?+XRBF!>0]/(P!E2LWX8Y^XO8JW`[0^V5/R$F[AYA'OY6XY!VT?3B*
M:U,E-);I:64LHC#*@R=5]Q,F@P6^N(=!)P*'/B;UQ23.O;>^W--4R=O?<N:U
M*>I36GI[>GZG4;9KRYWFU4R1E4HD65M:ND+Y_P!IA-@-)E`P3[>,,:*^K$HH
M`7U#$D+2A$>?;T]OQY$WIQQ^''&1IA7L)N2&T+JBS;,F$%I)2(2;,*]66@@,
ME=KK87*4#2J-%^AS%D+39Y)JU(H`"5$IS*GX3(<P5%:77G4\OLC;*4!>5"VA
MMH^YI;E[)64S%%Q'[1[A7&/!_#T^.%`3H.:EUY@W":***9E$X]\46PD`"<X5
M<8S!8/(%1#^$HB'J8?,W("('X\3D$"\@/N//KP.)2'-R*8&VH7S+P''(&*8.
M>/<H@/X@(?AE@0,[\6SK?4=0L4>QK6Y)5HTZM/UFS:YKDY8-AZPGZI'OIYSM
MZM+UUD]E:@SUG#MEY!],@04&3/R^4IT3*%%:2BK+QO8?2Q(GL21Y67&PH*]Z
M^U_=+%&J$:TGN[INU-XAO7KK*UEFFJYH>XJLUD"\+E3^-5RV<$**K0Z?@X>U
MT/\`LR*8#`8#`C'V'Z]3.X&E2G]=;1DM);DUP[FG&NMI1M:C+JA!MK,V8,+-
M"S=(G'C.&M<#.,(ML19NNJEPHW34*8#%];:5^WH>O^C?\CZM.L)&[3>Q[S>+
M7*WW8NP9]HTCW5GN,TFT1?.X^"8G4CZQ`-T69$V46V.9NS3Y*01Y$<A3/>%,
M!@,!@,!@,!@<=PV3=%%-8"G1,0Y%$C%`04*H'@<IA]_$R9A*(?B`X$`JKT=L
ME?O-=1D>Q5NG^N=$NSO8VONOB].KS(]?M#B0FI5HRD]IMW9K19*1`OI]<8Z'
M6;ID:D2;$^4X(%YJ4L!(GX&,;S.;S\>?,>>/$/'T]`XY#W_?D5N8#`V''J0H
M<"(&4(03`8I?C\N2E/\`F$/+\P@'`>H\X)40V[>]]VU7XKMS<Z:@WI;2T7)C
MUJU;=3JL=;:=)KB7F(&W]G>T]D:H*LX]>++$+NH:(\5UQ'X$6Q3O%BB2IY6!
M=-HG1JE;?V77.Y8??NR=E0]6V;M;=4:];.IC8GZXK+LJO,&0:JKM*U3D1@Y"
M.B(5OXMV+9FHCXBJ150P]:3=*D8#`;Y!'@1$2@4H`/H```<>I0``]?VX&]D4
MP.$[8-7R"[5ZBB[:NBJINFSI%-=NX062.@LW725`R:B"R!Q3.4P"4Y#"`@("
M.6Q1U8ZC9>KVVXQC5&DS*67KDWL.Q]$QJ"Z30VZ>H%H=JGV]UW/ZJK3ULTFZ
M<*RT$FY5,IRF1T*8)$X%C\)U=)3[O7;]5:]>*A(H353M<#$6>OS3<%"M9&"G
M&"<C&OD?D*4_"S5<AQ*(`<@&`#`!N0!1;UV17"4='3Y-\!CIE%4#F3_.8O@(
M`3A,/S'%01X\0]0]QP-[YP`#B8ARE(3S$PE'@0Y,`@'(!^8/'V_?EI+5T]-3
M@CV@^ZD<YB`4W<35Y@X.!S<_\"W5`OQB0OYBJ_RP$`'W*(#A(Q,K$1>$$$_C
M`3&5-XI@/X@`>2AA`.3>*0>_[\4MN40WF4#<<>7J`<@/ISZ>WIZAD5JP&`P&
M`P&`P&`P&`P&`P&!QUB''S$#&`13$A"D]1$W/D(AR)2E,(!P'(@'[\J=49;R
MVILQQ8.[/:.-WB^UM;>@M@L]%U=HQA7*,>M[=K:>M=<[*;1&R'T]K:9W-(L=
MTW*3_1F#:HR+=LH]AT540D728-DJDWM#$_W$NVR.J=HZQ=;A;L^P2_;5QLNJ
M6`]6@R3-;Z,,.Q[/7%JB"P)X-2/5?U^TD7JC1R\;E67CC?4+.2.R\9%J?RMC
MZ(?</ENY=EV17I;1]SUNPK#$++4+8]INZ&-5LU5/8W5919/+!L[3^K8!U?#N
MVAG!F=<=62+^D,"J<BH'H%JLI$RLX*L!P4\0,(D'Q.')1$BGQ^8I%`HCY*$]
M.0]O7T$<RJK_`+$N=G[$[9+4:$@6CS_(/1<=NK1->DWK0M>V1NS8\[:-<#;+
M"P?HD(Y:=<HN(+*`DBJ=1T6>,0$P6(B8UP7-O`T)MV2T/UGW+3=<;'TK_7&B
MMH3\Y,;'V%K&;41OS)^*5IFXVQQ+38]?1D-AW65D%&2EF_4FK9(YDE_TY8W*
M`(JZ2I6J4*??V>HU:P2T0K7I6>K4'-R<$X.*BT3)246S>2,7YF*F<Y8IXN9`
M3B0@*"7R`.!`1*]ED4P-M4QBIG,4IC&`HB!2<>1A#\"\^G(X@5Z?<*ZY[<[(
M4*DUG3YJ$E.0-YC[!^IWJZV_7YZVZ:(./H+)"S%1JMM5M*3!RH(R56D6H15B
M:D^D<K()F,?+"3IV7<6>+5JOU.J5BD5'#W8?;'1.LEW$7'HH,7TL[A+=*JC]
M./S$BHIT:M'4'X^3)AP4/?&$3[]1X_`0XY#\!Y#VY_'C(TU8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`VU"E,!0.`B`'`0X,8O!O4`$1*8OXCZ?OX_'`JD9T*UV
MCHSNO5]$K<]:;76+]LVLP==KL]`PUP0?QEQ_74']!F;C(1E7)=X?]0^HBQE7
MS&-5=%`KI4B?)LN4PD7T5U/.ZST12R[#H;>F[=?Q\N38"OR0!IZ94"]7>Q0\
M_>?Z.DI.C'V):B6YS,6+]$66BRSTD\*W4,@5+A)'_":F13`^#SP/''/`\<^@
M<_AR(`(@&!A/L#L>UZLTMLG9%(K<!;K%1ZT\LK2O6.RR%4AY1E$&0>SA5)^*
MK5N>M%F\"5PHW^./<@J\(FB?XR',LG:_:7*LOOMM+L(5'4%VU1UU1N5CB*RO
MM;0%C@;N9_?9/9\?44;/:]-6/7B==*G_`):;-I)W$(_EF\HHY^50"G9)H?SP
M:&<^G5C?T'9%FZ_'AI^!U_=*+'=H]-U6;:N2VK445=Y4H;0TI=4"E,2$3JNP
M9@KR"*<YP>)/7R"7B@Q3`6MBR[(JOOM1<M=TSLUTB-==C-*9)VBV[=J<-"26
MR'52C;B:1UPY6/&&JZDS'0MPD&?P&<-!<-UU6:B9E$C%,`Y4G^6`OMX0IYI_
MN+9S>X,9W6%2VIN%#49-;=B;SV3U!>:/<1K;V/G&FQ+L9K(/+9&.8-Z1]#B1
MVQAW,@*#-7XB$,920P79=_[TZ[:+W1]P.MQ^@1HW:6N[`W"77K.IWEI>:]<Z
M?UJL*FH[E<[O([)?,-BK.:II>%C)J%CH"J*,TO(J:RBJ2K@[V3C/'GVGW=+K
M6*-U7V-M.MZVJ]>BM57NW]^TZVHK/(:MNE4B8Z*;:[UC+*6.,9,99&Z/4U7Y
M9,ZJ:$<N4ZBA"D45!/Q*]6P=..Y&J.[&IW>U=4`[:-(.XR^O[97WTW1;.ZK5
MSA&D=(R,,:U:NME^UO92E83#94KR$FI)@<513^8%4U4R)@B8F$LR&$Y"'$IB
M"8I3"0W'D7D`'Q-XB8.0_'@1R*U8#`8#`8#`8#`8#`8#`8&PHCYF$WF8HBG\
M?(>OY1'DP"4W)!`0_:'(?AA*82M_67K_`+`V53=RWC3>N+7MC79#)438L[5(
MN1N%12X-XDK\\Y04D(SQ$P_[HX<"(\>^6RH_+D&ZXZ(.<ZAM/:S^14DN@L?^
MC803KM9VW!?9=NJI])\ATI.Z%"6<$$1(K(_]H,`J?FQ97>MG5G6C0>D9>YS^
MHM0Z_P!:S6Q93]:ODG2*S&UQW<)4#"8)"PJ1B+?]2=`)A'R4`?4>??%E,UD1
M\1,/EY?G$Z?(`'A_+!/@1#@3^P^H\CZY"D'NY;4-=2.E>U3!H==;2-X0K&P`
M0:@]<O-);BDH2K71N1`0]$X.V-J],JK"/#1E&.5/;RPK7;.B6C+\AL`9"U=A
M6[/:6S6.ZIIU4NSV\*XF%M2CTV30E65KMZ8&JU7,VX.6'CA1BC&-\@(^0B.6
MY9KYM,6LP["N0T56XM)5*,@(MA$1H.';B0=BQ8-4FS<[Z0=G5=/'JA4A%510
MZBJBGD=0YC&$<-/09`P-!R^1>.`'U`0'T'Q$!`0,`"!@$Q?<,".O8CL73.N%
M1:VRUUW85N2=.'1B0FLZ^2S6%")AF*T[9K2YC5I6&1)`5:':+.WQP6^H,BF9
M-!%=8Q$CU&*NPCB#V#<>E23->,D8Y]O**V=".'*:[D5R56ESB[-ZP8-T_)"0
M(C9!_GG`I&@&$%!Y,7`G%D4P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!I,`"40'
MV_N]./4!]?Q`?7"2K^ZIR4?JYOW=F=CW&(A*O$=Q-Q7AS8[3)M8&O5.I3<'2
M7+5%Y+2KQ%A&Q\>HW6.HJH=-$OR<^G(Y4KY37K5GK%G2![5[)"6=J<B#M1[`
MS,9+MP;RC1%_&+?)&KKMS,WT:HDJW4*/"J0E,`F`PCA7K,BF!\,(`41'V`!$
M?3GTX]?0.1'TP,%=@=3.]WZ;V?J=E?+-JIUL&LNZZ?850C*I-6&OLI([<KUU
M&0]T@K'4GDB:.0.U#ZQ@Y^-)7S(`*`0P73+#$+U@MC;<6M]IO>TFRI6H:LH\
M;1FVHW=.TDSK$LM!QB;->TR=JCM?--C1LK(KI%</D&DLU:'*`HF0*@(IX7K@
M]06W^9$_OSM"^1!4^Y=BDI=`7<MG,>_;Z6T*_E*?5F;Q!1RNDX.XV"O:Y-N\
M2*F5ZP?M3&`W`&%Z/I.O(KIW,*R<F(=1LR4526%PW<+L6BZ[9RK^5PX;F51,
M5)9=/T,8`Y'G+:4W6L2P8H`U9-&;-L!%B%1:-&[5,@+F`3@1)!--$I3`'K^7
MD1`!'%E(4RWVYNK4Z^O2TS5K;*PE]AKU".:%);.V(_UC3DMFU:;IE]E=5ZW<
MV0]-U99;+7;-(MUY*"9L7O\`VY8Y5`.H)L%-QU]M_IT[8;#C%=1,08;7E8F<
MV`U3FI]-*Q34'3(ZA14PY`DD'PRC*NQ#8I%TO!0KE$KCGY_YF+(BD@M.:/J&
MCJ8PHM0DKS+Q$<JY72D=A7ZV;(MCA1TN@NJ60N5TE9FS2"!C-BA\:SDY`*''
M'&+*9?13%-,I!'D0Y$>!,)>3")A`@',<Q4P$>"AS^4O`9%;F`P&`P&`P&`P&
M`P&`P&`P&`P&`P/&;"J<%L"E6C7]G:B^KUZKTW49QH0Y4U5X:PQ;J)E`15-R
M"*Q&3LYB']RF`./7C+"2JXDML6MI]O/;\/;-C6/7FWNL\BXU)?+W6YLM$E$Y
M37ETAHJ-ML5)S+911G6+K5SH+-7+A("/F:AS$'@>01Y3=\2QH%K3<]M+;"M-
MI2EA8V#K[0K>77CJXQ,Q`P:R$P=FC:ZK76I0>1A+&TD@%Z\\U6[XP(F()?'\
MR5A,<Q@+QS_B,!?[Q`>/]F16V*Q0$P>HB`"(`'`B?@.1\/\`I>G^OTQ0T_)\
MO*8$,413*;DX"3CR]0+QZ#SP'KQZERZ1"GNMU@M'9VNZ[K=8M9M>C#W%^YM%
M]@K59ZI?J[2YVJS%=L)-?JP;"1BY:>EDI`&QVTN0&`M55#@(+%3'!Y1L[);I
MI&@.V'1JHHJ2$E2-::^[!/-HQ5,@G5VM6MZVM3:#%T&\7>*KI7<W5Z$Y=L)(
MKR370!M\Z90./'KCB7E9I0-H:^VK7F-LUM;H&\UF1;).FDY69-K+,#IKI$62
M(JHU5.9JX.D<#`DJ!%.!]2ABEB;>X!=(>?$Y3"!RD$"CY"!C>WH'X<?CD6V[
M@,!@,!@,!@,!@,!@,!@,!@,!@,#;5/\`&7R`OEZE`0Y`O!>?SFY-P'!"<F_?
MQP'K@<<[E(R)SCRGXH_,8BW\DY$P,8/,X'\?$O)!'U$.>,J*--Q2\1OHO>FB
M:*LD%M*V:OW_`-6;XM2(2OS.RZ39[&!DK0&M=L0%/;R+]]K>Y$KYFEA6;I."
MHL1444`Q4S`"!8MTKT$XZ_:;CX:P14/$;$MTG*W78D;7G9W\#7YB>?N7D=1J
M\]532^2MZ]A'#>&CP*4J9F[$#D`"B`8(2\!4@B`!SR)O$?3^$W'EP;GV'C(6
MTD<)J&*"9@.`\_F`?3\O//'/\7J'&"VX?@2'Y,(`)3`)BB(&#T$!$!#D0$,*
MJ<GM]=CF`?<#AXK8->;O^MO9?0=9UA)CK:+<%_RUV+K?0-_GZ9.L1E?CEWI5
MMG2+5.6`R3I),J2GQB8HE&L^^,G;XMF]Z/U\V]"R$U39+:NZ]RS&J^M2,=&.
M8R-85G:LO'0NOV-K5BSNY`\G!0;AZM)29"`;D"J'*4`]"IQ:\H<)K*ATS758
M3.E7*)4X&FP:3@_RN31==BF<2P4?./$#+O%$&8&64XY54,8X^HCD'ML*8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`V%DP4\.`3\P$0`Y@'S*F(E%0J8E$
MIP\_$`'@P!^(^W&!5SV/@:UJ?<=ULFS=;Q.R>O\`VFULQKNS:_8M2RVW==Q&
MX]9M?BJMIVLVCJY9D(R@S].*A&F6=1@H)/6PK'4#DI<J4\KHCL74OBB=TEZI
M:<N[Q*C)T9WV$Z(R]!WM#P]&KLBN:+UOY-8RE;]<0,0VBTCI0K2ONV3)XW4;
M$("B*?FE(3:UKVXZ[[IEU:?1-HPY;\T81$W*:VL2;ZD;3AXZ7*HO%JS>N+BT
MA;I"A()-5."N6*9O!,W(%_B`JL^\;FW<?>G=O23+L5:J)6R=K.I&N:/>SMZ*
MO,Z6INW^NS+9]NA]?N752_2$TG5F:"#,\XWES%3=*$\C"*?B]I,<A:-H/94A
M:-"TO9>QGK&*<J5E9W8YF1.C',R)PLA(Q:MA>+K"@V8M9=C'D?G$P))I`J(^
MA>`*5@-SO#;_`&G=O*YU.24HNHQ311F.VMMADUXN8!8[PKQIH"G/UTG]XDF:
M;5#_`-N/VS>M"F^!5JX?JMU6HBWH$/MZ];V<(H+.'M<7LURZ+,2O86!N$_#=
M@9VR>9U_UF?V5&ND92P-$GRIED(5Z1Q76PB!$H\B10(#P:RAE;>G>\="V25V
M-K-66N\DLJZ?RNR^OP5+578&32<KMG;Y;:&G)H4^O?85W(JLR#(3)4Z_:7*0
M"BU$@B`XV1'.LM];N\=HM\S)U?9C.GV>)J;&2DK=MFK_`":NG-8QL`U=/W9^
MQG7S:3R#V!J%06;=3Z==HI/13@X?(FX`#E*%R526VB^X.C>Q,[8:QKJ5N+>P
M5QNA(J1&P-8;'U6]GH!V<R;2V4E/8]6K`7VF.E2"1*8AA?1JA@X*L.95)_`8
M#`8#`8#`8#`8#`8#`8#`8'36&Q052A)6S6B8C*]78)@ZE9N>FGS6+AX>+8HG
M</9*4DGJJ#-BQ:($,=154Y2%*'(C@1!GN_G6)Q6*[-:EV1!=D):ZJR2-#IW7
M:9@=J3MR4B!%&45;NX"55KM>KL6Z432?S4N]80T>=4A7+E(QR<U+B5>L[LCL
MGWC?S-5JC*+GZLUF)6,<5#5MVF(;0%<3;.VIV([W[,PR#2;V9;6""?BZJ>N$
M5V+1^BLV>3!T3E.+@D50_MM/-1/93;^J]VR-&[-R<;"QCF?K=3@JOU_E8.NI
MK#`:OE]#P)&;1]KB.7<J_"Z4DUK2DHNHH23X.=$X\I!ZU[3N27.,TIV/IQ](
M;MD$#IP1572\AJ';CENT47?'TQLA=&/:R:_QD%88F31C[`B0JAC-!2+\N#6>
M.+]P'=NQ^N/6"V[IU:XJ_P#55-O&EV@L;?`O;%#R,!==Q4'7=BCOIV,W!.6$
M@$1;UE6[PJRH(N$B"=,Y!$N$F:A'1QW,W?/=HX36M(B:BM1KCV,V+ULAHJ6J
M\PUL5?ENOM1:[+VS?9RX!8?TJ1@[33U3LX-H2/25;O/%0QW'^ZPLK/K7<Z?2
M8&0L5YM%>J%=C6:[J5F['-,8&*8-4$E57;AU(R#EJ@V0012.8QS'*`%*(\^F
M05&6QYT?W-'=@(;2>@MX=KC=EI6D7C;\EIJR[4J.M-I2L4$9$U2<B>PMEV%K
MC4#%6NP]>;*>-=L2"Y&+)N`IG#Z8IKEF:9YK*C7=G<FF14%]`XU;TVUBT<+H
MHV0;,[8[XV1!&@V-:F5FZDG$R7]':V!147)WRKHDH(&X$P_*)I9+D4P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P''X_B&!Q'34CM$6ZA2"D<P`H0P"(&
M3`>1\?$2^)QX]_4./00'`C-LOISU^VE.-K=,Z^95V_,&CAA$[/US(RFMMH0;
M)XN@N];PU\I;F'L#%%VNU2443(L!#BF`&`<HC3M+HUL">AWL.TOFN>P%5668
M?2Z[[?:LKNP$(YI$J)N(]&&V54VU5V(:3:N6Q%F[N7=RYT51,<`\O$2+2E=]
M^U-IGIV38NS]_P#4/<E0H6SI"&F.R2>OI>D=N>OFWV<"]CJMKBK[(<;B81%P
MHR9YF18I0R44Q+]`H)4SO"D*)C,R8C:SBO=<MB[_`%828[3I1E1UI!)HGU_U
M"H4@*FNHJ(8D;(0[?><NT0:!M66:()DYAB`A66G`%!JX43*X$>(6`QT:UBF;
M*.CV[=FP8-4FC5HT00:M6J"!"D30;-FZ2:*"!2``%(0"D(!0```,6KL!#D.,
M@V5$04X`0`0#U*'!>"F#V$/R^0<\_@(<81'O?'7RO;CUQLNO-F-;B;[=]>6&
MDQMX?P+227CC3""AT4Y,3$!]+5PT@"9G+$ZOBJW`R91+Y<Y3+!VG-;]D;=N:
MG;.W_1M9ZI8:1H-CUM1HG6^P)#8"VS%;26$1E;I8%EZ;24ZE`H-(%((^OG"4
M49KG54^L-Y\`(OJ?F13`8#`8#`8#`8#`8#`8#`8#`AKWIU=>=JZ4B(^APB=O
M>TO<&G-JV+7II%Q%J[.I&L[]#VZWZW9N4GK%F=]<86-59I(/CFCG)S@BZ*9$
MYPRP2BUK#K;']J-F;NV_MGKW?]"Z<V-7=+UZ+T??Y%I3;;>;%K8^VD;G.[:I
M&M+C8:8\I-NB;Y%,#Q2KYX672A$%7H""+9-%;-6M/KU:@JM%,X"N0,-7(&,:
MMF<;#0;%M'1;1LV2*FDBU8,T6[5LFB4H$*!2_P`(?W9%IW)TOD\B*%**8\>0
M&'R^0/?Q$O``4`,'MZ@.56.-FZAUYM^KR5/V558>V5B053>KQ4BQ24!*4:&2
M4CYQ@[`"OH^>BE$"*-'2"J:K=8A%""!RE$%HK+W]U^N53U=(:4W,VV?VPZ3N
MWU:>N4:O9+7&]IM5_P!(VB*N%82?3]4D8:5W108>7B&BZHJN"3:96!#+&D3>
M*8"<X1T/=Z[L/?=NWGUNVK;[PPL\8T2K45U:U)=-@[$.BJR"&FK*\G>PDRAU
MQJUOET&2C6==1<6UL!2)F3<JF4``Q(SQ3>I&];3-IW`VL=9T>;0F@?,-B]K;
MY=NXVX`B5TFRGG6(EX^J%1T_)I+*JB$<BI,QR)R"'B8JIBE%92G1Z(U:TF3'
M?.U=K[Y8ECI.*4IMAL04?4SR*ETP0=Q$QIS6*%1UM98])L4$VYY..>.T2"?A
M83',(K*2RHNM:)K2`9U/7U,K%(K$:FU390U6B&4/'D*U1(@W$&S)!("F:I)E
M(0PB8W`>_'I@>\R*8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`^&
MYX]/40_#TY]A#T$?8?7`K3^[ZF(?;H[(AR4"_INN2``@(_Q[DUUR)C<\\#[#
MQEZS_;2R,P&(L*OK\14S!XE$?S'$WD(BEQ^97]@_L$0R--97*!S>!5"F-Y`3
M@/P.9,%2E']@F3'D/W8&_@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#28.?[0YX'
M]G/_`,88&E,#\`97Q^3@0'PY\`]?\/EP;@0`/[\#<P&!\'G@>``?W#^(?B'^
MC`PUORZNM;Z-VS>8P15G*SKRVR=<06=`S4>V@T.[3JT0F\-XD;.)2PJ-6J1S
M"'B=4HB(>^7PGEYOJWKEMJ[KUIRC(1):^O&TB'D)Z$#XBJ-+#86W]0V5%<6Q
M")N'"=AEW!5%A_,H8OF/(CBQ(8A3%_+[AZCY<`4/<``O`>HB`![Y%;F`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*U?N_"'_\`'/V1'GD`
M8:V]O7VW)KOG@`Y$1RPS_;28W8&6N]?TGL^>UQ.P=9O4)49B7J\[9*TK<8.-
ME(]L9TW<25:0G*TM+M_Y0E%(KYL/(\^?IP,6=(Q)6;M&[W;UREXG9^JVNGMD
M0R<A=--CI^:DMAOHEG07DS9+TRVZXV>Q95QDSO\`-1C5.*+790B;58H@\$5P
M!"\3*P'(T8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`PY<]\ZUU_?J[K:UR4S
M&V:U5*VW6#,6HVM]7GD-2&H/K$B:V,(9S6&T\V8B*Z,8J[)(.D2F.@BH4HB`
M='HSLCK?L="6:5UZUV5$!598D!.1>T]/;4TM96+]RP;2#=4M7VQ4*=8',>LT
M>$.1TDW.W-Z@!^2F`+27BV%>^31*ZT#4NCEHN0F6&_NP.K*+/!$/B,GD'6J[
M)N=J25J44!1-T:-C9#7[-NY^+DP@\*40X..-2>DY?#^8)Q`HCX@4H\<"4O("
M8HFY$3<F`!]@R*W,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,#2<Y4R^1Q\2\@'(\\!R/`<\>P?O'T#`\?8]B:_I[2=?VZ\U"JL:O#,K'9GM
MCLL-!-*Y7Y)TZ8QT[/.9-ZU1AX:0>L5T4'+@R:"RJ*A"F$Q#`!+5C?=KV$2T
M=2GNA-8UBS[AVWV?2AB::J&M/Z<D7%ICM?7"D;#NEA;2<W8(&$-!5RH,3/%U
M$W2JZJ9R`W16,;@+HG,/6[/[M]1]JTKN?J/8+W;E=@=&:#B]E;P0:L;?K:[.
M=9WN#G'1W6M)B`FH6[&F(?\`1E63D[,[)PS?K($15-\I3XLEFGJS=NK^P:CU
M_G-1W8)"95ZT:^LFN*7>=AA8-T0&C]A5NK6.`>W.MS%EGK61_+,DHT7\F\,X
M7<N42E.Z5\0$1%)JY%,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#;5\@(82&\3
M@!A+R4#%$P%,(`8O(")>??@0$?VA@5:=TMRO=#=J_M^6"S4QNYTY=-GVW4TY
M?FEM7;RU7V)M:KN*S28]Q0@KSPLC3G;I<ZSZ0-*MT6`$#S05`WD%S+-/=:`[
M3Z,0O?:.@VF_P]4V'KCL#%U79$]=WD71Z;8;G?H*,4U[`429GI.,:VZ3"A1,
M:U=)M2%$LJFNW2(H8@\J_:W#R"NZJ?N3O)JTL+7]SN*IU_E]WZ@<WMI2F,EI
M:7W;.LH.-EJX^LK&R/+5%3-09U%TBFL_A6D69=8_Q.SB8AC.'5HF13`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`V5BJF)PD8I1YY-R4#")0
M`1\"@;\O)Q].1]@'`K+[2=$)W=\QO^UT2P0%.LFX=<Z,KH`^=V6,/(6;3]RV
M/.J*6&PPQ)!VP@)")N;9LA]"V4524:&.9,04`<K.9ASM[=5-];+Z_:BU<+[K
MQN">J4"VK^QVV^JK;(RN6M4C9BB:SU.QZO5976F2[15D7P3;"FF\3`H+^(AD
M7B.\Y]K3:L]9*?/R.^HU\N1XT8[9=2,/)/Y+9VNHR`D7T/K-U(KJ"[95V.V(
MA"JJ%'Y?KX>*^%;A94PY2GB>DOVC-C]6=UZ7O=IVXWV%5=5Z[HC%)6.O.R*N
M_P#ZXK6B*OI218?Y=HQIZ=/:_40A%7C1.2>BY1552,*0*(%,*TB*7U9&C`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`TFYX'@!'V]`'C\0Y]1_=@0A[K]3'';BJ
MU:G&GHVOQ\"[M[N06?,'CLZRD_3)2!AG$:+91(Z3N(EW"#HQRF*<"I<$$!'G
M*DJD+Q]D7<5M=ZYNS[L"PL5Z8Z\=U;;D<G8-A:JKFT[9LF55L^YM@OIBHL)B
M?8RZEE>.1KB'PD%DU=F3,HE\*88QPSU(&>UP[T7V&2W+MK?G6K7VJ.MJ[&\7
M;9%64V+%]D9K6T@A+U>K:OW)',!=Z_L%5DIR4!-Y(?3J3<LK%MECE*K\HX^T
M^EVM?L$-:82(L=??I2<)/1[65B)!$JI$GT>]0(Y:NDB+II+%(L@H4P`8I3``
M^H`.1IW.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P-AR/")O0@\B0H^8F`H%.H4I
MC<D*8W)0'D/;U#W#W`*O.W_7O2.Z4]K,S]@M6Z9O5BKFN(-V[E',<FE6+;`V
M6[R%<GK='U#:NJ;R^>SWZW)-D")3D2Z.LT*9)T;X5$36*XF4_P#5E8>TVATB
MJ.K0YN9JY4J]$?U>[647<V?Z&/11/*.2N'+]RD5T!"F1,=X\4,00%5953DY@
7R7D4P&`P&`P&`P&`P&`P&`P&`P&!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g21538g61j13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21538g61j13.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-=6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YL<&%V86QA;6%N:3PO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\
M+V1C.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2`R,34S.%]%6$)?0U927R!%>&5C=71I;VXN9&]C/"]R9&8Z;&D^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V54
M97)M<SX*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G
M951E<FUS/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@
M("`@27!T8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O
M<F4Z0VE!9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX]
M(B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM
M<$-O<F4Z0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K
M/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T
M>&UP0V]R93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H\/WAP86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!/`$]
M`P$1``(1`0,1`?_$`)<``0`"`04!`0`````````````("0<!`@,%!@H$`0$!
M`0```````````````````0(0```&`@(!`P($!`0$`P<%`0$"`P0%!@<(`!$2
M(1,),11!42(587$R%H&1(Q>Q0B08H=$9\/%2,T,T)>%B<H(F"A$!``(#``("
M`@("`P````````$1(3%!87%1L8$"D:$B0L'1$O_:``P#`0`"$0,1`#\`^_C@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?E6#M
M5,2@`'`I@(<P>12>1B^0"7R*)A5*7H/RZX13A%.YG;3Y&-R];=B8=*9U]U^Q
M5@YQBW$<@I(M*U?ELGL7\S9\CVA)%X@C:AC7\<2.9@8JB+`PF`>CFY4[X0(V
M:S!D?%V"OG3UCJLY9'.(=1<(XMO^O]I:RSQY9L6V+*U,GK!)XJ"Q2#Y\[D(2
MGS=:9R\<@<Q%HV.D?MA**'VPB)F<^(>^^1&^9#;ZQ?%S6F=-RS7IB0W'TDI4
MS=EWT`G`6ROV.L3REQA7"E<N;RQ2:-E1CBJJHN6!6YBH=G,7Z"^Q](S5$J/^
MDC^AJ@FFW;H`0")HD0+[8$2^AC%`I0#U^G7IZ<BOV<*<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!V'U[]/SX&&<N9TQ3@R.:S.4KU7Z:WE
M7B$=!LI)VDI.VN36-XHP]4KS<ZL]89E93I)%NS;K****%`I1$0Y41B8Y<VXV
M$C/[AP%C>$P!058-O+4V[;4U2Q'OE_D"N%Q_;%L%P\U6;9CNJR;1(A32<\\:
M2[=0Y520[A$2&.T/UTS<";HKR!Q]N=C9WK_?WQ&L>GD&-=.[7K+<Y8Q3%.:I
MY<(P8)UX79A#VXVSM89\!C>)$U"@!Q"=K%PU=M473)9%RS<ID7:.&ZR:[9PV
M4(4Z2[95$ZB2C=0A@$ABCXB`]A]>18?J[#\P_P#?].!23\SWS"TOXOL95*"I
M=83S5M]FEZ$5@G`L<D_DG4L5!ZS1DK1:6<$"LNPKS8'`H-/$H+/W8B1`#`DN
M)+#/[324.%Z.&W..M>MOLG8@R=J-M,]Q:5J];M'C:!R70HF?'QG,?6YF^92E
M?LM=<NTOOFS";8NE6"ATUDTD7!1/PN7L;MH;@_)>MV2-8K.XOR]'S4]&4S19
M?[B02R+E^45"):2C^]7-"/"2DG<S#UU@P4.E]LHG%-4&K844DB%(,.US7I+C
M+/U/U[I=]M&0SQ>MEYHV3*$I#34-&+R-YQW&&C*E/6H2UQ5K)GC6ZZ_14$FJ
M8G<J?I]0``F4D4Y0`IS>?1"!V)``PF`/UF,<OB0PG-Z^A0]>)5S<@<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`_"L8OBH/J`%[.!_7KM/W#C
M]#!YF3,D(@`B!?7E1`:(RML5M)#I_P"S-/F-=<52SQXW+F[*L='J9$L5>*W]
MEO*XJQ0*S@T*O(.1%1J_L!R(?;=+)('./@`J&5\.:DXPQ"^:V_QM&3\PJ-5F
MLGGC,,P>[9:<`Y*JU>!$33Q`&-(82""XD<,8)K&,'*)2^^DJ8OEQ?!*IL4Y$
M$B'(FF<A"D,FC_\`)()0\?%'])1!(O7Z0$`$"]<BNBM$!"6J&D:W9H")L]<F
MV:[&:@9Z):3D+*L52@59G)Q+]%=A(-U0\?\`26(8ANA[^G+"('J:G9!PV]L5
MKTYRHXH/WM>.1IKIE`TU>M=I*?C%!4A35P7$@>Y8?:2"@?:N_P!G579IH'_T
MF13)E$73+R-WWWNU0:1V&9'7VP5_>7(44X:X6P7.3L:KC_)UB913IQ.6*M9:
MC^X=YC7'(I)O;(X.1%^P8K)%(@HJL4.!C_1_XH:E@+*UDW"V:OLEMAOED4K1
M[:LX7IDW/!XU.BV?-U:7K]75F_G0*/'I2:K5$Q!!RZ:%)[GB(F+Q]%9M;XD`
M]")A[$>NQ_4`#Z?\A3?0GKZ?B/$^%AR\@<!P'`<!P'`<!P'`<!P'`VB8H&`H
MF*!C`(E*(@!C`7KR$`^H@7L._P`N^!J!@'OH0'H1`>A`>A#Z@/\`$.!M%0@&
M`HG(!C#T4HF`#&'HQN@#OL1Z*(_R`>!N`0'Z"`]AWZ?D/T'^0\#7@.`X#@.`
MX#@.`X#@.`X#@.!T5C,D6!G?>*JHB$1(&6(BJ5%0R?VRW:9%!$`1,J7L/,>@
M+]1'E27G,4I*HXWI*2T6K"*IUR,*>)7=`]6CQ!N7_I5791,#@Z0>@G`1\N16
M0.`X#@.!5EM:5@I\D/QB`*0C+(*[4.47'LF,5.*'$J+5\B98`$J0N'SAJ(`/
M7D)/3E%IO('`<!P'`<!P'`<!P'`<#03`'U$`_F/`"8`'H1#O\OYCT'_CP`&*
M/8`(#X_7H?IV'?K_`(<#\KDAE/$I?/\`$.T_#LG?0F$_N`8@E$@"'0@/U_#Z
M\(^?_>&K[,89>VR]5K?K+LKMEFC/$`QTTUFQQ"5)''*E682\<K'XYM6,9:)L
MKR6K3.)2>.;7;73A`K=#H0423\4S5)_MR3ETV9VFRS\I;V.V?N.OE?T<>0F+
ML*Q>+VU;D8@+G'X6ALPW:]Y!B9>N.7MPCY%]/MXY"*<KBA]LT4,4"J&$0$7-
MTL_^/G/MAVFTIU@V(MR"#:VY>PK0KG:T&;)6.C_[GE(5!2?6BV*QSG;Q:TJ"
MIFP>H"B)?$1+UQ*QJTR.13@.`X#@.`X#@.`X#@.`X#@8\RPZ(SQ=DEV!$5C,
MZ'<7!4%Q,""JB%;DW`(K>V(*^"@!^H"^O7T]>$=Y3$4F=/K"":3%NDA`1)2H
MQPJC'I%!DCT5F*_^L+8/^03>O7UY>KQZ?D#@.!IV`"`=AV/?0?B/7UX%2VUJ
MXN?E.^+V(:K2GWB-3W#LKENDF0(886/HU*AG;IVN(>1Y%.1L#1)!$/JFLJI_
M]+L*BV=/Q`H%*/8%Z#Z]B'H'0"/8]CUR$-_"G`<!P'`<!P-`,`]@`_TCXC_`
M>@'K_(P<#7@.`X'B+W=Z7C2OREZR%;Z[2*E`LQ7E+%:95A!PL80Q^O<<R$@N
MW0]UV)2I)I]B<YP`I`$Q@`2(4UKY--3K%IDOO<UN,^QUY0D):*92LA6I`MJL
M$[&6QQ2V]:KE4(+B6GYJSV-$$(EN@4RKT5D_`H";H*1/>,M:_;BXKV$G+'1X
M>%R?C/)=3BF-BF<3YTQS.XIR0G4Y0Q48VW-*U8$RGDJP\<B*(.VQU2)+![:H
M)F$H&'A*P1*8Y>@'](&`OIT4P=#Y%`1`0$OH'?`^?BWZV0^L^TNP.P=;WCLU
MJVPV":QP*4-?`-.S]L!7*(P*<:UCC#%796B%>X^I?MG,=`CU$C9R<!456,;Z
M$J+OKR>0:%69O->5I/*67LZ?&C([=8QJ=2V+K]DA,=J8DS88Z<A5XZX4K.2,
MZ^JF)L_S=77_`&AVF+QPY9-#-D"HG63!02ROFPQC6BX7Q=C[%&-(QK"8ZQY3
M*W3*%&-7JLDV85*O1+>/@V+.1<'6<O&36/0(!%%5#F/_`%=]&#B2&4BG(<`$
MIBF`1Z`0$!`1_(!#T'D4$Q0^H_B4/H/U./1?\QX#R+^8#WUUUZAZCT'J'YCP
M!3E,`"4P#W]/S_R'UX&[@.`X#@.`X#@.!M\R]`/8="/0"'KV/K^7\N!H!R&Z
M`#`(C]/7Z^G?7\^N!$S8_/N-Z;`7/%I9E.ZYAM%2F&-;PM4"'M&0YU6>C0C&
M)5:K#'/*1$"I^XD57?.A;HI-BJ+E.($ZY4-;-N<,[!0=>CJG/O82^'JK"<?X
MLOD0>B90BXOVU6Z<@ZI$LL>15BW"C0XE7;&<H%+UY'`?3@B;BTL2J)@4/U%(
M'Z>P$P!XB?U`O8^GEZ_3D5R\#8*A`$0$Q0Z$`'L>O40`0#L>@^@AP.IF9N(@
M8UY-S4DPAX=@A]T_EI5\TBXQJB10J7D\?R"J#1JD)S@'D<Y0['Z^O"*3LTYP
M=9&^0?4S-&*,;9)RCKSKG"Y^Q[F?*],HDM)0T5=\L%QW"4-O43&20=72#:/H
MMX69?1P*MH\I2*&,<H\NH3Z730%BK4T,LC!3\),*P<HM$3B,3(L7AX.71325
M5B)=!FX6_:I1%%8ACMU@35`#`82AY<2L/1`<@B(`8HB!A*(=AWY`'8AU]>P#
MU_ER*T!0@]]&#])O$?P_5X@?KU^H^`]\#:"R(]]*$'Q'H>C`/J'7?T^O7?K^
M7`Y`,4>^A`>NA'K^(=A_F'`=AUY=^G7??\/KP->`X'2QSZ1<O)I%W$KL4&,F
M#..=*K(G3EF/[?&NQD4")J'.DF#QZNAXG`IO)L(]="41J.ZY%.`X&.<FXKQY
MF&N#3\H4JM7ZK$F(&R!7K;%(34(:;K$FA,P,DM'.`.DY<Q,JS272`Q1*!R`/
M0CRH^8VD8BE)+X$V41;JCE^E66D[#6W+-.+5,02V1;-3K)3MGY^TTN]O,0&2
M8V6WXXBG29'SYDS3%\I%^0H%,(%XB4C3TNLFR#Z?^3RT[`9%SD?:*5QUH[#8
M$FHO`&)[-`U1[DW*.6:]D6NP>)L;S"[ZUMDU*?6BKV^<L#YM"1\DNP9F=H'*
M*!$:7-U*XX*_M[LP#K^YIE[IUAN2C6R"<!27T=+;0V$BJKDK\LU>2E?5/$[=
MTR734;A"HN)ADX*;MT8IB@5HK/A)+$FNN(<(IR1L>TB)BIR>1(G:;NZ2&5O]
MP5*5(3O+==Y,SJRV)PY71!50J[CV"K"8Q$R]B'`]Q<Z'5,@5J5J5]I-3R!5Y
M4Z9Y"KW*$C+#`R9D#E4;F?1<VUD&"ZJ9TB"4YDS>V8`,4`$/4(06#4G,F#VD
MA+Z+999U$KITP=.=>\\*3^1-?UX^(C(Z,:Q5`23D$;CAU4C1B;Q_:GBD>X<K
M`HZ;J>V3H/5T'=&-86]IBS:#&]@U@RC(S+.!J@V==2RXAR8_<L"OA7QKF.(C
MTJJ=O[XBW(QFPAI11R/M(H+"`CR#9LS';2FNI)RH;*8TU5U@I6/)ZT9`R7(U
M*F6Z\&N#=ZQ!JVEU,IB-#K6/8Z&.Z>.GO9'7OHI)@8I#&$+LE$#!^XF]N3OB
MW2V1:XJQU+[$*HYE2B[-85)?'./W>.J*\O*=+V,=4-['OK`O&V^LUQA(HU]J
M<IW1GZ9TE"-S>!0FC\;V8\E[!:+:J9JS!)Q<_D_)V&JK<+W.0L0C7XF0L4FW
M5._=1L(@!21K58X!X(@4/;*'0^O?$D)P<B@CT'?Y>O`V&4(3KS,!?(>@$WH'
M?X!V/H`C^`?CP-1.4!`!'U$>@#\1_P`/KP6W<!P'`<",&<-J,4X7?(5)XYG+
M[E20(U6A<*XN@G-WR?/HNC"+0@04:8K.K,G?0BE)3KF*BS"02BY`1#A&(QI6
MW6PK>=2O=L/J3C>66.A&5S$T@QG,]S%><)(`1Q9,F/6SJ%QS.KMSJ!X5]J9Y
M'K?I!XL`=C2L)'XFP#B?"+4&F-Z5$P+UP@FWE[,JB$K=++UXJJ.;/<I7[RRS
MSA=5'R,+AR8A3F$2E+Z`#%"ASX<RXYW7TON>O&PT0QL^9-%\U9-UA?W^(DI*
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M=VWV;LU;D4#5?`]=DFJ1B@I4L0QRHQ*H**>)CKRZD@Y4,0ICB)@Y,$)KQS'[
M!F@Q38M&K)L!$F3-BFFU;,6S<4_M$$VC<$FY"I&*/0)`0@$`/T]]]W`P%(ZS
M5"+L>3LF8@*TPUFK*<"G$V/(M>B&$HUE)1D\.[C[39*1(@-4L\^D)SI"[<H"
MY%`_@*@@0GB(1VS-MC=-%-86V1MMHIEDZWP\?7X%S8L,1"M?@\DY<O-]9TC'
M^.ZQ69A]+2<#+68THV5<.55!CVWBL("!?`G!FL[=/?-G]EM8W^*KEM;6L*N<
M'9.R%3,2S\_B!.Y1=@P+=\EV9>!H\YD*6N5ADZ_8J&I*2,57GSQDE'F2DGGW
MP?\`2'!!,FMO.T#Y!K,I\@^8=)LS8XK^/:K'O8N'USSJQL+9*NYBNJF/Z5EB
MS8I-'2;\SMID"MTK(\0X*BD4J<MT[,V*/L*%)27<27R,PJGR#P6G4!7H:1QF
MRQ#E6ZY0SZM9HQO"4S(.+ED%9O'2297P@"U<BE!7F7#@B:<><Q4CF`W8<G%V
MS\CO[IJX0DG*.P5`4:Q"\*>2=%<R8M&<;8H*?M$);%G?[;[!:%)0-7D'"5B`
MPP(_:*$%V!P`HC"8O(IP'`<!P'`XSE$>Q#R`1``[#H?0H^771A#HQNQ#@?C3
M;JI_K`2@IX"(@D402`_EZ%(D=<0`H$_#Z`(B("'TY454:50J*6_/RLRK5O#M
M^\D:ZPS8C:';H/VWVF%FK]V5Q(@@U5>,)$9!,P(`(II*)F-Y&,81*OA]K84"
MJ%*8%>N_</X]'%3_`$P-TGY&$I?U"0`[^O7YC]1BL19DV#PKKW'5F7S9DJJX
MSB[G9X^E5:0MDB2,:3MNES>$36XY=4/!>9E5/T-D`'W%C_I*`CP-\MG[#,%F
M*KZ^S.1JQ&YINM:F+A4\;/)`B-IGZO`+(MYB<C(XP`=S'L%URD.H4>@-V'U`
M>$O-=9<[`X^@F`2"'8>I>A$`,'??0B'0_3A4&ODJA(R8T)VN93$8UEF(X9N*
MZC)P@55'W&[/[A-X@F=0!3>-#$]Q,Y#D."@`("`]#RWE-0KJSSH3M-NC0M"[
ME1]B<71^"L4X9PY:9?6#+&-\A63'^9[U_9M><,;+FJ4J.6:6^OM?K9"D690*
M[9)BJJ9;[P'8*E*DN$F)OPM<QK1]C)#`5IHNPULQ!*Y2L,#;Z\UFL+TNRT['
M\)'3<>_C8!JSKUMM5NDW`0B#DGFH9PF"I2>`)!X^1V%;]+\!RVKFJ^"=>INS
M)W&6Q%CZ)ILC:4FXM4IYS'"L)Y!-N8"G0(L*O8%Z#KDE4G_IZCP(W[1;'5W6
M7$ZV29FEWW)+M]9*O2Z?C_&T$2:N%SNEOD4V%<@XM-\NQAHT%7':BKR0<M63
M9-(QE%`'Q*:Z1AG6C=22SAF?+NNN2<%W?7[-6(*W4+U+TZVV&DW%G-8^OWW2
M55LD)9Z#.3L29X=\R5;/&:RB2S=4GZ?,O1N0?GPO\AV`\\[CYMTRQ1+25SNV
MO=$A;ADRWQZ39>C1\O,3R$%_8\;,M_,9:RQ'W(*2/M]HMA(5,3";W`+4C,I_
M<C1P'`<"GKX?6QIS#VS5VDR-).SVK?W=9*PV!XQ(:>EF4)FJ;AX9@^E#G.X6
M91#5D5)LB;S221*4A"D\1'E9COM<*'J`#ZAW^`_7_'^/(TV@'0B/J'X>O7KZ
MB;L.A^G9AX'RC?'/J'L%KS\\'RC9GIDSC&6U/R3.2$AER,CK*16ZT^Y6-BWR
M;0F!:@DS=N&JZ?[Z[`_BHE[C8Y3`42^(#;9C;Z0M>]C<.[4X]'*F#;0I=J(%
MFL=22GCPDU!H+3M0E%(>?1:M;!'Q+MRC'R:!T??33,B<Z8@0QNAX7CO\C8)P
MSF!6"<94Q;0\BN*PZ!]7G=RK,387<,\(J90JD<YDVJZ[4I5!$?$IP+W^'`R6
MU9(,6[=FS:MFK)FF1!HS:((MT&J*9?!))JBE[2""*)/0I0('0!T'`_83R`!`
MP?0P@4?(3")?P$>P#H1_+D5OX#@0L^0'4I7=762WX2BKBICNZC,5&_XOOQ6R
MKY*FY3QQ8XZWT.??1Z*[=61C&4Y&$!RW*<AE43&`#`/7"3IB7(^`]E=MJCA+
M'.R,1BO'=4I64L<Y6SK%T.T361JSFM;%LLG:JO2H%O*5Z@R];@'F0(>)G7B[
MP%CHBP"/]EZBJHX+1&3/'Q^[(;%QVWDR=QCK%&7'FUN(-GM%<H_W-*69UC>Y
MXAQ;CW%$=*WVLL:^V8?MDI7:H_(XC$W+YN\))>"Q"BD1016/+&.3_B3S5:\_
MXSE:G:Z)#X>C-$]D-:LJVN1L=@1R=:<R[*OTYZRY;CX&,K9XJ3(SF4S%<&?R
MB3QRV4!(#=$`PK,WX>0+\<VZ8ZPJXC+KW\;C7+A=<$-.%LH)1]M5:SU,/67%
M1;9M?.#5!*XL%:G2"*Q[2I%>KI.YF:</C.4&S8C5PM7TB\@<!P'`<!P-AU")
M]^0]``>0C^`!^8C]`X+;053.3R`W8>OX]?3U^OIV'_AP*O\`2P`/NO\`*B^(
M!2M_][\'1HGZ6()GC#`%26<@;W2%(;Q3D$@`Q!$HCZ?4!X3JT0!`0`0^@_3A
M5%OSE24,VKGQ[L)&:80SU]\C^M2D:L_69D12,TFWJCAZLD[]%&[,A@$PAZ`)
M@`?KPD_#I<AO9""^<[2^/R1DRDV248:6[:N8QM%5AK27%8&<N6*W+-E+*/K#
M.)R"LTQCG@M1(H@LH5BX4%/Q$1"I_M^%[L?)1\FR:248]:24<_03=,7\<X1>
M,7K55,%$GC1TW.H@X;*IF`2G(8Q!`0Z$>1=(;_(NL171';,J1A$W^Q]Y+^DW
MMF[4AUBEZ,/0D$1'ZCRY)S&&6M44E$-6];$50$%4<!8<24`3`<043QW7"G#S
M#T/T8/K^/(K/IC%*`F,(%*`"(B(]````B(_X`'`T\R]>7?IZ>OX>OT_P'@<8
MJ%-V4._J4`,(=`(F,8/T"(#V8O@/*(9[YY]S#KAKG:\DX#ULO.UN9$)"(AJ!
MAN@L_N'LI,S(JD/-3[PHD6B:U`Q[=RLZ=("*H"4B1`$ZI0X9G$>58.*,"YSR
M[AC:MKC&_P"?M=OD&VBAZ9(YFVVSIK'.4RJ1B+1N:%#'F`(*PN5DHJN4:NBH
MPC$0=/%FY1^^4$7"@'(5C3X[='MT-0_DDG(*>A<<2&J])TDQGBBNY*KD%<XV
M)DWL9>9.Q6*,B'4S(RKV:R_<+BK^\V5R_7.B9NJ44SF4*!#1(B(T^E<BR9P\
MBF[+ZAWT(=B4PE-T`@`CT8.&K/=)WUY!_44OY]F,'D`>GT[#@:^91'H._P"?
M0]?0P^H_3K](_P"/+0W\@J,^&,Q5-;<['(8#E-OYO0)3E]2F#_N&M_J'\!ZX
M9_7_`)6Y\-'`HDUGE;->?D/^5V5Q9GJJ8\85;-^"&-ZKEAQJ:\(S#.CZTT*"
ME9AC)N;32V<",986;EFY<)HO1`[0Q3J&\2B77VS&Y>M^!%244^/]%>:EG4R[
M=['[1O?W!_&'BW2S)WF>U.6BZC99PNNDUD$1!PU,<QNVJJ0`(E`HC")N+77<
MC1P'`<!P'`<!P'`<!P'`<!P'`<"J3Y`]GMK<%Y-U7KN(*71X;$F3=E<08HR3
ME6V*FM<_+-,@-KBY=4FBX]CD2.63A!"K@H^F7:PD02<%]E(W@J8*DHH_(I\D
M>2-9=E+GB9'-6.=;Z'C#7,^P\1/V/#%FS@.:9DC]>*=XVM/]IN'BN):\R=$0
M\))9)@JX]_M-4Q"'$HTD%\861"90R+MQD*PJQ,-DW*$CJ_DR^X_B9IU*-JQ(
M6W5/$\XY681[A=T5"`4F'KMBS=D'MS]@85!$P$$PSU<`FL0Q1-Y=]',01`!$
M/,AA(8@!_5V4Q?7\AXHMY2ST6DWD\8:WTRJ6TT"^3DH8;37(>>_:)-(P&0DH
MHTJS=BP>H&+Y%51\%"B'U#C0_#*8MQS.V%I;Y['U%FK>P*5%G:92I5^1L;9N
M1L]8%2;SKZ.7E$"`PDETA`B@![:RI`Z*H8!##;C7-]`Y8C<JXRRI>:(R;UX(
M"8PBV=LGN![(C%08P]:7)1U613TV0BR(MBJ.855L*Z"`)F3$>C<"`&\VR,G1
M/C>V+5W5@JIK==K/!7;$T(O$V20MU!N\X]3,WJTS7;&VB#NJ[%VDBJ8((S7V
MYVZIC)'/Z=BLTLLUB,FGK?KZ@"J:X-\(XH;`Y072=-7!TJ)!I',W=('.BZ*4
MR0_K((D$/4!$/H&7IQT_1AY1:#;,Y&80C';J+8/7/VC-\]!LN,>V<O2IK_:-
M'KLA4SK`0XD(83`41#KD65(TQL/\DV!LVZ6UO-,E@#*#G:S*/^W^2=><95&2
M2M6$*<FQ?S4YE*KWG]\2?W"%I#)LBG)*R#%)J85O(GB8``:SX8YW%WLWDTHR
M#2[!DJ\ZFNR9?VDI.)<*:AM(>T$OU_Q+>+I!8_2N89=5D4&L?<X!";/-.DU6
M8,"E:F:]&\O,!,S"^6<GF%<K<K:)%R[)%0,')V*9<>T<ZJ<;$QYWSDQVW^F)
MW7[<D)B$$"B<Q0$P`(^H54X#V!V_VKT_:;MTZT43%C6YU.R9/Q5@5Q3XZUQD
MCCROR,JY@4;S>G*P3C"YWF'C!^X,P3^SCE%"`5,PE-P0F3H[M77-V-4L,;55
M>OOZ5$YFK*\\2J39VJTA6IR,FI.KV"(?.F9@0>&1G(5<J2@^!E$@(;Q`QO$!
M>+>%SUF;<"&RRWQ+K)KI5+C&L\=.<BV7,>9+B]IN+0?KRCR'C\5UU:":RL^^
MO`)M`?R#A1,C)FT62Z]PQC%3+I`J[?,M8(35K3S,D-A6AUS+>W65IO%<)CW,
MF;*YCS'L,XIC>94MMU-E=1!TR<4;PA#*1STK58JR2R7EXB/!K*T;4C-E[S_A
MZ-R-?H+#\)*2TJ]:,D<)9LA<]X_?1+=1,$WC"_UZ-CHQZ]$@F]Q%,I_;_3V(
M=^@]I3>8>7CT;Z`/EU^GL1Z\?KWY!UV/\.15.?PB.XU?57,O[:[!XU'?/><$
M%14)[IR%V#MR@>9?/R`_MJ%'KUZ`0$?J'*S^L_<KC/,/'R`#&_3Y`!0[$0_(
M![\1-_CR--@+HF,)`,`CT<1`?01(0""<Y0'H3IE]PH"8O8=B`<M#RK>LP*3N
M;53KU<0=S_N)2CM"'8%7EF2A#I&+++?;E4E!_5XG(L8Y3!^'B/&933]L)!P5
M;;G80<9$1;5=<ZB[:)81\:BL[!(A%5SMF***9U_:2*!@\>RD*`?0.!WZ0B)`
M$?KZ^7KW^KR'R`!]1Z`WT_AR2L.3@.`X#@.`X#@.`X#@.`X#@.`X$+]S]6);
M:F-U[BXRW,:<GAG:/%6P$FZ=QBDL>;BL=1]O;NJTT0*NW*U>2JU@2`K@QA*0
MA3=E'H.ZB,N6]%=@HO:?..Q^LF3L-(H;98[IN,LXU#8S'=CR*RI04.%DX&NW
MG$B]9M=4=JB:+DC)OZ[)+#'.UBIK)K("!R'8*S;W&/\`XO\`7_'N%,%X_:'L
M$-E?`-"856L;+8^D7&/<P)NE/NW-JDR3T,H(JPMBEI-ZNI#/3/F";=T9N!!3
M`.P_'(Y,W"T_CF[[-T2EN!@B%B3GFLV8AJ"D+L76D4W"X_N%PU_J95X;*K8L
M:*!#.*<DU?)F\U1BSD!10+,I$,W'W[U1BW^`F$UE9.%1V?6^RPM/SU;M433+
M+8#H&70HB]W?036IU_("H)G33@Y)XUEEEB&(5$QBB'(K+\ML7BB#SW6=9I.:
MEF^8K?CJSY9K]>)4K6ZC'F/Z;)Q4+9+"M;6D,O4H]*,EYQFV,BY>I.3+.DBE
M3$5"=POG4?'6VUUS"X=1>F^+%\GI1DDC%3F7\HJS>+<$PJ;HS8SF6@9=[`N+
M5E]:'8G.L#:O-BQCA=,S->59K^9D;[+O6T$L8[$Z2Y(S?`0NQ^SKO:G)\Q>U
MH['-AD\/Y!@-%Z[D&+=NH-E7<)SCR#G<$O+BQ="I'I/G-CFI=R_*='[HZX>`
M1+8[R?L=I9K'G"9K6LF[4KKE(XULQ(O)>)7^,\AY.^/^/N=N<^ZK4\B6*%KI
M*5A*Y3KT?>2&&M,(X;OS%%=!0%CMUJNY3Z9[QO:PDRQELA0'>K^?+1#3K2B6
M6>&6N6K-FM2J"R-85@]@8^#3K3!I+.SM%!C)U.(D?)0R2:"X@50XXB5I1IKO
MK@/,4_FC+USU'V9OF7K`U6RILO+-\HH9@'&0N3KM<1XQC4II]0J-4*6S`C>.
M9Q;=I'/%"BY<MQ7,(\0G/+&V\N!=H);#63,&[9[/ZO3NNF1<JO;1!;"WJD*0
MFT>+\9)3S:Y0F'L,XRJT6XB\G92@%(;[6"G$G/[J<ZONF:.U4B)\+,6L^HV6
MLX;$2--=T7#S*@ZRSL28]PL&R$'+1>4,A0#^&Z;1=(Q+%R;)Y6(J5;NTA<O+
M:HV?$\7#<88Q#$7((8YQAHSD[!6`[7J;AS-%3KNOJP6F!QFE.8\G[%E'&^.K
MPL]=3U,1MRF16=?G1B%)5RWA7J\."[-F8A5ON%B`L(IZU]BS,>G.'\&8STBQ
M)C/(&&\/Q#&FV'#=DG9BI9(D:JU*@",QCO(R\H>J#8&CL[IZ[9SL<K^\.G'_
M`-^R]5."E66W.Q.Q^ZV;Z%K%AC'F0(+62*J,A.[0XP/DZA8!VSRY:V\H^B2X
M)=UK(TU'6R+PF^8QY33%E@P<)6)F\,FQ<K(`94Q/I,B9I678:+U"OM5^,C!S
MNHX8_O7&L]@AS*XQFL^X&Q\]8MX2KV+7:U/YR(P\M%23%@F$O!N7$>Y4;&)[
M;KS`Y.%^D:=19R]Z*73/\!/8?<VG/N^.T-\S+B+2+`ELQ]*1&NN/HNCHHLI;
M)MED9NK5''S>QFK9G$\,4620;23LA&I'O9C`]I_VGP75O8O9---[N5ES^T:!
M(-III)ZH:W3TY7L>R+%Z]EFJ#')&8R(U[)>3&DG7W*)9*.3+$0SE83E,U.0.
MS"OG3K\G_#_\?F4V=>;N<`16-I"G(-VM0LV"+1<<&VBOI-P<&34CIO&,Y6WR
M;D5')O>.<ZAG7I[PG#]/%E?RJQSS\1ORUX=9SLQ\=?S!Y\D&7_6JU[#&V<U_
MN.PBV;2)=?LM=K>095K,K,FY7J:34#.6!O;0-[ASG.00,WLJM/;9LQW\B-XT
M.^.#&^><P6[$7R(3&RDG"V.]XDLL/#PMCM6.,6[(Y3I%=M_]KK-*S9:#DUMB
M:`1F$E0+Y?>G.H4B@'3`.LWUVVM>R2^G<AKEDY=KA.K[EZ:U7(UTH]@<1+3,
M>1<J#/R<CCJ,F6101+7,?0+5N\DU4%5RKR#E2-<))G;&'CV3*5F-_E/R_F+-
M\#$XVT^GK+K;*;:W[5&;R\UM%D:66I.:"X:0[S,4]%OZ&PH#&AN[*LHS*R2L
M2TLJ4@'(0YC>T4+LR=^(=B!A]0$0```1`1[Z`!'H.^1IOX#@.`X#@.`X#@.`
MX#@.`X#@.`X#@4C?/K7,Q./COV%O6.]DKU@2LXYQ59K':(K&,<V96_)$R5["
MH5:O/K^HNI*52E&$[HDDA&HHO'XK)$%TFB55):PDZ94W.A=?JYHQ6=A=@Z/>
MKBI@'#U>L>/:_6LJY;Q_;'V3K3`UNL56N-I/%]VJDPZL%JM;YA')NE55UFQE
MCG()/U>1/>E?;O3;';6L?'MK!MC_`'AE2:V6O><,IY&J^3+CD3)[;$5WMV%7
M2M0A,:6BU2,S9,>M<3SAT&M<5.[%TG+)G5.[\S^X#BTS/J50MO\`'?R8X\Q=
MLJ:6RA$8!T8S_2<<[9+?;B.>Z#>,[:WO*!&9%.7P40S136-%?IV`Q4$D7W;=
MVD=4ZZ_A>)W*^*6!@SBY->14CT()&/>NI49-)']K2CDFR@OQ>%'VT2,`9$/[
MHG`P"0PB/H7KDXU#YCZ1N9J)\@.3\<:XXTFJ%J[H)K3L/`L8&,GQA\:RFW&7
MZ5-NY6JT'#U&1&.DZSB2-M`B\>/5"LW<H[!-)!/P,8PMLQX=-L_MWIYO3D7,
M_P`<-`M^',":E0>7&+O>[.U@E8;'EDRK?F-EB)5WBS7.L_9*N;/:[#8::=A;
M[<[;`SC$6QFZ)CO5TA"GA]-;FJ4:]44:S+PT#=<?V6N$C7$'/1["R5RSUI[&
MH-$T)9C)HNF4RQ?QWB!BKE,14ANC`(`'46J4S[?T&Q?&[6L6V[3+(5MQU1<R
M[`X5UF<ZZ2OVUWPE04\U6H\!(Y.Q179AJYL]*N%<;E%1G&MI,]9\@`HQI2%$
M!).,I?ZF8BU0E;5=+[1YVT["9QPADZ\86O>P><'KFZY1A\B1D9'2-NK4!(/H
MN&JU+BP@;:U050IT9"Q*J`E34344]T3B[6)$3\?4>A,'IYCZG$!$3"41-V(%
M`PCT'?H'(L0Y![Z'KKO^(B`?YAZ\*V^/8"4W1RB'71@[[`?J!OP'O^7`P!G#
M67$&QC**:Y8J3*8D*F^<3./KO%N7M=R5C2P.&9&AK'CJ_P`"M&V>ERY4R>*A
MVCGP=I_Z2Y5$1,D:I2DO)EUWRQYM-*:*XNS?>\\XQQIK]";.V65B4Z%7=WYZ
MKRN0IJHQV&X')-GCV^)+"P%*,.JM)KQ#&?49*(HHJF>>3CC27FO"9VCNXGQN
M2=@4P!@>QP6)]@+;:)Q]==>LG1TW3-F7F06L"XL%N=WF*NP&N5OG$8R$<+JR
MAW3U!9%J84%SI@0.%NUL0K`!@+XG']0D$P%'KL`*(F[_`/@#RZ$WT`0ZXHMQ
M+.R(G\3$4Z#P,=7Q\4B$,/CY"H/13"!A`/$.Q]>17**9Q]/("]]B8Y``IA'O
MT#Q,"A>A+Z"/UX$><S:VUK-]YP-?;#<<AUR0UVR`[RA1XBF34)&0$I<GE;EZ
M<=Y;FDE6)AY+-D*G9)6/3217;%]B5<B8#*^RHE;281[O_P`7VJ-RQ-A_!M<K
M$QAS%."LN-LYXZIV'95&I,6&36LVZLJ5EDEWC";>2CLEAD'3P0,<I55G*GO`
MJ`@`+*=M%_&YK1"YCE,Q1D;=FQY^]L,OV+%W]^SQ\(S><8EZRD(O-CC%AU#5
MQCD9L_CT7!G#,K9DJY3*LHU.L4J@+*3X(`E*`&,)S?B80`.Q$>QZ`/0`#OT#
M\N16[@.`X#@.`X#@.`X#@.`X#@.!^95TBB"ICG*4C<@*.#F,4B:"?]1CJJ'$
MJ92IIE$YNQ_24.Q].N`^Y)V`>)@#VO>-Y%,42I]B!1`/$0,)A*/H`]@'J(>O
M`_04P&#L/I_[?7\AX&!=F]?L=[7X*RAKCEIK,N,=9:JCNK6G^WY$T5,ECWBJ
M1O.,DTTUCQ\@BX2(=)3P$.RC^0\OE)J<2\]G#6/&^PN.*#C3(#VTK5.DW_&.
M0HM"-GC1SV=FL5/T)FJM[$[1+U,QHRC%%TX0$`(NJ@4W7IP,SW!4R-4LTBF!
MBK1D'+R3)91$@BW?,8MXZ:2#0%DS%0=-W!`,0X=]&#OTX$/_`(S[QD+*6D6"
M\B95M$M<LBV5G>7MAL\Z#0)62%+)MR81R+T&+1DW(6.AF+9J0A$R=$0+Y=F[
M,+Z$ZW+-%V@X:N4TUVSM-1%R@LF15)=!0GMG;K(JE.DL@JD(E.0P"4Q1$!#U
MY!C=7"6(%U6RJV*L9K"S70>-#*T"J**MG[58'+1\W4-$^3=TU<@"B9R=&(<`
M,`@/KRJ_&;`.#U)->95PWB=>6<@O]Q)K8YIRLDN9TY^_="O(FAOO%_NY'_J%
M1.<PG6_6/9O7C"998103;D(D@0B2"1"I(H)$(FD@DF0B::2)"`4J:9"DZ`H!
MT'(JHWYB#&_VTTN2`0*1Q\F&ER9SB8R?CX7J37`16*8OM`)T0#O\>^OQXY;/
M[;CVYOB7[-_ZD!B>`-@^4?9;[8!(L1P4PTS#0NBJE6`O28J]"3Q``$/7U[#E
M([[6Y<C1P'`T,'8"`#T(@(=]=]=A]>A]!X%/F/2JK_.;LB<5%BD9?'3@=N0H
ME+[1_O<V7U<3$,)1$/:,V'T`>A$P]_0.7C-?Y?AZSY(_B=PG\@E78V-"5D,$
M[6X_.A+81VPQND:'RA0)MBL5R@SD)&,<1SBRU5^8HHN&;A0PD2.)DC%,'1EK
M,*[<AV;Y!M.])_C,Q?LYM1)-]@KK\B%,UJSAF^C*QMI<9%PC<9C,$_7455WU
M;\8VQS=8K<+'E<I-C.HT%%1$ZJI3*"IFZI,R^;$9#LORPZ?85QYEZY-<`VW6
M_8&X7RE$AW<$C9,B8PF(%G7WKU]/5EG-+MD6TDH#A%%4K=ST4_K^)K/-+G"=
M^!>Q['Q+V/T['H.Q]/3U'D5NX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!3;<;`_
MR5\SK?`&4+`\=8<J6@I,H8UQ(\=E9U.]Y+M.792L7VWOHHQT_P"[9ZB5&$8-
M&OJ)(YM-N!.`^\027[2=NSUD>KXS^33<'7/%CI^YP'%X9PQF&U5>2G'4A&XF
MSC<W<]'.:Y2&CEVY4AX*X4:+CIAPQ3+[:;MP*A?$%0)P7E;RBL58ICD`0*!S
M%_4'B(B7KL1+WY%'^`]#^8<BOR2B+M9D[)'N$&T@=NJ$>L[2579I/2I*"W4=
MMVZ[5=TT*J("JD"I!.0!*!B]]\(^9C"5CR_K3O?\U[VVYJN>P&6L1:&8,SI%
MV:^J(-J/#61+'V9+FSJ=(Q?"E;PM/I$=88OR0;)G5>*-%"IJKJF**@WAW\(G
MXSCYW&.*_C>W`SQ6,R5Z;V:MU0F+IL70MJ9>=MMWS-GFM3DK_:NPF&9F#_MA
MQKS/OU$FQ(:M2#I>-%),>R$\Q!T^E_\`\1W_`$'QVZTI/`:(.U8>\`X1:)`W
M:GDC94OAWYFR8N7@^2[GS4$GO*F^O0CP:63%/Y"(=?3KU^H?B`@(]>(&*8!`
M0[$0Y%;^`X'&JH"10-T8>S%*`%`QA$QAZ#L"E,;Q[^H@`]!ZCZ`/`HG^1#+:
M.UL5C>B:MTN[YZ<:E;Y8-R'LO+T"&8N8/&++"TY(3MZKQ9&=DXK^];O%,UTS
M#$UUO-.`$?`X)J=%Y?'AF<_RL9TOC]97V/+CE?5>6";HNP>6[QFZU21)&7?'
M<Y2GTH:KW9-^RFP"1K$I&JU-%HYB5"I"T<('_P!,HB/"Q"8?(IP'`#]/_/Z<
M"GS&P*$^<G9TY^A*K\>&O0D(5R"IP]O,^1DSB+;P**`"<?3L1\@_5^/'$_V_
M"X/A4%=T])66Y3[61>6R?9L?,]9]AZILK#L:Y'1#TEONM"82K2IP]@&50<$2
MK:833HCL&Y4WBB"Y@1704Z5"VE?+\>2]-+'>]Z,#;JL,NK0B^$,/WO$+?%ZM
M;_<:Y/-,ERS*1M5D5D!F&SUC.D;QC=NS,4#)I)D'S*IWQ:TGMR#88W77IWV/
M0=`80[_'R$I3>(!_'@!-T'T#\/'R,!0,(_0`'U'L?Y<);<4>P`>A#^`_4.%:
M\!P'`<!P'`<!P'`<!P'`<!P'`P-EO6G#N;9RF6V^UA16\8Y<RKF@9!KLS-U'
M(%/"<:(LYIC!W*M2$9/-828(V1,\CA6-'O%&Z)ET%!3)U1X28QW&ZUXXR#):
MXTS'YLIV^9:V$1RI=YB&'*]Y=.4$S1UKRA-#9K/*V*0A$%6L.5V=RFV4*@EV
MBT*(D)UW^N6S5#V(K,DXKK&9J5\I<C_;V6</W1NC"Y(Q-;"D%16$M\`=3W44
M78![K!\CYL9)J8JZ"AB&'HJ1(N#]F-[0"0A1Z+Y%*=10ZOMI@0%/'H/$![$>
M@['H._7A/M$E_@G6S#F4]A=M;4>$JEJSU3*-2\SV^[S,8UJLE3<7Q$E'P,*L
MA.$*P_;TXM^[*HD8#_<D5,`!]>#[5&U73;'F4[YCE_J%4\ZW#"%`DK#;\4W'
M97)-S5U!PL_L+*4&)N6L^*;`B-WR?-Q)I%7]B564&MQJ*@D363`"EX/,O>4`
M=IM.L9X\^/A#(=0H63*Q(-'.GVSEQK:C[!6UL3!R,M=KE@_-K)-%POA'*<K'
M.7;<C2/=./>:`D[B3N#-W#,">%G>L6WN.=BR6NKMB.*!G'%QVT5F?`5P<-VV
M0L72GW3R/2-(LT%W+:;K$N[CW)XR:9&58R#<I1(IY`8I2I<)J>YZ@``'7?0B
M(']?Z1,00`2@(<BN7@?G<G]I+SZ5,(&*`%1*)U3"H/MAXE#T'Q$_8B("4`#L
M?0.^(25#7QXN9[XYJ!G;6G8:AY45G8W9[.N5<2WVG4.TWNM[(UG--O?7FOH4
MJ98-955YD:/*[.TD8A=5NY0.D"OC]N(&"\$L/B=UGR%K!K=<(K***\5<,V[(
M9XV3=4E1P=V3&$?F6VGGH#'XF`YV[-Y#P39!9ZW2_P!-"0=+I_U`/:2+ZL]Y
M%;3F\"B80$>@[Z`!$?\`(`$>!@S8O9'$6J.'K;G?.5D5J6-Z7^VDF)5"(E9U
M\N\FI)E#0L;#0D(T?R\U*3,Q(HM6K=LBHJLLH4I2B(\"/V-ODGU6R*_RO"R%
MEN.&K'A+&I,RY)JVQ.-;M@JSU_$*C9RY+E#]CR1#P+U[1DRLU2G?HE.B54@D
M$?/TY:2U8D3L?&VSY#B[2ZFQMPO]TV"U=A\?P.`\\8ERAK7'YJQCB2QO[X&2
M=;LZ7>K*T*[S[IM:"E;Q\F,3%KLUR+&D$_T@+B=OBWO`VZ.&L]2U@HL<\E:%
MFJDF(TOV"LCQRU6R?6)0K$CUVBWA'Q2%M<0@'N`23B3O&#@A/<34%,Q3"I;2
MN*X(8#"4#"4"@8#B'B4P"4I@$AC=`<H`;U$/0!^O%%GW`>(F]M3T*!P*)?$1
M*/7J'EUZE`?4/PX+>+N.3*%06YG=TN]+IZ`$`2J6ZU0U;*8Z@E!+UE'3<1*I
MWZ``"<P^@%$1Y%1HW5VN6U7I&,EH"E#?LFYXS;1]?L1U9[+MJY!.;_>R2S]M
M*6^>5$QX^K5N`K\@^=@@BX=."-@113,HH4>5&-*QMY>,>[ET;1S8*$KKBXY<
MQ'8\LX>R]C]%W%4VYC2WB+6^T:?JDRL]D*E9JT5XDM'^T_D4I-@(*G,@J!D0
M'CJQPO?B7L>QZ`!'H0[$`]1Z'U]1Y%;N`X#@.`X#@.`X#@.`X#@.`X#@.!@S
M8?7K%^SV,9K$F78(TW5)AQ%RC15B[/%6*M6B">$D:[<ZC/(?]5`6VLR**;EB
M\2_6DH3H0,0QR&(J1DL9["5'8*BUFQRCAGMK4J_():\[?I13AIBC=V@03<TE
M/Z_[<U>G,WCFO6JMUU$#(2+HY2@X*,C&*^Y[K-2[])-VSO%?(==,@XBOMNIN
M`I6B3F')VWT+89]F.:7<4G$>3*D:N*3%.AEL<MIVV9G6>Q=G2=QJE>:D!TV.
MB`B1=7VR%1"U6S=B7.FONV.ZVWS/)6:'FEV7]BZVO7LY1-8A8"&7PZW:OGJ]
M-U\8K/*K0)IZO&HMXM.=6E)AHJ!5/?155.'%)=Y3?T@WRRYMW+P:SS2Z5PIB
MR6IL=<DKY,[$X5N\E&IV",0E:G#R.,*3(.[G#/YEBL0QB.D6Q6A?ZP$.%C,6
MG5E[$&-<Z4&PXNRI28R[4VV-56[Z)F&Q5#-%UB&03FH>0."CRNV*)$PN6#]D
M9%ZR<)%6;J)K%*8!A`W&V*G&L5]M>1MI92B6['&`,=S$3@/<NWV(8/+-;Q!:
MI189#7[+Z:CLKO)<U6$()@NRGS`K^[G>@5)NF_,N*I*A(]EN9B5I*XQCK5&9
M'QRSS/+DKF+K+DBE.ZO5+3-KQ82\-$M9EP[7+%O+,P_7')OP:F=J?Z90]W]'
M"I?%,)OJ42^GIV(=B("(&#H/_A]/\^17&X0!P0"&,8H`<BG9?0W:9@.7HW_+
MV8`[_,.P_'@<9FQQ35(#@XBH?S*94I5"I]B`BF"?Z2F2_``'Z?GRC]!2>(``
MF,?Q$P@8_0F_4)A^O0?0!Z_D'(-_`T,'93!T`]@(=#]![#Z#_`>!"3?O9JB:
MCZMY$SO><3VK.3>DM8IW6,/TJF/K[8+W>EIAFWID/&0[*&G2QZI;*+=3]R41
M,G&)D%R/7M\K-X?-G>82-^0W5/Y$,X?[GDR%OGGC4O&\,G@O'>+,EH1&LVLV
M.\GPN3'.):TK>:A5W&5;TLHYDE)A0%1&<F"&:M$Q0*41LI&<]2VUEO$9=MW]
M-UM(L^;)Y_JZF/K(ZW7CL_P5K=4G%M&2QW7H['S2'6N5"J;?&N40LS06Q8>(
M5$5$/<%RF)2E.:?;7Q\+W,^ZEX9V/<42>O\`#R+'(V)I=[8L/9@I\D:MY6Q/
M8I*->P\A,4>VH(KG9G?Q$BLV<-72+N/<HJ""K<_H("D66EMWEU4708Y.KS?=
MC!$81\XD<P4%&,I^R-*KR)RJ(&M>(3>4%EA&-;?H4<0#IO)N_$5SMAZ$G`C3
M;ME83;^2<Y%UOREO!D[$,S$)5N$I^OM)B\,4)Y9&"R@S'[KF+);.)FCJR/G^
MWF*T0]M-=$P)G$1$_!&=/S8YT>R3)H3+UEJ)K/BVQ69!99[:-O,A6#=G+S:P
M!TYA+M&-5R/Z&S4KC]-%8&95FA3*D*3W2AV81]LMYN^/C8+/N'\=J9'W!97_
M`&.PMG;'&Q6$LJ&P_"4>@5>U4-9RF^J#VBU>;EOW:EWN*E'<:]7.X._(S7`Z
M1BJI@(S/!F*DZSY&R5N#3-U-AXFMU*UX?Q-9\08>QK2IQ6QQT42\2B3_`"%?
MK98E6;5*0D9MLP:,XYDDF`,4&YCF,914X!18V0PF*!A``$?7H![#KOT]?XAR
M*W\!P'`<!P'`<!P'`<!P'`<"`NQVY-VP)M7IUKQ'8*5R'5MMK+<:B.3(Z]HP
MCC%4C0X,+//2M@J3VLNDI^"4AG;4&QFTF@X4<G4)X=$[&X2V(<D?*15<([1;
M,8/S3C=*D8LUKUXJ&PLKG-O?V\R>U,+Q/&K%8H<)CDU5C'I[S.3:8H-&J<FN
M"YS)E*(F/T5]E_P]?D+>[)6!,:MMA=D-79_%NNZTE!HSTY'7V/NN6\40=LGJ
M_7ZW9,MXMBJ\WBXB,:KS1EK$,38)@]>32#]+TGNK(,%]XL<9.$'[5M(-5B+M
MGK=!VW62'R27172(H@X1$P=^VJB8#%^GH/J'`YSIF$Y3%.8``2`)0\2]]&`1
M,)O`3&#H.A+WU_CP*K?BW(@G7-VD0>/'[5O\B&PB[<TA%G8@S*$)BYX9BU!V
M``L@@]7$Z2_?1Q$WCUX^@1GUZU1S)3-7_ELJ%WUV;9-?[#[H[?9=QMAZ_6"/
MA(/-]"N\ZR?52.>S$5+*+0\7<4F!T/=<K(*^0@<Q2I'`W'4K&'2:_P"#\F9*
M^0O6/8NDZ:Y.T4QSAC4Z>QGG=2Y.<>0"&59F5BH^(HF'X2MT>XW8;=$XH7:J
MND+&]%JN5$"IHF$3#TX:G*_TK<BZ)B*E#P.<ICIB;W!$2&)XBH?H.S'(F4?H
M!@[X55'\T&OV5=@=)'D#AZ)D+C<,;YJP7G0U#CO95E[]6<-Y&B+G9JC#1RQD
MF\],.()DNX;,#F*9\LV*F014$@")UC:/?R.66N_)!K3BK5W5^:E97)69\N82
MNLI*$J-RC([!M,QC>X:VWN9RU)N8B.1QC98AC%J-6<)(+L9R07.`,T%B%,8%
MDZI?(V`G]29CG("21"G.I[OF`%`P'*<#G\A.4P"8P^IAZ'UY#R_5PIP'`<#0
M0[#KU#^0]#_GP-GM%`0\>R@`B;HH^(=B("(^GX#UZA].!P?8M?<!7V2`J7Q`
MJA2E(<A2$.1,A3%`I@(D54WB7Z!Y"/U'@<18MB03F1;(MSK.2O'"C9%-N=RZ
M*4"`X<&1(055O$H!Y&['H.N!V'`XQ3`>NA$.C$,'0%_Y3")@^GT.`B'\/J'K
MP4^3VH8MTUKNFFK&1=R"Y$V)R?DFAWRI:JZ2KOGS_P#OC,%SMUCG#36,\<55
M^E[5UDT3HL'EHEEFC&+CD??7^S4`0%'A)I)#)VJV)M?/B=Q7/;[8U@LW;`X,
MQ7)57&L9:KM9#2[/)V6K8JYQM@./N<'8H!]9$4I^3B8$[E5XH9U]EY`?P$HA
M?25C*R7XS=%JSH?JU3\6M0=*9$L:)+SFB7/8)F>;/<DV-()">B:ZXF7S]1C3
MJ@Y<C&0B"8E%*/:)"<3JF44,LB*A85[!.B@'92D#T`/0>_3HWD'Z@-Z?X]^O
M(U3F``*'0>@!_P"__CP->`X#@.`X#@.`X#@.`X#@.!4)O3@7,>;]YOC<M]+Q
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ML$Y.O6NIRK2=K<W'+GZ1>QDO''<MG;<X`/1R&$G8"'?!?PHAT+W2Q9B[9O+>
MEKLEQM&5MAM^MR;!7U6(0AV6.JUC?%6)[-)OKR#R;,HR+,NG!FT*S9$?NW29
M@<*)(I%6%(GCJSK<C>G7C2&#Q4_SO8W;.5S5F*DX8QA4Z^B$I;+1<+W-M8-D
MHRC_`+AJNS@(=5Z122?F$C9F02IB85%4R'0N$S4D0$5`[-X@=0"B)CG./D`>
M91]XIA(0I@`2@0?$?RX'ZBE`H``"(^@`(CT'8AWV80*!0\C"/KT'(H8I3=>0
M`/7T'KU`?S`?J4?XAZ\#\:48P0,NH@U114=*BLX523(DJLJ8?(3J*)@4YQ[_
M`#$>N6Q^P"``]AWWUU_4/77_`/'OQ#K^7(-W`<!P'`<!P'`<!P'`H!T!T3UR
MV6UDU$VXOK+*$7L-$X!+CFO9-QYF[-&.Y2N58E@DU73*%CX.V0L"8LE(D!R[
M,NT<I/%P'R%1,?'EEF*G*S*VZ*81R'BG&.'\DO<F9)K6*LNT;.$+)7_(]CME
MJF;_`(]LB%KKSNS6*:<.GTE$I2[<@F8$]AJ5(/;3(F3TXN5F+3+`.@`/R_EZ
M_P`?0`#UY%:\!P'`<!P'`<!P'`<!P'`A="[Y8'F=S+GH<9U:8;82G4*,R<A$
M6"N.(JN7BDR#5LY=RF/+(JNHUM*];,[33DVY")JMC&\NA)T8;7\);=>=[L#4
M3;O%&CCN0LE@V(R[3I_(,55J?7_[A94^EUWQ^ZL61)-!^@6I1S_]?V1EDS&=
M`DH)"B!1Y"TR!44`"]D$?/Q*`D*(B4QQ-T8Y3>/B0H==]^O!EK[::OB<0\P$
M2J%`P=@!@`/$Q0$.RB7KT^@^H\ME`H$'R[$_1^_(/,WU$0'R#U_2(=>G7TXM
M6AFZ9A$WJ4_70'*/B8O0*`7U`/U`0%1\0-V`?7KOD*8?S/KM@G8JL$IV=\08
MZR_6D"NB,H?(52A;.WCP>D0(\&+-*-%UHI9T1LF"BC8Z1S@F3L1\0ZJ*8IW3
MMC\1K29R)HGL?5<48RO=N1<K:/[67*P3N![#*O)$SZ1A-97T:20R)C.W@Q74
M%".BF4^V=&Z.Y2(0GN%&E>>!KG9JOOOH?/YUQ9<-9G%VW-^1+*QDLX036)B9
M*"R?A"NPN-I*&R"@<:<G*W#]@=(1)5EVC]XP9*H@A[HB4X>@^1G1[Y,Y[(V8
M-I%JWJSLV]R#G?7FC8&K[17+2MIU[P52\Y0%HK`P4<+!_4XL9%[#)NKM-MC&
M?N4GBP(>!$2IF:9FY?6=55;$K`10VY"&;VO]O8C9$JXY>NZ\2;,U2-))PCB2
M2;R"D:D[$Q4A7335$@`)B@(\C4._.82E$0Z[`.P[_'K\/_[#Z?X\*V`J/B7L
M`\A*)Q#OT``$/+^(^'?7T]>N5+:IJ>8]#T!A*!A*`@/CWZ``_0WZOK].%<O(
M'`<!P'`<!P'`<!P,=Y"R;3<64^Q9$R%:H"ETBJ,P>S<_8WI8Z/;]@**;4'2@
M&!9P]?+H(-4D2*N73@X(HIJ*'3*:I:LCX=<J4K_LRP%@"8D$Z5G7'%&>,KGA
MF[M/[+RE'@SF7;E2?2I4O]C.RE4DFDB@NWF&J"K)P14O^H!A$H$CXE;OY]@/
MB/\`S>/?B/IUZCY`;KH/P[Y%MO#OH._0>O7K\_QX5KP'`<!P'`<!P'`<!P'`
M<#YS=J]/]O,A;<;3;-X4Q`T99FPK=M3KYI)DF<L57A(#*L-"T>%K.Q.*9I^U
MFW4U7X.VH.'31ZYD&0(>RR0.D@L8H"-9S+R=JU3WG;;<8FS(GC*7LNP*>`MJ
M763=FX"1Q_'8MK.3LWUQ>"PMBJEOIBR-\CR5%PJT;D0,=:((@V756>HD6,X,
MFF,L=4S%7R"84POE;+FL^+-XHC<0^FN*:8VQ9G5/5V9P/=M@ZQ<:$I;;S#OF
MV;['(2609[]VGW#UU(&C6$BR*JJ8@N"H(F#-6KWR!_.;"A%P6Z'PY3EF;FC8
M=5WD;7G-V#&#YJ<[(BLO^[T&UY2>)R<JBJ)@]N/>-$#*!XI]@(#P7*1,5\ZV
ML+3*[/%.9\$;Q:J*KO):+<9&V4U>L5)PVTEX=/R5C5LD0,U;8E4S]4/9:NFX
M+L5%3%\EB%'RXHN4];3O%K'7*M$VJ,RW7\F'M36,=4JG84,.8<A6]M(.$6J+
MVO46@%GK*XC0=.2D>/E44XZ,*'F[<-R@8P1;8U'+6X&P*,O!XMPA8-1()%TW
M8KY5V0+0K'?%D%V)'+EWCG$^.KI>JTY.0ZQ4TG\W-D2(<A_*//T4PV"^O<X=
MTAP[CBX#F&U?W'FW/KS[19]FK,LFI;;:R=-&8L4QI4:Z,>M8V8)H'.1)"":L
MP(D<2B<P<%)!Y4Q-C3-51?T'+-$K&0Z7)F26>5ZV0[>9CA?(&#[%\DBNF8[5
MZU$3>VX0,FNEV/B<O8CP((M=9MEM7)8JVG.5XRX8B^X,]<ZI;%.)B8@XY!-G
M'-!C<.YT:&D+EC-J8C8QRM9=M/1"1P'V6I3J*'$E//0?R0VNX[&4S36%U:R'
M0=G)6BRF5[_`Y4LF/T\>T/&<++FKRUL;W&B6FU2-K+99LOM0J'[;'N7:/:KE
M-F4!*!;YU&[=?=?9]939#2^BFCM<=C*+J9E':9CGV/C%+A3;;@ZGM%(5S-8A
M6>2#9Q4,L)W5VR9.(J4:RG[?'.3/TG(JE1+Q1<L[4Z(S7LG\>^E,U$;.Y(H$
MS8,/8OR+E*WXS7B3YXSJ4,8(SJ]-H-LMCR)C(.?OL@*BJSI8A5A'KQ4;^!U2
MAC;XI-@,VV'.6[VK>;)'.*Z>"K7CNSX>@MDAJ4]GJI8IR-6U))FPRO?J38;-
M7K-)2\PFJZB2D?/G",8`>^J0X@D5)"[SD4X#@.`X#@;3G*F0QS&*0I"B8QSB
M!2%``[$QA$0`"A^/KP/QE<E5)[B"Z2R)RE.11$R:H^)U!*4Y3)F4(<GU`O0>
MHE'L>4:%>HJD,LW73<))_P!1VYBKD$Q3>)T@.C[HB</J(`41#A/I6?\`(7\K
M&`/CT3Q[4K-$6[-VP>9K"C3<.ZVX8+!6'+%OM$JU>*5PTG`*RR$K6JI,R+4K
M$DJ9FY3!TJ4I4SB!@`ES2C9';6[T;,T'L%\R^/,\Y(SI'*S61L"?&5J;BU38
M.%TOQM`R[IA$9]SVUQS8G=9G+=:@CP4BI67=.",4R"=!)$_9D7H]K@-P=@_C
M5R%K[AS8W*:,UD]KE^--(:RSVOE)NMKV<L$RRA%Y_P"UQ!_M='*Y&8V*O(.!
M5<MUE48]@[`OWOAUWPLTZG7?8G/:&'Z_FS!LO;_D8UKL:K&#CZV[85O&&YN'
MWJ*C*/GZQ<$KO)5&JY'G:8\6\9MO+KQ4X@HFJH5=T`$34(F71MZ\-6O,ULU[
MMK6Z8,RU7BU@T)6LZ1,%C\N4$[17F4_[V&9=:S2D'E3^V2O?MI8(APY%B\3.
MD8#>/D,5![?W.6\V!93,F2JEG?">.*@WAJG7=*=>T*3$9/ROMCF!XSB"V6KS
MD/('A[2U($^]%LV;UE=95E'B>0?*IHIF`EHOK!.6?D<VL_[E<%ZV98>Q7QHM
M<G:I1>8&F4,G5"A9%C)_8[W0B[+KRO-RELFZ(TB*^]Z<`K'JKRS\J[=%`X&.
M8Q1E83\76\C_`'[U>:9EEJVXKUCK>2<EX:MSHD#)URO6ZPXML[JNJWREP,\X
M4M<%7+<S!!W^W32364BW0KLUD1]@%E%)$VL>3,)R%,/79@`1Z^G?X]="8/\`
MQ'D:;^`X#@.`X#@.`X'&**0F*<4R>1//P-XAY%]SKW/$?J'GUZ_GP!TB'Z`Y
M?("F*8`-V(`8H@8INA_YBB'H/!37VR"0$S%`Q`#QZ-^KL`#KU\N^_3@5(9%V
MMVV@_DNUOUR?X[H.(-6<F,<WI15MM%IK=DR;G"QXKKM3F$E:Y`PSUZA1:D<M
MC$&:;A09IX9!515NW3*!.6$G=(Z?(;G_`.1?5JE[#[+O\KZJ06,Z7=(:N:P:
MP3F)IC(4_L&U?N(IC$L)V[)6R%G8W(UKEWBK=HRCFA63`"$675,GY=DS5PD-
MK;6XI[\G6REYE\;DI>0)+0?1QW88YLUAWB%(F;5<-FU[;4%91HFJ5"4^Z@VB
M0D:'!L]+'F5/YB4AN,T=\K<2())]B1,I1$?(3%#Q,(]%#L1^HF$I0`1_+DM:
M<A2E*'10Z#U]`^@=_D'X!PK40`?J'J'?0_B'?UZ'ZAP.,R*1Q`3$`1`Q3AZB
M'1BB80,'0^AOU#Z_B`\6E*[]C]6UVFS./OD&QK/UV'RGA3#M]QA<ZQ>3(1M#
MR/B*;<EM+MI*6UNV7F*/8:K+,!=M9<$GZ";;W$5&IRF["E0\9C+5:B[0V+(^
MXF2;[5<C*;1ZF,]<J:7"\M(N<?T_7FV/I:SSR=*N\H5%];YZ^/Y%FL[F18QB
M8DC&I$VA/`YU![9*RA\>&`LDX0P7A=1[D.BN-96<(77;*^-;HZIV7<02==@$
M*PC-U2R1A$FIW+ZOI`T?M'+5W'2#<QB+MU`,(<%?+(.KVG&*]5%+S.5.4OV0
M<I9<>0DGE_-V7;:\N^4,FRE<CS1<(K/S#K[-@Q9Q4:?VFL?%LV,:T*(@F@7L
M>QZ2T24.)_`X@(^)C>I#)CT`DZ`H"!BJ>('Z,8#==]>G(K]/`<!P'`<".&X3
M>*=ZI[&M9V`@;5"N,*Y(0E:W:#($KLY'JU24(ZC)D[H#-R1[Q$1(H)P$H%'L
M0X'SR?'GL%==+\1USXOZ<I>[;FF[8\Q;F71:WWJ,5M3=_A[8^/:35R?69XF5
ME^[-=6+<^L#^1%5)&/<QB48S]Q)P[*0MOY9C&'Y?BOS9,ZP:\8[UTQRSA[%D
MG9'Y`M^<>QF4KS,MY2":/,/7"1D1<S[2PVZFR,_(SIETF\9'L'ZCLR!#'*DH
M8IRA2)^TGM6OBRHV1M[J-\O&9&*N/MKZ]$9%I.2L)TJ^1F2\0R.6_MI:@*Y'
M934B_L;BOMBT9P1TE`L3M5(Z2]I4YQ43436GL[?7?_(+\D^*L`[)R>JV#W6&
M,6[AY8QQ$FRYMIF<D14<5Z^X<BAE%(FS6RS/Q8.LOWNK)SKIQ7*2W=E.9=T9
MTY,V8?<'%1,U*#64F&"J/:/BEPYK;M'%8%UAQ!2=@;I1ODJK$W1[C4YG.23)
M"K7/$+E6V'EL:N)/(J+EU,/VLD@Y0433]EJ(*(B81X6??"$JHIJ'D!FLV8SK
M:-VGS[&Q^;4*X>M);2LEYF&>)[$.8TDA*,EG60E7AV_O1ZQX]0D<442D`/;+
M3CVF]]%@,E[??&11;K7ZM;:8YR[FR<GJI;8EI-,Y0:[A.S.()V5N\CI)$R\+
M*K(N$Q,LCTH`"`"/H$.TA9@#X[=@L@$QCNQC+=0E1R%9-9,68XQDQR3@&"S9
M'X(A:XS61DWF+6%FN*B%;F<A.5?=L+AL!#O52]]@4.@>E6%9>TYV:OT[CR[5
M#=V?I-WB<.R^*LF(S&)*S?L<W*>D2)'C\QU#&TK+MX'&F3JM+IBX9/&X.F9B
M>*3INN0H@(2OU9UQHVI^!L?X%Q\ZL$I7Z2SE%W-BMLJ><MUQM%HFY2V76[VZ
M8,4G[I9KI;IY])OE`*"8N71@3*5,"E!)$5"08``>@?3_`-OI^0<BM>`X#@.`
MX#@.`X#@.`X$",OZKWW)6]NJ&SJ.0T8K&NNE"S="2&/_`&5%)"?M.4T*ZR92
MK-4[)5HDV19PQDG8`H184TT?$?4W=3JJRR_'7\G+[?6^[H3&3-+-A7S"7GH[
M5^E9UD<RHT[6>@R!D7"+>L42`HTC#?[BR0LR%5L`N5'B0'5!(?`WZ25GBP;6
MXDVI\C^XJMI"MH7;_L^^/PN1F]0=R#ZN'O*DWML,R>%7DR-I)&)242`K('**
M3D[3VSJ$(<Y@Y>$3E:&`=?G]1^OY]^O^',M->`X&&LU;`8>UWK;>XYJR#7L<
MUEY*1T%'2=@<F3/-6&77%"+KU?CVR;F4GIQZ=,W@T:(++"'0^/7KPDX13RIM
M)@G873+;NRXNND?:&]*PQEB"O5=?1CV/LM-EU,?33E*)M]/G6S.6B'#E`Y54
M170!-9+]:9CE#OE+AZWXSH]RP^.[1IJ^,JHN34W7Y<PK*)G5_P"IQ=6W*0',
M@1)(Q"MER%*'78%``-V(=\2GZZ3:<`0H$4,'94S=B'CY``=!^H"C^DHD`O?D
M/0%`!'B%F%)&V]BG8?YE/C0B:^>7EA?X"W,F)"DP]YG:ZWLIX2LPKR%<3,6M
M,LJ3*,H^16,*"SQN=PFNH'Z_;#KCA.X>QTIE+/,_*)\I*<Y,W4D?`4?2-PRH
M5@R!+V^NT6=N]1RU(VEO6(G]\=56N_?FKC(')6#0GOG;@H)_U#YN)$_Y3"Y#
MD:.`X#@.!XW(F/ZCE>BVW&M^B1GJ3>H"3J]JA0D)2*_=8*9:J,I)@,C"O8V6
M9@Z:JF(*C==)4H#V4P#Z\#SE9P?B6FHT=*LT.!B5<:T!UBRAR**"JLY5L>/4
MX)-W48JP.5EIQ&&<%K$<)DQ<&$3,TC=^1`'@1?=_&!H8^Q=.88<ZXU0V.)[*
M4IFU>!3FKL@ZB,LS;DKV6OM.L;>SI6B@V)^[*"JBT&]CNU.S==B(B2H3%HE`
MJ&,ZE"T:CPJ,%5Z^S(QC(Y-P]?*%1*'ZUGLE)N7LK+/W)_UKNG:Z[IPJ(J*J
M'.(F$KNWL%"2;=9K)1$9(MG!E#N&\@Q:O45SK,5(M8ZR3E)4BIUHU8[<XF`1
M,@<Q![*(@(=4\HM)D:R2E2%/JS^F)-&[!.HO*_$NJNFQ:=`U9IU]=H>)(U;@
M4/!,$0*3H.@#K@>B;-&K-NV:,VR#5JS12;-&S9(B#=JW02*BB@W13*5-%%%$
M@$*4H`!2@`!Z<"KO;PS[_P!07XO`3``8#:]ETW0E*!EB+GPP[^S.4X'`2HG*
MFH)NRF`#`7OKOE1EO5C)N(\6:Y:X8RO&3\85"XK8SKB,-4K/D*M1,]*%*8[1
M(8B)FY%C+R@&5#P(HFB8IE/0!XH24R5F/%.(F,0_RSE/&^+6%AD$8V$=9`N-
M;J"$U(NUD$4XZ,4L,E'D?O.W!`.5,QA_7^KQ+^KB!DV)D6$O&L92+>LI*,D6
MR3V.D(UT@^CWK%R4%FCED\:G5;.6JR!RF(=,QB&*("41#H>178<!P'`<!P'`
M<!P'`<!P'`KVW,^2O6;2*Q8OHV4;&\FLF99R!CZC5K&]-;%FK4P:9'L?]KQ=
MXM#5/I*N4=E+D%)9ZX,`G.(%2(H/EXU)=[NWOYK=H#C:9R'G*V>4TE"O)FN8
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M1:,A4G%]H<VV-J=GE7;]_DF2HWW)6#F;16,S*54C=+KQ,`-;2_I8QC?>?6S2
M#XR=(;]GK(",.>1U!UO1IM!K:`6;*.2Y<F&*8FE`8[H,>K^]6F7<N.T@!(I$
M2*>(**$^O$D:_"KW/3#YR/F)CG]6Q#&)?$WIE*O7;0EBR-*2QMK<LU=PF9JH
MI,5>KJ*&IT-(M06/]A]VQ<$\B$5,J'1N"YOPO9KNAN'8O)^N>?;-(7BR9EUC
MQ*?$M`M+FY2R4*A"S-:85^ZJ*5E=PHR<JW(6)57@N3**'4`H^0"7A60L3Z@X
M@P[GW.6RM*/>$\G;'M:NCEE29N<Q,5VP#2D5&E/=)5QVH>+C7E:CG*[5F=N!
M/:;.EB=#[@CR*E1P'`<!P'`<!P'`<!P'`<"IW<)TM_ZD/Q5-`=QZ#96:VN7,
M@JHK^XN5VV'V2:)F*1?)N=LD1R<%Q/T8IC$\?KT-%7^]NM.$\W:'Y;OF":IJ
M;8LP8VQE4";1Y%R>X=R6;L,53&U3B)>+A\3V"/;.5<8Y3+362YHO[MLDS%XL
MFJJEYB8P$U#,^MU(UCV^W2O4]GF@QF2*:G\<>H<SKC1MAVL;;9>"Q/?*I8EL
MNVA6!GA=1QK2:0:Q#26FF[0CL5#]$4!)0>$CY3P^&06"?QXXB85Z6<3U$@[S
MLA7<4RZ\J,PD_P`.5W9;+T)B`T7(BFG]Q74,;,8M*,'Q`/V]-'T#Z<2L:6E\
MBH3[_P"X$?H[KE.YS>59W>)52V4#&E'J+-Z2-3G,@Y4M<=2*8TE9)0I_V^&"
M?ED3NEB![@-RG`O1A`>5)8$VFV"V8T9PS"[(Y$LM1SG58.ZXPA-@:%!55M1D
M:E7<BST/1Y.P85EP6<RDF2IW&=;N?MK"Y<*'@R+F45!P4AA#\U=WY3K?R![/
MZZYVRMA/&N&,:X@UXR3B>9N,K$X^F9=]F(M@9R\/.VBU6)I!SSEM+0`_8(QZ
M**A$EB%6]TY@'@B<TRE\>6R%^V<K6Q]JN-KHMQA,=;79@PECJ>QZS01@IBDX
MY<Q2$;-G?-'\JRE7LB:3$JBS=RJ@(H_I\1$Q051$S.UA7(IP'`<!P'`<"E'Y
MI\5NK!AS#-JQOB^3L>4)C<?3VNV6WT*F1,[?(_&=9RB]L3I:5E56QY-E2ZV\
M=+K.%"G`&P.3F+UYF[J,S_+SCR3N?QZ;G$HN+4LAY7E==,A4BK)PT&$E=#Q-
MI*W3E8>`<M8Y:6="X5*#D\>V.!G"B1?J(`((2>LH'T]Q/FW!."&F5:2I#9'H
M^)\7Q\%D&MN)&@9CQC-PE:AC`K5KU#'8VR`>1,LU,4&AW'VQQ\R."*D,8@NJ
M\I(6C=[5QW,3-HB'&\6"3OR.D7-&AZ]3=J\9PBADVOV;FCM/L,?9Y8PY"BY>
M/(YW!3@E$2-XV04#L0EM@_8'$^PM0+<\56]"R1Z;IW'RT<O'R<#:JY,,5O8D
M(.TTZ>09V:K34>MT19F^;(K)C]2@`AP6S(*P%\_(Q0]LISJ!V'1`*4!\3*&\
M"$#H0'LW\?RXH0\SELYKU`*R.);"57.=VDXPSAY@7&U,<YHN,G$N42E04L50
M@F,TA7:ZZ=&*F$E,'9QR:IR^;E,O8@Z,$RU)V?V2Q+,8@1Q;1=(<`7.N3],F
M8B<)6K[F]2B3T,K&N$8:I4.2+B/&,\(.#>(J/;2D4@@)T"G`2\'M&G`>E>4_
MCC1:.JCAR'WQJM0A86HP^6K-:S+[W0.-ZQ'-(6D4N,/DU<<3V.OT"'.X3;1D
M%(4MHFT]&T>N]55^X)&%C.)-U-=LPV!>C0MQ<U/)\:1`97$N5X2;Q?E&/`5G
M!$7`TZ]-8B3D&)E&;DB;UI[[1P*!_955*'?'D\)<D`X@(*>OYAT44Q$?7]/I
MYCU^/?X\*Y`*`=]``=CV/7XCR*UX#@.`X#@.`X#@1PQ3M9@/->1<FXFQME*M
M6;)F&GZ,?E/'+9T9M=Z(Y=.!09&L%=<`21:,W)B=E<=>P8IR=?U@/*CNL=["
MX9RM?,CXXQKDF#O=OP_,%K^3HNN.BR9:+.*HHN0K]A=-`,P9S`I'#INH87)`
M`_?T'IL95FK##P4-*3DO-Q4)$0K9X\EIN6?-&43%-F!3J/UG[YTLW;M$6*1!
M,H=00*0H"(]]=<"`!=WK)G%V-7T;QL^SB*A91N^V'MJ,G3M6:F\;(@W;KI75
MXV:3&8U?O5DU/LJ>@Y2.F`@J[:]^7!#\\?\`'Q5,O6^AYLWFFHK:3-E&@9N-
MJL>YA#0&!<6+6:1!Y:4L7XG*]>H+.7B35DP-+3[B7G3-V).G28&%/@07R1\0
M%5QEEEUGFB8>Q_N7"HU&'K[_``EF6>#'V0'C*I/B/:C'QV3(5JVIV8SPC0!1
M8M<C1S]\4$44BS2#<H)@,)0S%?\`CM^02T4VI9^P>R@L_P!`ICU2-PUG.IR&
M*,OU^B/7;>+FZZT;@M'(W3%[B2(D@<T6\DX%TH0ATCFZ*(#*T*H5JIT:KU^G
M46O0M2IE7B6$)7*U7HMM!04%!QZ0,XN.AXIBW0;,V3=!`J:*21"D\`#H.A#L
M*Y]_/EIU,^/9B$-DVY/+KF^<8E/CW7#&<2YN>6[U)KF<(QK)M!P:+U2%:R;I
M+P^Z>>RDD7H>C"(`8DS4*S,!QOR-?,'';3P'R#:S2^FFI-MHM6>ZDTF5;59_
MD"D9BK=LB;74<O3#YT:)R%)V^HJ-$G;8AVL?!*E\D@(94ON<&9VLNREJCL1M
M_B7'&O>V5GQ<YQC7[;BJWYHM>,PFD9_8EWB>R-KG&Q/]FR<6VA,4PEFN=6B'
M4TV!W.`JR6=LFX-C`BY(D>BQSJEDBO[X;-;*WDN);#C+-6-<18_H=(!-\[M%
M2##+:7*C)/E).#/$/T[6XGS*'31\#18$(4%7/IXCMO0_'MK3EC5NIYWJ>4)3
M&<V&3-C\H9\KKO&B$K&,(MMEB23E7U4?04BS118_VTHS2107;JJ$>@8Z@IHB
M`%$L12P;D4X#@.`X#@.!M$A#"`F*4PA]!$H"(==]==A_'@/$OU\2^GT]`].!
MKT`AT(`(?ET'7^7TX'YE1*`G$>@,4H&+X%,93Q/T0.O$"F\C'+T``;U`.5%6
M65EM!LF;L5#"T-D`M#W_`/[-M=]@[3@N4<0][AX&(;I-)E?)QX="2H-D.JR'
MQ;QEP922@H^0MB)"(*`(J90POFSFND3(Y8QQO'OCFG--%Q18Z_BW,UBP]AJX
M8#UPQO9!^UE&T'F7*.*W-AG4K5-QLFV-+%0LS.-!)-8JC1%,PD`FMKU<38RQ
M5C&J1\3B2C4NE5E5FT49I4R%CHME)-!;(_:/U'3)`CB6,Y0`I_N7"BRJW?D8
MYN^^164```#H```#Z``=!_D'"N!4@=@IWXF\#$\_$1\>Q*8#FZ.4/`@E['OT
MY44E?)3L;`([$XITSEL8ZLN_]P,&9&V#=9CV^E'4)CV'AL762,@Y>@4F0AHI
M6RMLA2;65.Y*^8/$',2S[<)D5.)""$=L%[(Y6IGQ\ZD;>88L^0JI2LDY1H56
MG-=\T6&0V"B9*HY(OR]/0+B_,5K/"989P!#%/(0S^67E'"S02)F12+P1.'T?
MI`H41*8QU"?K$#J>/F`^X/91\2D#QZ']'0?TAZCWR+US\!P'`<!P'`<#0W](
M^G?H/H/T'T^@\#XTY.N6^N?(5=MBM5869E=C\F?)?N/II,/()-RC2CTG(>H-
M>L%%R/FQ.*<Q(6RB8AR)4PDD0D'#HJ*+9P2-3*[,4>:XS&_R]/4L@3NH2_R>
M4?5&48C#8MVGT>K>7\Q04"Z+8XK$Z^*,<5#8++,I+MHFTR\NNE<J],%L$FW8
MS+^->.Y%<IE%4P53)J9E;!J]B/'.YM8N*FP&=GV^6,J)L$?(&&%)."L=4Q;7
MX*?JT8\@<9S1X9"GUC:>`H0+F$KZ?BW;8KM0Q7"0N4Q$(M+F8Z.81#!E%Q;)
MG&QL<U;L6$?'-46+!DS:(D;MFC-FV(FW:M6Z"92)ID*!"$*!0```.1I^LQ2F
M]#%*8.P']0`/J`@(#Z_B`@`_X<#40`WH(`(?D(`/_'@1^SMK3@G96#2@,U8K
MK&0DH\RZ<)+2+$C.XU%9P*1E).C7N-5CK;295(Q"G!Q%O6KGLO\`7UZ<(JQN
M#+:/%NW6#?CZK&W-R<8.SOBC*61F>0[-7X.P[38YK>'EZ%#R./H3*+Y,(283
MLREP*9A8)6%=RL>D@NDH+Q8Q'2=T=8%R6PA_B@FL_P"9,7Z&8KF<4X3K%:N-
MQW&V-S\:9V?V6M-E2B7]H@\:6>ZP]OM4I-U].3705(]DXUDL\:BW:MP*)`XV
MB?6\OR3+ZEZX1>9Z1KOE?.=@LV*V>6V<##L!AJ+1*6X:1+B2L>7<F.4E8RHQ
M,$693,J@BD[DG?@8K5NH(=<>5E993Y<T_5J_-G01;'EH>.DE&[9119JBH^:(
MNCIM%U4TCN&8&5'V5/$ON)>)O$.^@BO1>!/$"^!?$```+XAX@`?0`#KKH.!N
MX#@.`X#@.`X#@.`X#@;>N^P$`$!^G\O3Z_Q[X%*N0,1UVH?,SJ#/T+&<;!Q1
M-8=I+3>;'7:J+)%[89R8@(Y%_8[!'-6Y7\Y('6%)(91PL`IB)4"D$.^*%2TC
MEJLX2^/WY2/C=OL)-/-XLP[#;@ML6X"C:C<I^V9<8;46P9["]YI\JW@25^8B
MSP=I1,+T[\6\:I!N4EU"%:B'+UBI_P#,P^JO6^CSN,]?\*8[L\@I*6&C8JH%
M3FWZR";99W*P%6BXQ^NL@DHLFDNHZ;&$Y2G,4#=@`]=<C4,U<*V*%$Y#E`0`
MQB&*!A`#`'D'7J`^@A_#@4H[E:MYUE=YZ]M+7-6,1;Q8ID-9'>`%\291R!`4
MF3Q/8#W"?M,E<*BWNU7M50D&.06DD@PEUP22DD2,&Y$1,F8X!<:2;16=:HWS
M2SXG]6]<\G68+#88?<7",G,KUC[ITQQ_"WC.:UE9TFA*OBINI)ACQB^3C&JA
MDD0432,8I"EZY#F7TK@/9Q_4'H4/0!`1_4(B`B'X?3T_/A6_@.`X#@.`X#@.
M!TT97*]"'=*0T%#1"CYR9X^/&1;%@=X\,"A3.G1FJ"1G#DQ53`)S]F$##Z^H
M\#B:5:L,#O%&-<@62DB19*04:1$>V.^2<.%G2Z;PR+<AG1%W3A10X'\@,H<Q
MA[$PB(=DPCH^*9MHZ+8LXV/9I^RT8L&J#-FU2`1$$FS9N1-%!,!'^DI0#@?L
MX#@.`X%1F56+.<^:;5!-0[E!W2]%=I+4W%%8Q"/U9/*6!:ZFP5(!P*=(J;I1
M02B'J8`_F%A)G-,-?('C7<3.Z.?=?+-H_AC:K&60*\XA]4LI*7QG3FF%IRYU
M=2&L,YF&*L+=Y)MGM$L+%&582<(1=TX**::8)'\C%&=,];2ZPY\LOQ&VW5&O
M2JV7]A4]8*OC5*8<2C2OHW>\PD)!L'KUV^<-CMC,73QD<QDU"IBY2*`',0QQ
M$"3JEF=$0GVM,JC6UA&DM3:N0:%G2AQ$8I&Q)130DVE&F%-(QH\LF"HH")"=
MI"7T`.@Y&GJ^`X#@.`X#@.`X#@.`X#@.!Q"BB*H+"DD*P)BD"HIE%4$C&`QD
M@4$/,$Q,`")>^NPX'XE8:'7D49=:*C5I9NF"+>458M5)%!(/<Z21>G2%RDF'
MO'_24P!^L?S'@=EP'`<!T`_4._\`]/IP*W?DVB0G\7Z[PAI:7A$)7=O5IJZD
M:\B1>=2;%OP.5"115FSIN5TO[`$\E"@0"&-Z@/7`AY\GEGW@PQ.PKO6/?.QU
MK*>TU_B,*ZM:R2FON"+=6V^2#QB4F]F7%YF<>RUGB\?52N0TK.S[N4^]4%N'
MLH*E4%J3E9F^KG,2QMX@L>46O90MK>^Y-AJ1565^O#>)CJ^C<K8WB4&]AM+:
MO1:35C`LYN917739HH(H-_,4TR@4H`"6F2>0<:O8)F$O0"`?43^`!_'R\3==
M?RX'S"'V`G--?DPW.V1MMS?QVG*VRF']3]CHZ5F7Z]2PL:_ZY8AR+A+.S".!
MB]-76+O,-[GHBV/BJ(MCA/,'2OB#990VF+SX>(O6U%GQE\B\YO-F9KEA[3*O
M\=>>\[8NUS4>R2[&N8OIF5$Z/1IEI6X-M)C#Y!RG$E0E9DSI.6%D#@?MA\""
M3D:[2Z;5#9'9O*]RKS+,F!:S4<:9&P?5,R8WRO6,B0$@9>7LZ;"4E<73%!7D
M%;8H:N0LNV.E844DF+TY#D5;-%C$3$>]K$.13@.`X#@.`X#@.!4;?B/E?FPP
M`=D#<@,_CTV35?G55.FH=F?,V`4VWM$142]\Y))9/]"_:($\C%-[@?IJ=0XM
MV;=L-4_D$U"Q!=-E<RY?3SOE2TPVP[V[X)98STKKM.LD5.6G']?P=?96->*P
M^4X146D4VAVEEEU'[=)0SP"N"]\)ET>ZDIO5KLA2[#$;]VBZ[RYMV4J45@W3
MG'E8H">$)+%LWD9DRD*^[HLQ!*9%/4ZMCH5',[;'TR4&CL#'*8A!*D9TYY?2
M>@``4X@`@!E5![,/9C=FZ`PF\C>13``"3_\`9T'X<-.;D&$<U[`XKP(TJ"N1
MK"9C,9!M#6DXXJD3&2=AN5[N#Y)19&#JE8@V[V9EUTFJ1EG)R)?;LVY3+.%$
MD@$X"7B\6;1XWR/DRR8-7B[UCS-%.KD9<)C&V1:J_K<E(U*7.DFWM%3F4E9.
MFWB&*[=$3?&AY1^K&N%"HO2HJB!!K/A)U(X&_2)BBH4.C@4!('8&,03%3,(B
M!!.4>A]?I]>):<O('`<!P'`<!P'`<#3L/S#T^O`UX&G8!]1#\/Q_/T#_`#'@
M:\#3L/3U#U^G\?3OT_/TX'0V>RUVGU^7M-LG8NLUN`8.)6;L,T_;1D3$1K,@
MKNGTA(O%$FS1JDFF/D<Y@#E%)T5GJ=^7.7BFVI2,A2-1<&9@KE_';&[5>0>0
MV?LH8PGEW<52<'U,TK".K-C2/F&IR6"><*-VQB@5%B54WD<"8_#BN]D6J>[&
MONR7R)UIEAW_`+=L09@H>),E4UK9;EKI)Y(S+/U:'FK^7(21"N,?SH8YKJ\<
MC$V:+;&33EGQD7*R2'O&)V)7=PTO$3S&.GH%_'34+-QK:1BYV(=(24;*Q[DH
M.6;ME)M%%6KIBX1<`HB=,YB*%-V4>N/M7<B(`'8B'0?B/70?^7(J*.S>U-7U
M]90%:90DCDC..2W2T%AK"U6(L]LUXL!TC`U<2IF:+H:A16;H`_=)Y\1..CD`
M,HJ?]/CQA)>>KNE^O<S6,OFR+@JJOIK:V8J60-FZI8)>7OM:N=^K+:ODBC.V
M\N]6@W#&K#7(]!F+1HT(<D<W55(=4HGY4][>LF-.=:[%FI#8V9Q9%RF96>,'
M^&4+BXF;.!38JE6ZC:4I#BNH3250<0C]!4P*)G8',;OL1[]>,KMUNN^F6N6J
MSE<,&8\>U-`T8,!'EE,A9,O_`/;E;>O4)=S6:@ED6XVEM0ZBM)1S508R&!HR
M5.V2\TNDD_$D82VY&C@.`X#@:"(%#L1``#U$1'H``/KZCP->`X$<,R[*47#Z
MM48+QMTR+9[O;/[/KE)Q)5)#(%L<O&2B"UH?.V4*4Z43&4Z,4%Y)*N54A;MR
M";Q,;HO"(%YKUHW1=[;*[O8_<XBLT[C[&%LUXQ[KT>RV2N)Y`PY?IBHVBU72
M9R@Z@VZ-%R_'SE>3^P8&9/X-5%!,%'**IP.6B)N%\+5#.5KP]@39G<K.LPTU
MES'$9@KFHVVE/@*YGIWDF+6E?]O6=TS\PF&,3L;0Z<]>+GK[J`8I#*E2(NL\
M<E`"\(SABSXH\M8=SSFC8NI;Q33_`#/G:\H6*UY/R%KM5;[DJ*H\9*&<I85I
MEML%^.VJN)6S`X-T(Z/8HB3Q]WS,?KHJZAW(-86-6?3#MA'LXYF9W)R;Q<L=
M'MR-T0!=\X=O3E;-6Z0IF,8RJG1">(B8>!#QGO/C:XWZ/J.'H*R9=J<<=^\R
MKG*O%CX;`N((6,:KJOG<]E.S+15:G)@#D(8D;%JNW0MU/N#>*(=B+0!VPGHR
MZ[4:!?(;AF0/L;KEJY<LYXHS>UQ:W-=E*0MEBI)5%GER&A6`.Y"UA2)=RDD^
M&+2<J-&*YW!!,0AO$E9CXADZP-IS:_Y,]7,O8H5L*>$M.<79C=W_`"*E'/8N
MJ9#O&;XN%K<%B2NC+5TC^RJP,;%+3DHHT7308*M&::W^HL0.#JXM(0,'8?3H
M/J'1A[#R\C?3H3`;Z==\2TY>0.`X#@.`X#@.`X'YE2?J$P"'D!?,OD'D`"7]
M/T`/H(#_`!'\N6*280AKF_N";%N=8]!G!;Q5-B:UCP,KDB+;7$X:M6FF+OP8
M1\G3[($J];SAI-9%XHBT`I'GL1SE8R14T3&X+C3T.4=U,&XRV:PMJ!)O+5:]
M@<YP4O<:Q1:-6%[*K5\>P2RC5]DK(;U)=LTJM$)+MS,TWRYC@=V'ME3$1`1>
M"DD;C:8*BU6P76Y3#2#JE2B7\[/2TBY,T8,(:.;G<R#^4<"F?INU0(8X@0HF
M$`Z`HB(`(0T9?(1A==.J3EMJV:<48LO\]&US'F=LH8[+4L16R0LCV*:T9..L
M8S#R7@F^1CORA!KS$;&D<B/@<4E#))J!25N5\;_R;_)7\D3C$6V>3HZM?$?0
MV89)K<!A1^YJ2^58N76*R8XEOZA'A)N9NS.3A?N))9P!XY"/4*+4`,Y#P),3
M,UQ]/6-,>4S$M%JV,\=5:&I5"H\*QK=2JL`S181$'"1:)6[)@S:H$(F0I$P[
M,(!ZG$1$1$1'D6'JY2.92T>\C))BTE(Y^W6:/XR0;-WC"1:+IF379/6SI-9N
MNU<IF$IR'*8IBB("`@/"OD>RUMI?\79ESG,?%1DC6_%M8PKF.:PU9M8-A<TM
MHRH[-Y8K`1B5TKV'\33TA%IZ_2B5A8*P,;*@]8,)A:'=D8M`)Y&'3/I9M>OE
M8R1CVK9)I-QUCL<%L)CR<P_0+/8H^PU^PZP5*W9Q@HB3J-@LF1$I1"Q14.R2
MEONW,1^VN9$2E31*H8RP'+.JGGK-J;#X5E9_*]]GW.7MH,BQ[-EE;/5A8)-9
M2::-ES.6]/H\*11=KCW&4.\.(,89D)2"5,JSDRJX^8!,!%`$CKG!18_O*>?B
MJ?S*F(=ATD'_`"$'OZ<20_1R*<!P'`<"GKYBXC)]GPCABHX*R=9L+Y[R5L92
M\=89R379MY&EAKR[K-TM,1'V.'1=I,+32+&O5?M9ALZ34]F/467('NHDY<,Y
M0NV%^3O*.;?CJR3":[6N%Q-N=2,(9E<[2JNW'_\`H-3K%@%DO#9+,[@O<6>Q
M]DNEPCU8ZH.'B?V3OM1;LP$+QHB;A*K%F_-GJ^%<84.A8%ROLG=<;X`TUM.7
M!@)YN-PFB[&T9G.'M-./+-';2[/XA-E(R,D19TR]P4S(H=C]&A^C4NRV??/*
MV_4GF6\W*+CL";/7[5'%6-L>V&5H\;C6H4VKU*0-D!X]8`VD9S*5\?S[EP5^
MX,LBRC!;HH)@)#*&+UD[X[<GY0WCTAQ%E',=I=(%NU-MU*N;6K5Q_3@R&YKM
MHD*['Y.K-F549V2&CY^-BR.$!:@1NX*J*B1O$2CP1.%@&(<+8RP)2T,?8GJ3
M"G4YL_D)<8MFXD'RKV8F5_N9F9EI&5=/Y27E9%QT=5PX6554'ZF]``(K*@`!
M0Z^@>0CZC^)C"/U'\Q'@4M;N[P?'#*WB]:[[*4.Y94B<02%&0S%E"MXEE[1C
MG6NS7-PP4HY[?F:'=,GF+[8V/--G?O,%!<1Z;DAG!D^Q*%IF\L(YXW2OOQX6
ME/'6%[AD+Y&H>ATR#R%E/7@\"\MVQV)<%SQ5'$+DB.S1%,6E?MD89(!42CIT
MII%6.1`[?W/4_!=8?H9;4X?^35YCG(.M^-\[;!J1U+@I60UXRG,NL)ZYXU>7
M5BYD*QD38AD^:N5,A.96#$ZT1&-#2;5\T;J%]LBJP&(/,)KP.A,CE%"FRFY=
MNB,E-*E$1I*SK1BJ+>XWU.Q^^0.HNLW1I,8[92646Z!O%NV/8CJ-4FZ8$%D/
M8F$OM8S6Z_!56&CZ]6(6*K=>AVB$?$5^!CF4/"0S)N3Q28145'-VK%BT0`>B
MD23*0/P`.)5WO('`<!P'`<!P'`<!P'`V&#L#=`)A$/0!$0*(AZ@'8=^(=_7@
M?,7MGK;L'E;<KY`<^X4QO?4]@=58727-^EELE*G/U2JY2MV-JYFYMF["U?O;
MJ*)$WB&N](NG[,NQ(X,W3DI%$Q_;%$QRUFIF7>7FD;B1>R6G.8`Q?.N-E\W5
M#;G(.7)>-QW99B@X!M=_PE2*IK%AVQWF%A25A"(H*V.FT:]<N'S9"0DV[A^Y
M0:F?)',PN;Q&&(ZGKWG+9W5&ZXO5BM[:YM:SU<NM`S+3<^QQJ;@NWYBA;6WN
M;*2E+FXKK.+S+/VZP1PL(B:A7SY!"'63*]$2$$HDS7E.'=2RV??C0(VK^,\*
MY$B<[YP;X@JMSQY-U.8K<;K)(M;;3Y:ZS-RNC^#CZ*V7PRBS4DF;1N[*]GD6
MB!XPAO>1$'3,Q4+Q8ILHT8,FRIP5.V9-&PK`"A16]ANFF90Q%/U$\S@(^(^H
M=^H\BP['A7"L8Y2E$B?NCY!VF`>IOR$#B8I2`4W0B(]^@#T`CUP2^;?(7QQ9
MOJ=%WNU1HNKN#,TT/>;,N6,PUG:2^V:NPDEA*4SXJDM.JW&BFJA[E/3.%IA[
M(/JNK$RI1=D!HD<[94[E0:S6,(^[#8^+B'&N_-*G[&U=-ZYLQ\8&/(Z:<K@V
M?3YZ3CK&]7:2\L_>)>T\L%F58>^L0%G*Y1,"9S"</(0^L[L/+Z_B)>@,(@`^
MIO4/P'KD5NX4X#@.`X`?I_Y==_\`CZ<"*VQVJU&V??X!?WZ:O,(MKOG&J["T
MK^SIHD,9S?*E'3,%$HSZJ;1<[V&<Q-D?HNFB?@51-P<!.`?6I5O!Y"^//6#(
M=0V_J;RBNJ^.\C7[+8BR522-#VVUHA#-:Z`QTT0IE(4/VQKV((^(&6446,`K
M',88,.6'XF]>Y^]8XR`PO&PN/YNAX;I&OL\WQGF:STF!S+A['!$4*C2LTP<,
MHBQNL<P9H^P83@FJL@=0ASB"A@Y9E*9Z>Z:UB$RE><N87O-UP#/Y9CFK+,43
MC1K43US)SZ(C!AH*XSD/:8*=0B<C1D6)&?[_`!9F4BY8M6J#A10C5'Q+7>I2
M4>FUK'M/K='IT#&5>K56'90<!7H9LBSBHB,8(E0:L6+5NFB@@W13+T!2E*`?
MER*]5P/SJE$3EZ[,!@`HE\?Z2>0>8D/Z%*)A$OD`CV)0]/7EA'S(?+SFS"V=
ML0[3:?2<SF'7S9"`ML8KC7!L;1'#R.WQLZ9:Q;<>NDV=)K\G,Y7Q-,2;0L9)
MI&=LA9J)JB]$H(IGXG%4DS&IVS=L[M7BM+&D_J3M(UV*T"O=OUMQ6[?YTP[2
M':-8RO892E%:S>`\.95A*W99R5M];?>4=^T&1;R)T#"DB;U[.*^6+_\`_G5+
MD)K6MG:]ES%9<0Y%HS?67'?]J"TDXI\&.Z;A\(W%TQ/UR1</&]/N5DIAFLS,
MQ"*R@-)&25$Q4S*^T0L/I5((?T^7D(``CWZ&$/IY#^8")?J'IR*W]@/T$/S_
M`,/SX&O`<!P'`<!P'`<!P'`<!P'`<#B5]P?'P`HAV(CV)@'L`_1UX_AW]>_P
MX27&@V1;G<'1222,Z6^X<&3123.X<>!$A<+F2*45E112(3R-V;P3*'T#A7Z>
M`X&@B`"`"/0F'H/XB`"/_`.!QJ'Z#H`$P]AV!0[$"]CV(]@(`'Z1_P"'U$.!
M\R6X%I:6J&^1-N+"3;QT7OWI934!D74?/@K(1;*D)O7[1J@'N0L2=V/^B17_
M`%4@#R#TY4]/IPZ`1`1#U*(C_'\0`?\`$O(-W"G`<!P'`<!P'`<!P'`<!P/P
M+,VJCI)XHP;+.VX"1NZ.W04<I%,'D)4%C$%5(@F^OZBAWP-CENFX*G]TU27\
M5"*(%6;IN`;N.^B'_4"_@)#>OF7H"_GRHI,U:R'5<+[;?.1F3)DK.P]5H>8,
M+VBPN5F!I%)G2*IJK2I5-Y6:Y!$=3DPJX=?>)A[9%74@Z$K=-/M$`,3N4U-?
M?D!PYG_*DIA9M5LSXGR2:N.,A4:K9TQA8\8RN5,6$4:)JY0QVUL*";F3J23]
M\5JH#@C9RW6+XF2`!`>%9#:[DZ\R&V,AIC#7Z/GMBH?'X9'M-$B$5I!>GU,Z
MK<K-U:9)(18PCZ32<D5;,3]+KHC[H!X]<'4J$504`0\?$2>("'\!*!B^G_((
ME'^D?4.17-P'`<!P'`<!P'`<!P'`<!P'`<!P'`XEN_;-XB4#"`E+YB($$Q@$
MI0/UT(E$QOP]>!7#9=]+(;.>8<(XAU.S3GIM@R4JE:O61Z%-T!G3XZ]6JLUN
MX#1__P`U8FDJ,Q`5:X,7+\?:%-(B@AW[I3$"ZRD*O/D"Q=<,:4?:_(-KPW86
MU(S-NUJ;E2$D*Y&'ML)68+&L73T;EDF_N:NX1D:K''DD%?)PX*X1373'S*1+
M]00V^D"KVJJW2"86VG6>!M]7EDA>Q%CK4S'ST'(MC>8>_'2\2X=,'S<?4`$A
MS`'7U[Y1Z7R#OKOU#\/\`'_@8.16H^GK^7`V^91`!`P"`]="'K_4/0?3^/`W
M<!P'`<!P'`<!P'`<#3R`!`O8=CWT'8=CUUWT'U'KO@>>LUKK%.A'MFMUCA*M
M6XHGN2<Y895C#1#(AS`B7[R1D5V[5L)ECE*7R.`F,(%#L1`.#;Y[=8]I:-CC
M83Y?<MEQADS)">0,DT_/&)89AC6V1DSG7"^),#XWH5U?8Q=6^*81]K&D6>%F
MCH1*94W;@WFHW34(X34&LYS+!]<R)><Z_(+8]HOC+L63]I7]PU0RG6,CO=DV
MEMIV,=;KU/V5O+X9H6,9R\4^J)51HUF)B57EX!DSEUUD(A--=T0YRG,+O3H]
M&=>MWM;_`)*=6JGEO!V/KA;%-3,X+[/;91F0W$U-Y8D[7EN&EE<D2#Q6&:+C
M-M)M=O%QD"[67,TB$S@V*DD0>A.WU:M@!,#E]PAP[("?@4`$J8`!`()@,;S#
MW`$?KV'EUQE8?I`Q1$2@8!$O7D`"`B7OZ=_EWR+;=P'`<!P'`<!P'`<!P'`<
M!P'`<!P-IB^0D'OT*;R$/7H?00#OKT'H1[]?Q#@?--L/H3+7/&^]$UC31C,5
M$W#R)L//VO`.=(+82`L`EMJ#BOJ4+8Z)MDA>ZS*XZ@4R1R9G]<_;':C1)L+)
M,CE(2J<MI7SM]#%)@K$UQU3:]>'3>Q69&F0,5>I1Z@W<(3TV6$9L[.Y6;`7[
M5<)>0*L<Y3$]H0./91[ZX5%*S:0P]7G)F_ZHWFPZP9#FK`UL\VPJIUYC"5[D
MT#LU'Z&0,*/7Z%3<)3S&/(P5D(PL?+-&RAS-5T51`_"3'PUI6Q&PM'<6"(VV
MUQ>5Z,J+!S+J9^P))'R?B&?BF#!%9S*N,?G4)G*F2JSER9NC$-8JU#XI&64?
M%3]0@]%D/Y!]-\:ZP/\`<BPYXI3[7)D=-F7(]7=+VN-?3:[XT4VK#1K`(/W_
M`/<RDR06:C)5))9JX`Q7((@0XE$S2GGXYOE-L6V?R>9AQ[=L\XD;XUN.L5%R
M)KUKQ5+S1[(XJ,H_M<FC*0\M:Z]+2#2^YF&KQ)Y*:8,S_P#X1BN5/VQ*0ZQK
M*1,7B7TI\C1P'`<!P'`<!P'`QED_,>,L-0[>;R7<XJJMG[G[*&9K`YD;#99+
MVCK$A:E5(AM(V>WSS@B1O:81;-V\6ZZ(D8?3E$9+YFC:*]3M:KFKV$8]I7++
M#M[#)Y_V&5>5:BU>%>)@1HP@,2QKAGEZU7A8XB9S'2[>L)1Y2![BRYC"BFPG
M?#I*OH#19V?K>1=IKG:MM\KUF55L=>G\K%9LZ'29?[A-PT/CG#%<)'XUJQ(D
M4B$1749.GZQ``SA=57LXA->P52$L\+(5N;AF,M`R\9)Q+Z/=)^*!XF;;BPF(
M\BB8IO&Q7C!PJ3M(Y.BF\?T@`=#Z0TFL/9NUAPY3*9HXQI%NCJ1)33ISB38B
M[WH[BUUZ5>(O&=6H^7$WEB>T5_6P,O\`:"_C)IFHEXH'(F'2Q0QWE3Y`G^!-
MKL1X`RU@Y2MXRR5C*'M\YL<SR/&R\-B^V6.P-*7!T2\T<*BQDVT38+\_1BF4
MTR?KLO?."CE-L3UX\GIZ#8+Y!*7A_9S7'4ZI49YE:_YRRFRQU=9!C/%K==PI
M#/:/;L@(2UBDE:_-IV.=DH*BOU4(9J*2I4DA5=.695&WODPS)4]W-3+1DNOX
MBKV;:B^O]X<V9E1X]09=I'Y%DJ*M]C;XO']M?QK>H9"F:HH3VG[:'D'SEN*1
M_<(4$SB!82V`0'Z<BM>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!M-T!1$P]%`
M.S#^'0>H]_PZ#U_AP/D@T7K5;97?XDT%:LW1-?\`8OY-[/<$7:8M&USLD%`"
MWA+7.QB'W4?/2<:F<`8N%BJIMTA\4EDP$"C?+/8A]'U1U`P12MFKWMQ7:,WB
M\VY'QO4\46:PH.CIQJM.I,F_DX1%I7T!2B&$J=Q)J^\[31%PJF4B9E`(7P$J
M4?(IP'`<!P'`<#:)RE#L>^N^AZ`1Z^OJ;K^D`Z^H^G`V^X3T#OU,`B4.A[,`
M``B)0^HAT/`J&FJ\\M7S`Y"]U=@W<USX[JVICBQRD>UGR8^M]ARW>F,C8X:,
M?N#MFK]9!FT,N()H?=HM02,H<O8)U/I"VC6K.VH7R:ZE:SW38#:FZP^9J'E9
M;-N8MD6D<MK[LWER'B8>RUVIZQPY9)Z?%^1FAI!\Y4@HQ1"+3BDB("#M5$1*
M3-TP-CK*VUN#VW_<_P#(#3_DSQ]2+7M-,*R%TA,P8+CL'8JQG9,J'IN(F%QU
MZDKC/95942'C/97F%`A2*.&SD%C)J$\3%L?V7\QA]82!?$@$$>SE`A5#"!`,
M8X)D]3>`%*)A+UWT`!^0`',M-Y@'Z@`&ZZZ`?3^?KT/X?PX%7^Q&BEFVHS;G
MA7+Z&.7>NN4=2E->H*+86.YGR8SM"MW9WUO<5T#P+:NUM"%FHUL=L,<]5="J
MB58Q@,'CRC`4!\9NP5<M_P`<UK>Y?Q_D6Q:N7RX9-V7R-:DYZ`NN<KK;L1.\
M+)/ZZSKU;<1;!E6*;(>TT;NED$UDV*"9P(*JRO%I,3+=I#\>.R>MBF%<;9":
M:53^+-9+[D24Q3F&KX]L$QLA9\>6=>8)`U>72ME;90>+[6=*3*M/SD1-RJLL
M9$B)4D@]Q55@J?PNZ(02F.(]="!`*`!T`>)>AZ#UZ`1^G`Y.13@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X&PY@*7L3E3#R(7R,(`'9CE*4OJ(!V<P@4/S$>!\L.
MDDFI(99^%J'?/S2?BO\`)Q:8U7]T0(HU8E8,HZ/8M0;'*Z=Q3%%0Y"IKATJ'
MJ;LR8<O&>P^J$?0!'U'K\`^O^'\>1IL*<IA,!1[$@^)O00Z'\O4``>!OX#@?
MG%T@'_U`$?`JA@#L3$3,10Y5#EZ\BD,"1NA$/J'7UY:DMT-:NE1ND*SLE.LT
M!;:[(^\$?/5B7CYZ&>BW.9)P5K*13AVQ5,@L02'`%.RG`2CT/IR)</2@/8`/
M0AV`#T(="'8=]"'X"'"M>!77LSO;8<(92D,4XSU3SKLC.T['J&6<J35"0A*K
M3\>4)TY?(-C(VR[.8R&NUR=IQ+IP6"C5%7A4"%,H*?F7E2743OR/T67I6N<_
MKKBW(>Q>0=K:[(W/%.)H)S`4>R-:)`(+&G;ID&2N$FG!T>JP<H4D>X>*G5`T
M@Y11)Y^8#P(Q:U7J,W+W7V(M=EQ[E/";^:T>QMA:]X]NPN*;D2DS:^4\YQ5W
M:QTC'%(,F+%VW0/"V%FH9FY3$R[00['B,$Z9HQO\8<C$7[$EGS=MKF[96FZX
M_P!Q_P#;E2;^W@H:6H;BRP!Z@M.W+(4$"=ERG;(:J'%K'R3T&CELJ=1?R,H?
ML$^2&/7/Q"S-GCJGB'*>[6?<KZ?T;)T5E&"ULMK*"</YEW6[#_=E7I.0LY+K
MOLCWK'<-82D<"P<"FX<^V5-9R=(/#B)^2ET!0$`Z$?(>S#WUUZ"81`.NQ_I`
M>OX\BMW`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#PF4,DU'#F.+UE>_
MR*D12,<52=NMLDT6;J1685ZN1SB5EG2+!BDN]>JHLVQS%21(=10P`4H"(@'`
MBQA+?C$F;LMQ6"CT7-V),I63%)<XTZHYOQNK17]RQ@E+,(ES9X$"2LRF12(?
M2K+[U@]%G*,!>(@X;I'-X@'ST?&5*P"^3/@Z@QE&+ZV0>&_D8G9IH1R@XGH=
MA//69X=I*Q*1U'C1N^;K&70=KIE45+T`&$!Z&L1Q]=KI\DU:KNC%54*BW<.!
M(@BHY6.5LD=50B:*!5%%5!`@@4I0$3&Z*'8B`<4VI\COE4OT+:\+R>;=%,W8
M-P'L1FN$P!B#+=JM-;=75Y?;4K.!3E[]@M..C[9CJI6<*\N=%Z\=JKI$%/WF
MZ9E"EX9M<<(@`"(]]``B/0"(]!Z^@``B(_RY&G!]RF(#XB8W7U\"B82_TB/D
M`?TF(!@$2CT;K\.6BT%]S'6JM\K$3@O8_+4I5XBTRCJ8DZ/5+[-4Z=O%?J-9
MGY^:97,]06;6&/Q>P;-S/'SUTNPB@>HLT#._>6105(A[\.V=-8<>_&EI[3EL
MP82I*R6+&0MZW+Y0J43)"5>5D0;F=,9N5:2)W[M(I3J=D.(G'^LW??'I(S"S
MYIM!K2_9OY!AL-@U['Q2IT))\SRS0G+./63(8YT7KA"?.DU5*1,PB4XE$`*/
MY<C3\Z>UFKRJ:ZJ6R&!5DFJZK9RJEF#'JJ:#I`GN+MEC)V(P).$4Q`QB&Z,`
M#].!3S\D^_6J+E7(^IFT&/M@;%@"]8JA[I0LSZDSMCR3(9,L$F6:BIG&#1CA
MINI.4^?C@$JC=.2?'92R2Q3&`B10\K]I:J6IDQUA^+T+S5\ABLE>L'(:77G6
M#(6.\6.'.0;A174?DA"Y8;_WSHF$'CFP,?NL>1[%&7.S3!"/LB":*X&,<YBD
MUF5B'P:TO(XYNW/S1-3MJ::_Y0@,+1^G&+,G950NF7\3X"J-ES*XB:C=:A)N
MW%TH#!4)U&:B64H!E4&$[['O*G3/XJ(_I])1![*`AUZ^O91[`>_7L!_$!Y&F
M[@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@8DSO?7^+</Y"R-'8YN
M>7'-*K,C9!QKCR/CI:[W)M%(B[>0E8B95_',I68=-4S@BV,H)ES]$(10YBD,
M%"VOEGKV=?E[Q]LMK!/YNS-4;EK5D:"V1FLY4ZW0]>U5A%)BJ3N.<2XEE;33
M8-2KV>]7!1\K8:T*BK@4HE!<QT@2Z/68S*TC:'3DUUN5.V@UX:4*B[C88@I6
M#QU=+#">=9N]%F3$4M>$LEI1Y2N%*'<TT"%(\;E"1AG92N&RG7N)GBUWK(VM
MFT,3G-E=:Y-5&:QEG;$SEM%9EP99GD2XMM0EG<<5[%S46XCWJ[6T8^N`HJC`
MSK?IO)))&\@362623ODB>*;L297V+SEM+5,R[^:=[;1S6KYE+"ZDZ^4G"4M<
M,.X12D9E]5*[LYF2[Q,F^9.\A+UB2=$<N'8DC*TQ*JHV1*NX.H9X-Y7]Y,S)
MBW#4#_=&5;W6<?UX[@K)O*VB6:1:+U\<WB5C&I+J`ZDG@AZ^V@FH;KUZ]!Z4
MJJO:3;/*<_$5!Q57UBUEUSN,O8ZG8\F2=4F'>ZN7I%Q&NVE+JVE>`755LKJ3
ME;-,JH'//3[$Q$H<ZB[5J</!<E9S^'7X\TOO>3XFY5MKCQGI_@;)\.WBLR/)
MQ2K9EW<VTKTE"3$1;(7.]]GD+G6*/5;$VDU4%`9/)VP/4')A0<0ATB%&0OB%
M@%7T7T[J51I](A-9\*H5FA0$;6JC'.<>5R0/"0L6W*W9LT'<BP<O3>V0OJ8Q
MQ.)A$3"(B(\A3TLKJ1K#-CU*Z\84D"?Z8#]YCBK.!-]O[`MA,4T64#&1,W((
M"(B(>`=?F`=(OI)J(XD?W9;6/`QY,B2S9"2-BZGG>(MERE%1))0\.()`H</U
M]>A@`.P'E*=C+:<ZL3<V:R2>O.&7L^*J#D)AUCNMJR`/&OO_`&KG[G[(JA5F
MWW)_;.42J$\AZ,'?%E.#_LPU0^]&4#7'"7[J+(T>,@?&U85<G:*J)K+ME5SL
M/N%4%W"1%#E$_P"LY`$1$0[XLIXZ4T5ULC[Q5\PXWQ#CO&F:L?.YN6I=^J-<
M3K;AQ*35;>UD8V]DK)XEY<Z>N@LB9S'.EQ3.=LDH04U4DSE%0R#@#*]UM=(J
M\7GJK0V)\^*HV%"Q8U0LD7*I2G]JS3J">W6A^#LTK)8[L!FI7L:NY22=ILW"
M97)$U@,7D.)$%5(8`$/Z1'Q`PB4`$W?0%`.^^QY:5J8X%^OXCT'X=F'OHO8^
M@=]?CT'(-2'`X=A^`B4?4!Z,4>C%'H1#LI@Z'^/`W<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<#:<#"40*;Q,/71NN^O7Z]#Z#Z<`(")BB!NBAY=EZ#]0
MCUUV/U`"^O\`/@:B`&`2F`#%,`@8H@`@("'0@(#Z"`AP(B;%ZKM<NR5<R?C^
MWOL/[$8PC95IBK+T(0SD6;&6]EQ)4B_P'N-F5ZQC+/&:"CB)>&.1-=,CA$4U
MDB&Y40B#?38B9D+/B>Z8RJFGMMQ(K6X#,N<L[R0/Z!*.+0SLC"`MFKM.CSH.
M,T,[3.5D3Q[-=TQ50;./9<E*X3$AP\-B+&>2<UW4,A8KQI='$[&W%X]#=W?B
MO'FK;"I.3+*2RNI6N#I..;TQH@]7]F)D5DHIJ>,.H0SMV)0(+1"Q+"6EN+<1
MV@^5;`_LN;M@7J<@G)9YS#(!:+NW0ER'1DXFCLA(C6L75ITU4%L9A7V;!-=J
M`$=&<B`G%927/M"("!P(;T)^H0[,)@'L1'](?T_\H_4.0<_"G`<!P'`VB`]^
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MM&SYW5+M6WZ:$K6+,S;.TSJLW29%"E4*8.RF`PI6&:^13@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X&A@\BB'H/8"'KZAZ_F'Y<#'UIQ90+S/4RS76
MH5ZVS>.)E:R4"0L$8WDU:A8W#1Q'JST$DZ*JWCY@K!<4B.4R`NF'8E,41[X'
MO#IG-T!5!(`!Z#]1_#Z@/Z3?3\?SX1S<*<!P'`<!P'`<#S-N8OY&MV1A&$2-
M(R5?EHV/%9<Z"1GKM@Z1:%45*DL#=,%U`$R@E-T'X#P*,X3X;I29PMI!3+#E
M)#%M_P!=6UGQMGBQ8?&615V!UJN5CL-HL>O\C+O%&K]C4)N8F&[E8ZA%%$'#
M<YD!)[GI68CCHLM_%EL#E"Y[Q2D58L*4:.SEE_5;-^MI7L)(6:`Q?/ZG1\!"
M0M3R54FA(-*7KMT)&JG:FAE6AXE!02B*BA$S`,K.=*\*Y9Q56+W8,X1>!(#)
MF3[6VM-C@M=JS.PU+9NFD#&0:CF3L-L>R%OO=BDU(TSA5_)+'5034(T2'V4"
M<>%B^[35`.@Z]1_F/8_Y\BM>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X'"I[GB?P_J]/'RZ\.OT]]^/Z_S_`,?X<#A)Y?J[
M]SZF\OZ_#^DW_P`KR_U/;^G7X=_3E1H/N=>GGY=%\_ZO+OV#_P#V_N?\WGU_
D5^G\_7O@?K)WT'?7T#\N^^OU=]?I[[_+TY%;N`X#@.`X'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g21538g70q57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21538g70q57.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-=6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YL<&%V86QA;6%N:3PO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\
M+V1C.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2`R,34S.%]%6$)?0U927R!%>&5C=71I;VXN9&]C/"]R9&8Z;&D^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V54
M97)M<SX*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G
M951E<FUS/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@
M("`@27!T8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O
M<F4Z0VE!9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX]
M(B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM
M<$-O<F4Z0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K
M/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T
M>&UP0V]R93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H\/WAP86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!(`&^
M`P$1``(1`0,1`?_$`+0``0`"`@(#`0$````````````)"@<(!08!`P0+`@$!
M`0$!``````````````````$"`Q````8#``(!`P$#`PL*$PD!`0(#!`4&``<(
M$0D2(1,4%3$B"B,6%T%1MI>W&#@9.5EY8;,D=9;6-W=XN#*RTC,T=-0UE;75
M-E97UUC8.EIQ@9%"0R4F*1IZ$0$!``(!!`(!`P4!`0```````1$Q(4%1<0)A
M$C*!D;'PP2)"`U)B_]H`#`,!``(1`Q$`/P"_Q@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@5L^I"[![3]U2'`USZ7OVDN>M0\>170$10].VISKO
M8FU-B7:=GJP\=#;8]!PZ>QU,81:;D6IP^!4C*^`_?$0O1F\UM7Z<[ALQLT[<
MYMO6Z+#ORM<C=<6;3FJ=A756+?WD]!=5&K7=G7;9/1(BC8)&L2%F79D=*^'`
MHI%*I^\7%TL_A-#D4P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(+O<CHGEF<D^3=M[8U!;+%L^
MU='ZJY>@MD:GW);N?]B5RJ[WL[.I3"S^Z4)N>9M4+"$<?E(Q#DZ:*JH"4%4B
MJ*?*QGVQCEF#U/HZ*UVQZ]Y:Y^T@WU#3>5NG)O7#^?<7&0O-MW+99ZH5>_SN
MS[Y/S$8TF'-HE'MI,W4_(<OS?:;D$%0`?MEBSMV2XX4P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P(8O=!_YF\(?Z2_C/\`NK1.6,>^OUCQZK_\(WV\_P#+Y7_N):MQT:FZF>R*
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8$,7N@_P#,WA#_`$E_&?\`=6B<L8]]?K'CU7_X1OMY
M_P"7RO\`W$M6XZ-3=3/9%,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"N[_`!!'3^H-':]Y!1L5
MD:6'8=2[7YOW0WTA3GL=-[IN5%UML*.EK7)4O7R;LDW-DCVY`*90J94"*'*!
MCE\Y8Q[Z_5UGT9]C::W[O7V8@SD'VL-F;1Z\EMF0//VWP84G?32E16MM=5*1
MGI36[UZ:;1CF5ACU&JJQ"*))K!\#&`WD,6<++M9(R-&`P&`P&`P&`P/`B``(
MB(``!Y$1^@``?M$1_J`&!Q+"P0,H]DHV,FXF1D8=1%&78,9%F[>Q:KA+[S=*
M1:MUE%V2BZ/[Y`4*43%^H>0P.7P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&!UJ5NE.@I^MU2;ME:A[3<OU7^:%:E9V+CY^U_H
M2+=S-_S;AW;I&1G?T=N[24=?BIJ_CD5(93X@8!$..JNR]<WJ4M<)2;_2;C-4
M27&OWB(JMJ@K#*4V>*3[AH2UL(A^[=UZ7*G^\+9X1%8`^OQP.A5GI_FFZWD^
ML*;T/HRV[+3<RC(^O*SMJ@SUY(\@RKGFVAZE%6!U/E<PY6JHNDQ;_)N"9ON`
M7XCX8J9CEMX[[TWS7KFP[:WMLBHZOU]6&#U_)V.X3;"&:'_"8NY$T?&D>+I+
M3$TZ;,E?QF+4JKMR<OQ23.;Z86W&T"TIWI["?:K4FT;ZIM72?,G/%CDE$%_8
M!T4PBV3Z?KS"3-'2Q=&Z:>,Y>3E%GS<J@HRT@"*1?W3("!OWPO\`*9O1OMQO
MZB.7N2KDWWC+J73I3K1PR%O8.K.AI]Q?-KO5%VCYF\2KQW0E@Z/%+MI)9'\6
M*:MP,D)?NF5.'S&9,=;MV/M_U6\Q]L.S[)EXB3U+U)7X4K+5_56J)*0I^WZ!
M*1Q7BU?<C,PCR/&T0<:_>&.K%R'WFK@AA+X*8"'(+,HT8+O#O#U'1KJC^U*B
MS?2')E2>P];HGL5TK"*S-G+#.W2[1D]Z;UL24<R4+)I((E,K)1Y%D`+X^\HH
MJ8#&$SU6#-/;IU-T#08':.E=AU'9U`LK)H^B;13)V.GHQ4CQFV?$:N5H]PO^
M!*-V[M/\AHN";EL<WP53(<!`"LGX#`8#`8#`8$9_N1VYL31'J^[6VOJB97KN
MP*GI68/7YUJU2>NHHTQ)15?DWS1%9%<@.T(>6<&24^(F14\*%\&*`@*@2-0N
M5N5(KTV[NX4Z+N4MT1T5MC5U0N3Z%OTGL>?[`UC:(]LANN?W37W#>4).FUTB
MHJ1O*KMV1X42_CIJ%$`3RXK/:SNN.Y&C`8#`Q+L_?NB=)&B"[GW5J749I\'0
MP)=G['IU!--@Q^T#T8@+7,Q(R0,Q7)]W[/S^W\R_+QY#!G&WT53>.E+XXK#2
MC[@U;<W=VAY2PTUM5-@5.Q.+;`0;L&$W.5A&(EGBD]#P[XP(NG+4%46ZH_!0
MQ3?3`[=`W&H6EW8&%8M5;L;ZI2PP%J90,Y&2[NLSI6R+PT+8&T>Z<+0TL5HY
M35%LY*FL":A3?'XF`1#LF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&!`A[.R[(-[/_3&.I!UZ6^E==T#$FV<G8SU4$/Z--2?G`X_FH8LV#@4
MO'VA(/V_GX^?[N7HS?SGA`ORCVG!<PW[WVZIN^R:S4NR>D.L=GT#0\#KZ(L[
MF-M&WUJ%-IHIU1:5;*NXZ/\`U5?X-E'ZI7`*&`1#Y>/))KAE?BYA_#^%T!ZV
M81H$TIW#$[PU7/RE4U@ZLSOK]ST\NZDH'8X[M_1"A:!UI'V8'SJ7;OCD9)QJ
M*`G#X^1%U)9B=T_P^FO1&Q^J-C]4]=WV_=ES$Y</YR:9U?NDS5747.\60'Z3
M>OT:C1BB<+,&:-G*":3V115<$_&`P?OG.866L3.:ETC(N,A(]G$PT<QB(J.;
MIM(^,C&C=A'L6J)?BDV9LFJ:39LW2*'@I"%*4H?L#(K[L!@<7-0D-9(F0@;#
M%1TY!RS55C*0\NR;R,9(LERB19J^8NTU6SINJ4?!B'*8H_UL"O#UEZ_]4>LB
M-Z$]FW%E\V?SD;7>N+1L;:_,>MG4&KHC>\C`,R/8F/E:K:"KQ5!3=2J"1WSN
M)*BJJ03B/]8;G/#-F.6L\?:/:)P?1?7=UWOCOE3JU+JKHK0>AMW<[2U.J['4
MD%&]4R:C>$G-6W6LMPFE)?7*!DE2JK',U>K)G32`&YQQDYS\+2]-V+0MB$L"
ME$N-;MY*G99:G68:[,,9;]`M4$O^-+U^6!FLJ+"6CUOHHBI\3E\@/CP(#D:=
MSP&`P&`P(G/<KU7<.6N16@:Q9Z^E]K[[W#JGG2A0>R:\M<JX[<;6M;*O3LDY
MI*+=S_.YO`0*Z[MPR.4$SMR',80^(99A+IJEQ#HGUQ:Q]G.]]!:/Y#J<#T)S
MEH_7&R+QT#7G*[JCPEIV@^.VFM?42INUG2.M954[<9%9LV,0JK58H?'Z"."2
M180R*8#`8%/CL1QR57/X@*YV7VVMZRGSJ;CJF,>*Y[=C&/=\^1:ZKI;^E*/E
M'<@V5CF-^?6QO)'8)G-]XZ`*B</@+?+T9Z\Z16\)ZMZ.E/81SXU]<][U+SKK
M^UUGV'6_DFW;2U=:KO`2//#C=$:1[^GU21=LB)04O)^5(1RU,DG^('DX&$0\
MJ3X[K,7HUAMNUZT^S^%W[=J;L?=$?W1((;'O.OJPI3*?9)_^BRC*%?0E76.=
M>&;EC5$$Q2.(F^9!-^PP86;OE/OD4P&`P&`P&`P&`P&`P&`P&`P&!K_TEU1S
MWR#KL^UNDMK534="+*1\(E/6IZ+=-[,2BY6[&,C6:":[^2?+J&\_;024,!`$
MP@!0$<);)S76N6^U^6.U*[8K3R]NNE[AAZC+IP5G/6'R@OH&36;$>-D96*?(
MLY1DF\;'^2*IT026^)O@8PD-X:)9=-I<*8#`8#`8#`8#`8#`8'7Y*IU:8FX"
MRR]:K\K8ZI^I!5I^2AHY]-UL)E)NA,?H$JY;*OH?]60:)$<_CJ)_?(D0#_("
MAX"-3J_U+<Z]8[SY\WI/R5BUO+\^[4)NMC7-71M0JT'L':!%FH_STV*NUKX3
M-DL(L6:;3\I9R90&P"4!^HB+*69;VU_GS0E3NSG9=6TAJ&M;&>.)1X[O]?UK
M3(:[.G<X"H3;IS:HZ%;3J[B8!PH#HYEQ,X^9ON";R/DK+V`P&`P&!C/<VG]>
M=`ZHV'I+;-=;6S6NTZE-TB[5QVHNBA,5VP,58^29F6;*(N$3*(+#\3D,4Q3`
M`@/TP*_NXO3Q,\P:#8;(T3=>BNZ+OQE5S7'BWCO>&RX=IIFO;'JZ;1G1+`WB
M8&!A'=HF-5Q(*OH2/=N%#O7;4C8ABG7\C<LXQ.%,#TK^YC;'KJ[^ODCTD\68
M::Z?V6X+UE&6.-F8UU0;>[D9`X[,BJ^T;KGCI6#DG8H/D/QO+ACX`ZA"H@.6
MQS]/>R_7V?JSTRYU/8E4KUZHMBB+;3K9$LIVM66`?(24--P\B@1RRD(Y\V.H
M@Y;.$3@8IBC_`*@_7,NSLV`P&`P*]W5>Q*]T/[L>4N>'-DAD=?>OS2-][4W&
MBXG';$C38UGC3U[73"9;!%?@MBUJGF--`NN^(B=M(CY)Y3^MZ,[]L=G>O0_&
MN]FZ9Z3[PLJK-Q=N\NF[_LUR=A,NYMJQU]K^1?:WU;")NEHR):*%C:_%*J$5
M;)"BLDX(;YF'ZXO99W[IU\BF`P&!3V_BP._N@N*H7C.&TTTU3*P.SI7;SNW1
M&VM/4?;T(N_J3.D%K[QG'WJ)EV$8^:)SKLH*(D(J8JHAY\!XS4G#'O[6:[?W
M2(_P\&Z=W=@\!Z\Z>ZHJU#<;14L^P:GJVWP>MZA35HW4#.2;LXR&J2$#'MS0
M=664:"4&[?[*"OVP$2#\?.9K7K<S-3LPM4JU;=3KVNUJ`@'MHE33EF=PL-'1
M;JQ39FZ+0TQ.N&+9!67E3-&R:0N'`J+"FF4OR\%``*Y_`8#`8#`8#`8#`8#`
M8#`8#`8#`KM^Z9@SH/5GJJZMVCIJX[8YCYWW]:7FY)2J14[9$=5REOKI(37F
MSIZK5>/FYZ=BZC9CINS-T6*Y%OM?;.)0,`C96?;<O1YX'LU0Z;]O/5/9'-VJ
M[K6N777(NI-&R6TY_5DQI^!VKO6`O,S:99W"0=EC:_8K0M7Z1*1\<O)N&"8I
MBT!N!A3(D)K=8ZI.?:V:6(\RV8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%?CW
M*>@3G#VAUJ:V36VS#4'7L'4%XJC;1B&B+.OVITR$J\1#[7B&#=(]C8@5,6J+
M[Y?FLD3E`ICI)@B-RS[>OK[;0Y^AKNSH#UD;G3].'M1C$=%MOQC/.3[;;6[)
M"O/I"5EG"SBK);%;/@@)2J6$R@JQ3D_R41=*%;KB@)_B54]<SCV7D\C9@,#Y
MW;MNP:.GSQ9)LT9MUG;IPNH5)!NW;IF67665.($3222()C&$0``#R.!2'ON]
MKHIR![4_8G!SD;#[8]JW5-8X2Y#DG-A9"5AI>NSB//-2E%FCFI)M7D:`&FUC
MNFB+HRT4LW<"K]TN:U?ECG%MTN`\J:(@N8>;-'<]UM/[</J#652HK<`<G>%.
MM!Q#9L_6(Z41;J.$W$@"IRF,0@B4P>0#]F9;TA3-N_W`]7;[]B\/R/M3EK5-
M#Y2V;`Z6T?3MET*6L4AL.]HU*I6ZT.]@VAL9RO6(']-L8E;+-&SM0S@Q/*)2
M)'^ZX3G-DZ,$;2]XFSN:D_9%J?IR:IU6Z9YTU9K*0TU7];:KV;L'7(;+G]`U
M>TVEL\N494W<>I6PV3).1:*SJD8;\+X_("A],UA+<<7:QOS;>I_:'/6C=DVH
M6@V>_:DUY<;"+!$&S(TW9*I%2\H9HW`Q@0;&>NSB0@"(%+X`,RLN9EFO"J@O
M\9A59J7]=.H++&P+J2CZCT3"KSDNV9BNE`M)6`DVK=1ZX*43LVKYTB"?R$0(
M8X%`?KXRQCWG']=DQOHHU5%:>]3?%%6B)1[+H2&GXBWN'C[[`'_.MRSF;=MV
MY4$R%(T:JNOMI@/R-X+Y$1$<7BM326W(I@,!@,!@,!@,!@,!@,!@,!@,!@0^
M^U;<&T=7;']74'KN]6&G0^W?8YI/6&T(R$=E;LKWKR=2E33--LB!TE22$#)F
M1(*R(@'R$H?4/&5+_=T7@>Q3[SVS^Z>JNYF3<5BJ3?$Q:O7%7BYH.NA+:)DW
MDK^BQ7S_``HTTF[`%7`I$**R@`8XB(!D(F\PI@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,"OK_$-;(X2K_)"^MNF]=J[DWUM1=&N\IZRULBT-T,^VD5ZV7KD]
MKR4:HKV"N1T!-`BX=N2!]A0I12^)SF#P2Z8TY0]:'L_W?HN@[+[U]I?8>G=_
M3U9KR4CJKFZX0=*I])@(R#CX^&96M']&=DG-HOTD#.K`^*(%5?JF`1,<IS#<
MI]<[M;'_`.)XW=_GDO:-_;E@O][F,I]/F_N?XGC=W^>2]HW]N6"_WN8R?3YO
M[OE>^FO<<DS=QS_W%>T%XP?M7#)ZT7W%`J(.F;M(Z#ELL0:Y^\DNBH8I@_J@
M.,K]?F_NB)Z&X5V?ZH=F\-6?9^Z-P=->GGF[<D5L.<A;'7(2Z["Y8OY*^YK%
M;L,R=K%E=NN=R3,E^>]2:D^Y%O3J.#^0'Y8SE+ZXQVBY#3KE4]AU6O7FBV.&
MM]-MD2RGJS9Z[(-I:$G8:11*X8R49(LU%6SMHY1.!BG(80_J?M`0R-H%>SO6
M]N#6[KN3H;G?N3:_/&C^A*=(;7ZAT_7*Y!6B=DIFCTY9I<9[2MQF?B_UC9;O
M1X)!@JH@(D!5(AOH'G*EF;G2K]J/W0^OJ3B>K^8M<:0ZZ>G]@,!JCGNNK69_
M0KM9]:%A=55CGV%D'<Z]*YF;Q).5(TDJY6.9194QC%_Z/P8+C]F)[>MXZU9P
M]9>A>NM.^Q+JQG;5NKE^/:YI+4.N]:O=WVN(1U;/[&J$-7HAS/:0I,>HJL%(
M/6V1DD5%BHKLEON)'`WDHA+RWSE8@R*@!_B6*-$[:]6VT=8EV7K:AV^6O.I)
M.K1NP[1&UM"VNRWV*@BPS-=ZY2,B!CS?WUG(IJ(MF[=4Z@>"^0LVEUA-MIR"
M:UC4>KZXR2AD6L'KVFQ2*==5:+P(%85Z.;",,X8%*R<QAS)B9%1(/MJ)B!B_
M0<BLD8#`8#`8#`8#`8#`8#`8#`8#`8#`@U]R?_"WZ=?]*MS[_K,UEFF?;IY?
M)Z_O\L+[QO\`;WA?^X!*9%G]TZN%,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"
M,#V@^T#4WK:U)'2\K&O=H]!;.>?S5YXYVJ0&D;YM6[O5$V<>BVB6?W9%O7&;
MQPG^6[!,0`!^VF!E#``$MQY:7>K_`-7^UT]LR'LY]F\BTV?W]L]J#NF4QR)9
M"B\CTEX148NC:_CEA6:LK2WC5RI.W*?D6IOD4IA6$YRC'?:PAA3`8#`X>PUZ
M"MD%+UBT0\;8*Y8(YY$3D',,T)&*EHN00.V>Q\@Q=$5;NVCINH8ATSE$IBCX
M$,"J!N"H]%?P\>['?0VD$+[O3T\;#EFJ&Z.>4'4E:+)Q8Y>O!`MSU`R<+',T
MUND\?'.JS*8&R28BFH!#?;7RLW,\+)$1;-&]P<P/)W7]VCMBZ*Z%U?.1;2VT
MF60.63JMQ@WD/*$9/2D<#%S;)%TJ@LBNE]]D\3,DLF51,Q`C4Y?F$?PX/%"7
M2/N(@C.X-U*:NY0E;ON"Q/'S&2>Q9)"KSJU=US#2DK'"V2CIB1FWOYS,RIB$
M<&BE@^)@`Q<U=./I/\[>D?JYS,U#UV,?3<_*QT)#QC99Y(RLL];1T<Q:-R&5
M7<NWKM1)NW013*)C'.8"@`>1',NR!3=ON'O6^MJ7?D?U`:GCNMM\5V,;DM/1
M$O)LV?'VF7+YV@Q>2,_L%*00;;"DZL1V1=:)B%CJNE/*"1S*$4*2X[IGL^?4
MGHEH6VYB2WM[7]F6/O\`Z,O5,_FW/5VX.CPW/6IX^1*Q?/*QIN@0A8Q:-)!R
M:2Y&<RHLF_4;JB"A?N"=0[*8[L8*<E^R'U%/+->.%KS;N\N)X:'.Y-PYNJTR
M4]O37C)#R[>FY]OB$,9U9ETUC?:9P;PPE!F0B*1?F4#B6YZ)*.&O:YR3W6R&
MO4JXJZUWY!)"VV)S'N%HMKO>-$GF:Z$=-1[FDV8L=*3L=&S*X-?U"/(Y9G6$
M"?,JGD@1<I+<!@,!@,!@,!@,!@,!@,!@,!@,"#7W)_\`"WZ=?]*MS[_K,UEF
MF?;IY?)Z_O\`+"^\;_;WA?\`N`2F19_=.KA3`8#`8#`Q'M/?&I-)OM91NT[K
M'T][N38D7J?6C=\TE71K7L.:CY.4BZRS-&,'Q&KIVPAW*@*N10;%!+P90#"4
M!#S2-[:EV/L/;&J*3=(^?V%HU_6HO:]9;-91%W37]PB3SM;;/G#Q@V8.SRD2
MF98HM5G!2`'@XE-],#+>`$0`/(_0`^HB/[`#`^(LG&G;_F$D&1V@J?9!T5V@
M9N*P'^V*7WP4%+[GW/W?CY\_+Z?MP/>NX0:HJ.'2Z+9ND'R5774(BBF7R`?)
M150Q2$#R/[1'`\HKHN4DUVZR3A!4H'2614(JDH0?V&34()B'*/\`7`1#`]N`
MP&`P&`P&`P(Z_8-["Z7Q%4*O`P58DMV]3[JEOYD\U<STPWYEVVA>'92D;N7Z
M#<3JUR@0!E2N9F8<`FV9M"F,)P\&,2X2W'EI]P-ZG;A3NA)WV+^PG8;'HWO&
M]QC$*ZW(R'^B[E:'<L1!YK[33!===)<T?^09K^K"D@H9(GE-,ISJ*J"3K=IU
M<BF`P&`P&!P]@K\%;(*7K%GB(ZP5V?CG<1-PDNS0D(N6BWZ!VSU@_9.2*-W3
M1T@H8AR'*)3%'`JL37.W37H/Z"M>YN1:3<=^>HW;C^5MG0O-%>7_`%JZ<@RQ
MD3.IW:NGH=T[(^EZH1)/YKQS8%3&0`4%$_!&SAM=L?C<S2*S^'^Z6T!P-H[:
MFX8:JV?JKL7O/:UWD]/<T\\P#.X;BAM4T&TN8*"-N&19/7C+3]=F[5).715Y
MG\=%!-8BI@$IR'%YT>N)S-VIQX+UO=U>S:R06TO;UM,FK-(0-F+,TWUS<[21
M&.OI6*;'`$2]!;(2=/K%?#ST<K]F1B4')6J2R0G;JI$.*>3JN,[6`M4:=U5H
MFEQFN=-:\J&L*+#E`(VJ4F"CZ]"-1!%%N*I6,<@@D=P=%NF4RA@,H<"!Y$?`
M8:9)P&!''W!ZM.4.\#5JT[(K<Q0-Y:]DB3^J^DM/RIJ)NW7%D;IE(PF(BU,$
MC)3)6!R%429RR#]D54A3@D!R@8"691IQ747LW]2]>L37OFDS_?G(-1=OG<9V
M5IAM#EW?K>@LG45%1`;LU&W9QRUI!M''%PZEV*RSD5@5.X,<G\J6\5.9X3B\
MR]4\_P#8FJ*[NGG':%5VC0;''L'R4A795F\?PJT@T3>IPMKATECR56L3=!4/
MO,'R:+E/]HE\"`C&LY;!X#`8#`8#`8&O73G5?/\`QSJ>Q;LZ/V;6M8:\K34'
M+R5GGR2;M\<SQDP28P400QI.>DEGLB@F"#5)50!5`3`!?)@""B;ZF]L'M5.Z
M;>N^L(<#\BR%51GZSV%T/2W;O:NV7RQ4G$8QU[JMT=%W7*L_53^7ZJL'WQ0$
M?)/B<`&IS;\,E:V]P6U^3+JQY^]R>ET.99\B<3%4KL.D'EK1RIN99?\`2HYN
M\=3[>/7-K6Q.UESKOT9!1)F@N?[*7CP4!8XS#//*?BMV.`N%?A;759F-L5:L
M<8RFH&=AWB$A%2\3(MTW3&1CWK8ZB#IH[;JE.0Y1$#%'(KFL!@,#IFP-BT+5
M-2F;YLRXUJA4NOM%WTU:+;,L(*$CFK=%5PJ=Q(2*Z#<IOM(F$I`$3G$/!0$?
MI@52>R^F-U>ZV\Z5I7J4H<N[B./.F:QNHO=&S6J,!H%&TU1A*MX5*C0LXT2E
M]FI.%U%E4EFI?QQ_'`#>/F7+.&;SQ'WZ(F^QO2MTCU;OKV,UZU]8Z=Z:8\\K
MWCNO1-50)!ZX1U/5G^OR/MOZJ;&<V>.0092"!GTNC\T1!$RYP\'$0;,V;TM`
MZ4WQIGHZ@0NT]$;-INV->V%J@\B+72)QG-Q;A%RD5=$%3M5#+,G!D3E,**Y$
MEBE$!$H><C3+.`P&!QTM+Q,!&/IJ=E(Z%AHQLH\DI:6>MHV,CVB(?)9T^?O%
M46K1LD7ZF.H<I2A^T<""FZ^YN>W]>;GHSU-\[3';.S*38D*C=]QSCYU0.4-7
M3OZD[9OD[1LAP@5Q:EF2#!4_XT/\E!`R9_E\#`)KY2WMMIYVWS7W>OS1ZV-6
M=)=.35DZFMGLPKMKF^@M(T4KC^A>.M5>V/,1<?68:2:NX@(K7K9P$6@X>%(S
M.0"C]/D7RB67'SEM5ZA=,[1T?V=[7Z?M;;6RM_3Y=E<\.2;KV=5XVLS5V14U
M4['[2"<`P85IVV@Q'\<#,P$"_P#YP`P^,=/U)OE8`R-.A[3,8FL=C'(8Q#DH
M=O,4Y#"0Y#%K\@)3%.40,4Q1#R`@/D!P/SE].]']+)^CN)UHZT!?`T@'L;A)
M![V0ON:$0B(TR?4L0]>5QY3EEBW;\5LNC^$HX_(!KX,)C!\//FL^MOZ+&G8O
M0W)/?'L,X!YKD.F:_L'CO9=3Z\C;O1J3M!S7Z%M3H#43K732OT:SR\&[CU)R
M0K(3#I5*/!P5-980^/S$2@+^2\W'3#=GD&X\#>NO5^RJ!"=YU^S:++U..M*%
M#;)V1$6"!T)L+84'&6:,YMJ]U^^Z</FRA'AY5HB_=*JMR/#%$Y2%\`)B<93)
MHK(N44G#=5-=NNFFL@NBH55%9%4H'2525()B*)J$,`E,`B`@/D,C3V8#`8#`
M8&)MX;VT_P`UZRLVY-[[$J^K=8T]I^98;C;Y-&+B&"9A^**(**C]QT\<G_=2
M01*HLJ;Z%*.!7MVK[*NTO8;`;+KWK0JC/E_E*N1*ZEY]HG2S&0JU:C8&/-'O
M;3,Z,H4NWCG<XM%PBJI@D7IDT`3'[Z!@,4HY=)FUC[U8\MZ<TU[9;_:Z9MRT
M]6/M@>N30VZ&/2VR;&XNTU=YG9ETLT58;I1WKXZJ-5K-QAZTR^VS8@FB1N0J
M8>2^0%<R,^OY7PM69&S`8#`8#`8#`^5^FFLQ>)+)IK(JM7":J*R9%454SHG*
M=-5)0IDU$SE$0,4P"!@'P(>,$VJH_P`)KK+74;QYT%M./H]79;*G>M-UU*9O
M;:'9I6F3J\-+Q[J)KSN8*G^4>(CG+@YTD`,"8&-Y$!\%\6]F?7KYJUQD:,!@
M,!@>ERV;O&Z[1XW0=-7*2B#ELY237;N$%2B15%=%4IDU4E"&$#%,`@(#X'`@
MCX2UM0-1>XGVJ4G5M/K^OZ<KK?DBUJ5:I1R$)7S6:S4M^^L$\$0R*DP3E)AT
M/S<*E3*900#SFO\`5F?E4\69:,!@,!@?#)R<;"Q[R6F'[.+BXYLL\?R,@Y19
ML631NF95PY=.G!TT&Z"*1!,8YC`4H!Y$<"`+>WN6N>]KG?N7_3MIYQV+T)4U
M&+&V[O<?B,N3--'>NV!0>6G8;J2CV5Q?N6*ZQF;6*46144;J%563^/@29O1W
MOGOTKU64VHPZN]E.T77?O51H^+4CD;W#E9<[Z?D4V$<C(,]2:;7</*^F4!8$
M;FD'J(JOD$P.L@50P^+E).MVF<NU"@;UK^S:UD@?1=;M%7DJBY_FT^<5Z1C8
MJ2CE8P1@I"+.V<0[IDW4`6RB`E%$Q"B7]GC(TK/[0X\[Z]?M1'4-4@YSV]^K
MFUEG8W;?+^X20DQU%K>FR[A%86NO[G/S2*NV4HV3=*R*!''X[MN9$J:0MP(1
MP2[9N9\M=N765FI3:P=!>@OJB&V_K^NU]I.;@]/W2EFG_P!>IK]HG!.;37M7
MRDV]>6K6%M(1N2,;-%F_Z"V6*L+=1RHJ1(6)U2?_`"F]XG]N6@NJ[6QT!L6)
ML?+G:T=!DD+QRCN>/?UNZQSILR;.)9U3).48QT9?ZPDHN/X[]B(@LF'D2%'R
M`334N4L&%0N]?>Z33&F=@->;.4J/8.[>R)B:<5QOHO1SUN^C*$]0>)0[B=W/
M?TTGD'K^JQ$Z[0;/U1_(=MA4$PH?$AQ*3/9KI0O4KT9W3*,-N^ZS;2&S$&5J
M0N^L^(-,V![$<Z:J$?QGC"-V`X:MV[C:UJ@%2F;BX%=1B)?D)#G!0P#?!CNL
M&U2I56B5V)J%(K4!3JG`-"L(*L5:'CZ_7X9B0QCE9Q4-$MVD='M2G.8P)I)D
M+Y,(^/(CD5R4G&1LW&R$-,QS&7AY=B[C)6*DVC=_&R<:_04:OH^08NTU6KUB
M]:JF3524(9-1,PE,`@(A@0"[Q]-EXT-<+_TOZ==PDY`W[=;"2WWW2D\=>2Y.
MW,[3?O9:08S6O$&:[>F34J9?\5N\C00012$$S`FD4!+>.J6=F4.4/<">R;D+
MQSWUH:U<5]BMFRH0L),JJVO3.\"1B(&F)W1^SHQI^G6!@U*'W%D%@3.B!A*0
MZWP,8&"7NWEJOL0XTN^@3]157>]1FM#IWZ-U>IL1F,@>(3O<Q9HFG1M=.060
M/"/'=BG6C<OE+X>5BF\_'R.0S&L?7'MNUQHG;$SRQH#3VUNRNS(YI!+.=!Z9
M@US(4Q*VPAIRM3NUK](HIUBAUITP417.JJHJY,W5^2**A@$`N#/;;4"E>L3L
M'V#.Y+9'N1W`[::ZFGGZK1?7[SQ=Y2!U/2XI^3PM7]UW*%;1K_;$BU*BF442
M+J1Z@&$QA^7\F5DQW3O:=TGJ+GRA1&K](:XI^K-?01"EC*G28-E!1")RMV[4
MSI5!FDF9[(+-VB1%7*YE'"H)E^9S>`R*RA@,!@?*^9-)-D\C7Z";IC(-7#)Z
MV5`12<-':)T'""@`("*:R*@E'_4'`TV?>OKDQ+FJ<Y1JNDM?5O34E.2MVC:,
MK".)RIQFQGTJI96MU<P4C)"$P[96P22!FZRWV%SI_`P?`1#*-`.?_1+SE5]4
MW_6_5AJ9T^O;=PS^[:K+Q.K8S1:>HKU;*Q%5RVSNK4:'.*R=2D;,K#-GRY6[
MTK-%XW1.@@F*8#D21NNX]6WK[6YHF^/T>5-3L.=I^:?6A_KEA!"@R_G=((*M
MU;@A*&74G$;4BBJ)$7P.1<))^$RF!/\`<PJ*.R\L>S#U)JV38/`-RE>\N/4G
MK.0?<)[KGIAQNG6L,5<Q'Z6@MN/E)=>=CX^.)\_P9415\$(BW1,`";+MG%FM
M)5>)?93S3W-'S$3KV=D:1NBDF(RVESIM!@M2]U:VETVD2L_;3M*F2M)5Q%MG
M4NF@G)-TU&3D_P!4SB`AC"RY2!9%,#U+KH-4%G+E9)NV;I*+N'"ZA$D$$$B"
MHJLLJH)4TDDDRB8QC"`%`/(X$$'0ONKC++LO^]:]7FHGG?W34BV=MY.>ILTV
MBN;]*.SHN31\EM_;JI%8=N1PFQ=*MVS,RH+J-!1460%0AAN$SSB;0];JL6L(
M/=U:D.[+M8O<1[.RWXSG7OKWY?DY%YR1SS+QKMR:)/=J@_;+U]&'ICN023E9
M2QD?.T1.?XMCD`383SS4FVNO59U7W&<]V]OVUB,=9%D$7FL_7AS1;WU8T+KN
MKIL58YC3]L3U=:Q*FU%HEB":/XZ2IHE4@>1+_P#IDC3/6GJ[`T_WD[NJ55AH
MRN5>L^M7G6"KM>A63>-AH.&C=M;,:Q\7%1S1-)JQ8,VZ92)I)E*0A0\`&7HQ
M/SOA-SD;?R<Y$R&44.5-,A1.<YS`4A"%#R8QC&$"E*4`\B(_0,"-;L;V;ZPY
M2V/1-"5C5>XNH.F-EUPUTI^A-`UI*?M"]'1G&]><W.>GY1S&T^J5Q&46%(KB
M0>H$543,0ODW@!LB6XT^7D[VU\?=EVO5M#TY8;>M=MJU#:=NBZW8Z38*^]A$
MM,69C4-A1%C/(LT4(V5B)V03(D03"5VD/W43'3$#8P9C:/ESJS4/8-!LFR=*
MR<I+5>J[0V'J"8<2\,_@G*-UU?.J5RV,TVDBBBNLT:R:0E37*`IK%_>*(AD5
MLE@,!@?.[_[%<_\`:ZW^MFPLVK$?PH7^3_W;_P`M7?W_`(PB<M8]=7S5G_(T
M8#`8#`8$*?*_^6Q]J'_$OQ9_8"^S7^K,_*_UT369EHP&`P&!4R8Z\VA[>X;J
M;=7L9Z@;:9]:7/70&PZ#`<]ZG>!0(^U1^EIYLG-6_H38:Z:TRZB$7"@(I,VZ
MQ6ZJ8BL;[9O!<NF9_EX69N?M7:)U#J2D5'FVD4&A:=)7XJ1I41K:$BX.KNH6
M2CVSN.F6J<4W;I2"LNR537.[4^:[H3_<4.8QA,,:9GP&`P(C.V?4'I7IZ^.N
ME]-7*[<@=PQD"VC:CU!HR7?UB8=N(A5-W",-IUB+=L(C9]3,NV21?LGH%4?,
M4RMU%12(F4M2SMM$9M75^P]U[8U)PG[J./X_9EZLB$?4>8_;=RG&34/+L[@V
M*X<5$EKDH>(;6G55Q6G6JLDLU_*&ND=`3R@J407%X3R^*"T+[)[IVT7TZV_V
M=;%<<X:?YYK?2EGW!7:NI7>L=H:JG]A%H']#]DW8C/.I9O8$3NSKGL:!".%D
M@*F9(0#&8F+K/"QKQIPGS#P-K'^BGF36L?1H)X\"7LLRLX=3=QNUA.U;MG=C
MN-KE574S.RST&X',*BOVB&,()D(4?CD;Q(V^P&`P&!B?<U-K-JHEB=SE5@K)
M*UNOV.:JCB5A&,P_@[`W@I`K*4@%739=S'2R1S^$UFXD6`1\`/UP/S>=>\U=
M8\<<:<N+5'7VT+MSS[.+OI&5VS2%H"XK3G/O2FC>NFL\A;96NFBG#>#KMXUO
M7_L$'[315<R8'54$B!`4LQ7/VF-:K])^K:UU[6;#9;_7J'3X&^;#;UXU_N<1
M6H>,M=U4KL0A#P`VVP-&:,M830<2B1JT_+55_&;E!-/XE``R.CO^`P&`P,1;
M]W=0^;-+;.WUL]X\84#4U,G;S:G,>R5D9`(F`8JOG"+!BC^^Z?.OM@DB3R4H
MJ'#Y&*7R8!KE$5SI[F;=>=XZ"U+UCPUM3B6N=>Q4F]Y.VAL'8M0NL!M25C(P
MED+4[%'0,;&/=:6F3JCIL\:-9`ZIEE%10\E4`OW"93I84P&`P(N.Y_4GS#V]
M9:GM]XC/:)ZDUS*-9[7G4>CE6%,V]#R\4@L6"3GYQLS$UT@XEV<JR3*2^\FF
M8H@02`8X&)9E'Q'^PCO_`-6T^6C>U[6#[HCFJ2M",%0/8/S=`-G:5;A55`8Q
M0](ZF;-XY]6'@QT>XEI:78B9@Q2`2)@Z.(`49QMOGT-[G^"=%ZR@+Q6MPP_1
M-OV)6EY_2^F>>5?Z4-H;=7\D081]>@*T206B2.GBI2*N9$&R38@&.;R)?B)<
MH6.E=C=(=(52J;G]OW10>LGAS8T?)Q=+]?FDK19C]8]`A(%<,@@-D66NQZ5G
M=.#NE&B:\%#M5FKY@]^#@&QS@`V:9N;OB.X\IZ,[A[.U-2]3<H:O<^E'UA5N
MS.A;Q,0680[?Z`J8O(R16D$9E4C=QJUE<&KU=P68.[6FD'`"B87*12JB++>)
MQ$__`!3Z_>6O7_0']!YLUXG6@L,B,[>+I.2+VT;$V'95DB)O+%=;G,JN9B9D
MGARB<P"<B!#&'[:9`'QD:TW2P(8*#_EZNBO]'5H+^[#L_+T8GYWPE3W%N35W
M/VM;=N'=%XK^N-9T2*6FK7<;,]*QB(B/0\`*BJ@@959=90P$212*=990Q2)E
M,80`8V_.$]XW\3;>.PV6R.2^)G#RA\ORZK:%L>X4!E(78VX(4K<PS$6R**S=
M>JTB5<'*F=$"$>.T"&(L()J&3S4CC_T]^D9-_A_^Y=LM+Y1NB0YKVIT?3N/N
M/I'BC:D7SNG'7+<E;A;WN=7;6I]A.-<SKJMI3\++.8M_!B5E**N$09*.%BID
M(4JJQKU]L^ORF[L?+'7'L&]@W).R^I-.;SX9JC#GOJ0&KSF#;LY0[E0H5?:,
M,XU;3]F;2H3M-!E=[C`.57DK&LE1:.5$2F\$$GQ+)5LSC+%7K'Z5WQZV+/R-
MZ\KIIMLXA^H>TNR&M@LFV]C!";LAH%]L`QM8WL\1+$.>S(7%@D9Z#M<ZSJ=5
M^2:0)*F^8QK7$TN*84P&!\[O_L5S_P!KK?ZV;"S:L1_"A?Y/_=O_`"U=_?\`
MC")RUCUU?-6?\C1@,!@,!@0I\K_Y;'VH?\2_%G]@+[-?ZLS\K_71-9F6C`8#
M`8%/^O@!OX?WW,%,`&`=V=\@("`"`A_.N-^@@/T$,M8]-7RLW<:``<@<I@`>
M`#FS1@``?0``-85?P`!D;;)8#`8#`]2J**WV_O))*_:4*LE]U,BGVUB>0(JG
M\@'X*$`P^#!X$/.!!70?_F.M]_Z*37'_`#C&F$ZIV<*8#`8#`\"`"`@(`("'
M@0'Z@(#^T!#^J`X$-UE[BZ0C>YB\PQ^O.&GNG&^RH&LMY*1ZXJK3H)*$>P\9
M)O7Y=`?@JRZ%I:+/ECH,0$#*MBD5^0`?*F><)DLBF`P&`P(]O:WHYOT5ZZ^N
MM5JFB$G,KI:X340ZG$G:T:QG:A'*6N&>K$9*)./FVD(=,R8@(@4_@3`(`(82
MS,5B-5]&=)^W_H'T_P#-FY.:[IR'IS7M<'MAK=)2<3D&G141HR-@65,<ZX.V
M5<+M8E=Q+1;I11Y\3BB[=$\"`I^+B>O#.<X7@,C9@,!@,#X).*BYM@YBYF-8
M2\8]2.@\CI-FW?L':"A1(HBY:.TU6ZZ2A#"!BF*("`^!P*N'K'Y'U]'=.>\Z
MP\Y:YTKJSH>B=;6'5?/.TI;7L?+L]11<[JRLSJ4-$QR"156%0"S.E'R[!G]E
M-190P^!\^,N<[2?"0?D3TPZ+TKL.&Z>Z9MUU[=[6!)G)/]^]!RZUS2IEB%LW
M!V73=0DBG@==QD>J0[9DJT0(\_!*FFH<?C]&23K=IEBE*0I2$*4I"E`I2E`"
ME*4H>"E*4/``4`#Z!D5YP&!6`ZR[ZT?Z_P#W(]&;"VNXF9NVV7US:1BM-:?I
MT4^G=B;KOJ6WMF$C:-1H=@W<'=2+IRN0RZI_";5H55<WDJ1@R]&->UOP@PWS
MQO[T?XB[<#6^;8HSGA_DJ%@VRVLJ1M)_88:G(Q\B110DL6E,5?U^_6N7<L@,
M\=NTD2LB?;3(4I`(&.(7[>WQ$I?*G\'3POK(L?,=-[&V5T5/HD4%Y!,Y(*'2
M#K*(M3)>&\*FC-.B-')%?`*+E*JF8H'+^T!6Y/7T]9RM/Z4YXT3S?4F-$T'J
M'7>H*C&L6\:T@M?5.'K#,K%HN[<M6RWZ8U06=IMEWZYR?>,H)3*G$!_>'(WB
M1F3`P39N8.>+INND]'VW3.O+)OC6T2\@J#M>:K,=(W:H1+\53.F4!-.4E'$<
MFJ9<X^4Q`Q1,(E$!'!\L[8#`8'ROE$TF+Q551-))-JX4555.5-)),B)S'444
M.)2)ID*`B)A$```\C@FU7_\`A/'[!QP-O!HW?L7#M+L_?#E9J@\;+.D6SF0B
M_P`9PLW25,LDW<_;-]LYB@53XC\1'P.6L^NOUJT5D:,!@,!@,"#'CZWU.Q^[
M/VKD@+/`31VNJ^1(-RG%R[%ZJC,UZD/&L_&'207.I^;".C@D[3`!%NH(%/\`
M$P^,U_JS/RO]=$YV9:,!@,!@5`*]_P#+_>Y?_CM[Y_LKC<M8]-7RLV\:?X('
M*?\`R;=&?W,*OD;;)8#`8#`8$$U!_P#F.M]_Z*37'_.,:83JG9PI@,!@,!@0
M:QU#J4/[=W#FS[=]9Y[98QE+E6M+MM"5QGWFYB_Z.E&C&>4VDO/*S#UPS<1*
M[E9V1B`FB411`0`!,%Z,R3[)RLC1@,!@,#7GKG_!6Z2_XB=L?V"SN$NE;GUU
M_P"$9Z`_]#EN#_I=.9KVVQZ]/"V9F70P&`P&`P('O48JFEV#[R3JJ$3+_C%4
M"_)0Y2%^1M/U`"AY,(!Y,/[/Z^$B=X%$Q4%(%""J4H',F!B_<`@CX`PD\_("
MB/\`5\>,*])WC1)4$%'39-8WQ`J)UTB*B)Q\$`$S&`X_,?V?3ZX'P35A@:VV
M2>V&:BH-FNY(S0=2\@UCFZ[Q1)99-HBJ[52(JZ42;G,5,HB<P$'P`^!P-!M=
M]LN>N414XOK3JZ:QE4MMTI;J&;391^O]<[CUE*HPZM6F]>SKN&V%9V;Y<YS-
MGS!FI'+F*4/O?`1.%PF],$]Y>GW4_8,_3NBJ9=;+HOO;39D;+IGJ6G.5".F5
MWBXZ-;1;2YUB1_6F4GKUPK%B52+:_9*V!VNJG]Q0ZA564OKGR[-Z^/859-VV
M:X<A=?5%CHSV":+:HI[+UO\`,4*GMBN@'QC]T:*D72GBV4&PMP(NL1N912-5
M4^"G[@D.*]UEZ7:6'(I@,!@,!@?PJJD@DHLLHFBBBF=5554Y4TDDDRB=1110
MX@4B9"@(B(B```8%>?<N]ME>X'<VQ.(>0+C<=;\/:V6D:IV7V]0%R,7]]LI$
MC)NN:N;[*H/XSY\J)OM6F?:"J6,;F,@F/WCAY?*;\.#F_4)H!6:B]U>F_HEA
MR#O?G"8=ZIMT5KB;D+QHO9EUUDT;0"VO.D=?EGSM7D]#ID.A)KE*61446$ZO
M\M_*Y=)OF._ZX]R%HYLV2CS7[?=2'Y-V:YGT82C=,UB,L$OQ7N1B^!`(F5B-
MJO4!;T"55\J&?LIHR",>;XIG7^8AY+G&T\4#/0EIA8NQUN7CIZ`G(]G*P\S$
M/&\A&2D9(-DGC%^P>M5%6[IH[:K$434(82G(8!`?`Y%<M@,#4+L#NOF#AC7$
MKL?HG:=<J"39DZ5KU,+),76Q-@2J+-T]:UF@4HCDLY:K#))LU`0;MDCB;X&,
M(@4IA!A+<(<9"U>UCV_UFL.-3-)SU;\/6YX6<7V3.OT5NR=V:Y=K*QX1D%5&
MJ+YIJ&&LU?=+.4GBZJ;\QA;*HF%(/*M_E,V^'>KM_#?</L]5*QG-EGWSS/TL
MTB9/\7KVB;EO!MT72SOVK@%Y;<4BK*DCKZQF)%8'$B@FV8&7.'R*<@^0%D^L
MZ;5?.K]H_P`2EZ-;=326#H.]])\VUEG**U2^2M0/M[3C]L^6DVP06T9=U!LK
MY#V)J+C\UN@^F$_D(%%%11)(Y`3%9M]_7YCD-#?QH77-9+6(OHGFG4.S4&TD
M^-<+31)"<H,W(1:WY)F;>&K#DTS$,GK`QDB&,J[,54I#"(%$?&7ZLS_KW6_?
M4Y[=J5[.^<M@=&/M36?G"I4"_*TA27V7*1:%0LH`V(X_4ZU;%%&D:_2CUC@U
M>E\@+=Y_)^1',NGK[?9+17+56+C&DF:E8H.SQ*ASIIR=?EF$S'G43'XJ)E>1
MZ[AN)R&^@A\O(8:<_@53>2]4SW6'J(]KO*^G9>HRVY]@=,]K4R*K,C9&+$\5
M-6RRQ[FO_P`YBIBZ>P3.4:E%5%59``42_>(!B_7+6?37ZK)O.=*G-:\]Z(US
M9R-D[+0--:PI5A39K_E,TYRJTB#@I8C5S\"?D-B/V"@$/\0^9?`^`\Y&F9<!
M@,#YW;MJP;+O7SENR9M4CKN7;M9-NV;HIA\E%EUUC$212(4/(F,(``8$8NM_
M;%SEOKM%SQ=S:SM._P">J$3*3.XMPZY082FC]5-VC=']/92.P4W:D38)B3DE
M#-`;,3*&(JF;P)_B;XU,\\-4]7SD),_Q'_2"$/,14LO!>K/7,3-HQD@T?JPT
MJ'0S%P,9*IM5E3QTB#=0J@H+`14"&`WQ\"`Y!/=A3`8#`8#`C,:4J99^U9[8
M9NUR4]79KEEQ.5&EARA44JW3)R'N,37)&?5[!2C1MBUME8^5600J*KD$C,%5
MG)2^"83JDSPI@,!@,#7GKG_!6Z2_XB=L?V"SN$NE;GUU_P"$9Z`_]#EN#_I=
M.9KVVQZ]/"V9F70P&`P&`P*)W5]TOU!U/[T+)K*6EXFZM_=7RJW@_P!&GWU8
M7EW;HVKDD:Z[FXXY7+**GUA*U='\'*"*IA,0X!\1)SSC:3OD_JC=\3[G>MI;
MOTNM>1F,7P?H9&)HCSHEE:=/LW4QN"48P\^UMMG8T6O-K?9UU%&IFQ&I7!BI
M$*!U/EX`3/73477.D.3NNM`]N=W=V=\;^U#L'7_:>ZJPMN_7/1LI23:"U_IO
M9JM;U33:;K&MI2U*^Q(5Z-:*I$=5R2DY`ZPKHG,)_EEUIF2>W-[IB[;ZY=A=
M0;KV=.[SZ<NVR>*[F7E;>'-=%A)N4K-^T]O+2(I.`N<-8B-@53A;S#&*L^;I
M_8277=*',W(M_*XUY:ZY3"5JI5>FL5XRI5V%K4>[D7TP[9P<8SBVSN7DU?OR
M4J[29(HD<R<BO_*.%S@958_[QS"/UR*[#@1Q>POU[5SM*LU.Z4FWR.B>O-'.
MU;-S5TS44BI6[7MC(8'"E?F1()/YR:XM)R?CRT4X^XBHBJ<Y"@<3`>RX2S/E
MCKUZ>PJQ[OLEMY!Z\JK#1_L'T6Q1+LO6P*&2JNV:R0#)Q^Z]'23GX)VBD6)N
MD"[E!`3JQBQS$.`$*/P6$O2[2Q9%,!@,#CIB8B:]$R<]/2<?"P<*P=RDQ,2K
MQO'QD7&,$#NGTA(OW:B35FR9MDC**JJ&*1,A1,80`,"L[9>NMO\`O3O-UY7X
M7D;SIC@&DVZ0J757<S`RD'8-PQ,>K]IUJ'F%59`JY`M'V5492=-^\S8F\E*4
M54_N#^%A'0NA-/\`+NHJ7HW15%@];ZKUY#)0]9JT`V!!HT;(@)W#MTJ/S<R4
MM(N!,N[=KG4<NG!S**',<PC@:A^M_<NG=U53H:TZ;Z?H_34([Z>VS).'E0U/
M':?=:Q&8EDWS36%DA6\)7Y6VS%9;'!,]ED$#.IKS]XRJ@AYP-T=PZ8U1T#KN
MR:EW9KZJ[/UM;F1F%BIMSAV<Y!2C<WU+]YF\34(1=$X`=)4GQ52.`&(8!`!P
M($;1Z^>Y_6;;K1N7U.7]7<_/RD:@\F_6COZWV:6JC04'#-2>4YTV-,6%5_2[
M(_BX\J48R?J'CT%C'*I]U$4D4KG+/,TW%Y&]S7*/1"\[K?;DE(<>]/ZWK)9_
M<G/?2B"NLYJF(LT(\LU-PMIM"<56+=2&\@_!)M*-W!`=$`%2I`D8IS,++*U5
MGO:OTI[`W-TU-Z=M*24[!1U@=42S]^[H:MZSHG7CU(!!_.:TJ<RR=R>Y99D5
M)7\4@(DCS*E+]X?B8`$<]--DN3/31I/2^TB]2=.W^Z]X=J.V*K%UT1T&#221
MK#15XH^)$:JUD@*E+UY#,%E3?B?91</6A5%$TG)$3_:"&$QH`!0`I0``````
M`/```?0```^@``85YP.-F(:(L,5(P4_%Q\W"2[)S'2L1+,F\C&2<>\2.W=L7
M[%VFLU=M'*"AB*)J%,0Y1$!`0'`J2^S_`/A/.3^FW]KW3R-:T^3MNS#MS-SU
M772_5-$661?R+I]+22L(JH22H3Q4'8`3],6"+330*4K(ICF4RRUCV_Y^M\NJ
M[^T'QCSYIKTC<<%VE0=G<`LNC[]0^I[-4KF>4T-LS;3"@H/*P3<T[5)^7@FJ
MLOM5991!A*/BH`Z_DS%`"B4"\3&/Q;5^LYIH/4?N6[?YXX3GUG7(+7E^A[&O
MM+HTM'V[G_7G2JVP(V$"%US-Q*\K&U24=U%P^/(PB3E$HN"*'^R(H"*;HNKB
M:6:\BH4^N/3!K+9U[#I7B_8LYP9V9'2Y;(3<VHV?FL['DFS<Y6\)NG7QG*,)
M=*X]7!/\L0(D\.F42@H("(#4QU8#UU[=-_<63[32_NGU`CIAR[NC.C:U[6U9
M$/I7FC<";PKU.,EK/^)^4KJJR29H\RRK)4!:I)JE`H@8I@$9Z581@9^!M,0Q
ML%8FXBQP,HC^1&3<#),Y>(D6X'.F*[&2CUG#)VC]Q,Q?DF<Q?D40\^0R*Y?`
MC)[P]LO)7`S=C7+W9GNS-\61=-G1.:M0MQNNYK<[,HB58R=9B"O'$+',4ER*
MN'#P$P31,!P*8H^0);B90J=31W0_2M2NFZ/=ET<R];_KU6%I)TCAS6%_B&FX
M-J-F)#K)5W;>PH$$[3+32\A$M7:4;#?4'[@&X"5$?`WA.;O3M?.D%UGW#KVI
M:J]:.K3>H'UKL8R0:/=XOJ'"$Z;WXR_4EX@ZVN*?),V[K7Y'3),ST)B7^\[<
MK*G,)C`)0%Y7>M)S.)_7-RSP16%([1="21O,[%(L]C[DLKES8=K[3DC*-WLK
M-7>WR:SF1D%Y:8;_`)9T"G*V25$`3(4I2@$7$FF]6`P&`P&`P,"(5B'<]+R%
MO4CMHDGHG3T=`-95Q,R)=.+1<U:GKYVSC(`'812NP$',.D9TZ%`5R,3I$`_Q
M,8,O0ZL]Y`P&`P&!KUUN43<K=)`4!$?Z"-LCX#^L%$G1$?\`4``#R/\`6#"7
M2JIZG^A='[EZU]*E)U5M"HWVW:4]3.Y*7MFO5V1%Y)T"UI&U$BK`V1`4D_PI
M%-=LJ04_)A^29OZG@1U[,>O3PN89ET,!@,!@,"MCP%H/2?3O2/O'U+O&I0>P
M:JT]FU)OX5.6<&\H3E-UY2IVH6`[5LX1=D+'SL:55!00!,ZB(@'GXF`"1ME[
M7?4;5/85JO:,3KE_KG4N]-S1^I*/?]U7"E.+U(.-5ZJOB-^BZY$1P/VB<;,-
M)A(5&;PGQ,D8Q@-Y*(A@LS,,A&]+'KLL%FJ&QMH\[4;:&UX&O42,LMWG(U2-
M9[#GZ)5H^K-+C;:-$.VU,?3<@WCRJJB9H<H'\?M^(#@Q,YZI46;-K'M&K!BW
M2:,F+9!FS:H$*F@V:MDBHMVZ*90`J:2*1`*4H?0`#QA7TX#`8$4/M:Y"TEO+
M4+;>=CW9$<?=!<XH25QT+V7^JLZ[*:AGDFYG#AA-/5UVQ;+1["DW%"0AU/O?
M?(83(IBL!0,$0/JS_B!-_;NTG8:YN3C3?_3EPT;:7VJ)WI;E"L,;UK;;\Q7G
M3MJ%@_33K0[J`?R,0BU>B?\`>0>)NBJ$*F/R`;AF>WE)S_C@[%_FS/8[_:/9
M_P"^#(N?)_C@[%_FS/8[_:/9_P"^#!GR?XX.Q?YLSV._VCV?^^#!GRCRZ51[
M]]X&XH/DF/TWOG@#UM0$?$6?IG8&T(MM4-Q]$'462=):HI\6W>KKQ=<3<-11
M=&`X@<1%=;Y$_'3RZ)<Q90T)H/47,.HZ3HO15'A==ZNU[#H0E7JT$W!!JT;)
M!\E7+A0?*[Z2?KF,LY<K&.LNL<QSF$1R*RZIY^V?Q\@'X&\"4`$WGP/CX@/T
M$W];S@1(>J5ELQI%]!'V/8NRK`JOL\QX8_7NGM8:D>-6`,B%!'7*&M6;1.?J
MOD/HY>_)Q\_ZOC*DVERR*8$6GLGX1XXZWA]>?WR&C],7N9L%T@]6H7*^R4K4
M;?'5VQL+$=:.I-HKAV\H^LZ#DOY$<P<',T%4AE!`#$+EB8EVBEWYZG?:/Q;4
M*ZIZ;N[KL75>N72<G7^.=^KPUIA$46ZB9A@ZS?9AH*\C!KI`H=9C+_=,JJ)0
M34`O[H.$Q9I#5>/XF#W;^OY=W0N\.(]=OK;*3;IU7K5?JM:=8QJ\4FJX8!%0
MCFCJ#5YI`SB,7607,I^4HF(F$HI_'$F6;[WUG^3?+3?\:3R-9CRB6[.7]R:J
M!G%1ZT6\KLW"[$1G)<_S+*,P:,6,6O$M41`IT5%3J?,IO`_4/.,4G_27M_7G
M"6O4?\2=Z?\`;LU#5YEU+%TN4EX568.;8=?FZK%QAV[9)PXBY*8=M3L$),@J
M"0J?R$%#D$"CC&&Y97-[-]Y_/=AL*&IO7Y2;E[&M]RC=@JUJF@T52ZZJR4DY
M4:EDMD;<E69*I4V<81,7+A$QCNC-_`D+Y'Z,)]HQ/7_7%WIWZ[)=/;'TFXI&
MI9)2-D8_@+DJ7DJ9K=F@W=NGY(O;6VV;A"Z;#407!N(IHJH)*IB=%83%*7&2
MRW:5RM<!\85+1,1S+!\UZE;Z%@Y=I8H_5ZU3CWM5+9&1S*H61=@\(N#J?*NH
M907:@F7%0PF^7G(TRUICGG1?.L++5W1.I:#J6$GI0TW-QM"K497&TO+F(*8R
M4F6.01%\]^`B'W%1,8/(_7ZCY#,F`P.@[.U7K7=5)G-;[<HE5V10[(U59S=3
MN4(PGX1^BJDHE\E&,@BNDFZ1*J(HKD^*R!_!TSE.`&`($+QZ\.WO7-94MG^G
MV]1UST`UDYZS7OUJ[MM"C;7STS]PX=?IO.NP'K"0>ZS245E'#@[!TL=$JC=/
M[0JG5,GAF3&M,DZ^]K6G>]=*[3Y[)N&W>KOMI6`?P\O2MZPD%&[9U4JU<%6>
M7.G1]F>1M5NL8]B&3A5DX2<&,B@J599(@E^`TSF8FT5O/MUTKJC9^QM5>C;0
M$SW_`-H[$9OW>[_9UT'8DYG5M#M"\?9&*\[+[9FH\3SLVDJX4.G7X$&C-^V*
M5L+@_@A<2+U2U\O>EVKL]C4GK'V-;.D.].U:]%OD6MHO:":VB]8K2KF56=Q6
MG]4/(]O$,(ULA*?9(Z?MSNEA1(J)$SE3!-DQSF[3DD(1,A$TR%333*4A"$*!
M2$(4`*4A"E`"E*4H>``/H`9%:\=,=9\Z<=Z^5V?TGMJHZFIP*JM6+^SR2;9U
M-R*+95X:)KT4G]R2GI4S=$QBMVJ2JH@'[,#1CF7W;<$=0;4:Z5@;[:-5[+G*
MW`6VD5C?M&L6FG>QZ_9@(I#/Z`I>&<4WM'YK9=%=--L8ZAT%BG*42^1`F9G'
M5+>`@(`("`@(`("`^0$!^H"`A]!`0PKS@,!@1D^SSV<:E];>H8^?G8YYLG?.
MSGAJESKSY5Q.YN^W+\]$&D:R9,FZ:SEK7F3]=+\]Y\!*D0P$+Y4.4N$MPB"T
MWZ>_85T71[+VQT]W?NGG#V2[/L,=L/6L)K>:?OM*<WU-"+?-8S2D]J8\LG4[
M.A*1KY-"47,F=RP,D4Q3+."J%&Y_9,=>K9"E^S?L;@%G'ZU]P?/4PM4J^12*
M:>P?FZ->7S1EQ9,Y!)@SL6SZ5&L$K;JB2DDWS<!$[51N82'45!N)P3`N;-Z3
MFZ6WGI_HN@1.T]&;&J6T]?38JIQUKIDPTFHE9PW$H.F:CAHH?\=^S.8"K(*`
M15(WT,4!R*RM@,".#NCVG\F\#M(>&V?;'=TW-<)!C"ZZYVU:W3N.Z+W-RASH
MQC.-J4>J9Q%L7;@OVQ?OQ;,DSF`#*!YQ$MPC<_O=?:3[6;:YD^QIJ:]=G!,C
M%2\6;D?6%N82/2VWV:RDFR9+;<V-&QJK.B0<S$O@_48AFJ9P0Z!4B&.FJ*Y;
MP8MVR-M?^'>XS9U2E37#CFS<#],:EC$&>K.CM.OY*3L*!DTP0D6NP8&:EAC;
M]&V-H)TGA7(D$#J`L4!,F0F,GUDTZ3K+VP]%\*2E8T=[K-3CJU6<MP4S6G<>
ML6A)SFS9;4R7F*4O)HUU(2>L[2#8I#OC.TRL@^8G,9$0^&$S<\K"%2MU6OM:
MA;E2+%"VVI6-BE)P%EKLDTEX29CE_/V7L;)L55VCQLI\1\'3.8HB`Y&G8L!@
M:T;[ZZT-S@QL0;%O$<%O@-<6S:Z6K(!0D]M>R4:D,7$E:)RI:^CSJV2QM8AD
MT546,U04`A4S"(_0<#%6J=G;EZL?6^;C8.=T=H2)LVD[WSWMV*DFSBT=%:ZL
M.O82[VMK9J%9J\@^U_"IS4Z,0HF<3/%A:&4*9(?)<#2'V1\:;2U;;Y;V?^O)
MHK!=DZOKWY&UM113-=:G=J:NB#)JRFN+S!,S%3->V4>516#FDTQ=(KE`IQ,`
M^<J6=9MN?ZZ?8IHCV2Z%8;DTZ_5BI^)7+7]M:FGCD;WW3]];?=2E*E;XHP)N
M&YTW+946KGX`D[2+\B^#%.0DI++IOWA3`8'\**)HIG55.1))(AE%%%#%(FFF
M0HF.<YS"!2$(4!$1$?`!@0C=%^YJG&N5\YL]>6I[CWMUM6#2%>DZ[JYL!-/Z
MFM171HMNYW)M=\9M686-CWI3J+-VJR[M0J(E*4H")RDSV0\^Q#G&]Z)Y#NWL
MJ]T.Y$>GN@*O5?T+0_%=;00@N1]<;;MOY<74V2U283Y%-M.X.:>-Y59^Z6(9
MJ9H()_>(`>;/A+Q,UMU_"24:/C/5W);8/(/Y&X;WZ'VK>KTLO^$WCAG&KB,A
M?E%1<<T9LXQ!9-F*ATTB%3`Z@@0I"@!<7L>ES,]UHC(T8#`T]Z1VW1-(;-YO
MM5ZO^O->L+M>I'4B3N[_`,ZC25BD;<Q16@JO3SQ)CUN.E9&88I@HXE$RD$OP
M324*8_@0W"P-;.PMKZET?S#N_:&]WL_':?J^OIY383RK%E!L:%9DFPQ$@>%-
M"&)+HR7VW_A)1N8JR1_!RB`AYRQ+<3-TT-Y'U+PQQ5U+7]$Z8L&_'FY^G>>W
M>YH>/VAM/:^UJ\KJVAV%B@X>M%[U-S$56)D)2VI@9)($EUTQ\"`E)]'./A)/
M6>:F%R-&!'7[#[3:JO"\Z*5?9>R];*2'1VNV,@OK;FI#I)>PLEY%-!:!L+%P
MHG_1K`/D%U$U[*3^4CDU#'+^P0&S'5+GHD4R*Q'NS0FE^D*'*:PWQK*G;6H4
MPFJ1[6KI"M)AB!UFZK4[IB=8GY45(`V<*)E<M5$7!"',!3@`CY"HCWE_!S\V
M;%A+%<.#]FSNBMC"LYDHS6^Q'+BW:FEO+>/33@6LHD0++4"?<;N52+_&1`ZJ
MY"&!-,HJ997/V_YRM,O6-_"`7A>^+["]G$Y&Q%-J4_\`&"T3K:P1D^.S&B*/
MR2D[3>(:15+7H+\H0'\)`AW;DH?$YD`^HK4]?^>.;M>CY[YFT%REKV,U9SMJ
M>E:DHT4@W03AJ="-(P7QFP*@D\FY`A!DIZ1#[Q_]D/%EUO!OB!@+X`(ZZTSI
M@,!@,!@,!@:&]P>M#C/V)0-9A.J=0Q]Y<4MZJ\JEGCI*4JUR@0=*)&D&+*SU
M]TPE!BY(B7Q6:JG40'Y"8I2G'Y83$;2Z>TSJOG_7-4U'I>B5O6^MZ3$MH2L5
M*K1J$;%1<<U^0D3(FD7YKKJ**'4565,=994YE%#&.8QA*[]*RD9!QDC-S4@R
MB8>'8/)26E9)TBRCHR,CVZCM_(/WKDZ;=HR9-43J*JJ&*1-,HF,(``C@0&;I
M]Q]]WML=AS7Z@=,MNO-ERKF4B+CTS9`L,)R!H=RT7=1PO+1>&,4JK>WS5V@)
MSM8@RI2%^/U6$QDRW"9SIW3F3TRQIMB4_JGV3[DL/>G857E%K'5Y>VKR$5H/
M34BZ=,)1&/T_I9-P6L18PKYL*97SA$YW92$6,BFJ`>%J2=VL/ME?N)6WV_7O
MLP]?=0V]ZV9YY&1>N.RN<W$K/[_Y;3=,T7+ZPWZ`+"N+K`I.Y^&3*X>U@P,6
M\6F7\O\`)$_X^)\%XW.&+M(="=Q<*T.(W!S=L8?='ZHXJMI1,?+4ZQ0[WLO2
M3:L)M&,D190(MFCMAE`H%.7\!</UQ;XE!440**IAGK.8GXXR[SYA[WUR&QN;
MMBL;4BQ18A<J7(%+$;%UK+/@<`6M[%IZRJDC6)Y!5HJ0Z*GR()DS?`YP\",6
M7+<7"M..X.W].\':9<[6VFM(S<W,2"=4U-J6II%D=E;KV5(E^$!KS7L"3Y.9
M.8DW)B`JJ!!09("*JH^/B4Y+<-"N'>&MO;9W4T]F'LC81DOU7+Q3EGSYH9(P
M2.O>*]6RZJ;]C5(!FX(=O);>>)_`TY.B`K?D!\$A+\"_`2=;M-YA7ROF+*39
MNH^29M9!@]05:O&+YND[9NVRY#)+MG39<BB*Z"R1A*<ARB4Q1$!#Q@067?TR
MR&B+E9MU^J3H>U</;*LDR%GM.GWGYNQN2ME3'W5EW_\`.C3\T[53KCZ9*L9(
M9"'6;+-0-Y3)\0%,:SCLQC0/=Y<^7;H^T)[C>?)KDR\P#.0",ZDH3"=NW(&W
MC0D,O-NW-8L_Z>G8:U+2+7["+*.6;NEGKTYR`5N)2IBQG1]NE<>ET_[./:Y)
MWFI<94D>`>,4W:]2<]>[PKTXYZ!VW!OP>)/[!SWK%9O"ITY%W#J)@VDI14%V
M*RB:Z1SJ`**31S=:2"<'^IOD[@QHM9ZA6GNV.B;$"KO9'56Z79M@[YV!./D`
M;RTF^NL]^8^@T)5,`!=K&BU;K_$#*E.?][(N(DWPI@='V3K/7^XJ-9]:;2IU
M>OU!N<.]@+14[3%M9>$FHB11%!VR>LG::B1R*$'R!@`#D,`&*(&`!`("WOJ_
M[&]=EJ:;#]0F\`D=',V[I6W^O#IBT6>U:DD`\R2WY.D;P[=O9[6,HE^HK+%C
M@.1G)/\`[1G+DI2CYJ8N>-.4N_O&VVXG.C;1S9ZW-Q=-<P<EW6>H.\>AX+:M
M+H2C*?UPU:O]S!1]86:#<3MV::^9*+'(H@\3*^,@8HBA]1"&96NN\_<=UKNN
M\K:LXEU+'%N$OKC6O7?-U8F&CFQH=R<5S2#=#;2=6FUB59YKK<M7*\-^/$`J
MV!%9(P?J*IB``W$,\X2<<1^M>J:EF:YOO=MANV\]UURX;1NO/MSW6^E9?</.
M^JM]UMBG/\ZS=K6LLXI=XJG?G/F"/YJSINV(;_8X%/\`-50N,):"$(F0J:92
MD(0H%(0A0*0A2AX*4I2@`%*4`\``?LR#^L"M5[$_77OGE??,A[9?4W'(QO0$
M0W,[ZFY4:D52U]UOKYL"9YDC>N,C-VK?8S9H0ZZ2B7P5<+D*JD8CHI3&N>[-
MEG/JE>]=OL3T+[)-#L-RZ9?N(F>BEPKVVM16-1)OL+3=_:?<0EZ?<H@?M.4#
M(O&RP-'8I)IO42?("D4*JBDQA999F-]\BHUNT_:QR3Q25W4;1<3[1Z$>LY(M
M%YAU`BM>MTWBP,XU:1:P*%:@$)):N`[!,H'=R0-T&Y%`.81+X\DSA&]"\L>R
MKVU#7[YWM>ICA#C&PPK]=OPEH2U3<?N^^Q<H,XT8H=$[A1;1;F*34BW:97D'
M%D,SD&RA/O)ME0,0+I.;X3>\Q<C\W\::W9:GYEU!3-0TEJ5L9TQJT6DA(S[U
MJV(S2F+9/K_?G;9.BV3*0SV1<.7)B@`"?P`!D:?FW_Q5GM#A^SNKH;F#4-B+
M,Z-Y+=S;&3D6B"(,;7NV11+'V>29O2+N5'T=58],8YN<OV2'557^29A*0^:D
M<?\`I[?ZQ>@]"FME]6>I#BBOOZ8E1IB3U66W2\4$2WAW;]>VSLO.L+!(H())
M&</)V#>M'`+J>5543D$P_LS-VZ^O'K)\)?<*8#`C^]G#B]P_(=[N.OMA;4UK
M*T.6JUKE)K1FKZQM_<TM7VLVU8OZKK2E7`Q8!W:)YS(-R)K+^003(<WCS^Q$
MK;/2UO<W[4NNKD]K]^JSNQ5"$DG,!M*&8UW8T:NJR2*HE=(*,<O(^*L2AB"H
MY004.DFH<0+]/``5HU[D==7G;7K%[)USK6JS=WO-MT_+15;JE;9*R,[-R"KV
M/.5G%LD`%9P[%-,QBE(`F_=^F6;9]N?6R;1J<K^N6W<H>U[E#8E;GNJ]JZS6
M]>&U:S=KSO\`VE;]O1.O]@2=SUR[CZ%"2EH<."U`KMHQ753CD/BF()F,`>?.
M.B28LQI9>R-F!$U[4MR;2UG7M+0^J8WN]&:F;HZL#ZS<2Z0UENI9"/JH1ICU
M?:##9<HP9Q%?LBDF'VC-2BNL5!8/F3X_6I=I3:\Z</H"#?.R/4G3R'C'3E*3
M:),))-PX9(++$D&*"BJ+-Z10X@JD0QBIJ>2@(@'G(KF,!@,!@,!@,!@,!@,!
M@1[>P+V*:QX%J%1-.4O8NX]T;>=V"O:%T+J6M.K->]H6^$@G4T=BDDW#[4)7
MVH(D!])K>4F2:@',40`?%Q^R6X1;0G`7>_M6<4O:'M4V/+<Z\X+,%Y-EZY.?
MK18ZL:4,Y<2_Z7_?%[`CY`K^P3+5HX:G.P9+`BB!5&YQ$JBGR<&+G-3]:4T5
MISG#7<!J;1&M:?JC6]8;?BP=/I$(R@H5BF)S**'*V9II_><+*G,=1503J*',
M)C&$1\Y%98P/G=LVD@U79/VK=ZR=)'0=-':"3EJY14#XJ(KMUBG262.4?`E,
M`@(8$!VYO2L\U)M$W37J8W$MPSN8[LTK==.M?U:0Y)WB=LF@+>&V!J-@X)'0
MZ3U8'"CAQ&IIF5=.?OG+\R`;"8YS$3L\MK+>_12;;JJL[2]'7MJBF,[`ZUZ/
MU3+N*3S%T<TAVL@6(5=V$[A.EW]&62(L)XV1^$K^G**E3/Y/\0O5+G6JD/GO
M<=U#Z^$!H'M)YBEKO/V*)9-><N@.*J_*W[4_2]Q?2$A%0=,?L72P'U3>+2[!
MC]ELN99L0KLIB?,!``8[&;/R;*<0\.;DVQN9M[)O9*BQF.HYJ-41T%SVBL>2
MUCQ9K62,#N-K=<C78*-WNXGC94!GIP0,N#@3IIF#][Q%DZW:;C"F`P&!KUTV
MPA7NM6HS<:211+L#5S0A?Z,8C;2Q22^Q:O$O$"U69;N6J+.19/%&[N1``/%-
M%5'@?5#+-I=-@$$$6R*3=LBDW01(5-%!%,B22290\%3323`I$R%#Z````!D5
M[<!@,!@,"LA+\B>V;F^N]R<E<JZNYNW#S7U?LG<UTU]N/:6U7%*N&H&'3C`Q
M-EQ\U2(V%6=W$:;,SDD[8F_(`[HH)I^0)]`O#/,UI-IQ?R?7>4.:.:-'NU(:
M[VWGK2]7U(UV6X@8]O.OFT1&-VTL,>\%N+^-BY1ZF906Y%"D,'Q$P";(TV[P
M&`P&!6H]BGKMWORKOJ1]M'J@8HQ6^89J=[U5RFS!5KKOK77;,!<SPI5Z.*B@
MELM)NF*Z2Q`*JX73(JF(."@)[GNQ9CGU?-#=1^W[VMUROQ',.BYSU;:`DU6:
M.S.A.@"(R&_IMF5$"3T'HJBH-?$2*RIE4D)]T1,[1PW#P7P8<<-<WX2@\,^K
M3EO@U.U6#7\58]E[IV+*'L.T.A]U3)]A;DOEB7^Z+V3?6J7346B$7BBYC':,
M`;-OD/GX".1<1(_@:L]K]"ZFY:Y;W-NO=UPL=$US5Z;(M)FRTI$7=Z8+6,H5
MV-4HD>11-Q(W$C^43.P12\J"N0#``_$<#\S7=/J6Y+M]HOCVN[B[1Y=M<Q0[
MMTW28?MO0`NQVYH"HQ`VRZ;,@+;5W[-Q);`GV?Y+Y"N+_P#[B0_[JP_RA1#4
MKE?66_+]%+0O4?/>G:1ZT.76-CN<_+],\T09^=IQU3UV2-JI^E]+Z_G)*9N(
MD7,A3Y9]5IQBY!H?[G\NJ=(!_<\CEU2/8#`8&!.I:A+7OG7<M6@;?LZAS,A0
M9]Q&6K3$Y'UK:L8]B6IIE`E#GY4AXR)L4B>/!J@LX#[)!7'YB!?(@$4GHTO$
MQ!Z2M?/-VJ[O5$O1K"XLE#UEMSJ-CT'U2ZJMG6=2%@L^ZXA.1?A07[JQ*"JW
M8,3G8`BY^28)^?C@B=;`8#`8%7'O!6Q^TS=F_M?Z<Y)M&WJEZT7UAILK;GW3
MFUN;'6S-^3$97K);=14"-U=-,4[*K&5=JP62?S("V3<+$3(``Z\EJ9YOPFZX
M9Z\U9UCRKH_>=.:2FOX2_P`0%=BZ7L%^U;6N*LU456KD]4U57+LYYV3B).*6
M2%5(RAW`$^YX_>'(2YF6ZF%,!@,!@0&/?:/VQNK:G7D9PWQ)`;DU#QI=U]76
M^=V%>WM'V'M?9M?1:O+A4M158K<\?(`R0441;/'3@B1G)"E.4/D`!?*9[.K[
M%]\E+UGH3V#[`NM:UWK_`'9QW8?T*E<[WO8<=%;!O[I2A5*VA%2<01Y^H?K#
M&3L#B/<`P(HE]QH/Q'Z_5U^$S^Z1G^_4D_\`%A?XP7^9#/\`6/[S#^^J_H[_
M`%!;\#]0_HB_I,_FG^I_]?\`Q?R/]B_>_P"B^/[W[<8YP?;_`!^R0+(T8#`8
M$)W;YC%]O7ID$IA*(R/:11$HB'DIN;[$4Q1\?M`P#X$/ZH9J?BQ[;GEDGU4[
MYV]O.1]C".V;S*79/4/L?WMI[6Q)-".1"IZTJ]6UJ^@*C'_I[)F*L?&.YAT<
MAU_NKB*P_(XAX`,MI:,!@,!@:]],<J\_=AZOF].]':NJNT:+-LI!K^GV.,;.
MGL*XD&2K%29K$J9,9"N3S=%4?LO&BB2Z9@#P;Q],%F4'_L)Y?HW%W$WKFYOU
MA9]EVFC:\]G?%R$!+[7N;B]7<[:3WF>;_$D;(LT8'=M8Y>1.BS3^T0K9L0B1
M?W2AEFV/?\5D3(V8#`8#`CP]GMWVA2.6Y-QJ-]T[#VN;NM)@1G>1-65G;>Z8
M2*=3:#F2?0U=M[YE`L8H[=H*+]\J5P9NU5/\$A.8H@$@$4<RD7&G.HNJ<[!F
M8ZKHI"NE#&;IB8[DJ7E,K@XCY.!?W0-Y\?3`^_`8#`8#`8#`8#`8#`8#`8#`
MB8]UG+.].NN%I_7'-]<K=TV_5-L:7W)5J1:9IE7HJZ*ZEOT5<'%7-,29THMD
MM+HL13`SE1-(Q/D7Y?(2@-G%3VF9A!KW'(>P?VO1]=FXCUL;GYRJ7)6A>BI*
M[+;DA2Q=]V-O#8>E;+1FNLM!U,A#S>QJ8M)E+^+)M4_L+G41,H"?[OET-UD_
MD_U77SE7L7TJ[>K*?86P&1>;ML%Z5+NZ\V+8]&YOM\AS[KAM$4R$C'\2S;:C
M1?VE_(QI&)E#?=".20#ZMOJR8UX6XLBF`P,-]%VXM`Y\WM?#PT?8R4G3>S[<
M>O2PJ!%3Q:W29R9-#28I`*H1\H#+["WQ_>^VH/CZX2W$RIL<E0^]?6QR%S][
M=X?7G&;"D='W'7]BZBUIKC4T_$;2B=1[9M+:NU-&@[>O>T)R3?3L$UG"G>Q:
M;4K9PJ!?M$,!1,6_#-MDST7B$SE53(H3ZE4(4Y1$/`B4X`8/I_4^@Y&W]X#`
M8%>"Y\)^T?F/H7M?9GK_`-OZ#NFK^Z['9=D6+7V^#V*FS>A=QS%.CJHAL?7U
MCK$'8R6%8$VR1CLWJ0(JEC6H&`@@<3W+.+G,ZL@07HTUM8/7GS9QSM;=FU6^
MU><IB1V72^D-1SSBAW"L[FLCUY-6&QQ3)$Z\?)PBLK('(9H[(/WT2`(&1,8?
M$7'&&"G';'L:]1Z*L;[)Z5)=G\A(VYC7*CW)H6OMU]IU&!DC2BC)YT=J*..F
MX,Z24^PFO+Q2"+$/W4B%55,4#5.9O2>_1G0^CNF*-'[*T%M6C;:I$F03-[!1
MK%&6!FDJ515!9H]_`<+*1[YLX042506*FJFJF8IB@)1#(TS+@:C=B=T\O\':
MO?[:Z8V?%T>O-G#)A'0[9%Q8+O9Y21<I-6434J3"IO+)8GZJBP&,5LW.5)(#
M**&(F4Q@&9-H8'$W[5/<8SL4'6XBV^J_@*R),%X38EAC5F_;^Y(3YMEB!"5T
MDPV3TY$+/F1UA<K`8\C&N4!05_ZX&7A-ZTZK&>L;VO\`#<+OO1?K0Z;UO,:"
MW[)H6N!N?4D_8++OGGR_S#ANEL*YUR?:5=>+V%(7%/[CWX2A/BV>>!\J!^[C
M@QV=2-Z"MG3?%_LAU;NBP:7Z7[!Z@L\K/:EZOVC481+8!GCVI5V,3E['/,:T
M=Y3G*$HQ<)HIQA1(5L1,Q@^8F#&;^B8Z]<L":CE^N)BE]:^FYUMG8%Z+5O7-
MIKGJ(NA.2+_`ZYT3O=0T/I";UX[F7K9!U=M?[/B;4S,SMS,7#="$1>32B:2;
M(R1V><ICCZ],8_5<JR-F`P&!";W!_E>O3'_MEVC_`,W"PYJ?BQ[;GEQGI1_[
MZ^U__2T]*?V&:CS+2<7"F`P&`P(3?>)_P3<0?Z3_`(;_`+K3/+-L>_XILLC9
M@,!@,"+[VK:YV7MW1M8UW0>>JET1'3%W:O;57;1U1<N33PS6(CW;J-EHN\T5
MJK.2S@7X@F=B"B:1B&^9O/Q#Q8EEO$;V:+@W=9TOJBNOZZA47L%KRH1+NK-;
M=(W]M77,?!,6JT*WO$N`2MO1C5$A1+).?Y9Z!/NG_>,.165<!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,"N[OWV9['[![+<^M/UV:RUWOJFP2<G6?8#O[8)K0KI
MS66N;$T4@[7KZFSM.FX-66V3)0CMXV;K)N5DDWW@"I*$244RQ+SPZ_6?0#:G
MIM+:9WC[!-Q[KX,YIV%'WW1G(TKK;74-^"G69(\A1ZELW:9&\E.;.JU7^Z*9
M$73-$YBD(*9T3E^63KDQ%D$``H`4H`4I0`"E``````\```'T``#"O.`P&`P&
M!\DA'L)5B[C)1DTDHU^W69OH]^W1=LGK1P0R2[9TU7(H@X;K)F$IR'*)3`/@
M0P(0NB?3RXK5^F^FO5[NV6X#Z/>)?J-GI]'@H)]S/OV1CS3LDW8[@U,X8_IQ
M9&6?RPMAF&(D49H*'4!LJL":B=REG6;1&5#WY>R?H"F\YZ`I?).O=/[^Z!Z$
MMG(DUUU9'LY-<S0^RZO+3=>G936-29R1;9*S[<D2JY3;/GBC=BX3#YD<I#X`
MF:F=XS]+VD-&2;#=G5=IG>\NRW:TA)6'HKH$%;*$0[E1:'6B=94*4>2=6H<%
M'_B`1`6Z(NS`8WR5`GP23F5QU3/``````>`#Z``?0``/V``84P&!X`H`(F``
M`3>/D(`'D?'[/(_M'Q@><!@,!@0F]P?Y7KTQ_P"V7:/_`#<+#FI^+'MN>7&>
ME'_OK[7_`*"'_P#;3TI^T!#S_P#PO4?U#S^T,RTG%PI@,!@<;,3,/7HM_.6"
M5C8.$BFJKV4F)A\UC(N-9H%^:SM_(/54&C-JB4/)E%#E(4/J(X$)WNNEXF?T
MIPG-04I'34/)>SCA=W'2T2];24:_:J[99BDY9/F:JS5TW4#ZE.F<Q1_J#EFV
M/?\`%.'D;,!@,!@0!>^QW3DM5:>'95'X9LU!B+1+S;Z6[:WUL;3L)"S*K1M"
MQ25*C-6O6=HLLB^+(J@X5."K5J0I?D4#'*8+&;,]F_G'70^NFN@^1*-=KISQ
M7-A;8HSJ'U;1]#WV4OFM9]EKJ&C%I"(UG9IA9],3C.KUA^P.X%ZJ#I/[H`H'
MR\@$6=KMMKKC<FKMO*7E+6=W@[FIK2]3>LKZ2%<'7-5K]6_L?KE6E0.FG]F5
MC/R4_N%#Y%#Y!X$<*R9@,!@,!@,!@,!@,!@,!@,#Q\@\@7R'R']@>0\C_P#8
M'[?ZF!YP&`P/`B!0$QA```!$1$?```?41$1^@``8%?[I;IC='LNW/=?7QZ]K
ML_H>G*%*?S9[O[IKI"N&E$9J@8)7GW0S\X%96#:]FCP5;OY)NHHA#IF'Y#_T
M7SK-N>(E'XKX:YN]?^F6&C>9Z*E3ZDB^<S,Y)O7;B:MUTL;Y0ZKVR7.SOS*2
MEAF7`G^(*KG$$TP`A`*4,C4F&W>`P&`P&`P&`P&!1,Y>$?Z+O4@'D?'_`/H7
MZP^GGZ?2W[6\?3_[Q_\`QRQB]/*]GD;,!@,!@,!@,!@0[^T;COKO<E^Y.ZRX
M;O&MXGH?C"UWZTP6M]KMG:%/W!6[Y3W57M5#4LK,%OYM2=@BCF9(.ER%;H_D
MF5.JG]L/-EXPEF>9MU3A7VS:6VGL^;Y9Z$T<_P"`>V'=CE74YH[83".BX;<,
M^V:+$GK_`*GV"P81L/LR)D%H)T1%VX!&3<H,@4%(4_@(L&><7:;/(I@,"+#N
M;VZ\N\3R!]9_>L'0?4TFM'Q]+Y-T0S)<]S666EB@JP0=Q30QFM78_B"+E5>0
M41\-R"8A3F$I3$S$.?2M+W9O:CV+HWWU=&5OB?A&;/6$Z1Z_M-;!=.;#;7"C
MIFYC8?<UWB(E&=O+NP'`IW$)%D`4U!,@L"94_P!ZICK7:Z!2>J?9O+<N:IT9
MS,QX/]4?'.XM!;@UG:]TPL\7>>_X72$HQEJ7#Z]UXX3;'H4`J]AE"JN)5<ZC
MB.>)KF$'``@+7E,?:8U%K#(V8#`8#`K%]E2?+M-]\NI+E[$D*FCH@W"KR/Y%
ML.Z6#"0TE7M[);$L1MW'?+2K1>M0\[(:]<Q"159@P-E3B@5#^7^(A>F6<_Y8
MNNB#7G"B;'?=@:/N/JG+0-?Z?O\`[#.]9KD*>WI`;!E-'C0V&B]'0MW=05>B
MT5K'#5Z1M3!^6-,1-(BA@^?R,`_+%TGKO]UE3T,1VVXND]^M=\O*E*;B+[#]
M\CL69U]%3,-0)FT"E7_U&1I3"P(-I=&N+F^/V`7*!_`#YQ6IN^4]613`8#`8
M#`8#`8#`8#`8'!6AY)QU:L4A"M#2$RP@I9Y$L"IG6,]DVK!PNP:%13\**F<N
MB$(!2_4WR\!@40#T%[-^GW?7N*VIU[M]7V)5V_V2[TV=B-RVZJ534EVH.U"T
M6M:"-IQZNQJSO\&%:+-)*/69.1>+B8Z:QRE^9KRS)+,U.O[`]R\QH5+D&R]5
M^Q7H+BNWW?2+:T1T/H^96@8S8RTI&4]_8YV<:MJ1;""XAI-Z1)N'S1`B;DP`
M4W[026GM9-W"-?\`IZ]7O^?P[S_W:OO_`&.9?K>S'V]/_5/Z>O5[_G\.\_\`
M=J^_]CF/K>Q]O3_U4?/871>MY'>'%VI.2?=7UG<=-;^W.PTSU+/6RU_J,S2*
M=<%DF;2<B4'M%J?X3)XBJ=BHX(L(IK*E-Y`?IDQCHN9TJ]US-S5I;D72U*T)
MH"G,*3K2D1P-HN/:F%R^E'J_A63LMCEU?+RP6>?=^7#U\X,95PJ;]H$`I2QT
MTSS@,!@,!@,!@,!@,"B7R]_P7^I'_P#Z%^L/[+]JY8Q[=/*]ID;,!@,!@,!@
M,!@,#4;LGAKFCO35BVI>E=<L+K!(.%92LS2#AU#6^C63\)RT96BFVB+6:RT+
M,1PN?N)B104%#D*"R:A0^.#&4+X$]J7IX=T^,;C>_:CZ^HPTP%B>)1X2/<6B
MZXW7=/6QQ=2-@1:;NC(^-^":(F,W<C\/MB")2E4/=I)9X3(<9=]\K=\Z[2V-
MS1M&)N#9`56]CJ#[Q!;&I$HS_$3DXBYT:0.G/0;N+>NRME5#)&:G<%,5)90`
M\C%1G[]W3[,>R=B;ITUSS!,?7#R3JMY.4/;G9'3$"FGM:[$1+9(NPS?-M6:S
MXU9A43,46ZK2SRLBR5;`Y1=)$!0AFY:S?M=:1PZ'VIJ/4=LV/I_T%\ZV?M3J
M6UWHM?ZB]C._IB7MVKH&2:.C&FI"U[DM$NWE]@61HH_,Y1C8=-)DLF4%"F=F
M,/A\D^$J/-'I/UY#[7>=4>P/9LG["NKI-R,G'V/;L1\]+ZC<.TC!(0ND]*2+
M^:JM5@04*@=$%DW"B3AN5PE]E4PB$7"<4`````````\``!X``#]@``?L#"O.
M`P&`P&!T?86L=;[;J\G2-J4"E[*ILV@1K,5.^U>$MU<E6R;E!ZFWD82?9/XU
MZB1XU25`JB9B@HF4WCR4!`.8@:G5JM$05?K-;@:[!5B/1BJU"P<1'Q457XML
M@DU;QT)'L6Z#2*8H-D2)D20(1,I"`4`\``8',HMFS;[OX[=!O]]8[A?[*2:7
MWEU/'W%U?ME+]Q8_CZF'R(_U1P/?@,!@,!@,!@,!@,!@,!@,")J]>C[UF;&V
MQ.[?M'.$<XF;;;B;`NM386VZ1.L+K>F[U%^PMMGUK&S[:GR,O'.4C&2_V*1$
M?NJ`=,X'-Y)B)2C5FN&:,&!Z_"'8Q31)A%LS13$S6-8H)IHH,V#<R`I-&J**
M12E33`I"E*``'@`PKT_S1JG_`*,5[_P+&_\`<V7-3$/YHU3_`-&*]_X%C?\`
MN;&:8C6/LOCO5?8',6Y.<[=6:\W8;+ILG$Q<PG7XA9_5[4D@=S5+=#'5;D%I
M.5J=31=-5R'3524)Y*<H_7&:62S#4CTS]5W#?O+LCIO=Z;R-ZLXENDCRMTA$
M2+%K%N7UDU^F5I3M@,&+=Z],:`V)2$V;U!P;X`X=$="0HI@0YYX)G'.TNF%,
M!@,!@,!@,!@,"C1H*KV:G:^]1<5;ZY/564<?Q!744FA&V2(D(.06C92S[3=Q
MLBDSDF[9PHQD6IP406`HIJIB!BB(#YRQCVZ>5Y?(V8#`8#`8#`8#`8#`\"`&
M`2F`!`0$!`0\@(#]!`0'Z"`A@0Y]B^FS2._-E5CIKG:TS7%G8E'EE)^%WKHY
MDPA4[D^`I#MXW<%/;I(0>Q8,KI$AC$=IF5$@J$^0E4$,N4PU(B?5GWQWJZJX
M>XCI^'EM6ZDN1#UOFSE@AZ1K?=@5D8UHQV3NF5310E9$+NV2>'5KI1_&CD7J
MJ)3>#CA,6[3\ZDTSJ;0E'A-::5UQ3-64"N,FT="5&BUZ-K<%'LV:)6[9%%C&
M-VZ0_91(!0,;Y'\!]1R-,EX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8%>#L9>*]:GM(T+WJS2;5[G;NQQ7>0.OACXA`C2-V\J)PY[W',."NF:8
M.EU$/T.4>J`<R,4W*<WDJ7@;MF\7/=8>`0,`&*(&*8`$I@$!`0$/("`A]!`0
MR-/.`P&`P&`P&`P.D;-LSRE:WV#<HY%!S(5*D6RS,6[KY_BN'D#`OY5LBY^V
M)5/L*KM2E/\`$0-\1'Q]<"GW/]/^U75GKLT;[<MC]0:MVU5)':>N]D2?,!]`
MZQA8.$U!=M@K5M\SA+Z^9HV=A>8NOK^4G3)0%E%1`"_/][SKXC$O'VJXI2;0
MUN],J-T8H+-65OK$#:&;5P8AEVS6?BFDLW07,G^X99%)V!3"7Z"8!\9EMV?`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`T8]D?%E/]@/&>[.8K63[#VZ5=P_H$\DHBV>U/:%<#];U[9&;Y5%8[,K&S
M,T"NA3^!U6*BZ/S*"@B%B69F&BOII]C=<W1QM#4/J'85.UYU/RO:)GF/H:O7
M2QQU<=JWS6(DC&D^S<3LD0DZA9JV5F]4<ME5T@<JJ)F,!R&`)25+#_?-<X_^
MOO3?]LNF_P#EG"G]\USC_P"OO3?]LNF_^6<!_?-<X_\`K[TW_;+IO_EG`RY"
MS<-9(EA/5Z6C9V$E6Q'D9,1#UM(QDBT5\_;<LGS119LZ;J>/H<AC%'^O@<I@
M,!@,#C9J'C+%#RU?FV:4C#3L:_AY>/<?(4'T9)M563]FL!#$/]ITU7.0W@0'
MP8?`X%=^2_AW:)-R5%U].]N=13?%6M-V,-TT7B&56J[W5->>14ZXLL55$+`N
MT/9G=9C)AR<S=NY,LDBD<Q")E^0FRY9^L_18K;-FS)LW9LVZ#1HT02;-6K9)
M-!LV;()E20;MT$BD21012(!2$*`%*4```\9&GOP&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P--.^^T=;\!\M[)Z4V2
M*[YO5&+:,I]2C`;.;'?]A6)RG#TRF5J(6>L7,U(RLTZ3%5%L)UTV2:ZX$$J1
ML);CFJMVCN=N8=7WW13[V*<CUCMKVG>W/9TWN:[T`L3$NX3G#6:ZY92.<RE<
ME6#>0UW5ZQ6I!,C]PNT65?3"*Z`NO@FF`:9QWG^2Q1_B9?55_P"X3S5_:YB?
M^IR?:M?6=C_$R^JK_P!PGFK^US$_]3C[4^L[-!>\N7?3%P-%Z0LFZ_6WIUSI
M_=NV6.C;1M:LZY@58C4$U<HYPE4I2VM$5T[$,98GJ:S9-S')**,U$A4,)!^`
MBS4L]9N1U3UE;'L_K8ZML?J-W]<7,KI6]H/-L>LW;$\M^G5BP:UF7)Y![S5!
M+/$G"A[+0@<G.S0<R*CARB7X()&^1<;6<<++.13`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'RO7K.-9NY
M&1=-V+!@V7>/7KM9-NU:-&R9EG#ERNJ8J2*""1!,<YA`I2@(B/C`J#[)Z-H7
M>73^Z/97OG\D?5!ZAW$Z30\+().2L.F^P*O*&12V?27+-%LA9(B-L*<?"0B#
MLKQJI).D#IG#[BY2WHSNY[)"_39RCM"SV';/M>[&BG`=:=M`PDZ16IMHLQEN
M?>8VS1LCK+49HP#)1K*<5B&Z3R161;H+'!5-)8!.F<1+)>NT^^13`P=TGSUK
M3JS1>S>>MO0Q)O7^U*I*56>;_$GY;0D@W,1K+Q2YRF%G,0SOX.6JQ?WDUDRC
M^SR`C:HQ5]`;8W[KS9'I\WU<QH_L;]:CR*W_`.M+I1`A%K7L/3=9<%?ZV<'M
M2BK-1]-/VZ:,+8$V7^R$F_A90X'2-E^6?_GJL.>J3OIOW?SD=]=(@M$Z?T3-
MK:;ZSU`X<'<RFM=Q5E5Y&2"#E<0$CEA9DXL[]JH0QR^#G3\B*8B,67,2>84P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P*^_N`Z3VMN;8.N/4)QI,OF'173Z$=)=`;-@#MI%/F3E=P_3:76W
MVN-(DY<MW-[B3JQT>!_LB9-4ZB9A.!`RI>S5;5?.FN>W>B-5>OS1T.@S]3'J
M4>QL+MMNWC[(V@NFNPZZJZ?&UJZ?&5:L)*"UG//RV29%%T\1<2[[X"4H%3$&
M6<9XFEJ\A"ID(F0H%(F4I"%#]A2E`"E*'^H`!D;?U@,!@0Y^V_A"U]!U/7O6
MO-+US6.[>)Y!SM/G6:9?IQ&=\3C/]GV+3%T"0=1S=Y4KPQ241^*K@$T5S^1(
M<#F+EB7..-H7[/U'$::LFC/X@#EF#D6FC-JFK?.GMQY[9IHQPZXF&=I0JDMN
M.9IL,L\DS;4UQ:7A4U2HLUE'T<9N=10B:ZJ@L=*F?]II<#I%TK&QZ=5M@4J8
M:6"H72`B;169QB?[C.6@IMDC(QC]N80`?M.FC@AP`0`0\^!`!R-.TX#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8%-WE:D]$I;[]NG-+6QU.I^WS<FU'[FI="[_E)LE>GN'K1-)LXJ3YN,QB&
MUG63UC3WBIDXQDW+&C--TSK'2(F8^7^&=YG59RXDX_U?PMS9KCG'5;1,\93H
MI-:TVU=JFC8=E[`D4TE[ELJXO/FN[E;1;I<#N%UG"SA4B?VT`4%-$@!%DQ,-
ML,*8#`8#`A8V/QQI+BG:7=?;=JV97ZKQ1T-I.Q6?L[FVRT:#F:K:-@UR"5BV
MFPZ@Z,+<L=(6"MK.F+Z&_%<A-R3LJGU7.&7^4U<]'5OX>+5FXM5^NFKL]CN;
M4QUS;MB7^]\NT._(D&^ZXYHM,P:2UA7;5()3<TB\</HY4TDV1(#8(]F]2:_:
M#[/D53UF)A.AD:,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@0;>Y'CO:5FAM>>PWC0'$'W+Q"=]=JK^@,57$O
MO+4#9NZ<;!Y\EV[<Z19:-M\:HK]A%?Y)`K\BB`@?QA+,I#N%>R-8]Z<PZRZ7
MU8\:?I=VAT"6>M)2"<A(Z\OS%NW+<==6)0B3<R-AJ,JL+=P0R9#"'Q.`?$Y1
M$2RS,TV[PI@,!@>!$``1$0``#R(C]```_:(C_4`,"N5O643]Q7?C3C^LH*RW
M`_`%^J^P>N[25.(=US=_2T.=M8-;:!BW)OST;+08!@=9:U)$,":JQOQE`*=$
MHC=>6;S<=%B]JU:L6S=DR;(,V;1!)LT:-44V[9JV0(5)!NW02*1)%!%(H%(0
MH`4I0``#QD:>_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`_DQ2G*8ARE.0Y1*<A@`Q3%,'@Q3%'R!BF`?`@
M/[<"L-=D2^C_`-D!]MH&6KGK#]CE\(RVNDD'Z;K;E'K.79MVT/<4HQF5R2/@
M=RO8_P`R+U46[5LNLL<P%3;I@&N+Y9O%XU5G=%9)PDDN@HFL@NF19%9(Y5$E
M4E"@=-1-0HB4Z:A#`("`B`@.9:>S`8#`AN]Q/==VYGU13^>>:&BUK[?[#FC:
MBYZJ\*FA-35//-$.SGMSS590.I,+TZ@LSG56<)(G3(X^`"/T$!L2W'FMG_6_
MPG0_7GR[4M$514L[;GKQYL#=^Q5E7#J4VMNZV(M%]@7^3=NDF[A3]5D6Y4VI
M!32!%FBD42`?YB9;DDQ&^613`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&N76G+NJNS>>MH<W;EAF\M2-G
M5>3@%W)F,<]DZS*N6BR<+<JT:4:/6K"TU61.1['N?MF%%RD4?J'D!)9F850Z
M_P!;4W3VI+%ZL/:YVYT[Q9NSBG8$+$:NZ*YPG;X>U]/Z&<P*+_6EOL]LA:%M
MX/U!Q"/2)R3!R"*GS334'X'$Z2=O=);U=1_IG]1?_P!1![:/]W.T?_A,P9A_
M3/ZB_P#ZB#VT?[N=H_\`PF8,QV>E=4^H_4ENKNTT??+[0]H+ZZDT;DAK>YVO
M9\I4[VM`D4?IU2Q1A^7X9)_%39DOL*)'=MR&^8?)0@?O`7A)AZC=';<ZCW?M
M+W']@5.:K.R-UA-4GC74]T9K(37/'*H.3IPY6:0$BB(2&SFQA>N#NHY&1,@K
;_+&$#E`%[))SFK$&1HP&`P&`P&`P&`P&!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g21538g83j58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21538g83j58.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-=6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YL<&%V86QA;6%N:3PO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\
M+V1C.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2`R,34S.%]%6$)?0U927R!%>&5C=71I;VXN9&]C/"]R9&8Z;&D^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QX;7!2:6=H=',Z57-A9V54
M97)M<SX*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<%)I9VAT<SI5<V%G
M951E<FUS/@H@("`\27!T8S1X;7!#;W)E.D-R96%T;W)#;VYT86-T26YF;PH@
M("`@27!T8S1X;7!#;W)E.D-I061R17AT861R/2(B"B`@("!)<'1C-'AM<$-O
M<F4Z0VE!9')#:71Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')296=I;VX]
M(B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E!C;V1E/2(B"B`@("!)<'1C-'AM
M<$-O<F4Z0VE!9')#=')Y/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE496Q7;W)K
M/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE%;6%I;%=O<FL](B(*("`@($EP=&,T
M>&UP0V]R93I#:55R;%=O<FL](B(O/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H\/WAP86-K970@96YD/2)W(C\^_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`N`%O
M`P$1``(1`0,1`?_$`*D``0`!!`,!`0`````````````(`P<)"@($!@$%`0$!
M`0$``````````````````0(#$```!@("`0,#`04%`P4)$0`!`@,$!08'"``1
M$B$3"3$B%$%183(5%G$C%Q@*@9%"L3,DMSCPH9;66-@967G!T5)B@C0EU2:7
MIRAH>)@YF1$!``("`00!`P0#`0````````$1(3%!46%Q`A*!D;'PH2(RP=%"
M<O_:``P#`0`"$0,1`#\`W^.`X#@.`X%F9S+M0B,Z4?!;]Q.%O5ZQGD;*E?00
M9`:MFJ>+;)C6N6H9)\"X'1F?YKD^*%HF"1_<1*N(&+XB!ZG*[S94RR9C'(<A
MB*JI#YD`GG[2AB`H0`.?M-0"]E$>A$!^@?3D5V.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&/R__`/\`
M:'J[^[23<_K_`.^?2KCA/^H\3_AD"``#Z``>HCZ>GJ/J(_VB/"OO`<#I+KBD
MNF4I!44.0?!(IO`RG1R@<?(W27BD4WD/8]_[^5&O$ZW)^3_Y`LR9\JGQA_Y;
M,*ZSZZ9(<8S:[;9_A[#E*$V)OL$W,QO=;QG7Z@HLS"O4Z9.(*RY51`JZ/XJ@
M`H8Q2PVD'\9N\.S>0LLYZT/^0FLTRD;P:Y-HZZ-YZBF1CL?;(X"N,U+LZEF_
M&%9.Z</VL9#R#(D9,`801;.E44C"5S^2DE4\LT**ON"IT<AO$P!T4!`Q.R%-
MXJ`/T./??7[!XG"PK<BG`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<"&&7MI)W`%]ED,L84R*&"'1H5.O[`XOCI#*L'`N9*/1
M"0C,NX_K;13)U((RF2O%SS<?$R]3CH1`CR5F(PYC-TZFI2.QUDJAY5J\7>,:
M7JH9%H\^Q;OZW;:/9(*U5J<BU1620EH:?@9.4C92/?JMU/95(H)3>T;H1Z[X
M+0\OWI\H6KH?_HDW/_W?XSZ5=?41_3CA/^H\3_AD$Y&C@.!TG!BE63$$O<4`
M`/WYF*4I"";U$0`2%\0.8?N\0']H\J-3_4+='$_P22.R.DOR$0F6,28C3V1R
M;F?6G<AQB>Z6G#NQ<!FN46O\C5V9L:1=["L9!HB2B@.8PR[@YV:!G"X,S"F@
MH9NL2D]\=07_`'@^3_9SY7O\(\IX(UU'6;'^F&M2&7*<XK=FV4HR5Q<9@E]@
M(N#EW$?8*?373MY'!!@K'O&TO%R!5P<IKIN&J+CN1,S-\-BA$I2B?Q`>A$!$
MX]"*IN@`5/,HB`_3KKH.NOIUPU"OR*<!P'`<!P'`<!P'`<!P'`<!P'`ZBAA]
MP")&.!S>X80[*(%Z+U[IR'.!S(^71?L_XAY4=-!V18JQT5R*E0$"*^R=/MN!
M3!_<+F.X4(19J7L50-XGZ$/3].*/#DF^1&079@Y0!5)!)86IEV_Y!DUC"`/0
M3!P=P1L=0!3+Y)E*)RCXB(<#XZ>LVRHE</FJ'2)E/;7>(H*`4P"`*%(94@G*
M(CT(F$"]_3CCN.^@J58ISE'R+[@E[[#KLH%`2^/8F(8@^ABFZ$#`/IR*K\!P
M'`<!P'`<!P'`<!P'`<!P'`X'3(J0Z2A"*)J%,11,Y0.0Y#@)3D.0P"4Q3%'H
M0'T$.!!?(&CM(<7*RY7UWMURU*S?:I,)BV9!PE_(T(+(TM[+9HO)YFQ!9HZ=
MQ%ER56@VHQC.6GH1]-0S153^5NF*WBL6LS&<,?(;*9#QY\C6.YC<$<30]8PA
MKYE;!]KV!PF7)4GC)SDK8G(&"+_0X*^T1W`W%?7([6I8HDEW*\U;9IBFR:_S
M&2>1*#N.17%YRSU-E07;I+E.10BY"K)G34352%-4`.F*:J7V*I^!@\3!Z&#U
MY&E?@.!\Z#OOH.^NN^O7H?J']@\#$9\C"*2^R>@J:Z2:R9FF^GDFJ0JA![TJ
MR04>R'`Q?4IA#^P1_;RLSN$L/CR`!T#T;.(`)S:>:R^1A#U'K"]*$.Q^H]"(
MCQ.SU_K'A,/H/KT'?77^S]G]G(T^\!P+&YZV4PAK%`4RT9VR!&8\@LAY/I>&
M:9(2C.8>IS^3<A.732G5)J2&CI)9)].+LE0346*FW)[8^XH0.NP_=S/F7&VO
MV++YFO,-J;T3%^,*[(VV]6^0:R+UE7:U%I@=_+.6,*TDI1X@@0>_!!!58?\`
MA((\J6]+1;G6\BU"IY!ILNC/TV]UF#N-0G&X.$FTQ6+/$L9R`E6R+M!J\!O)
MQ+U)<GOIIKE`_1B@/8`+>PY%.`X#@.`X#@.`X#@.!P]LGEY^!?/H0\O$/+H1
M*(AWUWT(E`?]G`TKOC@^6#$&C^2?E=Q+DW`^[67YB9^6W<JY,)_7G7:SYJI<
M;!/[##P+.NOK%'2[9K&33-:"65/'"3I)NND</13TTY^LSGR\YCGY0X4-VOG4
M^1+%.+\W5EIC#XY-<9>K8XSQ2E\09`)9JU_,:]%R<A5K$VL96$.29=)O$#JH
M.$7K8##X"53KD:[PFUBK_3[:X;EZKT#,^]&9]B]DMU,\8D@[X^VMD\V9&K4_
MC9[D.#)=*?5L:XYCK,KCB+IF+G5@4&+CWD:[0%050\"H&1;-Q4;Y9`/@XV0S
M%G#5S+6*M@+I)Y9S%H[MAG;2*Z9RER,FC_.2F#YQDE`Y)>1#1'WXJ0?U:=8L
MW8.W4B_>.V2CQR[66<G-Q)ZZ9G>1HX#@.`X#@.`X#@.`X#@.`X#@.!"'/N7<
M@SN3V&IV`)EK`9:MU+<7^[9/>L&\Q&8'Q4A+-*^XL;2(4`[>RY.LD@^!O78A
MT9)`#`=\OY-6RI35)M?W%>"L98BQDABBIUU%>IJI31K&6Q'_`*DD[W+V=59Q
M<K)?Y.5(LO<+%<G[A5>3=/`.9T=42B4J8%3+"$,U]2<BZMKFFM`I]A!U\I?*
M8U4RQ:K/)X'D6#APO(R+C%2A3R,QB/(,C)B[<"Z`Z\1)/)`1?)D203ZOE*K3
M'NWV_P#E%^1[)6:X;XX)77S5_7+7R^EQR.T&98)SF]+/N2(.,29Y)I5!K<2D
MWB$*YC^Q.%$5IE$W]\Z:@D`=*&`@RD'\:6ZVTMPS#GG0/Y#H:H0VZ^M\1'9%
MA;ICY1M$4G:/7:ZV.3C:[FBCT]NF4T*A6I)DC$RB8"!$W:Z2/0+^_P!,*DL?
M.N_N32+(XCU'I.((AVHK*US)&T&4BG:25:3,`-&%BP_B]FMDJBW.;;+IK"U>
M*JIQ9DE4G`F4\`%27-+0WCX\M@\V24':\\;WV^P7W'\=>)#!<ICO#..<>1.(
M[CDBI2U&MR\@S8NES9EIRU-G7$:,18")H.$@*NH?\@`$!,<R]GA/,5NTLIN(
M-7-C\66&N8UQE4J3A+&NV-541LN%K)7*/"1=+J4_F%P0$9#`DU+-R1$<8LN"
MS"0G'#@S99-FF4_!K'#)C!RT=.13&7AY)G,1,DT0?Q<M'/$)".DX]VF"[-^P
M?M%%FKYFZ0.!TUDCF34((&*(@(<C4/UN!Q,;QZ]!'L>O0.^N@$1[_M`/3]_`
MUMO]2S8;"&I.JX8R;5RVY*K/RFZ6FKE3E+`G'L%[N+NW2U.KMM>MO>>5QC//
M'#43JB0%$F2Y5BE,7H1K,VBA\K><?G*GOCAW5A,_Z*:84#"TC@2\M,CW2C[2
M3]KM];J:K0H2,S7JVXKS1&<DVB0^23=0Z0*#Z?\`Q1&6R'H9ZZ/Z7='Z$VJ&
MNIQ(!0'L@8=IY?\`Y/WF^H?L`."-1?1+?D:.`X#@.`X#@.`X#@.!USG,4_?D
M'1?7P#L1$!$._0/N,?P[Z`/3EI,L1GQ.:B9LU'2^0=+,S"NQH['?)'LMM)C$
M:]94;#^7B?*RU:4J#R8%N@W"'G5QB%??9*>1D^@[$>^)9B*6EE/C3MN6?D4^
M3O*&;ZU5)?5/=G3C!.O,`89AE*3;N:IT4]96M:4JAR)*QPP+M9-VQ554\%E4
MB"40'OQ-(=2,M\SGQK:[-<!6/*VBMVP+CNGR=<I_R'[`Y*?8_NF*L;Q<<^2@
MU;'A9PU,&6+3A^IQ1'8)-EC'F"E(@4#>V8YB:2K_`-.Y<]9+EH/+2VMF3+?G
M.=5SMDV9V>SS>,</L;6K-6S]T2A,@Y'O#F!?K+.7K8T?:HQ@P<J"151DS2*J
M4%B'[$,]20]E\O(3"8"B/[`^T.N@^@=AZCU^O(TJ\"DH)@\0+]3=@)NP^POH
M(GZ-]I@#_?Z\(Q)?(COGFS">4M?-.M,<;4_,VY.S*T_*QT-<)]S%53".&H%$
M[*=S_D%NQ;KR#JL0\PY(BV3)_<NG391N/9SD*-2_N@E-[2?+7\:68L'W3Y'L
MIZ[;0:/9AN<!A?(N8\.XY)A1WJ[=KM8F$+1\C7I&1,X-,TB1?+_B.S=E23.J
M!4P!<4@4%TV543JG.(F_YL"`4INO^<,`_P#.@(?:)5"^H=?H/K^G$J[7(IP'
M`<!P'`<!P'`CEL!D3*5695NF83I+FV97R0ZEXJLS4Y'2B>)<;LHQ-JO.7_+%
MG9-3I,8N"9/2GCH=$X2EB>]-FH`D5V[:6DN7>P!@.LX2K,B5&6F+SD*[/RV+
M*N7;85$+QD^U>VHB$M.K-4FZ+&(BVZIFT/$MRE80[#Q1;E]5%%81$+_\*_,>
M'$%T.C>B2A#F**8K$,!BJ@/GT'34"%+W[PCT7Z"`]\J-4_57<*B?`_*[+Z?[
MZT;-E$P1([(Y*S3K)N/$X?O60\8Y\CLXRI[S,4E=#%\-=_Z5O]%#W?=:**J>
MZR0.LL5HH9%%8SVE)SX]H_)>YOR8;-?+',89RMKO@D^L5&TQU7BLN5=2O6S8
MBA(W!?,TSL,-1E3L+55JT].ZCRP+8S51&6CWON?D)N4'+9(NYML.M"E!(```
M#Q$R8B'0>0E,("<2E*0"G4'U'T^H\2L*H(I`/8$*`_=Z@'7\7\7?7U`1#O\`
MM]>17X]BKE?M<)*UNT0D59*].QC^%G:_/1[68A)R%E&IV,I#S,1()KL):)D6
M2QDG#9=-1%9,P@8H]\)+"?\`(,XR/\66FNX^W.I&0W<;`8WQ<G.U#6+(,'&6
M[`./+9*7NF1S>0Q1$1CVLVK'T0)9^5=O8-1_(1!_S6J,:C%MF(-U:G*\_P`<
MOR3N=[-+K+F*:H:V&MDL0P=AKV>\$VE1(+#CO)<#5CSD;(OJTJNTLL=2[\U]
MN3A32"#-9TP4'Q\@)[IA$WIX#X^\R;&?)_\`%GJGGN_YG?X$R%FEG:+)E2RZ
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M7<Y%.`X#@.`X#@.!^>JL<JJ104Z,8JI@3\3E$XD,'C[@>V?V4A-T43B/0]@`
M!V(=5'?*/D4!]0[`!Z,`E,'8=^H"`"`_NY%?>!P,0AOXB@/7?7[N_J(?L-^_
MZ\#Y[1![[+WV(F]1$?4>NQ#L1Z'T].OI^G+93F)2B`@(`("'0@/J`@/U`0'T
M'OD$.MX])-?=_<`6[778RAM+?3K"V.M`2:`)L[30;81JNA#7:D6`S1TO6;'"
MN%2BFX3(JF=(3I+I*H'42/4EJ9_Z:#$V>_C.^0W>CXP=H8:TQE\M.-J5GC%<
MA'38/\-6VDT6T2U7E\BT5-](LP>+Y!9W&,*59LQ_*3_D;EI(BW<,@0+9<_7$
M_%O%-TR)%,F3[2D-XE)Y"($*`?:!0$`$H"'K_P"[S+H['"NNOZ^V`CUY'Z\1
M+Y`IT`G]OT,7HQ@+Z"(]?7TY826OS\EM?RIJW\@.GWRL47">5=CL98TQ/D35
M/8G'6)*V%AO.+<47V8+?2[`0]?CG#FP6EE5WC=RA)QQ&)$F[1M[QW*8F(!R=
M^$,-T=VL9?.Y4<2Z`_'S2<VY/QU?=@L1V;9W:QYAR[XVQ?K)0L67*-R<NHL7
M*4-2RVS(%J85TYXV((HC^4@4_MG.Y$C<;7),WB&V<W(H#E0QBBFF)!*1$0_A
M\#%2!3R3$4!!9-(HE('0D#]XB`1>7?Y%.!YFYW"K8^JEAO%XLD)3Z=4XE[8+
M/:K)*L8.OUZ#BT#O).8FI>37;,(^,8-$C*+*JJ%*4A1'O@8=:U_J#_B>M>;X
M?7V(VE;KW&Q9`'&E?M:N/LA,\.3=C7?*L(E6(SBZK26)Y&`FW:8)L)1.6%A(
M"JG[*AO<)W6?E'5D9K^VV#[-M'>=-(BU.G6P>-\25G-]OJ'].V!*/CL=6^9&
M!@IA.TJQY*T[>.Y$/$623HSM,H@<Q`)]W%+?#ADK;G!N),_Z\:QWJU/(K,VT
M[7)CS"E90KL[(LK,AB&O,K3??S;$P8.:_7SQ,,^343%^Y;`Z$_@CYG`0XX)F
MIKE)KD4X#@4RI)E$X@4!%3OS$WW&,!A$?$1-V/@'?H7Z`'TX',I0*4"E#HI0
MZ`/V`'T`._T#@?>!3,D0QO(P"8?MZ`3&$H"01$IBE[\2F[-]0#L0]/IP."K9
MLL!`6;H*@F)A("J2:@$$P"4PD`Q1`HF*(@/7U`>!S!%("%3!),$RD!,I`(4"
M%3```$RE```I```#H/3H.!R*4"@(!WZF,;U,)O4PB80#R$>@`1]`^@!Z!P.7
M`==\#"M_J)Q`OPM;^@'V^6)H$QC`'J(AE''Y0`1$HE$#`;KU$!Z^@#^E24)-
MW=:,BZWX]Q/\P.GE)R%E+-]+T_Q_AW:?6BMV6>+`[*:WR6+V$$:;"*92XIQ6
M0\#HR8SD69M%3:+PC<Q31QUP*X(3PEU_IM?`WPG:'"7P\BT3(I1\!`!-WG/*
M0#[I2^AA`Q!Z$?7Z^GZBE89R>@`>_7O]XB/Z]^@"/0<BN($*'T#KOH/J/T#O
MH/K]/7@?0(4![`H=]]]_J(]`7R$?J)O$.N_KP/BAA(03%+Y"'71?("^7J'H`
MCZ>0_IWT`C^H?7@8==W_`)$,_P".]@L>:(:(Z_UW8K<;*..Y;(\O-Y#N8UC`
M^L%%2=J1<%D3/KBMM)"YN(^8E$1*WAFZ46]DD1\V3A93I`U_#-SKE8W7CY$?
MD/PSN=C/3_Y9,$:ZT./V?C7376#9/4^?N#K!CS*E<CI68L.#<DR&6IP)>/R!
M/1#5-2#322;*OG8IM6K=][RR[)70B9Y9_P#D:.`X#@.!"#=Q7(M#H=2V*QTY
MO4LZUEOJ.6[QBNH*3,BCF3#ZD)*U#,504H\)XOL@W&'QO8)&9IL4=RT:'N<;
M&*+F%$ARC<,Y2[KMGA;;!PEIK$Q&3]:LT=&S=>G(5\WF8>9AY=BG(QDC&2<<
M99B[CG\<JFNDX25514*H'@<Q1`1+X>B)_"7[A/Z?Q#UV;]_H`!R*Y<!P'`\Q
M:;-7:9!SUMNL]`U6G5R)=3-BL]GEXR$KT!"Q[=9U*2DY,2RS&.AXQF@G[BSA
MPL")"%$QA*`"/*C!=LKA!W\@^QNMFT.G^/"8LR7J[=GCV@_)#>T($:?;\>KH
MST;8\>T[$"(N+3M)A"UK.Y5@NM)R6/4HLKM.=JLM(MW1E'!G>83C#.F_.,7H
MEROI]3\STV%,>'5N^IN86*V1[[('$J$=;8_7'-L51ZYCRJO13.J\9+97GWT0
M44R$4DQ,8Y&%_E#]*&^2[61.;3J66Y#(6LER9E72ML3LABZZ8UIU%E$D0<)0
M=EV!/'2>KJDF]142_#&-O$D@_76*V;**.?)(JCY);PF6\86O'9<NU7)N/K)B
M8K"8GU,I0=TK<OCS^GH`\@G.S(7B-DE:P6)A%8UP1VY!R=)J+=0%1*)#B4MV
MQ.:O9ESWM3\A>2LHQD]<<=ZSXHQ8^QP]Q0]*5:H9!;VZPJ7+!F0[!5[0QC;3
M3LI7;'KQ"\)2+9FR30JT^Q@)-L=^Q4=G)&V9QHS;)&<@DDV(1<4U%2-T"HE.
M<0'^]4%,I2KF6*`"(_NZ^G"OTO$.Q-UT(AT(A^H?IW^WK]/V<BOO`X',)0]"
MF,(B`?;UV'8]>0^7_"7]?J/7Z#P-?#_4923Z1U1U?Q?/BH77W-WR#:EXRV]*
MY27C:H&M<I=3REN+>\A(H)*XMJI[/&PQ5ILKV*62.8B15P!4Q#W#'M=8ZIF_
M(?K;I_.?&1L%AS)^-,01VM^-]<K2_HL'(DB:A2<=FQU19)3%TI3Y5NO%%IKJ
MM2I&Z<:[9N4!'WO:*8Q')TSEG79JH:#7CY8+-NWC&VZJ5O6>P[+V'X5=-W&;
MVNZ[+)E`ARU9G?YQE6)&&A,3QT2\;6Q=BSBSD_);(M5F"AEP`RBA3&83-XTE
M!G>8^8=]\NWQ7J[8T_X_8K.C/$GR1'U$8X*G,Y/,;RN2B:S.A:-L]N+J/\^9
M5$]O1@4E#09??_ERCTP?WH)=7%)_+Y1;=4YET.`X#@.`X#@.`X#@.`X'XL]&
MQ\O'JQTHRCY%@\Z0=1\JS;2$<^2,8IQ:.FCM-5NJ10R8"'D40`Y0Y826%G='
M2771SG"NY"AL?_&M5K9?9-:U7Z7VS1N[7(MSL:,Q$MTY:DFK62J<P<I)-$P0
M5]ULX*#L4B]>'9!6DQ?1FJAXR,B&B;"'C643&-?-%DPC6C9BR;I^X914$&;5
M%!%L!W!S")0*'9@$WU$>1I^MP'`<#KN@,9NL4@`)C$$H`8/(H^7H/F'U$G0_
M=UZ]?3UX26M-GW*M?^,WYH;3N=L-&6E+5/>+5S'6%WF=H.L2KZC:]9!P=*J.
MBH9:=,$I)RU@+7&F!RG)BFV08IF*50J@>9BU%O\`9G:##?S!;M?&=@71B7F,
MQX_UFVTJ&]N=]HZQ5YJ0P938/!L+.HQN+%+`^:PI92^W>8L#1F!4#G_DYW3=
M19)4BIO:&YAM0\C1P'`<!P.HHR;*@Y*JD"J;M,Z2Z2@B9)1-4@IJE$@_;TL0
M>C?M``_9P,>NO"B^M^=;OI0]_)0Q0YIK/,.F:+A7_H4%BZ#"'J^2]?J\4RCJ
M8D&6"K@+&1:^9B-8ZM7&'BF:?M,!`*C(DGY`0@&$3&\0[,("`B/7KV`@`A_N
MY#+E_P!WZ_\`O<%J!S*^\4H`8J?B'W@`&*8PCV(#]HB02`3ZCT`^?[0X5##,
MFZ]'HUG4PYB&/2V)V;=M7IX+!5)GFK%5)Q%NC-)A;(^0?Y?*4_%$5!J`7\Y6
M44,]1!1/P9*@<!Y:2WB:CJID'*5CB<J;EY.G\D2+*39W"K:TUQ9K":\8JE$%
M&TE&P$I78DC4V>)JJ2;%J\9S5H!XHVDD%5&946RI$2$YRGU'Q;./9M&;=LV;
MMV+5-DT0:()-FC5HFFBF5JS;(E*DV9IE1*0B10`I"%`H`!0`.%=X4$A$!\0#
MQ#H`#T#H0\1#H/3H2^@\BOSIF`@K''J1%AAHJ>BECHJ*QDU'M)6/5.W4(LW.
MHR?(KMCG053*8@B41*8`$.AX$!<X?%GHGG)S>IJVX%@*_<<EPDA5[;DO&TA+
M8VO_`/3\Q6QI\\P8V:J/HQQ$L[%33+0T@5N5/\F.=K)'[!0P\K,^L;1]^)_'
M%NU#@<K:&9JR$[RIG;'ELG,^#EB66=A*9NQGG.>?3$/>&B$L\D9E./HL^1Q3
M'*CU<ZBCR&.9(B;?VPX7LS%@J;K_`)HWI[8=%Z$/NZ`WB(=>14OU'@4#KKE.
M4`3Z)V<RAA\1(5,.Q(/O=@0@"0OD;L!Z\@#C!ER17,JIX]'`"BH0?(I1*84S
M=`J4Y!Z\3]_K_NXH=E00`@]@(@/0"`!WZ#Z>H?L_;R*TK/GV^6F7)NYB'XI,
M8X'B-S,77:*9U?<S7!..1?6/*5@R:YA)/'>/Z-9VC$EGQGE'&$4U;6UA*M''
MX:*\A'K+B5-LKU:8GVJ:9-XGX!\5VA&!Q]GC;G=3.&GL*6&D:'H=D[++IWAS
M'R-8%DZH%3<2T6NC;[;&X]8%.P2;R3Q="03$?R/<$`'A:9'<::$8XQ9O5D/>
M"JV2=83-]U@QGJTWQ,C%PK*@U6E8SFTIFOOZ\=L@27!V0K<C06ZAA;HI>A?H
M``7O#]'-^CE,SCN1I;N5,W>UPUPTL9Y\94^EQ36(6K5P2SY2F--FU;6\>MU)
M=JG`M(SW&0LU$P.J?I3R+Z<O*;\IX\RT<!P'`<!P'`<!P'`<!P.LX\!`I3E`
M0^XX>1>TP,3H0$QA$"EZ`1$._P"T/4.6$E#;-6#5,H;#8+L]@HF+<EXK@H"_
MQ%TB+QA+%%YF*S-.&24Y1;*RR'=["C<ZU'_SMB1L6-@863%TY,1=THV33]SA
M,)D(*>XHH/CUUT!A#S$@F[,'13&`"F\0#H?'T`>PX6.KM<BG`<#X(`(=#W]0
M'T$0^@@(?3]X<"S6P#!@I@;,Z3N/C)-JGBJ^.!CIN+CIZ*<*L*O*O6OY\3--
M7\=)HI.42']IRDJD;Q`#%$/3A)8XOA>NDY==;L@N9\8<JD?D_&9FC:"J55IL
M8U/:]+-2LASZA(NG0<!#+.IBZW24D5U?9.K[KT2B8"%3(2IZS;,'R-'`<!P'
M`ZJBQB#X>9/(2&.`_:!@*!RE,KX"8"BFEYAY>O8\M);$QG+&D=OIL7DB@RE:
M8V7$6H='D*LW82%QN%`C,@;=Y/K<!=VM5GK?CY6%R97JEB>@%KJZ[Z$7D(N6
M4MKUNX;J/81,A"5$H:I_%-F84R"?4G1D#B4HG`OR`?)>!0-U]P%[J8#T`_3O
MBV?CVC]W/_T4V9?_`"2M&O\`_0#Y+O\`Q4XL^/;\O%96^/Q/!^"]A\K9CUJU
M@KR]-PA>7N'/\--Q]^LA3%DV)<M$(K!=&D:O>W^.HF7BKOD.491*3=&2*\>2
M3UJT1()U_(JUJ.=?5G+T[U^I&N.OV-*#4*PM7WZ=(J"UTDII%%>^6NVDKD<C
M)SF1[&JW3F[;<2JD%NX?R:CAZ<$@*HH;Q[Y&HA)SV$^NO7KQ$OU]1['^(3?Q
M^0=B'U^@CPJH4H%]`[Z].@_0H``!T'[O3_?P.7`<#@<@*$.F;^$Y3$'T`?0P
M"`^A@$H^@_J`AP(%[GTJR5"1Q?N+C9BB\MVL;BQR63(8I_;?7[6>8BE767:O
M&MRKQ[>8N$`VBT9>NIO7(-FSA%V5%,[AT4IB4ES1;?6LE4JI9!J#Q>3JM]J]
M:NE8DSMW3`[Z"L<6VFH1PM&O4VSZ/4=,'B9E45TTE"'$2'*4X"`5&C-\D^[N
M]N^7SP8/U,^*&WN6,MHX]E8ZS7%K((N\3*6A\^AF^>K1F,T1-R$-9\1T-@LQ
MJKJ.?,R23>>(_9M`_+=-AY=0S=^U1J&]Y%&D21T<E)"U_F9&K4LLNT;JMV*\
M@"!"/E6"+@053:G>>0D*<?,$^OKR-HM;M;=TG275C,&RF2#%298ZJTDZ@8!)
MW&DD[I>71#,*/C^N!)/XUC)6VYV)9NT8L@6*9=94"%'L?0,-7P.?%K?<&HY+
M^0[?>DQ;KY&MN+O<,DRJLF]DI:5P5CF_';2J./6$-**/D*)9GC@RH/VZ+ERM
M'116,291$S5R@9*>L?=LH"BD/U(4?X1[$`$P^("!1\A[-V4!]![[#D:<O;)V
M`^(=@`E[Z[-XC]0\A^[H>OV\#C[*8&$WB'9NA'T^O7CUZ_4``"_0/3]W'Y2E
M7A3@.`X#@.`X#@.`X#@<3&`O78@'8]!WWUWV'0"/T`3=]!^_@11SCM)7L63<
M+C"NUVP91V`NS!VOCO$M,AIV6_*(NJXCX>R90ML?%O:Q@O'#B1:.?<L%I69-
MG`1CUO%DDY!(C)6LS/'*R9-6]DLM@ID[,>UV4\,Y=.F@XJ>.]9YRI/\`!^$C
MIG!-W%Q"N1L2FG<Z.['$@9C-2]GCVR#A!45X2*K[TI70#-*G^8[936X7B&VV
M'PR9CUB**1-F-1J7;[8W214(*@OLGZJH.KEFRBB\F)1M&1:%/=9/15(BYD)-
MU$-P$A5%S&TT<=Y<QGE^F160L37^E9.I,VLZ:1-JH=GA;17I!['/%X^59M)J
M)>N8]5Y%/6JR+E#S!9!9!1,Y2G*8H&EQ2F\O4/4O]@@/]H]]#T/Z?MY$<53"
M1,Q@$H>(=B8XB!2E#^(P]`/?B7UZ_7A5ILLYUQ3@FK?UOF"\5S'M65>MX6,D
MK%*-VR]DM#]J[=P],IT2F9:5N=VL";%4D;#1:+J3DUP*BT066,"?*EUM"R7E
M]JMV("=B**D75#5:^0C^#;Y'MU3EG.W.2ZA/Q[B%FG=4PW?H.'K^LR[A)<R\
M1)7-K9ID4O).1JL<KX'XPF9A;+"^A64_CVK,A":"9":9&Q_.2\18K'KOMM=)
MYXC,62!H5)Q@G+XXV-@(.QWC'(*0-.;OI)A,5RY-'SADBRC_`.0LN_&^2(K2
M:N%]LJ+EBQOL86**E<(;"P[%>6F];LO2U'89>:5U$6(IW>&CZ9;KK6KSCUZA
M)MA3G*_)RD<W=*F8.U6LDW=,T(L2D[^3ZE#KOS`QBAT!3`4/M#L#J%.`&-]!
M$H!^WKBBWQ-V"AB%#Q^[O[@$QBB;Q4'P()`,F<Z8I&`X`<?$0_?P6[G(IP(P
M;*9X4PC3&!JS#IW;*^2KG6\2X<Q\262CE;)D*W/RQS-Z^_&83LRTIE$9.U;!
M;'[&+E'$-68UY("T6(@8@UF9J'[.L&`F.N.#J;BDLV-IL3$DU9LCWPK%2(5R
M/F"_SK^\Y=R@O!F?R;6!=Y#R5.R4T>/;J?A,#O10;$(@F1,JUK%)"@'0!^O[
MQZ[']X]``=CR%0^\%0QS[G-U,IYQTXU;0,`P]\R3-[&9=BI4ZC:N6_#6J25?
MER5=*08^],,[@TV`R+CR?CTT"-4';:"=INGA4@!JZO"3ND_I":80S%Y*S+]A
M%1,>T>2#^2DGC5FQ8Q\>BH\?RCIXY<IMVT8Q:)F4654,0B)"B8P@4.,+<_1K
M.VW_`%46A".^>#=1\6+FRIB/(U@4H>2-L6\XA2L;XMR!*3:E=K;-LVO+"!:W
M"DM))/W)NPIR#2.:LE$UV!I,IQ\5)\HNFSJV4.JB0ZGM^?71P3,4X`/[!$IC
M%`PAT(@`F`!'H!$/48TK\!P'`H.#&(4#D`3'*(^)?/Q*8?$1\3_:<1*/7_"4
MQOV!RPDM:3<[?:+^&#7K<+##I[%C8WL1)9-^.*J2:\6@$VUS;8BUJ=H"4>I:
MH";<U;7[,EG2D962>S7]0.8N=4=-VGX<<(EJ3-12.GP<XXURT!P>6PFQYFG<
MWY+-B6KVT9MRCAJB7+-53N,E/S;RUN\:8PW3MT'3-3%H>M,5!>6ER&0S-)*Y
M-)!N>1?.V[!N4S&.K.HC-?))EM5W(U^L:V:>51J8TM5PR<WL^UF4[)&RA0_&
MK>3L?T&V8-I&([5`IE*I)*0EYOS%RL<R""_MIE=JQK/B'AKU\;KK)E;6D\I;
M(Y)V*RS#2D5:Z,&P$90[-KO7)V*D6UA=4N4UVJ%.J5"N6-YF?03*DM8B3=VK
M[,J9XF?:NDQ<*"DR,"YS1RRE8*S9ZXKC;.&-7$?%9EQ)(O/Y@YK,M(M5E(JR
MU2>_"CT[]BFYHLU5JY9$$$DGZ"*K9RDQEF4G&,BI%<BG`<!P'`<!P'`<!P'`
MQK_+MNM??CP^/O/6WN,ZA4KU=,3DQZ,-6;R:8+5I$UQRA3**\&5_D$A%2W@U
M86559+VG!!]\A/+LGD'+$6S[346Q79I^2+YPM)\;QVU.X^E6D=AU*J$M5WN<
MW&M&6<ES.8JECFQJ$8N;G"1=Y<M(!P2OOG[7WTC%<'5,H5(I2%4,Y0%RDG8?
MF^P[B+>3.N&MDKEB7!VJF/M3-;M@:%EJW*6-K?[%:<_2R#5G6)&#9/9@LBS0
M8/$U`3CHPRS/P.HX6%+LQ5+:1M-VER%\A\(K.Z.Y#KV/=5E%5V1=X8-]5+W<
M[-88`R"D_3\2X+NU5F(6&2+(.6S9:PVM!5;V47Z#:(3448R8J293@P+KIA_7
M>OS,1BNHLX%[<);^J<AVA<RLA>,F79PT09R=\R5:WRKJ<N%XF_QP4?2#U=9=
M=<3&,;L1X(B.%\DT`3(!?,QO4PB(^(>7E]?("@`#Z<C3Z""8&`_71@*!.RB)
M0$I1[(4Q2]%,!`]`[^@"/[1X$*<KZ@JNK5+9<URR_<-9,M2IXES8U*L9I,8>
MR6M#-VC5NWR?AF=3=T:3E)QG$1L4[LS!JQM[>%:`T82;4![Y;2N86W+N?E'7
MQ4(;>G#+JC0:+M",:;/8.96'(^O\ZHJHTCFDC;*F@68RMA-[8YUT*3**7+:&
MC5N7WWDN@3R\6T\JLEN->]A74G2M%*8TM?X$H[BYO9O,=3MT=K)7'\([60E*
M_`-F$K4LC99MCMQ^$FT/$)M(`&4F241E7J+8[1<7>EV\-ZDL*7:"Y4R]E/(.
MS&;AC7$4AD7*Z\02(JT:\=M%G+3&&)JQ&PF*L3FDF<1'(2;F!B&+R:&.07D%
M%W`"H*2(SG:7@M43]B<H'$2G`?+U+]X]F-X?P>1OU'KZ!R-*HD`0Z-T;^T`^
M@]>0===?=U_W^!9+-FN6%MAZ\UKV8J%!7-K#RC&Q5J2?MBHV.F6B'2=A`V^E
MV9L*$W5;96W+Q1S&R+-=%RQ=B"R1BJ%`P6TF(Y8N=Q-B<N?&#A.N4_%=KN6Z
M>QNS&;ZKA+1_#&?9Z.!TQD9".2(XA[#E*,BV=YR-`4Q@BI*2<M;9I:P/`/X?
MS$>BAPG"%VP]O^?;0&EEWDR=L7K[NA@;&3Y6_P"S.GM(P=4L,RM+PPYCG\A>
MW6.LQF_-L5G5PN1T51HX<>TXD63#\MRBY'W&BI,QEG'?;RZ\,(3$UO5N0GQ_
MF;77)NUE/R*C%R"U-_P-Q)6L?VZW7"5>@D268)_T[DN->M$?P3K+MP6^PIR`
M0QJUY\7YLQQFJ$E;)BRTQMR@H&WS5#F)*-3D$TF5MK2J3>PP2A'[-DH#R,<+
MD*8Q0.D;O[3#P6AKBQ4NS>WUXS<JT1>8<U-<3F%,"E62,I'V/.4^R(;/.7HE
M!VFXCW(U&JND*?7I^(<@"Z4W9F#HG:0@%\IX9(2]>)?'KKQ#KQ_AZZ]/']W7
MTYEIUE7)B&`H$+WY!V(G]/$3"4H%$"^JIA#^']`Y4L*NMY=&2*(``>0D./91
M\B@8>A+ZE`HB/U[^W]_&"VOCL/\`)UI[J/O!LGEC:C)[MG9,2P.,M2=>M<JY
M!N<DYHM=EGX>EYLRMD+$-3C%2&AT<MLLVTV!=MEA:&DCT(BA7+@Q$FR`[L.V
MP=/^?GY[[$PI#*C2'QG_`!XV2/?N4ALT[(1MBRYBJY22Y8A]DNHQ<T2VWNS,
M8%H@9U6G85R-0$_N@F"WJ))N6331+_2M?&YJA(M;OEB(F]QKXFSBS-O\=&D0
MZQM`2A8)>-L1X3&$4PCZQ*L7LHY,Z8'FT)1[&&11%!P"A3J'7)'K$?1LU))%
M13*F3OQ*``'?Z``=`!0^A2@`=``>@!Z!R-*G`<!P.NN8H"F!@$?,PEZZ$2C]
M!Z,4.P$>P]!$.@']G+",6^3<?4O9_P"2;&%+OE+J^4<8Z:X4>YP_!GH:*D$,
M8;59#M,97L0S;[\PA7<G(R&'RVEU'(>+I@U7;`[,"3U)J?A.64)E&L(YH5A'
MLVK%@F!@18LFZ+1H@50YE5"(MVY$T4RJJG,8W0!Y"81'D:5B-RD*!?(?0A"`
M/10Z\`Z`Q0```G8?H'0<)3X=L0_E]RA?(``1(<2F`0*)0,F8/5(_0^HEZ$>%
M12V4PE;[3+XXSMA0T*UV"P6_EW]<9S+D\#"Y@HLY#OHZWX&O=GC6ZLM%U"V.
M56DHR7`KAK&6B'BY!=J[1;*MEJDZ[KF8*SK4<]U%>QUQO*P,Y`2SNJY#Q]:&
MQ8V[XROD3XEG*5<8D%%2MI..5,!DG")UF,@U.FZ:++MEDE30B;7JX4X#@.`X
M#@.`X#@.!@)_U/0D#X1]SA.(``(X.`IA-T!#GV(Q40IQ]0`/KZ"/Z^G+#'O%
M^M<K0+?!%E38"&QI6-S/E<V[VNUV83--O5OULN%>I51I]\3A(]5Q#5ZP3=2<
MM9Q*#2<N`]Y,/,%TR"42@82J$++SV)M><%7C_4F;8)7#%=&M*>%OCGUF)BYE
M8H5G.,J,5](K4]XG$1DB#F/(96JK?A>2B2AB(&#P$HCV(K[+O?Z=*-CF.!OD
M'81S-E'L8WY?=\&#)C'MT6K1BR;V"CI-6;1J@0C=JV:HHIE2(0@%(0@`4`#H
M.%AL)II^WW]XG[$QA$P!WY&.8X]"`!T4!-T`?H'(JKP'`I+)%73,D?\`A,`@
M/H`^O7H/0@(=E'U#]@@`\&UDMC7%$B<#Y6?9-R-8<28^;TF9&Y9/K,X:NV"B
MUS\80DK#$SA8Z7&,=,41$P*_BN!+V/9#!Z<J3IZK%K2KAC.@-ZC*J6*G'Q]3
MVU7L"R_ON;!5$Z^R)`S"SI%LP254DHHR2QE"(-P.903>VF`@0HC2XP%ZZ_=^
MG[_V_P!O(4Y<*<#B</(AB^OW%,'IT`^H"'H(^@#P,(7S.X#SE<Z[J+MGK7C.
M=SIF#0#9Z#V$B]?HI5HR>Y@K+J-5K%TA8206.#H+'%1"OY,>W:IN%'2W9?:,
M'TK,H);E_+/$_(CK!FW1#0G579;+^UV?J+*8)RC1+WBFZ8HJFL\-D`@8^R+>
M\H9"M44PK"[;&4Q-*,1,R<+-UI`I5#'_``RG4X)Z<LTE4^.3##37K`>!;S)V
MVWML%Z57'1]E8FTI_3+N<QED['&.\;Y)DW;"-]]HTLD[&8U8*-ETS&"/4%3V
M_+R[X6HB*2+QWK%A'%/]-J46CL8)U59FX6:+>M7<D1PI:LA1[*-O=GDR$>D9
MRLU:VT>D+M5=(X>Z`G3!,QA$84BWC9$-8-Q[OAAVL2.P[N,K.9CPB"Z@IM*[
ML)6HD%,X8UC7#M8$O?OU&C6]LA8:.2(W:-ZY/NU>U7(]W1V9(``````.@`.@
M`/0``/T].16&W(^VVP>-=MUL`3TS$+PDMG>J4VJ*,J7%N+Y*XKV>I#IKB;*,
M;!G=E8_T)KEFF"DX&<DCG$TZ*1"J@BJ`E4K/*:N#4-L9-YC&:SS)XY@&[#$E
MX@\DT:OH$D;#-Y<CLBQ491\HP]DC3J0L769S&,<]=2$*F*GX<E,)HE.<K7R%
MX5`?7#2[5/`_R,[&+67`%`?9SRX$WL7A'8.T1RD_>K=1;;88-QE_&9)VT/GK
MF5LN%<IM&D@"S1LBC!5:T5Q@@I_<'X33-61(J@`J)C]G3,`AZ_8)PZ$2>0`8
MI@#T[_9Q*]U=-,$RB4!$?7OL?J/10+V(_J/1?W<BJG`<!P'`H+I%5`I3"`?=
MV!NQ`P#]/L,'71A*(\L)+''\;_ED6K9QVQDU@>RVTN<KS.5A5^B@6RUG#6*)
MJ1Q3C;&4ZX9G,P=$IDK7YYVT%N)DRH3/1CG.!NH1^S)'PIP'`XF]"CZ`/IUT
M(]=]^GCV/T$?IP,:>\2R&`I.E;5XH5*QV#F;OCC#+/'K`X%1VM@K)8DD2XFE
M(D>PDKA6:ZI*3T+*-DU)*/1BW*(>XU44(2IW9)RJF$WJ4`)WXE]>SF$>A`?#
MZE`"C]P#T(#P6K\BG`<!P'`<!P'`<#R%ZQ]0LH5F3I62Z34LATR;*T),U&\U
MR'MM6ERL'K>28A*5Z?9R$1(?@R+1)PC[R)_:63*<O1@`>"<O3%:I))%1;D30
M3(4"I$(F'MIE*4"$*0A1+X%33#Q(!1*!2^@>@`'`\6QQC08N]3F3XRF4Z.R/
M9X9C7+)?V52K[:\3U?B5!6AX.8N"#!.Q2L3$N!\V[9RY602,/9"%'UY;2G8H
M^-\?XS93,=CNCU"B,+'99BYV!G3:U#UEK.V^Q+%<3]JF48=HT+*6.;73*=V^
M<>XY<&*`G.;H.HKVO`<!P.)A$H=@'8_V@``/0]=B(_01]/\`;P('?(R^IS?5
MRSJW^2Q+`UH+'2C.9'..U65-,,?I+'GVR;1)_GC#K!]>8&44==%:,6Z9DI)0
M015Z(8>5F=)`ZY6ZDWK"6*[-CBU4NZTIW2(%G#6C'&0W66J'*#`LQKL@WJ^3
MI)9:;OD;#2<6LT&5?^#Q\HB*JY2KF5("5A?+D4X#@?!#L!#U]0$/0>A]?3T'
M]!X'64:%.'VF$AO<!3L``2F$![,4Y1]3D4'^(.P$1_4.$IR*WZ4]PRBA_M$I
M2&,82$`W8F$H"8?[PQA_B'L0+]H=!WV5V.`X$1=P\,6/,V''P8S>Q<3G?&T]
M&99UZLTL$@C#PF7Z"X";JS.POZXT=60F.[B=F>#M#)F=%Q,5]^]8>X4C@>5F
M;I=#7_-]9V$PU0LPUM!Y#M;E"IKRM7G3,4+10K>Q54B[GC:\QK)[()P&0,=V
MMF\A9V,.J=>,EF+ALKTHD8.*S2VN22L5X;&M<P@X4+6X@TJT:S%BF`V,*XD\
M4DTX$9T4C2)H5.46.Y*U]S\<%SBIX>8B88K]4&GW)&,J<PI`?Q,/?GYG*8@*
M`(F$OD4AQ#H0$![^GTZMI2(VXF&+5D/'#B^8;:F_S+837').!I1D_81$O+V*
M!<,)B;PNI-RS]A`QM3SY7XQ:JRJDM^5%L1D6\LHW5<1;,423?U7BP=FJI9[P
M[C3-%(7!U5\G4^(M\0H8KUN"2<BV*=XR$DI'14D<T4]*H@H8[5$P^WY>``8.
M%O%\+Q%'L._3]/H("`^@#V`_L]>17W@.`X%,Z@$$H#T'EW]QO("!ZE*`"IXB
M0#F.<``!$!'].!#7Y`LHR6)].<_W*NB_/.DI8TN,<0TTM!2L'*9.FH?&+.RQ
M\LS15=LI6HN+D24;E2,DLJJU*F51(3@J2I,\KYX'Q5&X-P[C3#T2Z0D6F.:1
M6:D>81BTX0]CDH2'9L9NU.HE%9RBTD;7,)+R3P2JK"H\=JG4444,=0\(7;X4
MX#@<3@4Q>C``AV40\@`0`P&`2FZ'T[*;H0_?P,<6XK,F1-FOCNP?YJQ*`YLO
M.T0V9,OYP@MJ_246;>E&C%`;@9*[#F/R-("Y\F(1H`5!<5NTKGEG<PR-%1*7
MQZ_X1[+WV;Q[$?+Q$1$X>7?KZ]<C2KP'`<!P'`<!P'`<!P'`<!P'`<!P**_E
M[8]"4`[`#>0%$#%'L!)T;T$3=]!ZAZ_[N$EBO^3]U4V&/<9(6:9@(MH^OLJN
M4MM^1RY?'8R<+E@%Q!LA=:NPE?\`$I9IUV6"5`J3$/\`I10`2ARI.OU"4.CP
M0W^5_$`UYS#N(4(.8%F->V+DMM8@P#:["*BS78R8:L9;*!%7!E?-TND7\94I
MFA?1MV*2$M>1HX#@.`X#@.`X'65;^X8#=E+T`>OME,;LI@.0WW=E[3,'D4>N
MP,']O+:4QAMKK1]%-H<EUC)=OJ&*M7MGT9'.F.KA=+%$4F@8^V!BW$9$9UQV
MXG)MU6J74&.42OX>YQ+0%7$M9+/(6Y\JIXI=<%Q"1(?('H9T'>[>H@C^HALG
MAKK_`&?_`&S#BD^4/O\`Z0/0O_RV]1?_`.2>&O\`QTXH^4.JIOWH:=7W/\[V
MH8EZ#I,^R&&!`IB@/2I#A<P5(J`B'T-T`?IV/?!<=D$\?[CZA88WGEZ)2MK]
M:K!A;<:/?Y$K\14<]8WEV>/MEZ>FR8W]@$3!69K7JM6\SP+]C*@)P>RE@N:K
MTQO$!(`C'TEFF*<J``'@/WB*IA!,2&\1\2@<Q2IE`3@(@'C_`!]?H/7&UMS!
MP01_3Q\A()N^_O\`(">(``"(AY@("(]``AQ1:HFH"@")?H`]"(=B'8?7H1``
M,'[P[#DF*53.Y336(W$%!4.F=4/%,XD*0@E*(F4Z\`$3F``#OR'OOKH!$`C)
MGC:[&&$7;*IK)6/*.9IIFA(5'7##Q*[9<\W6)<+/DE;!$TN:LE8:0U3CBPSP
MZT[,O8J%(HU_'(\,[6;MEZDRB_8]8MHMF"Q-ZV"S/"8H?T>TQF6=?,-8FJ$-
M.U3%V2(5!P\Q]9<SVRXM9:TYDNM*7EG<>_;Q3BM5648K"8L4F\20>IO"9Y2=
MP#G^0OTI8<495@&>.-C<>-$5KW0$E530MHAS+)LF>7L1R+LPN[-B6S.C`0BJ
MGD]AWIOP'Y2+@DHYBQ/'*4)%0.(@`=="(`(F*('\?'LR?0B)B`)NNQZ]0X55
MX#@<3@`E,4W71@\1['K^+T_=]>^!CEQJW6O?R>[,Y"AS"2NX7UGP5K):6\@9
M9!^.2I:PVC8TCJ#:)E7:NJT?'N5(=)9X95%89%)9`43)HD5/4Y9'.13@.`X#
M@.`X#@.`X#@.`X#@.`X#@45Q*!``QO$#G(3L`$1$1,'10\0$?40_W<#7GS1\
M@^SNT><<V:]?')H)B7:F*U.R*I2<NYMVHMD;2\('O81Q$)JE8F7%@_>35JKR
MZY0>N2"=`S0!ZZ$Q/*LI4_%?OI.;1,<RZ]YQU[::C[>:DV=O5\T8$A4O:H1H
M*UNIE_1<AXF>G2;#8*/9V$>H?WDR'*DL8#F/XN4N)6&77D4X#@.`X#@.`X#@
M>0LM1J]H8K,[97Z]9X<KH)-6+LL''3D>+UJ@=%"0!I(MG:0.VC<13*<I`,!!
M'H?4>[A'C_\``W!GB!CX8Q2/8>7G_AW3Q`0'KP,8?Y,'C[G?H'7I^O!AQ)A#
M!)^^L,8I'KL!`N.JB80$@@54!#^3!Z)F$`$?U_3@QT>2R!2]6<54FV9(R/CS
M!U*H5$@I&SW"W6.ETB,@J]7XE`SN0E9%\O$`FBW;,R&./_$(]%*`F,`",-`;
M-^[3#Y]/E-UUT1UCQ>TQWH%6<P1=QN[VAX_J,1><HU/&,BK(S68KPH>,CGD-
M2&Y5DT&$6903H-WPKJ$.X.4I#-Q,X;L:'QE8/H:9Y;5*S9-TZLG2DFD;!MUF
MFE`L=H;@8];L.4L73;R0JN56\`8X@2/DR`U7;*JH*`*9Q`%K\>CBC2?DTQ"@
M5K7LRZ^;7030%)YXIEK'SO">5)(4$^U<;TL<0"RQ;%LW[2/ZCI:9;JG;/WIS
M.@4;))E!LS"FE\AC_&S$X[5ZG;$:]&ARJ/KW>(ROM\V8#Q_`"*AV<W/YMQ\`
M1!VR;8J8/DV\>JI'N%/:4`W0GXHOK`;,&SNWJG\CP!6[IJ=AM<I'_P#F>R;6
M:T[R-;F[150PPF+L%6M%PNR@[6S.W<-;5+=-U8M58S5%-V1,2B[2?P'K!A/7
M>.DT<74=A#S5AD7DY;[Q**JV+(=]L,J1BG/VFYW:7.ZFYV:M3N*3>O53*$2<
M.C"K[0'$1$M97^*R*F/]T?P*"14DR>(&!$"^@BGY=B4#E]!#_;R%+!9_P#&Y
MBBX*:A["]QOF#&[UQ/X?R]`-T5YVB3RC8[=P@Z:./^CV>EV-L86DY!N_-E*,
M3F3.4#>"A:3#\'`NP#Z[OK)BW+->;8]V0QPU:N+]0VZ[A6"L<`[<K,HC*V))
M%\4J]FQ9:SM3F1-VH\AWH*1TATY1]Q9M(G[I1&73*!3"8H$-T(F,8I0*`^@&
M$3"`"'D/7U^H\-/)W'(E"QVQ;2E^NU0HT:]<&9,9&Y6:&J[%X_*DHO\`@MG<
MX\9-UW7L)&/X$,8W@43==`(\):#\G\F.OLK*SE?PS6LZ;1251E74)?@UFP_9
M<F-*#+-7*K=LULDHJ2"B_;FUF3K^7.&2SU!V5HLH0_@4ICJ3Y1K:#GQ>;XX-
MRCL;NAB/+]F88E^0FT;696/?]<K1+`A8/\/L1MV-#PJK2O:1;URXLHK",9"M
MGTG&@`R3]!=<Q3CVH(C]V>DKP#*>W[*H")B>(@`"!DU.@!4!_80_H</J7AIW
M.06?S/EI7#U,&](8YR-E**CIB,:VB)Q+6W5ZND%7GH+E=VF/H<(#JWW=.*7*
MB52,@F<C,*E7]Q)J<B:IB6A3POL%AK8>J_UIA;(=8R+7DI*2@Y)U6I1L_<05
MBA3IH3U9L,>F?\^"LM?>J?BR#!RFFY9.BF16(10IBA$N)TNV5TD<H'3[4(*@
MD\TO[PO8*"D(_9Y=>*@"`_J'0B/H`\46Y"N!0[.4Q!Z$>A$H@'KT7LX")"^X
M/T['A5%9^W;I&664332(D=4RAU4B)%(F(`<RBIS@FF0H^@F,(%#]O+27]T%9
MWY$<*_SZ5BL55C,&Q\12IR5@,K7373%MPR_4,:RL&X=Q$W67DU3(J5;6_)$#
M918M9&HP`R=GCFC\LDX8IQJ#ETDHN$H,09UPYGZG,<@85R73,G4R16?-6MAI
ME@CIZ.,\C)!U$2;%19@NM[+V-E62S5=(X%.DX1.F8`,40!4EQ.EU2F`WEU_P
MF$H^H#ZAU^P1Z^OT^O(KY[A?,4P$!.4I3&*!@[*!Q$"B(=]]&\1Z_LX%)5RD
M@05%#`5,I3G,<1#Q(0A0,<YQ[^Q,@#]QAZ`H?7BDM"2^;^X9KUQL&/\`&\)D
MS9"XT"6%AEZ'URQ]9<NAAU%FD@_F4,@R%0CY..B+FV@E_P`^/J@*GM-@1*)8
MM@[/]O%%POOA38O"VQ-9=6O#>0J[=XV*E']?LC:-?)DFZ?:(=)H>?J%R@'/L
MS-6MU:7?)-Y.,>HHO(]T(HKID4*8H6EM>DAP/WT`^GU[`>N_W&Z\3=?NY`.<
MI``3"`"(@4H"(!Y'-Z%(`CZ>1A^G`Z;J39,&RCR0<(Q[1#_YRZ>JIM6S?U(4
M/=<+F(B'D=0I2^OW"/IWPEHJX9VZK&QEW41P34IS)N`FT*^45VMKLS4#X;D;
MO'/6S5WCNID=3[:YWB09$<'(\E8>,>P3"0:N8]R[3?-UD"4N]:8!OB:W"UD^
M,V.V?^.+=_,],UCS1A/9_-63X.RYEE2XMQ5FS&.;KNO;:3<\37.]D@V5B8@P
M<^TX;&\'0`4ZR(*MR'6(2,;7K^/.^US?3YE=Q?D7P,:5E-5L9:GT'0RJ9+FZ
M[-1$/F_)\)E!WE*XV_$$DZ9A'3]!J3,B3%RZ,JFNJJ^:KHIG:.$UC")O6FR/
MR-'`<!P'`<!P'`<"R.R>47N#=>L\9N81#6P/\-X7REE9E`/'*K)K.N\=4B=M
MS2'=/T4UUV+:2<1)$5%2)J&(0XB!3"'7+"3U6LT/V)?[?:<:Q[0R-1;45UG;
M#-,R6YIL?,O9]K6'=OC$G[B*;3CQG'+RC5D"OB155!,Y@]>N"$2-1_E(JV;-
M0-MMP<Z5-GA+'^I>=MG\9VQQ$2D[?4EJ7K,^;I+W<$&L''RJ\M.H*&-_*VR"
MYS*E`B9E!'K@NHOAANW?W;VGWRTRG,I9*^#S*.3/B_L\'#97=3\YL_%8SVE+
MC-M'>S+9<CM?:6K(2LDI78Z0>SU>0?KO8=XR;,I1R0B)2G2,[RO1\!?PA:KZ
M@R<3\A^"MBK+LM7]B<*0[C!TI=<6&QC-XXHUY<)SDHH5-*VS`R,S+Q!6T<^2
M>1[<Z:C4QR&)Y"7BR/6(TVG$2&3)XF\?XCB4"B80*4QA$`\CCY&'L>_T^O7Z
M<C;B=$#G%0#&*?VP(42F`.@`_F(>I3!]P@`#WWZ?3K]12VN1['8L=T*S6NL4
MN5RE98*)7DXRA0<W4*E(VQX18GE%LIZ^S]8I4$X7!3LJ\G)-F_1!`3^0AW=I
MIYG70B*V'*8HAC^=Q*JJE+O9+&5FOD%DRP4F6EIV2F92'F+K6[AD&#G'9WS\
MZW;28=MTD%RI)B0A"ID$+Y)$%,H$^SQ*4H%\0\0#KL/$I`#Q(0H==``\BJO`
MHK!V``'H<?($S"`F`I_$>A$.RE']W8AZ\)*%FWT!BR3B\<3EKMDOB#*4%>HB
MOX2S[!5][.*X?R)>4E8V!1OCMK[4-_ACD.60;P4E%3KII"V%VZ:,DET90\:Y
M;U)0%P7EW:W<W+>Q&#+KM35-5<@:ZWQYCO-6M&*L(O9+,:%%(LJAC[/V'\]Y
M-E(55O1<]QJ"$[#2`T278QJ2RT=Y.%4?R`&93>IOQN:H0<K(6B^T:0V,OT\W
M*G;;SLY./,U.;+)`*8FL@4:TE/A^IV0Z")$#.Z[6H43MRBEUX&4`RRDUXFOQ
ML!%P\'`1["`@X".:0\-!PK5O'1$3#Q[8C".BHIBU;I-(V-CF*1$T&Z"::214
MR$(`$(!>1::W_P#J$OAWG-V\/M-HM1JT>&^0;`*K:7I=RIEFD:#>\CXXBVTB
MI+X_;3$/[!Y*[,DUP-7EE7+15/\`O&I%O%1)$+A)B:?H_P"G-V/^3_.FK#^T
M_(;5J]!8JJK>$Q]@'(EV925(SID!:I.7%=L3Z]UV33!C+L6[IH#,DVL,<Z>O
M6IBD;..UG`*X(F\RV.VTQ$O&BK]I)Q[IB@+@%WK9XW<,T1:@87/O.DE#H)?C
M@4?<\C!X?KUR-*A67M*"=!3VTQ$#?C@0OM"L94RB[I02>"ZKE?S$#"8XE]._
M'OL>5$6LQZC4K)-L3R[1IB1P#L<U9-8E#8G$<+2V>2):MLD7#=*AWP+75[56
M\EX],W<G*G%3S%^G&+G_`#(PS"0(D[3>28Z;6<:;3Y"UX?MZIO15U(]L@5+V
M-O</8]GV^KUB2DE_R&<9<ZP6V9.R5@26K;5)XK)R%@,[IC&/C@?K61L=Y_+V
MY+F-O;7_`'WUUK2L5"8YLKC9O)-AKT18Z9A_5Q>$RU>;'#6J*1L%4FWLA&SK
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M][J\&/W#3I)';&E5*79:BWDS@%9`7;URYM-\N&NQX6+355F1NRY*K&%2+[=E
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M:`OD?Z&F7MJK%IK=[H"AIERI_)+'&3$0T=*@_;-T)%LT>(.Z3"S,;L]E#65X
MG3]W*RO)0JJQ%8W;;!F,I]/`+E.57`T?7LA8]9VW).3\1VN,\7BDC*.$I.H$
MC60R;V8BP7"/0;TNMO?Y`WGP>T;UZ)PB^)MSDVW0L+;:?BO6:UX]OEG>T>P)
MJJQ64)N76N</3JEBEP@B=5.;DY%!M*%2.C&$D7G@T447#QL?J_>]CW2-FWH7
MJUJK!A%>,TJ@W43D/6"OO(U/^7P]DO<Y/X^I]GV$MR:RSM]XS;)G5V+A1BJU
M@D)2,1E5B5E/Q)F#9(46A$FZ2+=)!HBC_=))@D02D*1$@?C()@'10*5,0``[
M]?IR+2S^9M;-?]C(N&A=@<'X?SE#UYZO*0$/F+&M.R;%0DJ\9?RYY(1+&XPT
MLWCG;EB(HJ*H%2443'Q,(E].6RLY70K]=BJM%1==KT9%P=;@&$?#UZ#A8]G$
MQ$'!Q3!*-C(:+BV+=%E'QL8Q;)(-T4"II)(ID(4H`7UBOW^`X#@.`X#@.!1.
MN0@_<!^O'S\@+V`%#^(P@'9@`OZ]APEN)'2"O8IJ`H``(_9]_90#^,OCV)B#
M]`,'H(AU]>6E1&^08?/0G>#T$H!J#LN7LP"`#WABY=F`/XA*`^GTX2=3X:W?
MQ<?"JRS=\>&E67U/DY^6S&)\AZ\XTMO^'6(-OWE-QE2!EH9%V>OT"MEICY.L
MUJ,%3P:-054]D@>AC=\MX9^.=RAOA#5?(^7_`/3?_)O@;$+RR9(N&._D2V)M
MS-6>7FK1D'),%KSFO%5\LB15("(DI*VY,NE>I3C\=(K<H2<NX*4QDR*&,6'$
MQ^M0V.X;YT/BX>ZBH;A&VIQ<WIC''"%U=8K>6&KH;$MWK,2QRF/`PTK-EM*E
M_;6A`T>1%$@QPJC^25U_+^GPU;CZOQO]/O@O(N!OC#P]&Y.AU:W/Y2M^5]@8
MVKR#27C;%6*CG*^S.0ZC`W&)FHR,=0UQ80,T@$BT(59%NX$Q$UUBAYCE89J^
M%<#'*3KR[]?IT43=]`)A]"@(AT`?V<#%9\K>W6L^O>`7]4SELIJ'AA7(+J&C
M'E3VPQ5.;'U2]TF0DG;&88/->J';JS?;/$K/F'M#)@"L3'N$1!T41$`+:9F8
M^KI_#[F[5[+^L<ZKK#E+4')-<KV4+*UL(:::_P`]J[C^%F9)I'.T$YO"EKL-
MBLT79I)DV%4\HJH5"612`R`"""@\+%,KWNDZ$>^@#R^H"`_8;Q-T40\A$!_=
MZ]AUWWR*I@Y3%0R90.<2>/D)2")2B8H&`._3L0*("/7?^_EI+1PRQL*VJ;VU
MT['E=<92R[0H2KY$LV&H^05JE\G,22<R#"P6G&86&)3A<@RD0@DHFFS;.T&I
MI,S=@\?QRKI`YA,K1:GP3;()'.R-AM4!E:T2DGDFH4+-M)<3-04R%@F7R5(W
M"F4G+.*&\57H^(O>O,J[>4PC"=;2<U"KQDBZ%9B^EY9@F3\M>/YRL@7;XD/D
M2U/^8#$8Y!D,=9F%MKIO!BJF)22D'E*H4UB5>F25@FK`^G:-"3Q(!PDU@6P1
MT:X.[B%#HNR'=.3%4EUEM-:X9_QAM+A'%^Q6&9Q:PXKS'4(ZZ4F5<QKR&>+Q
M<B4Q1:R,7(`"[&0CW:*K=9/T(5=(X$,<HE,8U&%\BJ%-T`=]]%$0[+V4#!V`
MFZ,(="/H'7?8AZ<BO/SMPJM8&#)8[-`5]2T6%K4JR6;EX^,-8K4_0>NF%:@R
M/'*)Y:??-8UPHBS;@HX4(@H8I!`ANE#685U\K?S3?(SOOCS:VYY5'3+0:PT;
M7"!TVJF1K+4<;9;RE.0AL@.=@,E.Z$ZIS^4>PSP$PAHMS^69@Z0(N#WVA4:'
MMLU$SV>!K^FN&_C1^27'/QUXG6O5C^.OYD]?]IZ1?M1+!>;"\K&&KUC+%T:-
MUOE+NLE(R61`C\JXUDW<*Z;-Y-E()NW'Y9I!<C5BW:7*8C'$MLGF6S@?E.8T
MCU)^T>IMWL?))*(.V;U,'C99NX04;.FJS9P"B"K19`0`R1@%,PF-V`]\J9>&
MHV'L9XM;S;;&%!I]!3L,O+S\U_2T!&PXRTQ.R3F8E7S\6;=(5S.I-ZLKXF'P
M3%0?;`H>G!2YA0Z*4!Z[`H`/7?7H'7IWV/7]O(KEP'`_-E(MI,-',;)-&4C&
M/$#MWL=(-DGC)ZBH'B=N[:N"*(.&IRC]Q#E$IOH/IZ<J4\-CS$6.<3QCF$QM
M2*I1HAV\DY%RPJL$PAD7LE-2TC-2+^0!HBF+UPK)2SE</<$P%.X4`H%*(`"R
MJTN24!`.N@``]"@'_P`$`Z]?T]>17+@45B"H4R?B0Q3D,4WGZE,!N@%,Q?J)
M3E'UY1$7?E(Y-%MUCAXCWJ5L@'ET4!`!PW<Q`0$``WB7HI.N^^B@/?UX9G$3
M/9`'3O&M"H&YN`D:/3Z[3@MWQ.UNX6C^F8IG#_SRT2N7<8KR<S(&9(I'<NWB
MI?N$PB'0B``'8]DC?T9N")"10QP$0*;R$2"(&`3F\`[*(AV0"@3Z!Z#Y=_7A
MM6Y`X#@.`X#@.`X#@.!$C;/.RF$,=1`UA,LIE7*EH:8KPY'JE148)7ZRL'X0
M]MN"[I!V>)H-!22-+3C\R"B#9HB`*``*E'E1C]U>U/8['XA99@MVT'R),GDW
M-V%BG8(+=;.M'K^2%JT]-!6/)=4QG&6!)IC"E72\1\JO7X!%1R@U@BM%$%/8
M63(0E7U7WLWQ4XINE9L-.MNSOR'V>IVV`EJU9ZU-;W;`/X>PU^>CW$7-04LS
M<6<4GD7+1KM5NNF?[5$E#%$.AXM:\K*V?XZM9M,->'+V&SY\DE)PA@^IQ4=%
MT7%&YFP:S6I5%H[90C"*JE6B[4W!"'@T7A%#`02$;-$SJ&$"ICPE>5XOC2AJ
M1C2@9BUL90-0JUYQ#EN>FKW)TJ-BH5IFV$RZB>W8WV;=EA%%S/WV4ZFP49.I
M5TNJ[F)BO/7RP]K$["_(?'MI"[S:VV8?ZB:[JY^1=)ND,LEQ;5`N[8Z$">K-
M%_YT:.,X%RWK`$8=AT((]@'0=!QA4R6J7L-TD0*!"I%!-,@#WX)D^U,G8=!]
MI``/3H/V<BNQP.HN!A.3P4*0P="8HB8/(.E#$[,F('`OD3U`?M$._P!>4:XG
MQIXWQ[L3\G/S`[$[#TZLW+8_#NSCC5[$BUQA(_\`.I.JU;JD*:E?TU3)%$R;
M..MBGN`O8$T/.;!,0]XQ?,HF52RT"DZT?ZBK6I/6VK0-)#<;47863W-A:=%-
M%(B8'%H1,QB.]62#8)BUHLT_L3(C7^<@FV4F`3_&$RAA'@Y;%A%"JM2*`O\`
M:IXJ)J*)F,;VRJE%'R]P#'-Y`8!^[[ON`0Z_0LM<JPV/<CY7=Q]OL&8*V_OF
ME>D>E5^88%N%TP6PC:WL_DS:"L1J$W<6K2US"4H6OXLA3R_L""!4V\NDDD/L
M^?N*`3,R\/K?5,[:N?)9CKX]MSMBL@;;53)$!<]J/C]V=M<_+!M#3Y3&!HG_
M`!APUEF]0JD88^-;%5Q<@LR!)6,F$#_B"1,BATRALWL8UHQ1_'8H(,4/>>.3
MH1Z"#-N+A^]4D':PH-R)D_(<NEU%5#B'FH=4QC")C"/"L=/RWZ9AOA\?>R>N
MS**@9:\6&BR,]B9Q/PB<Z,'D^K$-,U.3@&HK-3,;*K[3B.:.R*IJ(F>B(F$@
MF*(F&EK_`*73Y)\FZAWK,.EVR5<NZ.O[Y:U6R+L4NYLLLMA;)=)?ITZQTJIT
MQ%*2&P1]OMCMO'OT8-LH=C,&;KNA2;BHIPQ'\<3INDMLD;\["@T?X:Q?3M3,
M9/!.R4M&TD5)V?8=]#RHE82$U5<2U6:+5L;6RE.6;I5HWM3BP,)?WV*PID;B
ML@8UF5WL-Z2XYQM>$<T7FP7'/NQ8-7S8^=<PRO\`45GA&\TF@I88+&,(!4ZQ
MAZA2LFD=V6NUUJRBFJRQ_93(!A#BRN>6.W8S2'>_7[<')^]/Q?6?"<JZSY5*
M]#;%Z=9O"5I^+,JY!A%CQL5G-C<JC^.\@<AQ<(X'\QRHFHXD4D0;BI[8]`6L
MW#S.(-(/D-MV;+O\D6X\S@2[;:XVUHR?C_133FHN)G_+QKYDNS14@1],R.4)
M3WK:]L&57T#&,I:P,Q0=HPDJ[:*>X5LV\%I7+8%Y&C@.`X#@.`X#@.`X#@.!
M$G?S_L([K?\`[2=C_P#J=N7+&V?;^L^$,-:O^VGK!_['JE_]:^,^/]I&X_\`
M+,+R-G`<!P'`<!P'`<!P.LJ\;()+++K)HI-_+\A14Q4R(%*0%#G6.<0*FFFE
M]YC"/12`(B/0<);7SN-DL6^6:J^>LR3F':9RH-S9Z[2IR,PEL`:<NVS2J9FV
M*MM-73=R+>^;3S,>XJU5+(ILRMHD!;.RM7:1A4J9XTSTTZFP%"J=:HM0C&M=
MJ--KD-4JI!1Y?^A0-=KL<VAH"(CQ5$RI6<3$,DD$P/Y&\2^IA'L1*]9R*\U8
MJW&VR%GJM8X]O+5BS1,I!3<2X,8S65AYMBM'2\:_2[(8S5^R=*)&`AP'Q,/T
M'A&`I^_F=`-GJ42T3)AH^*:K(P:<J<AUHN5^-66LM)J;21NDK[T;`,+[I%EF
M5B7\A,RR:2A<5F>HQQ'*Q)!<*C850-YI$/YE.!P]PIB]="0_W%Z$HB4W11#[
M@]#?7]>1I5X#@==8"^O0![@D[*`"`&4]LP"`?H8P)F,'0=]=CRI+7VO>B4=O
MQL_L7N-K)GG,>BV<*/;&^JL?L]A:29SR>=JQB=JA"Y2C+_AR[,&L&Y4J%^;.
M(.#F2+G1<,(Y%XV%0IP.)-Y36T<^,#'NF]YR1G^QY8RELYMYFZN0E7S+LMF2
M1;GL-F@H)V5ZUK]5JD2!("@U91PU:J'CVHKI@LU(H4P=B42TR4%;.4T3`F)5
M'!`*"9W)NR*G!)$IE5C)`!C@)B=C]H&$P?H'!37+L=5W,^)_<3<#->"].[]N
MYI1NQD!GG^U5?!\M"S>RV,]H;,P;PEN*E5)IQ%&G,33HPX.`,B10D*@LEVL8
M_FF)+EW]&*SL+\DF]&/?EFS=B5MKQ@'#&%KYBS2'&2UOAY/,4\[R!/+5C,5L
MSHPA#RL=%&BCP#Z+2@SJ-5F3KP4**G1S<&\MC!)/H0.8@E/XB'J8.P[\2F#H
MHB40,"8"'8B(?3OB5?7!%#D*"8@`E4(<2CW]Y2CWX`8#%$@]]#WZ_3Z<BK70
M.$,1UB8C)^NXIQC7IR"4M#F"G:_0ZK"S4,]NZY'%R>Q4E'PR#V,<VQ8@'DSH
M*D,_.`&7]P?4*E+G)H^*@J=>/8=^(``!YF[`YAZ,/J;H!].@]?U'@[NUR*<!
MP'`<!P'`<!P'`<!P'`<!P(D[^?\`82W5_?J5L>'_`.#ES^O[.(VGM_6?"&&M
M7_;3U@_]CU2_^M?&?*S&X\,PO(V<!P'`<!P'`<!P'`QT[W2TC8RZ_:SOGB5<
MQAN+E:=P?F"UO$UES2F.W>-+]9;)A>HNFH2KZ!O6:(N%6:MI-:..P;UUE-E!
M]&2:D0J:LYM<36W7.:Q=?LUY0R`XK+FW7NTMJ3C1"NO):4C*!K)CAHA7\,8^
MAU;4V<S<#+O8=H$G:6C9VO%R%B55>(`0QQX*^Z:(#V`#^T`'U]!_VAZ=<C3[
MP'`A1O#K`OLCBIQ_2D;3'V9\;-K9:\$&R(A_-<?*WZ>HUBH<I7,D0#MA,1D_
MC6_TNRR$#.-#LU'(1T@JJR79/"(NDK$I,809TSW/V,@]>JA2`TFVLV22Q7,7
MS#33+-.N6MBRDJPP]>['C5A7LA2F7ME:;;K'FRB-*P2#O<LBP""EK?'2+R&<
M.XM9HY4)$S24?^=O8S_U5^[W_AEH[_YWO(MSTD_SM[&?^JOW>_\`#+1W_P`[
MW@N>DK!;&;][-1E#;5&`T-VRU^NF:[16\#4#/>1IO4"3QG@RXY5D"UB*RW>%
M:WL%D+V&-%_,/(,&3]@+&QSC=C!`H1Q)H=V$F>R6V@4]4F6"&V#(2E'Q=8=5
MI=YKW=L;N)1W)EA9.@@#./ME=<S8-K6_QOE"),G8:S(RC1DO)1#])<J)4Q*(
MI6.G*;Y3%.'91[#T]?T$!`!`0'Z&*(#Z"'IR*Y<#JNA.0H*@/]VF!S*```8P
MAT'7B7H!\@]?N\B^/U]>5)8Z]/"AAO8/<+6!XZ4)"*WR,VEPLF]53A(T^.<V
M,R,KE2<74H5%FQ*+AZ_UH`D9"+/^`:6M(>\W:.%>W(BN&1E)=)<OFB<%""`"
M"A/5,P"(A]IP^TW0E$!Z'T'Z\BJO`<!P'`<!P'`<!P'`<!P'`<!P'`<!P+8Y
MJQC%YKP_E;#<[(2,5`9:QI?,93DG#"W"9CHF^U>3JLB_B!>(.V(23-E*J*(>
M\BLE[Q2^1#%[*))1#PC&:D#L!0I[&>SF/,A93QSK&GJQ%XY@,JXOLTT\IU/L
M<+99*Q2E<KKE2QA:8]Y6R)O/:!-HW3%3R1*;H2U(ID)`>P[#]?\`9_R\C3[P
M'`<!P'`<!P'`<"/&SF#0V(P=?\5!+(5VP3<<SDZ!;U&;ET6D90I4TRN>*;RN
MP9OH]>795*_0,<_=1YER-Y1L@=HL`MUU2&MI5[>;U8S<]S529A"U1KNL96Q-
M;Y?$.:JFZ,B4&>1J8*;*3L]>$K:)7=T.ZB`RD(^,Q9HR,<X(JDB!?N$<)5!U
MT'0]AT'0]]]AU]>_U_MY%?>`X$*MW\JW&EXWA<78BEV\3L'LQ:&V"\%.EV#&
M8)`6*Q1[V0M^3WD#+)*1-DA<)XZCI6W24<J=`[^/AUFZ1_>43`:DI(8AQ=3\
M)8KQUA['S%:-I&,*56J)563EZ]DW:,%5XAI#QOYTG)+NI*4D%&S0IEW+E51P
MX6,910YCF,88JXO`<"S>?,-UW8+$M_PW;7#^,A+[67<.G8X3\#^I:?845$Y2
MI9`IZTDQD&<7>L;VN/93D"^.BM^#+L6[@I!.D7EA)8]]0Z]F^R96J.P<M$LJ
MM.OJE>-:MZ:R^":@Z]8\U:XRW])T3.6*FDDQ))Y$=V<4EH<;-,.3?DU9HQ*V
M12`!#CL5EED1\4P%/KP'OL"]]_Q?42@!0`$Q'_8`C^G`Y%<(F'Q*H4P^X*0@
M7LPE4`HG$I^@'P'Q]?7KT$/VAR4JW64\KXSP[4W5WRK>ZMC^ILET6JD[;9F/
MA8U23=D5-'1;15\N@K)SD@9$Q&D>T]U^\4'VT$E#B!>5)JF$;8G*^PEOROBS
M<W$>#\U:X5.DU2[8MF,T7K%\7EZ4NN+Y!PA?",LKZQQTX%KH.MKVYUN%GUK3
M6I)?([Q@V4BV\?&++"J4G*7."/DOQI+1L>UV.LN,,;/'ZHQ]?R]2[A(V+7*[
MK1<6BYL"\U;I2(8FUJOC)8R*TC0[ZZ;2D$G*QS0'\B]67(D(GJRAHNVKAND\
M0<)+-%TDET'*9RG0617(51%5)4!$ATE2'`2F`1`0$.N1I6*<INP*/?B82FZ[
M]#``"(#_`+!X'+@.`X#@.`X#@.`X#@.`X#@.`X#@8!?FZL=TR=D7XU_CM@\@
M7C$=#WZV1N-?S)DG%UE>UK(S?'F$*&GD%Y18!ZT\`;,KZ_?(I.W7F"K3\1,Y
M"J=F*))Z(M_*3\1>EFI&F.1MVM,L<)ZF[1:05MUL%0LMX9=NHFU7*1I;-%25
MJ62WZSE1:T0EZC"*I/U%.E/>6.N(*>1TU*GAL5ZUY0>9MP%@K,DE&,(*2RUA
M;%^4)""BW3AS'P[_`"#2*_;WL:R6<E*LZ8L',R9)!4P`8R9?N#OOI*POGR*<
M!P'`<!P'`<!P'`QK;%BIJEG:C[=01#1^,LHV6L8DW+;HF(G$I1#UFC5L1Y[G
M57)T8R"#%T@5*+F9$ZAE%H5RW;$((I@(5.5V<@_(AI3B>[6+&V1-AZ+4[S4'
MA(ZRUJ1_G(OX=\=DVD2M70-8EP@"@L7B2G13F#P.'(MO&#\JGQZ!Z?YJ,<>G
M[K#_`/4?"7"Z.'MZ=2,_W1''>',Z4Z_W5Q&2,RC783^;_G*1D2"`R+P/S(QJ
MC[30')/+L_?W!T`\%PLCKP3_`#-;.99VY<^XOCG%Q9S6/6-8%2KQ,ZSB9EF]
MSOF"'.@X>0LTSLETBFM=B9)+V7[)*$F69_[IT8#4VR/$*!"E(4.@*4"@`=^@
M`'0!V/J/(KEP'`H+#]HAT81Z`"@4P$$1,!B]`<?0!_Y.6$E@,VWSUN+M?O\`
MRWQE:7YAB=:ZCB?"=<RINAL6E7_YGF*H,LH.U28TJ>"6\F!(G^I9&):$=J2@
M$619&6526$#$(50G99:DV#>+XH]X=;,5[.[BW7>/3'?&Z1^`*=?<Q1L?_CAB
M+:AS%3+ZCU^+CJJF2/\`\/+\#$$'+@04;LQ`RS@R)TT_>#-!GC.&7*M:FN)<
M&:YWS+.2IJ#;VAK=9HAZ/KW3&#]\]KY9&X95=A^-,2U=D44'#ZK1!%["\B%3
M+-4Q$H=%FWE,<:40869OF#9ZQM-H]@6H"W87BV4]C#4NDP)%&[N/JN,\6H.Y
M"J5MK&.6I%QDCI+RKE^*CD5DSJ"F5^$K[IN)IN#E1,8Q@,0IO,QDP(HH4_W$
M#L!'VS%]/+KLPB'K]>%R@CG?0RJY.E)FV8SM[G`=WGD7!;*%5JE8M&(LIN59
M$\@WD,_8&L3$*'F25AUY-^K'.'IV[IL\<@Y,JN=)(A!3'OE7<+Y!MH=I,TZ;
M_&.WP'2JKJDPJU4SQNQFN*>W6A-LY$8%D)W`-0Q]5E3-5K'$,W[<)8AA!6#<
M(G(8HIJ("<G9[;0K<_=2I;?7?XZ?D[98O=9T?U"6S+K%L#BAB6H8TV0QK#J,
M&5OKE;J#URI(-KMCY591T^1#M5-B4QUR$#V3JEMG2Y%.`X#@.`X#@.`X#@.`
MX#@.`X#@8]OD<T'A=^L24NJ,,IVS7K-&(<F5[+V!-CL>0D/,7O$-\@`7;KO&
M"4BM&NW]=L,0Y4:R<:A(,22``A[YE4DA1/828MC&NOQV_+QO9#LL"_(_N#K3
M3M1X:Q5V=M-=TIH&0XG+.S<)6Y9`PT'-4QDMVM5ZG6+(Q8IOI%.(:OVR[Y51
MNHT5:@GXDRV(Z_!QM=8,H:&B8Z#AH>/90T)$0\>TBXF)A8QJW:QD3&L6()MF
ML9&-DP0:HII(IHHD\2D`/JE8?O\`(IP'`<!P'`<!P'`<#PEXI5=R-59^C76L
M0UIJ-JC74--0DZV,\CW[1RI]S=\@'1_`H`"B2R9O<1<$(H0Q#E*<*E<(6I?&
M#J(D(D+7L]D("H^1@W5W3*8_V"'Y)?'8-111941`IS*'`P@'8B/TX3XQW=T/
MC%U#Z#_Z&SX'[@W4W4Z#]P?_`)@P]`XL^,?JW2<?&#J`<Q@5@,_KD4*4A2!N
MEND)?,#B(&`W^83R36+]2G$2@7]!\N#XPF]0:'4,84ZOT"A5Z/JM0J[`L;!P
M46F8C5FV*HHLH<ZBJJ[EZ_?.5E'#ITNHJY>.E5%UU%%E#G-&GK^`X#@4%B]]
M=$$_Z#T/0^H&#T'Z%Z`1['LH_3UX26OIM?C7:?1?Y'+9\F^O&N-HVXP/G_`E
M4Q7NIC'',W&/=A:*.''*R>.[YK]CZ3&NEO`/(9ZBW?0*+R2?O715E"?A)$!4
M:G=;B,)M#\P>X.F&6+CIKFC3C0K2;*BVR#*3V32A\9;096VDHL:ZAJ37H[%:
M#RV/H;$\4O/)KNW;Y-!.=:D7_'?MUD004)$WQ--D]LD9+W?(I0`YQ$H_<!^@
M,8A2F**BI>@3*40$#?<(B(@`]]I;=KD#@=9T"PD`4>A$IO,Q/$IC'`A#F(4@
MF52*0_O`40$>P].AZ`>P$M7&J;"UWX2=X/D+;;?T;+<3I]NWG4^Y6+]UX#%U
MJO6,Z]DK)<6QAY_7.]1&.65QEZU9(V2A')(5XN"+B622,J=JW1,DL>L3,1O2
MX>L-VF/E,^6C$OR`8KQ7EG'FE6E^N63L?X7SEDJA2-(CMO;=L"+:-DG^.:W;
F#P=J88\IL4P=*I3`,W8/':`MW!&2AB%.E8FYQILJ<C1P'`<#_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
